Aliquot ID	Aliquot Submitter ID	Sample ID	Sample Submitter ID	Case ID	Case Submitter ID	Project Name	Sample Type	Primary Site	Disease Type	Aliquot Is Ref	Aliquot Status	Aliquot Quantity	Aliquot Volume	Amount	Analyte Type	Concentration	Case Status	Sample Status	Sample Is Ref	Biospecimen Anatomic Site	Composition	Current Weight	Days To Collection	Days To Sample Procurement	Diagnosis Pathologically Confirmed	Freezing Method	Initial Weight	Intermediate Dimension	Longest Dimension	Method Of Sample Procurement	Pathology Report UUID	Preservation Method	Sample Type id	Sample Ordinal	Shortest Dimension	Time Between Clamping And Freezing	Time Between Excision and Freezing	Tissue Collection Type	Tissue Type	Tumor Code	Tumor Code ID	Tumor Descriptor	Program Name
9c36e4e9-a971-4ee3-9e2b-4e25a0bb6191	SAMN05341218_N	ba497617-aba1-4037-90f7-fc2c66ad10dd	OSCC_56_N	ea7c9fbd-8353-4f3c-9fea-2fba79140536	OSCC_56	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
393737e9-6f66-4ea0-8d37-0148341af33e	SAMN05341175_T	bc756b33-21bb-4f30-b32c-d899199b1927	OSCC_23_T	1104505a-9890-49ce-8d7d-7a8070261324	OSCC_23	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
51401f66-a9b1-49ea-a97f-0c06c4145f4d	Refmix-P29	c1aaed81-3d81-4f77-8123-a243aca577d5	Refmix-P29	cb689d01-77cf-4552-ace6-f3a4a5512768	Refmix-P29	Oral Squamous Cell Carcinoma - Chang Gung University	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d8c7e1f2-ced7-45de-82ae-611b308ac42c	SAMN05341224_N	afca2ecb-386a-4456-a3fc-f55720051dcd	OSCC_62_N	58355fa4-e2ad-434b-a915-acbd09abbb77	OSCC_62	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
a3402806-a9ec-4233-8d0e-8cd2d2d28169	SAMN05341189_N	1c1d1b89-142a-4d11-acd7-453162134116	OSCC_40_N	df6bef95-c233-4b10-b321-36ef4e79b5d4	OSCC_40	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
81b28605-63d9-49c1-9f04-1d66221b146a	SAMN05341166_T	39002ad2-010e-43aa-b2fd-518cd3dae98f	OSCC_14_T	4633e71f-5fbe-49b0-9721-9769182a08eb	OSCC_14	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
5fd3bc7d-1b0a-4267-a96b-3fda9cd88a8f	SAMN05341221_T	833d168c-11fa-4019-a4d0-06769dc8cc3d	OSCC_59_T	3f8aba34-9229-4701-bd5d-869b3705d4a6	OSCC_59	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
14723024-1525-40e9-8dfd-340da98a2151	SAMN05341190_N	d41e54ef-0167-47bf-acd1-2066cdc86f72	OSCC_41_N	2b4204ab-87af-4a79-913f-fabdcb2d02b4	OSCC_41	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
93f78b75-72bb-418d-b895-fb5e51273619	SAMN05341214_T	008cd82c-3d04-4b57-9fe2-f6e6c205d8a8	OSCC_51_T	ced7d55d-fcb5-4b4a-8ba2-aaca18b958d7	OSCC_51	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
5752f6d6-84b9-4821-9692-5816bb1545ff	SAMN05341210_T	3a12f902-e54c-4144-84b3-766136b5c8b0	OSCC_48_T	ca087e3a-9e96-48e3-a28d-10bfaa39bcf1	OSCC_48	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
5f2eb1c3-dd5f-4637-9ba3-324e9e90cc47	SAMN05341187_T	90bfa434-2fd6-4a5f-b03e-551bb0440022	OSCC_38_T	f581075d-1b69-4812-9fe4-2bde4aad8bf2	OSCC_38	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
c8c4e66a-461e-47e4-9235-770d9f9e5ca8	SAMN05341178_N	537409ca-df9e-4f83-87e3-172de75e78db	OSCC_28_N	8ac42bc3-472d-42e8-8455-09528a9977ea	OSCC_28	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
299a3cfe-f620-4731-9722-7738f02d696f	SAMN05341213_N	bab408b5-4498-4976-a7e6-92a898c9b926	OSCC_50_N	c7a90e98-6f13-4480-8f69-74eea9e6efa6	OSCC_50	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
c6938e8c-431a-4c25-a77c-ea7bd0993478	SAMN05341222_T	ab9cc194-6571-411f-988e-d3c6387b2d00	OSCC_61_T	5e99d311-24f2-4ee5-abfe-c9d40771e8e3	OSCC_61	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
47e8d70c-646d-47e4-afbd-348e9646897a	SAMN05341186_T	5836c294-187d-4a17-96da-e1ee309ab854	OSCC_37_T	195cd133-0d53-402d-b31c-3d4fe0481858	OSCC_37	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
bd7fb4b4-6428-40d1-a395-b75327798290	SAMN05341220_T	e4daf91c-b701-4e31-8922-7ca23fc0ea57	OSCC_58_T	ff5a631f-93b9-486e-beb9-d16737db8c9e	OSCC_58	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
784547d0-0a9b-4225-b740-96dfcc3d6e71	SAMN05341197_T	3f20aed6-bf3f-4265-829b-80348e501c81	OSCC_44_T	9548db2a-702d-46a0-8d02-bfdc497bdca8	OSCC_44	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
57dbdb79-1d17-456b-b890-3e5220573575	SAMN05341189_T	6ae86730-dda1-43a0-90ec-ddec4d467846	OSCC_40_T	df6bef95-c233-4b10-b321-36ef4e79b5d4	OSCC_40	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
003503c8-b0c7-4dd4-ad3d-451b7afaf54b	SAMN05341225_T	2bf29ef7-d9ec-41ee-be40-63832fc081c0	OSCC_63_T	b2a945e3-e5cb-47d3-b74c-8bbf03fd33f2	OSCC_63	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f84465d7-46ef-4353-8891-e8ddf17b7e9f	SAMN05341195_N	1fbd56b5-807b-427b-8328-49a1715f6568	OSCC_43_N	4c848c55-2c7e-4d32-9a17-b2531a18a19a	OSCC_43	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
030c9e59-35a2-447f-9217-fa3a52d527b0	SAMN05341220_N	bea8daca-7b9a-4aed-8448-747be0f898e2	OSCC_58_N	ff5a631f-93b9-486e-beb9-d16737db8c9e	OSCC_58	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
8081a01f-91f7-44cf-a80f-361c7053d85a	SAMN05341184_N	168a3751-fd92-4f33-a71f-86873aba0085	OSCC_35_N	482dd5ba-9c50-4ee3-a3f2-3bb0ad6487dc	OSCC_35	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d8de4861-8b36-46c6-80b9-868b27ab0f1f	SAMN05341194_N	82fc8d50-9fe3-41d5-beeb-a094e13c8b67	OSCC_42_N	7e16a4fa-3063-4ead-95e5-922f2cce6fac	OSCC_42	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
38404eb4-20a6-4c14-9eda-88b868095c04	SAMN05341176_N	b6ecae8d-08a9-44e3-ac70-51331be42e55	OSCC_25_N	0e943de7-c277-48f2-8fa9-b2e836b03c2c	OSCC_25	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
49120058-8500-427c-975b-448defb97aef	SAMN05341183_N	93bb269e-55ae-4dd0-97ef-4c4aea7583ba	OSCC_32_N	7c02730b-5240-41ae-88b3-3f4e4514aa21	OSCC_32	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
fbdec9de-4c15-4257-9138-99e699968b9c	SAMN05341195_T	485ec393-b13a-4b0e-80af-eea41c690f8e	OSCC_43_T	4c848c55-2c7e-4d32-9a17-b2531a18a19a	OSCC_43	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
80850b66-96ba-4fec-a16d-348f22342456	SAMN05341161_T	cdb9ec65-b4e4-4648-a86d-88f91de559c6	OSCC_10_T	8782e6f7-d072-4107-8688-2289d001557a	OSCC_10	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
c11c8876-4eab-4e21-81cf-416ee91f1a2d	SAMN05341212_N	4debd1e2-e277-4b51-a068-ed33c30046d3	OSCC_49_N	71ebb445-ec2c-4ee1-aeaa-9cf30bb3bfff	OSCC_49	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e06c07bf-12fd-418f-b3f0-501c2c765b5a	SAMN05341173_T	d4a2684e-4979-4e88-91c4-a465427b1efb	OSCC_21_T	37ea85c2-5e02-4d7c-846a-7cd40ef1912d	OSCC_21	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d4376c2e-3993-456d-b37d-107c0919af3f	SAMN05341188_T	75383dbb-f784-4364-ae42-453dd65ba8e4	OSCC_39_T	3195cf36-998a-4f48-a7f1-a84f2b9fdcc5	OSCC_39	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
a4a085a3-2cff-4262-81ed-452b29a48544	SAMN05341172_N	259de38e-ff5a-483e-984a-039ff34a4e92	OSCC_19_N	96fdbd9a-c9a5-4db9-8e0d-6ea200f975db	OSCC_19	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
099d2282-ede7-4a35-92c9-a0ee91f61666	SAMN05341172_T	25b6989a-c23b-49c1-b169-372f142d7925	OSCC_19_T	96fdbd9a-c9a5-4db9-8e0d-6ea200f975db	OSCC_19	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1f80738d-3540-4cd8-a51a-92e4db5f9d9d	SAMN05341185_T	b9ab27c9-a1ac-4873-abc6-5edc0c20f623	OSCC_36_T	6e4c8397-715c-4dc5-8782-2437ff207241	OSCC_36	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
cd0f0f7e-7486-4df8-a719-71ae49806688	SAMN05341161_N	587cc557-a328-4b31-bab3-42b0d15d56c1	OSCC_10_N	8782e6f7-d072-4107-8688-2289d001557a	OSCC_10	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ca0ba7dd-f025-4d51-aaa4-64db08331d85	SAMN05341186_N	a0b938d5-2cd5-4dbb-bb2a-d063cb6aceab	OSCC_37_N	195cd133-0d53-402d-b31c-3d4fe0481858	OSCC_37	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7e1c1004-8150-4434-a762-63c0a13a1f91	SAMN05341176_T	ddbbffc9-9788-4f5e-949f-1a13a22ae0be	OSCC_25_T	0e943de7-c277-48f2-8fa9-b2e836b03c2c	OSCC_25	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d7e35922-ba04-4912-a24c-2477ffdc609c	SAMN05340949_T	309a2bc8-64f7-4476-9ded-7f4ef3b56868	OSCC_01_T	59448f1d-6be8-466f-bb1a-1a3aef693d4f	OSCC_01	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1df6c75c-c2bf-449d-bdf7-28c534a3cbb6	SAMN05341226_N	c999b871-d3bd-4a58-8070-c92c2ed48621	OSCC_64_N	8369a540-474e-4b9b-8f2b-f96153ac8bfe	OSCC_64	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
39cd4c87-01f7-4908-a9aa-eddac904b0fa	SAMN05341222_N	d12477a4-687d-4bfc-959a-9bac19c3f551	OSCC_61_N	5e99d311-24f2-4ee5-abfe-c9d40771e8e3	OSCC_61	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9d1789f8-d629-48ce-a9eb-cf20d4f2939c	SAMN05341205_N	c95750b7-ef96-4f6c-a0ae-e0ba4735414e	OSCC_47_N	e11e9155-4ac6-43dc-b8e5-1be822cd2dab	OSCC_47	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
dbdbfc4d-611d-4d1c-a244-a6a9f35a6a8f	SAMN05341178_T	8967db82-c17a-4930-bcfb-f0ec48451493	OSCC_28_T	8ac42bc3-472d-42e8-8455-09528a9977ea	OSCC_28	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
88d60288-4b00-486b-a925-39fb07459626	SAMN05341166_N	c28ff0e8-87d0-4fae-b7a4-c3b420039b37	OSCC_14_N	4633e71f-5fbe-49b0-9721-9769182a08eb	OSCC_14	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
333e24c9-ec45-4f7f-8acf-6ced428af8d0	SAMN05341155_N	37d52145-52cc-40f9-8d6e-e13f3d1ed2f4	OSCC_06_N	1df726a4-8520-4474-8c00-d238a7384be1	OSCC_06	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9b76d349-6ac8-4071-a124-c1f7f73fe401	SAMN05340949_N	4279459e-ff6f-4143-b7d3-2212c91e8179	OSCC_01_N	59448f1d-6be8-466f-bb1a-1a3aef693d4f	OSCC_01	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
15218d5b-fc40-4cdf-b8b9-b9c89c4af2d2	SAMN05341175_N	4dc515ba-6525-4619-8d57-520cc25f572e	OSCC_23_N	1104505a-9890-49ce-8d7d-7a8070261324	OSCC_23	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f8c04a19-06e8-4d17-929e-1f6a141a9223	SAMN05341210_N	1fd1cc2c-73e1-4087-8387-aa8bf44b45b5	OSCC_48_N	ca087e3a-9e96-48e3-a28d-10bfaa39bcf1	OSCC_48	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
3fe18885-8f27-490c-80f8-f78ed61e67bb	SAMN05341219_N	b86bf2ab-25b3-43f1-94c4-4c0c4e1240e9	OSCC_57_N	82b7bff1-63d8-47f3-8520-bee0c1b6b14e	OSCC_57	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
bbcbdf5d-250e-427d-8597-4a8bf135d04c	SAMN05341205_T	fe9556eb-1ad4-45b6-b78f-dd29cca9ed20	OSCC_47_T	e11e9155-4ac6-43dc-b8e5-1be822cd2dab	OSCC_47	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
c8fc9a87-4c64-4232-90e8-fa8b07dadaff	SAMN05340966_T	e25c6504-b430-4419-9c72-39d0a37ab78b	OSCC_04_T	9bad78c0-6cb9-45bf-85e8-86cffe0b96fc	OSCC_04	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
0007077d-2dbc-4df0-bb23-c59df19704b0	SAMN05341184_T	4fc7835d-7cf4-48eb-85c7-56c401d3194e	OSCC_35_T	482dd5ba-9c50-4ee3-a3f2-3bb0ad6487dc	OSCC_35	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
81399329-70b5-4265-a580-762d125345be	SAMN05340966_N	c9995f85-b7c8-4397-b43c-63ab923ecd87	OSCC_04_N	9bad78c0-6cb9-45bf-85e8-86cffe0b96fc	OSCC_04	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
57d2eab6-df58-47d9-8e7b-a836ad1b4d57	SAMN05341224_T	d46ac04c-fa07-4b95-9036-c85303548a2a	OSCC_62_T	58355fa4-e2ad-434b-a915-acbd09abbb77	OSCC_62	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1fcec2f5-17c4-4f15-9395-aa4c10c1d827	SAMN05341199_T	3ebd62c9-5402-4d50-97eb-fc6a20e0ab43	OSCC_45_T	b9c7c8c2-271c-4eae-87f2-19a89b1ac58f	OSCC_45	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
4059003c-b576-4d83-b02c-d6735180285a	SAMN05341187_N	2fee1b7b-3c77-41e5-9bfe-f46e224a629a	OSCC_38_N	f581075d-1b69-4812-9fe4-2bde4aad8bf2	OSCC_38	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
3cb156fc-02cc-451a-b785-2b30bea569f0	SAMN05341165_T	e65dfd5a-86d6-4f54-bc0d-bd60c86a7d9b	OSCC_13_T	0232701d-6d00-440c-af6c-5899fbbf4142	OSCC_13	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
92f7d383-24aa-4b8e-9174-2b085345a3f3	SAMN05341212_T	bf58134f-46d8-49e2-99ff-395d7d6fac93	OSCC_49_T	71ebb445-ec2c-4ee1-aeaa-9cf30bb3bfff	OSCC_49	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
4c90700d-1130-4afd-bd7c-ea1b930b59fa	SAMN05341218_T	dcc22b0d-0018-4601-b8ba-bbeab30ab624	OSCC_56_T	ea7c9fbd-8353-4f3c-9fea-2fba79140536	OSCC_56	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7d9b27e6-3d9e-4a74-a65f-cc191e9cef05	SAMN05341221_N	108c405d-dda1-49e5-b0fa-2934997ab448	OSCC_59_N	3f8aba34-9229-4701-bd5d-869b3705d4a6	OSCC_59	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
426a2696-f073-4a0e-bdcc-af62328b5d6d	SAMN05341165_N	d58e2a88-8b0c-4cc4-bb1a-e7734ad58209	OSCC_13_N	0232701d-6d00-440c-af6c-5899fbbf4142	OSCC_13	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7e72d9a9-d4bb-4d56-9d14-09c406b9f777	SAMN05341190_T	cc407168-acf8-4123-a7a7-e6b178d60cad	OSCC_41_T	2b4204ab-87af-4a79-913f-fabdcb2d02b4	OSCC_41	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
dd9c3983-f923-4b0f-a84f-c815d048c62c	SAMN05341226_T	a14d3203-d84e-4b53-8a69-9c779f82e82f	OSCC_64_T	8369a540-474e-4b9b-8f2b-f96153ac8bfe	OSCC_64	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e96314cf-abd8-4b41-9961-7b367405f1b3	SAMN05341155_T	4fc0fa56-50cd-42de-94cf-67a2f512ed3e	OSCC_06_T	1df726a4-8520-4474-8c00-d238a7384be1	OSCC_06	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ae8b1022-80ce-4cd3-83f4-0c965546db94	SAMN05341173_N	86eaabba-4815-4768-8bf0-de382a14f780	OSCC_21_N	37ea85c2-5e02-4d7c-846a-7cd40ef1912d	OSCC_21	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
76591537-4e5e-44f1-a417-3df935082a4c	SAMN05341197_N	cda2c235-7673-482a-b35c-5089a08f91ec	OSCC_44_N	9548db2a-702d-46a0-8d02-bfdc497bdca8	OSCC_44	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9d5ce9c1-518e-4e76-a7c5-1634a3e2291f	SAMN05341225_N	793b9aaf-9d6a-4af4-aa4a-ec6d5882d0b1	OSCC_63_N	b2a945e3-e5cb-47d3-b74c-8bbf03fd33f2	OSCC_63	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
37ad0fb3-6971-4113-9294-ecff0f35c997	SAMN05341213_T	b580b54a-1dd6-4ad1-910a-b2d581ff2787	OSCC_50_T	c7a90e98-6f13-4480-8f69-74eea9e6efa6	OSCC_50	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
2b5f9884-c169-413c-af8b-06707acdb031	SAMN05341194_T	27276f1e-3665-4553-a0e6-03870e749ad2	OSCC_42_T	7e16a4fa-3063-4ead-95e5-922f2cce6fac	OSCC_42	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
472e7e51-9788-492c-b6b7-a2aab72566b7	SAMN05341185_N	1ed72838-8ce8-4e7e-91e4-0930747d12c3	OSCC_36_N	6e4c8397-715c-4dc5-8782-2437ff207241	OSCC_36	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
512b5a1a-a376-40c7-93f4-e00b3c8844c2	SAMN05341188_N	87356cc6-6e50-4d47-ac12-b13db10b33f8	OSCC_39_N	3195cf36-998a-4f48-a7f1-a84f2b9fdcc5	OSCC_39	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
97660f1b-44fc-4b41-be6c-5937888aa84b	SAMN05341183_T	0362992b-cc5b-4e58-b9c2-92df71f69e7b	OSCC_32_T	7c02730b-5240-41ae-88b3-3f4e4514aa21	OSCC_32	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
53c412d7-0f8d-4208-9e86-ccefab23a2ec	SAMN05341174_T	59d9977a-59c2-465c-88f5-1d69596aedca	OSCC_22_T	b5988f8a-f71d-43f8-9474-51a8974e0bf7	OSCC_22	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
08c1afd8-bdfe-48ef-9880-e873926a4f30	SAMN05341174_N	0872aa6f-e1e3-422f-9053-fce8a315b9ea	OSCC_22_N	b5988f8a-f71d-43f8-9474-51a8974e0bf7	OSCC_22	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
6dff130f-6882-4887-aa3f-e33100d2188f	SAMN05341219_T	14b7f7dd-1ace-4a9a-920b-0c5697f070f5	OSCC_57_T	82b7bff1-63d8-47f3-8520-bee0c1b6b14e	OSCC_57	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
21c1898f-b0c6-4123-84f3-9d8d954968e5	SAMN05341199_N	caa6a64e-b4f4-4fed-a980-ce3fc0ebc20e	OSCC_45_N	b9c7c8c2-271c-4eae-87f2-19a89b1ac58f	OSCC_45	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
fd197789-bb9e-4a78-b238-f1d5593a21b3	SAMN05341214_N	f403e032-4754-4749-9337-a3118ab49da0	OSCC_51_N	ced7d55d-fcb5-4b4a-8ba2-aaca18b958d7	OSCC_51	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
2b80c888-ff89-4a54-a831-6ca5d8a83e8f	SAMN05341202_T	0380c374-1346-41bc-937f-1ab9a222c556	OSCC_46_T	d5b43f05-8489-44b4-8b3c-81a428f17fbd	OSCC_46	Oral Squamous Cell Carcinoma - Chang Gung University	Primary Tumor	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1a0b4513-3177-4f6b-af84-c4711f5a2f04	SAMN05341202_N	5303128f-5504-4b52-8d13-37818541fde4	OSCC_46_N	d5b43f05-8489-44b4-8b3c-81a428f17fbd	OSCC_46	Oral Squamous Cell Carcinoma - Chang Gung University	Solid Tissue Normal	Head and Neck	Oral Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
0ea3763a-cd8d-4f0a-b6fa-125b446a8b35	CPT0204020003	4412f91e-2e7a-49e4-b7b4-9343a7cb2d45	C3N-00721-06	89b98008-bc22-4bcb-9869-e67edbc0e272	C3N-00721	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db6501fa-7983-4067-b9b5-f048456a5a8f	CPT0161840003	6dcc45a1-05d8-4d90-b659-1a1b21b5baf1	C3L-02556-06	cfc5cdbe-604a-4546-9f51-d277a8da8237	C3L-02556	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
46b3088d-6e9b-4967-8ab0-124b99496e34	CPT0124170003	16205cf0-a332-4a7a-aea6-8e0ad53ea5ba	C3N-01657-02	03b220ed-d7f9-4873-aa29-f038107198e7	C3N-01657	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d790f4b3-8896-495a-9296-91348bb9256e	CPT0102280003	42b2e552-d715-4cb1-a746-0b2fa13f8d8e	C3L-00970-07	dec06ee9-6531-4bf0-b9e3-495f84f6de41	C3L-00970	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da8fb2ea-4bb9-41e9-be43-9702961ea70c	CPT0123030003	3b4c1ffb-8d83-4eb5-9178-a84a71bd97a8	C3L-00991-06	d4ab7ec5-327f-4e42-9096-7d8e012cf215	C3L-00991	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6be16b2c-68bd-4ef8-8d4c-fbbb29d1be2b	CPT0112490003	70705f57-dc97-46d0-bff8-711d6058c035	C3L-02346-06	7bae6951-e412-49b7-8a98-4241956c874c	C3L-02346	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c9de0084-56b9-45e7-85ad-329c4d22c6c5	CPT0147300003	f00ae03b-2b19-4346-955e-7bb21c1ca350	C3N-02429-03	03d0deb3-78fe-4c6b-b34f-984e2cfb5e33	C3N-02429	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
12c45e6d-8920-4232-94bd-1fc0858dac9e	CPT0188850003	bc973b43-455c-4d8a-a980-51a521872f81	C3N-02264-01	b28a9345-4e6f-46e9-8e21-10afd81fb12c	C3N-02264	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb5680cc-9884-4223-9c2d-017d4ab0d83d	CPT0122670003	247e30a4-cce7-493f-9ee1-58e70510607b	C3L-00980-06	5d3eca31-7a37-4db9-b5ed-67b49099a6cb	C3L-00980	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa0d743e-e9c3-4818-a089-db5d82013bf7	CPT0113120003	730867c3-d9f2-4b6a-9865-d9e05b17517e	C3L-02544-01	34eda8e1-69d9-4e62-8350-95337f1cb0c7	C3L-02544	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d4cfaa1-2628-4557-b56a-fe4f12b9cf52	CPT0161930003	34241bd6-5b36-408a-91b0-8abc0b5f0d47	C3N-01656-07	44635ad8-58ca-4adc-8ab0-92ca00ba8dde	C3N-01656	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8c541f7f-b9a6-436d-baae-a344dd3e01c9	CPT0109500003	0948a886-aa90-44bd-a2a2-9d7f276b0dca	C3L-01976-01	7bceea7a-6a39-4b5a-a2bd-c97128df85c7	C3L-01976	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3872d7e2-b98b-485f-99f9-4aa89265635b	CPT0214120003	f0a983f9-8505-49fc-809a-a4f399f7168a	C3N-02224-02	38dc2806-482f-4f76-b453-b3db91e4b6be	C3N-02224	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
861eee69-558c-4335-8fcc-a0569d23cc57	CPT0110070003	079bb145-7708-460b-a8d6-7edd4beae32e	C3N-02085-03	4a0b2e2d-bdeb-4c03-9388-57bba5735505	C3N-02085	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae37ccbe-1b84-4064-a127-be769ef29827	CPT0183570003	258048e5-7608-4df2-b238-7131653bd9a7	C3N-02577-03	516ca172-b609-4b5d-87e1-044ff22bc59d	C3N-02577	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
61f5b7f2-2401-4845-848d-d885cf739299	CPT0124300003	14d33d6d-55f6-4b77-824e-3c57af9b5d2d	C3N-01905-09	c6b87349-293d-40c9-9f30-3d267681c0d1	C3N-01905	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9924784c-8761-4140-babf-29d3582855ce	CPT0113280003	bff05825-f311-4e1b-81d5-5cd1a901b19b	C3L-02364-06	72acdfce-342d-44e5-b7c0-c588f4690a83	C3L-02364	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b2896395-154e-4fa0-bcd5-5ac31fcc18bf	CPT0096890003	149ac83c-5c35-4fd6-8011-74cfbd79587f	C3N-01536-03	10fae524-2581-4ae5-97fa-7a677fe942dd	C3N-01536	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aacb5b6e-0bc9-445c-815c-eeff2fbb79c2	CPT0104250003	508ba312-c1dd-4c9c-8c08-c0dc381a30eb	C3L-01869-02	5522c20e-841e-49eb-ae4b-de17b19a66db	C3L-01869	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c1a44880-5318-4fac-a555-121dfad80de3	CPT0158980003	326d7b2e-cc86-49f2-99c7-79b533b0f8d8	C3N-02945-06	10e97ad4-5464-4ed2-9b16-554f8714f41b	C3N-02945	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a1278a5e-31ab-4ce0-a9b0-fda62be0207c	CPT0135770003	a87d9621-785d-46ed-ba4b-2fca1c39855a	C3N-02332-06	2956fdfc-5bc2-4446-84a0-20092b07a792	C3N-02332	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba529881-54a0-441a-842b-07581f9e703d	CPT0109790003	d84783af-f10c-496c-8f09-65577c44209c	C3N-02005-03	af12abd4-d315-4bc6-b8be-cc4308cd0105	C3N-02005	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
85d34e3a-31fd-4394-9053-36222e4baff8	CPT0170170003	151ec2e1-7e3d-4f13-8f87-110f6ff26085	C3L-01034-05	e58a8242-3535-49f4-b083-9914c933088d	C3L-01034	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dd7e5715-d7cf-45ea-bd51-9fceb8f33644	CPT0203930003	1d1e006e-57c0-4c45-b5ef-c86328ebc5c2	C3N-00715-01	664c0023-23cd-4e55-82e6-4359d6696891	C3N-00715	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8504bae3-2f92-4fab-88a9-5b0d4a21c3e8	CPT0102010003	73ea2798-3727-4d8a-894f-f0eed0ee75bd	C3L-00969-01	7327f919-d75e-4992-842f-4e0ab63fce69	C3L-00969	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e81b400e-0ba9-4bd4-93c5-4c6313412f81	CPT0188950003	6c97240e-1cb4-413d-b0be-959118a94cd3	C3N-02266-01	91c6ea62-dddf-4812-811a-38d4bbad7c56	C3N-02266	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5566423f-240f-485a-8ee4-da3de0a36c39	CPT0203410003	62398d76-7ae7-4eb3-aac5-8006c03dba24	C3L-02857-01	8b92398f-b166-45c1-bf1c-aae152b7bd77	C3L-02857	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
654f5f62-b3c8-4e3c-b2a8-329a6d8e9109	C3N-02015-06	612a5154-f250-46a8-b331-2017e2bb1437	C3N-02015-06	35f2b9d8-4422-4c8e-91ad-a71959dc3726	C3N-02015	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
900f9a1d-de69-4954-a020-0850e7b636f9	CPT0210440003	4644b125-3f37-4a12-9aee-fe87556be051	C3N-00647-06	1086ba40-2dfc-4828-8b5b-ded36a4b2176	C3N-00647	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4824290c-a00c-4d08-ac30-f088379f63fa	CPT0085910003	7438fbac-5f5a-4e6f-8a4a-35e91de4b689	C3L-01462-01	b39822b8-075d-48f2-9495-f59a3ed3cfbd	C3L-01462	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3f9ef65d-5c06-4f59-bccc-09c135bbbf56	CPT0100370003	94879735-7edb-48da-8ea4-2469e82cc1b3	C3L-01958-01	8ce33989-c9f0-4164-b06b-f50d5012bce5	C3L-01958	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
171ce063-e907-43d5-abe9-1146eeea6702	CPT0086350003	02b234f1-e4d8-4662-8f0c-8839d3dd4c64	C3L-00908-01	ee6b0cb5-1fb8-11e9-b7f8-0a80fada099c	C3L-00908	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3c0e975a-3a28-4462-abd7-79daafe3fc63	CPT0158390003	753c2905-ae37-4a26-bb50-513635afabd9	C3N-02811-02	3645cf95-3be4-4b1f-828a-0e65e8c098e6	C3N-02811	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ab71d2f3-70e4-48b3-937c-5b5165de44bb	CPT0104450003	e7da8f1a-9399-4cca-92e8-1a5effffa85f	C3L-02352-06	13012ed3-ed29-41ab-8733-973140233700	C3L-02352	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59a65788-53a5-42d2-bc57-54325d7c086f	CPT0170150003	56cc18e5-d517-459f-a998-f1bc783d29e6	C3L-01034-02	e58a8242-3535-49f4-b083-9914c933088d	C3L-01034	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9c534451-2ac8-4ffc-af54-88eec5c95e0b	CPT0204010003	93817585-81e0-4dde-89b5-769b2dcad451	C3N-00721-01	89b98008-bc22-4bcb-9869-e67edbc0e272	C3N-00721	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
421ae42a-55ac-4a36-a4de-5b61eb1c8b65	CPT0128220003	ceea6451-46ae-4645-9d94-c2366dba7865	C3L-01107-07	93f75337-fc67-4033-a03d-3d405759082c	C3L-01107	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d8377250-0df6-45dc-931b-47e91cd8ab2d	CPT0127560003	f75bf267-9e27-46c0-9b04-53af3050c826	C3L-01106-06	1a1f506d-b1ca-4117-aaad-ff410f915dd3	C3L-01106	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01f0253e-5235-403e-86ee-cdc45a1f8bdf	CPT0211880003	3b57d3a3-bb70-4e9a-80ca-be83c150675c	C3N-01083-06	e7c0a24c-0ec8-4e07-9517-b0449b5cb08c	C3N-01083	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b16930fe-3563-45d0-8d62-52ecd2b9743f	CPT0161540003	32f6489d-d559-4dc2-a947-4f81bc2bf1f3	C3L-02551-06	22b3e9f3-10db-4733-964a-6f607da5c63a	C3L-02551	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7c267a89-b20a-40a4-9f95-a1008d4d01e9	CPT0085790003	d14fc323-d28e-4eac-9791-e1ab36db61e8	C3L-01465-01	7d5f89fc-e0e0-494f-b250-44dfe5c93355	C3L-01465	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a6b68df3-d768-4114-bd08-212e89776614	CPT0109970003	c28ff05b-20ea-459b-8a78-273fd20ff7f5	C3N-02084-03	48c2f98b-4194-435b-938d-7a2f24b6a9b3	C3N-02084	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57c791e9-a835-4f5c-9480-84cba67fef90	CPT0172140003	5713dbf6-b893-4109-b736-a0f73cf0a49b	C3L-02841-02	fbc79ab1-bbfe-40bb-8854-3b3072cf53fc	C3L-02841	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9d7d65e6-7d2f-41bc-bac7-a9c26393b617	CPT0122730003	f2924a41-a4a4-4867-a43c-707ab63fdab8	C3L-00981-06	ca9dc6e8-2862-427d-bc6a-987ba71c8e83	C3L-00981	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
617967c6-71db-490c-9a9e-7bdd5ad65a5a	CPT0129170004	d92427ad-b855-4eea-9121-0ed32e20db18	"C3N-02248-72, C3N-02248-73"	8ef381bc-0db3-4fe7-93b9-752bca7ec2d0	C3N-02248	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6873c989-eafa-4137-8f7b-f719dc20e63e	CPT0203350003	50fee315-215d-4772-9a7d-ac9a34aceeef	C3L-02202-01	09b738d0-562a-4e08-aee6-593ec9aa99ca	C3L-02202	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ff51730e-523b-4cb2-91a1-2c847b55073a	CPT0113260003	321ea318-31ac-4c6e-92c6-f629225fd2e1	C3L-02364-01	72acdfce-342d-44e5-b7c0-c588f4690a83	C3L-02364	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4118f8c9-9f67-4563-98cd-676ff06e6580	CPT0210980003	7625b3fa-216d-4cde-aae8-1b4a534c94f0	C3N-01078-06	37c09d33-1e4f-4e11-929e-96345a433fff	C3N-01078	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
53a2c17a-469b-47bc-81e2-87cc3ffe991c	CPT0147280004	02131d77-ed32-4ed9-8ab3-5843e0b4f733	"C3N-02429-01, C3N-02429-02"	03d0deb3-78fe-4c6b-b34f-984e2cfb5e33	C3N-02429	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a3ae5942-339c-41af-9b12-a7e94a5c5f5d	CPT0188910003	9b3335cd-2a13-4cfd-b083-4f2f7627abb7	C3N-02265-05	c1a229cb-ff73-4461-87a0-ca58baa83078	C3N-02265	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
74a663b8-500a-48a7-b9c8-c37a07879bf5	CPT0129200003	75da35ff-54e9-495e-a9c7-9b53982e8484	C3N-02248-75	8ef381bc-0db3-4fe7-93b9-752bca7ec2d0	C3N-02248	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
28095552-a5f1-4320-bd43-44192eabde33	CPT0135740003	94e7eb2e-6204-4fc3-9d92-6b3f5c27b60f	C3N-02332-01	2956fdfc-5bc2-4446-84a0-20092b07a792	C3N-02332	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3b8c2308-2c31-4e76-9bd3-3d75138d9a2b	CPT0115710003	1a5ab346-a413-481d-b589-1950238a12cd	C3N-01806-06	8aacec66-59fa-4070-9929-b908284c504d	C3N-01806	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
662bfa89-c4ab-4d9b-abba-9ffd5f77f533	CPT0161790003	894f2f8e-8b50-40c0-81cd-ddec19812adc	C3L-02553-01	f35f1a07-ac40-4e9b-9260-bc555c01b4d5	C3L-02553	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8279fbbb-e57d-4582-abe7-26920aab7694	CPT0109910003	30b93aa3-dd5f-4e3c-af6e-b01fa99ad7a4	C3N-02070-03	31659499-6500-4dbb-8fcd-8abaeebd2211	C3N-02070	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f906866-429b-4b7e-8c3a-fa5fc5c0db78	CPT0172130003	ffd18a36-8ba1-4bc5-baff-ba3169f3b88c	C3L-02841-01	fbc79ab1-bbfe-40bb-8854-3b3072cf53fc	C3L-02841	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9ab2954d-400d-4847-a615-044f84173ad3	CPT0188990003	dff24d8c-1494-44fd-94ec-c6ad2ca63311	C3N-03018-06	957b07d7-77f3-4753-a873-2bb00948b4f0	C3N-03018	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a862960-0d3c-4270-a86d-1241ccb9d495	CPT0127920003	4be0893e-c8df-41a7-9d2a-88247212ddac	C3L-02214-01	8c2522ce-85ac-4ea8-b65e-f899c3f8434f	C3L-02214	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d27f3950-1f0c-4d51-84f8-e49f534dc3b7	CPT0109940003	51aa06c6-a87b-40d4-977e-a14a07082243	C3N-02082-03	9fbb232c-c471-4953-8ffd-fd4bddcf480e	C3N-02082	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
808da586-1e4d-45cf-aea8-dd4fa6d17d09	CPT0093020003	a0deb53f-f725-4835-9be1-0d85d763b239	C3L-01929-01	45439896-b780-4b9e-a517-95dfb6994adb	C3L-01929	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
77983d52-a918-45bf-98f2-d8bed4a1fefb	CPT0127860003	130ed9b0-3e57-4136-b59e-8c57ecaf2408	C3L-02211-01	1b2350ca-cd83-4fa7-8b67-08723698df89	C3L-02211	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df2f0b8c-38d4-46b2-932d-9d6deee0a924	CPT0110740003	cb2385c6-3b69-4c50-aac6-ab66cd066ac3	C3L-01681-01	a55164b4-5970-4737-8947-968a9fb766e0	C3L-01681	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7360ffa7-b554-4227-a435-bbc8989f35e5	CPT0121610003	52ec008d-bf92-4952-8cb3-15fa62544f9b	C3N-01656-01	44635ad8-58ca-4adc-8ab0-92ca00ba8dde	C3N-01656	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7814f713-6f70-4848-90e6-cde7019e0208	CPT0158410003	9bef8133-1968-49f6-b231-9398826578df	C3N-02811-06	3645cf95-3be4-4b1f-828a-0e65e8c098e6	C3N-02811	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e990e76f-d8dc-4e5f-801a-c596353c58b0	CPT0186410003	4bb32241-7553-4b82-8099-905f05b724fc	C3L-00165-06	719aeb75-fc2f-490a-a89b-556b18788d61	C3L-00165	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c0195e59-e801-4b69-83ba-dcbaae7f3f40	CPT0115350003	b0ebdbde-133f-4392-ae0f-6a83b6a58d50	C3N-02015-01	35f2b9d8-4422-4c8e-91ad-a71959dc3726	C3N-02015	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
461885b5-3c15-4eb3-9345-aa421daab70f	CPT0172660004	404e8284-5ddc-4cfe-a48a-dc39a081e4d6	"C3L-01676-06, C3L-01676-07"	1f79bdee-1e11-4750-9f08-a0ba6523133e	C3L-01676	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2508f6ab-6389-43d2-8b87-1f6ebe116514	CPT0186400003	3a34ebac-c49d-4d87-9b21-42498ee0fd7e	C3L-00165-05	719aeb75-fc2f-490a-a89b-556b18788d61	C3L-00165	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6dfed1be-5f45-405b-b82d-3024d6e15111	CPT0212940003	7c49a018-fde2-4453-874c-65cf21b04f6a	C3N-01091-06	e5d39201-72d3-4911-9077-bb15eee72e33	C3N-01091	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cbae1e30-2278-4d06-9161-818448424652	CPT0169530003	98e7619b-97c5-43be-860f-0c585acc6943	C3L-00976-03	309801a3-3169-4987-9aef-47f25005eca6	C3L-00976	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b9aff4c8-dcc2-4568-84c2-90257dc410ca	CPT0097850003	266a6305-2eb9-4d38-b0b5-9c92a80227c0	C3N-01828-01	7bdc92f8-8b6c-4635-b8be-ad14726425e3	C3N-01828	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
15008079-3c31-43fb-ab7e-b20b19efc44a	CPT0122990003	9fb8dde1-3d29-42b5-a76e-61732b510d58	C3L-00991-01	d4ab7ec5-327f-4e42-9096-7d8e012cf215	C3L-00991	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a38441d-f2c2-466a-a9b5-804d76948167	CPT0158690003	0bb1ea6f-8f34-4e18-955e-efd160922be1	C3N-02439-07	109080ea-8c45-4b76-9311-51115576b110	C3N-02439	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f9652a46-ddc0-4aab-b5fa-ac529c90219d	CPT0188180003	90a10726-a4ac-403e-8a38-2d2f06d8df91	C3N-02263-01	40453a62-6664-42fc-ba26-f624589b36e5	C3N-02263	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
31a4f700-85be-47fc-afe9-420a4f527d16	CPT0127870003	9f30b5b1-b5ec-4eab-883d-b0742f0753cd	C3L-02211-02	1b2350ca-cd83-4fa7-8b67-08723698df89	C3L-02211	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e767159a-326e-4518-846c-e33bb26c50b8	CPT0101710003	0912fb9c-3f83-4325-a4fa-187c55b93478	C3L-00968-04	4791e768-de1f-4f46-bf3b-96e9bf402c07	C3L-00968	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48075eae-d6ed-4b85-8eef-be065aa9a9cf	CPT0109920004	edc8f73a-f8fe-47d6-88ad-47b5a78dc469	"C3N-02082-02, C3N-02082-01"	9fbb232c-c471-4953-8ffd-fd4bddcf480e	C3N-02082	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
31a50e2b-f416-4d63-a4d3-3ae110566132	CPT0170080003	1d35945c-e159-4b13-b695-2390ed8a6069	C3L-01033-05	83676156-7486-49c6-bc34-20dc924eb0d7	C3L-01033	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bf1ded0e-6dd6-4210-ac1c-0c66d7fe8046	CPT0102240003	2abf3518-fc91-435c-b23c-e2ff217c4fb1	C3L-00970-03	dec06ee9-6531-4bf0-b9e3-495f84f6de41	C3L-00970	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d1487704-e030-4672-a020-fc75c78f17fb	CPT0212780003	a3bdbb59-789a-4714-ab54-644d39bc875b	C3N-01090-06	0e55cd78-015f-4747-8163-1f20cf20a434	C3N-01090	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b02d5653-85a7-4308-bc4c-63b2b5e4bf89	CPT0124070003	e66910ec-0b9a-4a04-a69b-756d98aba986	"C3L-01102-01, C3L-01102-03"	80ad75c2-57a9-4ba1-997f-abdd7817a585	C3L-01102	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c1c85623-ab89-4373-b3fe-eb6639d89fda	CPT0183360004	d0bf71a1-9e07-4b0e-a9c4-30f58a49f62b	"C3N-02431-02, C3N-02431-03"	f61365bc-8ba9-4de8-9c11-368e75d272ba	C3N-02431	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b4e79f9-70cc-4d15-ba8f-1edc5b8c59cc	CPT0211320003	c5384b76-87b7-42e9-b4dd-74e199d1d185	C3N-01080-03	5c1beb3a-88ba-474f-94b4-0efe617d451b	C3N-01080	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7b646147-e301-4468-a0fb-d7523018c88f	CPT0134660003	d27c2b8b-d44d-4b62-9e8c-73f8e094e672	C3N-02063-01	e8e42739-58ce-4e65-afe2-1d6e948ae103	C3N-02063	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4d767abe-56b3-4b9a-af1c-35ae141d2e7c	CPT0125660003	d46b227f-4673-4ec8-9d9d-5162e63e694d	C3L-01978-05	de1f0e2a-972d-44dd-b988-b218b42fd20a	C3L-01978	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a7236f6e-0064-4846-942d-541e31de76ed	CPT0100470003	f0fe38e6-29b4-4f79-89ce-797f321e0a90	C3L-02176-01	d770baff-a23c-4de2-a152-6e78200df061	C3L-02176	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
23fea07d-e49b-4fab-90ec-8141367c02df	CPT0127800003	a294b222-6480-4b59-9a88-f2f7d657f9db	C3L-02201-01	f3c29dab-039e-4ead-b074-a75d30dd4a36	C3L-02201	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a97ba3e-9e8e-4974-8430-e393c9b9056d	CPT0176400003	5755ac47-efae-4913-918d-b16c4cd6d98e	C3N-02726-01	52005a80-e7c0-47a1-9607-18538ff0b267	C3N-02726	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ca0f5b5b-9b68-492c-83db-24f00514a5c9	CPT0100320003	ab7ea0b6-6dc9-473c-8f1f-17ba8a3d3301	C3L-01963-01	439d3376-3ac9-4698-893a-63bee91c9f94	C3L-01963	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4de9c72b-23d4-4223-9033-6ecddda3c867	CPT0085850003	43f81286-05e8-4f10-b7d2-11ec60ab099f	C3L-01464-01	1b069720-0562-4840-b45e-1c7aa11e5dc3	C3L-01464	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f0bd9c8-1960-4bff-b452-168366a21dcb	CPT0188140003	e9f5f462-5a80-4556-b59f-382256962888	C3N-02262-02	2d93f181-de35-4553-978a-ac868cf40322	C3N-02262	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e9e8c25b-1537-4fcb-a368-9fa9e47a1f9b	CPT0210800003	481e3eef-261c-4cd0-a7a8-d38e0dad9a64	C3N-01077-06	cd1b1b0f-8641-4e2f-bc83-26c377c14e30	C3N-01077	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c16c0103-6e82-4a72-a035-3db7143a2a55	CPT0172020003	303c983a-b8aa-48b5-b770-b973b1311ab3	C3L-02856-02	f554b94d-dc6a-4d43-82c6-365a3a69570c	C3L-02856	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
054f1a53-8f9b-496b-adc1-d39e1c0c556a	CPT0112240004	cb83ddcb-4ea6-4af4-8aca-97b0d4824b0b	"C3N-01989-03, C3N-01989-04"	0761408b-d4b6-419a-a474-2ce5351a2e4a	C3N-01989	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4556bcb8-bf0f-44db-ac0a-336919db86fd	CPT0183350003	911d4f9e-5bf6-4fc8-bf8c-e42fdda709f5	C3N-02431-01	f61365bc-8ba9-4de8-9c11-368e75d272ba	C3N-02431	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c125b0fe-0766-4edf-bb40-409bbca86c6b	CPT0104500003	82690871-e87c-4886-ad88-32096f20fe5c	C3L-01665-03	fa05727b-01b1-48c3-9b1d-93d2a1cc0cef	C3L-01665	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fc58bb4c-a1d5-4f70-abd0-aef04743194f	CPT0124160003	6fe48a1c-4e3b-46f5-9d5b-8ded5ac0e5d6	C3L-00982-01	05207fb4-ba30-4fc2-ad21-e5610ead7b89	C3L-00982	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0847ba64-587f-4c14-8893-1c4b89c978d3	CPT0104550003	0fc6668f-aa14-4dda-a82a-ffbd20e38fea	C3L-02220-01	24f12372-b37a-4967-a9c0-ab237940a959	C3L-02220	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
52ffd96b-4c65-488b-b742-237c26b41248	CPT0104580003	00235d67-33b9-4a8a-bc0b-6358702619d2	C3L-02220-06	24f12372-b37a-4967-a9c0-ab237940a959	C3L-02220	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8fa8fe9d-11ec-49a8-abae-acbdcec20e00	CPT0100530003	17997d1e-a8b1-4d00-8fcb-c461b77e9a7e	C3L-02177-01	b61e6d54-fe64-45c6-a226-09a7aaf805ec	C3L-02177	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
234aeb30-e2b2-4b52-8c44-61cc0c94b198	CPT0110770003	77c95a21-9148-440a-a2ba-33688d7dd00f	C3L-01681-04	a55164b4-5970-4737-8947-968a9fb766e0	C3L-01681	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63a4979d-7172-4eb3-bf42-f5d5387bdf8c	CPT0212210003	edf745ea-794e-4106-8e40-195ebfdd9df1	C3N-01085-02	7dadea19-53d9-4c5f-a379-916612d948d3	C3N-01085	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
684293d8-009d-44f6-a825-6efffdc78381	CPT0203940003	862a13fd-69f1-455f-b953-385b69a025dc	C3N-00715-06	664c0023-23cd-4e55-82e6-4359d6696891	C3N-00715	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a482a3ea-aef9-4592-99d2-42ed32230884	CPT0109950004	0fa1f760-ca36-427c-af19-335b57b3faea	"C3N-02084-02, C3N-02084-01"	48c2f98b-4194-435b-938d-7a2f24b6a9b3	C3N-02084	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a439418-eed5-4a28-99d3-0a6e5f341ecc	CPT0171900003	b4470670-b770-4bdb-b34e-28cf199ce69d	C3L-02208-02	b1456e51-a18a-431c-8899-ead3cdcf23b8	C3L-02208	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fa14d8a0-c90c-43fd-99db-819444120529	CPT0161820003	4a904388-fc90-4c44-b8c0-e2f5949cf0f3	C3L-02556-02	cfc5cdbe-604a-4546-9f51-d277a8da8237	C3L-02556	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
40cd36d0-a3f9-477f-b568-4750bb2f996e	CPT0212590003	c08f00f9-d4f6-4577-b483-dd1432480370	C3N-01088-04	6e0a57bc-442e-4b07-abf0-bab5b435b98a	C3N-01088	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0fdd9118-f211-435d-a309-32e6b1d37d9b	CPT0211700003	533a1fcd-d91d-41c4-acfd-32344ef99093	C3N-01082-06	5db30623-1c54-4607-b6bb-16cdad8869ac	C3N-01082	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
47ddf0d2-f08f-474e-aa8e-1122e126866b	CPT0096900003	37367aa8-cb94-4859-b924-951945c62c68	C3N-01536-06	10fae524-2581-4ae5-97fa-7a677fe942dd	C3N-01536	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4a03fa9-983d-43c2-8945-17d8e0fa09cf	CPT0101740003	77700f29-ce13-4455-805b-7288b5dd5163	C3L-00968-07	4791e768-de1f-4f46-bf3b-96e9bf402c07	C3L-00968	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5026f628-1708-4be9-9cba-a104df8aa11f	CPT0128200003	9bb0654b-c784-4f52-8b66-c22b4ce6f167	C3L-01107-01	93f75337-fc67-4033-a03d-3d405759082c	C3L-01107	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
757a742a-286f-451b-857c-1be0bcbded1d	CPT0122660003	8564d3b1-d993-4b08-aa37-08cc99efb170	C3L-00980-02	5d3eca31-7a37-4db9-b5ed-67b49099a6cb	C3L-00980	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
30adb110-7c5b-4296-b0ba-0cf2b879c448	CPT0124090003	ea58e351-ab24-4345-aac8-3f3512dcacde	C3L-01102-06	80ad75c2-57a9-4ba1-997f-abdd7817a585	C3L-01102	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e5e8e7c-1172-465c-b032-d90393a2cf5a	CPT0101310003	50be67c4-4054-4eec-990c-774bf3e00f11	C3L-00966-03	233611b9-9c0f-4137-983e-867a541a2646	C3L-00966	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
65e4bf56-2f3e-49f1-a4a7-7d89a483f73a	CPT0171890003	d0a23a38-71e6-401f-9556-4a575aa8c3c5	C3L-02208-01	b1456e51-a18a-431c-8899-ead3cdcf23b8	C3L-02208	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da20a9ab-f893-4581-8b22-04e1c42d082c	CPT0212920003	91fccc3d-62f9-4a82-a3f1-02a5085fc294	C3N-01091-03	e5d39201-72d3-4911-9077-bb15eee72e33	C3N-01091	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8871f677-171f-4777-ae17-f8f69256adb3	CPT0097880003	e45cb1f7-f53a-4bbe-90ca-9c32d2257a5e	C3N-01828-06	7bdc92f8-8b6c-4635-b8be-ad14726425e3	C3N-01828	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0b786f4a-11d0-4bd3-8693-67219caedb4e	CPT0172080003	4f2f2ad4-fb3e-421e-8433-06c73d552e34	C3L-02842-02	f86d2084-8fc6-4835-ae08-3bcfde9b8e9f	C3L-02842	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2d62d89c-fa2a-4ea1-ab05-e9d3fe878e04	CPT0189040003	651d8727-7574-4cde-a8cd-759695ac07c4	C3N-03019-05	b26b8168-7348-47be-b119-a9c3398ff545	C3N-03019	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
231e7d7d-2453-4901-a0dd-57e3cedba8e3	CPT0109980004	8275dd44-d2fe-4266-9abc-7c94fb3ebc06	"C3N-02085-01, C3N-02085-02"	4a0b2e2d-bdeb-4c03-9388-57bba5735505	C3N-02085	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
511667e4-385e-469e-9131-dab80aa61de3	CPT0158660003	30536d59-3449-4442-b1bd-46f94b7c565f	C3N-02439-02	109080ea-8c45-4b76-9311-51115576b110	C3N-02439	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c7cad3b-1588-4cb0-b762-4a76d8b1f02e	CPT0109800004	2e7fb687-3588-4baf-96c6-f6f63307318f	"C3N-02066-01, C3N-02066-02"	a774825f-9658-4e89-936b-9cb69b36cbfd	C3N-02066	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f62899c5-f961-434c-99d2-ad7503762172	CPT0189080003	69e3dc92-fc85-46cb-a20f-9ef08f577948	C3N-03020-02	b43c7c9d-ec92-47f1-9c61-7e68554cf66b	C3N-03020	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f76ac664-dcd5-49f6-8f8f-7b027494affd	CPT0213960003	9c01ded3-b922-42c0-b64a-171e98c6ff91	C3N-02160-04	4aa84758-d881-4d0e-9c9d-cd085ae05eac	C3N-02160	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7db83034-1faf-489e-9190-c0109699f7bb	CPT0172630003	97490cbd-f774-43c8-b82c-58484512b094	C3L-01676-03	1f79bdee-1e11-4750-9f08-a0ba6523133e	C3L-01676	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f40a76e-9f69-44b0-af4b-229689a7f750	CPT0101350003	08d6e9be-ac7a-430d-b2dd-474f918fc7a2	C3L-00966-07	233611b9-9c0f-4137-983e-867a541a2646	C3L-00966	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1edd30d3-5874-46f9-a25e-b53d01487384	CPT0109770004	02157796-afe8-41b9-9f10-621aca11854a	"C3N-02005-01, C3N-02005-02"	af12abd4-d315-4bc6-b8be-cc4308cd0105	C3N-02005	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
560e2f54-abe8-46d6-a38e-c999662d11a7	CPT0210780003	ca0be657-f7d9-463a-a150-4f50239db216	C3N-01077-03	cd1b1b0f-8641-4e2f-bc83-26c377c14e30	C3N-01077	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ab43acca-400b-4863-9737-cf568a6282dc	CPT0100480003	adfd8320-20d2-4d14-833a-0b6c4f953683	C3L-02176-02	d770baff-a23c-4de2-a152-6e78200df061	C3L-02176	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2fd5bf1c-fd96-4167-a045-e9d362f6a525	CPT0212410003	2480e229-61c7-4b0a-a2eb-3ad0b7c23b34	C3N-01086-04	9494db09-6942-43e6-99f8-7fff17b895cc	C3N-01086	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b43191f3-4903-4936-bc51-8ca6acff4d28	CPT0109530003	4beb20b2-bab4-4578-b758-19264a7ae4a4	C3L-01976-04	7bceea7a-6a39-4b5a-a2bd-c97128df85c7	C3L-01976	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
464cfa55-3544-43e4-9bc9-3890b8ea68f1	CPT0085630003	94808423-7b5b-4331-af09-df0593ceaa1b	C3L-01459-01	5c6510ff-7c6f-4a37-9aa4-a3854a00fdf4	C3L-01459	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d46c3590-a4d2-400d-9491-e4877c934967	CPT0121560003	5b8cfc68-7c88-485b-ac3a-abbd15ad90e2	C3N-01655-01	57056fca-096c-4850-ac88-be4c74fe8b2d	C3N-01655	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
717e89e2-53b0-45ef-ba80-7aeafcd0f6c4	CPT0211850003	c86c8b05-20ee-4410-a0f7-03b3ffc27239	C3N-01083-02	e7c0a24c-0ec8-4e07-9517-b0449b5cb08c	C3N-01083	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ccd7b16-3bbd-46e9-b188-5bfa3e785f65	CPT0102070003	b920a180-5d7b-43ce-9344-907ab3fef3e0	C3L-00969-07	7327f919-d75e-4992-842f-4e0ab63fce69	C3L-00969	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62422958-8882-437c-b1a4-b042849bee08	CPT0189030003	4e126440-a60f-4002-9185-0274b1c78706	C3N-03019-02	b26b8168-7348-47be-b119-a9c3398ff545	C3N-03019	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
97ab4bf3-a86f-4de3-8e52-7931e9f49e3e	CPT0104270003	1dd79ff5-528f-4cb1-9d6c-2b98ee69c4e0	C3L-01869-06	5522c20e-841e-49eb-ae4b-de17b19a66db	C3L-01869	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae8230c9-afc2-431c-acfb-7b33f0513117	CPT0169550003	83b75743-4b78-47fa-a1c8-7b4c0e964023	C3L-00976-08	309801a3-3169-4987-9aef-47f25005eca6	C3L-00976	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b98fd33d-9885-4f6f-8a0b-76b7f60b9c60	CPT0213970003	4f486473-d87c-4e2f-a1e8-7133ac9ddce3	C3N-02160-06	4aa84758-d881-4d0e-9c9d-cd085ae05eac	C3N-02160	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1bc6ecf1-dd0a-4401-8532-3c0c110f934d	CPT0170070003	fc940565-0f81-4452-95fd-ebaccb18f409	C3L-01033-03	83676156-7486-49c6-bc34-20dc924eb0d7	C3L-01033	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f4fb8bc0-1650-4f42-899e-da21a7171793	CPT0161510003	7408edfc-d741-4909-954d-c5c3c4767d74	C3L-02551-01	22b3e9f3-10db-4733-964a-6f607da5c63a	C3L-02551	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2829522b-522c-4562-b20d-c6e0c3e977a0	CPT0211680003	f181c4de-10f5-47d1-ab51-698ecfd1b46a	C3N-01082-03	5db30623-1c54-4607-b6bb-16cdad8869ac	C3N-01082	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c064c9be-1482-41fd-b83a-c48592606228	CPT0125620004	1cdd608f-8e22-44a1-af6c-d53f9f303ba9	"C3L-01978-03, C3L-01978-01"	de1f0e2a-972d-44dd-b988-b218b42fd20a	C3L-01978	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
41863a46-9717-4ce1-b3fa-c7723ab53166	CPT0121490003	32c062b6-efe9-4800-a34e-9673a319d4a0	C3N-01654-01	99250cb9-2a52-47ad-893c-b29eb9d9d698	C3N-01654	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d468872f-74a2-41a4-a850-3d50fcbc5a9d	CPT0113150003	61c50897-17e2-4063-a754-2f8c9fcd74cf	C3L-02544-06	34eda8e1-69d9-4e62-8350-95337f1cb0c7	C3L-02544	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aede96e1-080f-4104-b664-f06c7dbde5d7	CPT0085920003	1c90fac2-07b3-4b16-8baf-2dd7aa93d2b6	C3L-01462-02	b39822b8-075d-48f2-9495-f59a3ed3cfbd	C3L-01462	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
78655273-16e9-49ca-8c5d-76032c9fb249	CPT0100590003	b0545a85-80e3-4324-a759-057b2c3751d3	C3L-01954-01	b046b38f-3da2-4e95-a32e-7fce831be20a	C3L-01954	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
205f0e2f-cb06-4f6e-b5ea-79c51213de3c	CPT0158950003	5e2beed9-a764-425c-b990-52088c914b6e	C3N-02945-01	10e97ad4-5464-4ed2-9b16-554f8714f41b	C3N-02945	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
96af3b6c-2562-4081-9e89-307fca03a4d3	CPT0212600003	d54ef8fa-8add-4772-be40-8f149efeb8c7	C3N-01088-06	6e0a57bc-442e-4b07-abf0-bab5b435b98a	C3N-01088	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a0d60eb-89d2-4f0f-b37c-fae78907d958	CPT0183550004	8ebd84b9-c59e-446d-b7f6-0af18a766723	"C3N-02577-01, C3N-02577-02"	516ca172-b609-4b5d-87e1-044ff22bc59d	C3N-02577	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db3e39ff-cd1a-4f3b-a944-7a6506a9dc2d	CPT0184260003	f77b94bd-0a25-4daf-a5f1-2e82387e3f59	C3N-02763-03	7e199623-a32e-40e5-8629-3febb8b42b56	C3N-02763	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b851fe0-4fde-4ad5-8674-aba1a223fcfe	CPT0085730003	459e3323-e275-43fb-9d55-c4907335d399	C3L-00815-01	1477014f-e3d8-485a-81e0-e7fd623178fe	C3L-00815	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dfdb69af-8f18-4176-a351-725151850481	CPT0188810003	0df0e1bf-0fe4-4d58-9893-290438bc882c	C3N-02263-06	40453a62-6664-42fc-ba26-f624589b36e5	C3N-02263	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ad92ad09-6788-4031-aa53-17dc7eb9ba78	CPT0124210003	29b95814-e535-401d-9b6f-4062bcfbf20d	C3N-01905-01	c6b87349-293d-40c9-9f30-3d267681c0d1	C3N-01905	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a66385f-64ca-4fda-9fcb-c0dcc58e547b	CPT0214150003	821be4d6-41e1-4703-af41-05b518bf103c	C3N-02224-06	38dc2806-482f-4f76-b453-b3db91e4b6be	C3N-02224	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4e3ad8d2-c1e9-4e0a-bb16-4095b42d8f90	CPT0181270003	104a611d-f0fd-4ec0-b9d3-9642b6ecf41a	C3N-01902-09	0f0e4bc0-4bc6-4d5a-8e41-f730f4cab85c	C3N-01902	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83bb3637-7c6a-45ca-a413-36c396d13e05	CPT0115680003	76ec46e2-57c4-41b2-95d0-d46b3c18ee70	C3N-01806-01	8aacec66-59fa-4070-9929-b908284c504d	C3N-01806	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
04594406-803c-404c-ac94-6bf54e6e76c1	CPT0176430003	dd77e9ba-0a1c-40a1-8aba-eabe49e3ead1	C3N-02726-06	52005a80-e7c0-47a1-9607-18538ff0b267	C3N-02726	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
40b928de-e66c-4ab7-bd71-eb826687e4a5	CPT0212240003	0e399d7d-ef1d-461d-aa8b-b6fe7ce5d23f	C3N-01085-06	7dadea19-53d9-4c5f-a379-916612d948d3	C3N-01085	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b142df9a-dfdf-475a-828b-a0d3d47bf47d	CPT0210400003	4b5a2ab6-fca2-4c3e-bf59-3e10854d00bd	C3N-00647-01	1086ba40-2dfc-4828-8b5b-ded36a4b2176	C3N-00647	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
605b3f56-ba76-4e5b-beec-711baa039a98	CPT0126920003	c10d408c-299b-421a-88a6-afadb768db07	C3L-00982-07	05207fb4-ba30-4fc2-ad21-e5610ead7b89	C3L-00982	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f5f61afa-b89d-4e8f-8873-e1e77f6752eb	CPT0100410003	c7d2dc16-49ef-4f6a-9762-8fa072d224bb	C3L-02175-01	7fcd53f0-1ca9-44bd-9579-a85e614aba33	C3L-02175	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5bd38628-b718-4899-8170-550f41f163fd	CPT0211520003	67ee4e90-24f8-4544-a026-2acc4432b61b	C3N-01081-06	d2ca9397-5a6f-40db-ace6-5742f753eb5a	C3N-01081	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
410438b6-76d6-4561-b85a-a3f973105d54	CPT0188900003	227e7505-0605-4ec2-b367-553b0a87a4f2	C3N-02265-01	c1a229cb-ff73-4461-87a0-ca58baa83078	C3N-02265	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
313e97cc-4e16-40a4-96d3-8f18fd4a478f	CPT0109860004	11e7904f-4eb5-4c34-98dc-ea5b2143db81	"C3N-02068-02, C3N-02068-01"	afb7f148-60b8-415d-be35-a60ed7be197e	C3N-02068	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f2e85d18-0759-4dac-8671-d0fe146d35ff	CPT0211340003	3088391a-60f4-49c7-8776-9f4cda3e288d	C3N-01080-06	5c1beb3a-88ba-474f-94b4-0efe617d451b	C3N-01080	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5ff98b-a018-4715-be0d-5bdd61017c53	CPT0184240004	98444696-5642-40d2-a3da-d3bb8bb2136e	"C3N-02763-02, C3N-02763-01"	7e199623-a32e-40e5-8629-3febb8b42b56	C3N-02763	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
11fd803a-79a5-4a20-87bf-94842dd7bc4a	CPT0172010003	9c0f2363-3696-4564-b42f-897886a4138b	C3L-02856-01	f554b94d-dc6a-4d43-82c6-365a3a69570c	C3L-02856	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e7992a84-e305-4416-8e23-9bd3453a7884	CPT0136460003	ab8e74c3-8695-4f07-8716-e63b01356520	C3N-02338-02	160d8256-b9ee-4823-ad80-707a10818c58	C3N-02338	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
af98822f-31cc-4a48-826a-b2df4bf233e0	CPT0210950003	6ab098ba-b678-4e34-948f-fc5ac45ce09f	C3N-01078-02	37c09d33-1e4f-4e11-929e-96345a433fff	C3N-01078	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d1fe0d3-4ae3-4971-8787-169c48b26297	CPT0109820003	261fcc52-60c5-4fc5-88bf-4551a0baebd9	C3N-02066-03	a774825f-9658-4e89-936b-9cb69b36cbfd	C3N-02066	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c749c5bd-f108-42ba-8ad6-2198fa2e6647	CPT0109880003	b9b635b3-8de6-4a48-9324-5a73631d1fa9	C3N-02068-03	afb7f148-60b8-415d-be35-a60ed7be197e	C3N-02068	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f2c00316-7f68-490e-8e68-605b912cdf8c	CPT0212770003	4df0a1ee-5adf-4a5c-8a06-b2e52343f989	C3N-01090-04	0e55cd78-015f-4747-8163-1f20cf20a434	C3N-01090	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
02052891-aa97-4378-aebd-7a7e233e3a79	CPT0122720003	3e89bc9f-263d-4afb-82ac-8d3831b1e65d	C3L-00981-01	ca9dc6e8-2862-427d-bc6a-987ba71c8e83	C3L-00981	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b95d7e82-88a0-443e-928f-04713785f384	CPT0092680003	d1bb3d7e-b1e2-421e-bc3f-aa2dce7e941b	C3L-01951-01	fd688ca2-82e1-4a6e-95b6-e7c78f273b97	C3L-01951	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fa9b5b35-84a5-4618-989c-31faf2211b6a	CPT0184140004	380b64e8-700e-4eeb-afad-e1b4d0250e7c	"C3N-02761-01, C3N-02761-02"	5e60818a-bed9-4d00-ade5-98ee3c7887fe	C3N-02761	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
07693205-30a7-4b04-aac5-567153c5ac2e	CPT0112460003	04a161e9-ce6d-4d37-8d33-6731ced83f2f	C3L-02346-01	7bae6951-e412-49b7-8a98-4241956c874c	C3L-02346	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8f3067c7-3a37-4589-a12b-fccd1dea65d7	CPT0112230003	7d8d5b30-c5ad-4f08-b1d7-f8240184e65f	C3N-01989-02	0761408b-d4b6-419a-a474-2ce5351a2e4a	C3N-01989	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7584a7fe-b910-4193-826c-c6b0a4542481	CPT0109890004	6c5e1790-620b-4502-a8a6-875099a63f31	"C3N-02070-01, C3N-02070-02"	31659499-6500-4dbb-8fcd-8abaeebd2211	C3N-02070	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6737f3d0-7cdc-4341-a433-c7658fcae6a1	CPT0176220003	895da4f5-b929-4b0f-8529-3930fb9ef585	C3N-02723-01	b9a07a90-78e8-439e-96fb-8c1201042e6f	C3N-02723	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb66a719-189e-47e9-86a0-0aa9cbf93221	CPT0121510003	b1a6c03e-8380-46fc-9005-1cf3ca1022f8	C3N-01654-09	99250cb9-2a52-47ad-893c-b29eb9d9d698	C3N-01654	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4497660e-bf73-4b18-adab-dcc7c42f6842	C3L-01470-02	e28a5d4d-2c6e-401e-b012-8b02c7b0d962	C3L-01470-02	d2ede591-f704-46e5-8ebc-d19c72ea4c26	C3L-01470	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
280489aa-dc55-42d7-bf73-6fe8acaadb08	CPT0188980003	dbd033f2-d391-4add-8782-4681d8e9e3d7	C3N-03018-02	957b07d7-77f3-4753-a873-2bb00948b4f0	C3N-03018	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9608d11d-4145-40ca-a455-ef61550708e1	CPT0176250003	e426018b-4d4e-47ba-81ad-af3b67bccc23	C3N-02723-06	b9a07a90-78e8-439e-96fb-8c1201042e6f	C3N-02723	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ec769209-d4aa-4c08-bb43-3e949fdae1e0	CPT0085860003	602ceae3-e0df-46fc-98bd-2146f3e7eec2	C3L-01464-02	1b069720-0562-4840-b45e-1c7aa11e5dc3	C3L-01464	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4bda4de3-3080-4ace-9cf4-188ccebade99	CPT0093070003	0868f7c4-1ea1-429a-9e7e-cf18d4c727de	C3L-01952-01	488c2146-5542-43ec-a814-6e609e8baeae	C3L-01952	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d7a01e16-295b-41b5-8b51-46846e5a9e3c	CPT0212420003	253d2ee4-94c4-4041-8135-8074839579b9	C3N-01086-06	9494db09-6942-43e6-99f8-7fff17b895cc	C3N-01086	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1ec04c1d-05e1-4431-87bc-969db05ce50f	CPT0172070003	91f41324-8738-4ed2-9325-180c0e7db639	C3L-02842-01	f86d2084-8fc6-4835-ae08-3bcfde9b8e9f	C3L-02842	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
72d36c82-51ce-4ec8-b302-d16f772ca073	CPT0184160003	75eb61a2-ea9c-421d-a531-2fbae9c30c73	C3N-02761-03	5e60818a-bed9-4d00-ade5-98ee3c7887fe	C3N-02761	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c68ae03-19fb-44e6-83eb-8d18f7eb510b	CPT0104510003	e7a49abf-5c34-4bba-8fb3-7490d037b892	C3L-01665-06	fa05727b-01b1-48c3-9b1d-93d2a1cc0cef	C3L-01665	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dc039aa4-0272-441f-bcbe-879a6c89fdc4	CPT0211500003	1b72eb7d-8089-48d7-b83d-07ac13d090ab	C3N-01081-03	d2ca9397-5a6f-40db-ace6-5742f753eb5a	C3N-01081	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f770acd6-c41b-423c-95d1-d498af4b5a3e	CPT0104430003	3b3f297a-f17e-4f23-aafc-5a1930a27f34	C3L-02352-01	13012ed3-ed29-41ab-8733-973140233700	C3L-02352	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7eff419f-cd2f-4fce-a2c1-28f77d5d9cc5	CPT0181260003	731695c7-1ced-42b0-b53c-c1e906a24835	C3N-01902-05	0f0e4bc0-4bc6-4d5a-8e41-f730f4cab85c	C3N-01902	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a022188-7ae1-453b-92a9-5955ed2bc0c8	CPT0085580003	1599bd2d-d4a8-4af8-956b-4439619947cc	C3L-01470-01	d2ede591-f704-46e5-8ebc-d19c72ea4c26	C3L-01470	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
248ee647-5761-422e-aad7-327b8b008c03	CPT0127540004	a689fa3f-2980-48fe-9380-4e6c470e8dcf	"C3L-01106-02, C3L-01106-01"	1a1f506d-b1ca-4117-aaad-ff410f915dd3	C3L-01106	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fb04fdb9-a847-411b-82a1-03043237dfa1	MB206_SHH	53ad9230-ef4c-4ada-a43d-1422e514a156	MB206_SHH	9ccab32d-c30d-49eb-b861-333139365cfa	MB206	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
50b7e6ad-a1f6-4e4d-88e9-871e13bb67e2	MB287_SHH	cd37006a-f988-4e99-a422-24ed5ff9a34d	MB287_SHH	086e75d7-3bdc-4dfb-9a0e-ff0da1a29403	MB287	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
3da7f67a-38a5-4d7a-991d-5bc43f2ad5b2	MB281_GR4	92ce421b-e503-484a-a80d-9d629a29e649	MB281_GR4	0848657d-76f9-4dbf-a7c7-f19685365270	MB281	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
3983d721-3cab-4d7f-917a-afdb6bb41a7a	MB177_GR4	08806dc2-0c8a-42ff-a509-4f16765526aa	MB177_GR4	c922e604-c549-4629-a2e9-be8e4564e4b4	MB177	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
338bb59a-974f-46a8-992a-19dede9d9aca	IR	c0fb3324-0264-4e8d-8251-e19ff2e582ba	IR	94383f6d-aa4d-4a34-966c-a33cdcc0e984	IR	Broad	Not Reported	Not Applicable	Other	Yes	Qualified						Qualified	Qualified																									Broad Institute
f41401e5-e285-4b8c-a418-a4ea02ab8d32	MB095_GR3	aa2d81c2-35ef-45cc-8e16-9cd29ac9d6d2	MB095_GR3	7b3b844f-47ea-4765-aa3e-9ec2a41fb510	MB095	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
3a8b7cc7-a41f-430c-8688-46ecb5d9501a	MB106_GR3	cb97d41c-2383-4716-80d4-14164fcdeed5	MB106_GR3	9b2c1ef9-147b-4d75-ae09-f160293efd10	MB106	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
53824b53-7495-4950-9070-4adf5f722ee4	MB136_SHH	1ea53053-6610-4e69-990f-ef49d14ff1c4	MB136_SHH	10bca000-c4a8-4501-b4b8-7ad5f17c5961	MB136	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
a9a198aa-9fc1-4b91-947c-bdf22e8d2f17	MB278_GR3	8fac7d96-bdf5-40f9-a2db-df233acebb36	MB278_GR3	bd83e74c-a1c3-4ff0-aa9d-8dc879d44c88	MB278	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
d189dc62-0411-4e0a-8c40-d915e75c8514	MB282_GR4	c65dc914-78b5-4dfe-a7cb-13d7dd972fef	MB282_GR4	1cb787b1-0023-4435-b4ae-a26a8a5c53f3	MB282	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
ca1e6e13-6418-4292-94ea-e0a46f0f2645	MB037_SHH	588ff70b-895b-47b2-8ccf-690bafa219b1	MB037_SHH	cb4522d8-9b62-47af-9e5b-52bc868edec4	MB037	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
7da61af2-beed-4dcd-8bff-5353ae2e20b0	MB118_GR4	2b5c7554-b674-4f6f-a2df-6ea5f968db9f	MB118_GR4	2e36da05-deef-49b5-af92-09b5c17dd5bc	MB118	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
4652a081-33e4-425e-b7ab-6776dd55e156	MB164_GR3	edeacd26-9e10-4791-8e5c-6ac4c016cac5	MB164_GR3	dce382d2-eaa9-42a3-8fdd-cf0e39555c75	MB164	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
47aae55f-7a77-4af3-af5d-5735a3d1f19e	MB099_GR4	8741c2fd-6c88-4709-84f4-f6fc281245cf	MB099_GR4	27c73fcd-8c45-475c-bcfc-4c51a01f2e67	MB099	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
67934d13-d918-4d34-887c-fb4a651d9f28	MB266_SHH	5acf7287-98d0-4306-98b0-51cd586b0e22	MB266_SHH	ec338fe9-3c52-4b17-b5b6-259c4d63ff46	MB266	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
676b34a1-399e-4e7e-ba5b-7662e328055e	MB226_GR3	8af76eaf-2d97-423b-8067-2eed907a6030	MB226_GR3	319d0e7a-a654-4146-8fc6-1f9654d1de59	MB226	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
2325365f-e4d4-43b5-819b-f5c05659a4d6	MB284_SHH	568a14df-3571-4b36-8014-fd12465710d6	MB284_SHH	d77d0758-e697-4cd4-8e31-4aeb6f8e749c	MB284	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
53d69b61-d7cb-4f78-a0b5-57f846601d85	MB174_GR4	e811652f-7ee0-441a-81f4-40b7b1a88014	MB174_GR4	2aa8dafc-2f41-424c-90f4-a1be93e1cb68	MB174	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
42c08285-0f1a-4c5e-9bed-beffc1073089	X5M15_WNT	02d4868a-0860-47f4-868b-78f34d01990b	X5M15_WNT	b0323adb-21db-403f-8568-f2894e58f5a7	X5M15	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
66fd05c0-df1c-4892-8f66-da079ea956a3	MB248_GR3	3fe551c7-0913-4aa1-a6c6-c1abf1f4bc81	MB248_GR3	8637d9be-cd81-41a8-960a-eaaf3da55ede	MB248	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
9ea3ff22-4e20-4862-af0f-54acde0f834b	MB260_GR3	185512b9-9820-49d7-a463-a5d56e150be0	MB260_GR3	58b20ae0-7890-46eb-9004-72a38093df8d	MB260	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
169980c8-a3d8-43da-a98e-4dab82e6fe73	MB264_GR4	8b54f564-e569-4625-bd89-9de60561305d	MB264_GR4	39cdf46f-8489-433b-8a38-e5d24bfd52c1	MB264	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
96d5851e-7ed4-4d5a-865a-6166c2c87a61	MB244_SHH	ad150a4a-25ae-41cd-a84b-7e39135e741f	MB244_SHH	de421f1c-fbdc-4f9a-a474-77bd828cb428	MB244	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
37b96ae2-a924-444a-87d4-876aec78c6a0	MB166_GR3	ff0cc93f-d29c-420e-9f1f-fbc7708945f2	MB166_GR3	6ca3c5dc-9ddd-40f3-9ca7-90329df28422	MB166	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
a04b0d43-f090-4438-9f82-736739285b1b	MB199_GR4	fbdf71fd-5460-4e48-afac-a1948d4638eb	MB199_GR4	8a4d61f6-776a-4c40-9dd5-fbadbe9b4e90	MB199	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
1e15589a-2177-403e-961a-17a2f6b6f3d0	MB268_SHH	8899bc77-3693-4481-853a-ea29151dca92	MB268_SHH	e183cc13-0800-4d5c-b63d-8b135026cb3e	MB268	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
3ffd36bd-7fd9-4638-9149-7f0d72f33ef3	MB274_SHH	20144048-79b3-498d-8d97-74f7ff45bd3e	MB274_SHH	6777c1c7-362e-4603-bd94-a1be78ec5306	MB274	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
d62fb420-4556-4c39-bf4d-8b2017ef881b	MB270_GR4	8d6da80f-b190-4903-96b0-8e01699819ec	MB270_GR4	97ccecc5-b1ca-4b96-bec9-c8b79e5a39cd	MB270	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
58fe5960-c86d-4200-ad51-b0c40b334ad7	MB265_GR4	fba77516-8b0e-47a5-825d-ee7020624b14	MB265_GR4	119d6747-1d4a-489c-8dde-a346020b0ea7	MB265	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
6ee859ca-ce47-4b85-8fe6-54794ff94bab	MB234_SHH	f9990408-30a7-44c9-9691-209917284ad0	MB234_SHH	0dbb0ac7-5c68-461d-b02d-34af63506dff	MB234	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
6a4de439-5ca4-4c7f-85d2-3ab6cd781e4c	MB018_GR3	7186b288-848d-42b5-87dc-ded01e7bcc5d	MB018_GR3	60a125d8-c9d9-4092-b9d5-c22182b5c0e4	MB018	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
0ec58e64-b215-4a93-bf89-e62d4464edb9	MB277_GR3	267df01b-f581-47f3-a51c-637df680170d	MB277_GR3	dca5e9bc-74e5-4e1d-b549-d8c3f472ac48	MB277	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
ecafd7b2-9ccb-4299-9b8d-9e4eaaea0687	MB275_SHH	c3f87c24-4da3-4fde-9c28-9a71ff35f041	MB275_SHH	b406d900-ac1d-4f98-bdc5-94e791bc96f0	MB275	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
45510523-699a-4f7c-94df-eb35acf70271	MB170_GR3	bb2b0600-cae1-4a43-9c81-dc587be9f791	MB170_GR3	028bc843-491a-4708-be65-e1ad695e8ee2	MB170	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
c3b5a1c2-594f-42d5-89e9-9f8e272076f2	MB104_SHH	74d37925-cbef-4d5e-ad89-fea0aaf4ad96	MB104_SHH	351f0feb-de40-472d-815d-822aa1611a09	MB104	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
75f44e98-0084-4c7d-b015-112f96c52891	MB239_SHH	2c207324-4aa3-4dac-969b-5820da8e157b	MB239_SHH	69fcab73-ca86-4d83-850b-eaec4dfeb280	MB239	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
e4203c58-41a6-48ef-9207-10f9dae33900	MB088_SHH	e87a4107-a913-437b-9077-0d5076111818	MB088_SHH	f024723c-8b33-4505-841a-a6ff9ea4cada	MB088	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
92536243-a25f-4e79-881d-7b9d32a5774b	MB269_GR4	c32dc58f-eecb-4b3b-aa3d-9d76eadcad58	MB269_GR4	f81f0851-dc81-4c8f-b7d7-94f40c542b26	MB269	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
eae00300-5309-4b0e-b27f-3584f7c19ca9	MB227_GR4	1718a307-6357-48e1-9efe-f24ea2628b0f	MB227_GR4	69cee145-e701-4f59-b30c-2cf293463bfd	MB227	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
a6dd1e02-11e1-48a2-a20b-c041b99df269	MB271_GR3	66670dcf-d83f-4c8b-aec6-a1aadff35e9a	MB271_GR3	2e864bd1-d1fe-4942-b6a4-f80624f72802	MB271	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
ab8d6259-6278-4247-9ed2-d454b98ce1ee	MB102_SHH	c95bab3c-9419-434b-8a5a-323ef3308f50	MB102_SHH	1f59a7fc-e0a5-4135-8c40-2dfbe9a7a551	MB102	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
b9c14c4a-8b7b-4ae9-99e8-13e52735c683	MB247_GR3	258115d1-a4b5-4cef-83d5-643fa142c3b1	MB247_GR3	d2ff9543-d032-4025-8e56-8efdf062da59	MB247	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
a340b006-a491-4ed2-8ab3-cb48050f41a6	Burdenko_1360_WNT	f14c5776-a700-4f57-9fab-6b2303179942	Burdenko_1360_WNT	e0865cab-fcae-41a2-b51c-b49614be7f11	Burdenko_1360	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
5c8edeed-1d4a-4938-b24b-d1fb6f597fe9	MB091_GR4	363748f9-59e5-48c4-8f28-180d17048920	MB091_GR4	f5719333-bb76-4355-b59b-a35510350492	MB091	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
3df59b57-fc05-4457-9516-ff0eb1871e76	MB288_GR4	8599fa1e-d955-4abd-b23a-8d1458a611d5	MB288_GR4	db881926-36a3-4c78-808a-cc50b867af9d	MB288	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
853efb24-8b7f-4ab3-9b7f-38c8357a0526	X1M6_WNT	18813442-e51a-448d-a285-580f5bdd6789	X1M6_WNT	22923fe7-21ea-4b3e-9159-ae3da2c7434e	X1M6	Broad	Tumor	Brain	Pediatric/AYA Brain Tumors	No	Qualified						Qualified	Qualified																									Broad Institute
70fe2828-cccd-4b8f-a9d8-abb3ba4be6b2	PTRC_exp12_29	16f68505-2600-46fe-b776-d120e3c602fa	"Early Gilteritinib, MV411, Flask11, FGF2"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
936b614a-789d-4278-9ae0-e185fa2e5a3f	PTRC_exp12_38	5451c6e2-1b90-4f12-b69c-15658fb78146	"parental MV411, 10M"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
28ef247d-5440-44e6-9683-588247214653	PTRC_exp12_21	e3d4e4aa-59d2-4c1a-9c4d-764bd299cd02	"Late Gilteritinib, MOLM14, Flask11"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32625657-f893-466b-969f-849c5aa6985a	PTRC_exp12_Ref	4281fa73-61a8-4c2a-86f1-ebc931e81502	Reference	dc69117a-ea67-4beb-91d5-301c8ef2c7db	Reference	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0085a3c2-516f-48d8-8966-567e126eebda	PTRC_exp12_04	d32daad7-7ef9-4319-9a0f-bb2b793ae976	"Early Gilteritinib, MOLM14, Flask6, FGF2"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c4edecfe-91a8-4518-9701-4f9c92d2017d	PTRC_exp12_28	31818927-2c75-40f0-80dc-6e0bd07cbf2c	"Early Gilteritinib, MV411, Flask10, FGF2"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c1d03c77-5378-49ad-b034-6f1124df78c2	PTRC_exp12_13	baf671ff-e1b6-4cd9-9dfd-5d263db4f5df	"parental MOLM14, 10M"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ee1c6ab4-45a1-4a94-965a-27309f02837f	PTRC_exp12_08	af9e6966-35fd-4c21-be18-78aee9cc3a0b	"Early Gilteritinib, MOLM14, Flask10, FLT3"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
478552d3-ab79-4a82-9272-c5b2f94f1d07	PTRC_exp12_19	cc4b5a5a-0479-44b1-a149-5465a259f799	"Late Gilteritinib, MOLM14, Flask9"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
11e5db52-a605-43c8-844f-22db1d83c4ca	PTRC_exp12_10	254c5c83-bee0-48a8-891e-194c5ab6b0df	"Early Gilteritinib, MOLM14, Flask12, FLT3"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8cd8b54-b66a-47da-879f-f135582ea0f5	PTRC_exp12_01	baf671ff-e1b6-4cd9-9dfd-5d263db4f5df	"parental MOLM14, 10M"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c65c83b4-5adf-48e7-bd3d-87e732f0fead	PTRC_exp12_34	fbe5fa5f-b347-4072-adee-d4cf5facdc43	"Early Gilteritinib, MV411, Flask16, FLT3"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1fcbc7fb-75de-4b26-b81e-5170dcc78ded	PTRC_exp12_31	907d54f3-7422-455b-892a-17548110df0e	"Early Gilteritinib, MV411, Flask13, FLT3"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b25faee2-eb25-44a6-8db8-b3046ad96889	PTRC_exp12_32	99449511-4491-422e-9835-976d4382da63	"Early Gilteritinib, MV411, Flask14, FLT3"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e82f42f-3d96-4a1b-8847-6cdadd09072d	PTRC_exp12_22	cf1e371e-6514-47ca-a7ab-01d1fbfe8215	"Late Gilteritinib, MOLM14, Flask12"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0b37067-1bf5-411f-904b-3a79f538b511	PTRC_exp12_41	1ac1547e-11c7-43f2-a274-71e331508396	"Late Gilteritinib, MV411, Flask10"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8abcb6d2-7a91-4acb-9e33-bc71e824ef22	PTRC_exp12_25	5451c6e2-1b90-4f12-b69c-15658fb78146	"parental MV411, 10M"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f643e0bb-978d-446a-8a92-9cc971c68785	PTRC_exp12_20	765e708d-9c2e-454e-a392-eb5d9dc3bd76	"Late Gilteritinib, MOLM14, Flask10"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9b4f6ec2-a19f-4504-825a-f92ff5b95cd4	PTRC_exp12_17	1bdf61bc-6ddd-484a-a832-435e65219ca7	"Late Gilteritinib, MOLM14, Flask7"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
54392849-6448-4fb2-9ed5-50fb540eca55	PTRC_exp12_40	576d1aa2-97b3-4ee1-a8ed-f6f947c05739	"Late Gilteritinib, MV411, Flask9"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
34439803-71b1-4df9-af94-8804542e587a	PTRC_exp12_27	9656e643-6e26-4328-86f7-5504ebf81e8b	"Early Gilteritinib, MV411, Flask9, FGF2"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7dff9a2f-1e21-4432-b3e8-eddf400c17a4	PTRC_exp12_14	baf671ff-e1b6-4cd9-9dfd-5d263db4f5df	"parental MOLM14, 10M"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5be0a000-46c8-464b-8627-6d1e59350215	PTRC_exp12_45	0dd94901-2462-42d6-83e7-425178387311	"Late Gilteritinib, MV411, Flask15"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
25866f8b-8992-43ed-b132-38495507054a	PTRC_exp12_46	447dddbb-3c3e-4739-af8a-1d375c49130b	"Late Gilteritinib, MV411, Flask16"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7937928a-9bf0-4abf-9d0b-cddd41c9604d	PTRC_exp12_37	5451c6e2-1b90-4f12-b69c-15658fb78146	"parental MV411, 10M"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e05fc7fd-c729-4907-8852-e0ed22e665a0	PTRC_exp12_09	b5b4b68d-8044-4211-a3d2-d497fa5b84ab	"Early Gilteritinib, MOLM14, Flask11, FLT3"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8088e412-b446-4928-88a2-07655fe8202f	PTRC_exp12_05	e70bb879-bacc-48a5-9026-723d14d987b7	"Early Gilteritinib, MOLM14, Flask7, FGF2"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
36cbe03e-6a5c-4021-bb22-66b9c7cf8dec	PTRC_exp12_44	c068793a-d1e5-4085-90cf-8b1c6437ed64	"Late Gilteritinib, MV411, Flask14"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba20a08b-bf78-4556-9c92-eac85f7e89a9	PTRC_exp12_18	16e8aeac-2c96-4557-b90d-0e93032fa1c7	"Late Gilteritinib, MOLM14, Flask8"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bceb5804-0b4d-4acb-976c-a9901944a2e6	PTRC_exp12_06	d9b3838f-1562-4556-9772-d941b0c2fb14	"Early Gilteritinib, MOLM14, Flask8, FGF2"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d456bdf5-10a4-4770-b7d6-48a07297a974	PTRC_exp12_03	1c7d064e-98f5-4907-bfe2-a0deaaf97dbe	"Early Gilteritinib, MOLM14, Flask5, FGF2"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a4d68f8d-a3ce-4c44-85b3-f5e2812f95f9	PTRC_exp12_15	6d1a4851-c1a7-4e08-aabd-78129b13a8d3	"Late Gilteritinib, MOLM14, Flask5"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cae0cb3d-8d4d-4a61-b879-ae037762cb57	PTRC_exp12_33	cec263a4-65c8-437d-9384-6db25bd242d3	"Early Gilteritinib, MV411, Flask15, FLT3"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9bfdf5e9-f0c1-43e2-98c3-3dfc61976c08	PTRC_exp12_30	bf639cc5-4fc8-4284-aff8-16a3c67c4b35	"Early Gilteritinib, MV411, Flask12, FGF2"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea89613d-9c7c-4ab4-a09b-687aeea07b7a	PTRC_exp12_43	289ba486-1b7c-48d0-a2c7-2e6589d68e79	"Late Gilteritinib, MV411, Flask13"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ab82956f-c3e5-4d52-ae63-53c9b9002db7	PTRC_exp12_02	baf671ff-e1b6-4cd9-9dfd-5d263db4f5df	"parental MOLM14, 10M"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62e9cfd5-1af6-4fe5-8045-3a7e2139fd19	PTRC_exp12_16	05982bce-839d-4560-9610-5ccb00e6ab7a	"Late Gilteritinib, MOLM14, Flask6"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f18565fb-6db8-481a-85ba-96759c9f083e	PTRC_exp12_07	3676d0ca-de14-438d-b862-98eb9210f062	"Early Gilteritinib, MOLM14, Flask9, FLT3"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1426f499-61c4-46e3-97f4-6452869af9fe	PTRC_exp12_39	5451c6e2-1b90-4f12-b69c-15658fb78146	"parental MV411, 10M"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
253197f9-454d-4c51-a88c-ae76699e3460	PTRC_exp12_26	5451c6e2-1b90-4f12-b69c-15658fb78146	"parental MV411, 10M"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f77e49dd-7bce-4587-9633-63fead03b48f	PTRC_exp12_42	d9d97340-dcd8-4771-b254-e8f22a45009d	"Late Gilteritinib, MV411, Flask11"	4a9ddc6a-11ad-4165-82c4-af3ba4fda9c6	MV411	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f929300c-0986-43ed-8086-1e3f92e26a44	CPT0111720003	0f8d918e-e737-4cdc-967c-964a9ca606b1	C3L-02408-02	bc2e2a27-9d23-4749-a2b4-ce6bbcad85b7	C3L-02408	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57230a62-81ec-4477-a13b-c90307c95d1a	CPT0128770003	49ab72c9-5008-47a8-af6f-3f257bff64c7	C3N-02253-74	18cbb873-a702-4a7e-b646-7d67671646eb	C3N-02253	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d83205db-757c-4696-81aa-95a339512ca5	CPT0113060003	1e89405b-919b-45b7-9c31-d91f4cee33f7	C3L-02545-03	e1559e51-1c77-4528-b69c-5fd3a9d23a14	C3L-02545	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
09c6279b-5c47-4354-8fa3-d6f272c21185	CPT0275270003	3adf2c28-677f-4bb8-8c27-50a71e73c962	C3L-05571-03	89945eae-f410-4ab3-b806-7a2732b66c14	C3L-05571	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Disqualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
315b34a8-10fc-414d-b810-3692092eab99	CPT0134500003	4a3625eb-e231-4ae7-8969-062fcf006e7b	C3N-02062-03	e6cf0d7b-c1cc-4155-9139-ffc921c2b772	C3N-02062	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8db105fa-3da3-4355-975a-d8facc869f43	CPT0186720008	3d9cef17-7473-446a-b402-628373756f4e	C3L-02449-01	37944a65-4fe5-4a3a-8c19-010cba3ecfa8	C3L-02449	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e191ef1b-5a07-4e98-851c-fa3c5fa77dc5	CPT0181810004	0792fe71-77d7-4df6-bcb9-c866be71bff6	C3N-02595-01	8dfb4b6d-da44-4873-a312-1f04dc296d94	C3N-02595	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fe3bcac2-ecc4-11e9-81b4-2a2ae2dbcce4	Ref	fe3bc950-ecc4-11e9-81b4-2a2ae2dbcce4	Ref	fe3bc4e6-ecc4-11e9-81b4-2a2ae2dbcce4	Ref	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes							Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
96f855df-c436-4436-b1b4-76b0f29a8533	CPT0188270004	9d91e0ac-fab6-41c6-9f55-3e6c477187bd	C3L-02746-01	8fa258e3-9adf-45f8-b4b6-8aca20efbc7e	C3L-02746	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a6afae65-b0da-4f06-8e31-6dc465aac29c	CPT0188610003	cf0f7c9e-42eb-4ada-8143-0d2a65d26dbd	C3L-03467-01	fbabfdb8-3113-4086-af3a-35cfec53009d	C3L-03467	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1b7490ac-c63a-4f8a-ab8e-94e3b2495c1d	CPT0129080003	1aec909a-4abf-4f49-86b0-1560e8193fc5	C3N-02249-75	b8d7abe1-55e9-4395-8ad0-fd6275a9a94a	C3N-02249	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
91805996-3332-4e41-9004-ff1eeb4a3b1d	CPT0098270003	86403cea-0354-4962-be2e-3116ca82330a	C3N-01843-01	fb670370-be43-4608-83d2-f2ae18484b28	C3N-01843	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
02d93d41-94b4-4a0f-b6a0-4c418c1425b3	CPT0196790004	ffa13fd8-baff-4c2b-a34c-0d44059a5277	C3L-02894-02	b89cddd6-7cfb-44c7-8e16-a2e55810dc83	C3L-02894	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
816649da-a375-4cb9-93de-02587e68aee6	CPT0117370004	a4d4e268-57bf-4d29-a623-e55899e2fcb8	"C3N-01875-01, C3N-01875-02"	aa4629a7-d6b5-4ab7-92d5-d4c07b92a415	C3N-01875	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a5d65f4-c641-4993-be88-4a9fac42caa4	CPT0115530003	d1ba5830-1f01-42f2-974c-fc4fc7c9b7dc	C3N-02436-01	e9e9baad-0996-4fee-91f3-3d10de0ac5ab	C3N-02436	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db1542d7-59f3-44fb-b664-39959ca9eb86	CPT0182070004	4869951e-7a76-4849-84de-70770e11a8ce	C3N-02635-01	22a90157-5e79-433c-8859-76893b79fbb0	C3N-02635	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7c6a12bf-4548-44dd-bdbe-72a694b99230	CPT0203150008	278452fa-db86-489b-93f5-0d4fcb99da25	C3L-02403-01	7d6fbd07-9bfc-437e-9d67-2cf7f008fa21	C3L-02403	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f83c230-7663-4431-8b24-08d190c399e8	CPT0137140008	41d2ba1a-7853-49c1-b90e-4431382125a6	C3N-02372-01	fc14681f-89d3-4f29-a644-cd78fb3aff02	C3N-02372	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
200a2e6d-e655-497b-a469-2a5743a5b389	CPT0095230003	2bc34421-ed2b-4c0f-8105-c3e0b4d248cb	C3N-01172-01	c7722558-6d06-4049-bf4c-aadaf32b2dff	C3N-01172	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f8928033-cb7a-444f-8693-d81cff933013	CPT0092460003	566da6e1-d7e9-4aab-910b-72d85ddefa75	C3L-00086-01	fe090773-9de2-4fbb-b832-7cc057bc1862	C3L-00086	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a727391-5180-40e3-bbe7-c2a5aac538c5	CPT0226810003	5ee3fdd1-e8e3-46ec-a3c2-0b9e5aec1df7	C3N-01766-04	0c0e9203-ab48-4005-afbf-8c0db774a9b2	C3N-01766	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d8fed15e-0cd2-4515-8d19-790ae6aee43d	NX034	b1f84575-5bcf-4ae7-b5d3-5f99e0273ef8	"C3N-03710-01, C3N-04323-06, C3N-04323-07"	c03d373a-86f1-4837-90e0-27ff5833b14c	NX034	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d5cfa121-6882-4193-9ea8-b282c72516b1	CPT0244510003	8e479c91-b33b-472d-a8cf-3486a25a608d	C3N-01880-04	89a067a3-0858-49f8-929f-48774c5bb560	C3N-01880	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8bbcce01-4ae1-491b-897d-0c7dc60724f8	CPT0181670008	9222dfea-1dce-4c6b-9946-92cac3f3b5fa	C3N-02271-01	22e32210-cd82-4cad-a7c9-b6ae39e05ad1	C3N-02271	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7c20b962-cb4d-4e1a-bc2c-d71c7d30d310	CPT0104690003	1db6653a-8599-4d75-88ef-c7bb65cf8000	C3L-02216-01	63252ba3-3e1d-490d-aecc-b1c424d28606	C3L-02216	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
47cd7f61-50ff-4ca0-83e5-ca635f41b423	CPT0234080003	16d0ebdb-ef54-4140-8495-031c053fddeb	C3L-03143-01	7f53bd9a-71e0-4c91-982a-f7ec8496bf4e	C3L-03143	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0fbc1ea3-a862-479d-bfca-7371d17429f9	CPT0248000003	efb33025-0f48-4687-b5ec-5f4b7b8fbed1	C3N-02994-01	2b6db9ed-9fbf-488e-927c-fc3cd273ec5f	C3N-02994	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dd5a9f51-546d-42d3-9950-81d457c86285	CPT0111950003	dff72144-dddb-41fc-b4b4-014bb0fe12b5	C3L-02412-01	1e7a2c18-f528-44b6-b4d8-3d3198e55d0f	C3L-02412	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ecd5476-a2a9-434c-87ca-8124d090309e	CPT0129520003	59307d3d-3dee-43b4-9776-f35211f7a821	"C3N-00755-71, C3N-00755-72"	d32af673-556f-4195-8391-39cd5189c282	C3N-00755	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b9d1e090-422a-47b5-91f0-3a8a78431800	CPT0127700003	612d6ae2-9470-42c7-81f8-515259bce501	C3L-01749-01	3cf0a0ac-6fa7-4c71-851a-5e9b771d7afc	C3L-01749	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8a4f551-b92a-4291-b021-f78dd30cf834	NX023	ef2a91aa-34d9-47d0-b591-aa4ddf2f3de7	"C3N-03698-01, C3N-03698-02, C3N-03698-03"	e799c252-9519-42d5-9ce8-dda625bfa323	NX023	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9e918de0-1888-4bd8-8ea1-ae95ad172492	CPT0265300003	4186486c-3ebf-4904-b534-4963aba386d6	C3N-02247-72	62d6a247-8c3a-4efc-a135-728af7a7c3a6	C3N-02247	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
274a1346-f186-4dd9-b441-2e50daa34d79	CPT0104820003	7ce9ad1c-3de1-4eb6-9fea-dea1bdb0d760	C3N-00155-04	75533b4a-b4a6-46b0-8030-4ac968e512d5	C3N-00155	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d47dbcd-0afc-41d5-b1c1-db3736f60696	CPT0247880003	2da8ad1f-f8f0-4f51-ac54-3a8b8696cb9d	C3N-03417-01	033d8be8-274d-4e76-a060-c72386f91096	C3N-03417	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03cb7dd1-c655-4dcf-b3f9-7827f4d6754f	CPT0133400008	018273c1-689d-450a-baa3-bb935bc57cea	C3N-02027-01	5aa447a4-84ce-4215-81b3-107210b3f38d	C3N-02027	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e68ca32-329d-4313-b410-cc5d51a183a0	CPT0133600003	b129a791-28d2-4f9a-a7ce-977d04a6f95b	C3N-02028-03	e035bd2a-9a53-47f2-9a34-0c93380ac6c7	C3N-02028	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
262a29d4-4204-4343-905c-8e9837df5d0b	CPT0247970003	b00bfae9-1499-4b2f-b752-65883d9318c8	C3N-03767-01	202a6ed9-9417-4436-bebd-30d8d560276b	C3N-03767	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b5da4e37-1573-48d8-a671-c5344a3d0664	NX031	d0e63016-da8e-4f12-9e83-ffdeefe4e8a9	"C3N-03709-01, C3N-03709-02, C3N-03709-03"	2bf62061-246d-46e4-adcf-9f122748d0bc	NX031	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a63075a5-351d-4db2-a1ef-372553e93e9e	CPT0098920003	7d5ed238-12b0-4665-8950-e1b77bb034b1	C3N-01847-02	1dbc2b35-d3f2-47d1-89c1-87dfefeeeee6	C3N-01847	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1baf6cf8-40a2-41f1-8eb2-c01b7d1b29de	CPT0182150003	5eaa48f1-d377-44fd-a839-e0ad80afd8dc	C3N-02636-02	dc4c0919-e02b-4c2f-8a43-2102cf535bca	C3N-02636	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1ff08d2f-0c16-4897-ac68-93de13c446ea	CPT0133770008	07d373e4-ff7c-4132-85c3-da11302eb625	C3N-02030-02	6aecf005-aecb-4438-b591-b82d30baa842	C3N-02030	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
731daa5e-1d5b-4e40-a69c-ed2a0d9eeca8	CPT0186560008	176e8d0a-ea6d-4c2f-bfa2-e502191188e9	C3L-01668-01	49441ac0-645e-41b4-bf61-e7a78ec534b0	C3L-01668	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2acb9583-347e-4825-bd59-ca26d8b048ee	CPT0117560003	dc189c3b-518b-448d-bd60-fd1bef9118e6	C3N-01878-01	dce1ec8e-8e5c-4f65-a171-bdfd0acc339f	C3N-01878	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a290332-2688-41f5-83f8-da66076e5c6e	CPT0099050003	131bf6a7-e595-4eeb-9ac8-aeb53dd2ece7	C3N-01848-01	8fcfa3a0-13c2-4819-b6f3-a40d99bb1527	C3N-01848	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7d328d94-dda6-4ead-ae52-31467d90966e	CPT0247910003	a25cb2ad-817d-481b-8573-c427ac94dcdb	C3N-03415-01	ea711b96-7083-4514-93ce-701a345052a3	C3N-03415	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
920cc21e-fca5-48b8-8684-caaf69cf62fe	NX037	e38fde44-3ad4-4676-add7-922127cdf71c	"C3N-03710-03, C3N-06306-01, C3N-06306-02, C3N-06306-03"	b135787d-c6ac-4704-8f78-d11b2ab863e8	NX037	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6846c2c5-5d7c-4c7f-bb45-c81e4847c730	CPT0182210004	693c7a85-4f87-437b-a689-ac323a2f0211	"C3N-02637-01, C3N-02637-02"	f946f751-b5ac-4940-b869-accbc3765257	C3N-02637	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e5260888-6e63-4364-ac03-397f1f02653e	CPT0108750003	7c0d2ca0-d0bd-4112-b219-a58bd601db4e	C3L-01967-02	26cb8025-b6c8-4943-8532-47bc895166b3	C3L-01967	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a7153d26-efb7-4ab1-b67e-774f2984539d	NX026	ac976dbd-0d21-4a8c-99c7-3e3bd0830860	"C3N-03705-01, C3N-03705-02, C3N-03705-03"	716f932c-5ca2-476e-beb2-2599733115c2	NX026	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
082f12ce-1438-467b-8dbc-8d13fe4781ce	NX035	d37bd94e-d900-4b1d-988c-7fa25cc9ce1e	"C3N-03710-03, C3N-05927-01, C3N-05927-02, C3N-05927-03, C3N-06301-01, C3N-06301-03, C3N-06302-01, C3N-06302-02, C3N-06302-03"	46823369-5e7c-44a6-ab05-649e0c59dfd0	NX035	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d11771a-1be7-42b9-bd9c-2b918d3d3c76	CPT0181960004	1bb275e7-9e14-4f08-8c81-2660f87159da	C3N-02631-02	fb0acaa6-876d-4fb1-8cc1-d301a72bff28	C3N-02631	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f8397ca-7b78-43b9-8d9c-780213f00a63	NX022	75eca9e2-ae63-407c-8845-fc8fdb321c95	"C3L-03605-01, C3L-03605-03"	e696328d-d090-4405-99f9-57b0e2de7012	NX022	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ed06aad-1661-4459-8f9d-3337daa5ebcd	CPT0127610003	c06810f3-2a38-44d1-9f72-a52d878b1718	C3L-01729-01	99f28016-6f48-46d2-b9eb-5ec1727a1fee	C3L-01729	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
094d8e85-84ca-4fce-a20b-7373028cf3a8	CPT0113910003	2ba605d6-52f1-4115-a359-035b9038320c	C3L-02602-02	48c0a8d3-75be-4055-9e38-da84f1c340bd	C3L-02602	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62afc82e-3da5-4775-855f-63b256ac28b6	CPT0092860003	35606d76-84bc-45ef-9cb0-ad4621e1663b	C3L-01864-02	85b024a2-1250-4881-8376-39631d505144	C3L-01864	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4100cd49-8f06-4a8f-b59e-8fa8a331c58f	CPT0128960003	a5693869-96a7-4eea-8d09-da7947ec121d	C3N-02244-72	3b1a2314-101b-40e6-b9fa-bca6acf47b0a	C3N-02244	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cca44e41-26a6-4b52-a147-f1238f4f7302	CPT0265110003	7681411f-3d51-4a04-83db-5b163c5f6351	C3N-00750-02	e64e9303-894e-464d-83a0-a66e08d2c385	C3N-00750	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dc1d3266-7d28-4c5c-9266-d84b4b8c1df2	CPT0100010003	f074682a-c659-42ce-8d0c-6a43b0f55272	C3L-01833-01	aef60166-8440-40a9-875c-4fe7e125bdde	C3L-01833	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3b2681c1-46da-4619-892a-94f9b99453f9	CPT0116140004	bfd223ab-8b5f-474a-9268-4b3439c13c08	"C3N-00860-01, C3N-00860-03, C3N-00860-04"	ca27c5c6-2aad-4acb-bb1a-557d4738227c	C3N-00860	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
708e3cd9-9163-4491-bea4-c38097f4c7e1	CPT0182290003	6391615a-829e-4714-a8eb-bf478be5879b	C3N-02639-02	5c441a41-89ca-4727-b00b-3fff3ecbcfd8	C3N-02639	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4dd53623-bb00-4aea-9076-127532c2da99	NX036	e3593f52-c351-4d7e-8301-59a77f2744f5	"C3N-06303-01, C3N-06303-02, C3N-06305-02, C3N-06305-03"	05c52807-7cd0-415f-844c-8a6b1d0c897b	NX036	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83306ea2-3fea-4434-8bc9-1e6ad1647cf6	NX025	2301dbea-158f-446c-ba5e-697e7204677a	"C3N-03703-01, C3N-03703-02, C3N-03703-03"	6915ff3b-1fb1-47a3-a36c-b43e8756718f	NX025	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bfb6fc8c-89d8-447c-bfaa-8e75e55f1d28	CPT0083580003	0d416a46-8233-4ad1-b336-ea1e1960e35f	C3L-01355-02	51c65bc0-2ae1-4566-9509-3a06140e4c2d	C3L-01355	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b12afe78-2a2c-460e-a0fa-6268a85f65b1	CPT0225010003	f7b059dd-cd3e-4294-9364-d80ec4023da4	C3L-03264-01	2f35aea1-2028-429d-8e54-ed360f3cf078	C3L-03264	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f977907-ec12-41b1-8393-d00380fab330	CPT0181320003	e8b0aecf-ad5d-4e54-890e-8952de8175b7	C3N-01764-01	cf669d6c-266e-47b6-b223-103f74a963d8	C3N-01764	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
06fe446f-2bda-4fb8-bcea-847595d911cb	CPT0117510003	a4e44f95-2078-4ec6-b37c-89cb3d9e4baa	C3N-01877-04	c962a026-05d7-456e-83d2-376c20ca42f5	C3N-01877	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
94335dde-795b-4646-8e95-0cb2f78e2033	CPT0171090008	b19f38ad-e948-4c83-9af3-0099a1eba8f8	C3L-02399-01	f2cbeec4-baa8-4e6c-b61b-11166d5438c7	C3L-02399	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bcb1f5c5-23ee-4c89-9458-bec76635e33c	CPT0097300003	d3f0ef3a-e33a-4779-9389-1bf8cb52810f	C3N-01830-02	f6ec2b0d-cb36-4c41-8b7e-3c5d5a5fba83	C3N-01830	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3d489c51-ce0b-45f2-bf45-9e76383debfe	NX029	e06a50a0-ee97-4d08-880c-70b8e89ffe73	"C3L-04186-01, C3N-02273-05, C3N-02296-05, C3N-03704-02, C3N-03704-03"	2945b77e-33ec-470b-93ab-a7052251b9f5	NX029	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e056e152-ccbf-431a-b905-2aa9547e3a30	CPT0247940003	6ca47845-20f5-4e2f-9e08-88ff707877c0	C3N-03005-03	70eaedcb-0537-4122-b8f5-2d91d3fce5b2	C3N-03005	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f8e556a-51cf-40e3-9eac-5a36fccbf8b7	NX032	45f7c88a-0859-4659-bdda-548bd60272ee	C3N-03710-02	a638bb20-4185-45d5-8953-f28d96a766c2	NX032	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a138b49-c32e-449b-b452-58255eec74ce	CPT0096010003	c8d570c6-29b7-4a14-ab5e-30bba4653479	C3N-01526-01	01ba6a03-ac4e-40f8-be7d-179452b1ad88	C3N-01526	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d0dca51f-d439-40a6-b44a-d5e2e5e2733f	CPT0116010004	30e729d1-6787-4ebb-afea-23df62fb12e3	"C3N-00859-01, C3N-00859-02, C3N-00859-05"	2a4d5c2c-db95-43d9-98ca-4af132ffbbc3	C3N-00859	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
156c6597-a870-4abd-a0ff-90606b2303bd	CPT0111880003	f6e90277-7ec2-4822-85d5-28d475a77b4a	C3L-02411-02	c90b0d73-297a-405b-973c-40df3ac96525	C3L-02411	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
81505cdf-37ce-49be-854e-b7b96668978b	CPT0190700008	75345b8e-c15c-4fb9-b568-c1845721377a	C3L-02382-03	34318a9c-8e98-448d-835b-5fb7d2789217	C3L-02382	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df6b45e6-248b-4916-b6f4-b943332555d0	CPT0089600003	b8ba9976-ade7-4cc0-aa5e-2dc90712cff4	C3N-00732-01	b988a348-eb1d-4725-a5ab-0f94eea576d6	C3N-00732	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c663416c-b20d-488b-9f12-7c91e092c9ff	CPT0095280003	a03317fb-db6c-41e8-be87-805b9ddafa8d	C3N-01341-02	316c9b11-048b-4d88-a90e-03c478b5211f	C3N-01341	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
862cd03e-eab3-46c1-a5d6-d10ca770108a	CPT0111810003	535826e0-df0e-4728-84b3-b2f744712149	C3L-02409-03	4e845b20-de08-42ae-8226-13adacfe432a	C3L-02409	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d1fb863b-f438-46c2-969d-0089f385ce45	CPT0112780003	03713ca4-23dd-42dd-8546-e472d95d50dc	C3L-02353-01	af727cc6-3100-46b0-be52-8c8eded0215d	C3L-02353	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0914cc04-68fd-4d31-96c4-8fa47f526a3e	CPT0182380004	e651e407-227b-46b6-bb7a-d2c95e40eb19	C3N-02274-01	e9c69663-652f-428e-8f4c-d0e4545a0fdd	C3N-02274	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63477d00-7120-4c8a-a9fd-78ca5155ab9a	CPT0097440003	9429b75e-7cb8-4be0-a08d-df3651fb7f29	C3N-01529-02	18cffd55-6993-48ca-81ed-9096a5ec7f9a	C3N-01529	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
436d4670-0a43-455d-9b32-ac295a3aa765	CPT0181540008	a04c55c7-7753-493c-8130-1e8d31db32a0	C3N-02298-02	097a21bf-5143-4c26-95fb-7fa946712967	C3N-02298	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da9adda0-1854-43ce-98e0-aab1c31bfbbe	CPT0091720003	181dd78f-6cd4-4bf1-805d-c18a301d13eb	C3L-01631-01	97b079c8-c207-41ea-8e2f-4b6117dd8dd5	C3L-01631	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b088e39a-84a9-4dbd-b0d7-4895a353b6bd	CPT0211120004	7922019a-a643-4210-a76c-c1c69cbba344	C3N-01079-01	a73281f0-258d-44d2-ab2c-e58d9794a6a2	C3N-01079	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
045c0390-fad3-4fa9-a845-ffc8ef2aa45c	NX033	7d854b07-fdb0-445c-b434-e6a56c768ee5	"C3N-06305-01, C3N-06305-02"	23856a8c-9b2b-455a-ab55-fb2791b79d05	NX033	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2071ed65-520e-42f8-8e9b-3a9b50efca9e	CPT0226860003	707103ec-0443-4398-a109-1677daa18b79	C3N-01879-01	b85900d3-7ec2-4f21-9b0e-f58d42ccccbb	C3N-01879	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4ba24f1-b8ec-4d1f-bf89-9671127cc074	CPT0172200008	c591243f-0c7b-4671-b51b-24fa4076fc1f	C3L-00898-02	6c011edb-1341-4284-9bc7-a309bac3b4a1	C3L-00898	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c30580a1-e7dc-4ba9-8788-f98112f466d9	CPT0128610003	01f31a62-1442-405b-900a-cfcc1b6bf274	C3L-02557-02	93988c5e-79b7-4b9b-8c2c-e2de477268be	C3L-02557	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9db423c8-75b7-45a7-8b48-56a8f6bfe981	CPT0114340003	e5ae94eb-55c4-4f84-8d10-8b867391edbf	C3L-02119-06	941865bf-bef9-4e9a-b430-4e6e6956570d	C3L-02119	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c8cd5dc7-1588-4244-b613-15c38a38af78	CPT0114100003	1a912d2f-db26-402e-9513-69968ee97c85	C3L-02121-06	5cce075d-02fb-4fd0-8c93-7dc2a0c3cdb1	C3L-02121	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f4b496c4-fe09-46e9-bf56-87924268ea7e	CPT0203250008	1aaeb23f-ac67-4332-97dc-e4bcc383f8a0	C3L-02392-01	f40fb1ed-230f-497a-bf2a-0cc032d47aa9	C3L-02392	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48e29fd8-d732-4412-8091-baee8be014ae	CPT0172460008	2cc363c7-c4c6-4df2-a2c0-88290d653297	C3L-01672-01	fd785cee-89b5-404a-9d5a-f6608db928e7	C3L-01672	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6973a242-d777-42a6-b2ff-2a5e754a8034	CPT0117300003	08baddc4-7c65-4949-9e48-4becefbd1400	C3N-01874-01	c6931b91-32cb-442c-9b0b-41f418f84509	C3N-01874	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e2f53f8a-97fa-40f9-852f-56188df57802	CPT0238260003	b1a32031-2b64-4c73-82a6-141b37d633ac	C3L-02990-08	2f7cf95f-e94e-4898-8ef0-60739e313422	C3L-02990	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
baab3887-2dd5-4b89-9f0b-fc483e0f4f7a	CPT0244470003.1	91a45253-f35f-4e19-b3b6-4d221e003afa	C3N-02978-02	615cb54c-3246-430b-8ea7-259314ba5aa2	C3N-02978	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83abfa9b-8acc-4153-adb8-cd89079ed630	NX028	b7385fe8-b4da-493c-be62-2f63d37b86bb	"C3L-03570-01, C3L-04181-01, C3L-04185-01"	6c798241-06f0-4893-a465-7fd32d40f95c	NX028	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
12d1bc77-efb3-4e7a-8f59-651059f7eb2e	CPT0128370003	d2f5e655-20ce-4725-8caf-6b2204ee8d2f	C3L-02555-03	9ae40b89-f98a-4a17-899e-b6655a549fc5	C3L-02555	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c3245bad-8065-4b81-8114-3e1cd165f806	NX021	d2c6a26e-8113-4325-9439-f8bfac132f77	C3L-03604-01	75330a2d-d702-4683-b428-87a32aed5a5e	NX021	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de1b9431-9b1f-4124-a0de-1050a88dd093	NX038	eb571e4f-0d8a-493d-b17c-9c4509c1fa51	"C3N-03710-03, C3N-06308-03, C3N-06309-01, C3N-06309-02, C3N-06309-03, C3N-06310-01, C3N-06310-03"	e54b0487-4eac-4d6f-8491-3bbdbf23614a	NX038	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b6d14020-5fa1-44df-af17-3f2ed5c370a7	CPT0186010004	87a2dc50-4b8b-49ff-b06e-1e4945273c58	C3N-02789-01	54035534-1ed4-498e-9eac-62b0880b7d87	C3N-02789	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bd5585d2-142e-431a-9bce-3737f415942d	CPT0093170003	86c84d16-d5e8-4ef6-b60d-b8107477a6fa	C3L-01277-01	297ac34a-cdfe-487d-8210-346932eedbbe	C3L-01277	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9b7ebb41-81a2-4cbd-b22a-9f5269b33bc3	NX020	c32d4a1f-84ec-4ba6-9954-933f352ad630	"C3L-03603-01, C3L-03603-02"	085aa512-e5af-41f1-bb5f-852fd0c33258	NX020	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
81187eff-2cea-4168-bd76-9acafd38eb67	CPT0086090003	d2d25665-bcaf-4bf9-807d-2343f8f5e788	C3L-00943-01	de1260e6-4932-4d48-bdac-0e02abaf11ec	C3L-00943	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d6309277-b7bb-47fb-945e-15db5c3895ce	CPT0112910003	080b1ff5-a87e-4731-bd6a-bbd98d13c7d6	C3L-02354-02	a9c38858-adc7-4d21-b930-1328205b5994	C3L-02354	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4caf0075-2ce1-4662-b581-245901cbb1c4	CPT0244470003	91a45253-f35f-4e19-b3b6-4d221e003afa	C3N-02978-02	615cb54c-3246-430b-8ea7-259314ba5aa2	C3N-02978	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Disqualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a12cbd1-5228-41ea-b4cb-b51fcd392337	CPT0174890008	e24e2e4f-057a-489f-9dcc-ed174e0cf4b8	C3L-02802-02	0e9c47ed-1bb0-495f-bb4a-b73ff49ca2d9	C3L-02802	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
76c9910f-fddc-486f-8fe6-7d52c65a3247	CPT0288830003	e0694148-f92b-4088-9ba1-365f32169fe0	C3L-05849-02	d430a3f8-5314-4efa-b904-2aa17ecc88af	C3L-05849	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
52f2f2f6-7c13-4e75-9736-97220de17a24	CPT0116340004	c03da66a-f632-4afe-a015-f86256a03d5d	"C3N-01344-01, C3N-01344-03"	9b4f319e-9d9d-4069-9fd8-2b5fd2c13aad	C3N-01344	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
827800d7-1183-4552-bf9a-e092daef288e	CPT0117010004	1104d046-00b7-4554-9071-b56bb11fb203	"C3N-01871-01, C3N-01871-02, C3N-01871-03, C3N-01871-04"	f777c0f1-e13a-4b07-9a07-97a44e6f43a3	C3N-01871	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e21a27d-91e1-4eae-a1ba-c29dd9453206	CPT0288750003	e5e1a777-f249-456b-b14f-94f4176b67ff	C3L-05848-01	f3f4d99e-152f-4e65-8eef-6521081b1ba7	C3L-05848	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4151522f-9860-48a7-9215-25fce0bb299d	CPT0113850003	ca5326d3-2fd9-487c-a78a-0514b053e344	C3L-02347-02	baa53a6c-e81c-45a6-92c9-8b9c6f0632db	C3L-02347	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4c862740-094e-41b8-8b3e-f131197de8ae	CPT0126000003	6e074124-f9c1-4d7a-a431-60255be5cf3d	C3L-02468-03	b55d40a5-36e0-4c30-922e-eee7bbfc269b	C3L-02468	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e4238d39-4153-4446-8170-174474db15d4	CPT0091780003	426b19a6-00bf-4e23-a82c-d4c6e15d0897	C3L-01639-01	47ab50d9-2905-41ac-825e-dc3370dd5eb1	C3L-01639	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
502763f7-855c-4bc3-8f9b-03f5b1df89c3	CPT0115470003	aff124b6-4b17-420c-980e-61247045bc83	C3N-02012-01	4ab8aa9d-c16c-442e-8f9c-daf1003de902	C3N-02012	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b915a849-174d-47ad-981c-c063ec8ead12	NX024	7c68e1ac-f398-45e3-b78f-8e7d32c76d3b	"C3N-03702-01, C3N-03702-02, C3N-03702-03"	9ac73d0c-5990-4f08-a0ef-cdc100d02b40	NX024	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10982065-1f18-47c9-a521-4e3d4d69d5a5	CPT0158520008	ab6872d0-9583-48bc-83bd-23d124ff005d	C3N-02947-03	099a979a-7127-4e88-a39f-a6a5e5ce84ec	C3N-02947	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ead0b636-0252-46f5-8f15-e301126ac264	CPT0113430004	8da0714c-b015-4637-91ef-d052d472d80a	"C3L-01064-01, C3L-01064-02"	53e22614-3ea9-43b6-a8fc-3c45a4f5ee0e	C3L-01064	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f67ddcd-2cdf-4b14-a73d-a14a5d3a705d	CPT0091990003	e34254fc-41db-48eb-9863-9c1dc2ca4106	C3L-01840-02	c3112d27-f661-4e23-8344-fb446cccd32b	C3L-01840	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
787b76ef-a916-44a3-820b-90e2e55b3100	CPT0116710003	a37a470c-2ca5-4e23-8653-50afa1c9e559	C3N-01761-01	25bf2158-3ab8-4f85-b801-c0d646b3893e	C3N-01761	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d68c72a-b352-4d9a-a055-524288c0e3d4	CPT0086490003	7f233c1f-8abb-40d1-98d7-cca05b34ee6f	C3L-01664-01	bed55930-5999-4000-ab9e-b2a50149c47e	C3L-01664	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
af659b12-7138-4c6e-af95-434164a1e00f	CPT0116940003	67758596-342a-4072-ab5d-5b923cbd5bcc	C3N-01765-01	172fa521-c7b8-4b12-b306-7b147f1a283d	C3N-01765	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a18df28-89d7-40f8-a786-a48965af641c	NX027	68db2f05-458d-407b-84bd-1dd3455febc4	"C3L-03467-04, C3L-03566-01, C3L-03569-01"	b7e61ab2-6828-4d4b-b12c-b82d6c77386d	NX027	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3da70d06-7b20-4fd6-ba8a-752109291af3	CPT0197250003	aabb2bdb-f7db-4bbb-88aa-f174e8c7f924	C3L-02125-07	4aaeb5f7-55bd-44ac-aa60-bdadca895243	C3L-02125	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
66f7a9ad-dc1e-4c5c-9e6b-2039f6abb1f2	CPT0188190004	41af6874-8678-4946-a645-132592ba01ac	C3L-02741-01	976bd9ec-7d84-4b17-adec-2ea094d79111	C3L-02741	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9c5d7cad-5da0-4a6b-b6a5-0d4a15ab57a7	CPT0115000004	9ecc122d-f0f2-4aef-a5da-86e61eb3a9e2	"C3N-00520-01, C3N-00520-02"	fdf5a66b-89af-467f-b6d1-26a5821bf22c	C3N-00520	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ad5f8937-30a4-4483-9cf0-93834e4a898a	NX019	87509f7b-a00b-4eb1-b9ad-69ec0a5078db	C3L-03574-01	d9bb3679-4610-4ab7-9ebc-9059f5db23c7	NX019	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
656881c8-d3e0-47c0-a032-37870c99eefb	CPT0100100003	ad6a8423-023c-4044-906a-235b456c73ba	C3L-01739-01	d6e830e8-4fc3-42bb-b271-5957b2a5e525	C3L-01739	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e0c8e870-1047-4c63-8ff4-33a6fc8b7621	CPT0117230003	4360ee10-ee19-47f4-96c4-cfb460209e21	C3N-01873-03	b56f311f-4d04-468c-a549-05b7b87c4492	C3N-01873	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
51edc5e4-fe31-4926-8c34-9241f2e5f20c	CPT0113330003	02077dd2-286a-4628-8dbd-c6b25b8d2783	C3L-02357-02	26e577e8-0794-4234-b401-9de63fc51a6a	C3L-02357	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4a8eb596-f024-4654-9d9b-0bcdb5ecade0	CPT0159220008	9c2bd2d6-ecf9-49bb-b17f-b4c82f7db2dc	C3N-02972-01	0670e9b8-07ff-4b46-b4ac-98b622cc6e87	C3N-02972	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
93227a01-19aa-4f3f-972a-267738704bc9	CPT0087260003	c021cefb-5929-40a5-b8a0-3f731264fc5a	C3L-01599-02	c737b5c2-3ea1-4a84-b297-4e74cb3fba23	C3L-01599	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9bdd41fb-31eb-4f0b-9e86-95faae074c6b	CPT0095130004	83e75306-9df4-4315-8357-e80d44c71db5	"C3N-01008-02, C3N-01008-03"	878c2f0d-3bbd-49d3-96ac-11777d884893	C3N-01008	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d4012a7-1504-4626-b2da-23999873c941	CPT0182020004	77f73bf6-aa7c-4d96-82d8-19781d3f1c59	C3N-02632-05	2d564f02-68ff-40f7-8925-9387d98582f3	C3N-02632	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a5b5f4d2-80f3-41f9-bee7-7871edb9688e	CPT0095880003	b081edea-876a-48b6-9215-027c9132bc4a	C3N-01525-02	2ec22c96-ee70-48a6-bc34-4923a31adc9d	C3N-01525	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4f4ab7b6-efa7-4400-875b-cd53a93cd38f	CPT0188480004	09d021cb-76f3-4dd2-ba09-c73fa10f82d3	C3L-02747-02	a7c49126-6bd2-4f9b-a700-d24c1e8813ae	C3L-02747	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
382c6d1b-4ed9-493d-9fc0-a7376e6af0b2	CPT0088140003	0ff5dd3f-a7fa-49eb-b284-2815e331e6d9	C3N-01342-02	1b42f935-3efa-4508-9d54-07247c6973e1	C3N-01342	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
85a0d63d-31ae-4ba1-9f85-fe69e47ef81a	CPT0092690003	c9ff5ef3-cceb-4652-b7fc-9245a5f9bca9	C3L-01913-01	654a927d-2695-49c0-91e6-33adb9e26d08	C3L-01913	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
831b6f43-1986-40b0-95f7-c87fd5cd95e6	CPT0161590008	01a4451c-5c92-4c42-953f-e263a6806a3c	C3L-02953-01	0843167c-f874-4e23-a334-6e5ad7a6c04b	C3L-02953	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bcfee5a2-1c9d-44e4-a57e-af8fdb5906c5	CPT0159110003	e08004aa-a487-4a64-904d-aeffcdbd212f	C3N-02437-02	761dc1a7-720d-458f-b8b3-639674546cb0	C3N-02437	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9701a109-c4f5-417c-a485-c6f4b7363a8d	CPT0186900008	7e45c04b-b641-4852-ac88-ad3756cf0a98	C3L-02800-01	040cb595-4bd9-48da-a20d-b3a329294aa4	C3L-02800	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a27cdc9-262d-476e-8665-3b8fd3ecf312	CPT0203040008	3bed99f0-2631-4c65-9fe3-7da8499ecbcf	C3L-02389-01	0515d2dd-3c2d-424d-93b3-14860e228378	C3L-02389	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2e0ac9dd-81c9-49cd-af66-0c013d8ad1b3	CPT0188370003	abefca5f-75c3-4b1f-8dd6-acfcd97dc024	C3L-02744-01	62fed149-d8b8-4462-93fd-ec190649b379	C3L-02744	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a234dba3-ea73-4ac6-ac31-888e11bb9574	CPT0129640003	0447baa3-6dd7-4358-99ca-a39133d408a4	C3N-00753-01	8218cf07-6312-4330-a7e3-bb78dc34700c	C3N-00753	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eaa0e454-8837-404c-b9d0-82ad9b4f1382	CPT0182340004	0eb14567-5232-46ae-b267-23de40a5bc69	C3N-02678-02	651c6f2e-413f-4c02-aeb5-4f9199e1e0b9	C3N-02678	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a247b61e-4ebe-47e5-911f-a335517cf4d4	CPT0127980003	ba2506bd-5fb8-42d5-b1bf-5ebe209a00cd	C3L-02384-01	bcd05dfe-d499-4f4b-bef9-12205ac394b6	C3L-02384	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
224cae38-6728-487a-bb9a-04bec754df88	CPT0181750004	989a04b0-5a6a-4966-b5ac-52479927c7fe	C3N-02296-02	9c46406b-3ebe-44c9-82cc-6baf3467878a	C3N-02296	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bbf5bf1c-3e46-4869-9eba-3cbbb8e532ff	CPT0134310008	db13f7b8-1ed9-4be3-8450-2aa32928377b	C3N-02061-02	41556113-b239-46b4-a176-a2dfd04cb666	C3N-02061	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48ca1839-9737-4a0f-b65a-9dbcdf991709	CPT0181610003	b8da35a7-5aa6-4a48-9b30-6a3ee05770d3	C3N-02302-02	e2a46f60-056b-428c-898d-d10c2f80baf6	C3N-02302	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8d0429d7-001e-420c-ad6e-514fd023d24b	CPT0188710003	dced4392-0ab3-4748-924f-7f0b0c696ece	C3L-03589-03	27e42cfa-a743-43ee-bd6a-a8020a982a8c	C3L-03589	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2853e5bd-e110-4481-96ac-b282ddcf72bc	CPT0187960004	832d5ea3-9d65-4bcd-bdad-05751c98b101	C3N-02598-01	59a60dc7-c1eb-4b8f-a100-4927c2199561	C3N-02598	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f7029b8-a59e-4b99-99d6-dc3697aea73d	CPT0117440003	020e90f3-34d2-45d3-ac59-de333b6549d9	C3N-01876-01	6d89f470-f821-4ea0-bb6e-143b103fc5bb	C3N-01876	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fb614561-4d01-4905-85ac-c05f2250b3e9	CPT0095190003	f06ccea2-507f-485a-afff-0bba047635af	C3N-01171-03	91638dc9-fc1a-4721-a1cb-884d3b047f29	C3N-01171	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c00cc42-839f-4091-b2ef-3734aef50b01	CPT0275270003.1	3adf2c28-677f-4bb8-8c27-50a71e73c962	C3L-05571-03	89945eae-f410-4ab3-b806-7a2732b66c14	C3L-05571	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
708643e6-bf2e-4f68-92c6-0e83be45043e	CPT0095100003	6628d266-cfda-4e52-8009-f06a176c0f96	C3N-01007-01	6f19e788-95f1-45d1-8dcc-191799f146d2	C3N-01007	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4feeb11f-eb19-456e-b0e8-5db30da6da91	CPT0099910003	bfdb64fb-3a70-4733-a198-5c4ccf0594d9	C3L-01732-01	26f4d1fa-ee01-4bf5-b0d2-766619d20a5c	C3L-01732	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
025f7122-b19d-45dd-b8f5-f7ea171cab70	CPT0188030003	f2921c8f-2065-4c4b-afa4-51a25480b029	C3N-02976-01	cb74e02b-315f-4638-8820-56fb0345e9b9	C3N-02976	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
68fd1aa6-a3d6-48ec-8708-57f07013e499	CPT0116250004	8b5e68c4-8a7c-4fc5-86fc-02af41c2c773	"C3N-00872-02, C3N-00872-03"	07209754-7cb3-4ead-bcf8-7fd5e1f3fe9d	C3N-00872	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ddfa8423-0214-4811-a2c4-c2982be6adc1	CPT0091910003	b32a97d3-71cf-4cb5-acdf-53e9ae8c7f3e	C3L-01633-02	2bd188fe-2c61-4481-af47-7805ca1d9ea8	C3L-01633	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5226a966-a625-41a8-bbf0-f77bf0fcb3b6	NX030	aa7b683e-ef9e-4834-9885-116f411c8fc3	"C3L-04186-01, C3L-03604-02, C3L-03604-03"	fc0205dc-9920-44e2-939e-e8bd7c2737ae	NX030	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7eaa2a1a-88fb-4fdd-ab42-fc94939102de	CPT0136280003	5cd93713-f54c-4409-92dc-7102e6d02665	C3N-02337-02	065e375b-3719-4e27-9246-2e80a50f0902	C3N-02337	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ad377174-2ee2-44b0-812f-383ad2ced196	CPT0188100004	4983d096-60b2-4eeb-a3c7-a5e7319ad183	C3N-02979-01	35b3d3ec-1f17-443b-830f-07f741dfbffd	C3N-02979	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
87455bb5-b3f4-4948-b7e2-430a217434e6	15-00276-3	f64b5e83-a18f-4901-892f-4496cd25e874	15-00276-3	ecbde1d1-d1d9-4de5-913d-090a0571edd9	15-00276	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d9a038c8-92b3-4fff-afeb-799d93b97841	15-00276-1	c00046d2-ffee-43d8-a72f-64a187590a7b	15-00276-1	ecbde1d1-d1d9-4de5-913d-090a0571edd9	15-00276	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3f72a7a9-821f-4fb9-b7ae-acad05592839	15-00701-4	783b98af-8004-4d0e-80dd-36284f71780c	15-00701-4	f569d994-6edf-4471-9227-d0fed6a0df18	15-00701	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63aff0cb-b45f-4738-aee2-a604c484248b	15-00701-1	1934d5d6-05a2-40b5-8f71-fe74baefe7c0	15-00701-1	f569d994-6edf-4471-9227-d0fed6a0df18	15-00701	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
feca950f-da2f-4ca9-9fa1-b22b273c6ba8	16-00886-3	769179d5-e9dc-4a6a-a10e-d6b4e6d87429	16-00886-3	d4d98800-dd46-4d74-8a94-d39627ae8c3f	16-00886	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cff35196-61b7-40c0-98bc-9f312f2b657f	16-01225-4	27f22e37-69e0-45a8-9b39-cd721d9440ce	16-01225-4	1725f439-598a-420f-8f5c-e355e14cedd9	16-01225	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cca82e9b-b5d9-4bc9-a9f5-66974226a711	16-00886-4	b04cbe96-f9e3-485c-867d-dce7fff60ddc	16-00886-4	d4d98800-dd46-4d74-8a94-d39627ae8c3f	16-00886	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
af3cc200-9c90-45fa-90b0-1a196486a488	15-00276-4	478fd372-9717-440b-935a-116da4036029	15-00276-4	ecbde1d1-d1d9-4de5-913d-090a0571edd9	15-00276	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
69e58049-a5aa-4585-8698-7bc7a3d89a30	16-01225-2	28304da7-818c-4521-bece-048d62f5231f	16-01225-2	1725f439-598a-420f-8f5c-e355e14cedd9	16-01225	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df629d26-e279-40a3-8fcd-2f59eb3252de	Universal Ref	e23b393b-78c5-4763-8673-5fef81765124	Universal Ref	d705133b-96f1-41dc-b613-3672f1d93488	Universal Ref	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
82d76a23-f792-4650-a648-cdbb19d4b995	16-01225-1	996489dc-ce5c-46f6-b4f3-d3edcced24a0	16-01225-1	1725f439-598a-420f-8f5c-e355e14cedd9	16-01225	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ee1ff253-e2a4-41a9-adfa-95d38061e170	15-00701-3	58d4a87f-21de-499b-ab88-a51dcc6cda7f	15-00701-3	f569d994-6edf-4471-9227-d0fed6a0df18	15-00701	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
28289067-02fd-4552-bac6-d75437cf5e3a	15-00701-2	eccfa28d-729b-4278-8690-4faa640625cb	15-00701-2	f569d994-6edf-4471-9227-d0fed6a0df18	15-00701	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9b4f0616-4852-4f92-8adf-fe53aaf87506	16-01225-3	a4000a09-ae5a-4b27-a295-40cf8c65331b	16-01225-3	1725f439-598a-420f-8f5c-e355e14cedd9	16-01225	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a7a9d6d8-18fe-4cad-8547-27d1a9a23533	15-00276-2	91d21159-dca9-495b-b637-c47e65037250	15-00276-2	ecbde1d1-d1d9-4de5-913d-090a0571edd9	15-00276	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c80902c9-a9d8-4454-aad3-931236136687	16-00886-2	d52eaff5-927b-4647-85bf-658f62645103	16-00886-2	d4d98800-dd46-4d74-8a94-d39627ae8c3f	16-00886	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ec6e0c69-acfc-48b3-861f-380cc1a0caae	16-00886-1	cd1e16fa-db00-4844-b11c-6e208bdb6528	16-00886-1	d4d98800-dd46-4d74-8a94-d39627ae8c3f	16-00886	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ec07a96-d0b0-11e9-9a07-0a80fada099c	WHIM-P94	ae7ed6cd-d0a6-11e9-9a07-0a80fada099c	WHIM-P94	f1ee500a-cf1e-11e9-9a07-0a80fada099c	WHIM-P94	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6e8c6366-d0b0-11e9-9a07-0a80fada099c	WHIM-P93	ae67a900-d0a6-11e9-9a07-0a80fada099c	WHIM-P93	f1ee4ead-cf1e-11e9-9a07-0a80fada099c	WHIM-P93	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9e8ec9ad-d732-11ea-b1fd-0aad30af8a83	ICBI-000009-01-1	9e8eade1-d732-11ea-b1fd-0aad30af8a83	ICBI-000009-01	9e8e8f51-d732-11ea-b1fd-0aad30af8a83	ICBI-000009	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ecd06-d732-11ea-b1fd-0aad30af8a83	ICBI-000010-02-1	9e8eb31e-d732-11ea-b1fd-0aad30af8a83	ICBI-000010-02	9e8e9134-d732-11ea-b1fd-0aad30af8a83	ICBI-000010	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ebae6-d732-11ea-b1fd-0aad30af8a83	ICBI-000003-01-1	9e8e9a7f-d732-11ea-b1fd-0aad30af8a83	ICBI-000003-01	9e8e87a3-d732-11ea-b1fd-0aad30af8a83	ICBI-000003	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ecb2f-d732-11ea-b1fd-0aad30af8a83	ICBI-000009-02-1	9e8eafdd-d732-11ea-b1fd-0aad30af8a83	ICBI-000009-02	9e8e8f51-d732-11ea-b1fd-0aad30af8a83	ICBI-000009	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ebbc6-d732-11ea-b1fd-0aad30af8a83	ICBI-000003-02-1	9e8e9d02-d732-11ea-b1fd-0aad30af8a83	ICBI-000003-02	9e8e87a3-d732-11ea-b1fd-0aad30af8a83	ICBI-000003	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ecf0b-d732-11ea-b1fd-0aad30af8a83	ReferenceMix	9e8eb490-d732-11ea-b1fd-0aad30af8a83	ReferenceMix	9e8e9259-d732-11ea-b1fd-0aad30af8a83	ReferenceMix	Georgetown Lung Cancer Proteomics Study	Not Reported	Lung	Other	yes	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8eb85a-d732-11ea-b1fd-0aad30af8a83	ICBI-000002-01-1	9e8e96f9-d732-11ea-b1fd-0aad30af8a83	ICBI-000002-01	9e8e8659-d732-11ea-b1fd-0aad30af8a83	ICBI-000002	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ec029-d732-11ea-b1fd-0aad30af8a83	ICBI-000005-02-1	9e8ea36f-d732-11ea-b1fd-0aad30af8a83	ICBI-000005-02	9e8e8ad9-d732-11ea-b1fd-0aad30af8a83	ICBI-000005	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8eb932-d732-11ea-b1fd-0aad30af8a83	ICBI-000002-02-1	9e8e9958-d732-11ea-b1fd-0aad30af8a83	ICBI-000002-02	9e8e8659-d732-11ea-b1fd-0aad30af8a83	ICBI-000002	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ebf40-d732-11ea-b1fd-0aad30af8a83	ICBI-000005-01-1	9e8ea1a0-d732-11ea-b1fd-0aad30af8a83	ICBI-000005-01	9e8e8ad9-d732-11ea-b1fd-0aad30af8a83	ICBI-000005	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ec4e2-d732-11ea-b1fd-0aad30af8a83	ICBI-000007-01-1	9e8ea791-d732-11ea-b1fd-0aad30af8a83	ICBI-000007-01	9e8e8d94-d732-11ea-b1fd-0aad30af8a83	ICBI-000007	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ecc31-d732-11ea-b1fd-0aad30af8a83	ICBI-000010-01-1	9e8eb103-d732-11ea-b1fd-0aad30af8a83	ICBI-000010-01	9e8e9134-d732-11ea-b1fd-0aad30af8a83	ICBI-000010	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8eb77b-d732-11ea-b1fd-0aad30af8a83	ICBI-000001-02-1	9e8e95b1-d732-11ea-b1fd-0aad30af8a83	ICBI-000001-02	9e8e80e5-d732-11ea-b1fd-0aad30af8a83	ICBI-000001	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8eb67b-d732-11ea-b1fd-0aad30af8a83	ICBI-000001-01-1	9e8e933e-d732-11ea-b1fd-0aad30af8a83	ICBI-000001-01	9e8e80e5-d732-11ea-b1fd-0aad30af8a83	ICBI-000001	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ec5e3-d732-11ea-b1fd-0aad30af8a83	ICBI-000007-02-1	9e8ea97c-d732-11ea-b1fd-0aad30af8a83	ICBI-000007-02	9e8e8d94-d732-11ea-b1fd-0aad30af8a83	ICBI-000007	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ebd7a-d732-11ea-b1fd-0aad30af8a83	ICBI-000004-02-1	9e8ea06f-d732-11ea-b1fd-0aad30af8a83	ICBI-000004-02	9e8e89de-d732-11ea-b1fd-0aad30af8a83	ICBI-000004	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ec7b8-d732-11ea-b1fd-0aad30af8a83	ICBI-000008-02-1	9e8eacb2-d732-11ea-b1fd-0aad30af8a83	ICBI-000008-02	9e8e8e7b-d732-11ea-b1fd-0aad30af8a83	ICBI-000008	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ebc9e-d732-11ea-b1fd-0aad30af8a83	ICBI-000004-01-1	9e8e9e89-d732-11ea-b1fd-0aad30af8a83	ICBI-000004-01	9e8e89de-d732-11ea-b1fd-0aad30af8a83	ICBI-000004	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ec6bb-d732-11ea-b1fd-0aad30af8a83	ICBI-000008-01-1	9e8eaab4-d732-11ea-b1fd-0aad30af8a83	ICBI-000008-01	9e8e8e7b-d732-11ea-b1fd-0aad30af8a83	ICBI-000008	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ec1db-d732-11ea-b1fd-0aad30af8a83	ICBI-000006-02-1	9e8ea66a-d732-11ea-b1fd-0aad30af8a83	ICBI-000006-02	9e8e8bb4-d732-11ea-b1fd-0aad30af8a83	ICBI-000006	Georgetown Lung Cancer Proteomics Study	Solid Tissue Normal	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
9e8ec102-d732-11ea-b1fd-0aad30af8a83	ICBI-000006-01-1	9e8ea492-d732-11ea-b1fd-0aad30af8a83	ICBI-000006-01	9e8e8bb4-d732-11ea-b1fd-0aad30af8a83	ICBI-000006	Georgetown Lung Cancer Proteomics Study	Primary Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Georgetown Proteomics Research Program
1c671301-d028-11ea-b1fd-0aad30af8a83	CPT0209510003	1c6596c8-d028-11ea-b1fd-0aad30af8a83	C3N-03204-03	1c6449cd-d028-11ea-b1fd-0aad30af8a83	C3N-03204	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c65f30d-d028-11ea-b1fd-0aad30af8a83	CPT0001030003	1c64677f-d028-11ea-b1fd-0aad30af8a83	C3L-00081-06	1c63ce99-d028-11ea-b1fd-0aad30af8a83	C3L-00081	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c661789-d028-11ea-b1fd-0aad30af8a83	CPT0123370003	1c6486e2-d028-11ea-b1fd-0aad30af8a83	C3L-01000-06	1c63d909-d028-11ea-b1fd-0aad30af8a83	C3L-01000	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c663aa9-d028-11ea-b1fd-0aad30af8a83	CPT0175560003	1c64ad0e-d028-11ea-b1fd-0aad30af8a83	C3L-02170-03	1c63e5c7-d028-11ea-b1fd-0aad30af8a83	C3L-02170	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c666df2-d028-11ea-b1fd-0aad30af8a83	CPT0218280003	1c64eb69-d028-11ea-b1fd-0aad30af8a83	C3L-02891-03	1c63fcd6-d028-11ea-b1fd-0aad30af8a83	C3L-02891	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66c6e4-d028-11ea-b1fd-0aad30af8a83	CPT0126470003	1c6549e9-d028-11ea-b1fd-0aad30af8a83	C3N-01893-10	1c64279e-d028-11ea-b1fd-0aad30af8a83	C3N-01893	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664266-d028-11ea-b1fd-0aad30af8a83	CPT0112660003	1c64b4db-d028-11ea-b1fd-0aad30af8a83	C3L-02546-06	1c63e93a-d028-11ea-b1fd-0aad30af8a83	C3L-02546	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6730db-d028-11ea-b1fd-0aad30af8a83	CPT0237550004	1c65b2aa-d028-11ea-b1fd-0aad30af8a83	"C3N-03877-01, C3N-03877-02"	1c6457de-d028-11ea-b1fd-0aad30af8a83	C3N-03877	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6716a3-d028-11ea-b1fd-0aad30af8a83	CPT0245790003	1c6599c9-d028-11ea-b1fd-0aad30af8a83	C3N-03424-09	1c644bbd-d028-11ea-b1fd-0aad30af8a83	C3N-03424	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66090c-d028-11ea-b1fd-0aad30af8a83	CPT0007740003	1c647ae3-d028-11ea-b1fd-0aad30af8a83	C3L-00904-01	1c63d424-d028-11ea-b1fd-0aad30af8a83	C3L-00904	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c661541-d028-11ea-b1fd-0aad30af8a83	CPT0102840003	1c6483d2-d028-11ea-b1fd-0aad30af8a83	C3L-00993-07	1c63d788-d028-11ea-b1fd-0aad30af8a83	C3L-00993	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c669158-d028-11ea-b1fd-0aad30af8a83	CPT0233640003	1c6512f0-d028-11ea-b1fd-0aad30af8a83	C3L-04014-06	1c64108f-d028-11ea-b1fd-0aad30af8a83	C3L-04014	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c673fb4-d028-11ea-b1fd-0aad30af8a83	CPT0238130003	1c65c526-d028-11ea-b1fd-0aad30af8a83	C3N-04127-03	1c645ebc-d028-11ea-b1fd-0aad30af8a83	C3N-04127	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c673aed-d028-11ea-b1fd-0aad30af8a83	CPT0221650003	1c65c07c-d028-11ea-b1fd-0aad30af8a83	C3N-03886-03	1c645c44-d028-11ea-b1fd-0aad30af8a83	C3N-03886	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66b0df-d028-11ea-b1fd-0aad30af8a83	CPT0083980003	1c65366f-d028-11ea-b1fd-0aad30af8a83	C3N-01025-04	1c641f10-d028-11ea-b1fd-0aad30af8a83	C3N-01025	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c65f8db-d028-11ea-b1fd-0aad30af8a83	CPT0130410003	1c64700f-d028-11ea-b1fd-0aad30af8a83	C3L-00445-01	1c63d0a2-d028-11ea-b1fd-0aad30af8a83	C3L-00445	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664531-d028-11ea-b1fd-0aad30af8a83	CPT0112580003	1c64b7e7-d028-11ea-b1fd-0aad30af8a83	C3L-02552-02	1c63eaf1-d028-11ea-b1fd-0aad30af8a83	C3L-02552	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66f474-d028-11ea-b1fd-0aad30af8a83	CPT0241170003	1c6575db-d028-11ea-b1fd-0aad30af8a83	C3N-02435-01	1c643c43-d028-11ea-b1fd-0aad30af8a83	C3N-02435	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66205f-d028-11ea-b1fd-0aad30af8a83	CPT0086260003	1c649183-d028-11ea-b1fd-0aad30af8a83	C3L-01606-01	1c63dcc3-d028-11ea-b1fd-0aad30af8a83	C3L-01606	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c660139-d028-11ea-b1fd-0aad30af8a83	CPT0064050003	1c647532-d028-11ea-b1fd-0aad30af8a83	C3L-00603-06	1c63d345-d028-11ea-b1fd-0aad30af8a83	C3L-00603	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c668f5d-d028-11ea-b1fd-0aad30af8a83	CPT0233330003	1c650e8d-d028-11ea-b1fd-0aad30af8a83	C3L-04013-06	1c640ee1-d028-11ea-b1fd-0aad30af8a83	C3L-04013	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66a136-d028-11ea-b1fd-0aad30af8a83	CPT0079110003	1c6525a6-d028-11ea-b1fd-0aad30af8a83	C3N-00497-05	1c641892-d028-11ea-b1fd-0aad30af8a83	C3N-00497	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66c44b-d028-11ea-b1fd-0aad30af8a83	CPT0126400003	1c6546fd-d028-11ea-b1fd-0aad30af8a83	C3N-01892-10	1c6426b6-d028-11ea-b1fd-0aad30af8a83	C3N-01892	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66ab81-d028-11ea-b1fd-0aad30af8a83	CPT0104930003	1c65305b-d028-11ea-b1fd-0aad30af8a83	C3N-01018-03	1c641c39-d028-11ea-b1fd-0aad30af8a83	C3N-01018	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
1c66ba94-d028-11ea-b1fd-0aad30af8a83	CPT0105430003	1c653e09-d028-11ea-b1fd-0aad30af8a83	C3N-01411-06	1c6423d5-d028-11ea-b1fd-0aad30af8a83	C3N-01411	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c672b76-d028-11ea-b1fd-0aad30af8a83	CPT0237200004	1c65abf0-d028-11ea-b1fd-0aad30af8a83	"C3N-03851-01, C3N-03851-04"	1c64549b-d028-11ea-b1fd-0aad30af8a83	C3N-03851	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66df38-d028-11ea-b1fd-0aad30af8a83	CPT0146400003	1c656160-d028-11ea-b1fd-0aad30af8a83	C3N-02374-03	1c64363e-d028-11ea-b1fd-0aad30af8a83	C3N-02374	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c660b73-d028-11ea-b1fd-0aad30af8a83	CPT0063440003	1c647c04-d028-11ea-b1fd-0aad30af8a83	C3L-00923-06	1c63d504-d028-11ea-b1fd-0aad30af8a83	C3L-00923	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c661f7d-d028-11ea-b1fd-0aad30af8a83	CPT0108560003	1c64901f-d028-11ea-b1fd-0aad30af8a83	C3L-01455-01	1c63dae9-d028-11ea-b1fd-0aad30af8a83	C3L-01455	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6693fa-d028-11ea-b1fd-0aad30af8a83	CPT0221220003	1c651613-d028-11ea-b1fd-0aad30af8a83	C3L-04071-06	1c641170-d028-11ea-b1fd-0aad30af8a83	C3L-04071	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66b5cb-d028-11ea-b1fd-0aad30af8a83	CPT0079060003	1c653aa7-d028-11ea-b1fd-0aad30af8a83	C3N-01194-05	1c6421e2-d028-11ea-b1fd-0aad30af8a83	C3N-01194	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66d906-d028-11ea-b1fd-0aad30af8a83	CPT0126830003	1c655d49-d028-11ea-b1fd-0aad30af8a83	C3N-02300-05	1c643357-d028-11ea-b1fd-0aad30af8a83	C3N-02300	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6703bf-d028-11ea-b1fd-0aad30af8a83	CPT0208770003	1c6585a5-d028-11ea-b1fd-0aad30af8a83	C3N-03051-02	1c644364-d028-11ea-b1fd-0aad30af8a83	C3N-03051	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6683f4-d028-11ea-b1fd-0aad30af8a83	CPT0232670003	1c6502dd-d028-11ea-b1fd-0aad30af8a83	C3L-03961-05	1c6408e5-d028-11ea-b1fd-0aad30af8a83	C3L-03961	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c67484a-d028-11ea-b1fd-0aad30af8a83	CPT0222730003	1c65df0a-d028-11ea-b1fd-0aad30af8a83	C3N-04162-03	1c646074-d028-11ea-b1fd-0aad30af8a83	C3N-04162	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6704e1-d028-11ea-b1fd-0aad30af8a83	CPT0209040003	1c6587a2-d028-11ea-b1fd-0aad30af8a83	C3N-03072-03	1c644444-d028-11ea-b1fd-0aad30af8a83	C3N-03072	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66f9e8-d028-11ea-b1fd-0aad30af8a83	CPT0234930004	1c657bcd-d028-11ea-b1fd-0aad30af8a83	"C3N-02523-01, C3N-02523-02"	1c643ee9-d028-11ea-b1fd-0aad30af8a83	C3N-02523	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c669911-d028-11ea-b1fd-0aad30af8a83	CPT0090440003	1c651c5e-d028-11ea-b1fd-0aad30af8a83	C3N-00211-01	1c641421-d028-11ea-b1fd-0aad30af8a83	C3N-00211	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66280a-d028-11ea-b1fd-0aad30af8a83	CPT0104380003	1c649939-d028-11ea-b1fd-0aad30af8a83	C3L-01884-06	1c63df63-d028-11ea-b1fd-0aad30af8a83	C3L-01884	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6665fd-d028-11ea-b1fd-0aad30af8a83	CPT0202740003	1c64e06a-d028-11ea-b1fd-0aad30af8a83	C3L-02660-07	1c63f908-d028-11ea-b1fd-0aad30af8a83	C3L-02660	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c665d91-d028-11ea-b1fd-0aad30af8a83	CPT0204600003	1c64d4ba-d028-11ea-b1fd-0aad30af8a83	C3L-02648-02	1c63f40c-d028-11ea-b1fd-0aad30af8a83	C3L-02648	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c674ac1-d028-11ea-b1fd-0aad30af8a83	LSCC Global CR	1c65e64f-d028-11ea-b1fd-0aad30af8a83	LSCC Global CR	1c6462fd-d028-11ea-b1fd-0aad30af8a83	LSCC Global CR	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c672922-d028-11ea-b1fd-0aad30af8a83	CPT0237080003	1c65aa23-d028-11ea-b1fd-0aad30af8a83	C3N-03848-03	1c64527c-d028-11ea-b1fd-0aad30af8a83	C3N-03848	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66e6ac-d028-11ea-b1fd-0aad30af8a83	CPT0183250004	1c656822-d028-11ea-b1fd-0aad30af8a83	"C3N-02425-01, C3N-02425-02"	1c6438c7-d028-11ea-b1fd-0aad30af8a83	C3N-02425	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6638dc-d028-11ea-b1fd-0aad30af8a83	CPT0175410003	1c64aa28-d028-11ea-b1fd-0aad30af8a83	C3L-02168-07	1c63e414-d028-11ea-b1fd-0aad30af8a83	C3L-02168	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66c194-d028-11ea-b1fd-0aad30af8a83	CPT0098770003	1c65440d-d028-11ea-b1fd-0aad30af8a83	C3N-01846-01	1c6424b9-d028-11ea-b1fd-0aad30af8a83	C3N-01846	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6676d2-d028-11ea-b1fd-0aad30af8a83	CPT0196810003	1c64f69b-d028-11ea-b1fd-0aad30af8a83	C3L-02968-02	1c6402c3-d028-11ea-b1fd-0aad30af8a83	C3L-02968	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c663e9f-d028-11ea-b1fd-0aad30af8a83	CPT0112540003	1c64b002-d028-11ea-b1fd-0aad30af8a83	C3L-02349-01	1c63e6ac-d028-11ea-b1fd-0aad30af8a83	C3L-02349	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c65fb76-d028-11ea-b1fd-0aad30af8a83	CPT0023470003	1c64713c-d028-11ea-b1fd-0aad30af8a83	C3L-00568-01	1c63d251-d028-11ea-b1fd-0aad30af8a83	C3L-00568	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c665a27-d028-11ea-b1fd-0aad30af8a83	CPT0202530004	1c64cff3-d028-11ea-b1fd-0aad30af8a83	"C3L-02646-01, C3L-02646-05"	1c63f317-d028-11ea-b1fd-0aad30af8a83	C3L-02646	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66ac61-d028-11ea-b1fd-0aad30af8a83	CPT0117770003	1c65317c-d028-11ea-b1fd-0aad30af8a83	C3N-01020-07	1c641e23-d028-11ea-b1fd-0aad30af8a83	C3N-01020	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c67181b-d028-11ea-b1fd-0aad30af8a83	CPT0245840003	1c659aee-d028-11ea-b1fd-0aad30af8a83	C3N-03425-09	1c644ca4-d028-11ea-b1fd-0aad30af8a83	C3N-03425	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c669314-d028-11ea-b1fd-0aad30af8a83	CPT0233600003	1c65143c-d028-11ea-b1fd-0aad30af8a83	C3L-04014-02	1c64108f-d028-11ea-b1fd-0aad30af8a83	C3L-04014	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c666987-d028-11ea-b1fd-0aad30af8a83	CPT0192540004	1c64e57f-d028-11ea-b1fd-0aad30af8a83	"C3L-02665-01, C3L-02665-02, C3L-02665-03, C3L-02665-04, C3L-02665-05"	1c63f9f7-d028-11ea-b1fd-0aad30af8a83	C3L-02665	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66cc20-d028-11ea-b1fd-0aad30af8a83	CPT0126740003	1c6551d1-d028-11ea-b1fd-0aad30af8a83	C3N-02285-03	1c642d99-d028-11ea-b1fd-0aad30af8a83	C3N-02285	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c674507-d028-11ea-b1fd-0aad30af8a83	CPT0223820003	1c65dbb4-d028-11ea-b1fd-0aad30af8a83	C3N-04155-06	1c645f9f-d028-11ea-b1fd-0aad30af8a83	C3N-04155	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c666ed1-d028-11ea-b1fd-0aad30af8a83	CPT0197150003	1c64ed3e-d028-11ea-b1fd-0aad30af8a83	C3L-02951-02	1c63fed7-d028-11ea-b1fd-0aad30af8a83	C3L-02951	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664c5c-d028-11ea-b1fd-0aad30af8a83	CPT0227020003	1c64c11f-d028-11ea-b1fd-0aad30af8a83	C3L-02624-02	1c63ed9b-d028-11ea-b1fd-0aad30af8a83	C3L-02624	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
1c66722d-d028-11ea-b1fd-0aad30af8a83	CPT0197090003	1c64f05a-d028-11ea-b1fd-0aad30af8a83	C3L-02963-03	1c63ffbf-d028-11ea-b1fd-0aad30af8a83	C3L-02963	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6670ac-d028-11ea-b1fd-0aad30af8a83	CPT0197170003	1c64ee6c-d028-11ea-b1fd-0aad30af8a83	C3L-02951-06	1c63fed7-d028-11ea-b1fd-0aad30af8a83	C3L-02951	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c65f71f-d028-11ea-b1fd-0aad30af8a83	CPT0130440004	1c646de7-d028-11ea-b1fd-0aad30af8a83	"C3L-00445-04, C3L-00445-06"	1c63d0a2-d028-11ea-b1fd-0aad30af8a83	C3L-00445	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66e0a9-d028-11ea-b1fd-0aad30af8a83	CPT0146380004	1c65633a-d028-11ea-b1fd-0aad30af8a83	"C3N-02374-01, C3N-02374-02"	1c64363e-d028-11ea-b1fd-0aad30af8a83	C3N-02374	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6715ac-d028-11ea-b1fd-0aad30af8a83	CPT0245780003	1c6597f2-d028-11ea-b1fd-0aad30af8a83	C3N-03424-03	1c644bbd-d028-11ea-b1fd-0aad30af8a83	C3N-03424	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c662396-d028-11ea-b1fd-0aad30af8a83	CPT0091610003	1c649477-d028-11ea-b1fd-0aad30af8a83	C3L-01663-02	1c63ddae-d028-11ea-b1fd-0aad30af8a83	C3L-01663	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6639c8-d028-11ea-b1fd-0aad30af8a83	CPT0175390003	1c64abea-d028-11ea-b1fd-0aad30af8a83	C3L-02168-04	1c63e414-d028-11ea-b1fd-0aad30af8a83	C3L-02168	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c65f640-d028-11ea-b1fd-0aad30af8a83	CPT0010050003	1c646cc3-d028-11ea-b1fd-0aad30af8a83	C3L-00415-03	1c63cfc0-d028-11ea-b1fd-0aad30af8a83	C3L-00415	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66dc3c-d028-11ea-b1fd-0aad30af8a83	CPT0136640003	1c65603c-d028-11ea-b1fd-0aad30af8a83	C3N-02339-02	1c643493-d028-11ea-b1fd-0aad30af8a83	C3N-02339	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c669bad-d028-11ea-b1fd-0aad30af8a83	CPT0111150004	1c651d99-d028-11ea-b1fd-0aad30af8a83	"C3N-00221-06, C3N-00221-08"	1c6415e2-d028-11ea-b1fd-0aad30af8a83	C3N-00221	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6697bb-d028-11ea-b1fd-0aad30af8a83	CPT0234560003	1c651a55-d028-11ea-b1fd-0aad30af8a83	C3L-04391-02	1c641335-d028-11ea-b1fd-0aad30af8a83	C3L-04391	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c665e72-d028-11ea-b1fd-0aad30af8a83	CPT0204820003	1c64d704-d028-11ea-b1fd-0aad30af8a83	C3L-02649-06	1c63f5f6-d028-11ea-b1fd-0aad30af8a83	C3L-02649	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c670e24-d028-11ea-b1fd-0aad30af8a83	CPT0197860003	1c659211-d028-11ea-b1fd-0aad30af8a83	C3N-03093-05	1c6448e6-d028-11ea-b1fd-0aad30af8a83	C3N-03093	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66be67-d028-11ea-b1fd-0aad30af8a83	CPT0098800003	1c65429c-d028-11ea-b1fd-0aad30af8a83	C3N-01846-06	1c6424b9-d028-11ea-b1fd-0aad30af8a83	C3N-01846	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c673eba-d028-11ea-b1fd-0aad30af8a83	CPT0237990003	1c65c3b6-d028-11ea-b1fd-0aad30af8a83	C3N-04124-03	1c645d23-d028-11ea-b1fd-0aad30af8a83	C3N-04124	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66a4a4-d028-11ea-b1fd-0aad30af8a83	CPT0068280003	1c6529fc-d028-11ea-b1fd-0aad30af8a83	C3N-00555-02	1c64197c-d028-11ea-b1fd-0aad30af8a83	C3N-00555	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c661e4f-d028-11ea-b1fd-0aad30af8a83	CPT0108600003	1c648dfe-d028-11ea-b1fd-0aad30af8a83	C3L-01455-05	1c63dae9-d028-11ea-b1fd-0aad30af8a83	C3L-01455	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66328c-d028-11ea-b1fd-0aad30af8a83	CPT0175160003	1c64a2a1-d028-11ea-b1fd-0aad30af8a83	C3L-02163-07	1c63e1f8-d028-11ea-b1fd-0aad30af8a83	C3L-02163	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66b3c4-d028-11ea-b1fd-0aad30af8a83	CPT0091090003	1c65378e-d028-11ea-b1fd-0aad30af8a83	C3N-01028-07	1c6420fb-d028-11ea-b1fd-0aad30af8a83	C3N-01028	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66d4a8-d028-11ea-b1fd-0aad30af8a83	CPT0186180003	1c655804-d028-11ea-b1fd-0aad30af8a83	C3N-02289-06	1c6430e2-d028-11ea-b1fd-0aad30af8a83	C3N-02289	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c670243-d028-11ea-b1fd-0aad30af8a83	CPT0208780003	1c6583b3-d028-11ea-b1fd-0aad30af8a83	C3N-03051-03	1c644364-d028-11ea-b1fd-0aad30af8a83	C3N-03051	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66bd02-d028-11ea-b1fd-0aad30af8a83	CPT0105420003	1c65407f-d028-11ea-b1fd-0aad30af8a83	C3N-01411-04	1c6423d5-d028-11ea-b1fd-0aad30af8a83	C3N-01411	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c669fb6-d028-11ea-b1fd-0aad30af8a83	CPT0079100003	1c652397-d028-11ea-b1fd-0aad30af8a83	C3N-00497-01	1c641892-d028-11ea-b1fd-0aad30af8a83	C3N-00497	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c667ca4-d028-11ea-b1fd-0aad30af8a83	CPT0225470003	1c64fcb2-d028-11ea-b1fd-0aad30af8a83	C3L-03272-05	1c6405c7-d028-11ea-b1fd-0aad30af8a83	C3L-03272	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c661325-d028-11ea-b1fd-0aad30af8a83	CPT0101130003	1c6481f1-d028-11ea-b1fd-0aad30af8a83	C3L-00965-03	1c63d6b0-d028-11ea-b1fd-0aad30af8a83	C3L-00965	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66d591-d028-11ea-b1fd-0aad30af8a83	CPT0186210003	1c655a26-d028-11ea-b1fd-0aad30af8a83	C3N-02289-09	1c6430e2-d028-11ea-b1fd-0aad30af8a83	C3N-02289	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66b964-d028-11ea-b1fd-0aad30af8a83	CPT0079050003	1c653cd0-d028-11ea-b1fd-0aad30af8a83	C3N-01194-04	1c6421e2-d028-11ea-b1fd-0aad30af8a83	C3N-01194	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6684da-d028-11ea-b1fd-0aad30af8a83	CPT0233160003	1c650417-d028-11ea-b1fd-0aad30af8a83	C3L-03962-07	1c640b35-d028-11ea-b1fd-0aad30af8a83	C3L-03962	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c660ef1-d028-11ea-b1fd-0aad30af8a83	CPT0063430003	1c647dd8-d028-11ea-b1fd-0aad30af8a83	C3L-00923-03	1c63d504-d028-11ea-b1fd-0aad30af8a83	C3L-00923	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6622a8-d028-11ea-b1fd-0aad30af8a83	CPT0086270003	1c64934f-d028-11ea-b1fd-0aad30af8a83	C3L-01606-06	1c63dcc3-d028-11ea-b1fd-0aad30af8a83	C3L-01606	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c669d8d-d028-11ea-b1fd-0aad30af8a83	CPT0089880003	1c652193-d028-11ea-b1fd-0aad30af8a83	C3N-00247-02	1c6416ca-d028-11ea-b1fd-0aad30af8a83	C3N-00247	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c67253b-d028-11ea-b1fd-0aad30af8a83	CPT0219360003	1c65a714-d028-11ea-b1fd-0aad30af8a83	C3N-03662-01	1c645197-d028-11ea-b1fd-0aad30af8a83	C3N-03662	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66576e-d028-11ea-b1fd-0aad30af8a83	CPT0202580004	1c64cd8f-d028-11ea-b1fd-0aad30af8a83	"C3L-02646-06, C3L-02646-07, C3L-02646-08"	1c63f317-d028-11ea-b1fd-0aad30af8a83	C3L-02646	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c665b2d-d028-11ea-b1fd-0aad30af8a83	CPT0204660003	1c64d278-d028-11ea-b1fd-0aad30af8a83	C3L-02648-08	1c63f40c-d028-11ea-b1fd-0aad30af8a83	C3L-02648	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66e1d1-d028-11ea-b1fd-0aad30af8a83	CPT0146480004	1c65645d-d028-11ea-b1fd-0aad30af8a83	"C3N-02375-01, C3N-02375-02"	1c643723-d028-11ea-b1fd-0aad30af8a83	C3N-02375	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6737f3-d028-11ea-b1fd-0aad30af8a83	CPT0237780003	1c65bc55-d028-11ea-b1fd-0aad30af8a83	C3N-03882-03	1c645b1c-d028-11ea-b1fd-0aad30af8a83	C3N-03882	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c674409-d028-11ea-b1fd-0aad30af8a83	CPT0223790003	1c65d96c-d028-11ea-b1fd-0aad30af8a83	C3N-04155-01	1c645f9f-d028-11ea-b1fd-0aad30af8a83	C3N-04155	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66c8a4-d028-11ea-b1fd-0aad30af8a83	CPT0128890003	1c654ce6-d028-11ea-b1fd-0aad30af8a83	C3N-02252-74	1c6429b6-d028-11ea-b1fd-0aad30af8a83	C3N-02252	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6675fd-d028-11ea-b1fd-0aad30af8a83	CPT0197380003	1c64f48c-d028-11ea-b1fd-0aad30af8a83	C3L-02964-06	1c6401d8-d028-11ea-b1fd-0aad30af8a83	C3L-02964	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c675032-d028-11ea-b1fd-0aad30af8a83	LUAD Global CR (pool 2)	1c65f0f1-d028-11ea-b1fd-0aad30af8a83	LUAD Global CR (pool 2)	1c6466a3-d028-11ea-b1fd-0aad30af8a83	LUAD Global CR (pool 2)	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66a63c-d028-11ea-b1fd-0aad30af8a83	CPT0069900003	1c652b7b-d028-11ea-b1fd-0aad30af8a83	C3N-01017-06	1c641b53-d028-11ea-b1fd-0aad30af8a83	C3N-01017	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66270f-d028-11ea-b1fd-0aad30af8a83	CPT0091820003	1c64976a-d028-11ea-b1fd-0aad30af8a83	C3L-01838-03	1c63de88-d028-11ea-b1fd-0aad30af8a83	C3L-01838	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c670d34-d028-11ea-b1fd-0aad30af8a83	CPT0197480003	1c6590f4-d028-11ea-b1fd-0aad30af8a83	C3N-03092-01	1c6446ff-d028-11ea-b1fd-0aad30af8a83	C3N-03092	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6745e5-d028-11ea-b1fd-0aad30af8a83	CPT0222740003	1c65dcee-d028-11ea-b1fd-0aad30af8a83	C3N-04162-06	1c646074-d028-11ea-b1fd-0aad30af8a83	C3N-04162	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66cb4a-d028-11ea-b1fd-0aad30af8a83	CPT0126670003	1c654fe0-d028-11ea-b1fd-0aad30af8a83	C3N-02284-01	1c642cb7-d028-11ea-b1fd-0aad30af8a83	C3N-02284	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66e4d7-d028-11ea-b1fd-0aad30af8a83	CPT0146500003	1c656635-d028-11ea-b1fd-0aad30af8a83	C3N-02375-03	1c643723-d028-11ea-b1fd-0aad30af8a83	C3N-02375	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c665443-d028-11ea-b1fd-0aad30af8a83	CPT0202220004	1c64c915-d028-11ea-b1fd-0aad30af8a83	"C3L-02629-06, C3L-02629-07, C3L-02629-08"	1c63f13d-d028-11ea-b1fd-0aad30af8a83	C3L-02629	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66362f-d028-11ea-b1fd-0aad30af8a83	CPT0175270003	1c64a6a9-d028-11ea-b1fd-0aad30af8a83	C3L-02164-06	1c63e2ef-d028-11ea-b1fd-0aad30af8a83	C3L-02164	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6749b0-d028-11ea-b1fd-0aad30af8a83	JHU HNSCC CR	1c65e16a-d028-11ea-b1fd-0aad30af8a83	JHU HNSCC CR	1c646210-d028-11ea-b1fd-0aad30af8a83	JHU HNSCC CR	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c668717-d028-11ea-b1fd-0aad30af8a83	CPT0233120003	1c650601-d028-11ea-b1fd-0aad30af8a83	C3L-03962-03	1c640b35-d028-11ea-b1fd-0aad30af8a83	C3L-03962	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c674ebe-d028-11ea-b1fd-0aad30af8a83	LUAD Global CR (pool 1)	1c65eea5-d028-11ea-b1fd-0aad30af8a83	LUAD Global CR (pool 1)	1c6465b6-d028-11ea-b1fd-0aad30af8a83	LUAD Global CR (pool 1)	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c667a94-d028-11ea-b1fd-0aad30af8a83	CPT0217420003	1c64fae7-d028-11ea-b1fd-0aad30af8a83	C3L-02969-02	1c6404e3-d028-11ea-b1fd-0aad30af8a83	C3L-02969	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c661248-d028-11ea-b1fd-0aad30af8a83	CPT0063480003	1c6480d0-d028-11ea-b1fd-0aad30af8a83	C3L-00927-02	1c63d5d9-d028-11ea-b1fd-0aad30af8a83	C3L-00927	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6678d4-d028-11ea-b1fd-0aad30af8a83	CPT0196820003	1c64f7f8-d028-11ea-b1fd-0aad30af8a83	C3L-02968-06	1c6402c3-d028-11ea-b1fd-0aad30af8a83	C3L-02968	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66b4c2-d028-11ea-b1fd-0aad30af8a83	CPT0091050003	1c653986-d028-11ea-b1fd-0aad30af8a83	C3N-01028-02	1c6420fb-d028-11ea-b1fd-0aad30af8a83	C3N-01028	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66c2e9-d028-11ea-b1fd-0aad30af8a83	CPT0126390003	1c6545d0-d028-11ea-b1fd-0aad30af8a83	C3N-01892-09	1c6426b6-d028-11ea-b1fd-0aad30af8a83	C3N-01892	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66d29b-d028-11ea-b1fd-0aad30af8a83	CPT0186140003	1c655602-d028-11ea-b1fd-0aad30af8a83	C3N-02288-09	1c642ffd-d028-11ea-b1fd-0aad30af8a83	C3N-02288	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66f0d1-d028-11ea-b1fd-0aad30af8a83	CPT0115860003	1c657227-d028-11ea-b1fd-0aad30af8a83	C3N-02434-06	1c643b5a-d028-11ea-b1fd-0aad30af8a83	C3N-02434	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6605d5-d028-11ea-b1fd-0aad30af8a83	CPT0007760003	1c64790d-d028-11ea-b1fd-0aad30af8a83	C3L-00904-06	1c63d424-d028-11ea-b1fd-0aad30af8a83	C3L-00904	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c663522-d028-11ea-b1fd-0aad30af8a83	CPT0175120003	1c64a4a5-d028-11ea-b1fd-0aad30af8a83	C3L-02163-01	1c63e1f8-d028-11ea-b1fd-0aad30af8a83	C3L-02163	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c672ed2-d028-11ea-b1fd-0aad30af8a83	CPT0237410004	1c65afa3-d028-11ea-b1fd-0aad30af8a83	"C3N-03875-01, C3N-03875-02"	1c645582-d028-11ea-b1fd-0aad30af8a83	C3N-03875	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c65f51b-d028-11ea-b1fd-0aad30af8a83	CPT0010060003	1c646aad-d028-11ea-b1fd-0aad30af8a83	C3L-00415-06	1c63cfc0-d028-11ea-b1fd-0aad30af8a83	C3L-00415	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6681c3-d028-11ea-b1fd-0aad30af8a83	CPT0232690003	1c6500c1-d028-11ea-b1fd-0aad30af8a83	C3L-03961-07	1c6408e5-d028-11ea-b1fd-0aad30af8a83	C3L-03961	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66ec8c-d028-11ea-b1fd-0aad30af8a83	CPT0147180004	1c656df9-d028-11ea-b1fd-0aad30af8a83	"C3N-02426-01, C3N-02426-02"	1c6439ab-d028-11ea-b1fd-0aad30af8a83	C3N-02426	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c662d12-d028-11ea-b1fd-0aad30af8a83	CPT0130270003	1c649da8-d028-11ea-b1fd-0aad30af8a83	C3L-02127-01	1c63e03e-d028-11ea-b1fd-0aad30af8a83	C3L-02127	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664e76-d028-11ea-b1fd-0aad30af8a83	CPT0191750003	1c64c289-d028-11ea-b1fd-0aad30af8a83	C3L-02625-08	1c63ee84-d028-11ea-b1fd-0aad30af8a83	C3L-02625	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c674142-d028-11ea-b1fd-0aad30af8a83	CPT0238110004	1c65c6f0-d028-11ea-b1fd-0aad30af8a83	"C3N-04127-01, C3N-04127-02"	1c645ebc-d028-11ea-b1fd-0aad30af8a83	C3N-04127	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66e799-d028-11ea-b1fd-0aad30af8a83	CPT0183270003	1c656a0b-d028-11ea-b1fd-0aad30af8a83	C3N-02425-03	1c6438c7-d028-11ea-b1fd-0aad30af8a83	C3N-02425	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c661a84-d028-11ea-b1fd-0aad30af8a83	CPT0087210003	1c6489f8-d028-11ea-b1fd-0aad30af8a83	C3L-01285-06	1c63da0d-d028-11ea-b1fd-0aad30af8a83	C3L-01285	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6731b6-d028-11ea-b1fd-0aad30af8a83	CPT0237570003	1c65b491-d028-11ea-b1fd-0aad30af8a83	C3N-03877-03	1c6457de-d028-11ea-b1fd-0aad30af8a83	C3N-03877	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66c528-d028-11ea-b1fd-0aad30af8a83	CPT0126450003	1c6548c6-d028-11ea-b1fd-0aad30af8a83	C3N-01893-02	1c64279e-d028-11ea-b1fd-0aad30af8a83	C3N-01893	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c65fdde-d028-11ea-b1fd-0aad30af8a83	CPT0023500003	1c647364-d028-11ea-b1fd-0aad30af8a83	C3L-00568-06	1c63d251-d028-11ea-b1fd-0aad30af8a83	C3L-00568	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66aa68-d028-11ea-b1fd-0aad30af8a83	CPT0104950003	1c652e80-d028-11ea-b1fd-0aad30af8a83	C3N-01018-06	1c641c39-d028-11ea-b1fd-0aad30af8a83	C3N-01018	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
1c66d66a-d028-11ea-b1fd-0aad30af8a83	CPT0126810003	1c655b89-d028-11ea-b1fd-0aad30af8a83	C3N-02300-02	1c643357-d028-11ea-b1fd-0aad30af8a83	C3N-02300	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c669501-d028-11ea-b1fd-0aad30af8a83	CPT0221200003	1c651740-d028-11ea-b1fd-0aad30af8a83	C3L-04071-01	1c641170-d028-11ea-b1fd-0aad30af8a83	C3L-04071	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66114f-d028-11ea-b1fd-0aad30af8a83	CPT0063500003	1c647ef7-d028-11ea-b1fd-0aad30af8a83	C3L-00927-06	1c63d5d9-d028-11ea-b1fd-0aad30af8a83	C3L-00927	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c670b53-d028-11ea-b1fd-0aad30af8a83	CPT0197520003	1c658f2a-d028-11ea-b1fd-0aad30af8a83	C3N-03092-05	1c6446ff-d028-11ea-b1fd-0aad30af8a83	C3N-03092	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c671b4c-d028-11ea-b1fd-0aad30af8a83	CPT0245890003	1c659e1a-d028-11ea-b1fd-0aad30af8a83	C3N-03441-09	1c644ea0-d028-11ea-b1fd-0aad30af8a83	C3N-03441	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66c7c5-d028-11ea-b1fd-0aad30af8a83	CPT0128900003	1c654bc6-d028-11ea-b1fd-0aad30af8a83	C3N-02252-76	1c6429b6-d028-11ea-b1fd-0aad30af8a83	C3N-02252	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c668a53-d028-11ea-b1fd-0aad30af8a83	CPT0227400003	1c650947-d028-11ea-b1fd-0aad30af8a83	C3L-03963-04	1c640c5a-d028-11ea-b1fd-0aad30af8a83	C3L-03963	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c662fae-d028-11ea-b1fd-0aad30af8a83	CPT0130070003	1c649f8f-d028-11ea-b1fd-0aad30af8a83	C3L-02130-06	1c63e11c-d028-11ea-b1fd-0aad30af8a83	C3L-02130	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6706d9-d028-11ea-b1fd-0aad30af8a83	CPT0209020004	1c65899f-d028-11ea-b1fd-0aad30af8a83	"C3N-03072-01, C3N-03072-02"	1c644444-d028-11ea-b1fd-0aad30af8a83	C3N-03072	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66a82f-d028-11ea-b1fd-0aad30af8a83	CPT0069890003	1c652d57-d028-11ea-b1fd-0aad30af8a83	C3N-01017-04	1c641b53-d028-11ea-b1fd-0aad30af8a83	C3N-01017	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664f5c-d028-11ea-b1fd-0aad30af8a83	CPT0191710003	1c64c451-d028-11ea-b1fd-0aad30af8a83	C3L-02625-04	1c63ee84-d028-11ea-b1fd-0aad30af8a83	C3L-02625	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66af09-d028-11ea-b1fd-0aad30af8a83	CPT0117720003	1c653361-d028-11ea-b1fd-0aad30af8a83	C3N-01020-01	1c641e23-d028-11ea-b1fd-0aad30af8a83	C3N-01020	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66ca69-d028-11ea-b1fd-0aad30af8a83	CPT0126530003	1c654ebb-d028-11ea-b1fd-0aad30af8a83	C3N-02283-02	1c642a9a-d028-11ea-b1fd-0aad30af8a83	C3N-02283	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6680d7-d028-11ea-b1fd-0aad30af8a83	CPT0190550003	1c64ffa4-d028-11ea-b1fd-0aad30af8a83	C3L-03678-02	1c6407fd-d028-11ea-b1fd-0aad30af8a83	C3L-03678	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66199b-d028-11ea-b1fd-0aad30af8a83	CPT0123350003	1c648808-d028-11ea-b1fd-0aad30af8a83	C3L-01000-04	1c63d909-d028-11ea-b1fd-0aad30af8a83	C3L-01000	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c662475-d028-11ea-b1fd-0aad30af8a83	CPT0091620003	1c649646-d028-11ea-b1fd-0aad30af8a83	C3L-01663-06	1c63ddae-d028-11ea-b1fd-0aad30af8a83	C3L-01663	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c672139-d028-11ea-b1fd-0aad30af8a83	CPT0195510003	1c65a38f-d028-11ea-b1fd-0aad30af8a83	C3N-03486-03	1c644f86-d028-11ea-b1fd-0aad30af8a83	C3N-03486	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66cee3-d028-11ea-b1fd-0aad30af8a83	CPT0126760003	1c6552f2-d028-11ea-b1fd-0aad30af8a83	C3N-02285-10	1c642d99-d028-11ea-b1fd-0aad30af8a83	C3N-02285	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c667519-d028-11ea-b1fd-0aad30af8a83	CPT0197210003	1c64f371-d028-11ea-b1fd-0aad30af8a83	C3L-02964-01	1c6401d8-d028-11ea-b1fd-0aad30af8a83	C3L-02964	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c662c1f-d028-11ea-b1fd-0aad30af8a83	CPT0130310003	1c649c78-d028-11ea-b1fd-0aad30af8a83	C3L-02127-06	1c63e03e-d028-11ea-b1fd-0aad30af8a83	C3L-02127	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66370d-d028-11ea-b1fd-0aad30af8a83	CPT0175260003	1c64a8ca-d028-11ea-b1fd-0aad30af8a83	C3L-02164-03	1c63e2ef-d028-11ea-b1fd-0aad30af8a83	C3L-02164	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6646d4-d028-11ea-b1fd-0aad30af8a83	CPT0112600003	1c64b90b-d028-11ea-b1fd-0aad30af8a83	C3L-02552-06	1c63eaf1-d028-11ea-b1fd-0aad30af8a83	C3L-02552	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c666d0c-d028-11ea-b1fd-0aad30af8a83	CPT0218310003	1c64ea46-d028-11ea-b1fd-0aad30af8a83	C3L-02891-06	1c63fcd6-d028-11ea-b1fd-0aad30af8a83	C3L-02891	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c665032-d028-11ea-b1fd-0aad30af8a83	CPT0202040003	1c64c575-d028-11ea-b1fd-0aad30af8a83	C3L-02627-06	1c63f055-d028-11ea-b1fd-0aad30af8a83	C3L-02627	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66f565-d028-11ea-b1fd-0aad30af8a83	CPT0234820003	1c6577b5-d028-11ea-b1fd-0aad30af8a83	C3N-02494-04	1c643e02-d028-11ea-b1fd-0aad30af8a83	C3N-02494	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6630e1-d028-11ea-b1fd-0aad30af8a83	CPT0130030003	1c64a0b3-d028-11ea-b1fd-0aad30af8a83	C3L-02130-01	1c63e11c-d028-11ea-b1fd-0aad30af8a83	C3L-02130	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66d16d-d028-11ea-b1fd-0aad30af8a83	CPT0186130003	1c6554e4-d028-11ea-b1fd-0aad30af8a83	C3N-02288-03	1c642ffd-d028-11ea-b1fd-0aad30af8a83	C3N-02288	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c667e68-d028-11ea-b1fd-0aad30af8a83	CPT0225380003	1c64fdd4-d028-11ea-b1fd-0aad30af8a83	C3L-03272-02	1c6405c7-d028-11ea-b1fd-0aad30af8a83	C3L-03272	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c669cae-d028-11ea-b1fd-0aad30af8a83	CPT0111000004	1c651f93-d028-11ea-b1fd-0aad30af8a83	"C3N-00221-01, C3N-00221-02, C3N-00221-03"	1c6415e2-d028-11ea-b1fd-0aad30af8a83	C3N-00221	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c666a6a-d028-11ea-b1fd-0aad30af8a83	CPT0202400004	1c64e751-d028-11ea-b1fd-0aad30af8a83	"C3L-02669-06, C3L-02669-07, C3L-02669-08"	1c63fbee-d028-11ea-b1fd-0aad30af8a83	C3L-02669	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664a79-d028-11ea-b1fd-0aad30af8a83	CPT0191860003	1c64bcff-d028-11ea-b1fd-0aad30af8a83	C3L-02619-01	1c63ebdb-d028-11ea-b1fd-0aad30af8a83	C3L-02619	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66f8c2-d028-11ea-b1fd-0aad30af8a83	CPT0234950004	1c657aa8-d028-11ea-b1fd-0aad30af8a83	"C3N-02523-03, C3N-02523-04"	1c643ee9-d028-11ea-b1fd-0aad30af8a83	C3N-02523	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c65f415-d028-11ea-b1fd-0aad30af8a83	CPT0001020003	1c646987-d028-11ea-b1fd-0aad30af8a83	C3L-00081-01	1c63ce99-d028-11ea-b1fd-0aad30af8a83	C3L-00081	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c672829-d028-11ea-b1fd-0aad30af8a83	CPT0237060004	1c65a8f6-d028-11ea-b1fd-0aad30af8a83	"C3N-03848-01, C3N-03848-02"	1c64527c-d028-11ea-b1fd-0aad30af8a83	C3N-03848	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6666e7-d028-11ea-b1fd-0aad30af8a83	CPT0202720003	1c64e22d-d028-11ea-b1fd-0aad30af8a83	C3L-02660-05	1c63f908-d028-11ea-b1fd-0aad30af8a83	C3L-02660	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6711d9-d028-11ea-b1fd-0aad30af8a83	CPT0209490003	1c6594ed-d028-11ea-b1fd-0aad30af8a83	C3N-03204-01	1c6449cd-d028-11ea-b1fd-0aad30af8a83	C3N-03204	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c662999-d028-11ea-b1fd-0aad30af8a83	CPT0104360003	1c649a8b-d028-11ea-b1fd-0aad30af8a83	C3L-01884-02	1c63df63-d028-11ea-b1fd-0aad30af8a83	C3L-01884	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66fef4-d028-11ea-b1fd-0aad30af8a83	CPT0187370003	1c6580a5-d028-11ea-b1fd-0aad30af8a83	C3N-02675-04	1c644197-d028-11ea-b1fd-0aad30af8a83	C3N-02675	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c663f98-d028-11ea-b1fd-0aad30af8a83	CPT0112730003	1c64b1d4-d028-11ea-b1fd-0aad30af8a83	C3L-02358-06	1c63e857-d028-11ea-b1fd-0aad30af8a83	C3L-02358	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664340-d028-11ea-b1fd-0aad30af8a83	CPT0112650003	1c64b600-d028-11ea-b1fd-0aad30af8a83	C3L-02546-03	1c63e93a-d028-11ea-b1fd-0aad30af8a83	C3L-02546	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66ed7e-d028-11ea-b1fd-0aad30af8a83	CPT0115830003	1c65701d-d028-11ea-b1fd-0aad30af8a83	C3N-02434-01	1c643b5a-d028-11ea-b1fd-0aad30af8a83	C3N-02434	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c666b40-d028-11ea-b1fd-0aad30af8a83	CPT0202350004	1c64e874-d028-11ea-b1fd-0aad30af8a83	"C3L-02669-01, C3L-02669-02, C3L-02669-03"	1c63fbee-d028-11ea-b1fd-0aad30af8a83	C3L-02669	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66642b-d028-11ea-b1fd-0aad30af8a83	CPT0204990003	1c64ddff-d028-11ea-b1fd-0aad30af8a83	C3L-02650-05	1c63f6e1-d028-11ea-b1fd-0aad30af8a83	C3L-02650	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c672c5d-d028-11ea-b1fd-0aad30af8a83	CPT0237210003	1c65ad9a-d028-11ea-b1fd-0aad30af8a83	C3N-03851-03	1c64549b-d028-11ea-b1fd-0aad30af8a83	C3N-03851	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6660f2-d028-11ea-b1fd-0aad30af8a83	CPT0204800003	1c64d955-d028-11ea-b1fd-0aad30af8a83	C3L-02649-04	1c63f5f6-d028-11ea-b1fd-0aad30af8a83	C3L-02649	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c665686-d028-11ea-b1fd-0aad30af8a83	CPT0202170003	1c64cb24-d028-11ea-b1fd-0aad30af8a83	C3L-02629-01	1c63f13d-d028-11ea-b1fd-0aad30af8a83	C3L-02629	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66633f-d028-11ea-b1fd-0aad30af8a83	CPT0205000003	1c64db9d-d028-11ea-b1fd-0aad30af8a83	C3L-02650-06	1c63f6e1-d028-11ea-b1fd-0aad30af8a83	C3L-02650	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c671c1f-d028-11ea-b1fd-0aad30af8a83	CPT0245880003	1c65a011-d028-11ea-b1fd-0aad30af8a83	C3N-03441-01	1c644ea0-d028-11ea-b1fd-0aad30af8a83	C3N-03441	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c668e44-d028-11ea-b1fd-0aad30af8a83	CPT0207210003	1c650c6e-d028-11ea-b1fd-0aad30af8a83	C3L-03965-02	1c640e00-d028-11ea-b1fd-0aad30af8a83	C3L-03965	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6708a8-d028-11ea-b1fd-0aad30af8a83	CPT0236420003	1c658dbb-d028-11ea-b1fd-0aad30af8a83	C3N-03076-02	1c64461c-d028-11ea-b1fd-0aad30af8a83	C3N-03076	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66907d-d028-11ea-b1fd-0aad30af8a83	CPT0233320003	1c651004-d028-11ea-b1fd-0aad30af8a83	C3L-04013-05	1c640ee1-d028-11ea-b1fd-0aad30af8a83	C3L-04013	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66030b-d028-11ea-b1fd-0aad30af8a83	CPT0064040003	1c6477a0-d028-11ea-b1fd-0aad30af8a83	C3L-00603-02	1c63d345-d028-11ea-b1fd-0aad30af8a83	C3L-00603	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c667321-d028-11ea-b1fd-0aad30af8a83	CPT0197100003	1c64f17d-d028-11ea-b1fd-0aad30af8a83	C3L-02963-06	1c63ffbf-d028-11ea-b1fd-0aad30af8a83	C3L-02963	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c668b3a-d028-11ea-b1fd-0aad30af8a83	CPT0207250003	1c650a67-d028-11ea-b1fd-0aad30af8a83	C3L-03965-06	1c640e00-d028-11ea-b1fd-0aad30af8a83	C3L-03965	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6696d5-d028-11ea-b1fd-0aad30af8a83	CPT0234580003	1c651928-d028-11ea-b1fd-0aad30af8a83	C3L-04391-06	1c641335-d028-11ea-b1fd-0aad30af8a83	C3L-04391	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664b7d-d028-11ea-b1fd-0aad30af8a83	CPT0227070003	1c64bf01-d028-11ea-b1fd-0aad30af8a83	C3L-02624-07	1c63ed9b-d028-11ea-b1fd-0aad30af8a83	C3L-02624	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
1c66f20c-d028-11ea-b1fd-0aad30af8a83	CPT0241210003	1c657473-d028-11ea-b1fd-0aad30af8a83	C3N-02435-07	1c643c43-d028-11ea-b1fd-0aad30af8a83	C3N-02435	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c661b66-d028-11ea-b1fd-0aad30af8a83	CPT0087190003	1c648bf9-d028-11ea-b1fd-0aad30af8a83	C3L-01285-02	1c63da0d-d028-11ea-b1fd-0aad30af8a83	C3L-01285	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66eb16-d028-11ea-b1fd-0aad30af8a83	CPT0147200003	1c656bff-d028-11ea-b1fd-0aad30af8a83	C3N-02426-03	1c6439ab-d028-11ea-b1fd-0aad30af8a83	C3N-02426	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66b006-d028-11ea-b1fd-0aad30af8a83	CPT0083990003	1c653486-d028-11ea-b1fd-0aad30af8a83	C3N-01025-06	1c641f10-d028-11ea-b1fd-0aad30af8a83	C3N-01025	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6667bf-d028-11ea-b1fd-0aad30af8a83	CPT0192590004	1c64e448-d028-11ea-b1fd-0aad30af8a83	"C3L-02665-06, C3L-02665-07, C3L-02665-08"	1c63f9f7-d028-11ea-b1fd-0aad30af8a83	C3L-02665	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c673a01-d028-11ea-b1fd-0aad30af8a83	CPT0221660003	1c65be5a-d028-11ea-b1fd-0aad30af8a83	C3N-03886-06	1c645c44-d028-11ea-b1fd-0aad30af8a83	C3N-03886	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c673646-d028-11ea-b1fd-0aad30af8a83	CPT0237760003	1c65ba53-d028-11ea-b1fd-0aad30af8a83	C3N-03882-01	1c645b1c-d028-11ea-b1fd-0aad30af8a83	C3N-03882	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c665344-d028-11ea-b1fd-0aad30af8a83	CPT0202020008	1c64c73b-d028-11ea-b1fd-0aad30af8a83	"C3L-02627-04, C3L-02627-05"	1c63f055-d028-11ea-b1fd-0aad30af8a83	C3L-02627	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c672fff-d028-11ea-b1fd-0aad30af8a83	CPT0237430003	1c65b0d1-d028-11ea-b1fd-0aad30af8a83	C3N-03875-05	1c645582-d028-11ea-b1fd-0aad30af8a83	C3N-03875	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c67243f-d028-11ea-b1fd-0aad30af8a83	CPT0219390003	1c65a5ad-d028-11ea-b1fd-0aad30af8a83	C3N-03662-06	1c645197-d028-11ea-b1fd-0aad30af8a83	C3N-03662	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66a227-d028-11ea-b1fd-0aad30af8a83	CPT0068320003	1c6527c6-d028-11ea-b1fd-0aad30af8a83	C3N-00555-07	1c64197c-d028-11ea-b1fd-0aad30af8a83	C3N-00555	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c67203c-d028-11ea-b1fd-0aad30af8a83	CPT0195520003	1c65a161-d028-11ea-b1fd-0aad30af8a83	C3N-03486-06	1c644f86-d028-11ea-b1fd-0aad30af8a83	C3N-03486	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c67005c-d028-11ea-b1fd-0aad30af8a83	CPT0187380003	1c6581cc-d028-11ea-b1fd-0aad30af8a83	C3N-02675-07	1c644197-d028-11ea-b1fd-0aad30af8a83	C3N-02675	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6687fd-d028-11ea-b1fd-0aad30af8a83	CPT0227420003	1c650749-d028-11ea-b1fd-0aad30af8a83	C3L-03963-06	1c640c5a-d028-11ea-b1fd-0aad30af8a83	C3L-03963	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6616a7-d028-11ea-b1fd-0aad30af8a83	CPT0102790003	1c6484f8-d028-11ea-b1fd-0aad30af8a83	C3L-00993-01	1c63d788-d028-11ea-b1fd-0aad30af8a83	C3L-00993	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c67105a-d028-11ea-b1fd-0aad30af8a83	CPT0197740003	1c6593d1-d028-11ea-b1fd-0aad30af8a83	C3N-03093-03	1c6448e6-d028-11ea-b1fd-0aad30af8a83	C3N-03093	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c673369-d028-11ea-b1fd-0aad30af8a83	CPT0237690004	1c65b672-d028-11ea-b1fd-0aad30af8a83	"C3N-03880-01, C3N-03880-02"	1c6458c9-d028-11ea-b1fd-0aad30af8a83	C3N-03880	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c671a67-d028-11ea-b1fd-0aad30af8a83	CPT0245830003	1c659cd1-d028-11ea-b1fd-0aad30af8a83	C3N-03425-05	1c644ca4-d028-11ea-b1fd-0aad30af8a83	C3N-03425	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c674dbb-d028-11ea-b1fd-0aad30af8a83	LSCC Tumor ONLY CR	1c65e9e4-d028-11ea-b1fd-0aad30af8a83	LSCC Tumor ONLY CR	1c6463d7-d028-11ea-b1fd-0aad30af8a83	LSCC Tumor ONLY CR	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66fdf8-d028-11ea-b1fd-0aad30af8a83	CPT0147700003	1c657ebe-d028-11ea-b1fd-0aad30af8a83	C3N-02575-03	1c6440b1-d028-11ea-b1fd-0aad30af8a83	C3N-02575	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6707d2-d028-11ea-b1fd-0aad30af8a83	CPT0236430003	1c658ba2-d028-11ea-b1fd-0aad30af8a83	C3N-03076-03	1c64461c-d028-11ea-b1fd-0aad30af8a83	C3N-03076	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6647ba-d028-11ea-b1fd-0aad30af8a83	CPT0191930003	1c64bb01-d028-11ea-b1fd-0aad30af8a83	C3L-02619-08	1c63ebdb-d028-11ea-b1fd-0aad30af8a83	C3L-02619	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66fb6a-d028-11ea-b1fd-0aad30af8a83	CPT0147680004	1c657d9c-d028-11ea-b1fd-0aad30af8a83	"C3N-02575-01, C3N-02575-02"	1c6440b1-d028-11ea-b1fd-0aad30af8a83	C3N-02575	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6679bb-d028-11ea-b1fd-0aad30af8a83	CPT0217490003	1c64f9c7-d028-11ea-b1fd-0aad30af8a83	C3L-02969-06	1c6404e3-d028-11ea-b1fd-0aad30af8a83	C3L-02969	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c663c88-d028-11ea-b1fd-0aad30af8a83	CPT0112550003	1c64aedf-d028-11ea-b1fd-0aad30af8a83	C3L-02349-06	1c63e6ac-d028-11ea-b1fd-0aad30af8a83	C3L-02349	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66da96-d028-11ea-b1fd-0aad30af8a83	CPT0136660003	1c655e6e-d028-11ea-b1fd-0aad30af8a83	C3N-02339-06	1c643493-d028-11ea-b1fd-0aad30af8a83	C3N-02339	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6734c4-d028-11ea-b1fd-0aad30af8a83	CPT0237710003	1c65b85e-d028-11ea-b1fd-0aad30af8a83	C3N-03880-03	1c6458c9-d028-11ea-b1fd-0aad30af8a83	C3N-03880	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c664184-d028-11ea-b1fd-0aad30af8a83	CPT0112720003	1c64b2fa-d028-11ea-b1fd-0aad30af8a83	C3L-02358-03	1c63e857-d028-11ea-b1fd-0aad30af8a83	C3L-02358	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c66f7bd-d028-11ea-b1fd-0aad30af8a83	CPT0234790003	1c6578d8-d028-11ea-b1fd-0aad30af8a83	C3N-02494-01	1c643e02-d028-11ea-b1fd-0aad30af8a83	C3N-02494	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c673bc7-d028-11ea-b1fd-0aad30af8a83	CPT0237970004	1c65c1e4-d028-11ea-b1fd-0aad30af8a83	"C3N-04124-01, C3N-04124-02"	1c645d23-d028-11ea-b1fd-0aad30af8a83	C3N-04124	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
47b273c2-d4a5-4cf6-8ed8-551cd6c5fe0c	Frozen-bridge	16d7cf28-d501-4845-af50-581879c46b79	Frozen-bridge	6dc777d4-4a5b-4387-9ed2-0d2fa9f4ff72	Frozen-bridge	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Ovarian Serous Cystadenocarcinoma	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fba1c95a-905e-4a5c-b619-f91f8f812779	550490	e3f806da-56b0-4601-bcaf-ae648fb684cc	550490	c18d71bc-38a8-416b-8f0c-7daf32ff1e00	88	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b4420828-5af9-41d0-8012-bdf9af9dd7ab	497531	5da2ac09-e8ef-4fd3-b49d-ded4dee33c60	497531	a744a4c1-0ada-44d3-8dbd-b074d0b5ca41	72	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
053d5664-ea0b-41b1-9ea8-72f5e98b9b3d	517836	5cbe6bcf-9c43-4020-a5b2-5b64251300b1	517836	48a1f1f7-1624-45d1-aca8-e28b02937129	81	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
72e8d6fc-fbb7-49ca-bc6c-5884b5bd8717	315565	566916a6-9478-4120-a184-3805828d4912	315565	0d5fdb95-4a5a-4a03-a571-08a6e4e94aeb	52	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e2c3cbf8-d0b2-42a0-ad54-30dba996b3ce	497549	ed2a2c89-bb71-413b-8627-93e242d47d52	497549	3150e7be-07b2-4deb-ad73-b99fce3db045	73	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
133f5552-25a9-4539-8858-7363ce442e81	578943	30d4d8a8-29a4-465c-b2b0-bded765df050	578943	2ee1964f-9d11-48a2-8297-60f7921d8e9d	89	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7646fc8b-26c3-40fd-b833-ab86a49b171a	394775	8a0a33ee-064d-4860-96e9-af988f5af0ac	394775	d156dfa2-d56a-4c56-b6a6-b6007f84db27	61	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
824a6183-39eb-4330-9e6d-9fa494245b84	425197	653784cc-4791-4149-b047-6b3ad560c3ec	425197	fe0c8f04-c46e-4252-812d-d70e34bfe984	62	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64759c0b-9105-4c24-ae17-b33a0e2ff3b0	525809	b2be5ff4-0758-43b2-a36d-972bab783be8	525809	a451fbab-fdef-4ce8-adbe-547e02e11f89	79	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a5f2e71f-d75e-4413-bc1a-e2cd4827ee02	352396	b79dca14-2848-4cec-8803-a51dc012b759	352396	2024d5c3-8ddd-44a2-9114-3f454dfcf03f	55	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5bd24792-8f64-4de9-ae9c-33164bcc5159	484990	6d1e186d-3fdd-40db-9772-2e55677d277c	484990	df39bf96-1f43-48bd-85a5-fde1d3bf3396	74	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8c98a9a4-5c64-4412-8b35-b4e67b9dd834	348802	01628ce5-fc2a-45df-98af-94f325081157	348802	6d3aa7dd-ee5b-48aa-bf99-736a67a85eeb	54	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
35dd21e5-ad4e-4b66-bb37-16cd7e1d664b	510199	9af22e30-a5c2-4366-800f-a8188060907b	510199	458f0219-c07b-45a2-95d2-85a23c955ecb	77	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6b3828c0-93a0-44fa-8e84-dfe671694fc5	261437	f0f03a3d-5341-4b2e-8707-ee99fd6f7690	261437	82133ac9-a5e7-4b33-b3d4-7774056d17ec	35	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e0a07074-601d-4498-a96d-915067358a40	297950	8acc7a34-5e59-46e9-830d-1c3aa66ce359	297950	cd8fe248-0dfc-47c7-a91a-007c45c8bf00	48	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aad8e9a1-ef93-44bc-b4ac-e71bfd8fbbcc	Cell_line-bridge	1812a1f6-7900-4594-9fe7-00c4441a0794	Cell_line-bridge	cf60430a-2699-4645-a093-3ab0fbad7939	Cell_line-bridge	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
15aa685d-3c9d-4c5d-9aaf-fc87e3c55fb7	348590	8fafea5b-840d-4684-8795-3b211999121e	348590	762c9f38-6669-4c81-94e9-70f3e4b693aa	53	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dff7045c-f6ae-4981-b08f-5954fd720f44	218727	324f3cdf-bcb5-4c38-a647-3a51c30c57f5	218727	06d18ddd-b386-40af-acd2-6673929d656e	22	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c0c55aa7-ac2b-44cf-aae3-3d069df33a27	500489	bda8268e-1d90-453c-b684-5aacc592f23a	500489	40a7b022-671f-4fcc-a0be-9214ae433f5f	5	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
458e79f8-5dae-4222-bfb5-53406d416f77	500273	5f68f72a-c038-43ad-9da5-d1b4b439fd1b	500273	2ae9b699-e485-4880-a3a2-f84970d70a5a	1	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ca81440e-4528-4eee-a046-3e7fbf477563	532322	6d86c85b-2dee-4646-bff4-c02d8503c58b	532322	d58a7e0b-c515-4402-aa5d-c11eec85085c	85	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d61a148-d9db-47d5-a892-9fd858cecc76	315157	8f83138d-e251-4ec9-a316-3ef76bfa79d9	315157	d977d424-bfc6-4cb7-b9db-67e6e3fad6e8	51	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0b19779b-2ea3-4d70-ad0c-0d00b16c2cbf	265380	44d8d4e1-3159-403b-b317-22d2a8913ad4	265380	ceb780d1-4198-4910-a41e-f65660b17f38	36	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4b8811c-477b-45e7-849a-577634a4d803	501308	2a130025-004c-4c5b-95ae-d526a55d58af	501308	2794dfbd-93bf-4369-bbe0-01e692938eed	12	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8d8f6d3b-ad8a-43c3-a3f7-65a2cc77fb60	536710	c172d29e-8a62-4adc-8f0a-6685d5909891	536710	7702b2fa-2aca-47dc-9757-a517585ab11d	84	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0f20cb9-c152-4a9c-8dfd-ede002b70ff1	557978	1400b168-0ee2-4fb0-a502-c063c8ff79e1	557978	09cd7eb4-42a9-4619-8809-ef5cf6e66f67	87	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e322f3d-c8f0-4a37-8d8f-07131aa4805d	371244	7c3a9d98-8a34-4808-a548-c2c9ebdd5a45	371244	4c2b0b7e-648e-487d-8052-65dcbe84cb8d	98	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a4cf4102-30cf-43dc-ad5b-2f7a8ce6432b	356112	f9331194-8814-4f0c-b8e4-9e4f27442e72	356112	e90c7ab7-4382-434f-b13e-44bf0966d21a	97	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c396447-58e3-40bb-b66a-c9597dab3601	500359	c6a8c1ba-62c2-4171-89f8-fc84c7745153	500359	6a9ab0d8-41c4-4a3f-b4e4-feb265255493	3	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6f74c8f1-3287-4ab6-9902-78ce78632f31	245128	513b9487-94cf-4ccd-9915-5eb4097757ea	245128	57efbe85-edb9-4a0a-b18f-85d178623807	33	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
136372a3-f60d-4ff7-a93c-2f0c032396a0	439629	95cf25e6-0951-417b-8092-23e74c76bd51	439629	13ac1593-912d-47ff-889e-3a55d952773a	99	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c9e9f732-171e-40b2-87ab-edb162636a50	371279	11ce0586-5d84-4837-a4c9-67e4a8d68a29	371279	89525db0-dfe3-4ba7-a5a8-396454f8888b	58	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3bef520f-2fbe-4495-83bc-d7a39e576ec3	425572	33de3813-be7e-4f84-8960-624d071ac4c7	425572	d0be692b-a112-4263-9538-aa719b588f33	63	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f0daf9a0-a1b9-4423-8afc-0b59db898a20	439624	bf93d0ac-15ee-40c4-8a23-0b224e7074ac	439624	cadfbcb2-8840-46ba-95b6-1cc0ab1569fa	64	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4577aadc-4c32-475d-999e-89ff253f051e	454526	8a9e7529-3ec7-481f-8101-76858b4f9184	454526	be3b9ad4-2351-4809-87b4-15ad70153300	65	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a1d3249-3b31-481e-955c-6ea8ceafebdd	260522	45873a86-de2e-4693-b7f0-52ab58a6373f	260522	604e0a19-d354-45d2-a6c2-fda6872c199e	34	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
47130988-7848-40fc-9076-cb545b4ca065	589667	8d9c5933-055c-4b1f-8d81-a7749af94d03	589667	00cb6713-234c-465c-9c2e-397168bb3bca	93	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
694522ad-eaa3-4395-9ee5-9127647c950c	484931	949d6c90-42ba-49ff-b471-00322a5be991	484931	087198d9-0eb8-4891-9615-b7363a690dc9	70	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
43ce53b6-3013-49b8-9538-a1b98a7382bd	394759	461c1005-4f81-4c28-9efc-103ff18a51ca	394759	0d507744-28f4-48c7-8185-aef3dae3761b	60	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48ab0b13-47aa-4b65-9d8c-975f2526f3ba	630908	319dffab-eb24-47a0-abfe-37f93c3a497e	630908	7424dc9d-eb03-488d-906f-8abf12384771	94	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57e77c63-ad0c-43b4-aa92-9602bbddb6ff	494977	ab97466a-ad04-4b53-80f6-08634438781b	494977	a406851b-a980-4a6b-85fe-074a626a7035	78	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d52f8b1c-bfd0-40c2-9df5-954feb36f465	266574	cff30dbf-f6f4-4929-a1ed-d956daca15fe	266574	b98022cb-cdc7-4e76-9894-37309c1c656b	39	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c7a3281e-68d7-49ed-848c-15509d32b5e2	500864	775a3314-11ed-43ad-b819-0068ccbedf04	500864	e156560e-76b6-4eeb-ad0c-ead6b310b76f	10	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b28e7258-9f2d-40a6-bca6-a993cd231cac	550440	fe1174d4-0732-4913-b086-698d76b4aa35	550440	6c3a122e-9f69-4252-bbaa-3ee501db83c1	69	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
28293f86-88ba-452e-a94a-2fb297efab13	278004	71548e58-8d74-4977-a310-63e5442ee382	278004	56aeb967-2b35-43ed-b517-a577490f14d3	44	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d0a4e0ba-1e2d-4326-9f54-d0227f7737d3	394776	50f58aa0-3691-4798-9bd8-3110d14df3ad	394776	ae9df8dd-d642-402b-a24c-b6d36f5767c6	59	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9f79a089-24d8-435b-9be8-97d5cbe76969	516854	1956108e-fb35-41e3-bdb0-b409117fa107	516854	41422b5d-7ed1-4f9a-abad-498f1b8892d6	80	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4da666d-f50c-42ed-9cf8-2424f61e03d1	305257	f7425e94-5ae7-4837-9aca-7900a81cb6fc	305257	fb3ea6ea-190c-4acd-8302-d3121e8ffc2b	50	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f4b7ffb9-9887-47f8-b9ff-b1a8a42c2afd	265359	bbe7ee29-c83d-436f-8346-4fd6addfd2ec	265359	9add0362-ce18-4488-b9b2-5fe670d21001	38	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
78ca19ac-30eb-43b5-a52e-2dc101f32b44	233043	693c0fff-ff37-424c-85ca-e4e6e8771c6b	233043	2defc710-1e1d-4254-bab5-bda0839e5bd6	29	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
022d00d2-2f8b-4d89-80c3-300fb5d9136d	536669	1d2e05b0-bf02-462e-a0d4-71cc81414bb3	536669	61681af3-ac1b-469c-bf25-1c9de84e95d4	83	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d8493a0-ad5c-4191-92a8-c8576121fe76	305272	f48a4424-327b-4bb8-84c4-562c1d0c0b68	305272	8e2701d6-c0ba-4b8e-b1e1-899e72c35bab	49	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ca574b5-87c6-41d6-aade-423ef91106c6	215379	f864cd9c-c0ab-45e9-8e2c-9a6cea68b2bf	215379	0ba60abe-2490-4fd5-8998-503981650647	19	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3bab7e0e-65ca-421b-9e05-6b38e4eb4b91	522320	7d06f97e-0a52-40a5-b3cc-7db22365823b	522320	a3842772-b155-4d18-bc2a-966c960c1b67	82	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d5113b8-e74a-4485-8e93-6d0dd3be4fdd	222860	da5e441c-d621-4721-878e-1be8d30fd2b6	222860	0d98b6e2-f618-4449-b76a-1c197ff5b45b	25	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6413015f-6f33-42eb-873d-463e71da783e	277466	7efe80d1-a386-4dd1-888a-41491e288fcd	277466	1e05fbc3-c2f1-412b-8c4f-8fed99480130	41	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a85d59ba-7e35-4b5a-95e2-ee43b99df27f	497522	1451a5c1-0d35-4071-bc50-3734306e60ac	497522	f91df0ed-73ba-402f-8ca6-18aaaf557625	71	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a4193dc5-299d-4834-9529-573e30a437c8	216561	47749daf-aed8-4741-9cf7-5708b01b7d28	216561	d1643329-ccde-48ae-a4c3-93f269eaffd7	21	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e49f2a54-1b0a-45e0-8404-33096a4a9a32	454509	cfe2f46c-c5de-4e45-977c-78972fd4bfbb	454509	6f2c070e-a11a-4a0b-bbf8-1c109f400c5a	67	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c2bc5f04-6c80-4b47-9ff1-5d2255b287e3	501218	8b0941b1-ff1b-4573-84e7-cc9b36cc37aa	501218	fb3935ed-d07e-41b9-9347-14e72af3210a	8	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb6cade7-606e-4364-ad29-03bb6ef73a0c	500557	6d9e5ed9-d7c3-4811-b90c-623b52463c7f	500557	fbe4f529-26b6-4203-9f83-4a0405c9cf74	6	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
281fc61d-5839-4b58-9a1f-a97c9e8ac52a	272322	4b7057b2-8371-4dcb-a0b7-73c0844507fb	272322	094e5402-eac9-42f0-9fda-84c538381332	40	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
71721ab5-6751-4331-8182-f5aca5eac2ba	467901	6f306df3-63b7-4246-af43-d9abc97257f4	467901	6a865304-6c02-49b3-a9f9-3c49f12c7b76	66	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fe4bc9b4-b267-4d2a-93c4-cd3196732839	557959	9258aa87-6c68-41a1-a49e-a9eb888222d4	557959	7ac17db0-7fd5-4ac1-a8be-f6493c2ebe2c	86	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b14015ae-281c-462d-a9cd-4c53e790e313	243305	6aa3287a-093e-4da1-baf4-667dc06b4687	243305	e1f526c3-081b-42fd-923f-e270066b1ed3	32	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e2db87a9-05ed-48d2-b043-275dcccd6be0	NCI7-1.0	6af95db8-f59d-4ee3-832b-05a027a526c0	NCI7-1.0	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6aaaee1e-5794-4e53-b66a-5a3dedd7b31a	NCI7-0.5	676b6097-9e16-48c8-ad46-7c23b2caff6a	NCI7-0.5	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f256a2e-10a6-46fa-8d4f-24ab5bd490e1	15-00464-1	11e50d49-2870-4327-9316-4c69a4622ee9	15-00464-1	36506ff4-d802-4a8b-9f4d-0380f5e0383e	15-00464	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d45b53f8-9d04-413e-8e29-562e7d71aeed	13-00166-1	8c78cc8a-b631-457e-9e86-67518eff8d71	13-00166-1	471583d8-f3c3-4de8-ab99-697f68bf478c	13-00166	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd4de19e-7e47-43ec-845f-f5847dfa26ac	14-00034-1	970d5b38-2fe5-42d8-8c4a-d1444fd47715	14-00034-1	be63d5b8-5304-4669-8b03-b7970913f63f	14-00034	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
41e69fb9-7d41-4829-ab41-6d050aac1834	Cell based ref	e490d8b7-4674-4b78-8b25-a43f241fe4f0	Cell based ref	dbc5d128-9919-4828-82a8-0edf911934c8	Cell based ref	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2baac598-10f1-43e4-8adb-bce3e516a910	13-00515-1	2981ca0b-a2f9-4686-88ae-ddc0e612cea2	13-00515-1	8504fb62-b191-4b31-826a-21ec2fd5965e	13-00515	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0442ff95-bd92-4f0b-a1a2-5458329a8fab	14-00537-1	9e2f3f73-ac22-4a5f-818f-1a9020daa2a1	14-00537-1	99295144-497e-4739-a12b-37f2dd7b41c0	14-00537	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9064e298-fa35-4479-9f64-2fa75077f64f	Standard ref	b23c7354-ae7b-44fb-86ac-731c55481d7c	Standard ref	44159120-a5f5-4748-8d4b-0a092edb9416	Standard ref	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5bbc5be5-e4cf-48f8-847c-75b91d7fa2d1	14-00083-1	9f321083-bf93-4802-b0f9-33fa580df63b	14-00083-1	5f81b377-3e44-4442-bf10-cabfab4aec04	14-00083	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Bone Marrow, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f346dce4-352f-42ec-8b05-9bd58f3557de	13-00034-1	acbeeac0-a25c-4f17-ab8d-81fa84cb99da	13-00034-1	19518ff8-4c98-4ecd-8160-d240f9f65519	13-00034	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2849e39a-2958-4489-b242-b3b45d0bf751	14-00045-1	ef39a8b5-936c-4028-a90d-50ecb7dbe2ea	14-00045-1	1978e6d5-749a-45ae-b842-ec8aac61709a	14-00045	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e6ce5d01-4609-4c6a-aa71-541e3f4652a7	14-00240-1	85af460e-e2b9-4580-a02f-6897a1e882c8	14-00240-1	ff01e476-7788-4169-b0c3-c1326df53754	14-00240	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a8b340e4-fd0c-429c-9aa1-0e2ba99f2362	13-00602-1	daf2ddd9-f42e-45f0-9631-a533b1047d93	13-00602-1	715e0715-ccb0-4f6b-be65-133a28daa0ed	13-00602	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
18f0285e-e800-4952-b96e-6fbe1b500bc2	12-00211-1	d543bb75-f656-4834-8b0e-6b3b9bdba9c9	12-00211-1	d05e193d-6d8d-437b-8f72-ed0b915a58af	12-00211	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4910aecf-292c-4180-a7ae-918eebe96efc	14-00359-1	da235a5a-6f2c-406c-a347-98c2c29e01cd	14-00359-1	fda378ef-6b26-4983-b9ad-5f7fdc178d4d	14-00359	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f91c04b3-593b-4252-b1c4-5767e200df14	14-00488-1	aa8dd03f-5015-418c-b9f2-9bdd96899082	14-00488-1	6a320878-e4fd-4cf2-8639-b01352acd5cf	14-00488	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c94145c8-0ceb-4b33-bca3-20f484d7ea27	14-00495-1	04982f40-f5b2-4d8c-b181-8c920e39a882	14-00495-1	c32220ca-6d32-4f31-a90b-77494e68e28d	14-00495	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
597258f0-ff16-45a3-854e-45aa2b1d747b	15-00051-1	cb883da7-73ff-40b2-8c82-01c85506d538	15-00051-1	1411a35b-1847-4d87-b57f-993dfb9659f8	15-00051	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f47473b-12e4-41d6-8e18-14a3b2f4f76a	14-00127-1	a23e52b9-ab76-4d3f-a4fd-7cd503fb4b81	14-00127-1	f7558b71-faed-47a9-87e7-b71813be4cab	14-00127	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb8de4a5-a4ba-40fb-b4af-93c61072f895	231865;230368	0d946bcc-fc32-4619-9e00-64e6fd7c84b1	231865;230368	e64a4ea3-1723-4efa-910e-74adea72179e	28	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
441b928c-bf71-4fad-b180-260664fa9505	215376	fbce99ef-2c8a-4e58-9e7c-efd38a7b30eb	215376	0ba60abe-2490-4fd5-8998-503981650647	19	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
729dbb86-9667-4208-b1ae-b7915878b72a	206382;206375	7bdedcdb-6511-4989-bb43-3ade3a47a240	206382;206375	6cb0df35-8edc-4833-ac1b-1de94495208d	7	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae2945cc-6e9e-4f2e-b612-31740187adad	223154;222912	5c666146-5d62-4341-88ce-8b03282b311f	223154;222912	b5caec24-aa6e-4ef2-b74a-0bba909ce63f	26	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bde61f9f-67de-4d5c-a6ad-605e32a8fe15	210413	19b13e76-9941-452a-a616-b0be7f4412e4	210413	a048c5a5-69a5-49b5-b179-1e6cacbfe92e	14	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a1ccec8b-b9f6-488f-ba8d-c47d6021b619	38147_A2	094ab1c3-9dff-4e4c-9512-6e1c9a1997f0	38147_A2	92985d1b-bf75-4c22-930a-7ab88e484b90	3480	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a945da2d-8a79-4381-b0d2-a264c45e7aaf	S-07-0009498_A10	6754b470-4fe2-4bb8-bace-f2babb8895f5	S-07-0009498_A10	662e2c6f-8ed1-4494-b241-7e674e977bec	CU-01	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3b0afd8e-ab24-4431-a95c-04d80163750c	228608	49dde4a7-b58a-46b5-8b5e-7059127ca1c1	228608	0f36f356-056a-4474-b555-c63b76553cad	27	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
20b69787-87da-429c-808e-c09622288794	38735_A6	b7e50e1a-fc21-4699-8a8d-4d2ec4b2e30c	38735_A6	fea28bab-ee73-49f6-908f-001fba904960	3812	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59d77bc0-73fe-4b59-8e43-82d814961b30	S-15-0016317_B7	c2e2e569-57b0-47ac-942a-cfae88866715	S-15-0016317_B7	f1f7923f-f867-4950-ae41-c65a1bd9eb04	CU-16	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4cc80514-72c1-4167-81df-d38283aaea31	39433_A4	9088c3f9-0be4-4e40-b36a-7ed2cecce399	39433_A4	73e5b1c7-a06b-4255-b674-7b1700fcd111	4378	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da6f9d2a-2569-4d6f-859a-a15b61a7306b	36173_D1	cd0f793f-3bd8-4c51-87a2-2e9738478c58	36173_D1	d3c09427-73eb-4159-806d-2bc7fcdb9423	1711	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d897c637-e05f-4cd8-8898-019df64bc463	S-13-0034287_A2	2d4e9719-269d-4087-a153-18f5af9e03f6	S-13-0034287_A2	3d20a9a7-3477-423c-96be-1dde3eeb9d67	CU-15	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d2de0f30-da78-42b2-97b3-b4fb800cd67f	S-12-0007994_B6	a032657e-f1af-4c7a-a7ca-76846785210d	S-12-0007994_B6	ba206c6a-65fb-4eb8-952e-5bb9b95e63c1	CU-46	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a61b7dc-575e-4c0b-a8a5-e1244bcf5288	S-08-0007631_A2	7a8532a1-3414-4db8-bba1-9b6bf487c7c1	S-08-0007631_A2	d027bc04-d1b4-4af1-b578-e6dd62fa8a1d	CU-03	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e843461b-2b26-47cd-a8c5-fe1ce5ecd06f	FFPE-bridge	93ef31b4-9e34-40ad-89e8-21db980809be	FFPE-bridge	4fe131b7-427c-4e0f-99f4-f0ccc4a884cb	FFPE-bridge	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Ovarian Serous Cystadenocarcinoma	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d1be0f4-d71b-439a-bfb5-277326525b8f	37530_B9	c10f14bd-a813-4f23-9022-c61221ce16c2	37530_B9	f0da0133-d922-487c-a7f5-f962aa6d6123	2313	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2aa6b2fa-7517-4711-a275-6b368664020a	41634_A1	9dcc415a-6a92-4d5f-bc7c-0b72d5601c06	41634_A1	5de688b5-fd15-474f-8f3f-d82b708b18ba	5161	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
151d408d-9e96-474f-815d-4b7c723b8d6b	40885_B1	1340d71a-00f7-4d56-a139-cbb7a30c3479	40885_B1	3f0cf051-2ab3-4ad4-82c7-dfe4ff096342	7598	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
35c6fd5f-2456-4f62-bdf8-3bb4c473567d	S-15-0030998_A1	b29aeed6-f437-4ec5-b23e-37a6bc6f4465	S-15-0030998_A1	ac397d48-5a9a-43e5-9f4a-fc174ce3671f	CU-22	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e36245f7-dd4d-4df3-a102-8bbc49e01786	205927	f734cc5c-4309-4cb1-8f6a-8ea34c9faa83	205927	b77fc649-9ec6-4f67-82d6-f34923b4e1f0	2	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
80828f9e-64c7-4b12-9a2b-7f6be10525d7	277568	0e80d98a-a878-48d8-bdc0-e689c97ff488	277568	1e05fbc3-c2f1-412b-8c4f-8fed99480130	41	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3f466868-5b87-443e-a3de-32bc7d4ea986	S-14-0021444_B4	5c9d350d-253f-43ec-8a53-658a0747f4e6	S-14-0021444_B4	1186193d-462a-498d-8827-d2120814d9a7	CU-33	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5797f56f-cde5-473c-a313-037bc70d1e15	39955_B1	935448cb-5c8b-4bc4-be84-2e6e3c493119	39955_B1	098b33b8-0c30-4604-9469-ffc02e7c7dfa	7053	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cc8421f3-8e3c-40da-8c5c-5ccc627fad76	S-15-0033313_B1	73c322c9-46f5-47d3-b6fc-e6417b990777	S-15-0033313_B1	fdfb2d41-b56d-43b2-8817-b1a30058d47d	CU-23	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ad13029-4fb7-477f-87c6-4c256097e6f0	208877	0f95fbd7-4150-4eb2-83ad-37f2f27a0348	208877	f9ee7fef-2289-4046-9a9e-73a12f522e53	11	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f285209e-0f89-49b4-b223-bf28b7518d4f	41837_C2	362cd0e6-afc2-4023-be15-8b41d3882d8c	41837_C2	018f030a-4925-4514-910a-543e226721d8	3219	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
790bd7dc-9b57-4595-9a47-4f02fa0f61d2	260388	56200ce2-1750-4169-add3-6aff1b648ad4	260388	604e0a19-d354-45d2-a6c2-fda6872c199e	34	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
33bf9f25-aa12-46c5-8772-9bec69f010ad	S-14-0007480_A6	922cc5a4-211f-4005-a713-e5deb3ac3391	S-14-0007480_A6	72b5746e-c370-4bc0-a134-b86846c1ac37	CU-12	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b98c237d-407e-4006-9dcc-46db96627f1e	42571_C1	5e0a22b0-dde2-4ece-9d2e-742f4868a2b7	42571_C1	5f980495-81f1-4e46-b665-ec4c5a392401	13136	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
627fc0a1-aee0-491b-b214-16e42afcf6ca	360612	619a6f24-df15-4147-ace5-34ba6029e13c	360612	12a04b0b-19ac-41ee-be85-8a8682edfbd7	56	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df656c6b-f621-4f0b-9658-d04a6f96c207	S-13-0021879_A8	8616ce70-2f5d-4c2c-8c77-739f4f527e6a	S-13-0021879_A8	4f655fb1-aaba-457b-a0c7-93ae2ea0d9a8	CU-38	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9a1827ac-8de8-4303-90d3-1e44de6077b5	39184_A1	26ddb5d1-00c9-4515-ba4a-0bd29a0ba5e0	39184_A1	89bbca46-eb15-4ad4-8029-3b75fadb9e92	4114	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b80b2584-6c2a-48da-900d-e2c2a54aa406	38791_A1	998a124e-5520-45dd-bf4d-5deb472b94b0	38791_A1	3b26efed-c1e5-4e83-846a-9be38ede3168	3845	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9282abfb-abba-42af-8107-a755378826d3	39149_C6	085748b4-e03c-4372-ad2d-67bb42bb1f45	39149_C6	4ae1b34f-dd4a-4266-8f0a-85b8b164eb51	4086	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
358e7a90-2430-4323-8b60-90afa524f4c2	S-13-0010181_B3	5b0d0bbd-5c67-431b-93d1-ad68cdb391ef	S-13-0010181_B3	8f594864-d610-414e-8633-4b143afcdd6f	CU-32	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0b5bdfcd-c99e-4755-a5c1-423eb1290e7c	40414_A1	77ca2eae-c38c-4279-9a15-b22b56a65f21	40414_A1	fb24b127-337a-407c-b22c-9ae110971499	7339	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b2dcda73-5a15-4066-9e5b-9d89bc5479f0	39549_D1	336536c6-a999-45ea-b6c1-2bc5377a72b2	39549_D1	35627660-781e-4e75-8d88-55a347969544	4421	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a20f0e2a-2826-47ac-be32-9aec4d5cccdf	S-14-0022078_C1	94935dce-94e1-4690-9f84-ffeed9d5656a	S-14-0022078_C1	b9620eff-fa18-49d2-92ca-77c8aa54662d	CU-10	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c907a09a-3b5b-425b-b9d3-f000f0aa9fe4	S-07-0019837_B1	0c61209e-21a5-4c5c-a51d-ae8200d563e7	S-07-0019837_B1	08e33c2e-86d0-471e-8d4a-4e9b43145a9d	CU-05	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aba06334-b7d8-4b73-a377-f093792f4f94	654490	b24c0fc1-f563-4146-9f25-5bac25b2151d	654490	7424dc9d-eb03-488d-906f-8abf12384771	94	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
78afce15-5474-4164-bf2b-a186575827ca	297929	894e2d88-b730-4615-b0e8-f5e3179cb566	297929	cd8fe248-0dfc-47c7-a91a-007c45c8bf00	48	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
34056109-4cdf-4b40-be7a-3e8bb0df37a5	S-17-0024563_A14	696c3524-b4b6-4a9c-99c8-93847b2facf0	S-17-0024563_A14	676dfb4e-e4e1-4bbb-87ef-f71109212e18	CU-19	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cab52d5a-f79b-4341-9877-4c2dbb3d36f4	S-09-0000175_C3	85fce08e-90a2-4faf-905c-8d3c8364a5b8	S-09-0000175_C3	97c10567-b2f7-4175-b1ec-871dca5d1e41	CU-27	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7eac1855-4739-4c68-8ada-887020839f30	465021;465023	26998260-08d5-4544-9cf7-e57d7bebcd6d	465021;465023	be3b9ad4-2351-4809-87b4-15ad70153300	65	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fa52debc-a116-4e17-9f4a-61e68bdf7696	S-12-0006563_D3	623fe14d-cc58-475a-a362-ec4912bb2f61	S-12-0006563_D3	02f4f83c-b5e4-4416-9c34-3502900725c9	CU-44	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d76c8538-1890-4ff8-978e-b2c2a82032b3	S-11-0025953_B7	cc762a4a-38b8-4fcc-b762-c8fe1a966184	S-11-0025953_B7	3b406ce7-2293-4804-8547-c0831d71d1cc	CU-45	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cff213b1-3267-4961-ad58-b9d87652f79c	527499	13b0e5a2-1a55-4377-b223-2571e204fd94	527499	a406851b-a980-4a6b-85fe-074a626a7035	78	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8fe4ce4e-0ebc-4ada-bc96-79b71311e8af	372440	17b2bf09-faa7-42d8-98ab-faca79a7007e	372440	15d0c3f2-b9ed-45d0-add6-a9d7065072d0	57	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f8e03304-954d-4080-932e-8e3ef17c3c21	493391	b3e6c746-9709-4a00-ae49-47c9aee8e15b	493391	430aa4bc-cbce-4035-b426-1b343ba7ada5	76	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3c2c529c-84cd-4227-8d43-727b861fc542	501213	8b5e22bd-c366-4f63-a979-81a23da43b81	501213	fb3935ed-d07e-41b9-9347-14e72af3210a	8	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b948cb86-7406-412d-8a28-4372424ff0b6	265871	525d5f19-a435-44a2-b6d0-f64cb96fd8a1	265871	9add0362-ce18-4488-b9b2-5fe670d21001	38	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
98b71d14-39ad-4a25-98b4-7bf7e0490cb2	S-08-0003179_A1	348c024e-2725-4e8c-b79c-673023095baf	S-08-0003179_A1	ccd36fc0-a116-4083-bdac-49b0a54e2ea0	CU-07	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7e4bdfa3-7cbd-45fe-b79f-17ac2629281f	37624_B1	322f59cd-6b04-4d90-b545-46c0bbbab2bb	37624_B1	fbf58ac5-2c80-45d7-9eca-ac9aa92a979f	4968	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
42c2b6bc-6f96-4dd5-af4c-d212b34bdd1f	476540	5919adbb-5f38-4203-99d5-cf78de62d8b9	476540	a744a4c1-0ada-44d3-8dbd-b074d0b5ca41	72	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f8926934-0d7c-4707-a634-cc5e703254de	244726;246014	fcd127eb-ec23-4eef-97ee-4eb52ab4efd6	244726;246014	57efbe85-edb9-4a0a-b18f-85d178623807	33	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e662eb6-4b60-4901-8b54-482d06f6269a	39968_D7	cdd768d2-c808-4f79-bef2-6aac8ac7b924	39968_D7	8311ce43-ad06-4c31-97bc-c9aad468d221	7064	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d2b2bb33-0d14-48b4-863b-d3d2bd9cf226	S-11-0016358_A3	7ad09ee8-0239-4cfa-b6a5-356e7d3f2ff7	S-11-0016358_A3	8e1a9c85-c211-421c-a5cb-39af8606231e	CU-41	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ebefa119-1ab2-4158-96c7-4eeffd25a0bc	536848;533117	29aa49c0-90ac-4496-8089-6fc37b671687	536848;533117	6c3a122e-9f69-4252-bbaa-3ee501db83c1	69	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
35ff1e50-0016-4711-8445-bcabd9e2c3de	38616_A1	4d1d03b9-2406-4260-a2c7-f5379848a9ff	38616_A1	43a16a7c-0193-4318-97ad-0d7b22ffdb4d	3714	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0a76a7fb-c6ee-439c-abf5-fcc04fc387cc	37571_A1	f321dd27-0ccd-4dfc-8bfc-e4e67a787a29	37571_A1	e99a4313-ae34-4cc9-925e-6f5250833e93	2510	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c3fcbbe4-d03d-4c06-b5ad-0bb5cfe987c0	S-13-0003847_B3	2613d737-3fea-4d88-80fc-848a9426ea05	S-13-0003847_B3	933a939a-a85b-4d79-8821-765a9b1a8bfd	CU-14	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4909de7f-e5c5-4fbd-b60e-e4109acd4132	262427	fd1b8887-c60a-4ff9-96de-b3265b09f6c7	262427	82133ac9-a5e7-4b33-b3d4-7774056d17ec	35	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
acd06661-3f09-4e93-9772-5dbe16a0bd6b	S-13-0008803_J1	e44a8ea8-88d5-45bc-b365-5777b61a649a	S-13-0008803_J1	4f81b22b-9439-4f9d-8172-6b3be932ae26	CU-34	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fdd13fab-a7b7-4a60-9f88-eb5bce6f5795	36978_C2	01a5bd78-d7f7-4421-aaa5-bfdfc647dc7c	36978_C2	8144d374-a11a-4a28-9a7b-d867e6333854	2054	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
09dad0e5-73df-49a6-92d6-0175a1e16146	39099_A2	891e0db5-f2f2-45f8-ab90-b9c49988661e	39099_A2	f62ac819-d30a-41c3-adf7-40243db4b068	4050	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
609d6c87-6ea6-432f-80e8-e7adfa8c213c	S-13-0021202_A5	01ed2b0a-b69b-48b8-a971-516c29111aee	S-13-0021202_A5	b506fab4-6ae4-49d1-b504-e9eea92143a1	CU-02	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
353a28ac-281d-4c34-a1fc-e7b299000a49	351913;352452	8e61c84c-5962-4521-8855-d5197a82ecf4	351913;352452	2024d5c3-8ddd-44a2-9114-3f454dfcf03f	55	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa136fb1-5865-4b42-8ada-b0af1484ed21	41911_C6	4e313d04-3048-4b02-b0e7-e27e93eed351	41911_C6	34182d96-19ca-4892-a607-75682969b240	4541	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
35e56097-eac9-4924-ac3f-6b8e5cd62a97	555588	63396e11-5051-4eb7-893e-27f054ccc573	555588	00cb6713-234c-465c-9c2e-397168bb3bca	93	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
00e3ad8f-ae2a-4b63-9cb6-fa6aeb4dde19	S-11-0009142_B2	23a56b66-edd1-4a3e-8455-c79af6eeebbc	S-11-0009142_B2	5ae65a59-056f-46a1-a210-21c52df62aca	CU-39	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
87991bd7-4466-47d3-ab83-387186ee0657	222844;222854	3ee82115-1617-4e55-bb51-7bc73d9d0aac	222844;222854	0d98b6e2-f618-4449-b76a-1c197ff5b45b	25	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cb5b53e1-6197-4666-82c0-42a19cb64d03	40170_B2	e18ac824-03c4-404c-a756-dbd87cc3ea16	40170_B2	0ab4beb9-3dda-4847-aaa8-61cbe4c9976f	7203	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
412408e4-96a0-4e4a-b3eb-51316f18ac82	41218_C3	1f12d408-f300-4a3f-90da-62a22a2896f3	41218_C3	6a1d4639-edc2-4563-a0f1-6b17e73c31de	8318	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
470d4cee-d14c-413f-a5ed-d354e7401340	39918_C2	27d1548b-5e0a-47e0-b707-e079bcb85250	39918_C2	184bea79-034a-4b29-a66f-7d28a67365b0	8005	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0cdca3fd-2610-4d21-a911-59a9f260b6dd	277998	0ade138d-71d8-4000-bfa9-260e527aba8e	277998	56aeb967-2b35-43ed-b517-a577490f14d3	44	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f41a19a6-4c68-4ef3-8621-bbabc800f789	500263	b50e5d2a-acf7-464c-8c0c-e7315c3557cb	500263	2ae9b699-e485-4880-a3a2-f84970d70a5a	1	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21238fa5-2a85-4213-9ad9-ec13fca6a0e8	218317;218726	0d472019-0711-4df5-865f-71126dba7972	218317;218726	06d18ddd-b386-40af-acd2-6673929d656e	22	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0e14dadd-c830-4efe-8b30-0aa85235f83b	555596	96f90864-c784-4d56-b489-702cfecd64d4	555596	6807c77c-80b2-4de6-bea8-4d08b06f04b4	90	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de96517e-46f8-4abd-a6e6-d116a0ce9c4f	555175	46b73bea-7a05-421a-8120-49e66e5a649c	555175	96710b08-ebcc-45ed-9a71-19811c4f5fe0	91	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d86d344-0b03-44db-bcbc-79974e741e56	S-14-0005518_B2	9c424cba-434b-4753-9374-2294ae8cba1f	S-14-0005518_B2	1a918d3f-8bd9-493d-8cff-304981a8a932	CU-40	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dac0df10-ba8d-47e5-b5b5-01aca643ec25	265490;265491	b7e54fd9-84fc-4d4e-80e5-411e4989e169	265490;265491	ceb780d1-4198-4910-a41e-f65660b17f38	36	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
557e0da4-9f73-42a9-9674-0d07c0488756	37440_A1	d92cfd75-c44c-4708-86c3-6587d2ca8d09	37440_A1	d9cf41d0-1646-4b43-ad34-f35cf1d96b05	4787	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4c38c674-aee5-4a85-9c0e-109ab6084896	37917_D6	8c69f74f-7e16-4fd1-ab18-c8f92f227d67	37917_D6	38e2c451-b052-44d1-b1f7-54e6b3fc15d7	2807	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f2569388-46f0-4373-b829-e0e4dc7f1744	S-13-0022284_A4	4a822673-f001-4677-8fca-1fb707434aa3	S-13-0022284_A4	27d10bf9-bab9-4875-ac2f-8e44ab646fd7	CU-11	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0cc6960-bdf1-48d0-b0ae-2104ad9865bc	S-10-0035607_A4	16afe540-a351-4c47-9475-4c8a99a6a3ba	S-10-0035607_A4	af1784da-7316-4196-ac4a-dcb601506093	CU-30	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cfc5b819-6b43-4fd4-8c7a-6fb959145d28	503836;503834	925e0963-9699-4866-9e66-3f7058fec4b9	503836;503834	a451fbab-fdef-4ce8-adbe-547e02e11f89	79	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eecf7d50-f734-40db-bfe6-da81b91da349	S-14-0030753_E1	cb41bfcd-6362-46b0-a811-c962f52fda83	S-14-0030753_E1	36af1bb9-4655-43f8-860a-b686ef6ed570	CU-35	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a04e6875-a67b-48a9-af6e-a502ef1e790d	37572_A1	a35bdbcd-f402-487b-8faf-d91856826f50	37572_A1	682fe9cf-9425-4fc3-9764-777e54efe5eb	2398	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
861320fe-a414-4893-9cd0-6b1d8dbd072c	S-13-0006146_C3	81cfa266-ddca-483f-8f18-7cd16bbede33	S-13-0006146_C3	2d91591d-e2d2-4a13-af75-7cc0eca9c4ec	CU-13	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
61a9cafe-768d-408a-b1c4-211bf2b1e559	38471_A2	5bb6063a-0138-4c12-a0f9-b703f05adc43	38471_A2	512f2ad5-a686-48ca-9296-4cd80585ecfd	3604	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d9d5c97f-12bf-46f6-adcd-2b61fea35f36	232982	4f8d899b-2f16-47da-85be-e44a2418bc3f	232982	2defc710-1e1d-4254-bab5-bda0839e5bd6	29	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6aa48bfa-abc5-4c71-9b97-67c23a57a3cd	S-12-0032630_B14	82a66376-0953-424e-951e-3f2d296058e3	S-12-0032630_B14	15853521-e538-48f3-bc9c-c0a6e3ffc864	CU-36	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1efa6f14-38c4-4d8e-b49c-4116880ddfaa	218201	df180ee7-be03-446d-9c2a-4062bb00ccb7	218201	1f121037-782c-46b5-a26c-2e2063e0e204	20	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f9401a58-449c-46e8-b671-b2ec8876381d	S-07-0021920_B3	fa67248b-eacf-495e-a933-2ee08a5de0ae	S-07-0021920_B3	5cb83094-1c86-476f-bd52-efdcd2d3a01f	CU-28	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b32aeb6a-5e98-4b1a-a52f-6f0741ac316f	40353_A3	92995dc2-91fe-4e54-8afa-2faef55fddef	40353_A3	a008f512-5b53-4dc7-876f-b421e931ad50	7301	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a6f2b16-a234-4165-aa53-738cfd79801e	350407	fbba3dc2-350f-4996-bae3-a5bcfb4ca547	350407	762c9f38-6669-4c81-94e9-70f3e4b693aa	53	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
582cbccc-8e76-45bc-a7d1-2e8bef7832f8	S-11-0020094_A3	ad4ef1e6-3326-4030-8a58-ad7427ccc0ae	S-11-0020094_A3	edb6bf02-d2e5-4f38-9da6-d93bbcec9c92	CU-37	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
46fb4442-e551-4769-8760-f45259fe8ecf	41080_A1	a6a3917f-b882-42a6-a1b8-01a362f00cb8	41080_A1	dd2d82ac-a0a8-4f6c-9f07-8534c7f9663b	8228	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ce12b4f1-1506-46dd-a932-0dd706209792	S-11-0017293_B1	2bcf3f9d-a210-46a3-ba2f-9108afacac71	S-11-0017293_B1	aa29ba3e-538e-4cef-8fa9-0d8a9c7c56b7	CU-09	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ab8b732f-8abb-45f7-a0f4-4519ffdece2b	212713	35419dcb-3d50-4c66-9eec-366315265883	212713	d22024c6-0674-4a57-a38a-185046a0fb8c	17	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
25b0cc0e-497d-4cc8-bb99-0b475c756bd8	296927	a70fcad7-40e9-462b-9c27-5ecf4565468d	296927	8e2701d6-c0ba-4b8e-b1e1-899e72c35bab	49	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e97c7b16-733c-428c-966e-ebbf16e4fe82	352244	52e29de7-d6ba-407f-9d88-4f59fb5f9721	352244	e90c7ab7-4382-434f-b13e-44bf0966d21a	97	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
499ded3f-19da-4216-b0cf-245d7287e4c3	42454_F2	4fd02c5e-778c-4efb-a794-14e6e4fbf711	42454_F2	0ccb7a89-85b2-46f2-a140-97f77da85a1f	8985	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b9e9bdf2-03d3-485c-bd9d-d3d0a2e8b702	474534;474536	574b0e70-d27e-447c-8a86-701b488d2e30	474534;474536	f91df0ed-73ba-402f-8ca6-18aaaf557625	71	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f4e21006-f3c0-4716-bfd5-d642c03459db	271005	f66410ee-30b4-4eea-888b-da62fbdf1129	271005	b98022cb-cdc7-4e76-9894-37309c1c656b	39	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a6d9428f-a12f-4dd6-bdcc-086612896c7b	501301	c972454e-293b-4678-8282-c5c76568bdd1	501301	2794dfbd-93bf-4369-bbe0-01e692938eed	12	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
34dcd591-ab52-4160-b54d-d804e58f2f7a	S-07-0006305_A1	26f20f3a-9bb6-4442-8ea7-8d6eede6ca27	S-07-0006305_A1	ba309c4e-94b2-49e7-9bff-2af5030c3270	CU-24	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
79a36b13-5362-414a-9389-e6619d242f85	37852_F3	319d60b8-c80a-4c04-9786-d0ec95c42708	37852_F3	d859d6df-0a57-47bd-9a36-e7ceed71c946	2710	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
11b5a6a3-5cdb-49b7-8cc9-33802bcd31cb	S-14-0036688_B4	4d39fdc4-09ee-4502-ae8a-64c006f246df	S-14-0036688_B4	562f6eea-546c-4bd6-a9f6-5424499da28c	CU-18	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa507b7b-24b2-410b-94aa-c210a6b1e49e	525976;525977	dad58d8c-e42c-489e-99a6-6121899b397b	525976;525977	48a1f1f7-1624-45d1-aca8-e28b02937129	81	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9b8a9bfd-2b5d-4c4f-8830-a07256fc35f3	476423	44435d05-8b1e-4559-a6bd-1f7e80f7c207	476423	41422b5d-7ed1-4f9a-abad-498f1b8892d6	80	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7e3d434b-6e9a-466f-85a4-bc93ffc275e3	38999_B2	248e9e86-a98e-42ee-834b-7cdca0966852	38999_B2	84c91871-a0c6-4235-9dc1-e62b3220fa47	4350	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
37ba2c74-ceab-46ac-b518-7e8bb0ccffd4	206053	d961d82a-de10-412d-a184-065e9a30dfe2	206053	41438573-538a-42cd-86a1-b1d66a6c5478	4	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0103fe7d-2a23-4643-9de9-2795726066ff	533557	781d5ccc-bc67-4229-84c3-6d8c38061438	533557	7702b2fa-2aca-47dc-9757-a517585ab11d	84	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f0b8ff3d-7c7a-4c21-9a07-8da5efe41a36	S-07-0027436_B6	a32eef32-1ba9-46f5-aaf7-12a174b6e7fc	S-07-0027436_B6	1214f792-74c8-447f-882f-ce3bfc09a9af	CU-08	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
90a3b9a4-fba8-46d2-9bfc-d24d57b5baba	40298_K1	9133959b-d573-4f19-9a6c-8158bdb265f6	40298_K1	0e2161e1-bd0b-46f4-bc2a-c52288f522c1	7270	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56246336-12e8-471e-a621-72e98889458c	S-09-0003181_A5	cf43573f-24a0-4834-83ac-612f41c90edb	S-09-0003181_A5	e2d732d4-a3cf-471a-927d-0be3e77404e4	CU-26	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bf79df19-82bb-4e98-a9a2-183540d91191	555178;555177	a0c3e607-ab83-4d2c-99a4-321eb5d2f3e8	555178;555177	d58a7e0b-c515-4402-aa5d-c11eec85085c	85	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7e7bd029-c1be-4178-a4a4-fdeaa12eb1dd	37712_C1	d3d577d3-aec9-4edd-9dc1-85db9f491065	37712_C1	9b6173e3-9d50-40d2-aa8a-d45440a6c168	2553	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bca9f42b-a9af-4a1b-8fdf-e12b643acc66	S-07-0032072_A8	33304b7a-4b07-4b75-94c6-8e58ce226543	S-07-0032072_A8	731c9266-b4c1-4fe2-8492-444b0c10a51c	CU-31	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
568f4fac-969d-4858-a4fc-5291e1a381bb	487495	e1d54469-de86-49ee-b914-36d0fba330c7	487495	458f0219-c07b-45a2-95d2-85a23c955ecb	77	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a8509329-42f9-4257-b1cb-9da21fbe78bf	39352_B1	ae67ecfe-a533-4035-8d6f-389083ba7609	39352_B1	cc53495d-f1bb-4f1e-af95-939b785288f6	4237	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa941477-324a-4565-bcf9-977a002b142c	39996_A2	9f2ed310-3751-44e4-9b6c-9318853fa0cf	39996_A2	a7f7f405-c063-4bc7-8653-338f04dce30c	7078	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
14cf16f0-3260-43df-8745-daa6f10b1d0c	38435_B1	8f0d396d-2547-4395-b6e9-d1dd0b2e25fa	38435_B1	2e9286ac-bd5b-4565-bf9c-4f55fd48bb65	5462	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ab766b1b-6c53-4c07-82e2-eee7e3a8c11b	500869	2450a5c2-0ebf-4dba-875f-86657c33c019	500869	e156560e-76b6-4eeb-ad0c-ead6b310b76f	10	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
90c13bc6-09da-48e8-af35-57931c053ccf	319488	cf5402c8-41a5-4386-8c0e-4e7d83376762	319488	0d5fdb95-4a5a-4a03-a571-08a6e4e94aeb	52	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ceb03e61-18a4-40db-a1d0-4be3a3913cea	36754_C4	5759a78d-3a88-4cdf-8537-85b5f79552ea	36754_C4	e02faabb-6243-43ec-8dda-37931212a7fe	8986	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
702e95cd-e4c7-479b-9d56-28bd9f08694a	41550_A1	622666b8-3a93-40a1-a500-ac7ab20011cd	41550_A1	f636bb3a-687b-457b-bad9-10a2b759eabb	7924	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e6d523ef-a4f0-43c7-868e-3de36ed08991	S-10-0000363_C1	3f4ba9cc-8ecd-4eee-96c0-aba27ce3881e	S-10-0000363_C1	ac462fbe-4974-446a-b66e-bd5be817c526	CU-04	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32903995-d954-4e63-9189-eb7051a589a2	S-11-0002981_E3	0e55036b-4cfe-4464-85ed-aadbbc4d12fc	S-11-0002981_E3	6851595a-aa93-4c94-9977-5384ebedff4a	CU-42	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
453994ac-b687-4adb-bbad-51098d173e61	535474	a3fd4043-69ef-480d-a32d-926207d33290	535474	7ac17db0-7fd5-4ac1-a8be-f6493c2ebe2c	86	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b109d3d7-f41b-4390-a9e7-9e24fe777f4f	39738_D2	854a798d-3caf-4daa-92eb-12526326b91b	39738_D2	79a55d15-7f96-4ce7-ac9d-a06416b132db	5980	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01b9413d-2eb3-490a-a866-a9dd8250af5e	500550	121dfb7c-2251-4b88-9022-f74bbe4512c1	500550	fbe4f529-26b6-4203-9f83-4a0405c9cf74	6	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8958e3c-ad4d-4f74-af64-dca5f8e19299	206843	83676c39-828e-4596-bc33-6a697fda122d	206843	5cbebdb4-06f9-4230-aca4-f114e406bf12	96	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a9049f90-8ed5-4978-9e6d-940b5c09b881	S-15-0035461_B3	b5473693-19a0-411a-b677-f456f5f33550	S-15-0035461_B3	448f6d70-bd0e-46ac-95bb-fbe25683cffc	CU-20	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7c59f31d-64f8-4b64-aba0-caa661ff9d43	517758	41a7837b-83b8-485b-9dcd-1ac7c461efc8	517758	a3842772-b155-4d18-bc2a-966c960c1b67	82	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a30c44e8-b1c8-4249-a50b-13462faaa835	240716	d03efd34-9c1d-474b-86e9-7aa2acf75116	240716	ac10781e-c6a4-43b0-a763-9cf54ca8493c	31	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aeab2467-294b-4491-b986-1fa5f38cc0e5	38538_C14	66d489e4-2033-46f1-a9f4-2823de83e742	38538_C14	40fb622c-0e06-473c-87f8-e00c8fdfd070	4322	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3cd184db-7475-4a7c-8e1b-a70c156a1407	500395	54e60473-20cf-4e0d-ad4f-ab6ef587a113	500395	6a9ab0d8-41c4-4a3f-b4e4-feb265255493	3	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
65f0aa36-70da-4b53-a8fa-ec40d788518c	418442;418441	ebf187df-3275-4ec7-8ed7-524d50d81376	418442;418441	13ac1593-912d-47ff-889e-3a55d952773a	99	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e1edeec-cdf5-4185-a356-33039f5f2102	517774	d075bd36-b8e3-404c-a4cc-7b314b5486bd	517774	61681af3-ac1b-469c-bf25-1c9de84e95d4	83	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
07102d30-dd29-48f6-8e34-80d415b79135	S-14-0024532_A2	2eafd895-1d0e-4423-81fa-a57faac17919	S-14-0024532_A2	ecec76a4-c717-4db8-b55d-599bac282d9f	CU-43	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b4af249-ebf4-4495-b3af-ce561c652a7f	37845_B1	2c366587-03de-48e8-b361-0f785d9b3eda	37845_B1	215978de-53f4-4f53-a441-f062103fdee4	2685	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d9c1bda-62d9-4280-ba6a-f164a3374705	631766	c7d47720-ffd4-432d-84ae-966ef2c8491d	631766	db5c3f2f-3bda-472f-8806-c3345cf1050e	95	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
06cd2e6b-0ae5-4bfd-a6b3-0d8f34468dc0	37504_B1	6131cca2-47ff-4856-bfe2-863d175292de	37504_B1	2e8728ef-9103-44de-bcda-b6b429ea62e2	2303	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c54017f-af2b-4d2c-9e17-f892a1f84caa	210039	0761c86b-b4f4-43a6-b368-19deaef86226	210039	42a86377-86c9-43f6-b05c-5c0c2b1423eb	15	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
90dd8e3e-0a7a-4697-b341-727537f3e812	41079_A6	5a475754-d579-4a3e-a611-ec07289a640e	41079_A6	885a1766-22bb-4e34-8283-60d0790d956f	7715	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6cfe1001-adcd-41a9-87c6-5b4fedc7d10b	42569_E1	ca08a29c-6442-4b33-9871-b845aae073bc	42569_E1	350512c9-27a5-43f2-83d5-3a7748b98fde	13129	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
46814bb9-240d-4920-9ecc-b33895bcf558	S-17-0012504_C1	bf919b80-f3b1-40f2-b052-63eb39840be0	S-17-0012504_C1	8f4ccbd5-8fb7-4f3e-bab8-d5c132a84be7	CU-21	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5cca1153-c8e8-40aa-9d5a-b63cc176b48d	500475	002b62d5-e1ec-4513-b49c-e15e76570a80	500475	40a7b022-671f-4fcc-a0be-9214ae433f5f	5	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
18feb83c-7824-4595-a9b1-2882e3f7a77b	S-13-0008240_A1	a1e2eb0b-95e3-415e-bb15-8db5cfbcc54f	S-13-0008240_A1	4437ea63-21c8-42d8-9b4f-b922867e2e32	CU-17	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ca1f5a7b-baf1-4ece-acbc-9ff62f3862ff	S-07-0023499_A2	a235087b-22ad-410b-976d-aead1b3036a4	S-07-0023499_A2	6cff65ae-5de8-4779-a4d6-b029d6253dba	CU-06	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
527f2cc7-5e37-45c3-a0ea-cef22733b4f0	S-11-0010626_B3	5344d9d4-e363-4f1f-b38b-684653d7c156	S-11-0010626_B3	cd7679be-a992-47a9-8216-6c8cc6cd82e6	CU-25	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0e4f53d5-2c4a-4700-be80-36fe6a32350e	36517_G2	7675d7fa-3a56-4b6c-ada8-aec5d6b6f808	36517_G2	5b9e462f-18ba-442e-9004-4f52bb448d40	2121	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c1402d2-3ac6-4fd4-9b64-7c8809291f39	S-07-0001549_A3	5b28291b-1ca3-48b4-b2e1-9ebf93916578	S-07-0001549_A3	6afe4b38-f943-481e-90ec-a11c0df1da7c	CU-29	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a158af33-eaf1-4d5d-81aa-334cb0e4e0d1	42695_C3	4a754841-1b4e-428d-9390-9d651a5fff6c	42695_C3	f293c3e0-5589-49d3-afd2-3bfc9b0c9a5c	13280	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
109c3d49-23eb-4b58-9f5f-b3c5209b2d23	41946_A1	c72bb1c0-3455-429a-a822-bb62f3190096	41946_A1	6162346f-af60-4809-ae37-61d25bda9510	4564	Proteogenomic Translational Research Centers (PTRC)	Metastatic	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
663597bc-1495-4ae0-9842-fb0ed71ad53c	494830;494829	9cb7fa00-4589-4ea8-9b4f-9903c26e7613	494830;494829	087198d9-0eb8-4891-9615-b7363a690dc9	70	Proteogenomic Translational Research Centers (PTRC)	Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8f27440-32af-4fb2-97e4-0ec53decc8aa	CPT0186040004	067ad07f-6b59-491d-b8e7-e74a058135a4	C3N-03173-01	905a9e60-75b1-4c53-9905-e2d3d171da7b	C3N-03173	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
42b13ad4-7ab3-4044-86ed-bc3ebf9cac0d	CPT0208710004	73f2cb13-d15d-4ca5-a4ee-c94a817b299e	C3N-02944-03	71bdfdcb-358b-446b-86fa-7a3879bb460e	C3N-02944	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
92840232-671e-4662-affa-cafa11339e1e	CPT0065640003	d354629c-bf1b-44e3-8eb9-e6a2662ffcdb	C3N-01011-02	a251b23a-ae5b-4319-ab5b-ad425071eac3	C3N-01011	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1b678d69-49ff-4426-b071-e20b4b1eed98	CPT0226570004	5db188ff-f639-4b29-9010-d9927f30620c	C3N-03007-02	6fa52ee6-5dc2-4bed-8f6b-c6d4471fb81a	C3N-03007	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d715f9f-fa13-4cb4-883c-aa3ab9744627	CPT0093980004	b55b8dc2-3df7-4df3-ac66-c328cffb2ff9	"C3N-01166-01, C3N-01166-02"	a3e3b167-2d2b-462d-9d3b-849a5f7ddea6	C3N-01166	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
985e0e85-6d9e-4edc-b24f-4172c79d6c0d	CPT0086210003	d050b280-de10-42ce-80da-caa7bb1484e3	C3L-01637-06	25bac97e-ae38-44eb-b61a-1d8d383f0085	C3L-01637	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fb56c18f-5baf-4054-bfa6-445126fb6944	CPT0123770003	c96c19af-0d68-4a18-b36d-b8299a94a969	C3L-01052-04	622bfcbb-af4c-4893-8e1d-c6f65cbb8da8	C3L-01052	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1bfa07c7-8e00-4c78-a7ea-dfc258f088cc	CPT0247050003	d54d46dd-5ca5-44a4-92a0-d900fe8d09d3	C3N-04283-04	301c2377-cb9d-43d4-bf4b-3cf478fc2197	C3N-04283	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
9d33fca2-66c1-4755-9562-bda3a689dadf	CPT0063580003	fce524d7-5f84-4ece-a328-acf89022ad5c	C3L-00928-06	669af5fb-0ace-47d8-ad5b-40ab44ada190	C3L-00928	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b2f1ffad-4ff4-4cef-a6ea-4a6a45b55de4	CPT0236340004	7bc83fdb-7058-4392-a599-46c0dabd053b	C3N-03069-01	d21fa2fa-9a2d-4baa-b7d8-601b906a16c7	C3N-03069	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
25d07ae9-b584-4eca-a5d1-a06add9f1743	pooled sample	dfceff9f-e579-495e-966f-d4619f5e94ec	pooled sample	bbd98dcb-2e48-48d5-9a23-a90e36ef9bb4	pooled sample	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a54c0161-63e5-471e-94c4-2818b286bccb	CPT0236710004	5156e456-1a83-4339-b551-779d30c0f5cf	C3N-03839-03	c531b8d3-736b-4f87-b4f5-0234f5475cf5	C3N-03839	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c80f2da8-bb77-44df-a2a3-0238d402404f	C3N-02573-03	1c828a42-4064-4d59-9f15-47dfc77d5f7f	C3N-02573-03	5f0b87e2-c427-4465-9721-2c1e8923888f	C3N-02573	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
306d623e-eefc-4dc7-9d74-5d156f524e6c	CPT0238530005	1544171d-5a65-45cf-9412-4ddd3521c78c	"C3L-03635-01, C3L-03635-02"	fc08d3b9-1ea0-4926-922e-d4f4d4a77767	C3L-03635	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4eef727b-4ca1-4aa1-bea3-c3b7575a1b8a	CPT0347880002	7908c0f2-f21c-47d5-a63e-9a3aceff1ffe	C3L-07036-01	31d14399-b60b-4d00-ad37-72a55ec733df	C3L-07036	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a1c2e08e-4fe8-46b9-b502-c62b6187b8f9	CPT0161990005	5034bc45-43c1-42d7-be6e-5adea0415a9d	C3N-01719-04	cfd7ba3c-afab-465b-a121-c951b3fca259	C3N-01719	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9202d5b8-0e5e-47fe-ac32-bf6d4784e378	CPT0081060004	062bbe15-e7f5-44a0-bfd3-4c161586d79f	"C3L-00189-01, C3L-00189-02, C3L-00189-03"	e7ee4f4f-418f-4f96-aed6-0856d94f02f2	C3L-00189	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
309b17b4-6186-4287-8202-0a1883f6ebde	CPT0124410004	50d7a714-80b7-4c67-ba0b-2b6b4eb694cd	"C3L-02112-02, C3L-02112-03"	fe3b4978-c450-4943-bf87-e5974562f62f	C3L-02112	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da9b0832-5ee3-4f73-a6dd-ceaf5d4c77d4	CPT0207990004	9af287df-2b36-4a14-8d99-dc91ebfbeea2	C3N-02768-03	58b42d9e-bba2-4a1f-9066-77586c0d6eb9	C3N-02768	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
daf8c3b4-6ad9-44ce-a25b-5aedb5cdbe7f	CPT0198910005	4f22dcad-ddba-4ef4-b709-51f4f7fa22bb	"C3L-03630-02, C3L-03630-03"	d13f4bd1-0510-46a7-bd51-90546b8bfe4c	C3L-03630	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2d6b25e3-f360-4446-a0f8-eceea04df2f5	CPT0246260004	a0a9dcb1-7623-4b31-bae7-c3150a77a165	C3N-03439-02	ebe993cd-c210-459b-85c6-30c03fcca5f0	C3N-03439	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a4947d7-4994-4afa-9ef3-a49cab5e4100	CPT0019300004	88f41e3f-5891-4db0-baff-2d87b3ac3263	"C3L-00401-01, C3L-00401-02, C3L-00401-03"	72dabc4e-ff33-4ecb-8676-234e6ae27a8b	C3L-00401	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4697ae30-dd52-457d-9645-8ffc86bc48f0	CPT0125130003	ec814741-2996-4527-8bb8-fc4482792629	C3N-01716-03	92543483-685d-4fa4-ac04-870bf7161ec9	C3N-01716	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c3cfb526-3267-4037-9cdb-ae15da27be3d	QC2	a82758c7-530a-43b8-a4e6-f6bd450f72f5	QC2	51b3ee8c-69b9-45d9-a24a-0402b5f55601	QC2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9bd40f46-6b24-4b9d-b81c-688b73bd2760	CPT0198700005	43a29e0d-f089-438c-b35d-06caa947268b	"C3L-03628-01, C3L-03628-02"	47f2962e-1c0c-49da-bcd4-93d9c1874ec2	C3L-03628	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb0b8c21-abb0-45b5-a2c1-a051ef3e2f48	CPT0226650004	b6370c63-2f60-421a-bd11-15d229e43c90	C3N-03430-02	fdc414bb-04a1-4990-8921-baa6c205f1a9	C3N-03430	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4ed4047e-3f5d-4968-9db8-74f9d2ce3570	CPT0276030003	451d8247-e63a-40c6-a92a-9f9ab119701c	C3L-03395-05	df0ee52d-df43-401b-909e-ca25f708ae64	C3L-03395	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f057adf5-1f68-452e-91ef-ca6b09843a2e	CPT0088260004	4a8870a3-7c02-407a-ab29-3b8e9db7618a	"C3N-01380-01, C3N-01380-03"	9a2f657d-5c27-40db-9d87-ffabb7f6b9b6	C3N-01380	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ebc66e7b-3c30-407d-8b29-1a1e5f9c66ec	CPT0239140004	b3c460df-6265-450a-9204-f42fbce471b2	C3L-04495-05	daabb823-5e5e-4446-b14b-6962cd3d1111	C3L-04495	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ddd6fcaf-f8dc-41e2-a328-704c4904ea44	CPT0187930005	249ce178-113a-4ee6-af9c-62a9e1bccce8	C3N-02998-03	df77dbcd-94d7-4a66-b15c-9564f86ee42e	C3N-02998	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b1c81e36-3180-48e9-91b4-c64fe9c48f19	CPT0000250017	d71192d7-fc79-418d-af63-e41c82745f5e	C3L-00017-02	e146ea33-991d-40e0-81c1-d33f9c719f62	C3L-00017	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f30e7c2-0df8-4cf4-85d2-98d4181ae96c	CPT0081360004	4e892d84-0525-4045-89d1-13b433cfce85	"C3L-00622-01, C3L-00622-03"	81d2f222-b6ea-4593-9ccd-1619546ab73b	C3L-00622	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d0fdc98b-c1df-4ce2-8468-4225421444a5	CPT0208690004	85d11491-17a6-469d-96eb-ae4b9f2d5914	C3N-02944-01	71bdfdcb-358b-446b-86fa-7a3879bb460e	C3N-02944	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0eb4583d-ca0b-4fe7-a044-eae36934c5fd	CPT0124360003	74f04d37-a599-4274-b3d2-8e77c36c4c5f	C3N-01714-02	7e9a404c-2b80-4ea6-aa7c-7ebc02493cdc	C3N-01714	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64714378-881e-43f3-bd3a-f08290a66207	CPT0166780004	ff2dc842-8d42-47d2-9b61-5be02e20c029	C3L-03123-04	8d4aad8e-229d-4d7a-9244-b6343cb2fb5a	C3L-03123	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0ebb653e-c672-4c36-afca-3c69fd71c348	CPT0241510004	2592515f-76c9-4e13-ab42-5082257b8ee0	C3N-02010-06	d10e77a2-fc25-463f-b3f4-ecb738069aed	C3N-02010	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2160b38c-4250-4dd2-b4d1-98bd0dbfae9d	CPT0125090003	a5fe2385-2767-4db1-a6d1-335241a22307	C3N-01715-02	3406ba91-a386-4e61-931e-a6eceea00123	C3N-01715	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6b0b3bc3-01d1-481b-b269-7970d641e64a	CPT0063570003	b346c1a8-54e0-438e-a26d-826459ec4a0f	C3L-00928-03	669af5fb-0ace-47d8-ad5b-40ab44ada190	C3L-00928	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
97824494-a0ec-4d57-af24-c8bdaff82a80	CPT0108410003	c66c2bb9-b5ae-4c5a-9be9-5f622d1fd137	C3L-01453-04	48c5ef63-81a1-497e-89fe-21f96813de49	C3L-01453	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
e0c74e64-cc72-41bc-893d-7b98efca840a	CPT0123990003	dbe5c91c-1cb1-47cc-b127-b61eb87277d7	C3L-01054-04	320df578-47ba-41a8-9991-a4972ce48810	C3L-01054	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
96c7efdc-577b-4dea-b68b-d74d114216f2	CPT0236780005	830df98d-a596-4976-b35d-e1a977b6e753	"C3N-03840-01, C3N-03840-02"	d9465f75-1a21-4c4f-8b6f-14e0600dffda	C3N-03840	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0a0470c-613c-4835-9fb7-30d9b0092701	CPT0078160004	ed950eb6-a1c6-4ba1-85e9-61c9b0867833	"C3N-00512-01, C3N-00512-02"	2657813b-ca46-4047-889c-f98ed05f2796	C3N-00512	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f08e7c5-8830-4a4b-8809-f559809755ed	CPT0248320003	4bab2374-ef16-41b0-8d79-cc69bf0a8ce7	C3L-04475-04	2cb645f4-0733-48c8-9021-c880ebf23c4b	C3L-04475	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
1da9b9db-4f7a-4f09-b5ee-2dac579cae50	QC6	da05fe0d-88e9-4aeb-8a0e-e46bf4145ebb	QC6	08a154c5-ea51-4f89-810d-3e125a052c1e	QC6	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b86cc1b8-508c-4b27-8fd5-7036434b0806	CPT0109010004	5ee9c3ef-7018-45d7-b8ae-92b0fb5c302d	"C3L-02109-02, C3L-02109-03"	c89444ff-1751-41b1-af47-b96e36037a65	C3L-02109	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
683ae3b8-9456-49ad-b50e-81355428ae36	CPT0014040003	53830535-b74c-4900-bcde-674c4adbbf1d	C3N-00198-02	656b9d5a-ac9b-419d-8300-52b31eb56be6	C3N-00198	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
afa7c424-1e10-4c73-9a59-e5fd9c988864	CPT0248410004	4424ea97-0c17-4ce7-9319-5b274469e53f	"C3L-04848-01, C3L-04848-03"	6abdfa5b-ab89-4ac9-974f-427a4007a133	C3L-04848	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f3b20997-9e6c-4455-9e78-d7dae24310cd	CPT0241500004	fe037a2d-c78f-4217-a943-59c0f33785db	C3N-02010-03	d10e77a2-fc25-463f-b3f4-ecb738069aed	C3N-02010	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b4c56b6e-f5ac-447c-ab2c-18c8c0d3ca49	CPT0208850004	f184b653-e14d-4ea4-adf5-42de7ee9e9ae	C3N-03061-03	edde06b2-4a6b-4e5b-9be1-33d6efe922bc	C3N-03061	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9262746b-91c9-410e-af66-669fd5b0b183	CPT0174800003	4f988fa2-8199-48d2-bacd-02b94256252f	C3L-02809-06	b5f71e03-9c44-48ee-99b8-cf0fe4cb4dfe	C3L-02809	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f7997526-0686-44b2-b24d-25f85b9c7a2a	CPT0247040003	03d4433f-5ee5-48b9-9bf3-de31aef604c2	C3N-04283-03	301c2377-cb9d-43d4-bf4b-3cf478fc2197	C3N-04283	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
93984b0d-01e0-4730-a0a9-4e70f555b91d	CPT0183450005	d2ee6e6a-77bf-4aad-b8db-db2f63fa0204	"C3N-02573-01, C3N-02573-02"	5f0b87e2-c427-4465-9721-2c1e8923888f	C3N-02573	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
330d27ca-8597-46c7-a0bc-40c3f1cf2f3f	CPT0125010003	016fee6a-0f0f-449d-8499-e6eedf09aa7b	C3L-02610-04	78081bea-6b0b-404b-b9a1-f64ced91f728	C3L-02610	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10fbfce2-3cc3-4809-b97b-4f9da4bfa6c9	CPT0094740004	bf850d21-0499-4d07-9006-a694f6b669d6	"C3L-01689-02, C3L-01689-03"	354aa1db-a43e-4972-a704-6536c164b6f5	C3L-01689	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ecac9391-37d8-4abc-981e-5266597e3f96	CPT0185920004	12b376ac-0ba5-425b-8b38-fff13393ab6a	C3N-02971-01	ef64289b-f333-49f6-a05b-043ed6455e10	C3N-02971	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eba9c203-e7c3-4bfa-890a-8641a295eff3	CPT0226680005	9eb307a4-eb77-450c-ad13-29c4594b331e	"C3N-03428-01, C3N-03428-02"	bb7a9ee6-ba4c-4052-b826-d966016d90d2	C3N-03428	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
caf3934e-709c-48d6-b726-e562c286e07e	CPT0011540003	93a84224-48c2-449b-b41f-81697b8b5667	C3L-00277-05	61fe740d-ae0d-4541-8fae-ab0c33b0f708	C3L-00277	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b09f0386-30fa-4cd2-9564-2269d9680e0a	CPT0094030003	05ce4fb2-dcb8-4046-9638-cb1c3be6ff75	C3N-01168-02	4a4e4119-73e6-468a-8e6b-05acf4c1b7f5	C3N-01168	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
38fe376f-7278-4d18-ba67-4eb93bad7588	CPT0166650006	0d6732dd-d112-4179-a590-394f74739064	"C3L-02890-01, C3L-02890-02"	18b64ae1-2fe2-40d2-9126-bd1ed2ce4e95	C3L-02890	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
20fc05cf-890a-4bc1-8dff-8a9685e888bd	CPT0203850004	8c787959-a6f4-4a0f-93d7-163bde2ba2cd	C3N-00709-01	f6d401bb-8001-4157-a2ff-82fc946ba933	C3N-00709	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3c2584dd-6611-41cd-bd3a-98145de1f631	CPT0094230004	57dd9b7e-776c-45ac-85de-48570f4e1933	"C3N-01383-01, C3N-01383-03"	83672c84-e1f2-413a-8e9d-8c13d45f5291	C3N-01383	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
82ad1b4d-bc64-4e98-a015-eee01939df6a	CPT0209650004	2b79c388-3bc4-41b2-994f-e594ee6fc4f3	C3N-03211-03	1fc52010-b6e7-4f19-9cad-afb7bb55d487	C3N-03211	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
79eddf52-8bb0-4159-9777-d0d55713fb3d	CPT0224470004	34e1d8d7-f579-4a21-971e-30c1d6ae8f3f	C3L-03394-04	bc01b9f6-2355-47c8-bc06-6ad5865804ad	C3L-03394	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
3a2e66ac-7e4c-4ecb-b453-bbcd23db48ad	CPT0238940004	d2599881-afee-41d5-97f4-4c06f49d55cb	C3L-04479-03	dfbdbf47-7379-4d98-b6e4-175cd09ff0a4	C3L-04479	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3d51aa7b-b9a8-439a-b75b-886f0eca77dd	CPT0123650003	3dc5cf6a-f911-4ce7-8510-146f07349fa2	C3L-01051-02	77e6c9de-2a62-4c1f-9fb0-f07e86c9b6de	C3L-01051	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ffa74e1-7945-483b-b348-8dfd55e3457c	C3L-01687-04	f8c149e3-eadd-4e67-88cd-c15a52b152b8	C3L-01687-04	04606c9c-ff6f-4acb-a9bd-e0122bf19ee1	C3L-01687	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
d0976eb6-7d5a-459b-a37a-f1ec31e85214	CPT0198930003	f0fec5e3-73d1-4cfd-96cf-554dc058bdda	C3L-03630-04	d13f4bd1-0510-46a7-bd51-90546b8bfe4c	C3L-03630	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9a5fd214-6053-4bb8-9fc8-28a9c32505c4	CPT0239920004	cd82d82f-a8dd-40bc-8dda-5c660bf7f06c	C3L-03388-06	bcd1c547-3d14-48f4-9398-a775697cbcfc	C3L-03388	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd46e060-8ca3-44a5-a668-f598911c0651	CPT0198340004	a711e0e0-bec6-4e62-a6f3-168b5f0cd89e	C3L-03350-04	9955c013-c8fd-4315-8946-f0c41edb024d	C3L-03350	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
dcb75ac6-2feb-4d81-99d2-faf2bb5580ae	CPT0162670004	c46d7374-196f-4d11-ade2-8c23dead5ff4	C3N-02589-03	0d000f9c-f76f-42a0-b88b-9a9054919adb	C3N-02589	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f40308e4-8eeb-42ad-a5dc-6c2cc7fa8d7e	CPT0218200004	0b3fed57-4876-4a86-85ba-68235cfa7f2d	C3L-01124-01	5a3fd9f7-cd11-4ed9-b122-3096ba0e93a5	C3L-01124	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dcaf6d2c-85b6-42fa-8b94-1dec3e1114c1	CPT0226760004	7f5eabe9-cc92-4e64-9d98-a48909fe424b	C3N-03665-01	96501b19-4b91-49c1-beff-06b3c46dbc3f	C3N-03665	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0bf985dd-8726-4324-b968-73675faa4d2e	CPT0138890003	8afa0a07-0bcb-4503-bde7-298958aeed8e	C3N-01997-01	b389c04b-e42a-4143-970b-f39cc6882ba0	C3N-01997	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
abc4b388-3e29-4380-a06b-eb0893962fd5	CPT0237850004	6cad495c-3eb1-478b-8e19-2b4f6310c4bb	C3N-03884-03	a3cbf3f4-b398-43c8-b323-c4e07c04d8d7	C3N-03884	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8dd75586-d707-4897-8f31-5373cbdc30a4	CPT0208840004	063d2553-b4d4-4e91-b26a-6e3b088ebaf0	"C3N-03061-01, C3N-03061-02"	edde06b2-4a6b-4e5b-9be1-33d6efe922bc	C3N-03061	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a7597edf-b082-47a9-88ae-ef7290b52478	CPT0246940003	96992b98-0ba2-4e78-b0fa-fba5d4bd7603	C3N-03780-01	becc9d95-b799-4238-ab2e-0da05d48179a	C3N-03780	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aede12e9-606c-48fa-b6a5-1714c6d82f86	CPT0123860003	4ba98792-07d4-4a15-a183-c077fc4b07bc	C3L-01053-01	ed932161-7b37-4bc4-aa09-b8adeb044f17	C3L-01053	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b70112ce-613b-4d37-a28c-4541ebafe79e	CPT0088320003	79926341-ad5d-4bcb-b639-7534ab6d40f8	C3N-01388-03	ebab18a1-9760-4e31-8255-23082ad5c097	C3N-01388	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
847aab1c-4468-49f7-9991-53abcd0cff20	CPT0246950003	7e3f0b48-11e0-45a0-96b2-08b429bec429	C3N-03780-04	becc9d95-b799-4238-ab2e-0da05d48179a	C3N-03780	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e12cb52a-ee28-404a-89b3-12cca573f6fc	CPT0275870003	7fe00111-9ccf-4203-aae7-db7e108ff586	C3L-03371-04	45e072c0-3603-46f9-a86b-3d8492532eef	C3L-03371	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
eab7d885-68cb-48da-b247-4ac978799172	CPT0064110003	1a8f24b0-e87d-4e8c-8ff9-d352bd79a8d4	C3L-00819-06	9a0345e6-ba08-4f07-b768-79a039ba14f2	C3L-00819	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a6dfe26-594f-4df2-9ef3-fa7b0a1f2f1d	CPT0109110004	5466d9a3-4a4a-490f-99ea-aef731b27292	"C3L-02115-02, C3L-02115-03"	f4c7d3bb-f214-4fb6-b2d7-bc173b715220	C3L-02115	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
27208a5b-44ae-4b39-896b-84664c33552a	CPT0227930004	d8089f96-ff3e-42bb-8818-d748031cc813	C3L-02701-02	d26a6b06-5d02-4220-9ec3-5788c0b643ec	C3L-02701	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2fa02aca-b90c-4b65-8fba-3803e2805c9f	CPT0066020003	b79a35b2-3952-4e8a-8025-a9b98673debc	C3N-01011-06	a251b23a-ae5b-4319-ab5b-ad425071eac3	C3N-01011	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a6338376-baf6-4fff-96ba-6026f3e5e087	CPT0247000003	571d9b23-93cd-4563-8599-8e185d63df81	C3N-04282-03	33f484e3-9bf2-4985-8999-567e3022ac15	C3N-04282	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
12f66b2e-9da1-48d4-a2b2-cb5b504823c0	CPT0025750003	40436fa7-cbac-442f-89c8-5e44ea28ceac	C3N-00249-03	9bb79b5f-fa75-4d05-8a23-eda606a6cfdc	C3N-00249	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea5f24eb-5cc0-4594-ac3b-5f9b53f14abd	CPT0094630004	4dfa4789-a0be-425b-8387-fb63691f93fd	"C3L-01687-01, C3L-01687-02, C3L-01687-03"	04606c9c-ff6f-4acb-a9bd-e0122bf19ee1	C3L-01687	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10ab1edf-8040-4349-8919-7ee0e126d714	CPT0239100009	bf7740c4-d5ef-4b62-bcb9-20dd53c508c7	"C3L-04495-01, C3L-04495-02, C3L-04495-03"	daabb823-5e5e-4446-b14b-6962cd3d1111	C3L-04495	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4a8bebd5-5543-42f2-ba9d-3d7f51b052e3	CPT0248620003	5b091d7b-8a61-43fe-bfdb-c61c9ffcbbdc	C3L-04853-04	28c67334-e064-4692-8868-add8d830e983	C3L-04853	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4d6ade17-768b-40b5-a50a-f46457725859	CPT0077930004	751d8164-cadc-460e-8b9d-a649716303d7	"C3N-00514-01, C3N-00514-02"	65786c81-1ca9-4836-89a4-d80d7dbf773c	C3N-00514	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1151c734-8d0a-4f45-b7ea-db277bb8de99	C3N-01900-04	99317eee-ba49-4c34-b83c-82e2f16f151c	C3N-01900-04	10784784-5101-4f5e-aefa-1311e0000fdf	C3N-01900	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
fc1e05d6-48d1-4d77-981a-e3009cbc0c90	CPT0078250003	c1fdb6ce-ea52-4b15-b6ec-3efd795a0824	C3N-00511-03	dc5c98c3-f062-4a93-917f-1854af37c3f4	C3N-00511	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3f3637fd-bac8-47d0-a3a7-72c01c0e5082	CPT0355190003	f3367bfe-8a1f-4c4d-978e-992b2a24e497	C3L-03515-01	c524794e-ccd7-49ae-a005-eba41cfdb6b3	C3L-03515	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64bfa2f1-22d7-4f4d-a37e-7cc24e467320	QC3	2e50ce14-6709-4f13-8204-0f722df24328	QC3	e9f88e5c-8015-4c3d-ada9-6001e0fba4a0	QC3	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ce6858e-088b-4c59-822d-dfc4ad749e46	CPT0078030003	5f9d0bd6-6454-4fc7-8b09-cd3048674b46	C3N-00518-05	0f06151e-53a2-4573-84c3-76e1b5c0ce34	C3N-00518	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
38a4bd18-4444-454e-b00c-551c018806de	CPT0347760002	0c569dda-3e1a-4a4d-aa40-5f8f7101822d	C3L-07032-01	15004c8d-69c0-4772-8f3b-d88691fe8d52	C3L-07032	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e6c77293-ad89-4ea8-a284-083f0985e97a	C3L-00401-04	7344ef09-7bc9-46fa-ad5e-785df8a3737e	C3L-00401-04	72dabc4e-ff33-4ecb-8676-234e6ae27a8b	C3L-00401	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6963324b-4dc6-4c22-9d53-2bcbadeef2da	CPT0197440004	0c43f666-a91b-44ac-9631-d7393f6d38c9	C3L-02899-06	0fdc2d7a-e945-4c3b-9df5-5745197e1513	C3L-02899	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5349c20c-e308-4e9b-9474-39e69165c736	CPT0081260004	72e55421-b922-4c7a-8d0a-79da553d7cdf	"C3L-00599-01, C3L-00599-02, C3L-00599-03"	ddc466c8-7e8f-453c-920d-25ebb56be20f	C3L-00599	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ff398ac3-eea4-4d62-9553-5b61e1553546	CPT0086190004	06d33d68-e997-4c19-aaa4-20a4157f4b77	"C3L-01637-02, C3L-01637-03"	25bac97e-ae38-44eb-b61a-1d8d383f0085	C3L-01637	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b27a5764-da9d-4e53-863d-cc1bd3f4ca86	CPT0087890004	fed77b38-b228-4dc1-b1a6-2823dca5d54c	"C3N-01167-01, C3N-01167-02"	28294208-46e9-4581-ae2f-27f239f8ae78	C3N-01167	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d2683107-0c20-44b8-8148-8a38c6f7506f	CPT0077810003	f6191093-dee8-499c-8f8c-0103f224b490	C3N-00513-05	ca63469f-6f24-47be-8333-ebd44c3f831d	C3N-00513	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae180786-6d4d-4796-96d0-1d01688b399b	CPT0109300004	2d76a1fd-47ad-4726-9fdc-71d386f3af41	"C3L-02118-01, C3L-02118-02"	c4452d81-fb01-488e-998e-032af8453e4b	C3L-02118	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b18cca73-c96a-4bb2-af0c-b70e3cece4cf	CPT0019410004	565ba35c-4cc2-4b6d-ad35-b7685318d158	"C3L-00598-02, C3L-00598-03"	a415f239-a6ca-451d-81eb-196a7e7183d2	C3L-00598	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
efa60805-4595-4d34-8fe4-643093ec07f4	CPT0246840003	ba051263-2a0a-4105-8c4d-2bf10b7d167d	C3N-03670-01	da3a693f-01f0-4d7b-ae52-95c5438733d8	C3N-03670	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
18c0ad34-0b2a-45e4-8e3b-48136cce95f7	CPT0235230004	1247eb54-cbce-4f1f-a9d1-7ec5fded41cc	C3N-03039-01	4b51d6c0-4ac8-43db-8e4f-f7152318874d	C3N-03039	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d7bfc51-da10-4a71-a3b4-3a40013a6bff	CPT0236800004	6955adb8-11f5-4d83-8501-0b444a9af9f8	C3N-03840-03	d9465f75-1a21-4c4f-8b6f-14e0600dffda	C3N-03840	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a95da9c-87c4-4ea9-a062-0115582977d6	CPT0238820005	c844111a-d035-4f52-9f82-aa1b28714869	"C3L-04475-01, C3L-04475-02"	2cb645f4-0733-48c8-9021-c880ebf23c4b	C3L-04475	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
26646168-f06f-4ba8-8c21-739a236ad376	CPT0017130003	010d5178-a240-427d-83d2-45299db54b0e	C3L-00881-75	109369bc-354e-46c4-aa26-69d13194b085	C3L-00881	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5331aa87-3413-4016-b52b-aa2101560799	CPT0008800003	bfca53bb-af6c-4621-bd70-3486c17937d0	C3N-00303-01	86b39157-8b7f-4b7a-a79e-e73d538b7a06	C3N-00303	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ff273ff-7bbf-4c6d-9feb-f019c9d9e43f	CPT0077790004	ec760155-e30c-4632-a335-a21961bdee62	"C3N-00513-03, C3N-00513-04"	ca63469f-6f24-47be-8333-ebd44c3f831d	C3N-00513	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
19c3bbbb-0334-41b1-9034-a6bbc4cd5f4d	CPT0001750003	a2216faa-7a13-4838-89ba-6b99432c5046	C3L-00102-06	890f123e-71fe-4f22-9533-1019138d6aa3	C3L-00102	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
76a1571e-ec9b-464d-a920-9e45ebe26018	CPT0237270005	e5ed177e-9889-425c-90e0-58c8443b8638	"C3N-03853-01, C3N-03853-02"	69987aea-3042-4eb0-a30f-361caddde015	C3N-03853	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d8f2e715-57c1-4ef9-9312-94e17faf0c20	CPT0187550004	06ba1d19-29b6-4a61-bc5d-795989958353	C3N-02295-04	43cb11a0-b404-4a33-88be-0fa826110ab6	C3N-02295	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
65f938ef-6612-4b09-98c9-e56e7b7062dd	KoreanReference3	b097221f-67fb-4f04-aae9-d5e63f7071ae	KoreanReference3	a4b96c1c-6508-4439-84fe-39e3c5c37a79	KoreanReference3	CPTAC3 Discovery and Confirmatory	Tumor	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c76d568-0435-48a2-9e3c-15a172d32d12	CPT0077860003	72cc17c2-8487-457f-b72d-20a10aa1bf4e	C3N-00436-01	ac628f19-20c7-420e-8a7c-10db8ab77656	C3N-00436	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eff4a006-2683-44ea-8c7b-c4815f8a4113	WU-pooled sample	d8d2e110-3859-4f90-8ddf-09f9317c6c32	WU-pooled sample	dd7e1d91-d297-4933-b37c-4d69bec00cc7	WU-pooled sample	CPTAC3 Discovery and Confirmatory	Tumor	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
53503e2c-b233-48b9-99f7-0a7d8feffafe	KoreanReference2	595aaa4c-97a6-4ced-9e4a-6c90a8c52b05	KoreanReference2	ca8c623c-2c48-4dfa-b9a5-c3522d9c249f	KoreanReference2	CPTAC3 Discovery and Confirmatory	Tumor	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1554a5f9-48e4-4059-85ae-3d76eb6f4183	CPT0089750004	1680b329-2e9e-4daf-90b4-6d1515da2b0e	"C3N-00957-06, C3N-00957-07"	4c2fc223-0f54-4143-a379-290552598b6d	C3N-00957	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb40b331-370a-449d-9324-909bf68d0c41	CPT0238740004	ef035164-5476-4ef1-a716-53bbda47bec0	C3L-04473-04	588c0d27-fc63-4f2b-904a-09cd2507fc00	C3L-04473	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0a529be3-106a-4c5e-9f1c-bc29237ab688	CPT0014060003	6089dda3-3eef-49a3-9aec-374bd872bd3e	C3N-00198-06	656b9d5a-ac9b-419d-8300-52b31eb56be6	C3N-00198	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
1edf4274-f631-40bf-8b8a-018a5f04ddcd	CPT0239910004	3e2a5a80-9e5f-4272-9872-f82f92bc927b	C3L-03388-02	bcd1c547-3d14-48f4-9398-a775697cbcfc	C3L-03388	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fd65a24e-8558-42ee-8991-b3e757b1bdba	CPT0238610009	ae7875b5-547a-4f33-b80d-2e1961f6f65c	"C3L-03639-01, C3L-03639-02, C3L-03639-03"	9e815dee-cfa4-46a0-a284-741ca0547c92	C3L-03639	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63f2687c-05fe-493c-85d9-ab351cf46ce0	CPT0109130003	45a3f00f-eced-48ce-9f2d-762c6d92c616	C3L-02115-04	f4c7d3bb-f214-4fb6-b2d7-bc173b715220	C3L-02115	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
d8a9a2cf-26f5-45a9-9a88-a32e32bf898e	CPT0347850002	bea84ab7-93f4-46fb-b961-2508040dacf9	C3L-07035-01	088e15dd-a61d-4b2e-959c-9120060a4666	C3L-07035	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d1333c1-6b5d-4a8d-aa09-7594bebc1987	CPT0238040005	7e4e7c2d-7f3a-4ee6-979b-7717f74b0a91	"C3N-04126-01, C3N-04126-02"	c955e0ee-8b00-48ab-9a48-1094f1f11c06	C3N-04126	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
192ebe88-2da5-437e-bed2-dd8ad6adad43	CPT0089720003	9103d058-c054-462a-892b-59dac391f973	C3N-00957-01	4c2fc223-0f54-4143-a379-290552598b6d	C3N-00957	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03b3c1e1-9a09-402d-a78a-00291fc6f28c	CPT0236700005	383af92f-cbdc-40f0-b4d2-a633ee30d8cf	"C3N-03839-01, C3N-03839-02, C3N-03839-05"	c531b8d3-736b-4f87-b4f5-0234f5475cf5	C3N-03839	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
61787f30-5971-4929-bf49-7217e1082ede	CPT0138900004	4d4172ae-c7d6-4976-bb71-dd77f040b99a	"C3N-01997-02, C3N-01997-03"	b389c04b-e42a-4143-970b-f39cc6882ba0	C3N-01997	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ee76050-a94b-4081-a3ea-2611d4e5bbdb	CPT0254680003	b7d40f1e-16e2-4858-a977-fa8e05009ff2	C3L-04027-01	e59ead0d-ee08-4c0e-bf73-8953587b49fb	C3L-04027	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a1e041e6-852e-4443-8329-122d815974ef	CPT0162600005	fa339e82-16c3-4e10-8bb7-abc8844528d5	C3N-01900-03	10784784-5101-4f5e-aefa-1311e0000fdf	C3N-01900	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
87df2cad-c2fb-45a2-9237-ba5853c8e2d5	CPT0064520004	eec22e80-e1e9-4360-a903-3f8373bf6ce2	"C3L-00640-01, C3L-00640-03"	6abc5a95-7e95-4706-93f4-8ab0eac7d60e	C3L-00640	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
84ec459f-bafa-449a-a3cf-0ca43753e1c4	CPT0123890003	0b5bbf01-302e-4a59-9f37-2e7fe00e2446	C3L-01053-07	ed932161-7b37-4bc4-aa09-b8adeb044f17	C3L-01053	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df771786-ad93-436d-8a54-6f76d543ca64	CPT0241320005	18a60535-0633-4b7c-8df4-081b7562128d	"C3N-01012-01, C3N-01012-02"	5f38c09b-b5e6-4142-b3b0-dee4cf878e06	C3N-01012	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e188d752-e4fe-4ff8-b585-c166fbba41ea	CPT0088840004	417708dd-06df-44a6-9151-8d1f70cb8fd8	"C3N-01379-02, C3N-01379-03"	e75de5e1-5746-404a-adfe-52d1402f0e08	C3N-01379	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
4913f3fe-a138-4624-8d54-17bb1987ef4d	CPT0246720003	65d8be67-830e-4320-8f5c-6ce332dc6bc2	C3N-03666-01	1641e669-51eb-420d-92e3-cec18d23ea0d	C3N-03666	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bd4663bc-1ea2-499f-98be-d49973e596de	CPT0064570003	54399832-8f5f-4059-9d3f-2a2253739afb	C3L-00640-06	6abc5a95-7e95-4706-93f4-8ab0eac7d60e	C3L-00640	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1cef92e2-cd42-47f6-8b48-4931409d1512	CPT0221250004	1505a7a6-0bac-49c1-b68d-78cfee70f90c	C3L-04072-06	7ff83eb6-a98a-4cf5-b5e6-22479ad984dd	C3L-04072	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
672f66c1-cd89-4407-826b-c15ad79e5b33	CPT0166930004	9afee3af-aee5-40eb-b7ad-2661712d0f8c	C3L-03129-01	8202a1de-9592-456a-a318-6bc1fd56e0a7	C3L-03129	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
04c8346f-bb0a-46bb-8900-a9f1d3130a28	CPT0166680004	14a3d0da-8242-4a05-92a8-9745abfd430c	C3L-02890-04	18b64ae1-2fe2-40d2-9126-bd1ed2ce4e95	C3L-02890	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
a3fc13e6-e1b6-4dfd-97a6-a48988604caa	CPT0123460003	77d8ac01-48df-4fb2-8d4d-bec6db186e36	C3L-01036-05	f9149c15-2d78-4d42-815b-53fdbef4ed6b	C3L-01036	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9bfd5aee-d82a-4e58-b9b6-547a7096e8a5	CPT0093930004	50856b73-689d-46dd-8553-d47b0f28ede8	"C3N-01165-02, C3N-01165-03"	fdfb73d7-a1c1-4c3a-8a7b-bb9157af50d2	C3N-01165	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a01c659e-501d-4ca1-8af6-e625332efded	CPT0226530004	d3b94c9e-a205-4f01-8164-66f33b256c6e	C3N-03006-02	fae3dcf4-0303-4d82-8be4-c388ab49e7e6	C3N-03006	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f8da6e4-1fd8-43ff-a1fc-12b2d5b7ba57	CPT0064090003	5f689e7a-c8cd-4d40-8700-998d42bd2e1a	C3L-00819-01	9a0345e6-ba08-4f07-b768-79a039ba14f2	C3L-00819	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df88b55b-4fda-47a9-8bf8-dbc8f4333c87	CPT0355200003	a260b224-6bbf-4d35-a39e-67c3fecfe20f	C3L-03514-01	53097cb9-d461-4ad6-b7a2-a8d57520222a	C3L-03514	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8ad53de6-4a8a-4717-854e-17a1b82ea1ee	CPT0094760003	d8f422cc-74a6-4928-a57e-35e230d05eab	C3L-01689-04	354aa1db-a43e-4972-a704-6536c164b6f5	C3L-01689	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
7debc5c5-bb3b-4d5b-bba9-027840fc3a9f	CPT0170240004	7faa52d8-2403-402d-b8b2-248068fcc858	C3L-01037-01	c45a1331-dab4-4ba1-8237-5dc4a6991f6a	C3L-01037	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f2c3fc1c-aea8-42fc-a590-eaee95705dc2	CPT0247090003	e1508c10-30e8-4814-acfd-ef5906e94c56	C3N-04284-01	d7e4e6ae-165e-44c5-943d-7a58f9d37931	C3N-04284	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de0e9e1d-6ae3-4aac-9f45-bdcac5b26d97	CPT0226610004	113dafdf-9689-47d7-af0d-cd96b318cab5	C3N-03426-04	a2391397-3980-463e-8d1b-2290a993893b	C3N-03426	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
951b44e1-bf89-46ec-9d18-cfe54a74adc7	CPT0198420004	1594a8d2-da05-4f5a-844d-0dd28ae5f764	C3L-03356-02	9530b47e-9017-4dec-bd62-60ae4386aed9	C3L-03356	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a524c52-f2cf-419e-9622-ae312b98279f	CPT0209310004	99ef1653-2e16-4bb7-a286-df58d774de33	C3N-03086-02	4fc8d10b-c3c4-4137-881a-59148033b259	C3N-03086	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
87c85e02-7327-4b4e-9a3c-a05d203535bd	CPT0093860003	c10f14cf-411e-46e8-a0b1-e267f2965ecd	C3N-00517-01	07e96995-726b-4b35-8fde-49fa5d6a1758	C3N-00517	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b38c30cb-75cf-4b51-810a-b78bd2714407	CPT0083270003	d7796cc9-3b8a-4757-b0c6-90e039d5d212	C3L-01328-01	05e50d4c-1271-453c-a6c4-39a3565073ef	C3L-01328	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
24e6642e-573e-48ce-b65a-41d5d1633d19	CPT0091680003	a68e7bc9-773f-42c1-8890-f63580fb2d10	C3L-01598-06	1ce589d3-f145-422b-8f7a-85f1e608fc39	C3L-01598	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
650cfeae-460b-4bab-b7e5-60755a7e9696	CPT0237920004	dda357e0-f379-408b-a21f-1cb34f89274a	C3N-04119-03	b2412ff4-1532-4ace-b1ef-78ef45f492f2	C3N-04119	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dc4f63ea-386f-4551-abb9-8f72b1f881aa	CPT0093880003	f047b575-088b-4848-9b82-1f3eb2ef5183	C3N-00517-05	07e96995-726b-4b35-8fde-49fa5d6a1758	C3N-00517	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
67098c44-bf6f-41b7-8f51-f3080beb37ea	CPT0183750005	f75749e4-c335-4efa-b835-ba407e822f8f	"C3N-02585-01, C3N-02585-02"	0774e352-a193-4c70-8351-11f40108fd03	C3N-02585	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
81169283-21e3-4dc7-9d1a-70889cdd6e03	CPT0246990003	13fb00e9-64ee-425d-8297-c8844561c886	C3N-04282-01	33f484e3-9bf2-4985-8999-567e3022ac15	C3N-04282	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8edbda5f-7578-4e0f-a85c-93191740a99c	CPT0124530003	55fcfd7f-c7cf-4a54-a30a-4d274338c4ce	C3L-02606-04	fc5b03d9-405b-4514-9a4b-4b64761c48fd	C3L-02606	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
46e0c256-e7b5-411f-a28a-5e8aea02fd87	CPT0238710004	a9633e5e-d8f5-497e-b5fc-d041f968e136	C3L-04473-01	588c0d27-fc63-4f2b-904a-09cd2507fc00	C3L-04473	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fceb722e-43ca-4ef0-bd69-ed25920c6db3	CPT0091660003	44f2eb1b-1244-4e9d-8a84-fcfc1225c655	C3L-01598-02	1ce589d3-f145-422b-8f7a-85f1e608fc39	C3L-01598	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f4625955-57aa-4bc5-bf11-0581f77295a4	CPT0063970004	d158143c-93a2-42d6-88e5-10131cab9bee	"C3L-00589-01, C3L-00589-02"	814e1879-8a9a-4b1f-8533-91edbfcaad7a	C3L-00589	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a02aed9-33d1-4ef1-a242-43d0d7bdf964	CPT0108400003	e847ea5d-0a13-4b87-87f4-14cc5281e3b9	C3L-01453-03	48c5ef63-81a1-497e-89fe-21f96813de49	C3L-01453	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa8ead8f-673c-42c9-9e8e-f29e77bccfd6	CPT0186050004	aed422aa-2d02-459a-aa66-1d039a777830	C3N-03173-06	905a9e60-75b1-4c53-9905-e2d3d171da7b	C3N-03173	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
4c1d6dee-aaa8-4275-8096-b8cedf2811f1	CPT0124610004	049524de-4879-40ae-9e16-48892406dc3f	"C3L-02613-02, C3L-02613-03"	48772971-6230-4918-b9a7-dd1b5af9aade	C3L-02613	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb1600ae-7104-41cf-863e-9ecd4b50acda	CPT0237290004	f545fbc2-57b4-4893-b57b-a695bea0397f	C3N-03853-03	69987aea-3042-4eb0-a30f-361caddde015	C3N-03853	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
840c2f9e-7016-4dc0-b9d8-b4f669b80e0b	KoreanReference1	1b37c87b-7126-44f9-80d5-dfb1d8edbf0d	KoreanReference1	bf0af6d2-0d83-410f-b2cc-df04521f05e3	KoreanReference1	CPTAC3 Discovery and Confirmatory	Tumor	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d94c49dd-d1a1-4840-b603-61f92594d88d	QC4	3bbc5ea7-57dd-4707-ae80-f70dc4ceeeba	QC4	3beac08e-60f1-4ea2-85c9-f7bef1efb04b	QC4	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ec537b36-8c28-4b89-9bbb-5d6f25379c3b	CPT0017040004	cd470654-1164-40bc-a41b-7327cf71a62b	"C3L-00881-71, C3L-00881-73"	109369bc-354e-46c4-aa26-69d13194b085	C3L-00881	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6fe2fa5a-cfea-4edb-98d7-29581ba686c2	CPT0248440003	af948bb6-8012-4a6f-85f1-9c3f87ccc859	C3L-04848-04	6abdfa5b-ab89-4ac9-974f-427a4007a133	C3L-04848	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2103044f-c0cb-44cd-85ed-4ab235c1282b	CPT0198440004	717005f2-cc59-4d27-a21d-7bfd2a57eda2	C3L-03356-04	9530b47e-9017-4dec-bd62-60ae4386aed9	C3L-03356	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4899833f-560d-476d-bcdc-d83d9472b09a	CPT0123670003	be9dee73-9d28-4724-a049-83a25d007459	C3L-01051-04	77e6c9de-2a62-4c1f-9fb0-f07e86c9b6de	C3L-01051	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aefe89a2-929b-4b27-b2e1-35c24fccba57	CPT0077950003	16f91f45-d651-43db-a8a5-225859b319a4	C3N-00514-05	65786c81-1ca9-4836-89a4-d80d7dbf773c	C3N-00514	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f711621a-dc10-4bed-bb20-02a5bd790aae	CPT0248590004	47f6ef15-c532-4f95-92a9-d55f0a1ec17c	"C3L-04853-01, C3L-04853-02"	28c67334-e064-4692-8868-add8d830e983	C3L-04853	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
76cfe6f7-3a13-4661-8c45-aa0cf389cfc2	CPT0011520003	2adbd60d-5ad1-4acc-bbdd-75891d5f1177	C3L-00277-03	61fe740d-ae0d-4541-8fae-ab0c33b0f708	C3L-00277	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bab75f4f-b6a7-4ca8-a793-8d4df96a3341	CPT0226600004	349efe1e-43af-4a4b-920e-e0a3d4da347c	C3N-03426-01	a2391397-3980-463e-8d1b-2290a993893b	C3N-03426	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd2271cb-c57e-41ef-b82c-0d75279d8a61	CPT0161770004	f6a52d85-2cd2-420b-9471-a3632a06a3e3	C3L-02604-01	65961f24-e423-4dc7-b416-ec8f858ca39c	C3L-02604	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9b79b603-a0c8-4d10-a325-5c3941d9f969	CPT0264180003	4c55c6d3-c9f5-41c7-be43-2dc24ebb02ea	C3L-03743-04	dc7b5f90-ea1e-4e4d-8445-ec2950cf5d55	C3L-03743	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
71c6f0ef-dafb-45ed-9df1-588f7b4d9edf	CPT0065570003	5a33b20d-accc-4742-9565-977ac51befed	C3N-01502-01	3639f4a9-758d-4393-86d5-8c3222d0e869	C3N-01502	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9c36f5c7-d374-4f14-9344-495fde50cac0	CPT0124980004	749600a1-3156-4ffd-8f9d-511e345766c2	"C3L-02610-01, C3L-02610-03"	78081bea-6b0b-404b-b9a1-f64ced91f728	C3L-02610	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f5c40451-f1c2-4e4e-a204-9b60c29a7f89	CPT0238440005	653457fc-01f2-4898-b2ec-16f2a73947a2	"C3L-03632-02, C3L-03632-03"	d9eff2f2-2098-497d-91f2-f89165e25033	C3L-03632	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f01512e2-d443-4991-be96-4c2d34beaf4e	CPT0207780004	5d82e22c-f330-45d8-a392-7d0a14b101ba	C3N-02579-02	71565a38-0036-4748-b4e4-e4b921ad1f72	C3N-02579	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d8651d20-db5b-4f94-a0a0-34eddbb45208	CPT0246210004	cc47e3cd-1c14-4eed-936c-44d3e1c50e7a	C3N-03440-01	fcfe466a-ca53-4a30-94b1-f071130286db	C3N-03440	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
219868be-ba8b-493f-8338-b675ff18c24d	CPT0094180003	f3323b70-8945-47ae-8f7e-c25a5bf45961	C3N-01382-01	68141a72-2915-4223-a078-df4c0b3d3711	C3N-01382	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cf5fe7fa-2e5f-40db-a76a-b2e6c28ecfff	CPT0221470005	11794efb-6548-4a4e-b33a-f33bb30f05da	"C3L-04080-02, C3L-04080-03"	b11be1d7-8f96-4d28-b965-7ee2891291c6	C3L-04080	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ff120bb7-1d21-426a-a178-dcf90d97ca7c	CPT0108930003	613d5dc7-669f-43f3-8059-e61b256b8683	C3L-01971-02	bca26d15-e38c-4220-a193-143c5496d20a	C3L-01971	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fefd7317-5797-4fc0-9ae0-3547cfd5d885	CPT0207980005	05653bbc-db7b-44e1-9a21-712596295bb0	"C3N-02768-01, C3N-02768-02"	58b42d9e-bba2-4a1f-9066-77586c0d6eb9	C3N-02768	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7d9828fd-0ba2-4a7e-b25f-2a6329c6d668	CPT0109200004	f3b0ed98-a1d9-4151-81fd-64e768f73472	"C3L-02116-01, C3L-02116-03"	f78c3797-dd47-4d93-aacd-1d406cfcf36e	C3L-02116	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a4d57c03-6b89-4990-ad9b-5abc53d14953	C3L-00189-04	83306121-2152-47bd-ab68-8724471b77b2	C3L-00189-04	e7ee4f4f-418f-4f96-aed6-0856d94f02f2	C3L-00189	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
914cf15e-7006-43cb-a417-72cb924960c8	CPT0008750003	99c80d93-5c05-4a3a-8bad-810fed23e74e	C3N-00302-02	3d65abbe-5af5-4b1f-b887-43ac4f9fac6b	C3N-00302	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c663bb7-cf90-4b10-8bbe-a43f6d470970	CPT0078090004	62f74729-7eaf-44d2-8f44-1c72009bdf80	"C3N-00516-01, C3N-00516-02"	95fc8706-06da-4652-bcbb-0c02c4faeedd	C3N-00516	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b238f2a5-b70d-45f7-b6fe-31d6aad26a34	CPT0123440003	509363d4-fcff-484f-ac47-6e94ff7f0c5d	C3L-01036-01	f9149c15-2d78-4d42-815b-53fdbef4ed6b	C3L-01036	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2673de9f-fc2d-4737-8277-ffa665437b73	QC5	e5698cec-b4f0-48ec-9d41-c41df10e1344	QC5	0b2864ca-d12c-42bf-a74e-280213ca525f	QC5	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c96109b5-175a-45a9-8a00-ccf8e3681dca	CPT0238640004	ab0a4b59-c998-413e-8cdc-616b76e06b40	C3L-03639-04	9e815dee-cfa4-46a0-a284-741ca0547c92	C3L-03639	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c22e6f90-1f97-4129-8601-c90e0ac4071f	CPT0237840004	84fe8b2d-f523-4bba-a3f8-6c8486966ed1	C3N-03884-02	a3cbf3f4-b398-43c8-b323-c4e07c04d8d7	C3N-03884	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b1c551a3-3e30-4693-90a4-20a009114f5d	CPT0081470004	c59491de-fbcc-4368-8a8f-e24280af9e9a	"C3L-00625-02, C3L-00625-03"	5aff3251-f272-4dcc-8bbd-b4ee767469f4	C3L-00625	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de8274bb-66d6-40c3-b97c-4fcb3f81f1b9	CPT0127290003	31656e55-c403-4913-9c0c-4bc29b2cef20	C3L-01031-05	c8f56efe-fb3d-4f96-88d2-1c0e3b7bdd38	C3L-01031	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7cc34db3-213a-4b7d-a8b4-cfb7b8b8c334	CPT0264150003	55af224a-5c72-4bee-a129-8825e22435f9	C3L-03743-01	dc7b5f90-ea1e-4e4d-8445-ec2950cf5d55	C3L-03743	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de69f8bb-a87b-4bd0-8abb-c33f9c87d2d7	CPT0124500004	efbc0b93-9b3d-46f3-90d3-c787647dbbfd	"C3L-02606-01, C3L-02606-02"	fc5b03d9-405b-4514-9a4b-4b64761c48fd	C3L-02606	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e3b2ad6f-98ce-4289-98da-50e5a8eea1cd	CPT0187540004	10d69c66-8d13-4061-87d2-d01e8ab4ec54	C3N-02295-01	43cb11a0-b404-4a33-88be-0fa826110ab6	C3N-02295	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae7636d3-f10c-43e3-a2b2-afc5c8b4e7fa	CPT0209640005	0878c864-4ef5-4540-87b7-7375799fd39c	"C3N-03211-01, C3N-03211-02"	1fc52010-b6e7-4f19-9cad-afb7bb55d487	C3N-03211	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a3d79ac8-a559-4550-b2fb-4275a8017662	CPT0170260004	a386fa70-ec4c-4b48-be8b-c013bad36a57	C3L-01037-05	c45a1331-dab4-4ba1-8237-5dc4a6991f6a	C3L-01037	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
43395bee-6b38-4f8a-b220-e2f3a59d2abf	CPT0092630003	4a0974f0-fd95-447a-9e76-d173873c3e3f	C3L-01662-03	234b3e4e-525d-438f-a71a-4c007ba6ccbb	C3L-01662	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
933ba690-5847-4d5e-9f81-fb412274c931	CPT0063990003	0e211683-c493-4f1f-bbce-8addea7687c4	C3L-00589-06	814e1879-8a9a-4b1f-8533-91edbfcaad7a	C3L-00589	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
d0f3b272-19e0-4b01-8267-a714d0e01cd3	CPT0124000003	ae70d5e2-2e62-44b6-b4d5-ddf7fd957ff4	C3L-01054-05	320df578-47ba-41a8-9991-a4972ce48810	C3L-01054	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
013c73b2-d02b-40e6-a9d9-9c194a671c30	CPT0208550005	6a1dafd0-72d9-4580-9a15-b6b8a7b049a4	"C3N-02940-01, C3N-02940-02"	cf30c228-aa32-45e8-8b46-fed54dac650e	C3N-02940	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b01b8bab-4e30-4b4f-a99b-cf5d4c901019	WU-PDA1	eb992631-0de4-457a-9b57-40bd1cee140d	WU-PDA1	b4430371-3c29-47e0-844f-4dba28914afa	WU-PDA1	CPTAC3 Discovery and Confirmatory	Tumor	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8aa1d718-5989-4a86-846d-8aa283780e45	CPT0138990003	8c9701e8-1708-46e8-8520-6e74b0a1985c	C3N-01998-01	5f9e7f05-b8d1-4dbc-88f0-8b057ef87eea	C3N-01998	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
645da9c3-ee30-4257-9aa6-f1fe8c458999	CPT0183770004	0d7bb563-6c05-4da7-a19f-7d8edf119ef6	C3N-02585-03	0774e352-a193-4c70-8351-11f40108fd03	C3N-02585	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
94c3d3de-3494-446c-8909-869c4c318454	CPT0127270003	7472379f-b8cd-4fbb-bf95-6ce3c5b6dc2a	C3L-01031-01	c8f56efe-fb3d-4f96-88d2-1c0e3b7bdd38	C3L-01031	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
73bcd1ec-11dc-48f6-bb9f-61cd7c8238bc	CPT0162660004	0fff259e-6079-4667-bca7-e2ff36b37bce	C3N-02589-01	0d000f9c-f76f-42a0-b88b-9a9054919adb	C3N-02589	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f90ac50b-29df-4bea-ba78-f0c715a37729	CPT0094130004	b85b98fe-019a-43a8-a121-ec40b7aee3c4	"C3N-01381-01, C3N-01381-02"	81d7909d-4c3a-40ed-8283-0cbc599ac942	C3N-01381	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
77180fa8-e395-4150-b166-df7d4a00984d	CPT0126200003	1522490c-642d-4e42-937a-7cbba3534b0c	C3L-02463-05	a940e7fe-84e0-41f7-87fa-d188db8435f1	C3L-02463	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
52b9b6c5-055f-446e-aac0-076d03a13444	CPT0162760003	ca1decbb-5a62-4bc3-b35b-791abac3896c	C3N-02592-01	e3cf305c-f83f-474a-a095-542970bbf3c8	C3N-02592	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4027c33b-3b17-479b-b3b9-b14fe4531329	CPT0246220004	daa245cd-7a53-4f59-a3f4-cddf5fb69ed6	C3N-03440-04	fcfe466a-ca53-4a30-94b1-f071130286db	C3N-03440	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a8808d8e-8798-45c3-9528-40528f2d5f3f	CPT0001730017	9e2e650f-37cd-4e97-b0b1-61c7f9b59275	C3L-00102-01	890f123e-71fe-4f22-9533-1019138d6aa3	C3L-00102	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db9a1486-83d4-4ab6-baed-5d2e309608e8	CPT0197420004	6a8e7518-e848-48d0-bc09-d8be66e9cc6b	C3L-02899-01	0fdc2d7a-e945-4c3b-9df5-5745197e1513	C3L-02899	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
198f3231-4e14-4bdd-8296-96aec34c8653	C3L-03632-04	6c2ebd55-a59c-43f7-b77e-e4b83f75f787	C3L-03632-04	d9eff2f2-2098-497d-91f2-f89165e25033	C3L-03632	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29b093f0-2249-4b37-ae07-fb4d1d49206f	CPT0221240004	b5a31671-6cc8-4e94-8299-9a8f84069a7a	C3L-04072-01	7ff83eb6-a98a-4cf5-b5e6-22479ad984dd	C3L-04072	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb078240-7175-4d3e-bd80-aa104e481112	CPT0347820002	9fb1e360-7e64-4abc-a3d1-2a6910a55e44	C3L-07034-01	9398b8ff-6dbe-4ea5-b74b-36a8ec172acf	C3L-07034	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63815445-d313-4e33-acd0-59c9398894a2	CPT0226490004	41498520-4335-4e27-95a8-062672e835cc	C3N-03000-02	23434bf3-f0eb-4070-964e-0c9a3ba61140	C3N-03000	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
84498b3e-7437-4b59-9353-bdf6385eb34a	CPT0275880003	c554e846-6309-45f7-96b5-f543e1116c6a	C3L-03371-05	45e072c0-3603-46f9-a86b-3d8492532eef	C3L-03371	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
11478c2b-c5ef-4cb0-bfe7-9f0c04126f50	CPT0217700004	731f0416-7cdd-4054-8568-9611fbc8ff16	C3L-02897-01	f48ec6e9-5efc-41a8-8fa4-4508b31ef9c2	C3L-02897	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0a3f200-803f-4ba7-836d-0b16c03ea7c7	CPT0174700004	8e97e69d-c5fe-4749-a07e-72010b5def71	C3L-02809-04	b5f71e03-9c44-48ee-99b8-cf0fe4cb4dfe	C3L-02809	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f50d761-d84e-489a-bb1f-51175a724779	CPT0139000004	3b6451c5-0454-40e5-a0b9-5f9ae655c6fe	"C3N-01998-02, C3N-01998-03"	5f9e7f05-b8d1-4dbc-88f0-8b057ef87eea	C3N-01998	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cbdd3a54-4c1b-4134-b891-e8e2496d1826	CPT0126160004	d465d2c5-f957-40f1-bf26-e8bedc8e79db	"C3L-02463-01, C3L-02463-02"	a940e7fe-84e0-41f7-87fa-d188db8435f1	C3L-02463	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
889d31d6-bdaa-4b50-b67e-294e66ccd098	CPT0237910004	40e0839e-cee8-4e81-baae-f88ba5f4930e	C3N-04119-02	b2412ff4-1532-4ace-b1ef-78ef45f492f2	C3N-04119	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c309480-b061-47da-980a-ab2146372303	CPT0025760003	5b5e895c-c2f8-464d-a533-406f90655b64	C3N-00249-06	9bb79b5f-fa75-4d05-8a23-eda606a6cfdc	C3N-00249	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3f945616-6da7-44e7-9ed8-14d5d8e97de1	CPT0162830005	434b2aba-006c-4d0e-b164-7663ae25497e	"C3N-01907-01, C3N-01907-02"	d7597e55-49af-4dc7-b471-3d08a801c331	C3N-01907	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
27b66033-20cc-498f-ae88-b475ed63348d	QC1	3dfe6ae9-d5bf-4cb2-ad54-5bea84386e4c	QC1	54bd49cd-0642-47b7-b56c-70c1dc358435	QC1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01af84af-e1f4-4532-9e73-bb4e01b8f712	CPT0198730004	3e12f9b7-ada9-4b6c-bd40-f1000ffbfb26	C3L-03628-04	47f2962e-1c0c-49da-bcd4-93d9c1874ec2	C3L-03628	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
6a1d444f-c91b-4ef4-80f7-cc60187a7231	CPT0355180003	e932c6e9-8508-4572-96d0-03c5d903b9d6	C3L-03513-01	bad5524f-7eee-4486-bafb-97b745f66613	C3L-03513	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
13f256b9-be4b-467a-83e4-d1a322c06de1	CPT0224460004	a8171632-4b24-45c3-b80a-9cd730420de0	C3L-03394-03	bc01b9f6-2355-47c8-bc06-6ad5865804ad	C3L-03394	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba7e39fc-6e00-474d-8fe5-bb883c43e0be	CPT0108960003	e6ba66ee-9e5a-460e-b274-7fc824192a31	C3L-01971-05	bca26d15-e38c-4220-a193-143c5496d20a	C3L-01971	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8da7d81c-62f6-4722-b6d7-24502c17048f	CPT0347790002	92f180a2-8218-4a5e-8705-4eef4b9e0827	C3L-07033-01	d99c4c13-8b14-4340-bb4f-eff79d433c55	C3L-07033	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5169c8db-1924-4831-8f8a-675e4e1ae5b1	CPT0123750003	1addc17d-a6e4-4ef7-af42-4c1bb0ce18be	C3L-01052-02	622bfcbb-af4c-4893-8e1d-c6f65cbb8da8	C3L-01052	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
96af8747-5095-4a63-a2ee-b896f2dc0e00	CPT0236560004	b875be4e-2b13-4049-a58a-6b6304b37526	"C3N-03190-01, C3N-03190-02"	66180ee3-f012-4749-97a4-fb622843bd1a	C3N-03190	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
929ccd85-2d91-4c7e-93bc-5620b3ed45f9	CPT0166760004	46fbbf35-2497-4f20-91c5-4f1b91972940	C3L-03123-02	8d4aad8e-229d-4d7a-9244-b6343cb2fb5a	C3L-03123	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f68955d-92e9-4109-9e01-3be72fdbf398	CPT0276010003	048ae9e9-9d08-4697-8bbc-a24cc7d51301	C3L-03395-02	df0ee52d-df43-401b-909e-ca25f708ae64	C3L-03395	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d7f0fc37-4069-4a9d-b745-6120ccd43b1f	CPT0246810003	8587e1cc-5472-4e34-8787-4583ca233dd7	C3N-03754-01	f61386d0-dcb2-4d44-adf7-7b2cdae98b7c	C3N-03754	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
23641c4e-cd88-442d-a20e-da534f8629ab	CPT0238920004	d4e3fe28-91de-4e3e-a859-51b169dbb0f6	"C3L-04479-01, C3L-04479-02"	dfbdbf47-7379-4d98-b6e4-175cd09ff0a4	C3L-04479	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a3a09bf3-03c0-4936-ba10-11a9dad3dfe8	C3N-00709-06	a84890e0-e1b2-4771-b0ee-30ffd87b9d6a	C3N-00709-06	f6d401bb-8001-4157-a2ff-82fc946ba933	C3N-00709	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9e2512ab-4759-4099-b879-74638741e571	CPT0077880003	ba1eb13c-fb47-4ab9-87a2-39b4845b683f	C3N-00436-05	ac628f19-20c7-420e-8a7c-10db8ab77656	C3N-00436	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
707a4d1d-a211-49bd-a7a0-adc9c1c11699	CPT0078180003	66597520-d550-47e9-a9bc-e4d63e6a1ca8	C3N-00512-05	2657813b-ca46-4047-889c-f98ed05f2796	C3N-00512	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4715022-11c2-4924-baa9-d753be222ec0	CPT0088180004	0ba7bee5-c787-41af-a63c-7c7f570dc753	"C3N-01375-02, C3N-01375-03"	307fd220-d518-40ae-8eea-8cdc3476f145	C3N-01375	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1cfd38e5-0295-4ca4-9bd4-e1e96edeffde	CPT0236360004	778f5ab4-651a-4f9b-83a7-96f9243b236b	C3N-03069-03	d21fa2fa-9a2d-4baa-b7d8-601b906a16c7	C3N-03069	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7328da7b-0f55-49c3-8e74-5114fcb4fc18	CPT0218220004	d962522e-e61d-446a-9393-784867a459b5	C3L-01124-04	5a3fd9f7-cd11-4ed9-b122-3096ba0e93a5	C3L-01124	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c59055c9-e724-49cb-bfc3-9f0d072eea48	CPT0094940004	dc68bdaf-21b9-43e7-9dc0-31fbaddd164c	"C3L-01703-02, C3L-01703-03"	344f4536-d2cf-4162-99d8-dcc40972c80b	C3L-01703	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0efe015-7be2-4faf-a3f6-a5962316dc83	CPT0078000003	a2913672-6c34-44df-ad13-f3cf5144b481	C3N-00518-01	0f06151e-53a2-4573-84c3-76e1b5c0ce34	C3N-00518	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c3c6ec78-6ec0-4f27-aed8-62dcb3cb548b	CPT0162780004	4284e578-2b03-4f9f-86a6-b05fb12856a9	C3N-02592-05	e3cf305c-f83f-474a-a095-542970bbf3c8	C3N-02592	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
14c48c84-9265-401b-9aca-860287506974	NTN060_Baseline	36a28352-95b7-4dca-b70f-1291fba9478d	NTN060_Baseline	c5e27ec2-15ed-4952-a050-d1426382ac50	NTN060	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dde5488f-d068-4413-a41a-e3bacd3c07bb	H36960.019_Baseline	48df04c5-74e0-4570-b811-69193a058f6c	H36960-019_Baseline	b80397c3-a8f4-485f-9ef1-f954272d1493	H36960-019	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a3f86f0c-c834-4aa7-ace0-5452dfd863dd	NTN023_Baseline	209f42e5-1823-4913-9c5f-8a2a71a4a7f8	NTN023_Baseline	7d5fe672-a977-4463-94b9-2554ae3d600f	NTN023	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6dae5901-b0eb-4296-8b7d-1d7d6820dfce	NTN072_Baseline	ec46e615-3ef4-4737-b093-518e1767b175	NTN072_Baseline	15d4ab5c-f183-4a1c-b5b8-9f766b774d2b	NTN072	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f58e2ab6-969c-48df-813a-80d8b9ce0b51	NTN021_Baseline	3e569dc3-8dc2-4282-a172-77625d92a77b	NTN021_Baseline	51a3f71a-57e7-437d-b0be-3f143b2b44a0	NTN021	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ecaa0a8e-28a9-44af-b683-75fdb49a2cf7	NTN004_Baseline	7e6fb4dd-3d9e-432a-a5c3-d793322eab38	NTN004_Baseline	91d06323-a8ac-4005-a27d-fef004640099	NTN004	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8da31f69-2cfe-44c2-afec-20ac418ede0f	NTN080_Baseline	ca7be253-4d5a-433e-97c2-79efe98b060e	NTN080_Baseline	fd9b930b-debe-4c99-8a0e-23b2c424b836	NTN080	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e288985-1de8-47ce-80e9-7ddd3538f551	NTN007_Baseline	a2f5137c-5bb8-4765-87df-5286799c4900	NTN007_Baseline	82219595-3db0-4f7f-b41c-6437462fb11a	NTN007	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d1e02d6-ffcf-442a-b938-c9d382ecc104	NTN054_Baseline	8b5afb3c-26f0-428f-9cfd-957f7b5044eb	NTN054_Baseline	f1b49b2f-6b64-47e0-b993-8cde8a7c5c14	NTN054	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d140879a-bba7-4dc7-b823-54a0a4355fef	NTN006_Baseline	ec6b7a80-ecf2-4bce-a9ae-0fa7c7874ee9	NTN006_Baseline	b8c57863-cf07-4f82-a425-4fdfb1883776	NTN006	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a02bfad-59a5-4a8c-be17-aa01296f5f78	NTN062_Baseline	adc67424-b176-4ecd-b34a-93b0b63a88ec	NTN062_Baseline	6113ff67-7e0a-45af-82ec-0f280c72e7d6	NTN062	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
628576c2-88d7-4541-853d-bc0ba4ec3dcf	NTN007_Cycle1Day3	4cd3610e-bb99-4ba6-8008-45ace54cfc3e	NTN007_Cycle1Day3	82219595-3db0-4f7f-b41c-6437462fb11a	NTN007	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e226ea7-f016-4f08-8d13-e9ec17aefe19	NTN031_Baseline	deb549e5-3fbd-4389-83a9-444fc9981a02	NTN031_Baseline	8520def8-1bfc-47a4-b65b-3a0aae6f1fa2	NTN031	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3cf54675-9a63-471c-af5f-c17aa18aa5c5	NTN022_Cycle1Day3	ede38c66-a315-4bda-8942-6a77b20d80e0	NTN022_Cycle1Day3	015815e9-3bfe-4a73-a9a5-6f804dd8ed89	NTN022	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b3f2efaa-82bf-4de7-8e5a-9d679cbf71f8	NTN085_Baseline	5280e135-e9db-4de0-8e72-1993d1670b31	NTN085_Baseline	52ec0528-aa7e-42ea-a407-f934ecaf673c	NTN085	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a953f6da-2bc2-459f-8b6a-d5992bef4b1c	Core CR	b086928c-5ebf-4e41-9eaa-f1b3016838a4	Core CR	7eb59273-13da-4bee-b428-e14dfef3aee6	Core CR	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8b663bd8-9ac9-4383-abea-bb3d639fe9dd	H36960.023_Baseline	a7cd9c36-a0e0-4da4-b06a-4250846e97c6	H36960-023_Baseline	bc0d56fb-ce83-4b9e-afd1-366077467d1b	H36960-023	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c0aedfb1-964e-4eb7-8eaf-ea93892f13c7	NTN058_Baseline	609eea53-3985-4243-adb9-566422c9860d	NTN058_Baseline	7c898ce3-f7c5-4f55-b8cf-9c9a48e247bc	NTN058	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8501e008-ea04-45ea-bfe9-b72e0c34b0da	NTN059_Baseline	f388e63c-7bda-47c1-b78a-18026fa25ef4	NTN059_Baseline	e207114a-9e45-443b-91c9-cabf93168f19	NTN059	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8c159a40-16e7-488a-92aa-c3b2cc5141fe	NTN011_Baseline	8c4f1a52-acab-448f-afc6-571e27bc7609	NTN011_Baseline	c2d6a31d-87b5-4a84-9d9c-44ee8642c8f3	NTN011	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32a80714-3095-47b9-89be-d5cdd941d5b6	NTN012_Cycle1Day3	7e29ea42-c9de-4296-a4db-c67f8ae72b7d	NTN012_Cycle1Day3	5e3a7a9b-219e-46aa-916f-4b1b9c2a2cf5	NTN012	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0259875f-399f-4658-9886-6614370e0807	Pros BRCA CR	d7209267-4b38-4154-bf72-d17ed279491a	Pros BRCA CR	a3328f69-121c-481c-8c49-5d01685aaa3b	Pros BRCA CR	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f468c94a-7fcd-4135-aa35-aaabbe49a365	NTN049_Cycle1Day3	29651f29-669c-48e4-ac1e-deff65ab8c58	NTN049_Cycle1Day3	46e88769-bf3d-4aa4-a5fc-5ab149bc74ed	NTN049	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ab60cecd-6f12-45ec-b018-b0cad55ad073	NTN029_Baseline	9c313f01-c3fe-49bf-b430-9ba253ad9c86	NTN029_Baseline	960bf328-4e1d-4334-9a85-44faba6f5bd0	NTN029	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa267620-2176-402c-bd69-bdf9f006a587	NTN017_Baseline	099313c6-b5d3-46a9-bf39-c67fc5c7e069	NTN017_Baseline	b6e87c18-64e7-40d4-acc9-32f5016249b1	NTN017	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e08aece3-40c8-437f-8e71-b861a48edd2e	NTN081_Baseline	b9225f6b-d71b-4c73-bb69-efc267fabd7e	NTN081_Baseline	bd34a905-c5a0-4866-8e0a-20b56730b40a	NTN081	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21e09f44-b994-431e-a23f-a8d7e5c504a1	NTN078_Baseline	4a01efbf-5a31-4ee1-aa8c-37c47159eb0d	NTN078_Baseline	833606df-5079-4457-9469-416eb4bb5a5c	NTN078	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8fa18ba9-63d9-4534-a00f-f83e6e45a122	H36960.008_Baseline	b2aeffe8-c5fa-47e1-b2ba-5c6ce0a0d2f1	H36960-008_Baseline	4445d74e-8e23-4466-88d3-e6fdcdd48d18	H36960-008	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dbbc90fb-2c73-46d8-b212-bc91edc402f3	NTN033_Baseline	f25c6c66-3b38-4cb0-b811-4acd1862c7db	NTN033_Baseline	826a166b-f659-43a0-8481-e7e7252187b9	NTN033	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a4d9d4d-f33b-4668-bba0-42c4452e5753	NTN081_Cycle1Day3	ad7fa2fd-000c-4f12-8e6c-123e24bfa3c5	NTN081_Cycle1Day3	bd34a905-c5a0-4866-8e0a-20b56730b40a	NTN081	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
064b6ce5-2964-4ed0-b258-121db8ceab0d	NTN089_Baseline	ba08cd04-5fa2-4d7a-9c14-b5a572c53efc	NTN089_Baseline	961fcdab-129c-4ae9-8abc-2ec9ae61c866	NTN089	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7795a368-a191-4a6b-913f-929c4c2fb885	NTN040_Baseline	d77d038b-101f-45d5-896e-5e0b384ea71b	NTN040_Baseline	5bc65c89-e0fd-4de5-865f-591de7e93379	NTN040	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8efffebd-39a0-49e0-a4a8-3b1b266f89c8	NTN016_Baseline	78e0e532-51e1-40fa-8e14-7aeef3147ac1	NTN016_Baseline	77b97df4-53e0-4406-ae92-298e44bb2201	NTN016	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7e88bfe5-9725-4122-b3a3-387e0bb4ff9c	NTN017_Cycle1Day3	67d7aa06-374d-4721-ba07-5f8975ed6f1c	NTN017_Cycle1Day3	b6e87c18-64e7-40d4-acc9-32f5016249b1	NTN017	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8fb3fad2-bae2-450a-8f28-8e2f9d56755d	NTN025_Cycle1Day3	818caab1-099b-4f01-9705-07320acd2276	NTN025_Cycle1Day3	29787fcd-8aec-4ef2-aae8-de02ffc07314	NTN025	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1b2458ec-8efc-409b-8007-695653bff144	H36960.018_Baseline	5fd42267-4086-490f-8200-6d519392ba75	H36960-018_Baseline	fb05051c-d318-464c-a4b6-06c3558ab79e	H36960-018	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6aa63ffc-3bbb-4f35-bc44-14be42b85764	NTN044_Baseline	e35163cf-ae0d-4fea-b52f-4d65a5794b51	NTN044_Baseline	6f77ed26-36ec-40b1-854b-fb55699526e6	NTN044	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9796757b-8101-48f4-899b-db135b3ce087	NTN039_Baseline	36e2c103-d68b-49dc-a767-4e8a2ef5c687	NTN039_Baseline	9aa58058-d5c7-4f5a-8b68-30d1e0a02d59	NTN039	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2cd4ba8f-1d95-4e6e-a613-df086037801c	NTN005_Baseline	c76f7e25-a6a5-4537-b5a9-96e1040007fa	NTN005_Baseline	3f53f968-eda1-488d-a2bc-0f0b6a3b2e39	NTN005	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f8e06b24-01d8-4b08-9440-3724c4c03b6c	NTN062_Cycle1Day3	b2d3413b-d5fb-427a-8a13-29c68b495405	NTN062_Cycle1Day3	6113ff67-7e0a-45af-82ec-0f280c72e7d6	NTN062	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
175274db-2aff-4a55-807c-9bd48dbce40f	NTN067_Baseline	0bfe05b5-ae40-419c-8d5a-803fa0361c64	NTN067_Baseline	f01cf81b-5a50-479e-91d9-efe329f5f0a7	NTN067	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fed89053-2cbf-45a8-983c-74040827ced9	NTN012_Baseline	7e7df2df-a47e-4b28-be30-f7d5df93f79e	NTN012_Baseline	5e3a7a9b-219e-46aa-916f-4b1b9c2a2cf5	NTN012	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea42a9d8-7da7-4f89-9acf-59d41f6ff861	NTN085_Cycle1Day3	4a98e97c-05d6-44db-83dd-f7dea6885bd4	NTN085_Cycle1Day3	52ec0528-aa7e-42ea-a407-f934ecaf673c	NTN085	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
79b27e4d-4b1f-4cf6-adba-2f8daae7d61e	NTN084_Baseline	621b09e5-e33e-4d69-abfa-f93510af94cc	NTN084_Baseline	e2024061-4f11-4af3-9b92-224cc5e45310	NTN084	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
289aa3af-992e-4227-8d71-f9ee93678e77	NTN009_Baseline	89b1a3de-0e78-4de2-b941-5f1bf05ebf35	NTN009_Baseline	6fff5e5f-4966-480b-83df-8e475230d122	NTN009	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
870e06d4-11fa-481a-8dd6-7dcfff1e3c08	NTN087_Baseline	f0e327d7-6b50-48ef-8599-72f4c3361d45	NTN087_Baseline	d8abeae0-f8ea-4a7f-9d80-064dcd7a5173	NTN087	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
556ae1ef-7a87-4e03-a8a5-632f4473e337	NTN006_Cycle1Day3	5354b1ac-713a-4a43-8ba3-c5d4fee5fdc7	NTN006_Cycle1Day3	b8c57863-cf07-4f82-a425-4fdfb1883776	NTN006	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
08c8c345-ae07-4d49-adbd-94ef2e0d5e58	NTN042_Baseline	bc282c7d-66e2-48bc-bf56-0a6c38d67793	NTN042_Baseline	e36bdcd3-9b01-4229-8011-bbe47072aa6d	NTN042	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8b3511b6-9dc5-4148-87e0-730088194bdf	NTN038_Baseline	f118cea1-ad7e-4dc8-9aa4-8d6428c2ea66	NTN038_Baseline	fc1d46fb-2394-4f4d-a94c-5d06256a810d	NTN038	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f3f5cad-dbb8-444d-9ca4-747097c4eab5	NTN020_Baseline	512549c8-e114-4e27-8d63-3d0e97b2833f	NTN020_Baseline	35e0e07f-ddeb-4b90-9d13-3069d0fe4d8f	NTN020	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d3691d18-4166-4f21-ab8e-f7b68e826bbf	NTN074_Baseline	22ba6b2a-392a-40bc-a21e-8070b56fa783	NTN074_Baseline	045e5a19-36fe-4cff-91e4-04af0e418614	NTN074	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01e1dfb0-b637-43bc-b25b-b0c6628f4ea3	NTN033_Cycle1Day3	0ee96289-f91d-4aa4-ab48-9031fae2f744	NTN033_Cycle1Day3	826a166b-f659-43a0-8481-e7e7252187b9	NTN033	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5de026b7-337e-44e4-b141-73c95e4a7bb5	NTN025_Baseline	83ea162a-6d6a-4ba9-93e1-471915da865b	NTN025_Baseline	29787fcd-8aec-4ef2-aae8-de02ffc07314	NTN025	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0baa5c48-6d3c-42b3-8cd7-9f7ac53ee31e	H36960.009_Baseline	3ce3d300-ca06-427b-9ff9-7cbd472e0359	H36960-009_Baseline	8fcb9a4a-35cc-4165-a4f7-6e1f7f74275c	H36960-009	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
06666d01-dbfb-4924-b39d-62ef522cddef	NTN075_Baseline	727edb70-2a92-4143-a42b-4f2ad117819c	NTN075_Baseline	957077dd-f8b9-43c4-8ce7-dfe673e78607	NTN075	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
905e6050-2fff-477e-9f92-705cc850c048	NTN038_Cycle1Day3	d5b299a1-b784-43e4-967b-d61eed29f17e	NTN038_Cycle1Day3	fc1d46fb-2394-4f4d-a94c-5d06256a810d	NTN038	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8cb9b11e-dd07-4cb7-82e4-6384715a75f5	NTN084_Cycle1Day3	0354eb20-4a74-40df-97d0-df35df0f01bd	NTN084_Cycle1Day3	e2024061-4f11-4af3-9b92-224cc5e45310	NTN084	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ebb39a87-ed77-4506-a256-23502dfa41f2	NTN069_Baseline	36c079db-d783-46a7-8e3b-a7d9a54f8e3d	NTN069_Baseline	0640d7cc-de5c-45ca-9335-7a085fcfb0f8	NTN069	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32265347-c607-4304-932b-82fcf80d83da	NTN014_Baseline	08c567a1-40d6-44a3-823a-05ae996f5c61	NTN014_Baseline	75729ffc-ec0d-40cf-83c6-adb6f1d78d57	NTN014	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b1b76554-b591-49f1-8d9a-0066f4e46617	NTN049_Baseline	14bfc5ec-5700-48db-8f9d-3755edb1df41	NTN049_Baseline	46e88769-bf3d-4aa4-a5fc-5ab149bc74ed	NTN049	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cb5237ba-fb0e-4554-8716-f14beaef5a47	NTN056_Baseline	a52009f6-bc16-4dad-b52a-3d7b95af354a	NTN056_Baseline	35087999-242b-43fd-9188-84424d7bdbc9	NTN056	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b822429b-1ff4-44f4-8451-05f9ff2e1695	NTN029_Cycle1Day3	e55914e6-246c-48d7-ae41-f7259ea198be	NTN029_Cycle1Day3	960bf328-4e1d-4334-9a85-44faba6f5bd0	NTN029	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21ec8c76-ae78-4071-975b-9c447dc92048	H36960.002_Baseline	a6c842d1-e850-49c1-a2d9-ea1c309bc322	H36960-002_Baseline	11da2414-f1d8-4b91-9e8a-8e7ead0897ae	H36960-002	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cbf8fb81-78af-4cad-b2d3-291af4f6806f	NTN046_Cycle1Day3	b73f2aac-bf6d-4d5c-87b5-1c92da3a34d6	NTN046_Cycle1Day3	f77f177d-411b-4038-9a09-2301a4032044	NTN046	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
22279730-92f9-44fa-ba35-552df1705c2c	NTN057_Baseline	de58c75e-1e89-4b1f-9964-5761fef254ad	NTN057_Baseline	1bb1400e-04fd-448c-930f-2454805f39a4	NTN057	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1436c5c6-650f-49aa-85b6-9f550593c873	NTN052_Baseline	2c90327f-6ced-46ef-afe7-95f67b7f5b35	NTN052_Baseline	1bc93e93-d026-4010-b808-26c5d6b76ba7	NTN052	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fac9e97e-83e3-45f0-94f7-c1385753572f	NTN083_Baseline	827d94c6-185d-40df-b6dd-a20dabdc8f7d	NTN083_Baseline	8379de05-5310-4592-8ef4-38374ac89b8e	NTN083	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56441c85-320b-4b45-8d34-bb006f59b26a	NTN076_Baseline	168da2ff-6bdd-411c-b1e2-7e9c1d6dffd7	NTN076_Baseline	4c112051-2b65-43e4-a972-fe4aa5de7044	NTN076	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
081d0ba8-4971-43b1-b8b7-8f87bb867bbe	NTN022_Baseline	9f032a30-315f-4f46-94a3-0ed7400f4771	NTN022_Baseline	015815e9-3bfe-4a73-a9a5-6f804dd8ed89	NTN022	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3d9f0db9-5434-4296-abe6-9743dc00294a	H36960.01_Baseline	5439b608-0d06-4de3-9fa7-072d1b5d4344	H36960-01_Baseline	b5a7edc1-93ae-4f26-b129-cf897c58179f	H36960-01	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
b664fd75-e4ba-4fc2-8768-138602caeb6b	NTN063_Baseline	3b9a7138-b45a-4529-81e1-23d5fe803a24	NTN063_Baseline	2fc6f553-0f59-443f-a937-e5086611e9a9	NTN063	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dae9cf9a-976e-4b3c-b98a-45a282611c12	NTN046_Baseline	b1ab19d0-8de3-42e5-9578-414cdf1baa39	NTN046_Baseline	f77f177d-411b-4038-9a09-2301a4032044	NTN046	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
04f0af6a-1a56-4d0d-a688-123fdcc8e5d7	NTN050_Baseline	8cb64a16-c4c2-4c85-992e-47a84036391a	NTN050_Baseline	7ede448a-2bc6-4685-9db3-b43649777ea7	NTN050	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1b1e854e-308e-41c5-b9ff-133149c4f092	NTN050_Cycle1Day3	4ca1a3fe-d730-46b8-8904-d53e29250c12	NTN050_Cycle1Day3	7ede448a-2bc6-4685-9db3-b43649777ea7	NTN050	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6345781b-d0b0-11e9-9a07-0a80fada099c	CPT0105230003	a679f850-d0a6-11e9-9a07-0a80fada099c	C3N-01024-03	f1ee18d4-cf1e-11e9-9a07-0a80fada099c	C3N-01024	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
544593e4-d0b0-11e9-9a07-0a80fada099c	CPT0023320003	9b8946c4-d0a6-11e9-9a07-0a80fada099c	C3L-00412-06	f1eda701-cf1e-11e9-9a07-0a80fada099c	C3L-00412	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ca524e3-d0b0-11e9-9a07-0a80fada099c	CPT0147600003	ad015b2f-d0a6-11e9-9a07-0a80fada099c	C3N-02572-03	f1ee4315-cf1e-11e9-9a07-0a80fada099c	C3N-02572	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
661a5879-d0b0-11e9-9a07-0a80fada099c	CPT0105740003	a8550d49-d0a6-11e9-9a07-0a80fada099c	C3N-01416-07	f1ee25c3-cf1e-11e9-9a07-0a80fada099c	C3N-01416	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57805fe5-d0b0-11e9-9a07-0a80fada099c	CPT0092250003	9df4e399-d0a6-11e9-9a07-0a80fada099c	C3L-01889-06	f1edb75d-cf1e-11e9-9a07-0a80fada099c	C3L-01889	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d4908d3-d0b0-11e9-9a07-0a80fada099c	CPT0066930003	a212c839-d0a6-11e9-9a07-0a80fada099c	C3N-00545-06	f1edf936-cf1e-11e9-9a07-0a80fada099c	C3N-00545	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
53faa3fe-d0b0-11e9-9a07-0a80fada099c	CPT0063750003	9b5a06e2-d0a6-11e9-9a07-0a80fada099c	C3L-00368-06	f1eda5d6-cf1e-11e9-9a07-0a80fada099c	C3L-00368	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
50649795-d0b0-11e9-9a07-0a80fada099c	CPT0052170004	98f659a6-d0a6-11e9-9a07-0a80fada099c	5a84eae1-197e-4463-ad65-59becc	f1ed961a-cf1e-11e9-9a07-0a80fada099c	11LU022	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
624305ab-d0b0-11e9-9a07-0a80fada099c	CPT0079850003	a5901026-d0a6-11e9-9a07-0a80fada099c	C3N-00959-06	f1ee140a-cf1e-11e9-9a07-0a80fada099c	C3N-00959	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
61b61196-d0b0-11e9-9a07-0a80fada099c	CPT0090200003	a549145b-d0a6-11e9-9a07-0a80fada099c	C3N-00737-06	f1ee11c0-cf1e-11e9-9a07-0a80fada099c	C3N-00737	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56781537-d0b0-11e9-9a07-0a80fada099c	CPT0086770003	9d451f87-d0a6-11e9-9a07-0a80fada099c	C3L-01632-06	f1edb141-cf1e-11e9-9a07-0a80fada099c	C3L-01632	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
60c4180f-d0b0-11e9-9a07-0a80fada099c	CPT0069520003	a4acdfd7-d0a6-11e9-9a07-0a80fada099c	C3N-00579-02	f1ee0cd9-cf1e-11e9-9a07-0a80fada099c	C3N-00579	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
52704335-d0b0-11e9-9a07-0a80fada099c	CPT0001660013	9a72574c-d0a6-11e9-9a07-0a80fada099c	C3L-00095-01	f1ed9fdb-cf1e-11e9-9a07-0a80fada099c	C3L-00095	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6b5ee766-d0b0-11e9-9a07-0a80fada099c	CPT0146980004	ac1aaaa9-d0a6-11e9-9a07-0a80fada099c	"C3N-02423-01, C3N-02423-02"	f1ee3e8b-cf1e-11e9-9a07-0a80fada099c	C3N-02423	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
55f0a971-d0b0-11e9-9a07-0a80fada099c	CPT0102480003	9cc4caff-d0a6-11e9-9a07-0a80fada099c	C3L-00973-07	f1edaee5-cf1e-11e9-9a07-0a80fada099c	C3L-00973	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
50f400c1-d0b0-11e9-9a07-0a80fada099c	CPT0001380003	9976634c-d0a6-11e9-9a07-0a80fada099c	C3L-00009-01	f1ed99fb-cf1e-11e9-9a07-0a80fada099c	C3L-00009	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
573d045f-d0b0-11e9-9a07-0a80fada099c	CPT0092530003	9dc5cac8-d0a6-11e9-9a07-0a80fada099c	C3L-01862-01	f1edb635-cf1e-11e9-9a07-0a80fada099c	C3L-01862	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d8b2b52-d0b0-11e9-9a07-0a80fada099c	CPT0067110003	a22b6eda-d0a6-11e9-9a07-0a80fada099c	C3N-00546-06	f1edfb6c-cf1e-11e9-9a07-0a80fada099c	C3N-00546	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6af67fbe-d0b0-11e9-9a07-0a80fada099c	CPT0146780004	abe93deb-d0a6-11e9-9a07-0a80fada099c	"C3N-02421-01, C3N-02421-02"	f1ee3c31-cf1e-11e9-9a07-0a80fada099c	C3N-02421	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64ceb515-d0b0-11e9-9a07-0a80fada099c	CPT0117970003	a7a68463-d0a6-11e9-9a07-0a80fada099c	C3N-01410-02	f1ee2117-cf1e-11e9-9a07-0a80fada099c	C3N-01410	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
51ba2112-d0b0-11e9-9a07-0a80fada099c	CPT0091870003	99d82fa7-d0a6-11e9-9a07-0a80fada099c	C3L-00083-06	f1ed9c5a-cf1e-11e9-9a07-0a80fada099c	C3L-00083	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
532141b3-d0b0-11e9-9a07-0a80fada099c	CPT0001970003	9ac1706c-d0a6-11e9-9a07-0a80fada099c	C3L-00144-06	f1eda242-cf1e-11e9-9a07-0a80fada099c	C3L-00144	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d69fc75-d0b0-11e9-9a07-0a80fada099c	CPT0067070003	a24a810b-d0a6-11e9-9a07-0a80fada099c	C3N-00546-01	f1edfb6c-cf1e-11e9-9a07-0a80fada099c	C3N-00546	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56153793-d0b0-11e9-9a07-0a80fada099c	CPT0083390004	9d16152e-d0a6-11e9-9a07-0a80fada099c	"C3L-01330-01, C3L-01330-02"	f1edb013-cf1e-11e9-9a07-0a80fada099c	C3L-01330	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6c380901-d0b0-11e9-9a07-0a80fada099c	CPT0147480004	acb298ec-d0a6-11e9-9a07-0a80fada099c	"C3N-02529-01, C3N-02529-02"	f1ee41f0-cf1e-11e9-9a07-0a80fada099c	C3N-02529	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b41d095-d0b0-11e9-9a07-0a80fada099c	CPT0014260003	a0c77d41-d0a6-11e9-9a07-0a80fada099c	C3N-00199-02	f1edd951-cf1e-11e9-9a07-0a80fada099c	C3N-00199	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5fc50701-d0b0-11e9-9a07-0a80fada099c	CPT0068830003	a3c3564a-d0a6-11e9-9a07-0a80fada099c	C3N-00560-06	f1ee0832-cf1e-11e9-9a07-0a80fada099c	C3N-00560	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a700807-d0b0-11e9-9a07-0a80fada099c	CPT0014860003	a02ea9f3-d0a6-11e9-9a07-0a80fada099c	C3N-00169-03	f1edd1df-cf1e-11e9-9a07-0a80fada099c	C3N-00169	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
696dfac2-d0b0-11e9-9a07-0a80fada099c	CPT0118620003	aae9f058-d0a6-11e9-9a07-0a80fada099c	C3N-02149-02	f1ee3682-cf1e-11e9-9a07-0a80fada099c	C3N-02149	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d25f254-d0b0-11e9-9a07-0a80fada099c	CPT0066890003	a1f9d9df-d0a6-11e9-9a07-0a80fada099c	C3N-00545-01	f1edf936-cf1e-11e9-9a07-0a80fada099c	C3N-00545	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
5abb01d1-d0b0-11e9-9a07-0a80fada099c	CPT0013880003	a05de77f-d0a6-11e9-9a07-0a80fada099c	C3N-00175-02	f1edd3ac-cf1e-11e9-9a07-0a80fada099c	C3N-00175	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6321e1f0-d0b0-11e9-9a07-0a80fada099c	CPT0105190003	a627fb25-d0a6-11e9-9a07-0a80fada099c	C3N-01023-06	f1ee179a-cf1e-11e9-9a07-0a80fada099c	C3N-01023	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
60e50d5c-d0b0-11e9-9a07-0a80fada099c	CPT0069550003	a48ae544-d0a6-11e9-9a07-0a80fada099c	C3N-00579-06	f1ee0cd9-cf1e-11e9-9a07-0a80fada099c	C3N-00579	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
612710bf-d0b0-11e9-9a07-0a80fada099c	CPT0069720003	a4c6bcfd-d0a6-11e9-9a07-0a80fada099c	C3N-00580-06	f1ee0f62-cf1e-11e9-9a07-0a80fada099c	C3N-00580	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a4890a4-d0b0-11e9-9a07-0a80fada099c	CPT0146580004	ab81cf12-d0a6-11e9-9a07-0a80fada099c	"C3N-02379-01, C3N-02379-02"	f1ee39ee-cf1e-11e9-9a07-0a80fada099c	C3N-02379	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
516ec018-d0b0-11e9-9a07-0a80fada099c	CPT0001070003	998dfb88-d0a6-11e9-9a07-0a80fada099c	C3L-00080-06	f1ed9b2e-cf1e-11e9-9a07-0a80fada099c	C3L-00080	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5292a209-d0b0-11e9-9a07-0a80fada099c	CPT0001690003	9a56bdc1-d0a6-11e9-9a07-0a80fada099c	C3L-00095-06	f1ed9fdb-cf1e-11e9-9a07-0a80fada099c	C3L-00095	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6876bf54-d0b0-11e9-9a07-0a80fada099c	CPT0109850003	aa05f14c-d0a6-11e9-9a07-0a80fada099c	C3N-02067-03	f1ee31ed-cf1e-11e9-9a07-0a80fada099c	C3N-02067	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
677da403-d0b0-11e9-9a07-0a80fada099c	CPT0109680004	a96cd578-d0a6-11e9-9a07-0a80fada099c	"C3N-02000-01, C3N-02000-02"	f1ee2e74-cf1e-11e9-9a07-0a80fada099c	C3N-02000	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6e6c3624-d0b0-11e9-9a07-0a80fada099c	Tumor Only IR	ae4e2ad5-d0a6-11e9-9a07-0a80fada099c	Tumor Only IR	f1ee4d80-cf1e-11e9-9a07-0a80fada099c	Tumor Only IR	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a8c0cc4-d0b0-11e9-9a07-0a80fada099c	CPT0146600003	ab6a5e48-d0a6-11e9-9a07-0a80fada099c	C3N-02379-03	f1ee39ee-cf1e-11e9-9a07-0a80fada099c	C3N-02379	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
589d87c2-d0b0-11e9-9a07-0a80fada099c	CPT0114010003	9eb5710c-d0a6-11e9-9a07-0a80fada099c	C3L-02345-06	f1edbbf2-cf1e-11e9-9a07-0a80fada099c	C3L-02345	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c1c33f1-d0b0-11e9-9a07-0a80fada099c	CPT0111300003	a14853f8-d0a6-11e9-9a07-0a80fada099c	C3N-00223-01	f1ededdc-cf1e-11e9-9a07-0a80fada099c	C3N-00223	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
50ae4bfb-d0b0-11e9-9a07-0a80fada099c	CPT0001580009	99409636-d0a6-11e9-9a07-0a80fada099c	C3L-00001-02	f1ed989e-cf1e-11e9-9a07-0a80fada099c	C3L-00001	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
682c1e81-d0b0-11e9-9a07-0a80fada099c	CPT0109760003	a9e57c51-d0a6-11e9-9a07-0a80fada099c	C3N-02003-03	f1ee30c8-cf1e-11e9-9a07-0a80fada099c	C3N-02003	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6517afb6-d0b0-11e9-9a07-0a80fada099c	CPT0105510003	a7d6387d-d0a6-11e9-9a07-0a80fada099c	C3N-01413-01	f1ee223b-cf1e-11e9-9a07-0a80fada099c	C3N-01413	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
668274eb-d0b0-11e9-9a07-0a80fada099c	CPT0105940003	a8b5c109-d0a6-11e9-9a07-0a80fada099c	C3N-01489-02	f1ee27ff-cf1e-11e9-9a07-0a80fada099c	C3N-01489	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6076bf54-d0b0-11e9-9a07-0a80fada099c	CPT0069360003	a4732128-d0a6-11e9-9a07-0a80fada099c	C3N-00578-04	f1ee0bb0-cf1e-11e9-9a07-0a80fada099c	C3N-00578	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62641b48-d0b0-11e9-9a07-0a80fada099c	CPT0083780003	a5de8745-d0a6-11e9-9a07-0a80fada099c	C3N-01016-02	f1ee154d-cf1e-11e9-9a07-0a80fada099c	C3N-01016	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ee0c886-d0b0-11e9-9a07-0a80fada099c	Internal Reference - Pooled Sample	ae9680bf-d0a6-11e9-9a07-0a80fada099c	Internal Reference - Pooled Sample	f1ee49ee-cf1e-11e9-9a07-0a80fada099c	Internal Reference - Pooled Sample	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5344d6b5-d0b0-11e9-9a07-0a80fada099c	CPT0011710004	9af0d282-d0a6-11e9-9a07-0a80fada099c	"C3L-00263-04, C3L-00263-05"	f1eda37f-cf1e-11e9-9a07-0a80fada099c	C3L-00263	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57a1c9f8-d0b0-11e9-9a07-0a80fada099c	CPT0092930003	9e2e3c84-d0a6-11e9-9a07-0a80fada099c	C3L-01890-02	f1edb882-cf1e-11e9-9a07-0a80fada099c	C3L-01890	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5114f636-d0b0-11e9-9a07-0a80fada099c	CPT0001390003	995e574b-d0a6-11e9-9a07-0a80fada099c	C3L-00009-06	f1ed99fb-cf1e-11e9-9a07-0a80fada099c	C3L-00009	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
663d0c64-d0b0-11e9-9a07-0a80fada099c	CPT0118160003	a89e3431-d0a6-11e9-9a07-0a80fada099c	C3N-01488-03	f1ee26e0-cf1e-11e9-9a07-0a80fada099c	C3N-01488	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
69da0cd6-d0b0-11e9-9a07-0a80fada099c	CPT0118830003	ab195a64-d0a6-11e9-9a07-0a80fada099c	C3N-02155-06	f1ee37a4-cf1e-11e9-9a07-0a80fada099c	C3N-02155	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
52d4f809-d0b0-11e9-9a07-0a80fada099c	CPT0001810003	9a9053a5-d0a6-11e9-9a07-0a80fada099c	C3L-00140-06	f1eda113-cf1e-11e9-9a07-0a80fada099c	C3L-00140	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59b93822-d0b0-11e9-9a07-0a80fada099c	CPT0125830003	9f967a07-d0a6-11e9-9a07-0a80fada099c	C3L-02508-04	f1edcba2-cf1e-11e9-9a07-0a80fada099c	C3L-02508	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5fa42d74-d0b0-11e9-9a07-0a80fada099c	CPT0068800003	a3db1e4d-d0a6-11e9-9a07-0a80fada099c	C3N-00560-02	f1ee0832-cf1e-11e9-9a07-0a80fada099c	C3N-00560	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
698fa2fe-d0b0-11e9-9a07-0a80fada099c	CPT0118650003	aad16b38-d0a6-11e9-9a07-0a80fada099c	C3N-02149-06	f1ee3682-cf1e-11e9-9a07-0a80fada099c	C3N-02149	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
679e6aeb-d0b0-11e9-9a07-0a80fada099c	CPT0109700003	a984bd84-d0a6-11e9-9a07-0a80fada099c	C3N-02000-03	f1ee2e74-cf1e-11e9-9a07-0a80fada099c	C3N-02000	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
51979375-d0b0-11e9-9a07-0a80fada099c	CPT0091860003	99bd4e0d-d0a6-11e9-9a07-0a80fada099c	C3L-00083-01	f1ed9c5a-cf1e-11e9-9a07-0a80fada099c	C3L-00083	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6e4420d7-d0b0-11e9-9a07-0a80fada099c	Taiwanese IR	ae36b94a-d0a6-11e9-9a07-0a80fada099c	Taiwanese IR	f1ee4c54-cf1e-11e9-9a07-0a80fada099c	Taiwanese IR	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6cc7ec36-d0b0-11e9-9a07-0a80fada099c	CPT0147880004	ad32711e-d0a6-11e9-9a07-0a80fada099c	"C3N-02582-01, C3N-02582-02"	f1ee4435-cf1e-11e9-9a07-0a80fada099c	C3N-02582	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5f13d8c7-d0b0-11e9-9a07-0a80fada099c	CPT0090700003	a35afd6c-d0a6-11e9-9a07-0a80fada099c	C3N-00556-03	f1ee05e4-cf1e-11e9-9a07-0a80fada099c	C3N-00556	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
548b3ed4-d0b0-11e9-9a07-0a80fada099c	CPT0082890003	9bc6f67e-d0a6-11e9-9a07-0a80fada099c	C3L-00422-05	f1eda832-cf1e-11e9-9a07-0a80fada099c	C3L-00422	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5365e0c3-d0b0-11e9-9a07-0a80fada099c	CPT0011750003	9b0d9ed0-d0a6-11e9-9a07-0a80fada099c	C3L-00263-08	f1eda37f-cf1e-11e9-9a07-0a80fada099c	C3L-00263	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
541db751-d0b0-11e9-9a07-0a80fada099c	CPT0023310003	9ba63d11-d0a6-11e9-9a07-0a80fada099c	C3L-00412-01	f1eda701-cf1e-11e9-9a07-0a80fada099c	C3L-00412	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5830b891-d0b0-11e9-9a07-0a80fada099c	CPT0104630003	9e93cb46-d0a6-11e9-9a07-0a80fada099c	C3L-02219-01	f1edbacb-cf1e-11e9-9a07-0a80fada099c	C3L-02219	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
53001fbb-d0b0-11e9-9a07-0a80fada099c	CPT0001960003	9ad90ee0-d0a6-11e9-9a07-0a80fada099c	C3L-00144-01	f1eda242-cf1e-11e9-9a07-0a80fada099c	C3L-00144	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5cfab25d-d0b0-11e9-9a07-0a80fada099c	CPT0021490003	a1ca923f-d0a6-11e9-9a07-0a80fada099c	C3N-00433-07	f1edf6fb-cf1e-11e9-9a07-0a80fada099c	C3N-00433	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
68dc58bd-d0b0-11e9-9a07-0a80fada099c	CPT0118340003	aa667894-d0a6-11e9-9a07-0a80fada099c	C3N-02089-03	f1ee343a-cf1e-11e9-9a07-0a80fada099c	C3N-02089	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a910ac5-d0b0-11e9-9a07-0a80fada099c	CPT0014930003	a01705f8-d0a6-11e9-9a07-0a80fada099c	C3N-00169-06	f1edd1df-cf1e-11e9-9a07-0a80fada099c	C3N-00169	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
61719dfe-d0b0-11e9-9a07-0a80fada099c	CPT0062810003	a4f82966-d0a6-11e9-9a07-0a80fada099c	C3N-00704-03	f1ee1093-cf1e-11e9-9a07-0a80fada099c	C3N-00704	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
675a3328-d0b0-11e9-9a07-0a80fada099c	CPT0098130003	a94d9b22-d0a6-11e9-9a07-0a80fada099c	C3N-01842-01	f1ee2d3e-cf1e-11e9-9a07-0a80fada099c	C3N-01842	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6e041a4b-d0b0-11e9-9a07-0a80fada099c	CPT0148300003	ae009757-d0a6-11e9-9a07-0a80fada099c	C3N-02729-03	f1ee48c6-cf1e-11e9-9a07-0a80fada099c	C3N-02729	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
54d8093d-d0b0-11e9-9a07-0a80fada099c	CPT0011930003	9bf63c1d-d0a6-11e9-9a07-0a80fada099c	C3L-00510-04	f1eda95d-cf1e-11e9-9a07-0a80fada099c	C3L-00510	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e87169f-d0b0-11e9-9a07-0a80fada099c	CPT0067940003	a313ba9e-d0a6-11e9-9a07-0a80fada099c	C3N-00551-04	f1ee0373-cf1e-11e9-9a07-0a80fada099c	C3N-00551	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e65f5e8-d0b0-11e9-9a07-0a80fada099c	CPT0067770003	a2c41757-d0a6-11e9-9a07-0a80fada099c	C3N-00550-06	f1ee01d7-cf1e-11e9-9a07-0a80fada099c	C3N-00550	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
553b3375-d0b0-11e9-9a07-0a80fada099c	CPT0083100003	9c796277-d0a6-11e9-9a07-0a80fada099c	C3L-00893-02	f1edac24-cf1e-11e9-9a07-0a80fada099c	C3L-00893	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
538c163c-d0b0-11e9-9a07-0a80fada099c	CPT0082740004	9b3fb6e1-d0a6-11e9-9a07-0a80fada099c	"C3L-00279-02, C3L-00279-03"	f1eda4a7-cf1e-11e9-9a07-0a80fada099c	C3L-00279	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6de33aab-d0b0-11e9-9a07-0a80fada099c	CPT0148280004	ade87ebd-d0a6-11e9-9a07-0a80fada099c	"C3N-02729-01, C3N-02729-02"	f1ee48c6-cf1e-11e9-9a07-0a80fada099c	C3N-02729	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5bae5c11-d0b0-11e9-9a07-0a80fada099c	CPT0090370003	a0df847c-d0a6-11e9-9a07-0a80fada099c	C3N-00203-07	f1eddb3c-cf1e-11e9-9a07-0a80fada099c	C3N-00203	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e3b13bd-d0b0-11e9-9a07-0a80fada099c	CPT0067620003	a2e2fe89-d0a6-11e9-9a07-0a80fada099c	C3N-00550-02	f1ee01d7-cf1e-11e9-9a07-0a80fada099c	C3N-00550	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
58e0fedc-d0b0-11e9-9a07-0a80fada099c	CPT0115090003	9ee770b1-d0a6-11e9-9a07-0a80fada099c	C3L-02348-06	f1edbde6-cf1e-11e9-9a07-0a80fada099c	C3L-02348	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59da3b25-d0b0-11e9-9a07-0a80fada099c	CPT0113210003	9fc5b681-d0a6-11e9-9a07-0a80fada099c	C3L-02549-02	f1edcd99-cf1e-11e9-9a07-0a80fada099c	C3L-02549	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
65a6ba9a-d0b0-11e9-9a07-0a80fada099c	CPT0105630003	a81d1363-d0a6-11e9-9a07-0a80fada099c	C3N-01415-01	f1ee249b-cf1e-11e9-9a07-0a80fada099c	C3N-01415	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6201ba50-d0b0-11e9-9a07-0a80fada099c	CPT0112080003	a560cfca-d0a6-11e9-9a07-0a80fada099c	C3N-00738-03	f1ee12e4-cf1e-11e9-9a07-0a80fada099c	C3N-00738	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6c14c8a9-d0b0-11e9-9a07-0a80fada099c	CPT0147400003	ac9b1a82-d0a6-11e9-9a07-0a80fada099c	C3N-02433-03	f1ee40d4-cf1e-11e9-9a07-0a80fada099c	C3N-02433	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5df8e2da-d0b0-11e9-9a07-0a80fada099c	CPT0067450003	a2ab7843-d0a6-11e9-9a07-0a80fada099c	C3N-00549-03	f1edffb2-cf1e-11e9-9a07-0a80fada099c	C3N-00549	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
55c9746a-d0b0-11e9-9a07-0a80fada099c	CPT0102450003	9ce4682c-d0a6-11e9-9a07-0a80fada099c	C3L-00973-03	f1edaee5-cf1e-11e9-9a07-0a80fada099c	C3L-00973	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6be914fa-d0b0-11e9-9a07-0a80fada099c	CPT0147380004	ac8385f2-d0a6-11e9-9a07-0a80fada099c	"C3N-02433-01, C3N-02433-02"	f1ee40d4-cf1e-11e9-9a07-0a80fada099c	C3N-02433	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64f50ebb-d0b0-11e9-9a07-0a80fada099c	CPT0118010003	a783e1b3-d0a6-11e9-9a07-0a80fada099c	C3N-01410-07	f1ee2117-cf1e-11e9-9a07-0a80fada099c	C3N-01410	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56cee556-d0b0-11e9-9a07-0a80fada099c	CPT0110890003	9d5cc5d8-d0a6-11e9-9a07-0a80fada099c	C3L-01682-07	f1edb38f-cf1e-11e9-9a07-0a80fada099c	C3L-01682	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d098af0-d0b0-11e9-9a07-0a80fada099c	CPT0147980004	ad4ae9a4-d0a6-11e9-9a07-0a80fada099c	"C3N-02586-01, C3N-02586-02"	f1ee455a-cf1e-11e9-9a07-0a80fada099c	C3N-02586	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5cd8376d-d0b0-11e9-9a07-0a80fada099c	CPT0021450003	a1e245a6-d0a6-11e9-9a07-0a80fada099c	C3N-00433-03	f1edf6fb-cf1e-11e9-9a07-0a80fada099c	C3N-00433	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5bfb4e1b-d0b0-11e9-9a07-0a80fada099c	CPT0090600003	a11658cc-d0a6-11e9-9a07-0a80fada099c	C3N-00217-06	f1eddd2a-cf1e-11e9-9a07-0a80fada099c	C3N-00217	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ef2cf98-d0b0-11e9-9a07-0a80fada099c	CPT0068130003	a32b522f-d0a6-11e9-9a07-0a80fada099c	C3N-00552-06	f1ee049b-cf1e-11e9-9a07-0a80fada099c	C3N-00552	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
546920e7-d0b0-11e9-9a07-0a80fada099c	CPT0082850004	9bdece48-d0a6-11e9-9a07-0a80fada099c	"C3L-00422-01, C3L-00422-02"	f1eda832-cf1e-11e9-9a07-0a80fada099c	C3L-00422	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6030b0f3-d0b0-11e9-9a07-0a80fada099c	CPT0090860003	a42c1209-d0a6-11e9-9a07-0a80fada099c	C3N-00574-01	f1ee0a7e-cf1e-11e9-9a07-0a80fada099c	C3N-00574	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5710a593-d0b0-11e9-9a07-0a80fada099c	CPT0111590003	9d93aa93-d0a6-11e9-9a07-0a80fada099c	C3L-01683-04	f1edb50d-cf1e-11e9-9a07-0a80fada099c	C3L-01683	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5043e176-d0b0-11e9-9a07-0a80fada099c	CPT0052940004	98dcaa16-d0a6-11e9-9a07-0a80fada099c	93e30fd5-e57e-4503-a175-863c7d	f1ed9457-cf1e-11e9-9a07-0a80fada099c	11LU016	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
520410e3-d0b0-11e9-9a07-0a80fada099c	CPT0086320003	99f4b2c9-d0a6-11e9-9a07-0a80fada099c	C3L-00093-06	f1ed9d81-cf1e-11e9-9a07-0a80fada099c	C3L-00093	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
580fb469-d0b0-11e9-9a07-0a80fada099c	CPT0114690003	9e46f98e-d0a6-11e9-9a07-0a80fada099c	C3L-01924-07	f1edb9a5-cf1e-11e9-9a07-0a80fada099c	C3L-01924	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56570404-d0b0-11e9-9a07-0a80fada099c	CPT0086750003	9d2d8fd1-d0a6-11e9-9a07-0a80fada099c	C3L-01632-02	f1edb141-cf1e-11e9-9a07-0a80fada099c	C3L-01632	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5563dc34-d0b0-11e9-9a07-0a80fada099c	CPT0083140003	9c618022-d0a6-11e9-9a07-0a80fada099c	C3L-00893-06	f1edac24-cf1e-11e9-9a07-0a80fada099c	C3L-00893	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5bcf412f-d0b0-11e9-9a07-0a80fada099c	CPT0090570004	a12e54b7-d0a6-11e9-9a07-0a80fada099c	"C3N-00217-02, C3N-00217-04"	f1eddd2a-cf1e-11e9-9a07-0a80fada099c	C3N-00217	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ec8fbf8-d0b0-11e9-9a07-0a80fada099c	CPT0068100003	a3430b1e-d0a6-11e9-9a07-0a80fada099c	C3N-00552-02	f1ee049b-cf1e-11e9-9a07-0a80fada099c	C3N-00552	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6b3acf6f-d0b0-11e9-9a07-0a80fada099c	CPT0146880004	ac031c8c-d0a6-11e9-9a07-0a80fada099c	"C3N-02422-01, C3N-02422-02"	f1ee3d65-cf1e-11e9-9a07-0a80fada099c	C3N-02422	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
628eaef8-d0b0-11e9-9a07-0a80fada099c	CPT0083810003	a5c18d0c-d0a6-11e9-9a07-0a80fada099c	C3N-01016-06	f1ee154d-cf1e-11e9-9a07-0a80fada099c	C3N-01016	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ca8acd8-d0b0-11e9-9a07-0a80fada099c	CPT0008450003	a1b12cbe-d0a6-11e9-9a07-0a80fada099c	C3N-00294-02	f1edf49c-cf1e-11e9-9a07-0a80fada099c	C3N-00294	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
61502ba0-d0b0-11e9-9a07-0a80fada099c	CPT0055100004	a50fe6cc-d0a6-11e9-9a07-0a80fada099c	"C3N-00704-01, C3N-00704-02"	f1ee1093-cf1e-11e9-9a07-0a80fada099c	C3N-00704	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
66cebe57-d0b0-11e9-9a07-0a80fada099c	CPT0089340003	a906bebc-d0a6-11e9-9a07-0a80fada099c	C3N-01799-02	f1ee2921-cf1e-11e9-9a07-0a80fada099c	C3N-01799	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63d6f897-d0b0-11e9-9a07-0a80fada099c	CPT0070060003	a6d9c083-d0a6-11e9-9a07-0a80fada099c	C3N-01071-03	f1ee1bf7-cf1e-11e9-9a07-0a80fada099c	C3N-01071	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
67105d4c-d0b0-11e9-9a07-0a80fada099c	CPT0097580003	a91e4c49-d0a6-11e9-9a07-0a80fada099c	C3N-01823-02	f1ee2bd6-cf1e-11e9-9a07-0a80fada099c	C3N-01823	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59083b34-d0b0-11e9-9a07-0a80fada099c	CPT0104750003	9f168787-d0a6-11e9-9a07-0a80fada099c	C3L-02350-02	f1edbfe5-cf1e-11e9-9a07-0a80fada099c	C3L-02350	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
52b3d1f5-d0b0-11e9-9a07-0a80fada099c	CPT0001800013	9aa8f669-d0a6-11e9-9a07-0a80fada099c	C3L-00140-02	f1eda113-cf1e-11e9-9a07-0a80fada099c	C3L-00140	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5022ebd4-d0b0-11e9-9a07-0a80fada099c	CPT0053040004	98c196c9-d0a6-11e9-9a07-0a80fada099c	9f905736-f662-41d6-b3ac-16758d	f1ed884e-cf1e-11e9-9a07-0a80fada099c	11LU013	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5636260c-d0b0-11e9-9a07-0a80fada099c	CPT0083420003	9cfde8f3-d0a6-11e9-9a07-0a80fada099c	C3L-01330-04	f1edb013-cf1e-11e9-9a07-0a80fada099c	C3L-01330	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56efbc04-d0b0-11e9-9a07-0a80fada099c	CPT0110980004	9dabc65d-d0a6-11e9-9a07-0a80fada099c	"C3L-01683-01, C3L-01683-02"	f1edb50d-cf1e-11e9-9a07-0a80fada099c	C3L-01683	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
50858853-d0b0-11e9-9a07-0a80fada099c	CPT0051690004	990d9220-d0a6-11e9-9a07-0a80fada099c	2f2e5477-42a4-4906-a943-bf7f80	f1ed9765-cf1e-11e9-9a07-0a80fada099c	11LU035	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
55a88ec6-d0b0-11e9-9a07-0a80fada099c	CPT0106100003	9cad317c-d0a6-11e9-9a07-0a80fada099c	C3L-00913-06	f1edadb4-cf1e-11e9-9a07-0a80fada099c	C3L-00913	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
622262aa-d0b0-11e9-9a07-0a80fada099c	CPT0079830003	a5a7c996-d0a6-11e9-9a07-0a80fada099c	C3N-00959-02	f1ee140a-cf1e-11e9-9a07-0a80fada099c	C3N-00959	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63b60dbe-d0b0-11e9-9a07-0a80fada099c	CPT0091260003	a691a499-d0a6-11e9-9a07-0a80fada099c	C3N-01030-06	f1ee1a01-cf1e-11e9-9a07-0a80fada099c	C3N-01030	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5db41dd2-d0b0-11e9-9a07-0a80fada099c	CPT0067250003	a27c1ef6-d0a6-11e9-9a07-0a80fada099c	C3N-00547-01	f1edfd98-cf1e-11e9-9a07-0a80fada099c	C3N-00547	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56aa9b38-d0b0-11e9-9a07-0a80fada099c	CPT0110860004	9d7c3106-d0a6-11e9-9a07-0a80fada099c	"C3L-01682-01, C3L-01682-02"	f1edb38f-cf1e-11e9-9a07-0a80fada099c	C3L-01682	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
53d9d805-d0b0-11e9-9a07-0a80fada099c	CPT0063730003	9b719f00-d0a6-11e9-9a07-0a80fada099c	C3L-00368-01	f1eda5d6-cf1e-11e9-9a07-0a80fada099c	C3L-00368	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
684d1ef8-d0b0-11e9-9a07-0a80fada099c	CPT0109830004	aa1f8b24-d0a6-11e9-9a07-0a80fada099c	"C3N-02067-01, C3N-02067-02"	f1ee31ed-cf1e-11e9-9a07-0a80fada099c	C3N-02067	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
67ea5efa-d0b0-11e9-9a07-0a80fada099c	CPT0109710003	a9b6136a-d0a6-11e9-9a07-0a80fada099c	C3N-02002-01	f1ee2f9f-cf1e-11e9-9a07-0a80fada099c	C3N-02002	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b8c644b-d0b0-11e9-9a07-0a80fada099c	CPT0090340003	a0f739b8-d0a6-11e9-9a07-0a80fada099c	C3N-00203-03	f1eddb3c-cf1e-11e9-9a07-0a80fada099c	C3N-00203	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
65cf51e3-d0b0-11e9-9a07-0a80fada099c	CPT0105680003	a83d3cd5-d0a6-11e9-9a07-0a80fada099c	C3N-01415-07	f1ee249b-cf1e-11e9-9a07-0a80fada099c	C3N-01415	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d315ad0-d0b0-11e9-9a07-0a80fada099c	CPT0148000003	ad62ca30-d0a6-11e9-9a07-0a80fada099c	C3N-02586-03	f1ee455a-cf1e-11e9-9a07-0a80fada099c	C3N-02586	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5f8142c7-d0b0-11e9-9a07-0a80fada099c	CPT0068650003	a391af1d-d0a6-11e9-9a07-0a80fada099c	C3N-00559-06	f1ee070d-cf1e-11e9-9a07-0a80fada099c	C3N-00559	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63664a5a-d0b0-11e9-9a07-0a80fada099c	CPT0105250003	a659a6f1-d0a6-11e9-9a07-0a80fada099c	C3N-01024-06	f1ee18d4-cf1e-11e9-9a07-0a80fada099c	C3N-01024	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6c5b253e-d0b0-11e9-9a07-0a80fada099c	CPT0147500003	accaa16c-d0a6-11e9-9a07-0a80fada099c	C3N-02529-03	f1ee41f0-cf1e-11e9-9a07-0a80fada099c	C3N-02529	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c5f2973-d0b0-11e9-9a07-0a80fada099c	CPT0008410003	a18f6ec9-d0a6-11e9-9a07-0a80fada099c	C3N-00293-04	f1edf269-cf1e-11e9-9a07-0a80fada099c	C3N-00293	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6e2404f3-d0b0-11e9-9a07-0a80fada099c	Normal Only IR	ae1a211c-d0a6-11e9-9a07-0a80fada099c	Normal Only IR	f1ee4b27-cf1e-11e9-9a07-0a80fada099c	Normal Only IR	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ea7e771-d0b0-11e9-9a07-0a80fada099c	CPT0067950003	a2fc18c4-d0a6-11e9-9a07-0a80fada099c	C3N-00551-06	f1ee0373-cf1e-11e9-9a07-0a80fada099c	C3N-00551	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ce8b547-d0b0-11e9-9a07-0a80fada099c	CPT0147900003	ad195f55-d0a6-11e9-9a07-0a80fada099c	C3N-02582-03	f1ee4435-cf1e-11e9-9a07-0a80fada099c	C3N-02582	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5fe5f9dc-d0b0-11e9-9a07-0a80fada099c	CPT0015410003	a412721e-d0a6-11e9-9a07-0a80fada099c	C3N-00572-04	f1ee0957-cf1e-11e9-9a07-0a80fada099c	C3N-00572	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6db79362-d0b0-11e9-9a07-0a80fada099c	CPT0148200003	add0f179-d0a6-11e9-9a07-0a80fada099c	C3N-02588-03	f1ee47a8-cf1e-11e9-9a07-0a80fada099c	C3N-02588	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
69fbbd9f-d0b0-11e9-9a07-0a80fada099c	CPT0118880003	ab52c951-d0a6-11e9-9a07-0a80fada099c	C3N-02158-04	f1ee38cb-cf1e-11e9-9a07-0a80fada099c	C3N-02158	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
641b2bcb-d0b0-11e9-9a07-0a80fada099c	CPT0084140003	a7108efd-d0a6-11e9-9a07-0a80fada099c	C3N-01072-02	f1ee1da6-cf1e-11e9-9a07-0a80fada099c	C3N-01072	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5afedf9e-d0b0-11e9-9a07-0a80fada099c	CPT0066780003	a098554b-d0a6-11e9-9a07-0a80fada099c	C3N-00180-02	f1edd776-cf1e-11e9-9a07-0a80fada099c	C3N-00180	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
694c7e7c-d0b0-11e9-9a07-0a80fada099c	CPT0118600003	aa9f2b2c-d0a6-11e9-9a07-0a80fada099c	C3N-02145-07	f1ee355d-cf1e-11e9-9a07-0a80fada099c	C3N-02145	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5dd4f951-d0b0-11e9-9a07-0a80fada099c	CPT0067290003	a2624220-d0a6-11e9-9a07-0a80fada099c	C3N-00547-06	f1edfd98-cf1e-11e9-9a07-0a80fada099c	C3N-00547	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
54f94712-d0b0-11e9-9a07-0a80fada099c	CPT0063810003	9c4a1eb0-d0a6-11e9-9a07-0a80fada099c	C3L-00604-01	f1edaa88-cf1e-11e9-9a07-0a80fada099c	C3L-00604	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a27e600-d0b0-11e9-9a07-0a80fada099c	CPT0013600003	9ffd0965-d0a6-11e9-9a07-0a80fada099c	C3N-00167-02	f1edcf73-cf1e-11e9-9a07-0a80fada099c	C3N-00167	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6105e469-d0b0-11e9-9a07-0a80fada099c	CPT0069700003	a4e09163-d0a6-11e9-9a07-0a80fada099c	C3N-00580-03	f1ee0f62-cf1e-11e9-9a07-0a80fada099c	C3N-00580	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d96bbaa-d0b0-11e9-9a07-0a80fada099c	CPT0148180004	adb95469-d0a6-11e9-9a07-0a80fada099c	"C3N-02588-01, C3N-02588-02"	f1ee47a8-cf1e-11e9-9a07-0a80fada099c	C3N-02588	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
680b4fa5-d0b0-11e9-9a07-0a80fada099c	CPT0109740004	a9cdc77e-d0a6-11e9-9a07-0a80fada099c	"C3N-02003-01, C3N-02003-02"	f1ee30c8-cf1e-11e9-9a07-0a80fada099c	C3N-02003	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59fb2b82-d0b0-11e9-9a07-0a80fada099c	CPT0113220003	9fae40cb-d0a6-11e9-9a07-0a80fada099c	C3L-02549-06	f1edcd99-cf1e-11e9-9a07-0a80fada099c	C3L-02549	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5225d754-d0b0-11e9-9a07-0a80fada099c	CPT0000920017	9a3ef50b-d0a6-11e9-9a07-0a80fada099c	C3L-00094-03	f1ed9eb2-cf1e-11e9-9a07-0a80fada099c	C3L-00094	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5f58553a-d0b0-11e9-9a07-0a80fada099c	CPT0068610003	a3aaae31-d0a6-11e9-9a07-0a80fada099c	C3N-00559-01	f1ee070d-cf1e-11e9-9a07-0a80fada099c	C3N-00559	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57ca50d1-d0b0-11e9-9a07-0a80fada099c	CPT0092940003	9e14cdb5-d0a6-11e9-9a07-0a80fada099c	C3L-01890-06	f1edb882-cf1e-11e9-9a07-0a80fada099c	C3L-01890	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
53b1b181-d0b0-11e9-9a07-0a80fada099c	CPT0082770003	9b27ce6e-d0a6-11e9-9a07-0a80fada099c	C3L-00279-05	f1eda4a7-cf1e-11e9-9a07-0a80fada099c	C3L-00279	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6b869538-d0b0-11e9-9a07-0a80fada099c	CPT0147000003	ac3290c7-d0a6-11e9-9a07-0a80fada099c	C3N-02423-03	f1ee3e8b-cf1e-11e9-9a07-0a80fada099c	C3N-02423	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62f48bef-d0b0-11e9-9a07-0a80fada099c	CPT0105060003	a63fde14-d0a6-11e9-9a07-0a80fada099c	C3N-01023-04	f1ee179a-cf1e-11e9-9a07-0a80fada099c	C3N-01023	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
68bb5d9d-d0b0-11e9-9a07-0a80fada099c	CPT0118240003	aa371c94-d0a6-11e9-9a07-0a80fada099c	C3N-02087-06	f1ee331b-cf1e-11e9-9a07-0a80fada099c	C3N-02087	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6b19c1b7-d0b0-11e9-9a07-0a80fada099c	CPT0146800003	abd1811d-d0a6-11e9-9a07-0a80fada099c	C3N-02421-03	f1ee3c31-cf1e-11e9-9a07-0a80fada099c	C3N-02421	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e19ef2e-d0b0-11e9-9a07-0a80fada099c	CPT0067470004	a293c474-d0a6-11e9-9a07-0a80fada099c	"C3N-00549-06, C3N-00549-07"	f1edffb2-cf1e-11e9-9a07-0a80fada099c	C3N-00549	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5f37199f-d0b0-11e9-9a07-0a80fada099c	CPT0090720003	a379c3b7-d0a6-11e9-9a07-0a80fada099c	C3N-00556-06	f1ee05e4-cf1e-11e9-9a07-0a80fada099c	C3N-00556	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
551a3dca-d0b0-11e9-9a07-0a80fada099c	CPT0063840003	9c2ab08f-d0a6-11e9-9a07-0a80fada099c	C3L-00604-06	f1edaa88-cf1e-11e9-9a07-0a80fada099c	C3L-00604	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
67bf6bf5-d0b0-11e9-9a07-0a80fada099c	CPT0109720004	a99e0f4d-d0a6-11e9-9a07-0a80fada099c	"C3N-02002-02, C3N-02002-03"	f1ee2f9f-cf1e-11e9-9a07-0a80fada099c	C3N-02002	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5584ec02-d0b0-11e9-9a07-0a80fada099c	CPT0106110003	9c945b6c-d0a6-11e9-9a07-0a80fada099c	C3L-00913-03	f1edadb4-cf1e-11e9-9a07-0a80fada099c	C3L-00913	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
51423fa3-d0b0-11e9-9a07-0a80fada099c	CPT0001060010	99a5884e-d0a6-11e9-9a07-0a80fada099c	C3L-00080-01	f1ed9b2e-cf1e-11e9-9a07-0a80fada099c	C3L-00080	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
587c982a-d0b0-11e9-9a07-0a80fada099c	CPT0113990003	9ecd5135-d0a6-11e9-9a07-0a80fada099c	C3L-02345-02	f1edbbf2-cf1e-11e9-9a07-0a80fada099c	C3L-02345	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
66abe1e7-d0b0-11e9-9a07-0a80fada099c	CPT0105980003	a8d5ea27-d0a6-11e9-9a07-0a80fada099c	C3N-01489-07	f1ee27ff-cf1e-11e9-9a07-0a80fada099c	C3N-01489	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c3cf6d6-d0b0-11e9-9a07-0a80fada099c	CPT0111480003	a16022df-d0a6-11e9-9a07-0a80fada099c	C3N-00223-07	f1ededdc-cf1e-11e9-9a07-0a80fada099c	C3N-00223	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57eb65d0-d0b0-11e9-9a07-0a80fada099c	CPT0114660004	9e64abad-d0a6-11e9-9a07-0a80fada099c	"C3L-01924-03, C3L-01924-05"	f1edb9a5-cf1e-11e9-9a07-0a80fada099c	C3L-01924	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6008a16d-d0b0-11e9-9a07-0a80fada099c	CPT0015420003	a3f2a3d2-d0a6-11e9-9a07-0a80fada099c	C3N-00572-06	f1ee0957-cf1e-11e9-9a07-0a80fada099c	C3N-00572	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
54ac41f1-d0b0-11e9-9a07-0a80fada099c	CPT0011910004	9c0dbed0-d0a6-11e9-9a07-0a80fada099c	"C3L-00510-02, C3L-00510-03"	f1eda95d-cf1e-11e9-9a07-0a80fada099c	C3L-00510	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b69bdbb-d0b0-11e9-9a07-0a80fada099c	CPT0014290003	a0aff722-d0a6-11e9-9a07-0a80fada099c	C3N-00199-07	f1edd951-cf1e-11e9-9a07-0a80fada099c	C3N-00199	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
69b7883d-d0b0-11e9-9a07-0a80fada099c	CPT0118810003	ab01cb56-d0a6-11e9-9a07-0a80fada099c	C3N-02155-03	f1ee37a4-cf1e-11e9-9a07-0a80fada099c	C3N-02155	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
666185dd-d0b0-11e9-9a07-0a80fada099c	CPT0118180003	a886b4ca-d0a6-11e9-9a07-0a80fada099c	C3N-01488-06	f1ee26e0-cf1e-11e9-9a07-0a80fada099c	C3N-01488	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
655ab860-d0b0-11e9-9a07-0a80fada099c	CPT0105600003	a8057f9d-d0a6-11e9-9a07-0a80fada099c	C3N-01414-04	f1ee2374-cf1e-11e9-9a07-0a80fada099c	C3N-01414	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
51e12d1c-d0b0-11e9-9a07-0a80fada099c	CPT0086310003	9a0d2e2d-d0a6-11e9-9a07-0a80fada099c	C3L-00093-01	f1ed9d81-cf1e-11e9-9a07-0a80fada099c	C3L-00093	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
592af3cd-d0b0-11e9-9a07-0a80fada099c	CPT0104760003	9f2e2433-d0a6-11e9-9a07-0a80fada099c	C3L-02350-06	f1edbfe5-cf1e-11e9-9a07-0a80fada099c	C3L-02350	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6194f426-d0b0-11e9-9a07-0a80fada099c	CPT0090170004	a52a503f-d0a6-11e9-9a07-0a80fada099c	"C3N-00737-01, C3N-00737-03"	f1ee11c0-cf1e-11e9-9a07-0a80fada099c	C3N-00737	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6c7c281f-d0b0-11e9-9a07-0a80fada099c	CPT0147580004	ace221ef-d0a6-11e9-9a07-0a80fada099c	"C3N-02572-01, C3N-02572-02"	f1ee4315-cf1e-11e9-9a07-0a80fada099c	C3N-02572	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
575f5dbe-d0b0-11e9-9a07-0a80fada099c	CPT0092240003	9ddd4f18-d0a6-11e9-9a07-0a80fada099c	C3L-01889-01	f1edb75d-cf1e-11e9-9a07-0a80fada099c	C3L-01889	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6539929d-d0b0-11e9-9a07-0a80fada099c	CPT0105550003	a7beab01-d0a6-11e9-9a07-0a80fada099c	C3N-01413-06	f1ee223b-cf1e-11e9-9a07-0a80fada099c	C3N-01413	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ad583f1-d0b0-11e9-9a07-0a80fada099c	CPT0146700003	abb14fb1-d0a6-11e9-9a07-0a80fada099c	C3N-02380-03	f1ee3b12-cf1e-11e9-9a07-0a80fada099c	C3N-02380	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
594cb141-d0b0-11e9-9a07-0a80fada099c	CPT0114840003	9f4df913-d0a6-11e9-9a07-0a80fada099c	C3L-02365-01	f1edc1bc-cf1e-11e9-9a07-0a80fada099c	C3L-02365	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d52a7f6-d0b0-11e9-9a07-0a80fada099c	CPT0148080004	ad7a73de-d0a6-11e9-9a07-0a80fada099c	"C3N-02587-01, C3N-02587-02"	f1ee4684-cf1e-11e9-9a07-0a80fada099c	C3N-02587	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
65850a6f-d0b0-11e9-9a07-0a80fada099c	CPT0105610003	a7edf839-d0a6-11e9-9a07-0a80fada099c	C3N-01414-06	f1ee2374-cf1e-11e9-9a07-0a80fada099c	C3N-01414	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a1cb12d-d0b0-11e9-9a07-0a80fada099c	CPT0118890003	ab3956d4-d0a6-11e9-9a07-0a80fada099c	C3N-02158-06	f1ee38cb-cf1e-11e9-9a07-0a80fada099c	C3N-02158	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6aace7f0-d0b0-11e9-9a07-0a80fada099c	CPT0146680004	ab99a4e8-d0a6-11e9-9a07-0a80fada099c	"C3N-02380-01, C3N-02380-02"	f1ee3b12-cf1e-11e9-9a07-0a80fada099c	C3N-02380	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d760135-d0b0-11e9-9a07-0a80fada099c	CPT0148100003	ad9d7b92-d0a6-11e9-9a07-0a80fada099c	C3N-02587-03	f1ee4684-cf1e-11e9-9a07-0a80fada099c	C3N-02587	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
50d10aca-d0b0-11e9-9a07-0a80fada099c	CPT0001590003	99253541-d0a6-11e9-9a07-0a80fada099c	C3L-00001-06	f1ed989e-cf1e-11e9-9a07-0a80fada099c	C3L-00001	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
638933f0-d0b0-11e9-9a07-0a80fada099c	CPT0091240003	a6a92cc3-d0a6-11e9-9a07-0a80fada099c	C3N-01030-03	f1ee1a01-cf1e-11e9-9a07-0a80fada099c	C3N-01030	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c87b314-d0b0-11e9-9a07-0a80fada099c	CPT0008420003	a177e0f2-d0a6-11e9-9a07-0a80fada099c	C3N-00293-05	f1edf269-cf1e-11e9-9a07-0a80fada099c	C3N-00293	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64ab2b60-d0b0-11e9-9a07-0a80fada099c	CPT0105370004	a7530a59-d0a6-11e9-9a07-0a80fada099c	"C3N-01405-06, C3N-01405-07"	f1ee1feb-cf1e-11e9-9a07-0a80fada099c	C3N-01405	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6897f86a-d0b0-11e9-9a07-0a80fada099c	CPT0118200003	aa4eb9fd-d0a6-11e9-9a07-0a80fada099c	C3N-02087-01	f1ee331b-cf1e-11e9-9a07-0a80fada099c	C3N-02087	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6736c856-d0b0-11e9-9a07-0a80fada099c	CPT0097600003	a935f16d-d0a6-11e9-9a07-0a80fada099c	C3N-01823-06	f1ee2bd6-cf1e-11e9-9a07-0a80fada099c	C3N-01823	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6903f5af-d0b0-11e9-9a07-0a80fada099c	CPT0118360003	aa7e32f7-d0a6-11e9-9a07-0a80fada099c	C3N-02089-06	f1ee343a-cf1e-11e9-9a07-0a80fada099c	C3N-02089	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5859c180-d0b0-11e9-9a07-0a80fada099c	CPT0104650003	9e7c53af-d0a6-11e9-9a07-0a80fada099c	C3L-02219-06	f1edbacb-cf1e-11e9-9a07-0a80fada099c	C3L-02219	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
65f057ce-d0b0-11e9-9a07-0a80fada099c	CPT0105710003	a86e6aa1-d0a6-11e9-9a07-0a80fada099c	C3N-01416-03	f1ee25c3-cf1e-11e9-9a07-0a80fada099c	C3N-01416	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b1fecc9-d0b0-11e9-9a07-0a80fada099c	CPT0066810003	a07f87f2-d0a6-11e9-9a07-0a80fada099c	C3N-00180-06	f1edd776-cf1e-11e9-9a07-0a80fada099c	C3N-00180	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62d35a81-d0b0-11e9-9a07-0a80fada099c	CPT0105010004	a6103c5f-d0a6-11e9-9a07-0a80fada099c	"C3N-01021-06, C3N-01021-07"	f1ee167b-cf1e-11e9-9a07-0a80fada099c	C3N-01021	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a4cbb57-d0b0-11e9-9a07-0a80fada099c	CPT0013630003	9fe5403b-d0a6-11e9-9a07-0a80fada099c	C3N-00167-06	f1edcf73-cf1e-11e9-9a07-0a80fada099c	C3N-00167	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
644582db-d0b0-11e9-9a07-0a80fada099c	CPT0084170003	a6f43a46-d0a6-11e9-9a07-0a80fada099c	C3N-01072-06	f1ee1da6-cf1e-11e9-9a07-0a80fada099c	C3N-01072	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64695387-d0b0-11e9-9a07-0a80fada099c	CPT0105270003	a72896a1-d0a6-11e9-9a07-0a80fada099c	C3N-01074-01	f1ee1ecb-cf1e-11e9-9a07-0a80fada099c	C3N-01074	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
66ef980d-d0b0-11e9-9a07-0a80fada099c	CPT0089360003	a8ef13fe-d0a6-11e9-9a07-0a80fada099c	C3N-01799-07	f1ee2921-cf1e-11e9-9a07-0a80fada099c	C3N-01799	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5246c8b5-d0b0-11e9-9a07-0a80fada099c	CPT0000930003	9a27554b-d0a6-11e9-9a07-0a80fada099c	C3L-00094-06	f1ed9eb2-cf1e-11e9-9a07-0a80fada099c	C3L-00094	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6929e0f9-d0b0-11e9-9a07-0a80fada099c	CPT0118570003	aab86d56-d0a6-11e9-9a07-0a80fada099c	C3N-02145-03	f1ee355d-cf1e-11e9-9a07-0a80fada099c	C3N-02145	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ba77caa-d0b0-11e9-9a07-0a80fada099c	CPT0147080004	ac4a2160-d0a6-11e9-9a07-0a80fada099c	"C3N-02424-01, C3N-02424-02"	f1ee3fad-cf1e-11e9-9a07-0a80fada099c	C3N-02424	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6097e39a-d0b0-11e9-9a07-0a80fada099c	CPT0069370003	a45b6aa0-d0a6-11e9-9a07-0a80fada099c	C3N-00578-06	f1ee0bb0-cf1e-11e9-9a07-0a80fada099c	C3N-00578	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6bc83057-d0b0-11e9-9a07-0a80fada099c	CPT0147100003	ac69f431-d0a6-11e9-9a07-0a80fada099c	C3N-02424-03	f1ee3fad-cf1e-11e9-9a07-0a80fada099c	C3N-02424	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
61ddf51d-d0b0-11e9-9a07-0a80fada099c	CPT0112060003	a5786a80-d0a6-11e9-9a07-0a80fada099c	C3N-00738-01	f1ee12e4-cf1e-11e9-9a07-0a80fada099c	C3N-00738	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5addfb85-d0b0-11e9-9a07-0a80fada099c	CPT0013910003	a0465f5c-d0a6-11e9-9a07-0a80fada099c	C3N-00175-06	f1edd3ac-cf1e-11e9-9a07-0a80fada099c	C3N-00175	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5998470c-d0b0-11e9-9a07-0a80fada099c	CPT0125810003	9f7effde-d0a6-11e9-9a07-0a80fada099c	C3L-02508-02	f1edcba2-cf1e-11e9-9a07-0a80fada099c	C3L-02508	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
648a5e8d-d0b0-11e9-9a07-0a80fada099c	CPT0105330003	a76bf6a4-d0a6-11e9-9a07-0a80fada099c	C3N-01405-01	f1ee1feb-cf1e-11e9-9a07-0a80fada099c	C3N-01405	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
58be95d5-d0b0-11e9-9a07-0a80fada099c	CPT0115070003	9efeea9b-d0a6-11e9-9a07-0a80fada099c	C3L-02348-02	f1edbde6-cf1e-11e9-9a07-0a80fada099c	C3L-02348	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63fa3fca-d0b0-11e9-9a07-0a80fada099c	CPT0070080003	a6c1f4e5-d0a6-11e9-9a07-0a80fada099c	C3N-01071-06	f1ee1bf7-cf1e-11e9-9a07-0a80fada099c	C3N-01071	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62afd61f-d0b0-11e9-9a07-0a80fada099c	CPT0104970003	a5f651d7-d0a6-11e9-9a07-0a80fada099c	C3N-01021-01	f1ee167b-cf1e-11e9-9a07-0a80fada099c	C3N-01021	CPTAC3 Discovery and Confirmatory	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6055ea89-d0b0-11e9-9a07-0a80fada099c	CPT0090900004	a443a398-d0a6-11e9-9a07-0a80fada099c	"C3N-00574-06, C3N-00574-07"	f1ee0a7e-cf1e-11e9-9a07-0a80fada099c	C3N-00574	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
596dab3e-d0b0-11e9-9a07-0a80fada099c	CPT0114880003	9f675837-d0a6-11e9-9a07-0a80fada099c	C3L-02365-05	f1edc1bc-cf1e-11e9-9a07-0a80fada099c	C3L-02365	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Bronchus and lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d93dc61f-1271-11e9-afb9-0a9c39d33490	CPT0062940003	a4ab6a41-1259-11e9-afb9-0a9c39d33490	C3N-00743-01	a91770bc-118a-11e9-afb9-0a9c39d33490	C3N-00743	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fabee473-1f2e-11e9-b7f8-0a80fada099c	CPT0078880003	bb3f7d7a-1259-11e9-afb9-0a9c39d33490	C3N-01001-03	b7d3d05e-118a-11e9-afb9-0a9c39d33490	C3N-01001	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
3ac016de-1272-11e9-afb9-0a9c39d33490	CPT0116630003	d34c036b-1259-11e9-afb9-0a9c39d33490	C3N-01349-02	c5f5e38e-118a-11e9-afb9-0a9c39d33490	C3N-01349	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
36d94ae6-1272-11e9-afb9-0a9c39d33490	CPT0116550004	03d9b745-125a-11e9-afb9-0a9c39d33490	"C3N-01346-03, C3N-01346-04"	c4417cc1-118a-11e9-afb9-0a9c39d33490	C3N-01346	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cbcb44ca-1271-11e9-afb9-0a9c39d33490	CPT0027130001	0436c650-1259-11e9-afb9-0a9c39d33490	C3L-00932-02	41032920-118a-11e9-afb9-0a9c39d33490	C3L-00932	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0aa77b22-1272-11e9-afb9-0a9c39d33490	CPT0076500003	c8a6ef50-1259-11e9-afb9-0a9c39d33490	C3N-01217-01	bf1f593d-118a-11e9-afb9-0a9c39d33490	C3N-01217	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9406f000-1271-11e9-afb9-0a9c39d33490	CPT0016260003	06c5ce93-1259-11e9-afb9-0a9c39d33490	C3L-00938-01	456587bd-118a-11e9-afb9-0a9c39d33490	C3L-00938	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
1b54b88d-1272-11e9-afb9-0a9c39d33490	CPT0078710004	01393724-125a-11e9-afb9-0a9c39d33490	"C3N-00880-01,C3N-00880-03,C3N-00880-04"	b609ffcc-118a-11e9-afb9-0a9c39d33490	C3N-00880	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ac2dd1b6-1271-11e9-afb9-0a9c39d33490	CPT0022530003	7706792f-1259-11e9-afb9-0a9c39d33490	C3N-00326-01	8c09d59a-118a-11e9-afb9-0a9c39d33490	C3N-00326	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb69ba54-1271-11e9-afb9-0a9c39d33490	CPT0064210003	4c4addeb-1259-11e9-afb9-0a9c39d33490	C3L-01304-01	759378e9-118a-11e9-afb9-0a9c39d33490	C3L-01304	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10d6861b-1272-11e9-afb9-0a9c39d33490	CPT0077660001	46df7666-1259-11e9-afb9-0a9c39d33490	C3L-01282-06	71dfac9d-118a-11e9-afb9-0a9c39d33490	C3L-01282	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
823c4a51-1271-11e9-afb9-0a9c39d33490	CPT0007660001	d8ca9525-1258-11e9-afb9-0a9c39d33490	C3L-00601-06	0c47fcef-118a-11e9-afb9-0a9c39d33490	C3L-00601	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c513b2cc-1271-11e9-afb9-0a9c39d33490	CPT0026770003	f1da316b-1258-11e9-afb9-0a9c39d33490	C3L-00771-01	1cc0625d-118a-11e9-afb9-0a9c39d33490	C3L-00771	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b79e957f-1271-11e9-afb9-0a9c39d33490	CPT0024130003	adf4653b-1259-11e9-afb9-0a9c39d33490	C3N-00848-02	af3bac3b-118a-11e9-afb9-0a9c39d33490	C3N-00848	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e304d936-1271-11e9-afb9-0a9c39d33490	CPT0063670003	59d40ecb-1259-11e9-afb9-0a9c39d33490	C3L-01312-01	7ae2b631-118a-11e9-afb9-0a9c39d33490	C3L-01312	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
08ebd92c-1272-11e9-afb9-0a9c39d33490	CPT0076160003	cb76f744-1259-11e9-afb9-0a9c39d33490	C3N-01219-03	c0d54c8c-118a-11e9-afb9-0a9c39d33490	C3N-01219	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
38b550cb-1272-11e9-afb9-0a9c39d33490	CPT0116570003	d0a5db4e-1259-11e9-afb9-0a9c39d33490	C3N-01346-05	c4417cc1-118a-11e9-afb9-0a9c39d33490	C3N-01346	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
68aadf74-1271-11e9-afb9-0a9c39d33490	CPT0001460012	9392f7db-1258-11e9-afb9-0a9c39d33490	C3L-00006-01	bf8aa73f-1189-11e9-afb9-0a9c39d33490	C3L-00006	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7d9c0c4e-1271-11e9-afb9-0a9c39d33490	CPT0002630003	b0abdd42-1258-11e9-afb9-0a9c39d33490	C3L-00145-02	e061c1ea-1189-11e9-afb9-0a9c39d33490	C3L-00145	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
983e5c21-1271-11e9-afb9-0a9c39d33490	CPT0016490003	1989a270-1259-11e9-afb9-0a9c39d33490	C3L-00963-01	5be58e2e-118a-11e9-afb9-0a9c39d33490	C3L-00963	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9264430a-1271-11e9-afb9-0a9c39d33490	CPT0016220003	99a4bcef-1259-11e9-afb9-0a9c39d33490	C3N-00386-02	a023e964-118a-11e9-afb9-0a9c39d33490	C3N-00386	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
78855ee0-1271-11e9-afb9-0a9c39d33490	CPT0002450001	c07fa13b-1258-11e9-afb9-0a9c39d33490	C3L-00361-06	fb305e6f-1189-11e9-afb9-0a9c39d33490	C3L-00361	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a20ac4c5-1271-11e9-afb9-0a9c39d33490	CPT0018570003	819ea1bd-1259-11e9-afb9-0a9c39d33490	C3N-00334-02	912bec48-118a-11e9-afb9-0a9c39d33490	C3N-00334	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d799fbea-1271-11e9-afb9-0a9c39d33490	CPT0027970003	ce10e933-1259-11e9-afb9-0a9c39d33490	C3N-01267-03	c289029e-118a-11e9-afb9-0a9c39d33490	C3N-01267	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
76c34130-1271-11e9-afb9-0a9c39d33490	CPT0002430011	bde65c14-1258-11e9-afb9-0a9c39d33490	C3L-00361-01	fb305e6f-1189-11e9-afb9-0a9c39d33490	C3L-00361	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2b701576-1272-11e9-afb9-0a9c39d33490	CPT0080980003	1eab80c2-1259-11e9-afb9-0a9c39d33490	C3L-01246-01	5e29a8d7-118a-11e9-afb9-0a9c39d33490	C3L-01246	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
231b7c6e-1272-11e9-afb9-0a9c39d33490	CPT0080610003	2eb552e1-1259-11e9-afb9-0a9c39d33490	C3L-01252-01	66ee6e22-118a-11e9-afb9-0a9c39d33490	C3L-01252	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f4ce8258-1271-11e9-afb9-0a9c39d33490	CPT0066620003	645daacf-1259-11e9-afb9-0a9c39d33490	C3N-00151-03	8116b9ae-118a-11e9-afb9-0a9c39d33490	C3N-00151	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1959431d-1272-11e9-afb9-0a9c39d33490	CPT0078610003	bdd6bee3-1259-11e9-afb9-0a9c39d33490	C3N-01003-01	b9bcc643-118a-11e9-afb9-0a9c39d33490	C3N-01003	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
feb8e334-1271-11e9-afb9-0a9c39d33490	CPT0073520003	3bfd9ac1-1259-11e9-afb9-0a9c39d33490	C3L-01257-01	6e7501ca-118a-11e9-afb9-0a9c39d33490	C3L-01257	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9b63f5b5-1271-11e9-afb9-0a9c39d33490	CPT0016830003	09532dc1-1259-11e9-afb9-0a9c39d33490	C3L-00942-01	4a109eb2-118a-11e9-afb9-0a9c39d33490	C3L-00942	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dfc6fef3-1271-11e9-afb9-0a9c39d33490	CPT0063260001	cdfb76bf-1258-11e9-afb9-0a9c39d33490	C3L-00563-06	052c671d-118a-11e9-afb9-0a9c39d33490	C3L-00563	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1fd8187c-1272-11e9-afb9-0a9c39d33490	CPT0080300003	26cc88f8-1259-11e9-afb9-0a9c39d33490	C3L-01248-01	619df278-118a-11e9-afb9-0a9c39d33490	C3L-01248	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d279d3cc-1271-11e9-afb9-0a9c39d33490	CPT0027520003	0c492abf-1259-11e9-afb9-0a9c39d33490	C3L-00946-01	4bc3f300-118a-11e9-afb9-0a9c39d33490	C3L-00946	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
88f4d0a4-1271-11e9-afb9-0a9c39d33490	CPT0010610003	71a0f210-1259-11e9-afb9-0a9c39d33490	C3N-00323-02	8849af9c-118a-11e9-afb9-0a9c39d33490	C3N-00323	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
004c5675-1272-11e9-afb9-0a9c39d33490	CPT0073530001	3e888cef-1259-11e9-afb9-0a9c39d33490	C3L-01257-02	6e7501ca-118a-11e9-afb9-0a9c39d33490	C3L-01257	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f6a113f1-1271-11e9-afb9-0a9c39d33490	CPT0070260003	f72aa2b6-1258-11e9-afb9-0a9c39d33490	C3L-00781-04	22ac5d1d-118a-11e9-afb9-0a9c39d33490	C3L-00781	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
773b6317-c63a-11ea-b1fd-0aad30af8a83	NX13	773a8a16-c63a-11ea-b1fd-0aad30af8a83	C3N-03697-03	77399f35-c63a-11ea-b1fd-0aad30af8a83	NX13	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
809a7f8a-1271-11e9-afb9-0a9c39d33490	CPT0007600003	d610304c-1258-11e9-afb9-0a9c39d33490	C3L-00601-02	0c47fcef-118a-11e9-afb9-0a9c39d33490	C3L-00601	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c0037b61-1271-11e9-afb9-0a9c39d33490	CPT0026540001	e6575f7d-1258-11e9-afb9-0a9c39d33490	C3L-00769-02	168e87be-118a-11e9-afb9-0a9c39d33490	C3L-00769	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
773b65cd-c63a-11ea-b1fd-0aad30af8a83	NX14	773a8b2d-c63a-11ea-b1fd-0aad30af8a83	"C3N-03699-01,C3N-03699-02"	7739a015-c63a-11ea-b1fd-0aad30af8a83	NX14	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a593e1e-1271-11e9-afb9-0a9c39d33490	CPT0002500011	c36c6848-1258-11e9-afb9-0a9c39d33490	C3L-00362-02	fe9f9137-1189-11e9-afb9-0a9c39d33490	C3L-00362	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f7f7d57-1271-11e9-afb9-0a9c39d33490	CPT0007100003	c89baa8f-1258-11e9-afb9-0a9c39d33490	C3L-00449-01	032d27ba-118a-11e9-afb9-0a9c39d33490	C3L-00449	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
773b6705-c63a-11ea-b1fd-0aad30af8a83	NX15	773a8d55-c63a-11ea-b1fd-0aad30af8a83	C3N-03700-01	7739a270-c63a-11ea-b1fd-0aad30af8a83	NX15	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
734ffa0a-1271-11e9-afb9-0a9c39d33490	CPT0002130003	b8c70dd6-1258-11e9-afb9-0a9c39d33490	C3L-00356-01	f610bc43-1189-11e9-afb9-0a9c39d33490	C3L-00356	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
773b67d7-c63a-11ea-b1fd-0aad30af8a83	NX16	773a8ec6-c63a-11ea-b1fd-0aad30af8a83	"C3N-03701-01,C3N-03701-02,C3N-03701-03"	7739a390-c63a-11ea-b1fd-0aad30af8a83	NX16	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e4a931bb-1271-11e9-afb9-0a9c39d33490	CPT0063790003	fc706127-1258-11e9-afb9-0a9c39d33490	C3L-00918-01	2eca2103-118a-11e9-afb9-0a9c39d33490	C3L-00918	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
773b5f18-c63a-11ea-b1fd-0aad30af8a83	NX10	773a8534-c63a-11ea-b1fd-0aad30af8a83	C3N-03693-03	77399a00-c63a-11ea-b1fd-0aad30af8a83	NX10	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7bf9870f-1271-11e9-afb9-0a9c39d33490	CPT0002560003	b63d60c2-1258-11e9-afb9-0a9c39d33490	C3L-00157-02	e67bed99-1189-11e9-afb9-0a9c39d33490	C3L-00157	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
773b5ff3-c63a-11ea-b1fd-0aad30af8a83	NX11	773a8711-c63a-11ea-b1fd-0aad30af8a83	C3N-03694-01	77399c25-c63a-11ea-b1fd-0aad30af8a83	NX11	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
773b623e-c63a-11ea-b1fd-0aad30af8a83	NX12	773a8825-c63a-11ea-b1fd-0aad30af8a83	"C3N-03695-01,C3N-03695-03"	77399cfd-c63a-11ea-b1fd-0aad30af8a83	NX12	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
773b68a3-c63a-11ea-b1fd-0aad30af8a83	NX17	773a90a8-c63a-11ea-b1fd-0aad30af8a83	"C3N-03706-01,C3N-03706-02,C3N-03706-03"	7739a462-c63a-11ea-b1fd-0aad30af8a83	NX17	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5fdb6874-1271-11e9-afb9-0a9c39d33490	CPT0000730011	a6147e81-1258-11e9-afb9-0a9c39d33490	C3L-00136-03	d0f63b69-1189-11e9-afb9-0a9c39d33490	C3L-00136	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
773b696b-c63a-11ea-b1fd-0aad30af8a83	NX18	773a91bd-c63a-11ea-b1fd-0aad30af8a83	"C3N-03708-01,C3N-03708-02,C3N-03708-03"	7739a536-c63a-11ea-b1fd-0aad30af8a83	NX18	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c70bfb9-1272-11e9-afb9-0a9c39d33490	CPT0079650003	d5df727f-1259-11e9-afb9-0a9c39d33490	C3N-01510-02	c7ab207d-118a-11e9-afb9-0a9c39d33490	C3N-01510	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
31c544cf-1272-11e9-afb9-0a9c39d33490	CPT0097010003	06c02d40-125a-11e9-afb9-0a9c39d33490	C3N-01537-01	cd581d86-118a-11e9-afb9-0a9c39d33490	C3N-01537	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
144d56ed-1272-11e9-afb9-0a9c39d33490	CPT0077780001	572852d0-1259-11e9-afb9-0a9c39d33490	C3L-01311-06	78ff5de8-118a-11e9-afb9-0a9c39d33490	C3L-01311	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
28084b1c-1272-11e9-afb9-0a9c39d33490	CPT0080880003	295411a4-1259-11e9-afb9-0a9c39d33490	C3L-01249-01	636ec295-118a-11e9-afb9-0a9c39d33490	C3L-01249	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fce5c1aa-1271-11e9-afb9-0a9c39d33490	CPT0073460001	39743eb5-1259-11e9-afb9-0a9c39d33490	C3L-01256-02	6b043589-118a-11e9-afb9-0a9c39d33490	C3L-01256	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2e4a15ba-1272-11e9-afb9-0a9c39d33490	CPT0093280003	5c9c74ae-1259-11e9-afb9-0a9c39d33490	C3L-01744-01	7d468d2e-118a-11e9-afb9-0a9c39d33490	C3L-01744	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b97429ff-1271-11e9-afb9-0a9c39d33490	CPT0026030004	f9f192f1-1259-11e9-afb9-0a9c39d33490	"C3N-00734-01,C3N-00734-03"	a7378d52-118a-11e9-afb9-0a9c39d33490	C3N-00734	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9ed8805a-1271-11e9-afb9-0a9c39d33490	CPT0017870003	66f140e8-1259-11e9-afb9-0a9c39d33490	C3N-00200-02	82d09fee-118a-11e9-afb9-0a9c39d33490	C3N-00200	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
afa6b211-1271-11e9-afb9-0a9c39d33490	CPT0022830003	9466dcfe-1259-11e9-afb9-0a9c39d33490	C3N-00383-04	9e2da4f9-118a-11e9-afb9-0a9c39d33490	C3N-00383	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b5fc362a-1271-11e9-afb9-0a9c39d33490	CPT0023810003	a7f09045-1259-11e9-afb9-0a9c39d33490	C3N-00836-02	ab61bb80-118a-11e9-afb9-0a9c39d33490	C3N-00836	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b4552a7a-1271-11e9-afb9-0a9c39d33490	CPT0023640001	d3232b6d-1258-11e9-afb9-0a9c39d33490	C3L-00586-06	0a088f7a-118a-11e9-afb9-0a9c39d33490	C3L-00586	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0d9af6ac-1272-11e9-afb9-0a9c39d33490	CPT0076860003	d87c1bd1-1259-11e9-afb9-0a9c39d33490	C3N-01520-01	c9bdcd45-118a-11e9-afb9-0a9c39d33490	C3N-01520	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c1ab98fb-1271-11e9-afb9-0a9c39d33490	CPT0026650003	e94e9012-1258-11e9-afb9-0a9c39d33490	C3L-00770-01	1907a949-118a-11e9-afb9-0a9c39d33490	C3L-00770	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
217a9440-1272-11e9-afb9-0a9c39d33490	CPT0080400003	344cb588-1259-11e9-afb9-0a9c39d33490	C3L-01253-01	694ab8e6-118a-11e9-afb9-0a9c39d33490	C3L-01253	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
c66a8402-1271-11e9-afb9-0a9c39d33490	CPT0026780001	f4916919-1258-11e9-afb9-0a9c39d33490	C3L-00771-02	1cc0625d-118a-11e9-afb9-0a9c39d33490	C3L-00771	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fc85ab67-1f2e-11e9-b7f8-0a80fada099c	CPT0079570003	498613c6-1259-11e9-afb9-0a9c39d33490	C3L-01284-02	73a51a51-118a-11e9-afb9-0a9c39d33490	C3L-01284	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
a3dd49f9-1271-11e9-afb9-0a9c39d33490	CPT0018790003	8438ac1a-1259-11e9-afb9-0a9c39d33490	C3N-00335-05	92faa00d-118a-11e9-afb9-0a9c39d33490	C3N-00335	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2673cdfd-1272-11e9-afb9-0a9c39d33490	CPT0080700003	240e65d8-1259-11e9-afb9-0a9c39d33490	C3L-01247-01	5feac127-118a-11e9-afb9-0a9c39d33490	C3L-01247	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
efe19325-1271-11e9-afb9-0a9c39d33490	CPT0064320001	51beec6d-1259-11e9-afb9-0a9c39d33490	C3L-01307-06	774332e2-118a-11e9-afb9-0a9c39d33490	C3L-01307	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a57e643a-1271-11e9-afb9-0a9c39d33490	CPT0018960003	86d8b169-1259-11e9-afb9-0a9c39d33490	C3N-00337-04	94bad53c-118a-11e9-afb9-0a9c39d33490	C3N-00337	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b15e1dd6-1271-11e9-afb9-0a9c39d33490	CPT0022850001	9708211b-1259-11e9-afb9-0a9c39d33490	C3N-00383-06	9e2da4f9-118a-11e9-afb9-0a9c39d33490	C3N-00383	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
073cdda9-1272-11e9-afb9-0a9c39d33490	CPT0075940001	c3481853-1259-11e9-afb9-0a9c39d33490	C3N-01211-06	bb818b02-118a-11e9-afb9-0a9c39d33490	C3N-01211	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
90924c28-1271-11e9-afb9-0a9c39d33490	CPT0015520003	91c19819-1259-11e9-afb9-0a9c39d33490	C3N-00379-01	9beb3211-118a-11e9-afb9-0a9c39d33490	C3N-00379	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e9d28147-1271-11e9-afb9-0a9c39d33490	CPT0064150004	e821e924-1259-11e9-afb9-0a9c39d33490	"C3L-00921-02,C3L-00921-03"	36c681be-118a-11e9-afb9-0a9c39d33490	C3L-00921	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d423dc9c-1271-11e9-afb9-0a9c39d33490	CPT0027650003	ab0eb1bd-1259-11e9-afb9-0a9c39d33490	C3N-00847-01	ad580ba0-118a-11e9-afb9-0a9c39d33490	C3N-00847	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fe204583-1f2e-11e9-b7f8-0a80fada099c	CPT0097730003	e04e42e0-1259-11e9-afb9-0a9c39d33490	C3N-01825-03	d10cafea-118a-11e9-afb9-0a9c39d33490	C3N-01825	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
17c5d6ae-1272-11e9-afb9-0a9c39d33490	CPT0078360001	b319473f-1259-11e9-afb9-0a9c39d33490	C3N-00858-05	b2a27cfc-118a-11e9-afb9-0a9c39d33490	C3N-00858	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d69101d-1271-11e9-afb9-0a9c39d33490	CPT0001910016	ae1219ce-1258-11e9-afb9-0a9c39d33490	C3L-00143-01	dc9f2a6d-1189-11e9-afb9-0a9c39d33490	C3L-00143	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
65837702-1271-11e9-afb9-0a9c39d33490	CPT0001300009	98ce2074-1258-11e9-afb9-0a9c39d33490	C3L-00008-01	c3ca10d9-1189-11e9-afb9-0a9c39d33490	C3L-00008	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bcb643ce-1271-11e9-afb9-0a9c39d33490	CPT0026430003	e0d93838-1258-11e9-afb9-0a9c39d33490	C3L-00767-01	12997b94-118a-11e9-afb9-0a9c39d33490	C3L-00767	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eec20625-1271-11e9-afb9-0a9c39d33490	CPT0064290004	eac78fcf-1259-11e9-afb9-0a9c39d33490	"C3L-01307-01,C3L-01307-03"	774332e2-118a-11e9-afb9-0a9c39d33490	C3L-01307	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e82ded78-1271-11e9-afb9-0a9c39d33490	CPT0063900001	de408513-1258-11e9-afb9-0a9c39d33490	C3L-00605-06	0e06b68f-118a-11e9-afb9-0a9c39d33490	C3L-00605	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
74ef895e-1271-11e9-afb9-0a9c39d33490	CPT0002210011	bb56d00f-1258-11e9-afb9-0a9c39d33490	C3L-00358-01	f91c655f-1189-11e9-afb9-0a9c39d33490	C3L-00358	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f315fb5-1272-11e9-afb9-0a9c39d33490	CPT0077650003	44156ce5-1259-11e9-afb9-0a9c39d33490	C3L-01282-01	71dfac9d-118a-11e9-afb9-0a9c39d33490	C3L-01282	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a3a926f-1271-11e9-afb9-0a9c39d33490	CPT0001470001	961f13f8-1258-11e9-afb9-0a9c39d33490	C3L-00006-06	bf8aa73f-1189-11e9-afb9-0a9c39d33490	C3L-00006	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9d366f1d-1271-11e9-afb9-0a9c39d33490	CPT0016940003	9c6f2eb2-1259-11e9-afb9-0a9c39d33490	C3N-00388-01	a1d6b22d-118a-11e9-afb9-0a9c39d33490	C3N-00388	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0bf710f0-1272-11e9-afb9-0a9c39d33490	CPT0076680003	db1e173c-1259-11e9-afb9-0a9c39d33490	C3N-01521-01	cb83f272-118a-11e9-afb9-0a9c39d33490	C3N-01521	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
24c7d3d5-1272-11e9-afb9-0a9c39d33490	CPT0080620001	3194c827-1259-11e9-afb9-0a9c39d33490	C3L-01252-02	66ee6e22-118a-11e9-afb9-0a9c39d33490	C3L-01252	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
daea4ae4-1271-11e9-afb9-0a9c39d33490	CPT0063090003	b5e7ec63-1259-11e9-afb9-0a9c39d33490	C3N-00866-01	b455abd8-118a-11e9-afb9-0a9c39d33490	C3N-00866	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a068baee-1271-11e9-afb9-0a9c39d33490	CPT0017930001	698d99a6-1259-11e9-afb9-0a9c39d33490	C3N-00200-06	82d09fee-118a-11e9-afb9-0a9c39d33490	C3N-00200	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
adfef44c-1271-11e9-afb9-0a9c39d33490	CPT0022620003	8c5f4158-1259-11e9-afb9-0a9c39d33490	C3N-00340-03	9858289a-118a-11e9-afb9-0a9c39d33490	C3N-00340	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4110039b-1272-11e9-afb9-0a9c39d33490	NX1	15cf94d2-125a-11e9-afb9-0a9c39d33490	C3N-03691-01	d4cd4b91-118a-11e9-afb9-0a9c39d33490	NX1	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3c731608-1272-11e9-afb9-0a9c39d33490	NX3	0c3265f4-125a-11e9-afb9-0a9c39d33490	"C3N-03320-01, C3N-03320-03"	d8ac4953-118a-11e9-afb9-0a9c39d33490	NX3	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ca228336-1271-11e9-afb9-0a9c39d33490	CPT0027120003	0198bad6-1259-11e9-afb9-0a9c39d33490	C3L-00932-01	41032920-118a-11e9-afb9-0a9c39d33490	C3L-00932	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e2a1c33-1272-11e9-afb9-0a9c39d33490	NX2	10380be5-125a-11e9-afb9-0a9c39d33490	"C3N-03411-01, C3N-03411-02"	d6a94773-118a-11e9-afb9-0a9c39d33490	NX2	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4426bcb9-1272-11e9-afb9-0a9c39d33490	NX5	1e13661f-125a-11e9-afb9-0a9c39d33490	"C3N-03692-01, C3N-03692-02, C3N-03692-03"	dc6e3ede-118a-11e9-afb9-0a9c39d33490	NX5	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8c88b93c-1271-11e9-afb9-0a9c39d33490	CPT0011000003	7c42d5e2-1259-11e9-afb9-0a9c39d33490	C3N-00333-03	8f7b7b50-118a-11e9-afb9-0a9c39d33490	C3N-00333	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48f77136-1272-11e9-afb9-0a9c39d33490	NX4	1b179872-125a-11e9-afb9-0a9c39d33490	"C3N-03692-01, C3L-03602-02, C3L-03602-03, C3L-03563-01, C3L-03567-01"	da69274f-118a-11e9-afb9-0a9c39d33490	NX4	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3ff32a19-1272-11e9-afb9-0a9c39d33490	NX7	1334d1ed-125a-11e9-afb9-0a9c39d33490	"C3N-03412-02, C3N-03413-01, C3N-03413-03, C3L-03564-01, C3N-03692-02"	dff78dee-118a-11e9-afb9-0a9c39d33490	NX7	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4230d350-1272-11e9-afb9-0a9c39d33490	NX6	185a7733-125a-11e9-afb9-0a9c39d33490	"C3N-03691-02, C3N-03691-03"	de3650a9-118a-11e9-afb9-0a9c39d33490	NX6	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa8aa4e4-1271-11e9-afb9-0a9c39d33490	CPT0021650003	8ef37752-1259-11e9-afb9-0a9c39d33490	C3N-00377-02	9a36e995-118a-11e9-afb9-0a9c39d33490	C3N-00377	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dde38739-1271-11e9-afb9-0a9c39d33490	CPT0063250003	cb6753bc-1258-11e9-afb9-0a9c39d33490	C3L-00563-03	052c671d-118a-11e9-afb9-0a9c39d33490	C3L-00563	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
46ff0651-1272-11e9-afb9-0a9c39d33490	NX9	f0368ba1-1259-11e9-afb9-0a9c39d33490	C3L-03601-03	e3e93bc1-118a-11e9-afb9-0a9c39d33490	NX9	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e15ba60f-1271-11e9-afb9-0a9c39d33490	CPT0063380003	f9b43882-1258-11e9-afb9-0a9c39d33490	C3L-00905-02	2995a447-118a-11e9-afb9-0a9c39d33490	C3L-00905	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f85348d6-1271-11e9-afb9-0a9c39d33490	CPT0070330004	e5795ffb-1259-11e9-afb9-0a9c39d33490	"C3L-00780-03,C3L-00780-05"	1ef863b4-118a-11e9-afb9-0a9c39d33490	C3L-00780	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
45de8f3e-1272-11e9-afb9-0a9c39d33490	NX8	ed9f0d12-1259-11e9-afb9-0a9c39d33490	"C3L-03601-01, C3L-03601-02"	e1e441b1-118a-11e9-afb9-0a9c39d33490	NX8	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8e852f3f-1271-11e9-afb9-0a9c39d33490	CPT0011020003	7efc80a6-1259-11e9-afb9-0a9c39d33490	C3N-00333-07	8f7b7b50-118a-11e9-afb9-0a9c39d33490	C3N-00333	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ed0b95e6-1271-11e9-afb9-0a9c39d33490	CPT0064240001	4f171907-1259-11e9-afb9-0a9c39d33490	C3L-01304-06	759378e9-118a-11e9-afb9-0a9c39d33490	C3L-01304	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
99f0b03f-1271-11e9-afb9-0a9c39d33490	CPT0016530001	1c14ea16-1259-11e9-afb9-0a9c39d33490	C3L-00963-02	5be58e2e-118a-11e9-afb9-0a9c39d33490	C3L-00963	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cf43a98d-1271-11e9-afb9-0a9c39d33490	CPT0027420003	0f31e2fe-1259-11e9-afb9-0a9c39d33490	C3L-00947-01	5498017e-118a-11e9-afb9-0a9c39d33490	C3L-00947	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a71f8fee-1271-11e9-afb9-0a9c39d33490	CPT0019840003	79abd4d9-1259-11e9-afb9-0a9c39d33490	C3N-00328-05	8dbf9afd-118a-11e9-afb9-0a9c39d33490	C3N-00328	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8ac612b2-1271-11e9-afb9-0a9c39d33490	CPT0010820003	746850ba-1259-11e9-afb9-0a9c39d33490	C3N-00324-04	8a413c6c-118a-11e9-afb9-0a9c39d33490	C3N-00324	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb0a5d00-1271-11e9-afb9-0a9c39d33490	CPT0026270003	9f0519a7-1259-11e9-afb9-0a9c39d33490	C3N-00389-04	a3b1451a-118a-11e9-afb9-0a9c39d33490	C3N-00389	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03c123d8-1272-11e9-afb9-0a9c39d33490	CPT0075380003	c5e18a33-1259-11e9-afb9-0a9c39d33490	C3N-01212-03	bd69cf78-118a-11e9-afb9-0a9c39d33490	C3N-01212	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2d2a341a-1272-11e9-afb9-0a9c39d33490	CPT0080990001	21425db2-1259-11e9-afb9-0a9c39d33490	C3L-01246-02	5e29a8d7-118a-11e9-afb9-0a9c39d33490	C3L-01246	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6fe800d3-1271-11e9-afb9-0a9c39d33490	CPT0002010011	a8a483e8-1258-11e9-afb9-0a9c39d33490	C3L-00137-02	d4873729-1189-11e9-afb9-0a9c39d33490	C3L-00137	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
353280f3-1272-11e9-afb9-0a9c39d33490	CPT0113690003	61c4d96e-1259-11e9-afb9-0a9c39d33490	C3L-01925-07	7ef278e9-118a-11e9-afb9-0a9c39d33490	C3L-01925	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
678d9887-1271-11e9-afb9-0a9c39d33490	CPT0001420009	9b9a8639-1258-11e9-afb9-0a9c39d33490	C3L-00032-01	c5f06f4e-1189-11e9-afb9-0a9c39d33490	C3L-00032	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
620c77d4-1271-11e9-afb9-0a9c39d33490	CPT0000980012	a3843896-1258-11e9-afb9-0a9c39d33490	C3L-00098-02	cdbb0274-1189-11e9-afb9-0a9c39d33490	C3L-00098	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0561b6d6-1272-11e9-afb9-0a9c39d33490	CPT0075900003	c0af1d3f-1259-11e9-afb9-0a9c39d33490	C3N-01211-01	bb818b02-118a-11e9-afb9-0a9c39d33490	C3N-01211	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1877853-1271-11e9-afb9-0a9c39d33490	CPT0064930004	f7430286-1259-11e9-afb9-0a9c39d33490	"C3N-00729-02,C3N-00729-03"	a57fa8f2-118a-11e9-afb9-0a9c39d33490	C3N-00729	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1623e0e4-1272-11e9-afb9-0a9c39d33490	CPT0078320004	fe762caa-1259-11e9-afb9-0a9c39d33490	"C3N-00858-01,C3N-00858-04"	b2a27cfc-118a-11e9-afb9-0a9c39d33490	C3N-00858	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
71abb420-1271-11e9-afb9-0a9c39d33490	CPT0002080011	b3a98d38-1258-11e9-afb9-0a9c39d33490	C3L-00156-02	e47da4ba-1189-11e9-afb9-0a9c39d33490	C3L-00156	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
12779c60-1272-11e9-afb9-0a9c39d33490	CPT0077770003	5490611e-1259-11e9-afb9-0a9c39d33490	C3L-01311-01	78ff5de8-118a-11e9-afb9-0a9c39d33490	C3L-01311	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a8c3221e-1271-11e9-afb9-0a9c39d33490	CPT0020530003	896be99b-1259-11e9-afb9-0a9c39d33490	C3N-00339-02	967262c9-118a-11e9-afb9-0a9c39d33490	C3N-00339	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d0ea2cea-1271-11e9-afb9-0a9c39d33490	CPT0027430001	11b8f015-1259-11e9-afb9-0a9c39d33490	C3L-00947-02	5498017e-118a-11e9-afb9-0a9c39d33490	C3L-00947	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fb112a88-1271-11e9-afb9-0a9c39d33490	CPT0073450003	36dc6ebd-1259-11e9-afb9-0a9c39d33490	C3L-01256-01	6b043589-118a-11e9-afb9-0a9c39d33490	C3L-01256	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e6810773-1271-11e9-afb9-0a9c39d33490	CPT0063890003	db5c4a91-1258-11e9-afb9-0a9c39d33490	C3L-00605-01	0e06b68f-118a-11e9-afb9-0a9c39d33490	C3L-00605	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
968cb2d1-1271-11e9-afb9-0a9c39d33490	CPT0016370003	14647007-1259-11e9-afb9-0a9c39d33490	C3L-00949-01	575574a0-118a-11e9-afb9-0a9c39d33490	C3L-00949	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dc99c615-1271-11e9-afb9-0a9c39d33490	CPT0063110001	b87b2d7e-1259-11e9-afb9-0a9c39d33490	C3N-00866-03	b455abd8-118a-11e9-afb9-0a9c39d33490	C3N-00866	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2feaa4e3-1272-11e9-afb9-0a9c39d33490	CPT0093290000	5f2f59fe-1259-11e9-afb9-0a9c39d33490	C3L-01744-02	7d468d2e-118a-11e9-afb9-0a9c39d33490	C3L-01744	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b27ba349-1271-11e9-afb9-0a9c39d33490	CPT0023630003	d0894f7d-1258-11e9-afb9-0a9c39d33490	C3L-00586-03	0a088f7a-118a-11e9-afb9-0a9c39d33490	C3L-00586	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f32b47c0-1271-11e9-afb9-0a9c39d33490	CPT0064950001	a1e6da01-1259-11e9-afb9-0a9c39d33490	C3N-00729-06	a57fa8f2-118a-11e9-afb9-0a9c39d33490	C3N-00729	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f92888db-1f2e-11e9-b7f8-0a80fada099c	CPT0000820012	9e5c2385-1258-11e9-afb9-0a9c39d33490	C3L-00084-01	c81ae16c-1189-11e9-afb9-0a9c39d33490	C3L-00084	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
63b02b96-1271-11e9-afb9-0a9c39d33490	CPT0001140003	a0fbf81e-1258-11e9-afb9-0a9c39d33490	C3L-00090-01	cb07dc57-1189-11e9-afb9-0a9c39d33490	C3L-00090	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e11c590-1272-11e9-afb9-0a9c39d33490	CPT0080030003	ddba3e09-1259-11e9-afb9-0a9c39d33490	C3N-01802-01	cf31f3d1-118a-11e9-afb9-0a9c39d33490	C3N-01802	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29aa2a10-1272-11e9-afb9-0a9c39d33490	CPT0080890001	2c11bbd8-1259-11e9-afb9-0a9c39d33490	C3L-01249-02	636ec295-118a-11e9-afb9-0a9c39d33490	C3L-01249	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6bdaf0c9-1271-11e9-afb9-0a9c39d33490	CPT0001850012	ab791718-1258-11e9-afb9-0a9c39d33490	C3L-00139-01	d898b2a0-1189-11e9-afb9-0a9c39d33490	C3L-00139	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c813b058-1271-11e9-afb9-0a9c39d33490	CPT0027020001	ff0a9f7b-1258-11e9-afb9-0a9c39d33490	C3L-00930-02	3d30e438-118a-11e9-afb9-0a9c39d33490	C3L-00930	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83e1dd48-1271-11e9-afb9-0a9c39d33490	CPT0009980003	c61441a1-1258-11e9-afb9-0a9c39d33490	C3L-00413-01	01072f05-118a-11e9-afb9-0a9c39d33490	C3L-00413	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd6f0a01-1271-11e9-afb9-0a9c39d33490	CPT0027320003	16f1921f-1259-11e9-afb9-0a9c39d33490	C3L-00961-01	596e1d74-118a-11e9-afb9-0a9c39d33490	C3L-00961	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
87522f0f-1271-11e9-afb9-0a9c39d33490	CPT0010430003	6ef93bc6-1259-11e9-afb9-0a9c39d33490	C3N-00322-03	86340bb8-118a-11e9-afb9-0a9c39d33490	C3N-00322	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
336f8e64-1272-11e9-afb9-0a9c39d33490	CPT0097710003	09940636-125a-11e9-afb9-0a9c39d33490	C3N-01825-01	d10cafea-118a-11e9-afb9-0a9c39d33490	C3N-01825	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01eda787-1272-11e9-afb9-0a9c39d33490	CPT0073730003	415399d3-1259-11e9-afb9-0a9c39d33490	C3L-01275-01	70207e73-118a-11e9-afb9-0a9c39d33490	C3L-01275	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
85a194c2-1271-11e9-afb9-0a9c39d33490	CPT0010260003	6c5b857d-1259-11e9-afb9-0a9c39d33490	C3N-00321-01	8484f653-118a-11e9-afb9-0a9c39d33490	C3N-00321	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d5f7a8a2-1271-11e9-afb9-0a9c39d33490	CPT0027810003	b087a1b2-1259-11e9-afb9-0a9c39d33490	C3N-00850-02	b0effb8f-118a-11e9-afb9-0a9c39d33490	C3N-00850	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
be5b6538-1271-11e9-afb9-0a9c39d33490	CPT0026530003	e36962f5-1258-11e9-afb9-0a9c39d33490	C3L-00769-01	168e87be-118a-11e9-afb9-0a9c39d33490	C3L-00769	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f96e68c0-1271-11e9-afb9-0a9c39d33490	CPT0070380004	e2e2dc56-1259-11e9-afb9-0a9c39d33490	"C3L-00161-01,C3L-00161-02"	ec955c22-1189-11e9-afb9-0a9c39d33490	C3L-00161	CPTAC3 Discovery and Confirmatory	Primary Tumor	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c35e62cc-1271-11e9-afb9-0a9c39d33490	CPT0026660001	ed890dec-1258-11e9-afb9-0a9c39d33490	C3L-00770-02	1907a949-118a-11e9-afb9-0a9c39d33490	C3L-00770	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	"Uterus, NOS"	Uterine Corpus Endometrial Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0873732d-1cb5-4506-91b4-beb020c680b4	CPT0171630008	2ea9b1be-78d9-4e08-acc9-7ec107d23d64	C3L-01158-01	b3c36b01-fa4a-43d6-b387-b99a3eabf2af	C3L-01158	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3b7c4ae7-b529-42aa-be4e-964f71d7b1ab	CPT0171630014	2ea9b1be-78d9-4e08-acc9-7ec107d23d64	C3L-01158-01	b3c36b01-fa4a-43d6-b387-b99a3eabf2af	C3L-01158	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2fb26edd-593e-4471-ac58-80501ac54c50	CPT0171650052	beee57f8-e788-4bdf-9b0d-ea02d8aac71c	C3L-01158-05	b3c36b01-fa4a-43d6-b387-b99a3eabf2af	C3L-01158	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1dccf18a-adcd-4085-be36-81816f24e54b	CPT0171650000	beee57f8-e788-4bdf-9b0d-ea02d8aac71c	C3L-01158-05	b3c36b01-fa4a-43d6-b387-b99a3eabf2af	C3L-01158	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a9ad9315-fe2a-4a2c-9e47-6f2ad5d61e46	CPT0171650044	beee57f8-e788-4bdf-9b0d-ea02d8aac71c	C3L-01158-05	b3c36b01-fa4a-43d6-b387-b99a3eabf2af	C3L-01158	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2477115d-92c5-4499-9e5f-a904d6b362fa	core pool	6d1e45cf-66f3-4bf2-919e-20a8c4135c67	core pool	43015b48-4788-400e-a307-a9c7c9bc2555	core pool	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
684cd860-d5bd-49d8-abd1-af0be14a9cf1	CPT0170510008	c24046ca-21cc-466b-9383-7df6b63ddb33	C3L-01032-01	ffc0f05f-8915-4db9-ae61-f0cee8d80b2c	C3L-01032	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ffdcce01-d8f8-4978-bd6b-a0aaf6c0601c	CPT0170620030	1802b615-c15b-47af-b8bc-a3a85bb936ba	C3L-01160-05	aaa5ac4e-74c3-4d42-ae0d-f672aa3ed6da	C3L-01160	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5911e862-14e2-4fc6-b5ea-b3714a18c0c3	CPT0162300013	2b400dfc-c02c-4bd8-8835-e7557b4bea63	C3N-01897-01	047d297b-d99f-4f49-9744-11364d047dcf	C3N-01897	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9d2aeeb0-9778-47bf-aa26-a4b2905b09a9	CPT0187590010	365ca655-2d7c-4b30-8840-25d2544f8578	C3N-02590-01	3c96e1aa-43e1-47e2-84bb-0ea3a8624a71	C3N-02590	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1dd3c882-c1fe-4e01-ba54-1e5add18f04e	CPT0198600017	d484cb5b-0440-4b49-9d0c-66289e433e72	C3L-03624-02	477424c6-349d-4620-a354-24c6652da2e3	C3L-03624	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6f0d28a8-6f86-4408-b30e-c92326a74e98	CPT0198600000	d484cb5b-0440-4b49-9d0c-66289e433e72	C3L-03624-02	477424c6-349d-4620-a354-24c6652da2e3	C3L-03624	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3c84f235-06b3-4bc4-b4da-166a1ddf435c	CPT0171630000	2ea9b1be-78d9-4e08-acc9-7ec107d23d64	C3L-01158-01	b3c36b01-fa4a-43d6-b387-b99a3eabf2af	C3L-01158	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a704cdb0-93e3-4199-a8dd-933da1b948bb	CPT0187590000	365ca655-2d7c-4b30-8840-25d2544f8578	C3N-02590-01	3c96e1aa-43e1-47e2-84bb-0ea3a8624a71	C3N-02590	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
92e127e0-a2cb-4411-b086-aef0f76e7fa7	CPT0170600007	ebe5e481-caf0-445a-96be-e1735420511b	C3L-01160-01	aaa5ac4e-74c3-4d42-ae0d-f672aa3ed6da	C3L-01160	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ddf91d69-7c8d-475a-883a-93845b42b407	CPT0187590014	365ca655-2d7c-4b30-8840-25d2544f8578	C3N-02590-01	3c96e1aa-43e1-47e2-84bb-0ea3a8624a71	C3N-02590	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03a3a1e4-4ccc-4729-a2fd-3f001a1be96e	CPT0162300008	2b400dfc-c02c-4bd8-8835-e7557b4bea63	C3N-01897-01	047d297b-d99f-4f49-9744-11364d047dcf	C3N-01897	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b82f6fb7-75b2-4ebd-9660-edc71016e5c7	CPT0170530000	949973f1-00ca-47fb-adee-a411740d8532	C3L-01032-05	ffc0f05f-8915-4db9-ae61-f0cee8d80b2c	C3L-01032	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0df254c7-ffd7-4929-90d9-6fb1baf2fc72	CPT0198600011	d484cb5b-0440-4b49-9d0c-66289e433e72	C3L-03624-02	477424c6-349d-4620-a354-24c6652da2e3	C3L-03624	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bf66b3fa-c86c-4d9f-ae6e-cc548ad7478f	CPT0170510014	c24046ca-21cc-466b-9383-7df6b63ddb33	C3L-01032-01	ffc0f05f-8915-4db9-ae61-f0cee8d80b2c	C3L-01032	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
714de11d-f9e5-40cc-be7e-2537ef9e5ddd	CPT0162300000	2b400dfc-c02c-4bd8-8835-e7557b4bea63	C3N-01897-01	047d297b-d99f-4f49-9744-11364d047dcf	C3N-01897	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d5fa57e-11fc-41fd-9173-1e64d7572367	CPT0170600012	ebe5e481-caf0-445a-96be-e1735420511b	C3L-01160-01	aaa5ac4e-74c3-4d42-ae0d-f672aa3ed6da	C3L-01160	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
90e07c84-d4d3-4cfd-9cf1-048b7117b677	CPT0170600008	ebe5e481-caf0-445a-96be-e1735420511b	C3L-01160-01	aaa5ac4e-74c3-4d42-ae0d-f672aa3ed6da	C3L-01160	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a796e2cf-dd7f-47e5-8dab-28c5e835d072	CPT0170530027	949973f1-00ca-47fb-adee-a411740d8532	C3L-01032-05	ffc0f05f-8915-4db9-ae61-f0cee8d80b2c	C3L-01032	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10f1f18c-9cf0-4f25-9988-1d9976030776	CPT0170510010	c24046ca-21cc-466b-9383-7df6b63ddb33	C3L-01032-01	ffc0f05f-8915-4db9-ae61-f0cee8d80b2c	C3L-01032	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6f7dd476-0d56-441e-b3a2-2fe304a98305	CPT0170620000	1802b615-c15b-47af-b8bc-a3a85bb936ba	C3L-01160-05	aaa5ac4e-74c3-4d42-ae0d-f672aa3ed6da	C3L-01160	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dcc5106d-5262-44e9-841a-0cb13b211921	CPT0170620026	1802b615-c15b-47af-b8bc-a3a85bb936ba	C3L-01160-05	aaa5ac4e-74c3-4d42-ae0d-f672aa3ed6da	C3L-01160	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b9d448d7-6543-4dd9-ba59-68e552e74960	CPT0170530030	949973f1-00ca-47fb-adee-a411740d8532	C3L-01032-05	ffc0f05f-8915-4db9-ae61-f0cee8d80b2c	C3L-01032	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
91598dae-2053-11e9-b7f8-0a80fada099c	CPT0012570003	724088e6-204d-11e9-b7f8-0a80fada099c	C3N-00437-05	84411cf7-1fb9-11e9-b7f8-0a80fada099c	C3N-00437	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
53751736-2053-11e9-b7f8-0a80fada099c	CPT0000870016	75353fcb-204c-11e9-b7f8-0a80fada099c	C3L-00088-01	b445c2be-1fb8-11e9-b7f8-0a80fada099c	C3L-00088	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dbf3270e-2053-11e9-b7f8-0a80fada099c	CPT0077310003	e25b44ca-204d-11e9-b7f8-0a80fada099c	C3N-01524-03	aff10fc2-1fb9-11e9-b7f8-0a80fada099c	C3N-01524	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d60222d3-2053-11e9-b7f8-0a80fada099c	CPT0075560003	ce7f8464-204d-11e9-b7f8-0a80fada099c	C3N-01214-03	a767e303-1fb9-11e9-b7f8-0a80fada099c	C3N-01214	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a5fb996e-2053-11e9-b7f8-0a80fada099c	CPT0017850003	6bd52cbc-204d-11e9-b7f8-0a80fada099c	C3N-00435-05	82a380f2-1fb9-11e9-b7f8-0a80fada099c	C3N-00435	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
be054298-2053-11e9-b7f8-0a80fada099c	CPT0026420001	b8cb59d1-204c-11e9-b7f8-0a80fada099c	C3L-00791-02	dae8930e-1fb8-11e9-b7f8-0a80fada099c	C3L-00791	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
15d31398-2054-11e9-b7f8-0a80fada099c	CPT0092290003	16524cb1-204d-11e9-b7f8-0a80fada099c	C3L-01861-02	2e6540fd-1fb9-11e9-b7f8-0a80fada099c	C3L-01861	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
acb06978-2053-11e9-b7f8-0a80fada099c	CPT0020130001	368e55fb-204d-11e9-b7f8-0a80fada099c	C3N-00177-06	695400f2-1fb9-11e9-b7f8-0a80fada099c	C3N-00177	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d539e2ef-2053-11e9-b7f8-0a80fada099c	CPT0075170001	cb02100c-204d-11e9-b7f8-0a80fada099c	C3N-01200-06	a4300f90-1fb9-11e9-b7f8-0a80fada099c	C3N-01200	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
905f7baa-2053-11e9-b7f8-0a80fada099c	CPT0012550003	705881d9-204d-11e9-b7f8-0a80fada099c	C3N-00437-02	84411cf7-1fb9-11e9-b7f8-0a80fada099c	C3N-00437	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4d459888-2053-11e9-b7f8-0a80fada099c	CPT0000780007	7be7a634-204c-11e9-b7f8-0a80fada099c	C3L-00097-01	b76d3749-1fb8-11e9-b7f8-0a80fada099c	C3L-00097	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6070affc-2053-11e9-b7f8-0a80fada099c	CPT0001270001	73982b96-204c-11e9-b7f8-0a80fada099c	C3L-00079-06	b2aeaffe-1fb8-11e9-b7f8-0a80fada099c	C3L-00079	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
885ec533-2053-11e9-b7f8-0a80fada099c	CPT0010170001	9b7e4c21-204c-11e9-b7f8-0a80fada099c	C3L-00448-06	c78d3ad0-1fb8-11e9-b7f8-0a80fada099c	C3L-00448	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f77520ee-2053-11e9-b7f8-0a80fada099c	CPT0084560003	2623bd28-204d-11e9-b7f8-0a80fada099c	C3N-00149-02	61ea104e-1fb9-11e9-b7f8-0a80fada099c	C3N-00149	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bf9ec79a-2053-11e9-b7f8-0a80fada099c	CPT0063330001	d4ecbd48-204c-11e9-b7f8-0a80fada099c	C3L-00902-06	eb3dc37a-1fb8-11e9-b7f8-0a80fada099c	C3L-00902	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
92258546-2053-11e9-b7f8-0a80fada099c	CPT0012640003	74ccdefc-204d-11e9-b7f8-0a80fada099c	C3N-00491-02	85de9e26-1fb9-11e9-b7f8-0a80fada099c	C3N-00491	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c2d72c8-2054-11e9-b7f8-0a80fada099c	CPT0088780001	dcc57217-204d-11e9-b7f8-0a80fada099c	C3N-01361-06	ac5af110-1fb9-11e9-b7f8-0a80fada099c	C3N-01361	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64ddd86c-2053-11e9-b7f8-0a80fada099c	CPT0001510001	6fded9f7-204c-11e9-b7f8-0a80fada099c	C3L-00026-06	b118086f-1fb8-11e9-b7f8-0a80fada099c	C3L-00026	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f64a7c8-2053-11e9-b7f8-0a80fada099c	CPT0007470001	a390c4b5-204c-11e9-b7f8-0a80fada099c	C3L-00581-06	caf0e98e-1fb8-11e9-b7f8-0a80fada099c	C3L-00581	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8eba312d-2053-11e9-b7f8-0a80fada099c	CPT0012290003	603229bf-204d-11e9-b7f8-0a80fada099c	C3N-00317-05	7bfae873-1fb9-11e9-b7f8-0a80fada099c	C3N-00317	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0d281254-2054-11e9-b7f8-0a80fada099c	CPT0088900003	c1d76bd7-204d-11e9-b7f8-0a80fada099c	C3N-01179-01	a0f46ace-1fb9-11e9-b7f8-0a80fada099c	C3N-01179	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f221a71b-2053-11e9-b7f8-0a80fada099c	CPT0079510001	e7c6ab7a-204c-11e9-b7f8-0a80fada099c	C3L-01281-06	0a72ab09-1fb9-11e9-b7f8-0a80fada099c	C3L-01281	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d35bf686-2053-11e9-b7f8-0a80fada099c	CPT0071150004	00b54352-204d-11e9-b7f8-0a80fada099c	"C3L-01352-01, C3L-01352-02"	15a3cb22-1fb9-11e9-b7f8-0a80fada099c	C3L-01352	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f97c38c6-2053-11e9-b7f8-0a80fada099c	CPT0085670003	04d55a38-204d-11e9-b7f8-0a80fada099c	C3L-01557-01	20e173fc-1fb9-11e9-b7f8-0a80fada099c	C3L-01557	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cb92eb25-2053-11e9-b7f8-0a80fada099c	CPT0066470004	8498ede7-204c-11e9-b7f8-0a80fada099c	"C3L-00183-03, C3L-00183-05"	bc4ae19c-1fb8-11e9-b7f8-0a80fada099c	C3L-00183	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0986e931-2054-11e9-b7f8-0a80fada099c	CPT0088690003	f24761ae-204d-11e9-b7f8-0a80fada099c	C3N-01651-01	b8514a40-1fb9-11e9-b7f8-0a80fada099c	C3N-01651	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
07e62862-2054-11e9-b7f8-0a80fada099c	CPT0088630003	ee937d7d-204d-11e9-b7f8-0a80fada099c	C3N-01649-02	b6b4f9ee-1fb9-11e9-b7f8-0a80fada099c	C3N-01649	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fb835187-2053-11e9-b7f8-0a80fada099c	CPT0086360003	da93e2c6-204c-11e9-b7f8-0a80fada099c	C3L-00908-03	ee6b0cb5-1fb8-11e9-b7f8-0a80fada099c	C3L-00908	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e20f82c0-2053-11e9-b7f8-0a80fada099c	CPT0078660003	b7a4afa3-204d-11e9-b7f8-0a80fada099c	C3N-01175-01	9bebecf3-1fb9-11e9-b7f8-0a80fada099c	C3N-01175	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4f9821f1-2053-11e9-b7f8-0a80fada099c	CPT0000790001	7e25284f-204c-11e9-b7f8-0a80fada099c	C3L-00097-06	b76d3749-1fb8-11e9-b7f8-0a80fada099c	C3L-00097	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c2e473d7-2053-11e9-b7f8-0a80fada099c	CPT0064400001	d8ec6129-204c-11e9-b7f8-0a80fada099c	C3L-00907-06	ecd1a90e-1fb8-11e9-b7f8-0a80fada099c	C3L-00907	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a3197bc4-2053-11e9-b7f8-0a80fada099c	CPT0015910003	b223c344-204c-11e9-b7f8-0a80fada099c	C3L-00765-01	d43bcf73-1fb8-11e9-b7f8-0a80fada099c	C3L-00765	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c8e39c2a-2053-11e9-b7f8-0a80fada099c	CPT0065870003	ca2fe14a-204c-11e9-b7f8-0a80fada099c	C3L-00817-01	e9ac28c9-1fb8-11e9-b7f8-0a80fada099c	C3L-00817	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ef59c2bc-2053-11e9-b7f8-0a80fada099c	CPT0079410003	f0d4bf39-204c-11e9-b7f8-0a80fada099c	C3L-01287-02	0f345723-1fb9-11e9-b7f8-0a80fada099c	C3L-01287	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b27dfff1-2053-11e9-b7f8-0a80fada099c	CPT0024680001	b1d3f574-204d-11e9-b7f8-0a80fada099c	C3N-00852-06	987b103d-1fb9-11e9-b7f8-0a80fada099c	C3N-00852	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a3e44d5a-2053-11e9-b7f8-0a80fada099c	CPT0017410003	67b64ec8-204d-11e9-b7f8-0a80fada099c	C3N-00390-02	810c2c81-1fb9-11e9-b7f8-0a80fada099c	C3N-00390	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0138f4b-2053-11e9-b7f8-0a80fada099c	CPT0023690003	e2be63e9-204c-11e9-b7f8-0a80fada099c	C3L-00917-01	f1909c4f-1fb8-11e9-b7f8-0a80fada099c	C3L-00917	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d7f24a7-2053-11e9-b7f8-0a80fada099c	CPT0001220008	65eefbda-204c-11e9-b7f8-0a80fada099c	C3L-00010-01	ade302cd-1fb8-11e9-b7f8-0a80fada099c	C3L-00010	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d12f7891-2053-11e9-b7f8-0a80fada099c	CPT0069160003	9b69ad2d-204d-11e9-b7f8-0a80fada099c	C3N-00577-02	8e59b323-1fb9-11e9-b7f8-0a80fada099c	C3N-00577	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e61fac48-2053-11e9-b7f8-0a80fada099c	CPT0078930003	bb1024a6-204d-11e9-b7f8-0a80fada099c	C3N-01176-01	9d8e171a-1fb9-11e9-b7f8-0a80fada099c	C3N-01176	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
858dc2df-2053-11e9-b7f8-0a80fada099c	CPT0010110003	8e8ff266-204c-11e9-b7f8-0a80fada099c	C3L-00416-02	c2b91945-1fb8-11e9-b7f8-0a80fada099c	C3L-00416	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
af16a68f-2053-11e9-b7f8-0a80fada099c	CPT0023360001	9f01ab45-204c-11e9-b7f8-0a80fada099c	C3L-00561-06	c9556afa-1fb8-11e9-b7f8-0a80fada099c	C3L-00561	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9ad19a79-2053-11e9-b7f8-0a80fada099c	CPT0014370004	40350dbe-204d-11e9-b7f8-0a80fada099c	"C3N-00244-01, C3N-00244-02, C3N-00244-03"	6e67aadb-1fb9-11e9-b7f8-0a80fada099c	C3N-00244	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ed591c66-2053-11e9-b7f8-0a80fada099c	CPT0079300001	aa660472-204c-11e9-b7f8-0a80fada099c	C3L-00606-06	ce22af84-1fb8-11e9-b7f8-0a80fada099c	C3L-00606	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c06bd10b-2053-11e9-b7f8-0a80fada099c	CPT0063630003	f7b570ea-204c-11e9-b7f8-0a80fada099c	C3L-01302-03	12689277-1fb9-11e9-b7f8-0a80fada099c	C3L-01302	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ee7c02f9-2053-11e9-b7f8-0a80fada099c	CPT0079380003	e9f56258-204c-11e9-b7f8-0a80fada099c	C3L-01283-01	0c06c8bd-1fb9-11e9-b7f8-0a80fada099c	C3L-01283	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
faad7a51-2053-11e9-b7f8-0a80fada099c	CPT0086030003	06e1bb9f-204d-11e9-b7f8-0a80fada099c	C3L-01560-01	227bf2e8-1fb9-11e9-b7f8-0a80fada099c	C3L-01560	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9f0ef73c-2053-11e9-b7f8-0a80fada099c	CPT0015810003	c4393499-204c-11e9-b7f8-0a80fada099c	C3L-00813-01	e4a0071d-1fb8-11e9-b7f8-0a80fada099c	C3L-00813	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a8451484-2053-11e9-b7f8-0a80fada099c	CPT0019130003	a51fb8fe-204c-11e9-b7f8-0a80fada099c	C3L-00583-01	cc8a63fd-1fb8-11e9-b7f8-0a80fada099c	C3L-00583	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03e278f2-2054-11e9-b7f8-0a80fada099c	CPT0087050003	0a491feb-204d-11e9-b7f8-0a80fada099c	C3L-01603-06	241693ab-1fb9-11e9-b7f8-0a80fada099c	C3L-01603	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b1accc22-2053-11e9-b7f8-0a80fada099c	CPT0024670003	afbd986d-204d-11e9-b7f8-0a80fada099c	C3N-00852-03	987b103d-1fb9-11e9-b7f8-0a80fada099c	C3N-00852	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
04b2aee8-2054-11e9-b7f8-0a80fada099c	CPT0088480003	e6d1a940-204d-11e9-b7f8-0a80fada099c	C3N-01646-01	b325c35f-1fb9-11e9-b7f8-0a80fada099c	C3N-01646	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
820e7e1f-2053-11e9-b7f8-0a80fada099c	CPT0009000003	4bf5eb59-204d-11e9-b7f8-0a80fada099c	C3N-00310-03	73b649eb-1fb9-11e9-b7f8-0a80fada099c	C3N-00310	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ce7c37fb-2053-11e9-b7f8-0a80fada099c	CPT0069000003	980e537b-204d-11e9-b7f8-0a80fada099c	C3N-00573-04	8cbd7a01-1fb9-11e9-b7f8-0a80fada099c	C3N-00573	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8659f104-2053-11e9-b7f8-0a80fada099c	CPT0010120001	908fbac8-204c-11e9-b7f8-0a80fada099c	C3L-00416-06	c2b91945-1fb8-11e9-b7f8-0a80fada099c	C3L-00416	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c742f8ec-2053-11e9-b7f8-0a80fada099c	CPT0065810003	c65c174d-204c-11e9-b7f8-0a80fada099c	C3L-00814-01	e63a8d1a-1fb8-11e9-b7f8-0a80fada099c	C3L-00814	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1acbd2cb-2054-11e9-b7f8-0a80fada099c	CPT0092800003	202672ce-204d-11e9-b7f8-0a80fada099c	C3L-01885-06	3346ca6e-1fb9-11e9-b7f8-0a80fada099c	C3L-01885	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fc4fb74c-2053-11e9-b7f8-0a80fada099c	CPT0086370003	dc2b8047-204c-11e9-b7f8-0a80fada099c	C3L-00908-06	ee6b0cb5-1fb8-11e9-b7f8-0a80fada099c	C3L-00908	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7cb022cf-2053-11e9-b7f8-0a80fada099c	CPT0006900003	9630dc9f-204c-11e9-b7f8-0a80fada099c	C3L-00447-02	c5f8631d-1fb8-11e9-b7f8-0a80fada099c	C3L-00447	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5f6434ad-2053-11e9-b7f8-0a80fada099c	CPT0001260009	71bc0515-204c-11e9-b7f8-0a80fada099c	C3L-00079-01	b2aeaffe-1fb8-11e9-b7f8-0a80fada099c	C3L-00079	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
19d0521c-2054-11e9-b7f8-0a80fada099c	CPT0092790003	1e4475ff-204d-11e9-b7f8-0a80fada099c	C3L-01885-03	3346ca6e-1fb9-11e9-b7f8-0a80fada099c	C3L-01885	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9e2bb964-2053-11e9-b7f8-0a80fada099c	CPT0015730003	bb1f3990-204c-11e9-b7f8-0a80fada099c	C3L-00792-01	dc7bd788-1fb8-11e9-b7f8-0a80fada099c	C3L-00792	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f5916838-2053-11e9-b7f8-0a80fada099c	CPT0081990003	a07f6826-204d-11e9-b7f8-0a80fada099c	C3N-00646-03	901a5db5-1fb9-11e9-b7f8-0a80fada099c	C3N-00646	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a6c6e30-2053-11e9-b7f8-0a80fada099c	CPT0002370001	89b29b3b-204c-11e9-b7f8-0a80fada099c	C3L-00360-06	bf7ade95-1fb8-11e9-b7f8-0a80fada099c	C3L-00360	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
87624ed1-2053-11e9-b7f8-0a80fada099c	CPT0010160003	996c819b-204c-11e9-b7f8-0a80fada099c	C3L-00448-01	c78d3ad0-1fb8-11e9-b7f8-0a80fada099c	C3L-00448	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
17d44044-2054-11e9-b7f8-0a80fada099c	CPT0092730003	1a057d68-204d-11e9-b7f8-0a80fada099c	C3L-01882-01	31acb306-1fb9-11e9-b7f8-0a80fada099c	C3L-01882	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
12e9e8fc-2054-11e9-b7f8-0a80fada099c	CPT0089480003	f7ff6095-204d-11e9-b7f8-0a80fada099c	C3N-01808-06	c31ccaca-1fb9-11e9-b7f8-0a80fada099c	C3N-01808	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae4c8249-2053-11e9-b7f8-0a80fada099c	CPT0023350003	9d3cd667-204c-11e9-b7f8-0a80fada099c	C3L-00561-01	c9556afa-1fb8-11e9-b7f8-0a80fada099c	C3L-00561	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
67338432-2053-11e9-b7f8-0a80fada099c	CPT0001550001	63fb3588-204c-11e9-b7f8-0a80fada099c	C3L-00004-06	ac4960f0-1fb8-11e9-b7f8-0a80fada099c	C3L-00004	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
99f0a620-2053-11e9-b7f8-0a80fada099c	CPT0014350001	41fed6c6-204d-11e9-b7f8-0a80fada099c	C3N-00244-06	6e67aadb-1fb9-11e9-b7f8-0a80fada099c	C3N-00244	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db253409-2053-11e9-b7f8-0a80fada099c	CPT0077140001	e0ac260f-204d-11e9-b7f8-0a80fada099c	C3N-01522-06	ae0489d0-1fb9-11e9-b7f8-0a80fada099c	C3N-01522	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0ebc2c10-2054-11e9-b7f8-0a80fada099c	CPT0088970003	c6665806-204d-11e9-b7f8-0a80fada099c	C3N-01180-01	a296befc-1fb9-11e9-b7f8-0a80fada099c	C3N-01180	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d6e1efd5-2053-11e9-b7f8-0a80fada099c	CPT0075570001	d0f841b6-204d-11e9-b7f8-0a80fada099c	C3N-01214-06	a767e303-1fb9-11e9-b7f8-0a80fada099c	C3N-01214	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9ba114ad-2053-11e9-b7f8-0a80fada099c	CPT0014450004	3c78841a-204d-11e9-b7f8-0a80fada099c	"C3N-00242-01, C3N-00242-02"	6ca0d37c-1fb9-11e9-b7f8-0a80fada099c	C3N-00242	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c21a6173-2053-11e9-b7f8-0a80fada099c	CPT0064370003	d6f7be55-204c-11e9-b7f8-0a80fada099c	C3L-00907-01	ecd1a90e-1fb8-11e9-b7f8-0a80fada099c	C3L-00907	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59a6a989-2053-11e9-b7f8-0a80fada099c	CPT0000890001	76b8e57f-204c-11e9-b7f8-0a80fada099c	C3L-00088-06	b445c2be-1fb8-11e9-b7f8-0a80fada099c	C3L-00088	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ff9881af-2053-11e9-b7f8-0a80fada099c	CPT0086870003	122d192d-204d-11e9-b7f8-0a80fada099c	C3L-01836-02	2c9d2692-1fb9-11e9-b7f8-0a80fada099c	C3L-01836	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
82f7a76b-2053-11e9-b7f8-0a80fada099c	CPT0009020003	4eef9ce2-204d-11e9-b7f8-0a80fada099c	C3N-00310-05	73b649eb-1fb9-11e9-b7f8-0a80fada099c	C3N-00310	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cab02680-2053-11e9-b7f8-0a80fada099c	CPT0066430001	82def6f7-204c-11e9-b7f8-0a80fada099c	C3L-00183-02	bc4ae19c-1fb8-11e9-b7f8-0a80fada099c	C3L-00183	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
848b99fe-2053-11e9-b7f8-0a80fada099c	CPT0009080003	538887c1-204d-11e9-b7f8-0a80fada099c	C3N-00312-05	754db279-1fb9-11e9-b7f8-0a80fada099c	C3N-00312	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0e49b69-2053-11e9-b7f8-0a80fada099c	CPT0023710001	e47b6ab6-204c-11e9-b7f8-0a80fada099c	C3L-00917-06	f1909c4f-1fb8-11e9-b7f8-0a80fada099c	C3L-00917	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c59c0fac-2053-11e9-b7f8-0a80fada099c	CPT0065690003	b5760324-204c-11e9-b7f8-0a80fada099c	C3L-00790-01	d95673ac-1fb8-11e9-b7f8-0a80fada099c	C3L-00790	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e6eb058b-2053-11e9-b7f8-0a80fada099c	CPT0078940001	bc93c54c-204d-11e9-b7f8-0a80fada099c	C3N-01176-05	9d8e171a-1fb9-11e9-b7f8-0a80fada099c	C3N-01176	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b99be172-2053-11e9-b7f8-0a80fada099c	CPT0025580004	444dba93-204d-11e9-b7f8-0a80fada099c	"C3N-00246-01, C3N-00246-02, C3N-00246-03"	7001a54f-1fb9-11e9-b7f8-0a80fada099c	C3N-00246	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
664fbd43-2053-11e9-b7f8-0a80fada099c	CPT0001540009	6240511e-204c-11e9-b7f8-0a80fada099c	C3L-00004-01	ac4960f0-1fb8-11e9-b7f8-0a80fada099c	C3L-00004	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e06bb96f-2053-11e9-b7f8-0a80fada099c	CPT0078530001	96119bce-204d-11e9-b7f8-0a80fada099c	C3N-00495-05	8b0fd240-1fb9-11e9-b7f8-0a80fada099c	C3N-00495	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10c8f4d7-2054-11e9-b7f8-0a80fada099c	CPT0089040001	a9114454-204d-11e9-b7f8-0a80fada099c	C3N-00831-05	9361a39d-1fb9-11e9-b7f8-0a80fada099c	C3N-00831	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7dc52b7d-2053-11e9-b7f8-0a80fada099c	CPT0006950001	97ce9086-204c-11e9-b7f8-0a80fada099c	C3L-00447-06	c5f8631d-1fb8-11e9-b7f8-0a80fada099c	C3L-00447	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b8cd9dff-2053-11e9-b7f8-0a80fada099c	CPT0025350003	c263ed01-204c-11e9-b7f8-0a80fada099c	C3L-00812-01	e30c24ef-1fb8-11e9-b7f8-0a80fada099c	C3L-00812	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0a5631c7-2054-11e9-b7f8-0a80fada099c	CPT0088710001	f4299e8d-204d-11e9-b7f8-0a80fada099c	C3N-01651-10	b8514a40-1fb9-11e9-b7f8-0a80fada099c	C3N-01651	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
94ba8798-2053-11e9-b7f8-0a80fada099c	CPT0012900004	8f2dcc7e-204d-11e9-b7f8-0a80fada099c	"C3N-00494-02, C3N-00494-03"	8966aab1-1fb9-11e9-b7f8-0a80fada099c	C3N-00494	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6cd5f341-2053-11e9-b7f8-0a80fada099c	CPT0006440003	8b83ea22-204c-11e9-b7f8-0a80fada099c	C3L-00369-01	c1195940-1fb8-11e9-b7f8-0a80fada099c	C3L-00369	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a946e1bf-2053-11e9-b7f8-0a80fada099c	CPT0019160001	a6e9da6a-204c-11e9-b7f8-0a80fada099c	C3L-00583-06	cc8a63fd-1fb8-11e9-b7f8-0a80fada099c	C3L-00583	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e554c1bc-2053-11e9-b7f8-0a80fada099c	CPT0078840001	aded59d8-204d-11e9-b7f8-0a80fada099c	C3N-00834-05	96d4ed52-1fb9-11e9-b7f8-0a80fada099c	C3N-00834	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b483c688-2053-11e9-b7f8-0a80fada099c	CPT0025060001	ae645749-204c-11e9-b7f8-0a80fada099c	C3L-00607-02	cfd3d3fd-1fb8-11e9-b7f8-0a80fada099c	C3L-00607	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d06075c2-2053-11e9-b7f8-0a80fada099c	CPT0069010001	99d0348d-204d-11e9-b7f8-0a80fada099c	C3N-00573-06	8cbd7a01-1fb9-11e9-b7f8-0a80fada099c	C3N-00573	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cc5d8c5e-2053-11e9-b7f8-0a80fada099c	CPT0066480003	2964fdc0-204d-11e9-b7f8-0a80fada099c	C3N-00150-01	6386852c-1fb9-11e9-b7f8-0a80fada099c	C3N-00150	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de9a8037-2053-11e9-b7f8-0a80fada099c	CPT0077500001	d8db02e0-204d-11e9-b7f8-0a80fada099c	C3N-01261-06	aaa7336a-1fb9-11e9-b7f8-0a80fada099c	C3N-01261	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8df23afe-2053-11e9-b7f8-0a80fada099c	CPT0012280003	5e4a6fe0-204d-11e9-b7f8-0a80fada099c	C3N-00317-04	7bfae873-1fb9-11e9-b7f8-0a80fada099c	C3N-00317	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb9861c9-2053-11e9-b7f8-0a80fada099c	CPT0025880003	a3b10dc8-204d-11e9-b7f8-0a80fada099c	C3N-00733-01	91b4e8bc-1fb9-11e9-b7f8-0a80fada099c	C3N-00733	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b7183efe-2053-11e9-b7f8-0a80fada099c	CPT0025230003	be9debc1-204c-11e9-b7f8-0a80fada099c	C3L-00799-01	dfc9d964-1fb8-11e9-b7f8-0a80fada099c	C3L-00799	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a73df512-2053-11e9-b7f8-0a80fada099c	CPT0018250001	6d74fa3d-204d-11e9-b7f8-0a80fada099c	C3N-00435-06	82a380f2-1fb9-11e9-b7f8-0a80fada099c	C3N-00435	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8b0601ba-2053-11e9-b7f8-0a80fada099c	CPT0012080003	5831d54a-204d-11e9-b7f8-0a80fada099c	C3N-00314-04	78a71616-1fb9-11e9-b7f8-0a80fada099c	C3N-00314	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6f2a42d9-2053-11e9-b7f8-0a80fada099c	CPT0006530001	8d0f0479-204c-11e9-b7f8-0a80fada099c	C3L-00369-06	c1195940-1fb8-11e9-b7f8-0a80fada099c	C3L-00369	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6232ada8-2053-11e9-b7f8-0a80fada099c	CPT0001350001	6c5d0dd0-204c-11e9-b7f8-0a80fada099c	C3L-00011-06	af7c2225-1fb8-11e9-b7f8-0a80fada099c	C3L-00011	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
67fd9d0c-2053-11e9-b7f8-0a80fada099c	CPT0002270011	86641cf5-204c-11e9-b7f8-0a80fada099c	C3L-00359-01	bddeedd9-1fb8-11e9-b7f8-0a80fada099c	C3L-00359	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9699e606-2053-11e9-b7f8-0a80fada099c	CPT0013790003	6449d306-204d-11e9-b7f8-0a80fada099c	C3N-00320-05	7d95243f-1fb9-11e9-b7f8-0a80fada099c	C3N-00320	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa1c3fef-2053-11e9-b7f8-0a80fada099c	CPT0019990003	2edad2f4-204d-11e9-b7f8-0a80fada099c	C3N-00168-02	675d0c38-1fb9-11e9-b7f8-0a80fada099c	C3N-00168	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
08b7e712-2054-11e9-b7f8-0a80fada099c	CPT0088640003	f09033ee-204d-11e9-b7f8-0a80fada099c	C3N-01649-10	b6b4f9ee-1fb9-11e9-b7f8-0a80fada099c	C3N-01649	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e5ff060-2053-11e9-b7f8-0a80fada099c	CPT0001230001	688b503e-204c-11e9-b7f8-0a80fada099c	C3L-00010-06	ade302cd-1fb8-11e9-b7f8-0a80fada099c	C3L-00010	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b3af4a84-2053-11e9-b7f8-0a80fada099c	CPT0025050003	ac9d0ff9-204c-11e9-b7f8-0a80fada099c	C3L-00607-01	cfd3d3fd-1fb8-11e9-b7f8-0a80fada099c	C3L-00607	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bd34fbb3-2053-11e9-b7f8-0a80fada099c	CPT0026410003	b72322c6-204c-11e9-b7f8-0a80fada099c	C3L-00791-01	dae8930e-1fb8-11e9-b7f8-0a80fada099c	C3L-00791	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fd90e5e8-2053-11e9-b7f8-0a80fada099c	CPT0086820003	fbfa1f47-204c-11e9-b7f8-0a80fada099c	C3L-01313-03	14074e8f-1fb9-11e9-b7f8-0a80fada099c	C3L-01313	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
89331156-2053-11e9-b7f8-0a80fada099c	CPT0011240003	491bfee6-204d-11e9-b7f8-0a80fada099c	C3N-00305-02	71a049ed-1fb9-11e9-b7f8-0a80fada099c	C3N-00305	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01f9a8a7-2054-11e9-b7f8-0a80fada099c	CPT0086970003	edd548f5-204c-11e9-b7f8-0a80fada099c	C3L-01286-06	0d99be24-1fb9-11e9-b7f8-0a80fada099c	C3L-01286	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd83e35b-2053-11e9-b7f8-0a80fada099c	CPT0066520001	2b2b1036-204d-11e9-b7f8-0a80fada099c	C3N-00150-06	6386852c-1fb9-11e9-b7f8-0a80fada099c	C3N-00150	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
95bc5c0c-2053-11e9-b7f8-0a80fada099c	CPT0012920003	9176bb5d-204d-11e9-b7f8-0a80fada099c	C3N-00494-05	8966aab1-1fb9-11e9-b7f8-0a80fada099c	C3N-00494	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da2cf998-2053-11e9-b7f8-0a80fada099c	CPT0077110003	dec911f0-204d-11e9-b7f8-0a80fada099c	C3N-01522-01	ae0489d0-1fb9-11e9-b7f8-0a80fada099c	C3N-01522	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ec75810f-2053-11e9-b7f8-0a80fada099c	CPT0079270003	a8b3330a-204c-11e9-b7f8-0a80fada099c	C3L-00606-01	ce22af84-1fb8-11e9-b7f8-0a80fada099c	C3L-00606	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1191606f-2054-11e9-b7f8-0a80fada099c	CPT0089460004	f5f2482d-204d-11e9-b7f8-0a80fada099c	"C3N-01808-02, C3N-01808-03"	c31ccaca-1fb9-11e9-b7f8-0a80fada099c	C3N-01808	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bed318fc-2053-11e9-b7f8-0a80fada099c	CPT0063320003	ccb725f4-204c-11e9-b7f8-0a80fada099c	C3L-00902-02	eb3dc37a-1fb8-11e9-b7f8-0a80fada099c	C3L-00902	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d9591f45-2053-11e9-b7f8-0a80fada099c	CPT0076350001	d447f891-204d-11e9-b7f8-0a80fada099c	C3N-01220-06	a90d356a-1fb9-11e9-b7f8-0a80fada099c	C3N-01220	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fe57f949-2053-11e9-b7f8-0a80fada099c	CPT0086830003	fdece182-204c-11e9-b7f8-0a80fada099c	C3L-01313-06	14074e8f-1fb9-11e9-b7f8-0a80fada099c	C3L-01313	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c8117eba-2053-11e9-b7f8-0a80fada099c	CPT0065820001	c85b0efd-204c-11e9-b7f8-0a80fada099c	C3L-00814-02	e63a8d1a-1fb8-11e9-b7f8-0a80fada099c	C3L-00814	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
012c44e4-2054-11e9-b7f8-0a80fada099c	CPT0086950003	ebe5374c-204c-11e9-b7f8-0a80fada099c	C3L-01286-02	0d99be24-1fb9-11e9-b7f8-0a80fada099c	C3L-01286	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dcbb61d1-2053-11e9-b7f8-0a80fada099c	CPT0077320001	e46343f9-204d-11e9-b7f8-0a80fada099c	C3N-01524-06	aff10fc2-1fb9-11e9-b7f8-0a80fada099c	C3N-01524	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
45faaa52-2053-11e9-b7f8-0a80fada099c	CPT0000640003	7fa0d903-204c-11e9-b7f8-0a80fada099c	C3L-00103-02	b9017fed-1fb8-11e9-b7f8-0a80fada099c	C3L-00103	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0064556c-2054-11e9-b7f8-0a80fada099c	CPT0086890003	149392b0-204d-11e9-b7f8-0a80fada099c	C3L-01836-06	2c9d2692-1fb9-11e9-b7f8-0a80fada099c	C3L-01836	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48b575ca-2053-11e9-b7f8-0a80fada099c	CPT0000660001	8165afd5-204c-11e9-b7f8-0a80fada099c	C3L-00103-06	b9017fed-1fb8-11e9-b7f8-0a80fada099c	C3L-00103	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6338743e-2053-11e9-b7f8-0a80fada099c	CPT0001500009	6e266f02-204c-11e9-b7f8-0a80fada099c	C3L-00026-01	b118086f-1fb8-11e9-b7f8-0a80fada099c	C3L-00026	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
93e0b56d-2053-11e9-b7f8-0a80fada099c	CPT0012770003	8d39bb06-204d-11e9-b7f8-0a80fada099c	C3N-00492-05	87b7a6db-1fb9-11e9-b7f8-0a80fada099c	C3N-00492	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aae4af3e-2053-11e9-b7f8-0a80fada099c	CPT0020020001	31a9e5e0-204d-11e9-b7f8-0a80fada099c	C3N-00168-06	675d0c38-1fb9-11e9-b7f8-0a80fada099c	C3N-00168	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f4c2fe53-2053-11e9-b7f8-0a80fada099c	CPT0081880003	2d0994b2-204d-11e9-b7f8-0a80fada099c	C3N-00154-04	65556ece-1fb9-11e9-b7f8-0a80fada099c	C3N-00154	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e2dc3c41-2053-11e9-b7f8-0a80fada099c	CPT0078670001	b978469d-204d-11e9-b7f8-0a80fada099c	C3N-01175-05	9bebecf3-1fb9-11e9-b7f8-0a80fada099c	C3N-01175	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f88aa0f-2054-11e9-b7f8-0a80fada099c	CPT0089020003	a72b75d4-204d-11e9-b7f8-0a80fada099c	C3N-00831-01	9361a39d-1fb9-11e9-b7f8-0a80fada099c	C3N-00831	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7e98f5d2-2053-11e9-b7f8-0a80fada099c	CPT0007320003	a1a3a269-204c-11e9-b7f8-0a80fada099c	C3L-00581-01	caf0e98e-1fb8-11e9-b7f8-0a80fada099c	C3L-00581	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e3aab02b-2053-11e9-b7f8-0a80fada099c	CPT0078800003	aac0b0c5-204d-11e9-b7f8-0a80fada099c	C3N-00832-01	94fe058e-1fb9-11e9-b7f8-0a80fada099c	C3N-00832	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea45839d-2053-11e9-b7f8-0a80fada099c	CPT0079180003	7879ca88-204d-11e9-b7f8-0a80fada099c	C3N-00492-04	87b7a6db-1fb9-11e9-b7f8-0a80fada099c	C3N-00492	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
97637c91-2053-11e9-b7f8-0a80fada099c	CPT0014130001	3a5dd901-204d-11e9-b7f8-0a80fada099c	C3N-00194-06	6aeed922-1fb9-11e9-b7f8-0a80fada099c	C3N-00194	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8d29bd68-2053-11e9-b7f8-0a80fada099c	CPT0012180003	5c73da50-204d-11e9-b7f8-0a80fada099c	C3N-00315-03	7a618496-1fb9-11e9-b7f8-0a80fada099c	C3N-00315	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c4d3ef91-2053-11e9-b7f8-0a80fada099c	CPT0065450001	b5d5b153-204d-11e9-b7f8-0a80fada099c	C3N-00953-06	9a4966c2-1fb9-11e9-b7f8-0a80fada099c	C3N-00953	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f854c681-2053-11e9-b7f8-0a80fada099c	CPT0084590001	27cb601d-204d-11e9-b7f8-0a80fada099c	C3N-00149-06	61ea104e-1fb9-11e9-b7f8-0a80fada099c	C3N-00149	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
189cdaa0-2054-11e9-b7f8-0a80fada099c	CPT0092740003	1c17b4c6-204d-11e9-b7f8-0a80fada099c	C3L-01882-06	31acb306-1fb9-11e9-b7f8-0a80fada099c	C3L-01882	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b7ebe6a4-2053-11e9-b7f8-0a80fada099c	CPT0025290003	c08cbe25-204c-11e9-b7f8-0a80fada099c	C3L-00800-01	e169f383-1fb8-11e9-b7f8-0a80fada099c	C3L-00800	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8ef690e-2053-11e9-b7f8-0a80fada099c	CPT0079000001	c02d012f-204d-11e9-b7f8-0a80fada099c	C3N-01178-05	9f588023-1fb9-11e9-b7f8-0a80fada099c	C3N-01178	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a79f564-2053-11e9-b7f8-0a80fada099c	CPT0001180009	787def6b-204c-11e9-b7f8-0a80fada099c	C3L-00096-01	b5d88141-1fb8-11e9-b7f8-0a80fada099c	C3L-00096	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba9a14f6-2053-11e9-b7f8-0a80fada099c	CPT0025610001	45cf164e-204d-11e9-b7f8-0a80fada099c	C3N-00246-06	7001a54f-1fb9-11e9-b7f8-0a80fada099c	C3N-00246	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dd849244-2053-11e9-b7f8-0a80fada099c	CPT0077490003	d6d4053d-204d-11e9-b7f8-0a80fada099c	C3N-01261-03	aaa7336a-1fb9-11e9-b7f8-0a80fada099c	C3N-01261	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1509b20-2053-11e9-b7f8-0a80fada099c	CPT0079480003	e611d742-204c-11e9-b7f8-0a80fada099c	C3L-01281-01	0a72ab09-1fb9-11e9-b7f8-0a80fada099c	C3L-01281	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
abb2dce4-2053-11e9-b7f8-0a80fada099c	CPT0020120003	3434a355-204d-11e9-b7f8-0a80fada099c	C3N-00177-03	695400f2-1fb9-11e9-b7f8-0a80fada099c	C3N-00177	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d87f3759-2053-11e9-b7f8-0a80fada099c	CPT0076330003	d2c3464f-204d-11e9-b7f8-0a80fada099c	C3N-01220-02	a90d356a-1fb9-11e9-b7f8-0a80fada099c	C3N-01220	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f6a1ab36-2053-11e9-b7f8-0a80fada099c	CPT0082010001	a238b6ee-204d-11e9-b7f8-0a80fada099c	C3N-00646-06	901a5db5-1fb9-11e9-b7f8-0a80fada099c	C3N-00646	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6925bdc4-2053-11e9-b7f8-0a80fada099c	CPT0002350011	87e49ce8-204c-11e9-b7f8-0a80fada099c	C3L-00360-01	bf7ade95-1fb8-11e9-b7f8-0a80fada099c	C3L-00360	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
712733c4-2053-11e9-b7f8-0a80fada099c	CPT0006630003	92755b36-204c-11e9-b7f8-0a80fada099c	C3L-00418-01	c455fb22-1fb8-11e9-b7f8-0a80fada099c	C3L-00418	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
92f01328-2053-11e9-b7f8-0a80fada099c	CPT0012670003	767653ca-204d-11e9-b7f8-0a80fada099c	C3N-00491-05	85de9e26-1fb9-11e9-b7f8-0a80fada099c	C3N-00491	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e7ebb428-2053-11e9-b7f8-0a80fada099c	CPT0078990003	be50c407-204d-11e9-b7f8-0a80fada099c	C3N-01178-02	9f588023-1fb9-11e9-b7f8-0a80fada099c	C3N-01178	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b5826276-2053-11e9-b7f8-0a80fada099c	CPT0025110003	b018dc5e-204c-11e9-b7f8-0a80fada099c	C3L-00610-01	d1f00743-1fb8-11e9-b7f8-0a80fada099c	C3L-00610	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7bd5e41d-2053-11e9-b7f8-0a80fada099c	CPT0006730001	942e2494-204c-11e9-b7f8-0a80fada099c	C3L-00418-06	c455fb22-1fb8-11e9-b7f8-0a80fada099c	C3L-00418	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0715fd5a-2054-11e9-b7f8-0a80fada099c	CPT0088570001	ecc2bf49-204d-11e9-b7f8-0a80fada099c	C3N-01648-08	b5158703-1fb9-11e9-b7f8-0a80fada099c	C3N-01648	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb78ba07-2053-11e9-b7f8-0a80fada099c	CPT0079230003	f63a7ca4-204c-11e9-b7f8-0a80fada099c	C3L-01288-02	10c9e898-1fb9-11e9-b7f8-0a80fada099c	C3L-01288	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d278fe80-2053-11e9-b7f8-0a80fada099c	CPT0069190001	9e72e587-204d-11e9-b7f8-0a80fada099c	C3N-00577-06	8e59b323-1fb9-11e9-b7f8-0a80fada099c	C3N-00577	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0df2e325-2054-11e9-b7f8-0a80fada099c	CPT0088920001	c3a317f6-204d-11e9-b7f8-0a80fada099c	C3N-01179-05	a0f46ace-1fb9-11e9-b7f8-0a80fada099c	C3N-01179	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a4bb44a7-2053-11e9-b7f8-0a80fada099c	CPT0017450001	69f24452-204d-11e9-b7f8-0a80fada099c	C3N-00390-06	810c2c81-1fb9-11e9-b7f8-0a80fada099c	C3N-00390	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1486f626-2054-11e9-b7f8-0a80fada099c	CPT0092190003	0f3cfc89-204d-11e9-b7f8-0a80fada099c	C3L-01607-06	25e420f4-1fb9-11e9-b7f8-0a80fada099c	C3L-01607	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0b618083-2054-11e9-b7f8-0a80fada099c	CPT0088760003	da72df9c-204d-11e9-b7f8-0a80fada099c	C3N-01361-01	ac5af110-1fb9-11e9-b7f8-0a80fada099c	C3N-01361	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9927a7f6-2053-11e9-b7f8-0a80fada099c	CPT0014160003	389044ec-204d-11e9-b7f8-0a80fada099c	C3N-00194-02	6aeed922-1fb9-11e9-b7f8-0a80fada099c	C3N-00194	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
16e97175-2054-11e9-b7f8-0a80fada099c	CPT0092310003	182ae977-204d-11e9-b7f8-0a80fada099c	C3L-01861-06	2e6540fd-1fb9-11e9-b7f8-0a80fada099c	C3L-01861	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a03a9e2-2053-11e9-b7f8-0a80fada099c	CPT0011410003	563a9bbe-204d-11e9-b7f8-0a80fada099c	C3N-00313-03	77001dc1-1fb9-11e9-b7f8-0a80fada099c	C3N-00313	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Non-Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
057b25a7-2054-11e9-b7f8-0a80fada099c	CPT0088500001	e872e924-204d-11e9-b7f8-0a80fada099c	C3N-01646-10	b325c35f-1fb9-11e9-b7f8-0a80fada099c	C3N-01646	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
13b0b0f4-2054-11e9-b7f8-0a80fada099c	CPT0092160003	0d0146ba-204d-11e9-b7f8-0a80fada099c	C3L-01607-01	25e420f4-1fb9-11e9-b7f8-0a80fada099c	C3L-01607	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8bd79931-2053-11e9-b7f8-0a80fada099c	CPT0012090003	5acf035a-204d-11e9-b7f8-0a80fada099c	C3N-00314-05	78a71616-1fb9-11e9-b7f8-0a80fada099c	C3N-00314	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d7af16f2-2053-11e9-b7f8-0a80fada099c	CPT0075720003	cd078adc-204d-11e9-b7f8-0a80fada099c	C3N-01213-01	a5cc95b2-1fb9-11e9-b7f8-0a80fada099c	C3N-01213	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bc6a904a-2053-11e9-b7f8-0a80fada099c	CPT0025920001	a56c79c3-204d-11e9-b7f8-0a80fada099c	C3N-00733-06	91b4e8bc-1fb9-11e9-b7f8-0a80fada099c	C3N-00733	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5bb1ff66-2053-11e9-b7f8-0a80fada099c	CPT0001190001	7a6c3d64-204c-11e9-b7f8-0a80fada099c	C3L-00096-06	b5d88141-1fb8-11e9-b7f8-0a80fada099c	C3L-00096	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b64adca6-2053-11e9-b7f8-0a80fada099c	CPT0025170003	b3d4c7a4-204c-11e9-b7f8-0a80fada099c	C3L-00766-01	d610d697-1fb8-11e9-b7f8-0a80fada099c	C3L-00766	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83c4063e-2053-11e9-b7f8-0a80fada099c	CPT0009060003	518199e6-204d-11e9-b7f8-0a80fada099c	C3N-00312-03	754db279-1fb9-11e9-b7f8-0a80fada099c	C3N-00312	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e47c3dce-2053-11e9-b7f8-0a80fada099c	CPT0078830003	ac3baed1-204d-11e9-b7f8-0a80fada099c	C3N-00834-01	96d4ed52-1fb9-11e9-b7f8-0a80fada099c	C3N-00834	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f2ea2af7-2053-11e9-b7f8-0a80fada099c	CPT0081600003	21acc511-204d-11e9-b7f8-0a80fada099c	C3N-00148-03	6039aa8e-1fb9-11e9-b7f8-0a80fada099c	C3N-00148	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
81442959-2053-11e9-b7f8-0a80fada099c	CPT0007870001	e0af77cb-204c-11e9-b7f8-0a80fada099c	C3L-00910-06	effb1654-1fb8-11e9-b7f8-0a80fada099c	C3L-00910	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9c7750a9-2053-11e9-b7f8-0a80fada099c	CPT0014470001	3e85d49d-204d-11e9-b7f8-0a80fada099c	C3N-00242-06	6ca0d37c-1fb9-11e9-b7f8-0a80fada099c	C3N-00242	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
064e8edb-2054-11e9-b7f8-0a80fada099c	CPT0088550004	eb49c8b3-204d-11e9-b7f8-0a80fada099c	"C3N-01648-01, C3N-01648-02"	b5158703-1fb9-11e9-b7f8-0a80fada099c	C3N-01648	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
803029c0-2053-11e9-b7f8-0a80fada099c	CPT0007860003	ddfe36d0-204c-11e9-b7f8-0a80fada099c	C3L-00910-02	effb1654-1fb8-11e9-b7f8-0a80fada099c	C3L-00910	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c40d7a9a-2053-11e9-b7f8-0a80fada099c	CPT0065430003	b3e4b8b4-204d-11e9-b7f8-0a80fada099c	C3N-00953-02	9a4966c2-1fb9-11e9-b7f8-0a80fada099c	C3N-00953	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ad7cbcee-2053-11e9-b7f8-0a80fada099c	CPT0021240003	65fe3a4f-204d-11e9-b7f8-0a80fada099c	C3N-00380-01	7f6a0cac-1fb9-11e9-b7f8-0a80fada099c	C3N-00380	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df94912b-2053-11e9-b7f8-0a80fada099c	CPT0078510003	937aa65b-204d-11e9-b7f8-0a80fada099c	C3N-00495-01	8b0fd240-1fb9-11e9-b7f8-0a80fada099c	C3N-00495	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c9de158e-2053-11e9-b7f8-0a80fada099c	CPT0065930003	02c6815b-204d-11e9-b7f8-0a80fada099c	C3L-01553-01	1f4311cb-1fb9-11e9-b7f8-0a80fada099c	C3L-01553	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0310b558-2054-11e9-b7f8-0a80fada099c	CPT0087040003	089c445b-204d-11e9-b7f8-0a80fada099c	C3L-01603-03	241693ab-1fb9-11e9-b7f8-0a80fada099c	C3L-01603	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d471cfe4-2053-11e9-b7f8-0a80fada099c	CPT0075130003	c8988ee6-204d-11e9-b7f8-0a80fada099c	C3N-01200-02	a4300f90-1fb9-11e9-b7f8-0a80fada099c	C3N-01200	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c675a936-2053-11e9-b7f8-0a80fada099c	CPT0065750003	bcd1ba03-204c-11e9-b7f8-0a80fada099c	C3L-00796-01	de178b14-1fb8-11e9-b7f8-0a80fada099c	C3L-00796	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c14a1860-2053-11e9-b7f8-0a80fada099c	CPT0063640001	f9d222d1-204c-11e9-b7f8-0a80fada099c	C3L-01302-06	12689277-1fb9-11e9-b7f8-0a80fada099c	C3L-01302	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
614e3482-2053-11e9-b7f8-0a80fada099c	CPT0001340003	6a3e4388-204c-11e9-b7f8-0a80fada099c	C3L-00011-01	af7c2225-1fb8-11e9-b7f8-0a80fada099c	C3L-00011	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f3f9bf93-2053-11e9-b7f8-0a80fada099c	CPT0081620001	246f39bd-204d-11e9-b7f8-0a80fada099c	C3N-00148-06	6039aa8e-1fb9-11e9-b7f8-0a80fada099c	C3N-00148	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f02c5363-2053-11e9-b7f8-0a80fada099c	CPT0079430001	f2a7a3cf-204c-11e9-b7f8-0a80fada099c	C3L-01287-06	0f345723-1fb9-11e9-b7f8-0a80fada099c	C3L-01287	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8f93f6ea-2053-11e9-b7f8-0a80fada099c	CPT0012370003	622ad8f3-204d-11e9-b7f8-0a80fada099c	C3N-00320-02	7d95243f-1fb9-11e9-b7f8-0a80fada099c	C3N-00320	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
92f64ed4-2e07-4fce-a3b1-b8717652c669	B561	e0407cf5-bed8-4d65-ac9a-fa2d26d620d6	B561	a10fd102-5146-4fb9-b0e0-86f0f76806f7	MDA-15	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
06805ed8-643d-407f-be53-1d20b0616cbd	B799	8c6f2b2f-3ef2-4c57-a158-4988699b7e42	B799	dfca24ba-e158-46e1-99d6-dc0431fc85a8	MDA-17	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b68bfdff-e596-4707-bb8c-0e443f08aa09	B1190	bd5c64fb-ab9f-4a51-83cd-8a4d6f16955a	B1190	561e83fa-6042-4c7f-adbd-a513ad273f3d	MDA-05	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
be2cd61f-f612-46c4-b3fe-4ea2bee978b9	B1650	3bca70fe-48a7-427e-9254-596e7af8062d	B1650	094251a9-3970-4f02-bb00-43bce5a6e5d9	MDA-13	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
81bcc64b-f371-450e-9156-86864de87e6e	FP-bridge	96e75d0f-9086-43a0-b4c5-5825aedf3f18	FP-bridge	024d00a1-9124-452c-a525-e4a087aab6d5	FP-bridge	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Ovarian Serous Cystadenocarcinoma	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
763a0ebf-e30a-45d4-bd25-a1268ec667f0	B1279	94fe5a77-a9f2-484b-9498-b10489305c88	B1279	7cc8c834-8568-4272-aa30-95107b456187	MDA-06	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7cbc292a-74c4-4a1e-9762-c5f06a9b2637	B1179	6e644689-5826-45c8-b352-7d5c171a45ad	B1179	a168b146-c127-43ac-aa86-3c16c18fdd26	MDA-03	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
547e50f0-2648-4305-9f30-845dce05ae75	B549	b07e6710-60fd-41f8-8d42-f6f3939195c5	B549	833f25bc-c4b4-4550-90fd-42e6dc55a1d0	MDA-18	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8d979e22-522b-457e-9a28-1563a2f5d624	B792	4411088b-a3e4-47d6-afa4-f60521450cf2	B792	98738137-a994-4f40-9c30-28f5ed8b3dd7	MDA-07	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
425655d0-1992-4d1e-b52c-874de9447edd	B1760	95eb3382-58a3-4c4c-905f-be0afbe00310	B1760	1da67c04-9de1-441e-9626-c9a5470a7f02	MDA-20	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b80b003d-0086-4a45-b9a6-7de591e4f031	B1072	06cd9b04-3ae9-4c37-9c2b-8934dd8fdc1a	B1072	bde8765e-c891-42e5-acae-ff865d307dd4	MDA-02	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
72dd2492-9910-4874-bdce-3f0d70d5e2db	B565	405762ae-9160-464f-80c9-827ca589e881	B565	15279ad5-f36f-4197-aea1-1ea7e83d40be	MDA-09	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
79985350-7af8-4882-a06b-91f63ea61c04	B1644	6fc869a2-b86f-4918-b1b2-d481188ec03e	B1644	df877063-1fa1-4c40-9539-38bd91484810	MDA-12	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a437ea1-e260-4ffb-9ed4-78c05fcb4695	B1605	b51d52b3-b006-48ed-ba1e-69262108d915	B1605	af5e6b3c-eece-4a71-b205-929b3d368620	MDA-10	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62f6e950-fc84-4808-877b-518ef12334f8	B572	213598b4-eec7-4125-b1c8-da249bd7facf	B572	a25d73bd-a0e9-45de-bd29-6ab859d46306	MDA-08	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f7af67a-d9d7-43c3-8dc7-2a9b6b742139	B797	e5d329eb-e449-4568-a6c6-3c0a98346d91	B797	99fb2339-e843-4d1c-a322-5c0de83396ae	MDA-19	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
58983648-88de-45f1-b0de-2363e6256ce4	B1626	6ac29415-1f51-4258-b03f-6db526adcbdd	B1626	b28c1aba-1655-404b-8363-9774c22eff7f	MDA-11	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
11983926-6403-4bf4-9eaf-39f6facc93a3	B564	f7753cc2-3a48-459e-875d-775343b62578	B564	8cd446ce-a0c7-4d55-ba46-07ffa99752d7	MDA-16	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7cf69e4c-4dc3-4115-9a27-e5b93fffc04f	B986	5626a3ef-8c44-4a32-beb6-4f6017033b29	B986	f60c0cf2-0b8a-4c81-a125-662367790ce9	MDA-01	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4cf9270f-0a48-405b-b1ab-240febfffbcb	B1185	fd0af3b7-c4cd-401e-8ec7-d1db9bbfa5f0	B1185	5d645d2c-6a59-4f82-a19b-28f052ac6771	MDA-04	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2043a989-735f-4434-a313-ede422a02171	B1689	b1bc1827-5e82-4ce0-b5d9-bf6957e24b80	B1689	ab9faea6-5f31-4fb3-9aa6-7438f616827d	MDA-14	Proteogenomic Translational Research Centers (PTRC)	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
41a4361f-ec86-421e-bc06-d7edd054ecab	X1410004P	afea4a47-6806-4ba7-bcc4-06b99bbb781d	X1410004P	e544fb5a-5b53-4e1d-a3ab-e80239baca87	BCN 1326	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7d9c7f97-26ad-4a3e-901b-12f0fb1c40c7	X1509146	c66e0b16-e3c3-4873-9026-b9b11f96178d	X1509146	ff073c3d-e1b2-4baf-a817-7101fd29ab41	BCN 1358	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
169d6c9a-8b1e-457a-8e42-089bdcb4408c	X1408001P	90640cd3-e6bf-4d66-ab79-03bfc038bead	X1408001P	e544fb5a-5b53-4e1d-a3ab-e80239baca87	BCN 1326	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
73651d29-100e-4f1f-b537-cb4dc903d40c	X1402968	a5dbce85-5893-414b-aa48-9950ed891c47	X1402968	af051b71-95cf-495b-93cb-da7d5457a586	BCN 1300	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b489d1ce-fcd1-4169-918e-b88851349c47	X1518280	f6693a20-87db-4583-83ec-02d3fdab596e	X1518280	45dcaca6-c4bb-4f11-a014-c55c78ee175d	BCN 1367	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c0bb566-4209-4675-9d7d-4c31c34c2ab0	X1523623	49c4411c-21d9-495f-9534-c809230c735e	X1523623	3f603218-b2e1-4e76-8cf9-b7a432257a35	BCN 1365	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
11bc1be7-fef0-458b-963e-3b18a46678fe	X1410003P	cb796159-78ca-4643-8d4e-bddc33596f37	X1410003P	e544fb5a-5b53-4e1d-a3ab-e80239baca87	BCN 1326	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb379a5f-765e-4ca7-8e05-2301106cf479	CR4	d850aa0a-70f0-4995-bc29-122056f7c31b	CR4	df044e27-1d57-4877-8cf0-86ae0f5908b5	CR4	CPTAC3-Other	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
153e3082-b225-43a6-9333-cf15d16c904b	X1407999P	5b7badc8-5383-436f-8556-f238bd980498	X1407999P	e544fb5a-5b53-4e1d-a3ab-e80239baca87	BCN 1326	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ee76743e-dbf4-404e-8b6e-3e0627a955ec	CR5	1453b409-5d2a-472b-b84a-e8e367f7c29f	CR5	d38f3993-b08a-400e-893a-ce75821d2c9b	CR5	CPTAC3-Other	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
18fc366a-e5c3-43f7-b6b2-7d58d1059916	X1514936	0ac7e421-022c-4f1b-8ce7-5835caf192e4	X1514936	ae1e8dc5-856f-4133-8853-3656c9708a17	BCN 1359	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ed650eeb-eb73-4d06-aea3-ed5c87f71ae6	X1525224	ff13264c-756f-4aba-957c-900fafcf291d	X1525224	4f9060a4-5dc6-42ef-8914-1fd12952bf5b	BCN 1371	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
141e1be1-0696-4fac-afa9-2d8253317693	X1420025P	5dda5055-db67-4e2c-b9e6-c8de0e4bb890	X1420025P	79659a0c-08bf-4127-afcc-23656e48207e	BCN 1335	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f850d8bd-d0ba-4f55-9b96-98519a9bb346	X1410005P	afd59840-0bf9-4592-ae25-0f7fb6774b42	X1410005P	e544fb5a-5b53-4e1d-a3ab-e80239baca87	BCN 1326	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd52713a-eb61-4dba-8ac0-6ffc15811cdc	X1406353P	c1bc5fc4-f690-4b1f-afdd-2253f3881966	X1406353P	c7a2171c-64dd-443f-8a69-1e4577c8e310	BCN 1325	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cdff4b6d-e264-4f7a-8b69-9efb590316c0	X1410753P	d6320a92-5a32-4b3a-bded-9aac3fc5e477	X1410753P	338845cd-4ec7-404e-89b5-eecd05c9f3e5	BCN 1303	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9bca89ac-aec3-4841-a58b-b5c01b6672a8	X1539756	ed16b97e-52cb-476b-a4bc-e6a29afc428d	X1539756	3dd29f9b-382e-44c5-9f89-51799a668359	BCN 1369	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
279ddee8-649e-4d9e-8ab7-0e4d857cbab0	X1518399	9e3c6618-2ed9-4de0-b720-98b7bccba55c	X1518399	45dcaca6-c4bb-4f11-a014-c55c78ee175d	BCN 1367	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1550d76-5abc-4d8c-b887-1b1be6e05bb4	X1405799P	113eb184-241c-48b6-89c9-7b33043c36e6	X1405799P	c7a2171c-64dd-443f-8a69-1e4577c8e310	BCN 1325	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de0bbd78-95e9-4565-8934-2abb01b90c21	X1411848P	3dc2e070-6cbb-4846-b96e-ddef6a208cd7	X1411848P	338845cd-4ec7-404e-89b5-eecd05c9f3e5	BCN 1303	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a599dbf-e104-407f-9316-bb1954b7c5f6	X1518400	642671e7-13f3-4704-80f3-13c66d97a46f	X1518400	45dcaca6-c4bb-4f11-a014-c55c78ee175d	BCN 1367	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
05f88695-e53c-462d-849a-11cb2f4c39ec	X1509534	72d0c856-702d-44eb-a7ad-aa9e080e952c	X1509534	ff073c3d-e1b2-4baf-a817-7101fd29ab41	BCN 1358	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
342e3339-dc91-4421-adc1-c968b0eefad6	X1539910	a72f820c-f38b-4f35-ba58-c2838e17e14f	X1539910	3dd29f9b-382e-44c5-9f89-51799a668359	BCN 1369	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9c952cfe-49b2-4172-b92f-4628406d1531	X1422184P	4c4c7e54-0be7-4931-b83c-492c9bedb619	X1422184P	6db7609d-dba9-443b-9a71-62a631118ccd	BCN 1357	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df889195-b2a1-4174-ae9c-0403028af425	X1413835P	74037b6d-207f-4489-a0aa-8914ac4a8204	X1413835P	bcc85534-ab8a-4522-b3e9-502ca3cd1e27	BCN 1331	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21ffbbe2-8ec3-4d17-9ed3-bb056315b2ab	X1414049P	33a9283d-4311-4ec2-b22d-f5c517c63afb	X1414049P	bcc85534-ab8a-4522-b3e9-502ca3cd1e27	BCN 1331	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dc298e5a-3e3a-4d5d-95a4-5e0ac33cad01	Withdrawn	197ef1b7-cb3a-4590-a938-a8d8d29e9b2a	Withdrawn	854f02aa-4510-42fb-9537-28257187530f	Withdrawn	CPTAC3-Other	Not Reported	Not Reported	Other	No	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
af097085-b58c-4fd0-8b87-42393a370750	X1539757	644dbc14-22a9-4d6e-8682-94486f03a4b2	X1539757	3dd29f9b-382e-44c5-9f89-51799a668359	BCN 1369	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4bb4ab32-0ed3-4e5c-a596-601ec39e3911	X1514458	b7a8de6f-8ff8-44a3-8660-9b9bfa2bc325	X1514458	ae1e8dc5-856f-4133-8853-3656c9708a17	BCN 1359	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e2e823dd-1eb7-42cf-bc48-d267a2d8fe3d	X1539911	15c6ccbe-0c8a-4e58-90dd-8026a80778df	X1539911	3dd29f9b-382e-44c5-9f89-51799a668359	BCN 1369	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b3a2e538-84b6-413f-ad3e-6fd77d0632dd	X1518729	955126bd-749a-4bc8-aa1d-43558601f9df	X1518729	d8936359-79bf-43ad-a0a4-4641d4503a14	BCN 1368	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3ffca794-9703-4f48-8f89-64ed20a99134	X1523169	f795e681-1834-4d10-bccd-c7f22e5d3784	X1523169	3f603218-b2e1-4e76-8cf9-b7a432257a35	BCN 1365	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4a9ca012-75db-47a7-8dd1-91efee4c81ba	X1518282	b2c39940-3ce3-4189-a900-631fe2f3878b	X1518282	45dcaca6-c4bb-4f11-a014-c55c78ee175d	BCN 1367	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a10c764b-d8c9-4aff-92a1-9edc76e8e9de	X1402967	d67e58a3-4604-40b7-a250-3a23976ba713	X1402967	af051b71-95cf-495b-93cb-da7d5457a586	BCN 1300	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c2bcbe5-4581-439e-96c5-c48c0d070027	X1422185P	4a1ea83c-5f70-4a62-adba-47776c1644d4	X1422185P	6db7609d-dba9-443b-9a71-62a631118ccd	BCN 1357	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
94a863c9-20b4-439e-a5a7-19c3cca6994b	X1408000P	c230d692-79be-4386-ba6b-dacfe4c74888	X1408000P	e544fb5a-5b53-4e1d-a3ab-e80239baca87	BCN 1326	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6fc20592-6bd4-4e9f-9eb2-be8d7c6f4f55	X1401795	3b454192-0c5d-47be-995b-a9d8bafbcc68	X1401795	af051b71-95cf-495b-93cb-da7d5457a586	BCN 1300	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ff5c3fef-7418-400d-b1f7-2f5e54559230	X1401794	48779a0e-7653-4c9e-bdbb-9d6d987b4733	X1401794	af051b71-95cf-495b-93cb-da7d5457a586	BCN 1300	CPTAC3-Other	Tumor	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57479294-677e-4d61-9699-e46947bb4f5b	P94	a80e1b31-c78f-4ed9-81f3-b6a5a89cf546	P94	a50105c7-df56-4233-a96c-fdb0e2baeefe	P94	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dda76851-df7e-4891-b6af-a30a33d691de	P93	09ae374d-af2c-4346-8135-8aab0dec97c9	P93	bef66096-682b-4cb6-8e55-3fc4876904e3	P93	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
71d0bcd6-f5d8-40d8-8f18-32a55aee25a8	CPT0246850003	86ab92c1-9591-4d9c-83f6-05b9f5d825f5	C3N-03670-02	da3a693f-01f0-4d7b-ae52-95c5438733d8	C3N-03670	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e3885899-e33e-439a-8469-20b97abe2884	CPT0000270003	e16cbfd5-5fdd-46fe-a224-05c77e45225b	C3L-00017-04	e146ea33-991d-40e0-81c1-d33f9c719f62	C3L-00017	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
43d5dee9-b69b-403d-bcc1-a8f9b599a314	CPT0019230003	b6b7400c-8edc-4aa8-9274-2204158fe8f1	C3L-00395-04	3c5685fb-b96f-4cf2-adb6-9e31e86c1b6e	C3L-00395	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cc3f86b4-0c5a-460b-a1cc-fccbd2d97ac8	C3N-02069-01	d198c8cd-c38a-4352-a89b-e0660fe096a6	C3N-02069-01	db60fa6c-6138-442b-9760-90386debca6b	C3N-02069	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
338c591a-25c5-4561-9e4a-ae271c19923e	CPT0246900003	24810735-ff55-422e-83cc-37c1c5ef2655	C3N-03778-03	89d63ffe-490c-47b0-8b66-b752f510033b	C3N-03778	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1acb85a2-3fd2-4532-ad3f-0b0b9d830521	CPT0083290003	d08b5f1f-4db2-45f4-98e4-80b3b07b866e	C3L-01328-03	05e50d4c-1271-453c-a6c4-39a3565073ef	C3L-01328	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1dc16c48-172b-447a-9afc-4c00bdd41aff	CPT0124430003	9559aa5d-1cb5-45b9-9f86-6c0fbc18fcaa	C3L-02112-04	fe3b4978-c450-4943-bf87-e5974562f62f	C3L-02112	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
500791d7-5523-487d-a743-32ea407d00ee	CPT0146130004	d0d02149-8175-4d2e-836f-73461372bd12	"C3N-02069-02, C3N-02069-03"	db60fa6c-6138-442b-9760-90386debca6b	C3N-02069	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c3402a8-7729-4cb2-b14e-df69faa23d99	CPT0081500003	b5906ccc-2598-4145-accb-ca31d656c87f	"C3L-00625-04, C3L-00625-05"	5aff3251-f272-4dcc-8bbd-b4ee767469f4	C3L-00625	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
435781af-0890-4575-9c50-5d80c2ea9f61	CPT0094960003	1731bc28-6df1-4469-b8d4-fb654ed91e00	C3L-01703-04	344f4536-d2cf-4162-99d8-dcc40972c80b	C3L-01703	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
129b8987-d248-4cbe-94a2-4aace84460b7	CPT0065080003	58d2db64-bed1-44f2-87f2-f0f77a416dc3	C3N-00954-02	a92fe986-efba-4604-9fdc-9186b2b32f34	C3N-00954	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a17a5a0a-8c23-4303-a47e-b2bc2d24807e	CPT0246890003	91646764-ead8-431f-b67a-ed8baccaaf17	C3N-03778-01	89d63ffe-490c-47b0-8b66-b752f510033b	C3N-03778	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6318895b-0bf6-4b31-8bad-b23ae8be1b48	CPT0124630003	5d06de95-87a6-4a26-aa93-e97b6da5bc1e	C3L-02613-04	48772971-6230-4918-b9a7-dd1b5af9aade	C3L-02613	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a450e27c-f19e-4266-ae0e-d47b83e593f2	CPT0065100003	00c4359f-f6b8-4725-8524-c91406839b4d	C3N-00954-06	a92fe986-efba-4604-9fdc-9186b2b32f34	C3N-00954	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
edd4f8fe-da15-4998-8621-cf8b30a92931	CPT0109230003	05245aa4-a18c-4559-875d-b3c127120834	C3L-02116-04	f78c3797-dd47-4d93-aacd-1d406cfcf36e	C3L-02116	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1b54884a-71d9-4131-9ffa-1615ad4f79f9	CPT0010020004	66866f72-d03f-4e13-8d49-96041777e326	"C3L-00395-01, C3L-00395-02"	3c5685fb-b96f-4cf2-adb6-9e31e86c1b6e	C3L-00395	CPTAC3 Discovery and Confirmatory	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b24e0bb1-cd9a-4430-ac7a-9a65e09a590e	CPT0081390003	c85940e8-36b3-4ce7-bf37-e6af67d5e940	C3L-00622-04	81d2f222-b6ea-4593-9ccd-1619546ab73b	C3L-00622	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d7f68bae-1e8d-4ee9-b001-deb81aeed9a9	CPT0081290003	b2275355-ac9e-4ad7-a6d5-209e236e6ff0	C3L-00599-04	ddc466c8-7e8f-453c-920d-25ebb56be20f	C3L-00599	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Pancreas	Pancreatic Ductal Adenocarcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48465062-8377-4817-bd7e-9acbc6de30ff	6_BKM120_2_5	fa81fb37-69ea-4cbf-9f59-4fc2c5290da1	6_BKM120_2_5	7f64ed63-d354-4c71-bec4-3fcad4d1d827	WHIM 06	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
82f744ff-73f5-436e-8fad-79febd8ab1c0	4_BKM120_VH4_3	35c9328a-b2a3-41ce-a834-096a08fd8190	4_BKM120_VH4_3	fbf8485f-63d5-4027-ba04-648297745a75	WHIM 04	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
41c56e7d-a4a0-42b2-9437-308c6d0edac5	12_BKM120_5_1	e70c8e59-22cb-4aca-ae34-46fa23aa60c2	12_BKM120_5_1	9e7efd1e-83a8-4700-8c8c-26f91061687b	WHIM 12	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f32c84d1-e656-4f07-ba6d-3eeca7117f4b	21_BKM120_VH1_1	9c5f22c1-f741-454f-9b09-58d504bf3cc5	21_BKM120_VH1_1	aee46ef0-7fd7-4ff8-b2d6-5911beac7108	WHIM 21	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eaa0dfcd-e6d5-437b-a3c7-325ede4b9d23	30_BKM120_VH4_2	bf978057-239f-4ac4-b8ae-19b40748f111	30_BKM120_VH4_2	651057dc-c9ab-488a-9795-2cb73704ea33	WHIM 30	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f26401d5-1504-4b87-becd-7499368d2545	12_BKM120_2_1	48b60b87-0c14-4a7d-af0c-7e81cceb6c7d	12_BKM120_2_1	9e7efd1e-83a8-4700-8c8c-26f91061687b	WHIM 12	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c0ffa36-0992-4eb5-a3fa-347748aa9938	2_BKM120_2_5	75a73f08-c173-4438-8244-6557d19cf082	2_BKM120_2_5	2f6b797a-5a51-482b-bc6e-fa7e5468180c	WHIM 02	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
74efd208-fbe7-4925-8166-138494d12619	2_BKM120_5_5	bbc67d7c-e987-4b5b-a493-c2bfb0bec8ae	2_BKM120_5_5	2f6b797a-5a51-482b-bc6e-fa7e5468180c	WHIM 02	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a7f7f989-0c0d-4488-b906-9c39b90532a6	2_BKM120_VH4_2	1744be28-ab63-4ebf-8819-1629b603b2ea	2_BKM120_VH4_2	2f6b797a-5a51-482b-bc6e-fa7e5468180c	WHIM 02	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
60ad6172-a946-4196-aea5-960cd49d7d5b	30_BKM120_5_6	1190fc65-4db5-461b-97ab-321e783bbabb	30_BKM120_5_6	651057dc-c9ab-488a-9795-2cb73704ea33	WHIM 30	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2de47a65-f5a6-4cb0-bc4a-4f20328cae63	4_BKM120_VH1_2	db2a20da-5f03-45a8-949b-4d66e280fc50	4_BKM120_VH1_2	fbf8485f-63d5-4027-ba04-648297745a75	WHIM 04	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
565df006-4249-401a-8f95-7b01eec73996	Internal Reference	cca3398a-68af-4d5a-a7b0-f9ae24a5a50e	Internal Reference	031977b7-2409-4b98-87cd-63efc023dafc	WHIM IR	CPTAC2-Other	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2ee30265-f6ca-4f88-b342-cbf47e08e598	6_BKM120_VH1_4	a22b85fd-bc9f-49a5-b39d-3aab6261f3bf	6_BKM120_VH1_4	7f64ed63-d354-4c71-bec4-3fcad4d1d827	WHIM 06	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
41712adf-b2d8-40bf-a62e-6b9c80a15522	6_BKM120_5_2	b7097a55-2eb3-46b4-a09f-6f093d2fa524	6_BKM120_5_2	7f64ed63-d354-4c71-bec4-3fcad4d1d827	WHIM 06	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
22a77d27-d2ff-428e-8a7c-7fd1eae2f37d	30_BKM120_VH1_6	26eb2aae-3e2a-42c9-ae2f-4e70210bed64	30_BKM120_VH1_6	651057dc-c9ab-488a-9795-2cb73704ea33	WHIM 30	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c4bf1690-af3b-4cc1-898a-e6c2812593d4	6_BKM120_3_7	4885337c-d425-4342-9168-a935bee16d6b	6_BKM120_3_7	7f64ed63-d354-4c71-bec4-3fcad4d1d827	WHIM 06	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
844e6940-8caf-4427-8634-b2b76b593875	4_BKM120_2_4	3043c183-1d7b-4904-93a2-7d2549056015	4_BKM120_2_4	fbf8485f-63d5-4027-ba04-648297745a75	WHIM 04	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c8571fc-854d-4311-9ff0-f58d590a2263	21_BKM120_2_2	e814b963-8e1e-4368-813a-8a44264b53f5	21_BKM120_2_2	aee46ef0-7fd7-4ff8-b2d6-5911beac7108	WHIM 21	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de2e3922-8ae5-416c-a019-dc43d9bd9982	12_BKM120_3_3	d0fd185b-50a8-46b7-96ed-a26b27b0b69e	12_BKM120_3_3	9e7efd1e-83a8-4700-8c8c-26f91061687b	WHIM 12	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4583f3e8-d015-4332-b4c6-639c70108c6a	4_BKM120_3_6	51e51f1d-62de-49a3-8def-ccadff7e87ee	4_BKM120_3_6	fbf8485f-63d5-4027-ba04-648297745a75	WHIM 04	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b079a0a-ba84-4b94-b3a5-32d1126d307b	6_BKM120_VH4_5	bc2f3423-1cbd-4e5d-ba5e-e650d6f23b7b	6_BKM120_VH4_5	7f64ed63-d354-4c71-bec4-3fcad4d1d827	WHIM 06	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eaab8d45-f83b-47df-94a3-0a2e4baf9352	30_BKM120_3_4	9e1cd0d6-63b7-45c2-a9fe-5afe501dfcf8	30_BKM120_3_4	651057dc-c9ab-488a-9795-2cb73704ea33	WHIM 30	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
15708bbb-c5b1-4a29-903f-5f848f5121be	21_BKM120_VH4_6	15f4f4ca-888a-4e63-bed7-d0189cff7068	21_BKM120_VH4_6	aee46ef0-7fd7-4ff8-b2d6-5911beac7108	WHIM 21	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a38cb83-dfb3-4629-b4d6-f54b597c5114	30_BKM120_2_5	105dbcb6-d769-42cd-b8ad-6cf4661cf68b	30_BKM120_2_5	651057dc-c9ab-488a-9795-2cb73704ea33	WHIM 30	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
72e7509d-9330-4744-b9f8-7ef31583f425	4_BKM120_5_10	a045b407-d754-404b-a549-73a96f279c4a	4_BKM120_5_10	fbf8485f-63d5-4027-ba04-648297745a75	WHIM 04	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
212aba15-0d70-4951-9fa2-eee81ab865f4	12_BKM120_VH1_2	fbd77c01-4742-49d9-bb2b-a8b66dd42fa6	12_BKM120_VH1_2	9e7efd1e-83a8-4700-8c8c-26f91061687b	WHIM 12	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a8f3461-3c08-4152-b293-e044d131f51a	21_BKM120_3_8	3d606eba-8a13-4787-8ab1-fd495c697fa5	21_BKM120_3_8	aee46ef0-7fd7-4ff8-b2d6-5911beac7108	WHIM 21	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7d0f57b3-8f90-4056-a18c-c7e63cf9975d	2_BKM120_VH1_3	75e8f6cb-aacf-416b-b027-60b804dcb520	2_BKM120_VH1_3	2f6b797a-5a51-482b-bc6e-fa7e5468180c	WHIM 02	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae60020f-9abe-4805-aa70-8d3a81ae2a4b	2_BKM120_3_7	d3b81259-44d7-410d-a67d-c4a83b98dd78	2_BKM120_3_7	2f6b797a-5a51-482b-bc6e-fa7e5468180c	WHIM 02	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f635aa68-f634-44aa-ac8e-bcc8f7f9446c	12_BKM120_VH4_6	d0ad281e-dc25-471a-a7a6-62fd011c5ca0	12_BKM120_VH4_6	9e7efd1e-83a8-4700-8c8c-26f91061687b	WHIM 12	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
19ffd165-b324-4443-941a-10fb39725848	21_BKM120_5_5	6790e8bc-2569-4d50-94d5-866c75d59515	21_BKM120_5_5	aee46ef0-7fd7-4ff8-b2d6-5911beac7108	WHIM 21	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bff5f1c8-c5cf-4375-81a6-40f47eec1e5b	16-01259-1	40a3a67b-8af4-4a40-b6e2-139c84a29820	16-01259-1	9f59690e-edc2-4abb-8c8c-fb5fda41498b	16-01259	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cc445b9a-5a06-48cc-854e-7a7611bf7b22	15-00756-1	dddc3c0f-af7c-453b-9929-fe6896297df1	15-00756-1	e4796a23-6e79-4159-8547-d7fbe13098c9	15-00756	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e37cc90e-00ce-420c-b9bd-af74c95ff932	17-00177-1	4a19b474-0ad6-4bef-a736-c64e5ed84519	17-00177-1	4b774462-0bf7-4d13-92fe-ca2c016a55b3	17-00177	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2511aa53-e409-49f7-af45-0b6ffdaa4319	16-00278-1	c9284855-7a4f-41b8-9af6-31e7dba54eaf	16-00278-1	ffcc7499-e355-4b45-8359-55e00a9a8fa8	16-00278	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b2d660b4-b0a8-4215-bfe4-22c1f082a917	16-01138-1	e33c9c22-9ec1-4baf-abc6-19100cc0bf30	16-01138-1	6f970451-69cb-4710-b77d-7b9f8706e71f	16-01138	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4cc5d04f-2ef7-4869-9256-e40ffa401773	16-00494-1	42093f24-b68f-4686-95c7-e81e65bce691	16-00494-1	e6fa63df-b57c-4ed2-8456-38b831e5a800	16-00494	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2ba26a20-6cd6-4432-8abb-01040358dd64	17-00093-1	eeb0b4aa-a2ab-4559-a468-9129b2b38a7c	17-00093-1	f83c359b-a08e-4403-a88a-ce41eb58bda9	17-00093	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
037e722e-0e81-4947-a609-a7dbc1c90ce1	17-00444-1	c0d32f8c-f3da-43e1-9977-a3a2bdceae7a	17-00444-1	2c58dc70-261f-4a1f-b1af-4b7324bed392	17-00444	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
836a66ed-2d5d-4057-baa9-c559d291e4ce	16-01102-1	d4b34e05-904d-4489-9adc-8b62703aea15	16-01102-1	620b0449-9eca-4cdf-bdf0-461925cac669	16-01102	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fec008bb-300a-44ab-b362-f8c50b753307	17-00638-1	54b1a2ad-b19f-40ea-aca6-2cc1d68658fd	17-00638-1	c1aad942-4fd5-47cb-bda0-f1c89b428e37	17-00638	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8abf022-ef86-452d-867d-a691eb72b7e2	16-00479-1	3b5947fb-d060-49e7-9485-60a253f92ca3	16-00479-1	02dc17a7-0261-45be-a70e-15189dc6c2dd	16-00479	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c8a1a545-b7c9-40b7-87f3-716fc27b1b6c	16-00981-1	85628b3e-e0be-4f77-8389-e886bf5bf5b4	16-00981-1	41a2e118-258f-4ba1-894d-042e403d5e04	16-00981	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea129240-8c05-4ff1-96a0-1881548558f0	16-01253-1	c63108d9-efc8-409a-9ada-cdf7685ae3f7	16-01253-1	fd439626-0a37-4700-ae6b-c564c8e016c6	16-01253	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7da36179-b7ba-4977-bc27-dca0bf27d640	16-01219-1	f5f42174-2657-4bd7-a73e-aad5092af64e	16-01219-1	dea8bbca-b6b1-4247-98c3-ec4ea86a61c1	16-01219	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea5abf22-d218-4649-97f5-a3c3f1b04f55	17-00676-1	6fd2a554-1a0d-4c37-839d-4d17b923a054	17-00676-1	71f6efc4-5999-49d0-8d8b-88feddda3642	17-00676	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
683a4144-df70-4985-94be-70a3c9a69e73	16-01227-1	84751c0f-cd48-4107-b32f-45db2235e52e	16-01227-1	7b176838-c84f-4d39-a923-75ce677127d5	16-01227	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
85218abe-df66-41c7-9045-66a0521d344a	17-00613-1	43895d6b-8346-4b58-89a6-fbb612f51403	17-00613-1	7e1df54f-736b-4f3b-968a-954bdc44d34f	17-00613	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Bone Marrow	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
532a9b69-71a3-4dfe-9180-54af58dcbcb1	16-00474-1	7b7bb988-6da5-4dc7-9e83-a3d536f040fa	16-00474-1	2dd556f8-37ae-4d29-8ab4-5ef7095dc39f	16-00474	Proteogenomic Translational Research Centers (PTRC)	Blood Derived Cancer - Peripheral Blood	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
47971f50-01f5-46b0-ac24-0f7025643ada	16-00611-1	56e4d529-710c-4195-a919-60bf86974220	16-00611-1	c09dce21-2ac7-4fb7-b4e1-60fd978e246e	16-00611	Proteogenomic Translational Research Centers (PTRC)	"Blood Derived Cancer - Peripheral Blood, Post-treatment"	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a5cbe21-1168-11ea-9bfa-0a42f3c845fe	471	7a5ab6c1-1168-11ea-9bfa-0a42f3c845fe	471	7a596431-1168-11ea-9bfa-0a42f3c845fe	70	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e0604-1168-11ea-9bfa-0a42f3c845fe	351	7a5bdf98-1168-11ea-9bfa-0a42f3c845fe	351	7a59dc5c-1168-11ea-9bfa-0a42f3c845fe	351	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cbef0-1168-11ea-9bfa-0a42f3c845fe	472	7a5ab7be-1168-11ea-9bfa-0a42f3c845fe	472	7a596431-1168-11ea-9bfa-0a42f3c845fe	70	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c37ff-1168-11ea-9bfa-0a42f3c845fe	231	7a5a29a8-1168-11ea-9bfa-0a42f3c845fe	231	7a592b54-1168-11ea-9bfa-0a42f3c845fe	23	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e06ca-1168-11ea-9bfa-0a42f3c845fe	352	7a5be179-1168-11ea-9bfa-0a42f3c845fe	352	7a59de69-1168-11ea-9bfa-0a42f3c845fe	352	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cc2e9-1168-11ea-9bfa-0a42f3c845fe	473	7a5ab971-1168-11ea-9bfa-0a42f3c845fe	473	7a5965f2-1168-11ea-9bfa-0a42f3c845fe	71	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5bf06d-1168-11ea-9bfa-0a42f3c845fe	111	7a59e90d-1168-11ea-9bfa-0a42f3c845fe	111	7a590d23-1168-11ea-9bfa-0a42f3c845fe	1	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c39fc-1168-11ea-9bfa-0a42f3c845fe	232	7a5a2adb-1168-11ea-9bfa-0a42f3c845fe	232	7a592b54-1168-11ea-9bfa-0a42f3c845fe	23	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c6195-1168-11ea-9bfa-0a42f3c845fe	353	7a5a55df-1168-11ea-9bfa-0a42f3c845fe	353	7a593e94-1168-11ea-9bfa-0a42f3c845fe	38	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cc3e6-1168-11ea-9bfa-0a42f3c845fe	474	7a5abb03-1168-11ea-9bfa-0a42f3c845fe	474	7a5965f2-1168-11ea-9bfa-0a42f3c845fe	71	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5bef7d-1168-11ea-9bfa-0a42f3c845fe	112	7a59e723-1168-11ea-9bfa-0a42f3c845fe	112	7a590d23-1168-11ea-9bfa-0a42f3c845fe	1	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c6287-1168-11ea-9bfa-0a42f3c845fe	354	7a5a56e1-1168-11ea-9bfa-0a42f3c845fe	354	7a593e94-1168-11ea-9bfa-0a42f3c845fe	38	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5bf13d-1168-11ea-9bfa-0a42f3c845fe	113	7a59ea34-1168-11ea-9bfa-0a42f3c845fe	113	7a59102c-1168-11ea-9bfa-0a42f3c845fe	2	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c648c-1168-11ea-9bfa-0a42f3c845fe	355	7a5a588b-1168-11ea-9bfa-0a42f3c845fe	355	7a593f6a-1168-11ea-9bfa-0a42f3c845fe	39	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5bf45c-1168-11ea-9bfa-0a42f3c845fe	114	7a59ebfd-1168-11ea-9bfa-0a42f3c845fe	114	7a59102c-1168-11ea-9bfa-0a42f3c845fe	2	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c6562-1168-11ea-9bfa-0a42f3c845fe	356	7a5a5988-1168-11ea-9bfa-0a42f3c845fe	356	7a593f6a-1168-11ea-9bfa-0a42f3c845fe	39	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cc610-1168-11ea-9bfa-0a42f3c845fe	477	7a5abcf2-1168-11ea-9bfa-0a42f3c845fe	477	7a5966c9-1168-11ea-9bfa-0a42f3c845fe	72	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c676e-1168-11ea-9bfa-0a42f3c845fe	357	7a5a5b3c-1168-11ea-9bfa-0a42f3c845fe	357	7a59402d-1168-11ea-9bfa-0a42f3c845fe	40	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cc6e7-1168-11ea-9bfa-0a42f3c845fe	478	7a5abee2-1168-11ea-9bfa-0a42f3c845fe	478	7a5966c9-1168-11ea-9bfa-0a42f3c845fe	72	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c6840-1168-11ea-9bfa-0a42f3c845fe	358	7a5a5c42-1168-11ea-9bfa-0a42f3c845fe	358	7a59402d-1168-11ea-9bfa-0a42f3c845fe	40	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5da015-1168-11ea-9bfa-0a42f3c845fe	911	7a5b7bf1-1168-11ea-9bfa-0a42f3c845fe	911	7a59b5e5-1168-11ea-9bfa-0a42f3c845fe	132	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5da0e8-1168-11ea-9bfa-0a42f3c845fe	912	7a5b7d07-1168-11ea-9bfa-0a42f3c845fe	912	7a59b5e5-1168-11ea-9bfa-0a42f3c845fe	132	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5da2fe-1168-11ea-9bfa-0a42f3c845fe	913	7a5b7ede-1168-11ea-9bfa-0a42f3c845fe	913	7a59b7dc-1168-11ea-9bfa-0a42f3c845fe	133	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5da3d2-1168-11ea-9bfa-0a42f3c845fe	914	7a5b80c0-1168-11ea-9bfa-0a42f3c845fe	914	7a59b7dc-1168-11ea-9bfa-0a42f3c845fe	133	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5da5ee-1168-11ea-9bfa-0a42f3c845fe	915	7a5b8317-1168-11ea-9bfa-0a42f3c845fe	915	7a59b8b7-1168-11ea-9bfa-0a42f3c845fe	134	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5da6bb-1168-11ea-9bfa-0a42f3c845fe	916	7a5b84f2-1168-11ea-9bfa-0a42f3c845fe	916	7a59b8b7-1168-11ea-9bfa-0a42f3c845fe	134	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5daa56-1168-11ea-9bfa-0a42f3c845fe	917	7a5b862b-1168-11ea-9bfa-0a42f3c845fe	917	7a59bab9-1168-11ea-9bfa-0a42f3c845fe	135	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dab5a-1168-11ea-9bfa-0a42f3c845fe	918	7a5b87bd-1168-11ea-9bfa-0a42f3c845fe	918	7a59bab9-1168-11ea-9bfa-0a42f3c845fe	135	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ccd3b-1168-11ea-9bfa-0a42f3c845fe	481	7a5ac0b5-1168-11ea-9bfa-0a42f3c845fe	481	7a596790-1168-11ea-9bfa-0a42f3c845fe	73	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c6a58-1168-11ea-9bfa-0a42f3c845fe	361	7a5a5e03-1168-11ea-9bfa-0a42f3c845fe	361	7a5941d9-1168-11ea-9bfa-0a42f3c845fe	41	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cd14c-1168-11ea-9bfa-0a42f3c845fe	482	7a5ac1b6-1168-11ea-9bfa-0a42f3c845fe	482	7a596790-1168-11ea-9bfa-0a42f3c845fe	73	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c6b2a-1168-11ea-9bfa-0a42f3c845fe	362	7a5a5f06-1168-11ea-9bfa-0a42f3c845fe	362	7a5941d9-1168-11ea-9bfa-0a42f3c845fe	41	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cd401-1168-11ea-9bfa-0a42f3c845fe	483	7a5ac391-1168-11ea-9bfa-0a42f3c845fe	483	7a59695f-1168-11ea-9bfa-0a42f3c845fe	74	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c6d51-1168-11ea-9bfa-0a42f3c845fe	363	7a5a60fa-1168-11ea-9bfa-0a42f3c845fe	363	7a5942ae-1168-11ea-9bfa-0a42f3c845fe	42	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cd4fb-1168-11ea-9bfa-0a42f3c845fe	484	7a5ac58e-1168-11ea-9bfa-0a42f3c845fe	484	7a59695f-1168-11ea-9bfa-0a42f3c845fe	74	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c6e1f-1168-11ea-9bfa-0a42f3c845fe	364	7a5a6209-1168-11ea-9bfa-0a42f3c845fe	364	7a5942ae-1168-11ea-9bfa-0a42f3c845fe	42	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5bf53b-1168-11ea-9bfa-0a42f3c845fe	123	7a59ed0d-1168-11ea-9bfa-0a42f3c845fe	123	7a5912dc-1168-11ea-9bfa-0a42f3c845fe	3	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7065-1168-11ea-9bfa-0a42f3c845fe	365	7a5a63e0-1168-11ea-9bfa-0a42f3c845fe	365	7a594378-1168-11ea-9bfa-0a42f3c845fe	43	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5bf6d7-1168-11ea-9bfa-0a42f3c845fe	124	7a59eeda-1168-11ea-9bfa-0a42f3c845fe	124	7a5912dc-1168-11ea-9bfa-0a42f3c845fe	3	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7152-1168-11ea-9bfa-0a42f3c845fe	366	7a5a64e0-1168-11ea-9bfa-0a42f3c845fe	366	7a594378-1168-11ea-9bfa-0a42f3c845fe	43	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cd60e-1168-11ea-9bfa-0a42f3c845fe	487	7a5ac6dd-1168-11ea-9bfa-0a42f3c845fe	487	7a596a2f-1168-11ea-9bfa-0a42f3c845fe	75	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5bf79b-1168-11ea-9bfa-0a42f3c845fe	125	7a59efe9-1168-11ea-9bfa-0a42f3c845fe	125	7a5913d7-1168-11ea-9bfa-0a42f3c845fe	4	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c725d-1168-11ea-9bfa-0a42f3c845fe	367	7a5a66bd-1168-11ea-9bfa-0a42f3c845fe	367	7a594537-1168-11ea-9bfa-0a42f3c845fe	44	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cd6d9-1168-11ea-9bfa-0a42f3c845fe	488	7a5ac887-1168-11ea-9bfa-0a42f3c845fe	488	7a596a2f-1168-11ea-9bfa-0a42f3c845fe	75	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5bf92c-1168-11ea-9bfa-0a42f3c845fe	126	7a59f1c9-1168-11ea-9bfa-0a42f3c845fe	126	7a5913d7-1168-11ea-9bfa-0a42f3c845fe	4	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7324-1168-11ea-9bfa-0a42f3c845fe	368	7a5a68b7-1168-11ea-9bfa-0a42f3c845fe	368	7a594537-1168-11ea-9bfa-0a42f3c845fe	44	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c05ae-1168-11ea-9bfa-0a42f3c845fe	127	7a59f2d2-1168-11ea-9bfa-0a42f3c845fe	127	7a591639-1168-11ea-9bfa-0a42f3c845fe	5	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c07be-1168-11ea-9bfa-0a42f3c845fe	128	7a59f4e8-1168-11ea-9bfa-0a42f3c845fe	128	7a591639-1168-11ea-9bfa-0a42f3c845fe	5	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dada8-1168-11ea-9bfa-0a42f3c845fe	921	7a5b8933-1168-11ea-9bfa-0a42f3c845fe	921	7a59bb8f-1168-11ea-9bfa-0a42f3c845fe	136	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dae94-1168-11ea-9bfa-0a42f3c845fe	922	7a5b8add-1168-11ea-9bfa-0a42f3c845fe	922	7a59bb8f-1168-11ea-9bfa-0a42f3c845fe	136	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5daf9e-1168-11ea-9bfa-0a42f3c845fe	923	7a5b8be8-1168-11ea-9bfa-0a42f3c845fe	923	7a59bd9f-1168-11ea-9bfa-0a42f3c845fe	137	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5db066-1168-11ea-9bfa-0a42f3c845fe	924	7a5b8da5-1168-11ea-9bfa-0a42f3c845fe	924	7a59bd9f-1168-11ea-9bfa-0a42f3c845fe	137	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5db2b4-1168-11ea-9bfa-0a42f3c845fe	925	7a5b8eab-1168-11ea-9bfa-0a42f3c845fe	925	7a59bea5-1168-11ea-9bfa-0a42f3c845fe	138	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5db3ba-1168-11ea-9bfa-0a42f3c845fe	926	7a5b9065-1168-11ea-9bfa-0a42f3c845fe	926	7a59bea5-1168-11ea-9bfa-0a42f3c845fe	138	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e18c9-1168-11ea-9bfa-0a42f3c845fe	MIX	7a5beda4-1168-11ea-9bfa-0a42f3c845fe	MIX	7a59e65a-1168-11ea-9bfa-0a42f3c845fe	MIX	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cd880-1168-11ea-9bfa-0a42f3c845fe	491	7a5aca00-1168-11ea-9bfa-0a42f3c845fe	491	7a596af3-1168-11ea-9bfa-0a42f3c845fe	76	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cd959-1168-11ea-9bfa-0a42f3c845fe	492	7a5acd33-1168-11ea-9bfa-0a42f3c845fe	492	7a596af3-1168-11ea-9bfa-0a42f3c845fe	76	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cda1f-1168-11ea-9bfa-0a42f3c845fe	493	7a5ace4c-1168-11ea-9bfa-0a42f3c845fe	493	7a596cd2-1168-11ea-9bfa-0a42f3c845fe	77	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c0895-1168-11ea-9bfa-0a42f3c845fe	131	7a59f5fc-1168-11ea-9bfa-0a42f3c845fe	131	7a59176c-1168-11ea-9bfa-0a42f3c845fe	6	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cdbce-1168-11ea-9bfa-0a42f3c845fe	494	7a5ad005-1168-11ea-9bfa-0a42f3c845fe	494	7a596cd2-1168-11ea-9bfa-0a42f3c845fe	77	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c0a42-1168-11ea-9bfa-0a42f3c845fe	132	7a59f7f6-1168-11ea-9bfa-0a42f3c845fe	132	7a59176c-1168-11ea-9bfa-0a42f3c845fe	6	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c74c0-1168-11ea-9bfa-0a42f3c845fe	375	7a5a69fb-1168-11ea-9bfa-0a42f3c845fe	375	7a59460e-1168-11ea-9bfa-0a42f3c845fe	45	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7697-1168-11ea-9bfa-0a42f3c845fe	376	7a5a6ba5-1168-11ea-9bfa-0a42f3c845fe	376	7a59460e-1168-11ea-9bfa-0a42f3c845fe	45	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cdca0-1168-11ea-9bfa-0a42f3c845fe	497	7a5ad10a-1168-11ea-9bfa-0a42f3c845fe	497	7a596da6-1168-11ea-9bfa-0a42f3c845fe	78	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c0b07-1168-11ea-9bfa-0a42f3c845fe	135	7a59f91b-1168-11ea-9bfa-0a42f3c845fe	135	7a59183e-1168-11ea-9bfa-0a42f3c845fe	7	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cdd64-1168-11ea-9bfa-0a42f3c845fe	498	7a5ad2c2-1168-11ea-9bfa-0a42f3c845fe	498	7a596da6-1168-11ea-9bfa-0a42f3c845fe	78	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c0cda-1168-11ea-9bfa-0a42f3c845fe	136	7a59fa61-1168-11ea-9bfa-0a42f3c845fe	136	7a59183e-1168-11ea-9bfa-0a42f3c845fe	7	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c3ad0-1168-11ea-9bfa-0a42f3c845fe	257	7a5a2c96-1168-11ea-9bfa-0a42f3c845fe	257	7a592c31-1168-11ea-9bfa-0a42f3c845fe	24	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c0da3-1168-11ea-9bfa-0a42f3c845fe	137	7a59fc11-1168-11ea-9bfa-0a42f3c845fe	137	7a5919df-1168-11ea-9bfa-0a42f3c845fe	8	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c3cda-1168-11ea-9bfa-0a42f3c845fe	258	7a5a2d9d-1168-11ea-9bfa-0a42f3c845fe	258	7a592c31-1168-11ea-9bfa-0a42f3c845fe	24	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c1070-1168-11ea-9bfa-0a42f3c845fe	138	7a59fd15-1168-11ea-9bfa-0a42f3c845fe	138	7a5919df-1168-11ea-9bfa-0a42f3c845fe	8	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d6532-1168-11ea-9bfa-0a42f3c845fe	813	7a5b4def-1168-11ea-9bfa-0a42f3c845fe	813	7a59a3e7-1168-11ea-9bfa-0a42f3c845fe	118	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d69a0-1168-11ea-9bfa-0a42f3c845fe	814	7a5b50d8-1168-11ea-9bfa-0a42f3c845fe	814	7a59a3e7-1168-11ea-9bfa-0a42f3c845fe	118	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d6c9a-1168-11ea-9bfa-0a42f3c845fe	815	7a5b52c9-1168-11ea-9bfa-0a42f3c845fe	815	7a59a58d-1168-11ea-9bfa-0a42f3c845fe	119	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d7241-1168-11ea-9bfa-0a42f3c845fe	816	7a5b54ca-1168-11ea-9bfa-0a42f3c845fe	816	7a59a58d-1168-11ea-9bfa-0a42f3c845fe	119	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5db484-1168-11ea-9bfa-0a42f3c845fe	937	7a5b9171-1168-11ea-9bfa-0a42f3c845fe	937	7a59c0e1-1168-11ea-9bfa-0a42f3c845fe	139	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d74bc-1168-11ea-9bfa-0a42f3c845fe	817	7a5b5614-1168-11ea-9bfa-0a42f3c845fe	817	7a59a663-1168-11ea-9bfa-0a42f3c845fe	120	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5db63c-1168-11ea-9bfa-0a42f3c845fe	938	7a5b9333-1168-11ea-9bfa-0a42f3c845fe	938	7a59c0e1-1168-11ea-9bfa-0a42f3c845fe	139	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d7adf-1168-11ea-9bfa-0a42f3c845fe	818	7a5b586b-1168-11ea-9bfa-0a42f3c845fe	818	7a59a663-1168-11ea-9bfa-0a42f3c845fe	120	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c3db6-1168-11ea-9bfa-0a42f3c845fe	261	7a5a2f56-1168-11ea-9bfa-0a42f3c845fe	261	7a592e26-1168-11ea-9bfa-0a42f3c845fe	25	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c1141-1168-11ea-9bfa-0a42f3c845fe	141	7a59fec1-1168-11ea-9bfa-0a42f3c845fe	141	7a591ab7-1168-11ea-9bfa-0a42f3c845fe	9	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c409e-1168-11ea-9bfa-0a42f3c845fe	262	7a5a3061-1168-11ea-9bfa-0a42f3c845fe	262	7a592e26-1168-11ea-9bfa-0a42f3c845fe	25	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7780-1168-11ea-9bfa-0a42f3c845fe	383	7a5a6ca8-1168-11ea-9bfa-0a42f3c845fe	383	7a5946d0-1168-11ea-9bfa-0a42f3c845fe	46	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c136b-1168-11ea-9bfa-0a42f3c845fe	142	7a59ffc8-1168-11ea-9bfa-0a42f3c845fe	142	7a591ab7-1168-11ea-9bfa-0a42f3c845fe	9	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c79e8-1168-11ea-9bfa-0a42f3c845fe	384	7a5a6e47-1168-11ea-9bfa-0a42f3c845fe	384	7a5946d0-1168-11ea-9bfa-0a42f3c845fe	46	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7adf-1168-11ea-9bfa-0a42f3c845fe	385	7a5a6f4a-1168-11ea-9bfa-0a42f3c845fe	385	7a594899-1168-11ea-9bfa-0a42f3c845fe	47	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7ba2-1168-11ea-9bfa-0a42f3c845fe	386	7a5a7101-1168-11ea-9bfa-0a42f3c845fe	386	7a594899-1168-11ea-9bfa-0a42f3c845fe	47	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c1454-1168-11ea-9bfa-0a42f3c845fe	145	7a5a0183-1168-11ea-9bfa-0a42f3c845fe	145	7a591b7e-1168-11ea-9bfa-0a42f3c845fe	10	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7e43-1168-11ea-9bfa-0a42f3c845fe	387	7a5a7201-1168-11ea-9bfa-0a42f3c845fe	387	7a59496d-1168-11ea-9bfa-0a42f3c845fe	48	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c165e-1168-11ea-9bfa-0a42f3c845fe	146	7a5a0285-1168-11ea-9bfa-0a42f3c845fe	146	7a591b7e-1168-11ea-9bfa-0a42f3c845fe	10	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c4180-1168-11ea-9bfa-0a42f3c845fe	267	7a5a321f-1168-11ea-9bfa-0a42f3c845fe	267	7a592f01-1168-11ea-9bfa-0a42f3c845fe	26	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c7f49-1168-11ea-9bfa-0a42f3c845fe	388	7a5a73b8-1168-11ea-9bfa-0a42f3c845fe	388	7a59496d-1168-11ea-9bfa-0a42f3c845fe	48	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c1733-1168-11ea-9bfa-0a42f3c845fe	147	7a5a0443-1168-11ea-9bfa-0a42f3c845fe	147	7a591d76-1168-11ea-9bfa-0a42f3c845fe	11	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c43b1-1168-11ea-9bfa-0a42f3c845fe	268	7a5a331f-1168-11ea-9bfa-0a42f3c845fe	268	7a592f01-1168-11ea-9bfa-0a42f3c845fe	26	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c19b8-1168-11ea-9bfa-0a42f3c845fe	148	7a5a0548-1168-11ea-9bfa-0a42f3c845fe	148	7a591d76-1168-11ea-9bfa-0a42f3c845fe	11	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5db715-1168-11ea-9bfa-0a42f3c845fe	943	7a5b9437-1168-11ea-9bfa-0a42f3c845fe	943	7a59c1cd-1168-11ea-9bfa-0a42f3c845fe	140	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d7e6d-1168-11ea-9bfa-0a42f3c845fe	823	7a5b598b-1168-11ea-9bfa-0a42f3c845fe	823	7a59a72a-1168-11ea-9bfa-0a42f3c845fe	121	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5db7d6-1168-11ea-9bfa-0a42f3c845fe	944	7a5b960c-1168-11ea-9bfa-0a42f3c845fe	944	7a59c1cd-1168-11ea-9bfa-0a42f3c845fe	140	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8156-1168-11ea-9bfa-0a42f3c845fe	824	7a5b5b3a-1168-11ea-9bfa-0a42f3c845fe	824	7a59a72a-1168-11ea-9bfa-0a42f3c845fe	121	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df589-1168-11ea-9bfa-0a42f3c845fe	1022	7a5bc46f-1168-11ea-9bfa-0a42f3c845fe	1022	7a59d0ba-1168-11ea-9bfa-0a42f3c845fe	154	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df261-1168-11ea-9bfa-0a42f3c845fe	1021	7a5bc228-1168-11ea-9bfa-0a42f3c845fe	1021	7a59d0ba-1168-11ea-9bfa-0a42f3c845fe	154	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c801a-1168-11ea-9bfa-0a42f3c845fe	391	7a5a74b6-1168-11ea-9bfa-0a42f3c845fe	391	7a594a32-1168-11ea-9bfa-0a42f3c845fe	49	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c4486-1168-11ea-9bfa-0a42f3c845fe	271	7a5a34e4-1168-11ea-9bfa-0a42f3c845fe	271	7a593100-1168-11ea-9bfa-0a42f3c845fe	27	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c81e9-1168-11ea-9bfa-0a42f3c845fe	392	7a5a767c-1168-11ea-9bfa-0a42f3c845fe	392	7a594a32-1168-11ea-9bfa-0a42f3c845fe	49	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c46c6-1168-11ea-9bfa-0a42f3c845fe	272	7a5a35e5-1168-11ea-9bfa-0a42f3c845fe	272	7a593100-1168-11ea-9bfa-0a42f3c845fe	27	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c82be-1168-11ea-9bfa-0a42f3c845fe	393	7a5a777c-1168-11ea-9bfa-0a42f3c845fe	393	7a594c16-1168-11ea-9bfa-0a42f3c845fe	50	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c8381-1168-11ea-9bfa-0a42f3c845fe	394	7a5a7947-1168-11ea-9bfa-0a42f3c845fe	394	7a594c16-1168-11ea-9bfa-0a42f3c845fe	50	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c8559-1168-11ea-9bfa-0a42f3c845fe	395	7a5a7b27-1168-11ea-9bfa-0a42f3c845fe	395	7a594cec-1168-11ea-9bfa-0a42f3c845fe	51	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c8629-1168-11ea-9bfa-0a42f3c845fe	396	7a5a7d1d-1168-11ea-9bfa-0a42f3c845fe	396	7a594cec-1168-11ea-9bfa-0a42f3c845fe	51	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c47b1-1168-11ea-9bfa-0a42f3c845fe	277	7a5a37b5-1168-11ea-9bfa-0a42f3c845fe	277	7a5931dd-1168-11ea-9bfa-0a42f3c845fe	28	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df19f-1168-11ea-9bfa-0a42f3c845fe	1016	7a5bc120-1168-11ea-9bfa-0a42f3c845fe	1016	7a59cfee-1168-11ea-9bfa-0a42f3c845fe	153	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c48f0-1168-11ea-9bfa-0a42f3c845fe	278	7a5a38b2-1168-11ea-9bfa-0a42f3c845fe	278	7a5931dd-1168-11ea-9bfa-0a42f3c845fe	28	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df0de-1168-11ea-9bfa-0a42f3c845fe	1015	7a5bbed6-1168-11ea-9bfa-0a42f3c845fe	1015	7a59cfee-1168-11ea-9bfa-0a42f3c845fe	153	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df013-1168-11ea-9bfa-0a42f3c845fe	1014	7a5bbdd3-1168-11ea-9bfa-0a42f3c845fe	1014	7a59cf17-1168-11ea-9bfa-0a42f3c845fe	152	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dbb2c-1168-11ea-9bfa-0a42f3c845fe	951	7a5b97f0-1168-11ea-9bfa-0a42f3c845fe	951	7a59c2dc-1168-11ea-9bfa-0a42f3c845fe	141	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5def06-1168-11ea-9bfa-0a42f3c845fe	1013	7a5bbc1b-1168-11ea-9bfa-0a42f3c845fe	1013	7a59cf17-1168-11ea-9bfa-0a42f3c845fe	152	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dbecd-1168-11ea-9bfa-0a42f3c845fe	952	7a5b99d6-1168-11ea-9bfa-0a42f3c845fe	952	7a59c2dc-1168-11ea-9bfa-0a42f3c845fe	141	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dc1b2-1168-11ea-9bfa-0a42f3c845fe	953	7a5b9bd4-1168-11ea-9bfa-0a42f3c845fe	953	7a59c3a8-1168-11ea-9bfa-0a42f3c845fe	142	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dc685-1168-11ea-9bfa-0a42f3c845fe	954	7a5b9d2a-1168-11ea-9bfa-0a42f3c845fe	954	7a59c3a8-1168-11ea-9bfa-0a42f3c845fe	142	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d3ff7-1168-11ea-9bfa-0a42f3c845fe	713	7a5b28dc-1168-11ea-9bfa-0a42f3c845fe	713	7a5993ee-1168-11ea-9bfa-0a42f3c845fe	106	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dcb80-1168-11ea-9bfa-0a42f3c845fe	955	7a5b9edf-1168-11ea-9bfa-0a42f3c845fe	955	7a59c53f-1168-11ea-9bfa-0a42f3c845fe	143	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d40f3-1168-11ea-9bfa-0a42f3c845fe	714	7a5b2a63-1168-11ea-9bfa-0a42f3c845fe	714	7a5993ee-1168-11ea-9bfa-0a42f3c845fe	106	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dce04-1168-11ea-9bfa-0a42f3c845fe	956	7a5b9fe8-1168-11ea-9bfa-0a42f3c845fe	956	7a59c53f-1168-11ea-9bfa-0a42f3c845fe	143	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d43b8-1168-11ea-9bfa-0a42f3c845fe	715	7a5b2b50-1168-11ea-9bfa-0a42f3c845fe	715	7a5995e4-1168-11ea-9bfa-0a42f3c845fe	107	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dd241-1168-11ea-9bfa-0a42f3c845fe	957	7a5ba194-1168-11ea-9bfa-0a42f3c845fe	957	7a59c611-1168-11ea-9bfa-0a42f3c845fe	144	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d44b7-1168-11ea-9bfa-0a42f3c845fe	716	7a5b2ce3-1168-11ea-9bfa-0a42f3c845fe	716	7a5995e4-1168-11ea-9bfa-0a42f3c845fe	107	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dd497-1168-11ea-9bfa-0a42f3c845fe	958	7a5ba29a-1168-11ea-9bfa-0a42f3c845fe	958	7a59c611-1168-11ea-9bfa-0a42f3c845fe	144	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dfba5-1168-11ea-9bfa-0a42f3c845fe	1032	7a5bd247-1168-11ea-9bfa-0a42f3c845fe	1032	7a59d41b-1168-11ea-9bfa-0a42f3c845fe	157	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dface-1168-11ea-9bfa-0a42f3c845fe	1031	7a5bcff9-1168-11ea-9bfa-0a42f3c845fe	1031	7a59d41b-1168-11ea-9bfa-0a42f3c845fe	157	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c1a8c-1168-11ea-9bfa-0a42f3c845fe	161	7a5a0715-1168-11ea-9bfa-0a42f3c845fe	161	7a591e5c-1168-11ea-9bfa-0a42f3c845fe	12	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c1db0-1168-11ea-9bfa-0a42f3c845fe	162	7a5a0816-1168-11ea-9bfa-0a42f3c845fe	162	7a591e5c-1168-11ea-9bfa-0a42f3c845fe	12	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c49c2-1168-11ea-9bfa-0a42f3c845fe	283	7a5a3a93-1168-11ea-9bfa-0a42f3c845fe	283	7a5933f1-1168-11ea-9bfa-0a42f3c845fe	29	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c4b62-1168-11ea-9bfa-0a42f3c845fe	284	7a5a3c9d-1168-11ea-9bfa-0a42f3c845fe	284	7a5933f1-1168-11ea-9bfa-0a42f3c845fe	29	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c4c32-1168-11ea-9bfa-0a42f3c845fe	285	7a5a3df1-1168-11ea-9bfa-0a42f3c845fe	285	7a5934ca-1168-11ea-9bfa-0a42f3c845fe	30	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c4cf3-1168-11ea-9bfa-0a42f3c845fe	286	7a5a3f99-1168-11ea-9bfa-0a42f3c845fe	286	7a5934ca-1168-11ea-9bfa-0a42f3c845fe	30	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df8c8-1168-11ea-9bfa-0a42f3c845fe	1028	7a5bcd13-1168-11ea-9bfa-0a42f3c845fe	1028	7a59d35b-1168-11ea-9bfa-0a42f3c845fe	156	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df804-1168-11ea-9bfa-0a42f3c845fe	1027	7a5bcab8-1168-11ea-9bfa-0a42f3c845fe	1027	7a59d35b-1168-11ea-9bfa-0a42f3c845fe	156	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df745-1168-11ea-9bfa-0a42f3c845fe	1026	7a5bc8f8-1168-11ea-9bfa-0a42f3c845fe	1026	7a59d289-1168-11ea-9bfa-0a42f3c845fe	155	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5df681-1168-11ea-9bfa-0a42f3c845fe	1025	7a5bc6bd-1168-11ea-9bfa-0a42f3c845fe	1025	7a59d289-1168-11ea-9bfa-0a42f3c845fe	155	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d4580-1168-11ea-9bfa-0a42f3c845fe	721	7a5b2dd6-1168-11ea-9bfa-0a42f3c845fe	721	7a5996bb-1168-11ea-9bfa-0a42f3c845fe	108	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dd7c2-1168-11ea-9bfa-0a42f3c845fe	963	7a5ba455-1168-11ea-9bfa-0a42f3c845fe	963	7a59c6d6-1168-11ea-9bfa-0a42f3c845fe	145	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d4736-1168-11ea-9bfa-0a42f3c845fe	722	7a5b2f77-1168-11ea-9bfa-0a42f3c845fe	722	7a5996bb-1168-11ea-9bfa-0a42f3c845fe	108	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ddbfc-1168-11ea-9bfa-0a42f3c845fe	964	7a5ba557-1168-11ea-9bfa-0a42f3c845fe	964	7a59c6d6-1168-11ea-9bfa-0a42f3c845fe	145	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d480d-1168-11ea-9bfa-0a42f3c845fe	723	7a5b3066-1168-11ea-9bfa-0a42f3c845fe	723	7a5998bd-1168-11ea-9bfa-0a42f3c845fe	109	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ddd01-1168-11ea-9bfa-0a42f3c845fe	965	7a5ba750-1168-11ea-9bfa-0a42f3c845fe	965	7a59c876-1168-11ea-9bfa-0a42f3c845fe	146	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d48cf-1168-11ea-9bfa-0a42f3c845fe	724	7a5b3290-1168-11ea-9bfa-0a42f3c845fe	724	7a5998bd-1168-11ea-9bfa-0a42f3c845fe	109	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ddf0c-1168-11ea-9bfa-0a42f3c845fe	966	7a5ba861-1168-11ea-9bfa-0a42f3c845fe	966	7a59c876-1168-11ea-9bfa-0a42f3c845fe	146	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ddfdf-1168-11ea-9bfa-0a42f3c845fe	967	7a5baa9a-1168-11ea-9bfa-0a42f3c845fe	967	7a59c947-1168-11ea-9bfa-0a42f3c845fe	147	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5de1e9-1168-11ea-9bfa-0a42f3c845fe	968	7a5baba1-1168-11ea-9bfa-0a42f3c845fe	968	7a59c947-1168-11ea-9bfa-0a42f3c845fe	147	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d4a8e-1168-11ea-9bfa-0a42f3c845fe	727	7a5b338d-1168-11ea-9bfa-0a42f3c845fe	727	7a599993-1168-11ea-9bfa-0a42f3c845fe	110	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d4b63-1168-11ea-9bfa-0a42f3c845fe	728	7a5b3556-1168-11ea-9bfa-0a42f3c845fe	728	7a599993-1168-11ea-9bfa-0a42f3c845fe	110	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dffcc-1168-11ea-9bfa-0a42f3c845fe	1044	7a5bd7f2-1168-11ea-9bfa-0a42f3c845fe	1044	7a59d6ca-1168-11ea-9bfa-0a42f3c845fe	159	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dfefc-1168-11ea-9bfa-0a42f3c845fe	1043	7a5bd6ec-1168-11ea-9bfa-0a42f3c845fe	1043	7a59d6ca-1168-11ea-9bfa-0a42f3c845fe	159	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dfd2a-1168-11ea-9bfa-0a42f3c845fe	1042	7a5bd53b-1168-11ea-9bfa-0a42f3c845fe	1042	7a59d5f9-1168-11ea-9bfa-0a42f3c845fe	158	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dfc6a-1168-11ea-9bfa-0a42f3c845fe	1041	7a5bd403-1168-11ea-9bfa-0a42f3c845fe	1041	7a59d5f9-1168-11ea-9bfa-0a42f3c845fe	158	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c1f48-1168-11ea-9bfa-0a42f3c845fe	171	7a5a09ed-1168-11ea-9bfa-0a42f3c845fe	171	7a591f23-1168-11ea-9bfa-0a42f3c845fe	13	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c2015-1168-11ea-9bfa-0a42f3c845fe	172	7a5a0b03-1168-11ea-9bfa-0a42f3c845fe	172	7a591f23-1168-11ea-9bfa-0a42f3c845fe	13	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c4ea5-1168-11ea-9bfa-0a42f3c845fe	297	7a5a409e-1168-11ea-9bfa-0a42f3c845fe	297	7a5936eb-1168-11ea-9bfa-0a42f3c845fe	31	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c4f7a-1168-11ea-9bfa-0a42f3c845fe	298	7a5a4245-1168-11ea-9bfa-0a42f3c845fe	298	7a5936eb-1168-11ea-9bfa-0a42f3c845fe	31	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8402-1168-11ea-9bfa-0a42f3c845fe	851	7a5b5c45-1168-11ea-9bfa-0a42f3c845fe	851	7a59a984-1168-11ea-9bfa-0a42f3c845fe	122	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8715-1168-11ea-9bfa-0a42f3c845fe	852	7a5b5e00-1168-11ea-9bfa-0a42f3c845fe	852	7a59a984-1168-11ea-9bfa-0a42f3c845fe	122	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5de2bc-1168-11ea-9bfa-0a42f3c845fe	975	7a5bad79-1168-11ea-9bfa-0a42f3c845fe	975	7a59ca0a-1168-11ea-9bfa-0a42f3c845fe	148	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5de4cb-1168-11ea-9bfa-0a42f3c845fe	976	7a5bafcf-1168-11ea-9bfa-0a42f3c845fe	976	7a59ca0a-1168-11ea-9bfa-0a42f3c845fe	148	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5de59d-1168-11ea-9bfa-0a42f3c845fe	977	7a5bb195-1168-11ea-9bfa-0a42f3c845fe	977	7a59cbb4-1168-11ea-9bfa-0a42f3c845fe	149	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d0afa-1168-11ea-9bfa-0a42f3c845fe	615	7a5b034f-1168-11ea-9bfa-0a42f3c845fe	615	7a5984b3-1168-11ea-9bfa-0a42f3c845fe	94	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8814-1168-11ea-9bfa-0a42f3c845fe	857	7a5b5f09-1168-11ea-9bfa-0a42f3c845fe	857	7a59aa77-1168-11ea-9bfa-0a42f3c845fe	123	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5de7c4-1168-11ea-9bfa-0a42f3c845fe	978	7a5bb3ee-1168-11ea-9bfa-0a42f3c845fe	978	7a59cbb4-1168-11ea-9bfa-0a42f3c845fe	149	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d0f08-1168-11ea-9bfa-0a42f3c845fe	616	7a5b051c-1168-11ea-9bfa-0a42f3c845fe	616	7a5984b3-1168-11ea-9bfa-0a42f3c845fe	94	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d4c28-1168-11ea-9bfa-0a42f3c845fe	737	7a5b37b1-1168-11ea-9bfa-0a42f3c845fe	737	7a599ba3-1168-11ea-9bfa-0a42f3c845fe	111	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d88db-1168-11ea-9bfa-0a42f3c845fe	858	7a5b60ca-1168-11ea-9bfa-0a42f3c845fe	858	7a59aa77-1168-11ea-9bfa-0a42f3c845fe	123	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d12ab-1168-11ea-9bfa-0a42f3c845fe	617	7a5b0614-1168-11ea-9bfa-0a42f3c845fe	617	7a598673-1168-11ea-9bfa-0a42f3c845fe	95	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d4df5-1168-11ea-9bfa-0a42f3c845fe	738	7a5b3a2b-1168-11ea-9bfa-0a42f3c845fe	738	7a599ba3-1168-11ea-9bfa-0a42f3c845fe	111	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d1558-1168-11ea-9bfa-0a42f3c845fe	618	7a5b07d7-1168-11ea-9bfa-0a42f3c845fe	618	7a598673-1168-11ea-9bfa-0a42f3c845fe	95	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c21b8-1168-11ea-9bfa-0a42f3c845fe	185	7a5a0ce7-1168-11ea-9bfa-0a42f3c845fe	185	7a5920da-1168-11ea-9bfa-0a42f3c845fe	14	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c2288-1168-11ea-9bfa-0a42f3c845fe	186	7a5a0eea-1168-11ea-9bfa-0a42f3c845fe	186	7a5920da-1168-11ea-9bfa-0a42f3c845fe	14	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c2354-1168-11ea-9bfa-0a42f3c845fe	187	7a5a1035-1168-11ea-9bfa-0a42f3c845fe	187	7a5921c0-1168-11ea-9bfa-0a42f3c845fe	15	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c2502-1168-11ea-9bfa-0a42f3c845fe	188	7a5a120c-1168-11ea-9bfa-0a42f3c845fe	188	7a5921c0-1168-11ea-9bfa-0a42f3c845fe	15	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5de899-1168-11ea-9bfa-0a42f3c845fe	981	7a5bb5ca-1168-11ea-9bfa-0a42f3c845fe	981	7a59cc8d-1168-11ea-9bfa-0a42f3c845fe	150	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8a89-1168-11ea-9bfa-0a42f3c845fe	861	7a5b61d1-1168-11ea-9bfa-0a42f3c845fe	861	7a59ab40-1168-11ea-9bfa-0a42f3c845fe	124	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5deafd-1168-11ea-9bfa-0a42f3c845fe	982	7a5bb77a-1168-11ea-9bfa-0a42f3c845fe	982	7a59cc8d-1168-11ea-9bfa-0a42f3c845fe	150	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d4ec2-1168-11ea-9bfa-0a42f3c845fe	741	7a5b3c45-1168-11ea-9bfa-0a42f3c845fe	741	7a599c7c-1168-11ea-9bfa-0a42f3c845fe	112	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8b59-1168-11ea-9bfa-0a42f3c845fe	862	7a5b639d-1168-11ea-9bfa-0a42f3c845fe	862	7a59ab40-1168-11ea-9bfa-0a42f3c845fe	124	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5debd5-1168-11ea-9bfa-0a42f3c845fe	983	7a5bb880-1168-11ea-9bfa-0a42f3c845fe	983	7a59cd53-1168-11ea-9bfa-0a42f3c845fe	151	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d4f82-1168-11ea-9bfa-0a42f3c845fe	742	7a5b3d99-1168-11ea-9bfa-0a42f3c845fe	742	7a599c7c-1168-11ea-9bfa-0a42f3c845fe	112	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8c1c-1168-11ea-9bfa-0a42f3c845fe	863	7a5b64a9-1168-11ea-9bfa-0a42f3c845fe	863	7a59ad05-1168-11ea-9bfa-0a42f3c845fe	125	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5dee18-1168-11ea-9bfa-0a42f3c845fe	984	7a5bbb16-1168-11ea-9bfa-0a42f3c845fe	984	7a59cd53-1168-11ea-9bfa-0a42f3c845fe	151	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e0276-1168-11ea-9bfa-0a42f3c845fe	1046	7a5bdab9-1168-11ea-9bfa-0a42f3c845fe	1046	7a59d8b3-1168-11ea-9bfa-0a42f3c845fe	160	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d5239-1168-11ea-9bfa-0a42f3c845fe	743	7a5b3f4a-1168-11ea-9bfa-0a42f3c845fe	743	7a599eac-1168-11ea-9bfa-0a42f3c845fe	113	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8e05-1168-11ea-9bfa-0a42f3c845fe	864	7a5b676c-1168-11ea-9bfa-0a42f3c845fe	864	7a59ad05-1168-11ea-9bfa-0a42f3c845fe	125	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e0183-1168-11ea-9bfa-0a42f3c845fe	1045	7a5bd9ac-1168-11ea-9bfa-0a42f3c845fe	1045	7a59d8b3-1168-11ea-9bfa-0a42f3c845fe	160	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d5326-1168-11ea-9bfa-0a42f3c845fe	744	7a5b404e-1168-11ea-9bfa-0a42f3c845fe	744	7a599eac-1168-11ea-9bfa-0a42f3c845fe	113	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8ee3-1168-11ea-9bfa-0a42f3c845fe	865	7a5b695a-1168-11ea-9bfa-0a42f3c845fe	865	7a59add9-1168-11ea-9bfa-0a42f3c845fe	126	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d54ef-1168-11ea-9bfa-0a42f3c845fe	745	7a5b41fc-1168-11ea-9bfa-0a42f3c845fe	745	7a599fc6-1168-11ea-9bfa-0a42f3c845fe	114	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d8fa9-1168-11ea-9bfa-0a42f3c845fe	866	7a5b6b4b-1168-11ea-9bfa-0a42f3c845fe	866	7a59add9-1168-11ea-9bfa-0a42f3c845fe	126	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d5802-1168-11ea-9bfa-0a42f3c845fe	746	7a5b4305-1168-11ea-9bfa-0a42f3c845fe	746	7a599fc6-1168-11ea-9bfa-0a42f3c845fe	114	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d9175-1168-11ea-9bfa-0a42f3c845fe	867	7a5b6d53-1168-11ea-9bfa-0a42f3c845fe	867	7a59afa5-1168-11ea-9bfa-0a42f3c845fe	127	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d9249-1168-11ea-9bfa-0a42f3c845fe	868	7a5b6ea9-1168-11ea-9bfa-0a42f3c845fe	868	7a59afa5-1168-11ea-9bfa-0a42f3c845fe	127	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d1a6d-1168-11ea-9bfa-0a42f3c845fe	627	7a5b0a12-1168-11ea-9bfa-0a42f3c845fe	627	7a59874e-1168-11ea-9bfa-0a42f3c845fe	96	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d1d56-1168-11ea-9bfa-0a42f3c845fe	628	7a5b0c6f-1168-11ea-9bfa-0a42f3c845fe	628	7a59874e-1168-11ea-9bfa-0a42f3c845fe	96	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c25d9-1168-11ea-9bfa-0a42f3c845fe	191	7a5a1328-1168-11ea-9bfa-0a42f3c845fe	191	7a59228f-1168-11ea-9bfa-0a42f3c845fe	16	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c2696-1168-11ea-9bfa-0a42f3c845fe	192	7a5a14d1-1168-11ea-9bfa-0a42f3c845fe	192	7a59228f-1168-11ea-9bfa-0a42f3c845fe	16	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c284f-1168-11ea-9bfa-0a42f3c845fe	195	7a5a15d6-1168-11ea-9bfa-0a42f3c845fe	195	7a592456-1168-11ea-9bfa-0a42f3c845fe	17	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c291f-1168-11ea-9bfa-0a42f3c845fe	196	7a5a1786-1168-11ea-9bfa-0a42f3c845fe	196	7a592456-1168-11ea-9bfa-0a42f3c845fe	17	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d930b-1168-11ea-9bfa-0a42f3c845fe	873	7a5b709d-1168-11ea-9bfa-0a42f3c845fe	873	7a59b080-1168-11ea-9bfa-0a42f3c845fe	128	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d95c4-1168-11ea-9bfa-0a42f3c845fe	874	7a5b721c-1168-11ea-9bfa-0a42f3c845fe	874	7a59b080-1168-11ea-9bfa-0a42f3c845fe	128	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cdf1c-1168-11ea-9bfa-0a42f3c845fe	513	7a5ad3c5-1168-11ea-9bfa-0a42f3c845fe	513	7a59700f-1168-11ea-9bfa-0a42f3c845fe	79	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d590c-1168-11ea-9bfa-0a42f3c845fe	755	7a5b44bf-1168-11ea-9bfa-0a42f3c845fe	755	7a59a0a4-1168-11ea-9bfa-0a42f3c845fe	115	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cdfed-1168-11ea-9bfa-0a42f3c845fe	514	7a5ad58a-1168-11ea-9bfa-0a42f3c845fe	514	7a59700f-1168-11ea-9bfa-0a42f3c845fe	79	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d1ed2-1168-11ea-9bfa-0a42f3c845fe	635	7a5b0e64-1168-11ea-9bfa-0a42f3c845fe	635	7a598841-1168-11ea-9bfa-0a42f3c845fe	97	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d5b11-1168-11ea-9bfa-0a42f3c845fe	756	7a5b45c5-1168-11ea-9bfa-0a42f3c845fe	756	7a59a0a4-1168-11ea-9bfa-0a42f3c845fe	115	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d96c2-1168-11ea-9bfa-0a42f3c845fe	877	7a5b73c0-1168-11ea-9bfa-0a42f3c845fe	877	7a59b25a-1168-11ea-9bfa-0a42f3c845fe	129	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ce0b2-1168-11ea-9bfa-0a42f3c845fe	515	7a5ad687-1168-11ea-9bfa-0a42f3c845fe	515	7a5970de-1168-11ea-9bfa-0a42f3c845fe	80	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d2110-1168-11ea-9bfa-0a42f3c845fe	636	7a5b0fa6-1168-11ea-9bfa-0a42f3c845fe	636	7a598841-1168-11ea-9bfa-0a42f3c845fe	97	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d978b-1168-11ea-9bfa-0a42f3c845fe	878	7a5b74c3-1168-11ea-9bfa-0a42f3c845fe	878	7a59b25a-1168-11ea-9bfa-0a42f3c845fe	129	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ce342-1168-11ea-9bfa-0a42f3c845fe	516	7a5ad859-1168-11ea-9bfa-0a42f3c845fe	516	7a5970de-1168-11ea-9bfa-0a42f3c845fe	80	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ce442-1168-11ea-9bfa-0a42f3c845fe	517	7a5ada9d-1168-11ea-9bfa-0a42f3c845fe	517	7a597372-1168-11ea-9bfa-0a42f3c845fe	81	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ce5d4-1168-11ea-9bfa-0a42f3c845fe	518	7a5adc71-1168-11ea-9bfa-0a42f3c845fe	518	7a597372-1168-11ea-9bfa-0a42f3c845fe	81	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d997f-1168-11ea-9bfa-0a42f3c845fe	881	7a5b7672-1168-11ea-9bfa-0a42f3c845fe	881	7a59b331-1168-11ea-9bfa-0a42f3c845fe	130	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d9a57-1168-11ea-9bfa-0a42f3c845fe	882	7a5b7777-1168-11ea-9bfa-0a42f3c845fe	882	7a59b331-1168-11ea-9bfa-0a42f3c845fe	130	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d21f1-1168-11ea-9bfa-0a42f3c845fe	641	7a5b1147-1168-11ea-9bfa-0a42f3c845fe	641	7a598a16-1168-11ea-9bfa-0a42f3c845fe	98	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d9c4e-1168-11ea-9bfa-0a42f3c845fe	883	7a5b792a-1168-11ea-9bfa-0a42f3c845fe	883	7a59b510-1168-11ea-9bfa-0a42f3c845fe	131	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d22b6-1168-11ea-9bfa-0a42f3c845fe	642	7a5b1245-1168-11ea-9bfa-0a42f3c845fe	642	7a598a16-1168-11ea-9bfa-0a42f3c845fe	98	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d9dfa-1168-11ea-9bfa-0a42f3c845fe	884	7a5b7a2e-1168-11ea-9bfa-0a42f3c845fe	884	7a59b510-1168-11ea-9bfa-0a42f3c845fe	131	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ce7f1-1168-11ea-9bfa-0a42f3c845fe	523	7a5adedc-1168-11ea-9bfa-0a42f3c845fe	523	7a597455-1168-11ea-9bfa-0a42f3c845fe	82	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ce9a4-1168-11ea-9bfa-0a42f3c845fe	524	7a5ae025-1168-11ea-9bfa-0a42f3c845fe	524	7a597455-1168-11ea-9bfa-0a42f3c845fe	82	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ceaa6-1168-11ea-9bfa-0a42f3c845fe	525	7a5ae246-1168-11ea-9bfa-0a42f3c845fe	525	7a597664-1168-11ea-9bfa-0a42f3c845fe	83	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ced8e-1168-11ea-9bfa-0a42f3c845fe	526	7a5ae33d-1168-11ea-9bfa-0a42f3c845fe	526	7a597664-1168-11ea-9bfa-0a42f3c845fe	83	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d24a7-1168-11ea-9bfa-0a42f3c845fe	647	7a5b13e8-1168-11ea-9bfa-0a42f3c845fe	647	7a598aee-1168-11ea-9bfa-0a42f3c845fe	99	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cee79-1168-11ea-9bfa-0a42f3c845fe	527	7a5ae55a-1168-11ea-9bfa-0a42f3c845fe	527	7a597739-1168-11ea-9bfa-0a42f3c845fe	84	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d2577-1168-11ea-9bfa-0a42f3c845fe	648	7a5b14e3-1168-11ea-9bfa-0a42f3c845fe	648	7a598aee-1168-11ea-9bfa-0a42f3c845fe	99	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cf074-1168-11ea-9bfa-0a42f3c845fe	528	7a5ae65e-1168-11ea-9bfa-0a42f3c845fe	528	7a597739-1168-11ea-9bfa-0a42f3c845fe	84	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c86ee-1168-11ea-9bfa-0a42f3c845fe	411	7a5a7f1c-1168-11ea-9bfa-0a42f3c845fe	411	7a594ed7-1168-11ea-9bfa-0a42f3c845fe	52	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c88d1-1168-11ea-9bfa-0a42f3c845fe	412	7a5a805f-1168-11ea-9bfa-0a42f3c845fe	412	7a594ed7-1168-11ea-9bfa-0a42f3c845fe	52	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cf16f-1168-11ea-9bfa-0a42f3c845fe	533	7a5ae80e-1168-11ea-9bfa-0a42f3c845fe	533	7a597955-1168-11ea-9bfa-0a42f3c845fe	85	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c89a4-1168-11ea-9bfa-0a42f3c845fe	413	7a5a8200-1168-11ea-9bfa-0a42f3c845fe	413	7a594fa9-1168-11ea-9bfa-0a42f3c845fe	53	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cf382-1168-11ea-9bfa-0a42f3c845fe	534	7a5ae90a-1168-11ea-9bfa-0a42f3c845fe	534	7a597955-1168-11ea-9bfa-0a42f3c845fe	85	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c8bbe-1168-11ea-9bfa-0a42f3c845fe	414	7a5a82fc-1168-11ea-9bfa-0a42f3c845fe	414	7a594fa9-1168-11ea-9bfa-0a42f3c845fe	53	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e0a6c-1168-11ea-9bfa-0a42f3c845fe	535	7a5be73a-1168-11ea-9bfa-0a42f3c845fe	535	7a59e23a-1168-11ea-9bfa-0a42f3c845fe	535	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d5d2e-1168-11ea-9bfa-0a42f3c845fe	777	7a5b4785-1168-11ea-9bfa-0a42f3c845fe	777	7a59a240-1168-11ea-9bfa-0a42f3c845fe	116	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c8c9a-1168-11ea-9bfa-0a42f3c845fe	415	7a5a84a4-1168-11ea-9bfa-0a42f3c845fe	415	7a59519f-1168-11ea-9bfa-0a42f3c845fe	54	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e0cac-1168-11ea-9bfa-0a42f3c845fe	536	7a5be93d-1168-11ea-9bfa-0a42f3c845fe	536	7a59e341-1168-11ea-9bfa-0a42f3c845fe	536	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d613f-1168-11ea-9bfa-0a42f3c845fe	778	7a5b488b-1168-11ea-9bfa-0a42f3c845fe	778	7a59a240-1168-11ea-9bfa-0a42f3c845fe	116	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c93b6-1168-11ea-9bfa-0a42f3c845fe	416	7a5a85a6-1168-11ea-9bfa-0a42f3c845fe	416	7a59519f-1168-11ea-9bfa-0a42f3c845fe	54	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cf459-1168-11ea-9bfa-0a42f3c845fe	537	7a5aeacd-1168-11ea-9bfa-0a42f3c845fe	537	7a597a42-1168-11ea-9bfa-0a42f3c845fe	86	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cf66e-1168-11ea-9bfa-0a42f3c845fe	538	7a5aebcb-1168-11ea-9bfa-0a42f3c845fe	538	7a597a42-1168-11ea-9bfa-0a42f3c845fe	86	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d276e-1168-11ea-9bfa-0a42f3c845fe	661	7a5b168e-1168-11ea-9bfa-0a42f3c845fe	661	7a598bb6-1168-11ea-9bfa-0a42f3c845fe	100	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d283f-1168-11ea-9bfa-0a42f3c845fe	662	7a5b178d-1168-11ea-9bfa-0a42f3c845fe	662	7a598bb6-1168-11ea-9bfa-0a42f3c845fe	100	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c94d3-1168-11ea-9bfa-0a42f3c845fe	421	7a5a8757-1168-11ea-9bfa-0a42f3c845fe	421	7a5952af-1168-11ea-9bfa-0a42f3c845fe	55	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d2a70-1168-11ea-9bfa-0a42f3c845fe	663	7a5b1942-1168-11ea-9bfa-0a42f3c845fe	663	7a598d92-1168-11ea-9bfa-0a42f3c845fe	101	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c96f7-1168-11ea-9bfa-0a42f3c845fe	422	7a5a8852-1168-11ea-9bfa-0a42f3c845fe	422	7a5952af-1168-11ea-9bfa-0a42f3c845fe	55	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d2bcc-1168-11ea-9bfa-0a42f3c845fe	664	7a5b1a44-1168-11ea-9bfa-0a42f3c845fe	664	7a598d92-1168-11ea-9bfa-0a42f3c845fe	101	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d6240-1168-11ea-9bfa-0a42f3c845fe	785	7a5b4b48-1168-11ea-9bfa-0a42f3c845fe	785	7a59a31a-1168-11ea-9bfa-0a42f3c845fe	117	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c97cc-1168-11ea-9bfa-0a42f3c845fe	423	7a5a8a0d-1168-11ea-9bfa-0a42f3c845fe	423	7a5954bc-1168-11ea-9bfa-0a42f3c845fe	56	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d2e28-1168-11ea-9bfa-0a42f3c845fe	665	7a5b1c07-1168-11ea-9bfa-0a42f3c845fe	665	7a598e67-1168-11ea-9bfa-0a42f3c845fe	102	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d6460-1168-11ea-9bfa-0a42f3c845fe	786	7a5b4c3a-1168-11ea-9bfa-0a42f3c845fe	786	7a59a31a-1168-11ea-9bfa-0a42f3c845fe	117	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c99e9-1168-11ea-9bfa-0a42f3c845fe	424	7a5a8c0d-1168-11ea-9bfa-0a42f3c845fe	424	7a5954bc-1168-11ea-9bfa-0a42f3c845fe	56	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cf73f-1168-11ea-9bfa-0a42f3c845fe	545	7a5aed94-1168-11ea-9bfa-0a42f3c845fe	545	7a597b82-1168-11ea-9bfa-0a42f3c845fe	87	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d2f07-1168-11ea-9bfa-0a42f3c845fe	666	7a5b1e25-1168-11ea-9bfa-0a42f3c845fe	666	7a598e67-1168-11ea-9bfa-0a42f3c845fe	102	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c9abb-1168-11ea-9bfa-0a42f3c845fe	425	7a5a8e4a-1168-11ea-9bfa-0a42f3c845fe	425	7a595593-1168-11ea-9bfa-0a42f3c845fe	57	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cf95d-1168-11ea-9bfa-0a42f3c845fe	546	7a5aee8f-1168-11ea-9bfa-0a42f3c845fe	546	7a597b82-1168-11ea-9bfa-0a42f3c845fe	87	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c9ce5-1168-11ea-9bfa-0a42f3c845fe	426	7a5a8f5a-1168-11ea-9bfa-0a42f3c845fe	426	7a595593-1168-11ea-9bfa-0a42f3c845fe	57	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c9db5-1168-11ea-9bfa-0a42f3c845fe	427	7a5a912d-1168-11ea-9bfa-0a42f3c845fe	427	7a5957a7-1168-11ea-9bfa-0a42f3c845fe	58	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c9fec-1168-11ea-9bfa-0a42f3c845fe	428	7a5a922d-1168-11ea-9bfa-0a42f3c845fe	428	7a5957a7-1168-11ea-9bfa-0a42f3c845fe	58	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d32b8-1168-11ea-9bfa-0a42f3c845fe	671	7a5b1fce-1168-11ea-9bfa-0a42f3c845fe	671	7a59904f-1168-11ea-9bfa-0a42f3c845fe	103	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d33d6-1168-11ea-9bfa-0a42f3c845fe	672	7a5b2181-1168-11ea-9bfa-0a42f3c845fe	672	7a59904f-1168-11ea-9bfa-0a42f3c845fe	103	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ca0d4-1168-11ea-9bfa-0a42f3c845fe	431	7a5a9411-1168-11ea-9bfa-0a42f3c845fe	431	7a59588f-1168-11ea-9bfa-0a42f3c845fe	59	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c503c-1168-11ea-9bfa-0a42f3c845fe	311	7a5a4344-1168-11ea-9bfa-0a42f3c845fe	311	7a5937dc-1168-11ea-9bfa-0a42f3c845fe	32	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ca1e2-1168-11ea-9bfa-0a42f3c845fe	432	7a5a960e-1168-11ea-9bfa-0a42f3c845fe	432	7a59588f-1168-11ea-9bfa-0a42f3c845fe	59	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cfa30-1168-11ea-9bfa-0a42f3c845fe	553	7a5af061-1168-11ea-9bfa-0a42f3c845fe	553	7a597d03-1168-11ea-9bfa-0a42f3c845fe	88	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c51ee-1168-11ea-9bfa-0a42f3c845fe	312	7a5a44f3-1168-11ea-9bfa-0a42f3c845fe	312	7a5937dc-1168-11ea-9bfa-0a42f3c845fe	32	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ca2aa-1168-11ea-9bfa-0a42f3c845fe	433	7a5a977f-1168-11ea-9bfa-0a42f3c845fe	433	7a59599a-1168-11ea-9bfa-0a42f3c845fe	60	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cfc5c-1168-11ea-9bfa-0a42f3c845fe	554	7a5af230-1168-11ea-9bfa-0a42f3c845fe	554	7a597d03-1168-11ea-9bfa-0a42f3c845fe	88	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c52bf-1168-11ea-9bfa-0a42f3c845fe	313	7a5a45f2-1168-11ea-9bfa-0a42f3c845fe	313	7a5938eb-1168-11ea-9bfa-0a42f3c845fe	33	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ca449-1168-11ea-9bfa-0a42f3c845fe	434	7a5a99a4-1168-11ea-9bfa-0a42f3c845fe	434	7a59599a-1168-11ea-9bfa-0a42f3c845fe	60	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c537e-1168-11ea-9bfa-0a42f3c845fe	314	7a5a47a8-1168-11ea-9bfa-0a42f3c845fe	314	7a5938eb-1168-11ea-9bfa-0a42f3c845fe	33	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ca521-1168-11ea-9bfa-0a42f3c845fe	435	7a5a9a9f-1168-11ea-9bfa-0a42f3c845fe	435	7a595a64-1168-11ea-9bfa-0a42f3c845fe	61	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ca5e7-1168-11ea-9bfa-0a42f3c845fe	436	7a5a9cb1-1168-11ea-9bfa-0a42f3c845fe	436	7a595a64-1168-11ea-9bfa-0a42f3c845fe	61	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cfe06-1168-11ea-9bfa-0a42f3c845fe	557	7a5af42a-1168-11ea-9bfa-0a42f3c845fe	557	7a597ed1-1168-11ea-9bfa-0a42f3c845fe	89	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d0089-1168-11ea-9bfa-0a42f3c845fe	558	7a5af62b-1168-11ea-9bfa-0a42f3c845fe	558	7a597ed1-1168-11ea-9bfa-0a42f3c845fe	89	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d0178-1168-11ea-9bfa-0a42f3c845fe	563	7a5af7a8-1168-11ea-9bfa-0a42f3c845fe	563	7a597fab-1168-11ea-9bfa-0a42f3c845fe	90	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ca795-1168-11ea-9bfa-0a42f3c845fe	443	7a5a9db1-1168-11ea-9bfa-0a42f3c845fe	443	7a595bff-1168-11ea-9bfa-0a42f3c845fe	62	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d027f-1168-11ea-9bfa-0a42f3c845fe	564	7a5af94e-1168-11ea-9bfa-0a42f3c845fe	564	7a597fab-1168-11ea-9bfa-0a42f3c845fe	90	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d361a-1168-11ea-9bfa-0a42f3c845fe	685	7a5b2345-1168-11ea-9bfa-0a42f3c845fe	685	7a599128-1168-11ea-9bfa-0a42f3c845fe	104	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5ca868-1168-11ea-9bfa-0a42f3c845fe	444	7a5a9f63-1168-11ea-9bfa-0a42f3c845fe	444	7a595bff-1168-11ea-9bfa-0a42f3c845fe	62	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d3873-1168-11ea-9bfa-0a42f3c845fe	686	7a5b2514-1168-11ea-9bfa-0a42f3c845fe	686	7a599128-1168-11ea-9bfa-0a42f3c845fe	104	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5caa41-1168-11ea-9bfa-0a42f3c845fe	445	7a5aa060-1168-11ea-9bfa-0a42f3c845fe	445	7a595cd7-1168-11ea-9bfa-0a42f3c845fe	63	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cac6a-1168-11ea-9bfa-0a42f3c845fe	446	7a5aa21c-1168-11ea-9bfa-0a42f3c845fe	446	7a595cd7-1168-11ea-9bfa-0a42f3c845fe	63	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d0363-1168-11ea-9bfa-0a42f3c845fe	567	7a5afa4e-1168-11ea-9bfa-0a42f3c845fe	567	7a598074-1168-11ea-9bfa-0a42f3c845fe	91	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e08d6-1168-11ea-9bfa-0a42f3c845fe	447	7a5be35d-1168-11ea-9bfa-0a42f3c845fe	447	7a59df3d-1168-11ea-9bfa-0a42f3c845fe	447	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d050c-1168-11ea-9bfa-0a42f3c845fe	568	7a5afc61-1168-11ea-9bfa-0a42f3c845fe	568	7a598074-1168-11ea-9bfa-0a42f3c845fe	91	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c5541-1168-11ea-9bfa-0a42f3c845fe	327	7a5a48a6-1168-11ea-9bfa-0a42f3c845fe	327	7a5939b4-1168-11ea-9bfa-0a42f3c845fe	34	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e09ae-1168-11ea-9bfa-0a42f3c845fe	448	7a5be54b-1168-11ea-9bfa-0a42f3c845fe	448	7a59e153-1168-11ea-9bfa-0a42f3c845fe	448	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c5616-1168-11ea-9bfa-0a42f3c845fe	328	7a5a4a65-1168-11ea-9bfa-0a42f3c845fe	328	7a5939b4-1168-11ea-9bfa-0a42f3c845fe	34	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d05e4-1168-11ea-9bfa-0a42f3c845fe	571	7a5afdcb-1168-11ea-9bfa-0a42f3c845fe	571	7a59821b-1168-11ea-9bfa-0a42f3c845fe	92	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cad46-1168-11ea-9bfa-0a42f3c845fe	451	7a5aa31a-1168-11ea-9bfa-0a42f3c845fe	451	7a595d9d-1168-11ea-9bfa-0a42f3c845fe	64	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d06a6-1168-11ea-9bfa-0a42f3c845fe	572	7a5aff61-1168-11ea-9bfa-0a42f3c845fe	572	7a59821b-1168-11ea-9bfa-0a42f3c845fe	92	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c56d7-1168-11ea-9bfa-0a42f3c845fe	331	7a5a4b5f-1168-11ea-9bfa-0a42f3c845fe	331	7a593b4e-1168-11ea-9bfa-0a42f3c845fe	35	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cae0c-1168-11ea-9bfa-0a42f3c845fe	452	7a5aa4e2-1168-11ea-9bfa-0a42f3c845fe	452	7a595d9d-1168-11ea-9bfa-0a42f3c845fe	64	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d0854-1168-11ea-9bfa-0a42f3c845fe	573	7a5b0058-1168-11ea-9bfa-0a42f3c845fe	573	7a5983e1-1168-11ea-9bfa-0a42f3c845fe	93	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c29de-1168-11ea-9bfa-0a42f3c845fe	211	7a5a1887-1168-11ea-9bfa-0a42f3c845fe	211	7a592530-1168-11ea-9bfa-0a42f3c845fe	18	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c58a8-1168-11ea-9bfa-0a42f3c845fe	332	7a5a4d38-1168-11ea-9bfa-0a42f3c845fe	332	7a593b4e-1168-11ea-9bfa-0a42f3c845fe	35	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d0a2a-1168-11ea-9bfa-0a42f3c845fe	574	7a5b01f4-1168-11ea-9bfa-0a42f3c845fe	574	7a5983e1-1168-11ea-9bfa-0a42f3c845fe	93	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d3bc6-1168-11ea-9bfa-0a42f3c845fe	695	7a5b2645-1168-11ea-9bfa-0a42f3c845fe	695	7a599315-1168-11ea-9bfa-0a42f3c845fe	105	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c2d2a-1168-11ea-9bfa-0a42f3c845fe	212	7a5a1a3f-1168-11ea-9bfa-0a42f3c845fe	212	7a592530-1168-11ea-9bfa-0a42f3c845fe	18	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5d3e06-1168-11ea-9bfa-0a42f3c845fe	696	7a5b27d4-1168-11ea-9bfa-0a42f3c845fe	696	7a599315-1168-11ea-9bfa-0a42f3c845fe	105	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e046d-1168-11ea-9bfa-0a42f3c845fe	213	7a5bdca8-1168-11ea-9bfa-0a42f3c845fe	213	7a59d987-1168-11ea-9bfa-0a42f3c845fe	213	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cafe8-1168-11ea-9bfa-0a42f3c845fe	455	7a5aa5e6-1168-11ea-9bfa-0a42f3c845fe	455	7a595f46-1168-11ea-9bfa-0a42f3c845fe	65	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e12cf-1168-11ea-9bfa-0a42f3c845fe	697	7a5bea94-1168-11ea-9bfa-0a42f3c845fe	697	7a59e409-1168-11ea-9bfa-0a42f3c845fe	697	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e0541-1168-11ea-9bfa-0a42f3c845fe	214	7a5bddbe-1168-11ea-9bfa-0a42f3c845fe	214	7a59db85-1168-11ea-9bfa-0a42f3c845fe	214	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cb1ee-1168-11ea-9bfa-0a42f3c845fe	456	7a5aa7b8-1168-11ea-9bfa-0a42f3c845fe	456	7a595f46-1168-11ea-9bfa-0a42f3c845fe	65	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5e1588-1168-11ea-9bfa-0a42f3c845fe	698	7a5bec86-1168-11ea-9bfa-0a42f3c845fe	698	7a59e584-1168-11ea-9bfa-0a42f3c845fe	698	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c2e3a-1168-11ea-9bfa-0a42f3c845fe	217	7a5a1b50-1168-11ea-9bfa-0a42f3c845fe	217	7a5925f7-1168-11ea-9bfa-0a42f3c845fe	19	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c2f04-1168-11ea-9bfa-0a42f3c845fe	218	7a5a1d19-1168-11ea-9bfa-0a42f3c845fe	218	7a5925f7-1168-11ea-9bfa-0a42f3c845fe	19	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cb2d6-1168-11ea-9bfa-0a42f3c845fe	461	7a5aa998-1168-11ea-9bfa-0a42f3c845fe	461	7a59601b-1168-11ea-9bfa-0a42f3c845fe	66	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c5979-1168-11ea-9bfa-0a42f3c845fe	341	7a5a4f1a-1168-11ea-9bfa-0a42f3c845fe	341	7a593c21-1168-11ea-9bfa-0a42f3c845fe	36	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cb4f4-1168-11ea-9bfa-0a42f3c845fe	462	7a5aabe7-1168-11ea-9bfa-0a42f3c845fe	462	7a59601b-1168-11ea-9bfa-0a42f3c845fe	66	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c30e0-1168-11ea-9bfa-0a42f3c845fe	221	7a5a1ec0-1168-11ea-9bfa-0a42f3c845fe	221	7a5927cb-1168-11ea-9bfa-0a42f3c845fe	20	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c5a38-1168-11ea-9bfa-0a42f3c845fe	342	7a5a50fe-1168-11ea-9bfa-0a42f3c845fe	342	7a593c21-1168-11ea-9bfa-0a42f3c845fe	36	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cb5d8-1168-11ea-9bfa-0a42f3c845fe	463	7a5aae55-1168-11ea-9bfa-0a42f3c845fe	463	7a5960e0-1168-11ea-9bfa-0a42f3c845fe	67	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c31b8-1168-11ea-9bfa-0a42f3c845fe	222	7a5a20d4-1168-11ea-9bfa-0a42f3c845fe	222	7a5927cb-1168-11ea-9bfa-0a42f3c845fe	20	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c5d31-1168-11ea-9bfa-0a42f3c845fe	343	7a5a52f4-1168-11ea-9bfa-0a42f3c845fe	343	7a593cee-1168-11ea-9bfa-0a42f3c845fe	37	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cb69b-1168-11ea-9bfa-0a42f3c845fe	464	7a5aaf98-1168-11ea-9bfa-0a42f3c845fe	464	7a5960e0-1168-11ea-9bfa-0a42f3c845fe	67	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c327e-1168-11ea-9bfa-0a42f3c845fe	223	7a5a22c7-1168-11ea-9bfa-0a42f3c845fe	223	7a5928a3-1168-11ea-9bfa-0a42f3c845fe	21	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c5e35-1168-11ea-9bfa-0a42f3c845fe	344	7a5a5434-1168-11ea-9bfa-0a42f3c845fe	344	7a593cee-1168-11ea-9bfa-0a42f3c845fe	37	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cb889-1168-11ea-9bfa-0a42f3c845fe	465	7a5ab175-1168-11ea-9bfa-0a42f3c845fe	465	7a596292-1168-11ea-9bfa-0a42f3c845fe	68	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c3463-1168-11ea-9bfa-0a42f3c845fe	224	7a5a24b4-1168-11ea-9bfa-0a42f3c845fe	224	7a5928a3-1168-11ea-9bfa-0a42f3c845fe	21	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cb95b-1168-11ea-9bfa-0a42f3c845fe	466	7a5ab275-1168-11ea-9bfa-0a42f3c845fe	466	7a596292-1168-11ea-9bfa-0a42f3c845fe	68	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cbb51-1168-11ea-9bfa-0a42f3c845fe	467	7a5ab417-1168-11ea-9bfa-0a42f3c845fe	467	7a59636b-1168-11ea-9bfa-0a42f3c845fe	69	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5cbc21-1168-11ea-9bfa-0a42f3c845fe	468	7a5ab516-1168-11ea-9bfa-0a42f3c845fe	468	7a59636b-1168-11ea-9bfa-0a42f3c845fe	69	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c3538-1168-11ea-9bfa-0a42f3c845fe	227	7a5a26b5-1168-11ea-9bfa-0a42f3c845fe	227	7a59296b-1168-11ea-9bfa-0a42f3c845fe	22	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Primary Tumor	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7a5c372b-1168-11ea-9bfa-0a42f3c845fe	228	7a5a27ff-1168-11ea-9bfa-0a42f3c845fe	228	7a59296b-1168-11ea-9bfa-0a42f3c845fe	22	Integrated Proteogenomic Characterization of HBV-related Hepatocellular carcinoma	Solid Tissue Normal	Liver	Hepatocellular Carcinoma 	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
37c85dd1-c6f5-4d38-a5a5-ac7a0d44b9cf	MOLM14 Pooled Reference	af83d59e-2526-40fd-be1d-5b02ea4d1753	MOLM14 Pooled Reference	1f44bbcb-2083-482a-9f75-25828c013e96	MOLM14 Pooled Reference	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a616948d-3036-4cb9-b606-7e451e5ad435	PTRC_Ex8_P14	500bb920-fcd2-4a63-a2a0-f2b8aaf8e21a	FGF2-primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7bff2a95-7e54-4620-9f20-806ddfead04e	PTRC_Ex8_P12	500bb920-fcd2-4a63-a2a0-f2b8aaf8e21a	FGF2-primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3d666e0c-6f33-44b4-abdb-b645b841b536	PTRC_Ex8_P11	500bb920-fcd2-4a63-a2a0-f2b8aaf8e21a	FGF2-primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a214ee4-3937-47a0-9c04-c2216eba1cf6	PTRC_Ex8_P28	b74f9699-bc96-4a94-ba2a-e587848889e6	FLT3 primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
99408736-a88c-41a0-a155-260afdbffb03	PTRC_Ex8_P8	735f6777-e929-4c49-8d91-c8a45fdaf046	parental MOML14 - b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cbdcb0a6-c2e0-449b-805a-592835555977	PTRC_Ex8_P10	735f6777-e929-4c49-8d91-c8a45fdaf046	parental MOML14 - b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
278e65ba-9f4c-4f8f-84da-1df9a374dd99	PTRC_Ex8_P19	171a2f52-7874-4eaf-b6be-b990cf1cb030	FGF2-primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3faec083-6276-4d00-ae6b-247515b21d4f	PTRC_Ex8_P25	613d23c3-7e88-4bbd-85e4-1d66f9ca8669	FLT3 primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
098f60c2-e140-47cc-b8a6-020c9346e5dd	PTRC_Ex8_P20	171a2f52-7874-4eaf-b6be-b990cf1cb030	FGF2-primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
96af5fc2-496d-4ace-a286-4fefd06b3d04	PTRC_Ex8_P7	735f6777-e929-4c49-8d91-c8a45fdaf046	parental MOML14 - b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7d7673ee-a585-4e59-bb3a-1815c489928e	PTRC_Ex8_P22	613d23c3-7e88-4bbd-85e4-1d66f9ca8669	FLT3 primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a83d652c-f92b-43d1-8241-37de7372493f	PTRC_Ex8_P2	1c1f661c-e8d8-44f0-971b-863c32c9ef59	parental MOLM14 -a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62c64702-6cec-4a18-b925-f338ec5ca469	PTRC_Ex8_P27	b74f9699-bc96-4a94-ba2a-e587848889e6	FLT3 primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4873b39e-414c-4d47-b7b3-b23158ca6811	PTRC_Ex8_P15	500bb920-fcd2-4a63-a2a0-f2b8aaf8e21a	FGF2-primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cbdbc3e3-2d01-42d7-ab7d-8498dfa8e441	PTRC_Ex8_P21	613d23c3-7e88-4bbd-85e4-1d66f9ca8669	FLT3 primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
124d3094-5c2d-4ac2-b7a4-c4854c5d4a7b	PTRC_Ex8_P16	171a2f52-7874-4eaf-b6be-b990cf1cb030	FGF2-primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ba34236-a6ee-45fd-be69-9d040eec7733	PTRC_Ex8_P29	b74f9699-bc96-4a94-ba2a-e587848889e6	FLT3 primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7ee366ac-a9e0-4852-9408-81c130ab45c4	PTRC_Ex8_P6	735f6777-e929-4c49-8d91-c8a45fdaf046	parental MOML14 - b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5635168b-a0a2-4849-979e-dd4dda958a0c	PTRC_Ex8_P17	171a2f52-7874-4eaf-b6be-b990cf1cb030	FGF2-primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2e2c8318-db8c-4131-aaa4-72a8dbfdb229	PTRC_Ex8_P1	1c1f661c-e8d8-44f0-971b-863c32c9ef59	parental MOLM14 -a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
14a6b221-3fe5-444a-81f5-55c497ead136	PTRC_Ex8_P3	1c1f661c-e8d8-44f0-971b-863c32c9ef59	parental MOLM14 -a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8c82153d-18d2-4865-a96a-148b99b1b6f8	PTRC_Ex8_P5	1c1f661c-e8d8-44f0-971b-863c32c9ef59	parental MOLM14 -a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a7579619-991c-448d-9f20-89137c090c3b	PTRC_Ex8_P18	171a2f52-7874-4eaf-b6be-b990cf1cb030	FGF2-primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
78f18a05-d7ca-4395-829a-77dd1c7ab49c	PTRC_Ex8_P9	735f6777-e929-4c49-8d91-c8a45fdaf046	parental MOML14 - b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cacc9a5a-ab5e-4d69-adc0-3a1707efed08	PTRC_Ex8_P24	613d23c3-7e88-4bbd-85e4-1d66f9ca8669	FLT3 primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a6adee6-6159-45cb-8bf9-cebce9f78ff7	PTRC_Ex8_P30	b74f9699-bc96-4a94-ba2a-e587848889e6	FLT3 primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
49e73773-817d-4319-ab98-fcbe380005ed	PTRC_Ex8_P4	1c1f661c-e8d8-44f0-971b-863c32c9ef59	parental MOLM14 -a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
071832e0-4043-4f09-a048-b3488e336771	PTRC_Ex8_P13	500bb920-fcd2-4a63-a2a0-f2b8aaf8e21a	FGF2-primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb815093-f972-4b44-ac13-fd4f1a3c7323	PTRC_Ex8_P26	b74f9699-bc96-4a94-ba2a-e587848889e6	FLT3 primed MOLM14-b	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b2c3ffbc-4a70-48cf-b30e-725a1b6ae012	PTRC_Ex8_P23	613d23c3-7e88-4bbd-85e4-1d66f9ca8669	FLT3 primed MOLM14-a	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a87918a-b41c-423b-94b4-74ddc9fa7d10	JX0128D	f965bf30-ffeb-4679-90b4-358a53128097	JX0128D	89459e7d-f97a-47ac-b8c4-52fd5e5e5758	JX0128	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4659df0a-6b9e-497c-8e4f-6f35efc293e3	JX0223D	156746cd-dc7d-4edf-a782-1a975eb9fc60	JX0223D	b3683350-3f71-4826-b8a4-2e5d56dd01da	JX0223	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
979220c6-52be-43af-91a5-1691bc8e7fa2	JX0141D	c297f431-5abb-447c-a688-174dc41d8364	JX0141D	4e5ae10d-eff7-4a93-8882-ad1594f52eab	JX0141	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8f8645e8-8d93-4073-b822-202a125fbac7	JX0176D	da0e8d40-3d87-4f77-963d-e2088d6c344a	JX0176D	bc3637d1-a28b-4143-b77e-745b985a59f7	JX0176	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e5c2941f-629b-4c76-8fe1-7814d063e232	JX0062A	eeb25241-0f9b-42f7-add7-eb6ff238d24c	JX0062A	0d6bdae8-4082-419b-a78c-8963d395d4ad	JX0062	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
17bfb072-5e6a-4639-959f-b2f9686dda39	JX0052A	a5983e33-8f5f-44b0-b774-b53a729f2e88	JX0052A	09433645-87bd-4063-9586-2686aba4ed00	JX0052	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f08606a-f02c-4d55-9c04-21a029298523	JX0163D	e84feae2-68fa-4489-b5b1-cee656a33bfa	JX0163D	baa3b600-ddfd-4051-a31a-cae0ba143592	JX0163	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
44fdbb8e-d940-441d-a630-d3115cdd884c	JX0244D	3c2b68d5-85f8-4595-a902-1085c28cc1b7	JX0244D	f4da9ff8-fd5d-4793-9214-8cda7b221ebb	JX0244	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
89a5fafc-612b-4adf-9f37-99d16c067399	JX0176A	f9aef15b-75ee-4b31-bb00-478bf06b3b38	JX0176A	bc3637d1-a28b-4143-b77e-745b985a59f7	JX0176	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f3da9642-671e-499a-99db-a869f478677f	JX0169D	d2521ebe-96be-4cf9-973d-726a81b66179	JX0169D	b7dd9263-594e-4fc7-b808-d09fef308f04	JX0169	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a0cb3e1-c5c8-4ff6-9175-c302e4da86d2	JX0108A	2ff25d06-6aea-4413-a61b-f6ebe86e2c0a	JX0108A	e879fba9-0a5b-44fd-a26e-4ceb51f97ceb	JX0108	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f6afdf01-9c3e-45da-87cc-0b91f2c911b6	JX0093A	5360831a-ffbf-4e60-8252-dcfda50d4e83	JX0093A	5ebff13b-dc1c-40b3-bea3-d6e12c5335fc	JX0093	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c553db8-20f3-4582-bcbe-b035618a7849	JX0114A	8fd87a55-0879-46fd-ba94-5e622144252a	JX0114A	5ca4d8a5-198f-4564-8c03-faaeb605620a	JX0114	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5f7d3197-fc9f-4ca8-9ffe-d5a45df8a0ab	JX0244A	91b9d984-bd16-4f9f-a4f0-feb342b7f19a	JX0244A	f4da9ff8-fd5d-4793-9214-8cda7b221ebb	JX0244	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c87f4b32-dcf6-471a-ae36-aa916a1407a3	JX0230A	4d44cc84-ae9f-4ba8-9f1c-798e32fb6fae	JX0230A	4532760f-499e-4da3-99ef-0015bf0ce2b3	JX0230	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f7a784c8-af74-4d51-8bee-e5436412ab3e	JX0088D	0ce2bf7f-3c72-4d43-9553-8156023167b2	JX0088D	8740338c-97ec-45e2-99e1-4cca2af50d57	JX0088	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e2ae66d8-61f5-4ff8-8065-e93f6311a2d5	JX0156A	7a1e71bc-42a5-4e68-9632-8eb09accbaab	JX0156A	b49991d9-7696-4476-8e59-5d8c6a82496b	JX0156	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1ca2532a-1fe6-4fd0-8d30-49dbc4cc0504	JX0211D	6acb16c4-0be9-4d71-b35a-99d33ac61239	JX0211D	96eacdef-56fd-463c-9e56-304464a5cded	JX0211	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a8e0b458-63ee-41ad-abbd-90f5509e6c06	JX0030A	bc04d611-e13c-4e13-ba79-0cbafb0a2adb	JX0030A	ee36f076-932f-42c7-9481-aafdbb3e61da	JX0030	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4215fa36-6de9-4c04-a308-b64981b6ade0	JX0008D	6d0a6f28-f287-4806-bb59-5ea890b172ce	JX0008D	54d8b0b8-123e-4ecc-8943-a9bedbbc9f57	JX0008	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aefeb464-c396-4404-86c5-fc59574af638	JX0163A	0feed333-e7ef-404b-981f-a0e6ad5d5c42	JX0163A	baa3b600-ddfd-4051-a31a-cae0ba143592	JX0163	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0a39114e-54fb-421d-9bca-267d43a31c37	JX0193D	61c78b2b-d99b-4749-9196-cb16aba69f80	JX0193D	33ae5c0b-cede-4d0e-a609-60a4d1d0717f	JX0193	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
97748fdb-3817-4d13-b9a4-11aa0d7e84a9	JX0088A	c1028b0f-739a-4791-82e4-3c975fb80e50	JX0088A	8740338c-97ec-45e2-99e1-4cca2af50d57	JX0088	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2734f7ac-63ee-480f-b0ae-3ce3b923852e	JX0135D	d54791e8-ca90-4f7c-aede-aefd63884e0c	JX0135D	af16947d-3bda-4bd2-99db-57b1bf7426d2	JX0135	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
deb52909-0629-451e-bfa6-24315c20f625	JX0141A	8b7703c0-aca8-48cc-a48a-c6cb39b54919	JX0141A	4e5ae10d-eff7-4a93-8882-ad1594f52eab	JX0141	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
98f37bc1-ce27-4c98-a1e8-8d46af88a72a	JX0079A	a9b707bd-56ed-4c25-96e7-48dc7d935f91	JX0079A	43906e3f-fbbf-4cc4-8364-c1c08a5ad94b	JX0079	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d5c8ecaf-9fae-48cd-9f2a-8895296f1848	JX0076D	dd3e70bd-a72a-4416-ac21-eb53d249c853	JX0076D	7166b8a0-f458-434a-b675-dc42b0bc3ee9	JX0076	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
54a0bffc-ab88-4578-ba84-2fdb286bfd48	JX0114D	d8a5f5f1-7444-4371-9432-45421e260e78	JX0114D	5ca4d8a5-198f-4564-8c03-faaeb605620a	JX0114	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
35687f10-f48d-4786-b7e3-5a584802870c	JX0201A	852c158b-5d73-492b-a3c5-3411f1610694	JX0201A	3c166691-515f-4ec5-8185-e740a7a7c5f6	JX0201	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2dd8962a-edd4-4379-bd35-7d2bc6bbd6dd	JX0102D	7ec37b34-5ddf-48f5-9ecc-92e90db33ed6	JX0102D	2db24546-75ad-4105-af29-e309dac3a889	JX0102	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d1d580df-e913-4331-bed5-7d8189735210	JX0223A	73f86519-ccfa-441e-ba62-226050bbb3d4	JX0223A	b3683350-3f71-4826-b8a4-2e5d56dd01da	JX0223	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0d404afa-6a31-4bf3-b6b7-2be164cb411b	JX0186A	b89dab19-76e4-4e3a-bbb4-73c7cb3084dd	JX0186A	3eaf30d6-8609-4091-9c15-9cb162d8de2a	JX0186	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9dcdca3c-8024-4383-8bc9-db918d181088	JX0052D	0a825ec6-f5f9-4477-98e0-8a8ad938881c	JX0052D	09433645-87bd-4063-9586-2686aba4ed00	JX0052	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
563bb393-64b1-48c1-bed2-cfc3ae1a133e	JX0156D	a253cc1b-81dc-4704-8788-4b6a9893dbc3	JX0156D	b49991d9-7696-4476-8e59-5d8c6a82496b	JX0156	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9f8fc7a2-5b4c-4d9d-8013-18bedb1fdda5	JX0236A	200b00c9-0fe1-4962-afc4-fcad2106ed7a	JX0236A	9a6ff46f-8382-49a0-aecf-2cb1aee9f7e1	JX0236	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e5d42d4-762a-4534-b51b-18d36288e332	JX0093D	1020c463-0911-48c9-a855-18d1578d642a	JX0093D	5ebff13b-dc1c-40b3-bea3-d6e12c5335fc	JX0093	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
92f66ba6-d046-4d52-9a9b-d2d57f23ac5d	JX0169A	213f2f6a-890f-49f9-8dd8-5dd02a03c1c4	JX0169A	b7dd9263-594e-4fc7-b808-d09fef308f04	JX0169	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d185debe-890a-404f-9093-ff11512a82bb	JX0076A	4f9e7539-ea03-4fbf-827e-365907be8662	JX0076A	7166b8a0-f458-434a-b675-dc42b0bc3ee9	JX0076	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9731d9dd-d36c-466b-921a-734691b0c398	JX0079D	26bd977b-482d-4c36-a966-1a061f99c982	JX0079D	43906e3f-fbbf-4cc4-8364-c1c08a5ad94b	JX0079	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f0fab295-0241-497c-b38a-2cae3c400ef2	JX0150A	304f1e68-3aec-4740-b7ef-2168753b44ca	JX0150A	6b882756-f4dd-4ced-8d22-61a123dfc3f1	JX0150	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3eb3c819-fa32-4236-927c-da15ce2688ac	JX0108D	50bbf360-5443-4299-a05c-3dc05e78da94	JX0108D	e879fba9-0a5b-44fd-a26e-4ceb51f97ceb	JX0108	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
acb8c5f0-a1aa-4c7f-a213-3031877635ce	JX0150D	b2ca134b-6c33-4d16-9a52-f6668335d397	JX0150D	6b882756-f4dd-4ced-8d22-61a123dfc3f1	JX0150	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2fc91dd1-c06e-49b6-973b-bd7eba8af986	JX0135A	3822de3c-03db-42c0-8ed4-9370c3981ea7	JX0135A	af16947d-3bda-4bd2-99db-57b1bf7426d2	JX0135	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
66919fb3-0725-4a05-8b95-2fecf87e0877	JX0128A	bb9efb1e-7696-4a15-85b5-6c42fef42f53	JX0128A	89459e7d-f97a-47ac-b8c4-52fd5e5e5758	JX0128	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e9392aea-031f-4853-bd59-cdb9ce5ef101	JX0030D	f99a7aba-06a1-496a-9806-a2a2c41af77a	JX0030D	ee36f076-932f-42c7-9481-aafdbb3e61da	JX0030	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fa7dd6a7-912f-4ff4-9fff-bba829b72d1a	JX0025A	1fac4ca0-653a-4c16-8a71-8f8e0163c8f6	JX0025A	76af815d-920b-4fe8-859a-bbaec597cab8	JX0025	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57b5dcab-e612-453b-98db-2a6e6c317f13	JX0186D	8739d371-c789-4d0b-a340-db30797ab45c	JX0186D	3eaf30d6-8609-4091-9c15-9cb162d8de2a	JX0186	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f695136d-92ca-4f2d-a6da-601db1b6b05f	JX0122D	9c1a6a80-9e5f-45dd-98d7-9ccf30e2d9b1	JX0122D	0ec91b79-a1fd-4a53-8d40-09f3b2a004d6	JX0122	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
239d5933-7182-4606-8ba8-f627b4df9102	JX0122A	1e0f4247-7fbe-4b0d-8165-8f7488877f1c	JX0122A	0ec91b79-a1fd-4a53-8d40-09f3b2a004d6	JX0122	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d7a3ca8-0552-4ec4-bbf7-f42d5ab8417a	JX0193A	82c7c60e-007b-40d1-a8dd-117a059ddb22	JX0193A	33ae5c0b-cede-4d0e-a609-60a4d1d0717f	JX0193	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
463f482e-4a9d-4e2c-8840-d2acad69523e	JX0102A	e564e5c0-5aa3-4e96-b16c-49c17aaab490	JX0102A	2db24546-75ad-4105-af29-e309dac3a889	JX0102	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ebfb80a4-d0ec-47b0-be0f-933c772d9e88	JX0062D	491156f0-6381-4d2b-9fed-2dedb698404c	JX0062D	0d6bdae8-4082-419b-a78c-8963d395d4ad	JX0062	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b9f34ae4-a699-453b-bd70-ec351840b725	JX0201D	ad39fd2d-a334-4003-8dbf-2ba5cb819e79	JX0201D	3c166691-515f-4ec5-8185-e740a7a7c5f6	JX0201	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db79dd6f-0b84-4f3c-b793-e53bdf700fe5	JX0236D	399eb8ec-fb7f-4e4a-8978-2e1045bcdcab	JX0236D	9a6ff46f-8382-49a0-aecf-2cb1aee9f7e1	JX0236	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
04824cab-9d81-4c01-a37a-dd9b302b8587	JX0230D	c2b7f8cd-4912-4608-944e-22a03d282686	JX0230D	4532760f-499e-4da3-99ef-0015bf0ce2b3	JX0230	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ff500582-f191-4f33-a431-d5126f12b5f9	JX0211A	6f9ade78-f797-4ab1-ba1c-9fc8c337ae48	JX0211A	96eacdef-56fd-463c-9e56-304464a5cded	JX0211	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
93c739cb-9696-43d8-b98e-521191c95ebf	JX0041D	e078fe4b-7760-42db-a24f-9f494f5ccfe2	JX0041D	7897abd2-6559-422a-9765-6235164f0f38	JX0041	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d9b932e2-bcfa-4389-ba09-18f903cad356	JX0025D	32460b1c-e43b-4eec-a477-3ae10640f3f2	JX0025D	76af815d-920b-4fe8-859a-bbaec597cab8	JX0025	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7495453d-9177-40e4-a0ec-5da62a9f034f	JX0041A	066a411e-a834-4d7b-a11e-c34eef87e393	JX0041A	7897abd2-6559-422a-9765-6235164f0f38	JX0041	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
960eeb08-1408-414d-af22-d08524c7308c	JX0008A	d703eef9-8634-43fa-a118-dfa371cf4b8f	JX0008A	54d8b0b8-123e-4ecc-8943-a9bedbbc9f57	JX0008	CPTAC2 Retrospective	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
18f1afa9-71a3-486e-be4c-554bf6adb40a	NCI7_F_B4-9_01	a602f3ae-83c7-43cf-a7a4-a2755115f2c2	NCI7_F_B4-9	e3ac310a-32e2-4392-a89a-34c47bd0f8f4	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5861160b-1b7c-418e-a8de-73bee5bf6ebb	NCI7_unFraction_01	321b5d60-65f8-43ce-9f83-78da8ea1f323	NCI7_unFraction	e3ac310a-32e2-4392-a89a-34c47bd0f8f4	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fc965013-2d90-4233-af19-61cd7ac1d093	P93_F_B4-9_01	d8fed53b-5a20-498b-b793-4a91d7864f57	P93_F_B4-9	cfa371c9-3ade-4102-ac44-57c9095ce581	WHIM-P93	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aea7e948-c696-4739-b172-8ad752838474	P94_F_B4-9_01	6d2a82d4-89d3-4539-ad97-f6065f5b7bc0	P94_F_B4-9	93ce8321-821f-4dcb-9e0d-1f1ca91af9e7	WHIM-P94	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b7884473-f9c6-4360-9ba2-98b5ca0dfa41	P94_F_B4-9_02	6d2a82d4-89d3-4539-ad97-f6065f5b7bc0	P94_F_B4-9	93ce8321-821f-4dcb-9e0d-1f1ca91af9e7	WHIM-P94	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
372922f4-f93a-4055-8256-2f6d56e3f8ab	NCI7_F_B4-9_02	a602f3ae-83c7-43cf-a7a4-a2755115f2c2	NCI7_F_B4-9	e3ac310a-32e2-4392-a89a-34c47bd0f8f4	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
23ad86e0-d55e-4444-be6d-a25b0ffdc1fe	P93_F_B4-9_03	d8fed53b-5a20-498b-b793-4a91d7864f57	P93_F_B4-9	cfa371c9-3ade-4102-ac44-57c9095ce581	WHIM-P93	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5afe50de-126e-4184-8dde-5ba7bf970b3c	NCI7_unFraction_03	321b5d60-65f8-43ce-9f83-78da8ea1f323	NCI7_unFraction	e3ac310a-32e2-4392-a89a-34c47bd0f8f4	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10a9e483-998b-4fb6-a563-bc42f41611c3	P93_F_B4-9_02	d8fed53b-5a20-498b-b793-4a91d7864f57	P93_F_B4-9	cfa371c9-3ade-4102-ac44-57c9095ce581	WHIM-P93	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
764b23fe-3898-4da0-af0e-504e9695947f	NCI7_unFraction_02	321b5d60-65f8-43ce-9f83-78da8ea1f323	NCI7_unFraction	e3ac310a-32e2-4392-a89a-34c47bd0f8f4	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bbcaaeb1-9695-4ca3-b829-6aa5f65dcb38	P94_F_B4-9_03	6d2a82d4-89d3-4539-ad97-f6065f5b7bc0	P94_F_B4-9	93ce8321-821f-4dcb-9e0d-1f1ca91af9e7	WHIM-P94	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fbaada12-1f50-460f-9d49-4694be5d8a7c	NCI7_F_B4-9_03	a602f3ae-83c7-43cf-a7a4-a2755115f2c2	NCI7_F_B4-9	e3ac310a-32e2-4392-a89a-34c47bd0f8f4	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6f3cf956-8ac5-4ec0-8eea-cdf5ef397915	PDAC029	56c62176-f6c5-49cf-9723-f1bc66fa7444	PDAC029	5be94d2a-2e05-4d82-b843-3b6b55f84582	PDAC029	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
4ac9101f-cbf2-4b1b-a260-e38bb3c15b20	PDAC038	19bc86fc-59e6-450f-8b3f-f3986b7ab767	PDAC038	2dadf04d-43cd-4335-94ae-47a465247d0f	PDAC038	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
aac14d80-6980-4d45-acab-ed7404dcccbc	PDAC159	f0520fbc-b034-4978-9c28-15917c32b503	PDAC159	08347a9e-778d-4a6d-9b3f-5a280ac40f9e	PDAC159	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d9c61553-5ec5-4c8a-811d-79df48862715	PDAC037	4a64413a-bddd-4634-9b5b-845b9e18623c	PDAC037	89ea1842-65fd-4195-865d-eef12e8dad4e	PDAC037	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
514e15ce-04a4-45be-a6ba-dec8487a93c4	PDAC158	8c932e25-fa71-4a75-b700-9c3072c3b999	PDAC158	74480206-a77e-4c1d-b33a-a8648990eba0	PDAC158	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ff5918e9-e651-427e-8f08-0ee93b17ff2f	PDAC279	4be9d21d-e53e-4522-bf0f-8c36a47c4d73	PDAC279	bb203813-c038-4f9b-9436-a8c5e0f8f0cf	PDAC279	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e0b86ce7-83ff-4ef7-9641-220ffaa154aa	PDAC278	30d4b17e-8ff6-4269-9a11-d5ab137aa046	PDAC278	89d1c327-a12a-42ee-b521-aedbc745dc32	PDAC278	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d4f9fed4-47a8-42a0-9746-dd2ba857c673	PDAC156	b80d793a-e501-40bb-8244-3f32e52dd96d	PDAC156	7d44718e-77de-4f75-8642-5c22fdf0c0e8	PDAC156	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9ad4b165-bb77-456c-8c8d-72dd722f1ab9	PDAC277	ad6e9033-24a0-4cc9-91a2-4a67d52f26e7	PDAC277	76cd4edc-6c8f-4bb4-91a8-f264281ece13	PDAC277	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
5eb09b95-1315-4bdd-a95d-982a4b4ce05e	PDAC276	3ff90481-570e-42b8-a3cb-b18be486f5df	PDAC276	d887c51c-75ff-4e36-975c-60604c54c6f5	PDAC276	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
68fab7e1-af4b-4276-8871-472573ae3f49	PDAC154	56d1f6ac-b572-439d-9893-c773b017fbc9	PDAC154	eea05bd3-0759-4685-b6db-2354c1475184	PDAC154	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
103b003b-b055-42a3-a980-3d76020b9ef6	PDAC274	d067e51d-6b27-4d5d-aa93-1e4b4a20b914	PDAC274	8774ddce-24ea-400e-a02e-7168c3eaf00e	PDAC274	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
5b472c21-dbaf-40a0-88ff-44dd7cc7e9f4	PDAC031	03e305f6-c3af-4810-bb34-a6e714313ecf	PDAC031	e4d5011a-6006-4ba7-8955-d4594c91576a	PDAC031	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
a140ad4e-e2c4-4134-ae6c-8c9d6795292b	PDAC152	12d72906-5f80-4b5d-84f3-9a9383054a15	PDAC152	5ad5ab78-553a-4817-9d94-e48b973ccc94	PDAC152	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1f802708-0a81-4c83-8daf-a5288a241da4	PDAC273	2bb8bf26-508e-493d-9c4c-7efd8e0dba38	PDAC273	0d62fbcd-9b05-4732-9f41-9b1cab8cef4e	PDAC273	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
da2f5768-6bb2-49a7-8d56-c804bc316716	PDAC030	d7a0efd5-684c-4f84-b83e-089458ae9859	PDAC030	de73a14b-36e1-4c67-b674-21d38f9d4a3a	PDAC030	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
fa2b14c3-628f-42eb-ae81-30a65b0e1e9e	PDAC151	8fac8263-b634-490f-81d9-219b4cc98e5f	PDAC151	844780de-6ff5-4180-8f55-0d8ae5bcaee7	PDAC151	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
2e488034-f8b2-4438-a0ef-a9e6088d5f74	PDAC272	3a39ca07-ccc3-4410-9883-a11d9f625ba4	PDAC272	13b998b5-93a9-400b-a694-3ee3cc682912	PDAC272	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ee8ac4ef-cbe2-4353-a89c-84205b425de1	PDAC271	cfc7b25d-fd41-4337-8666-043b7c6dd8e7	PDAC271	db0bca1e-182f-42de-9320-3a7dfe7f7c63	PDAC271	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
2b5570c5-3320-41f9-ad5d-975faf23993d	PDAC270	f7bca006-e5a4-45b8-ab1e-7141ab033d19	PDAC270	287855cd-a513-4142-88c7-a6734fd69e59	PDAC270	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
324d78e7-1a24-43c4-9b1c-2c18bd7c4eba	PDAC019	9b612202-197e-44c6-a3ee-28af4bd3577a	PDAC019	694efa39-8a4f-4e34-9b7b-d5643fc73f18	PDAC019	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9166de93-c923-461c-b830-fcd230308579	PDAC018	3ca7c93e-ad68-49b0-9e21-02b06c75643c	PDAC018	5dbe6168-33b6-48f8-a6bb-364e5b0f52d1	PDAC018	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
23a690af-6897-4b1e-96a3-c67b94692d35	PDAC139	54453848-2e7c-4e89-8238-f09d9aefcb62	PDAC139	9d148516-e96f-4731-ac97-34a3beab00e7	PDAC139	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
39cf900d-5978-446f-aa82-6f341580b32d	PDAC138	91c93ac3-f4f6-449d-9ca1-38473525ada0	PDAC138	f41ad01e-3bc0-4520-ae7f-e69dd205901b	PDAC138	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
3c6fc7de-2cc9-4b39-b71a-5832d2d66625	PDAC269	9b9a26aa-4612-4ec8-b156-b062c35e0fea	PDAC269	b1ec90cb-652b-421d-a81d-6f5c208a4e4b	PDAC269	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
324ce539-5993-4265-b25d-5ee73362f55c	PDAC268	dfe59072-ac61-4ffd-9e90-523ebc855ad2	PDAC268	3a09be31-4db5-4cf5-bd0e-2b40de692990	PDAC268	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
42cd442d-9fbb-4a52-ba58-507c56793c32	PDAC025	0e0c7346-b5e1-4607-a225-cc04d8aa45da	PDAC025	37ffb1e8-b6fd-4c6c-8405-3538034d21fd	PDAC025	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
aefa530e-ffcd-4fc5-8bf4-84965c6e621f	PDAC267	c4dd3f0c-c12b-4092-b7f7-d083c9ba4af1	PDAC267	83d06b87-8b2d-4a02-b816-2644595f4ad8	PDAC267	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
b4c36f06-b8e2-468e-972b-5cdcddd0c8bc	PDAC024	81988bb3-c736-4e7b-83aa-430ea7fa0ef9	PDAC024	c5b44d89-ce0f-44cc-ac74-676022932372	PDAC024	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
3035ede2-06b2-47ea-a1f4-89521040bec0	PDAC266	13468e84-5afd-4c1d-97ba-478e1ca18cc5	PDAC266	9e623d92-7acf-48bd-bd72-5c1802b7df86	PDAC266	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
527d9d28-89fd-4cea-84d0-17fec9aef94d	PDAC023	c8a3e2de-506c-47f4-a884-8feb3df17267	PDAC023	7111616d-0956-455e-b803-813d2f713dc7	PDAC023	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f1fa1650-c3af-41fe-baa1-eaf17e26a8f8	PDAC144	31f4baed-be26-48a1-a0e1-85483f155ef1	PDAC144	e3a54828-b184-470c-ad3f-955f16a9d6e8	PDAC144	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
354725bc-8fb5-4e50-bb85-98b03d9d6d09	PDAC265	882e48b3-381d-41b8-84a3-3a8de7c6b9a0	PDAC265	919c2e2a-a080-4ab9-9338-33defca8d491	PDAC265	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
276ef07b-6d20-41f2-9d55-feebfd79297b	PDAC022	bbe23fcb-b7fa-4756-8b65-00914e7422ee	PDAC022	4b289d27-ea64-415b-8f8a-c2e09310908d	PDAC022	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
4d9479b3-cd67-4d8b-8ffb-ce8a47505019	PDAC264	72beaf77-8656-4fde-a790-d430cc2d4f35	PDAC264	78783b04-18e8-4eb4-8f60-28c91ff26cf4	PDAC264	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ee54d850-6668-4112-ac5a-686cbb3549db	PDAC021	5a6b4037-2e7e-44c1-a310-8adee4085564	PDAC021	9af63f66-dad7-4ab0-9204-84b3b672c564	PDAC021	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
43d52bed-2a6c-4dd4-aaba-f78cd9d1ba1c	PDAC263	bf074691-4bda-4666-bb80-de139a8ed48f	PDAC263	f6a031f1-4c5a-48bd-89ba-fd410c52c663	PDAC263	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
78fad8b6-3eb4-4815-8734-52b10aae256b	PDAC020	97ca1935-e414-4480-b61a-5b59b9a01574	PDAC020	0d33d944-089d-4afc-b567-d2ce79e5cecc	PDAC020	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
c7f4b838-8645-460e-a1dd-6d94db52910e	PDAC262	1c3ec411-9e55-4a34-803e-d78279e24568	PDAC262	33dbd57e-9e0f-4d11-8abb-f24a8664d626	PDAC262	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
72ee9359-9d1f-4d4e-8f6b-49fe37e9cc8c	PDAC260	ba1ab1c9-ee85-40f6-b8d5-1f1e30e0efb8	PDAC260	f99dcf8b-7dff-4150-9871-e484d9cdc646	PDAC260	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9c7db889-3ba4-40e1-8a44-62df7a747921	PDAC209	30090129-5c72-45ed-8fe3-8ffae47af893	PDAC209	c92573e1-305e-4b91-9eb0-f1ae3a9db84c	PDAC209	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9f3990f6-044a-43d3-a05a-ad37b8e6baaf	PDAC205	94df0b64-225d-4faa-8d80-88013ea9619b	PDAC205	341a08dc-bb2b-4e5d-8c46-8e7a8a181eec	PDAC205	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
a35e7cea-a7f4-4883-8273-f0363ebcc8ba	PDAC213	baff3945-1398-4ab9-af9c-9b9d25d1e960	PDAC213	0dd9546d-9962-4bf5-bc5f-0d0d7c79207d	PDAC213	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ed070dde-ab88-45e1-8fcb-ff3cb48d7ebd	PDAC058	8d259b95-8de6-42ec-97f4-6d4f22607ad7	PDAC058	cbe590cc-9aa6-4531-b824-28b2c7d47363	PDAC058	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d0f805e7-c5d7-4dc1-8f5d-79810c3a3e37	PDAC179	a7d214fb-4d99-4834-85a6-952c2ef277af	PDAC179	5a724af8-ec98-473c-8f7a-f938eea86569	PDAC179	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
bf2d4b01-5c3f-4130-9108-35e07298ddcb	PDAC057	5122435a-e2bd-47ec-a943-c8b97ee42c18	PDAC057	f9f676ce-fe0c-4c60-9216-a61f4066b99d	PDAC057	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
339963ac-36a1-4464-b9ce-dbc3b8022b08	PDAC178	2747eddb-039c-471a-a885-a6bdeca0258a	PDAC178	bd982628-14a2-461d-af9b-7050661e9bca	PDAC178	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
917e098f-2f05-49dc-8e3d-89b53d9b1989	PDAC211	26bed5f0-9b0e-4358-a9e8-788c1c9aadd5	PDAC211	d75d7689-4481-42ec-ac0a-61da6ed2b991	PDAC211	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e39c214b-e37d-4ad6-a5b0-2df45509b8a1	PDAC056	190e2d05-df48-4a77-a8ac-f75f53a69b6b	PDAC056	689fbfab-258b-4895-8130-231e0277d545	PDAC056	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f8c76432-96e7-4669-b46d-e863561c58fa	PDAC055	f07178c4-3eb4-4fda-97c3-3b121f8b1b5e	PDAC055	75a184cf-d780-4d30-aa25-2d65efcac9e7	PDAC055	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
eb732a62-4152-436d-9b05-838da883975e	PDAC054	acf62f0e-b787-4042-b77b-de9ba0d52d1a	PDAC054	5b1cce78-d0fd-456f-b124-df8efcc0fae3	PDAC054	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
e67a8c77-846a-44bf-860d-0ddf5467491a	PDAC174	1468fb95-799e-44fe-8013-55df864822c8	PDAC174	b29c76cc-34e3-4af5-bcc1-2894f1127384	PDAC174	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
57dd6ddd-caa2-409d-850d-d39cd7229ba3	PDAC173	dc4345d9-0bb0-4a3c-aad8-4375ecd45b21	PDAC173	cff55ae5-9f39-4197-b4a0-d8bd4c06d910	PDAC173	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
5cfb8aea-d6d9-4bbd-bef2-4c083b94aef6	PDAC051	b3ba5a58-b92b-4d0c-be86-8348ec98aa38	PDAC051	6a5a6ef0-9622-40e2-9e62-8abb31ec4739	PDAC051	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
3eb8873f-580d-49e9-b8b9-177d252e61dc	PDAC050	b52520bb-cefb-47d3-96a9-353f6ab864cb	PDAC050	45c372ce-1d77-47eb-8098-de5943996fa4	PDAC050	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
a1b175d4-72d8-401a-b7a8-de8b5a281d9d	PDAC170	791e0789-b6bc-4242-a519-437bf6a9f790	PDAC170	df0fa249-a467-46ba-8fc9-0befa6d8d97e	PDAC170	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8168fd4-6dc1-4300-9c0e-611a9bfb4ea2	PDAC049	bca65859-ccb5-4bcb-b2bf-5b6e0a5a9065	PDAC049	e3831ddc-cf80-45fa-b1e0-3f548bc5abf9	PDAC049	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ec0206b3-2279-45c7-8ee2-a5b4e85bc657	PDAC048	da990b4a-e8bf-4c6f-828a-31d4e175f0b6	PDAC048	da202cfd-bff0-4cfd-9d08-92e917ad5a6f	PDAC048	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
db23e8dc-349a-4ce3-91bf-a7b88a3a2297	PDAC169	27e0003a-804f-4e3f-9912-0e2db15ca4db	PDAC169	d67d5dca-d8a6-4105-8899-022724a8ce03	PDAC169	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
90bf4fb7-3184-4bd9-8503-de0e978f6743	PDAC047	73c2cec8-9b64-4b62-a104-ab05035541c8	PDAC047	43f378ff-51c2-45c4-bafb-db37b72dff03	PDAC047	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
0820ceca-428e-4724-8096-f2e75a4fae86	PDAC168	10539332-b730-4ebe-9147-37654bd08b89	PDAC168	3cc8f7a4-0d29-4974-b4cc-f1ed5dfd2884	PDAC168	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
92b9a23a-fda3-4a3a-b0f9-3e52c38d121c	PDAC167	bfc701b9-3adf-40de-a1cc-fb23e50077a3	PDAC167	5f692f17-d1b1-42ae-b7c9-a76d46fa6966	PDAC167	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
977929c2-5b09-4dde-957d-4d71b98bda65	PDAC045	108c66b1-74c8-4784-9b39-d9c43308c038	PDAC045	3e2290e6-57ec-4975-a014-9daca3c2f91e	PDAC045	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9668536b-ee80-4800-b533-c86571f6412a	PDAC044	6a491634-9e3e-4c16-95e4-9afa52f0f9a5	PDAC044	ef6c1f02-9077-45aa-a09c-90ede66e6fb3	PDAC044	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
c2c10dc0-d637-40be-b4f3-2cd4f0d77909	PDAC043	ca37d77e-9e9e-4f25-bba1-147c5b0789fb	PDAC043	c863a18c-a537-436e-90ef-880ae59b20b4	PDAC043	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
47ec2876-766b-47cf-a2e4-a672d0f6d1de	PDAC042	a4487d4d-c1d7-430e-905e-d69123001f58	PDAC042	2bcedd65-d776-411a-a459-b7f062cc9134	PDAC042	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
4bfa70ca-621f-4261-9ef0-147e9d439a28	PDAC041	3351d678-f70d-497d-8610-6f1706c4d20a	PDAC041	9c1806eb-a8b0-42d8-a2ce-2271142900b2	PDAC041	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
72a1f340-f8c6-4313-b042-744cbff1622e	PDAC283	103e22a8-64d6-4e10-a539-2d2ae99a9d85	PDAC283	6eda4334-661a-4946-9b2d-33e564470017	PDAC283	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
6fa6d2a5-8d39-496d-84e3-51a981fb6dfa	PDAC040	6abda4ee-97cf-40f8-aa4a-fad23336c47c	PDAC040	b6aab1d8-57e5-4061-ac48-8513b7c98bfe	PDAC040	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
d75acbe7-dda7-4911-8448-9a4e51ceb2a7	PDAC160	08ecd5d6-b604-4f4a-8b52-1093cacc6710	PDAC160	b3f6b689-48fb-4713-a052-b9e26ef7001e	PDAC160	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
b769cc14-4e7a-4513-a8da-b61e0b8c255a	PDAC281	0c496e28-5640-4bc2-944a-650f916543c1	PDAC281	20873fc1-f8b7-41de-a237-d2c8d44a6069	PDAC281	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
77d7c338-f58e-4464-b67f-8c4967fa0c34	PDAC280	85118b51-ebdf-4a41-905d-921edb59a39e	PDAC280	2918bdf7-3046-416a-bca8-e6bea1d3859e	PDAC280	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
4c9876db-2a21-4468-9893-9f7e438bb936	PDAC229	26b7e07f-53cb-4e0e-864d-b7a73efbc42c	PDAC229	5189f07f-0070-4f24-b256-73b7396057db	PDAC229	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ec7182c6-32fd-45d3-bea8-2c33bb8c5a52	PDAC107	03527457-1fe5-4190-a8e2-c5a543185d49	PDAC107	80df2d73-b9f8-419c-9feb-c69a82b5fadf	PDAC107	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
01a34d15-a3e0-4d19-b58e-6fab5c613020	PDAC228	747dd4f3-b34e-4fd8-bd9a-99a70da0f048	PDAC228	8028ee98-1487-4014-b590-84e6512590c5	PDAC228	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
146c92b6-f41e-4a56-b9f5-bf867e299e49	PDAC106	407433c5-46ce-475c-931b-59382153bcf7	PDAC106	687af547-97c0-4d56-8469-ff4d9079f563	PDAC106	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
54963eb7-f79d-40ac-8db3-bae67c43514b	PDAC226	6a87c6a2-0803-4267-b0c9-cf924e9ea73b	PDAC226	77d3d027-7ded-4b8b-8164-cb5a92272d33	PDAC226	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
fdfba997-cefc-4f41-ae7a-18548b5aa56d	PDAC236	a096a8c0-8cd4-4881-806f-36ce1aa24ece	PDAC236	5ca01586-1a9e-4389-b6a8-d7b2af088b48	PDAC236	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
98f67c9f-cfc8-4b49-a5fb-0b70e86c1fdb	PDAC114	30343b09-eeb2-467e-b392-2a286ce6ba85	PDAC114	8c308fb6-105e-47b4-baa0-ddb3d8524742	PDAC114	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
5ead8bf3-f937-469e-b11b-0a6ae254f795	PDAC113	10429790-7fb2-4a2b-8383-af71665187af	PDAC113	099d098c-4e7b-4e4a-b5ee-c805daa56c5b	PDAC113	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
db11e7e2-89d7-48ed-9bfa-43a379bc18a4	PDAC234	96bcb004-737e-439d-a8c2-d7e5efa5105d	PDAC234	149f9c82-09d1-433f-82ba-82e7db9aec2e	PDAC234	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e155127b-8566-4920-b7be-2b773f83c7c8	PDAC112	a1250deb-a85b-4b14-8b2d-dd04768942fa	PDAC112	a5c16e2b-139d-4779-95b8-8b7c2cc39290	PDAC112	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
b894e659-0831-4fa8-8eae-a2b23cc75ed2	PDAC233	13359afb-c4c9-496a-af48-d0a88e452ae4	PDAC233	02dcc58d-656d-49af-a5bc-154bf2e86dee	PDAC233	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
69b56e93-67e3-4594-b5af-fee1dfa58c63	PDAC078	aeb407b6-3192-432b-aa54-03d3358a4286	PDAC078	3460584e-6f02-4ef1-aefb-3d4c8fbcf2ef	PDAC078	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
5d94569f-4698-44ff-994b-c15ebe8fd416	PDAC199	788edcab-010d-4990-ac95-44bcf6678910	PDAC199	af254622-f443-4020-84e1-095a9f3319f2	PDAC199	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
3ff98490-2bbd-4346-9ada-f20b5ec3ea9e	PDAC232	adb93a0c-ea23-4f7a-a4aa-08b9dafec145	PDAC232	d0612cb8-1860-47a1-9ecd-7480023c7f18	PDAC232	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
c12d07cd-4348-4b2a-b117-84702329a904	PDAC110	fe8efed7-dad1-424f-b72a-1421ac342d59	PDAC110	bf1d2010-01e1-4070-9de9-413bd3838384	PDAC110	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
807ece43-74c2-467f-b436-41607bf07f60	PDAC198	a4707718-6c8f-436e-b788-0a2c4a275865	PDAC198	ab577840-9ea6-4118-93ff-edfac0420cf3	PDAC198	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
cf65950f-036e-43b1-93b7-8a20b697f078	PDAC076	03940c1f-4009-4a64-b33b-71a83ede22b0	PDAC076	4e6f4885-bc09-451c-b1b4-c57bd9cf2c6c	PDAC076	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
649e6206-b5f8-41d0-87b1-02916fb911e9	PDAC075	4c831211-57e7-40f4-88dd-f72600b8ea13	PDAC075	c106307c-4293-4411-bd4d-32ce535fa9fb	PDAC075	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ba371c22-82f4-4b6f-bd44-e9957a56c4d3	PDAC196	4182b4a8-f81c-44d8-99bb-042f17da9dfd	PDAC196	a6dbcdb1-55f0-4afb-af56-b2fc0839ce53	PDAC196	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d3a4ebd1-acce-4fcd-8974-bfd8795d92b9	PDAC074	c8307ab5-bbdb-44c6-a7c1-8bd2e2069348	PDAC074	8d488e7f-5138-4e03-9637-84e5c631b78f	PDAC074	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
0fe22486-0bca-409f-8d42-97e9603e6979	PDAC195	7945c786-065e-4b07-bf83-3f71edcbf7c9	PDAC195	971bd7fb-c34f-4ff7-94cb-700d3853bbb3	PDAC195	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f97dbe70-7637-41dc-9134-19d68c2017cf	PDAC073	d9be6191-2c74-4706-8731-be6f4009aa22	PDAC073	77f95cb0-454e-456b-a4af-d56773467bff	PDAC073	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7adcc3f6-a557-49c7-94e8-fe5ccb8f59ec	PDAC193	b48fbe7b-692d-4d38-9478-b8458873d23c	PDAC193	60cc215d-be76-4e06-a94f-7c90d53a569a	PDAC193	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1b549435-5d42-4cb9-a57b-43635825d213	PDAC192	fae057b4-a8ce-4aaa-a49b-fd2ee30b5b2a	PDAC192	72a823aa-562b-445e-96bb-a954af508d21	PDAC192	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
11c56a69-7d0d-4a29-9852-e7c76d59fe6f	PDAC102	fc2e7aee-fe7f-46aa-8416-0fa8b59dcc0c	PDAC102	3e9936db-6201-4c92-9c54-1f8d90ced85d	PDAC102	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
6f8cb3cd-f7a9-4517-944f-642090b12c17	PDAC223	c8c38543-0608-4b21-88de-baf70c3c5faf	PDAC223	f923570b-d47a-4574-9b2a-0a1f0986e847	PDAC223	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
dce5290f-b7df-4c0c-aad7-4d6c05760641	PDAC101	b8dae266-fc25-44ae-b638-6e894ee3f322	PDAC101	84e5911f-737a-4278-b184-080da277e088	PDAC101	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
56eb9838-31c9-4e0a-9b70-28d1e3a7eb5d	PDAC189	3ef8c1d4-d144-4621-a0f1-31b0f547b827	PDAC189	3b54253f-accc-48ad-a3f3-c79ab97521bd	PDAC189	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
610396df-891c-4223-863f-cf63f7f11cd8	PDAC067	198b684d-f889-4e59-b2c9-edd2cde9d794	PDAC067	7b8cb3b0-8e2d-4554-be87-729c28100f7b	PDAC067	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ad19bac3-32b2-4edc-a3c8-9cc15dbd1eb3	PDAC221	6cc8e806-f019-4da5-a90c-e34de6a6db3e	PDAC221	6bd6c016-7321-49e8-be04-5c9c6583177d	PDAC221	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
a0f9b9b7-b6d8-4388-82eb-2cfc60449ea6	PDAC186	02c5d46c-6ae1-4d5b-9955-5c5cca3a288e	PDAC186	1c2a7daa-7cfa-4273-9e03-7bd7ef923ebb	PDAC186	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e16cba45-78ef-4489-a6cb-ba0de9639d17	PDAC064	967b92ba-da45-488e-9302-261a8f226619	PDAC064	3e99aeea-1913-42a0-81b6-f76a12470cb7	PDAC064	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
44aba329-20ab-4e89-85ef-6ddfa1041371	PDAC185	95c71446-8a67-4652-b85b-224be15bd172	PDAC185	9129a6b0-24d9-467c-979e-b1b070c022df	PDAC185	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9e54023c-7a1d-444a-98d6-cb2ae63e25f8	PDAC063	66ac33bc-2aeb-4459-869c-4c425debaebf	PDAC063	f998e351-96b1-4f92-9b0d-ccc02fdaa29d	PDAC063	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e1142c37-a675-4b62-bd94-1d585c8dab1e	PDAC183	dd2fae33-7a26-4122-9e65-07a342cb726f	PDAC183	5dc4d9fa-aae4-4f08-bbf8-d6c65a9fa444	PDAC183	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f2720c56-a887-4c5b-84d3-f6c4dd3741b9	Universal reference	f6723233-9380-4ce1-94bb-285505ed40d3	Universal reference	11b63998-52c4-471e-92c5-6ccd6ab7469e	Universal reference	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Not Reported	Pancreas	Pancreatic Ductal Adenocarcinoma	yes	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d87f4ba4-451a-440b-ba30-006f89987544	PDAC061	6aea5e66-46cd-4454-82f9-883a97ed862c	PDAC061	471bfec8-6509-48cd-b650-94424b39fb0a	PDAC061	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d4b348bf-9c13-49fc-8865-4fd7282447df	PDAC180	6b50fde9-b5a1-4e81-92f4-d4bc671f6426	PDAC180	a20a1e37-4031-408f-a09f-98bd3bfecfc2	PDAC180	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
dc995112-1f1d-4b70-890a-8efad31c5e64	PDAC129	28153998-9eba-4863-876b-65070ec17904	PDAC129	8469316e-4ee9-440b-a391-fba8d6ccd2c9	PDAC129	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ff8f1f09-37c3-4057-b904-02b2b0dd0336	PDAC007	a30ff1e9-ec40-43d6-8b01-5730b6d6d507	PDAC007	f343a3fa-f425-4b0b-b784-d14881ac869d	PDAC007	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
6851da8c-90ab-4332-9b2c-b071151aa53f	PDAC249	f2711e0c-09da-4516-bda4-3d900ac61430	PDAC249	b4cf9982-5ded-42d0-be02-cad563d11ac0	PDAC249	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
dadc4743-2015-4218-97c8-6ac1d0c3b6bf	PDAC006	dac3ac4d-a3f5-4a03-a7ff-9243fab02b84	PDAC006	7bb0a4e1-29b3-4b2b-b9ec-62bb6ca48348	PDAC006	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
eb38b6e1-031a-450c-9129-d418d9bfb0ba	PDAC016	aa30cc90-32c8-4c43-9ea3-0285253effe5	PDAC016	5a8d1b2b-cfbe-4939-baf1-9bcddf1b28cd	PDAC016	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1941d77d-d214-407b-8215-d9cd7645af65	PDAC137	759ce321-1faf-4efb-a03f-ba90364dfaa4	PDAC137	9fa742ba-a536-4674-98f6-994758bd69ca	PDAC137	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
542c9d74-e873-4d0b-8ef5-d2d3b6194a9a	PDAC258	2c2e9281-b16c-4cbe-8ce3-1483ba5b8f90	PDAC258	9dbb38e7-6af8-4247-8628-e53fd73dde3f	PDAC258	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e426876c-b261-4cc3-b2d8-46af7068226f	PDAC015	b844eb83-9ff5-4df6-8745-76cc66fbb035	PDAC015	b31b57b6-50ba-4048-8bc7-3c6586bc23dd	PDAC015	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f0500972-ab56-47d0-b026-30ee7ee73e68	PDAC136	71726c5b-4caf-4b33-b02d-2f9e014b8bde	PDAC136	cd32ac83-7414-465a-b679-788e5c451d20	PDAC136	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
6236454c-838a-45f8-8818-68f4175a4b11	PDAC257	711c4437-53a7-429d-912f-2ccababe8d82	PDAC257	3c0f892a-fd54-464d-891e-0bb89b4e7aab	PDAC257	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
d3e984d5-f66c-4761-afd6-bfcc925b0469	PDAC135	511a28c7-ff1b-4a81-9957-47362babf7a3	PDAC135	07c98976-ad56-4a3a-a255-eda12db5eca7	PDAC135	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f5b9e7c1-f2e3-4e1f-8780-a6bbbfd3a6da	PDAC256	d2261b8a-607e-41f9-82c9-38095a7c2907	PDAC256	cd22c2f3-2474-4543-86c7-b67b8cc2a7a5	PDAC256	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
7de51ef6-998e-4b6a-8af5-544bc9be9436	PDAC013	d63ff1b3-1e49-47cf-85d8-82908a9c43be	PDAC013	387c8fdf-39d2-467f-8324-6022658fc8d8	PDAC013	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
b25a7229-48a5-44d6-8b6b-6604f27ac7c2	PDAC134	f2c04146-5158-47d7-afb6-5fb6396b3d19	PDAC134	535262d2-313c-4d8b-84e4-761cd95003bf	PDAC134	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1fa5b1ab-61be-4aa7-8197-54f9cc04999e	PDAC255	47bbad9f-3095-464c-ad79-ddffdd8b8a88	PDAC255	dc436ad3-e534-41d5-9b2a-afb13e45240d	PDAC255	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f6f2bc00-3ebf-40f1-900f-b9c29508bc79	PDAC012	123b35fa-d244-4c45-a0b9-7032e0ecec8a	PDAC012	0896517a-e471-41dc-b829-582817f6f470	PDAC012	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ae0f437e-c6e8-456f-a75e-11fc9e100d1e	PDAC254	0a365d08-0d6c-452d-9360-18855fc5f60d	PDAC254	779c33cb-e62c-45df-9d7a-39c105e61632	PDAC254	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
82b12981-c3c6-4292-a90f-3df0f7e2f027	PDAC011	8a87aeba-4668-4937-961e-ee9339682616	PDAC011	9d7c0e43-f9f6-4504-8d4d-f6a9a71bf0f5	PDAC011	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
61807f23-b665-4a92-9f89-163cf9057463	PDAC132	823c4702-b67b-4323-97d0-64dd66397bee	PDAC132	6dee66bf-1c08-45c5-a2f1-b19adc5faef3	PDAC132	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e665ed30-e751-4b3f-8128-47028ffd3cb6	PDAC253	eef924d2-f480-4d87-b0a0-61b48af7b23b	PDAC253	d7480a6b-7963-4f93-b213-8e5f46a0bf69	PDAC253	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
666b891c-6ead-4af4-b903-11a74e90a41d	PDAC010	2646f260-32ad-4012-a2a8-a31b053bd7f3	PDAC010	2e5b4a35-6949-447f-bb2e-8160045c40d2	PDAC010	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
faccae21-b653-4923-8397-902bc0bf6067	PDAC098	472aa726-d274-4203-a474-48fb61426755	PDAC098	7f6f7909-9446-4ae8-9a9c-cfd1f8823579	PDAC098	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
9dd8c3dd-c5d7-4e64-b660-4b330a2cbbe0	PDAC252	1fc242e3-e806-4794-91fa-709af4d3c251	PDAC252	8915019a-232e-4338-99a3-24873ec6ccaf	PDAC252	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ffb86734-ed18-4948-afee-3c6b240ac586	PDAC097	6a3a82ca-9cc5-43b5-a276-0a425b6d638b	PDAC097	efd77164-77f5-4871-b0fa-025e390d5a58	PDAC097	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
f592c2c6-099c-4d44-8b34-de14425a37a7	PDAC130	e332ea22-34be-497f-a990-8d776e800728	PDAC130	8dc5ed9c-4d11-4cc3-9237-0c2dfa6ba508	PDAC130	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
61d590f7-1e06-474f-9a2f-5c5c32ab17c5	PDAC251	faf904a4-e4f3-4577-804a-c1ae31d16d0a	PDAC251	97b695fa-ba2e-4529-af38-f969bc759baf	PDAC251	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
8451aa16-3b2d-4e8b-a5d1-478bed1a7b33	PDAC096	10ede8e7-f40d-40b9-94ac-2d5192759948	PDAC096	937c9378-e004-4f89-894e-ad05929b09a5	PDAC096	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
00c9d45e-99a9-49f1-afaa-8dada49c3302	PDAC250	6a1a2c11-7cb1-4983-8025-a7c5c13d73d8	PDAC250	7283dd67-1777-4f7b-89cb-6167b69bf1a1	PDAC250	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
68ee699b-9ce3-4834-836a-61d75a1977e9	PDAC093	3e3a14a1-6b6d-4e93-8a8d-0e065e4f5148	PDAC093	b3282736-70aa-444c-a3a4-d1c9b36d1ceb	PDAC093	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
ff391aaf-d347-4221-8513-bd05fbfb6152	PDAC239	1d66850b-c7b3-4fe3-90a2-ec66e65e185b	PDAC239	3aec5261-2d0c-410a-b117-7513b5e54def	PDAC239	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
93c655c4-62ea-4e62-b396-432728f8cfd7	PDAC117	7566defe-3874-46a9-85a7-ae9c13114913	PDAC117	45b33376-aa99-48b7-aae7-5824d1ece67b	PDAC117	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1bb32078-5d42-4c82-a976-4951def59f42	PDAC116	5f23d2c3-cea5-416e-9e62-67ba6877a903	PDAC116	e9f9f658-9dc7-46a2-afc3-b90f10721909	PDAC116	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
0f335144-23d2-4496-8e46-7e30d0f07aad	PDAC005	bb2905fa-4588-4220-b01d-5a1984e22e1d	PDAC005	5d248f11-caf0-4269-9ff4-a559bb9de3f0	PDAC005	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
bea27af7-2367-4db6-99e1-a8f1252d4097	PDAC126	08ed6903-b583-4558-a31b-33fa1d836763	PDAC126	3778ba1a-64f8-4b7e-a926-94d95fbc1655	PDAC126	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
22f05267-bd25-4187-abf6-f97e1beae58d	PDAC247	098cfc20-1c4d-4b3e-a152-0fd2914a2813	PDAC247	b02967d7-2b61-4785-a583-4a7797229545	PDAC247	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8105e98-da4c-4d35-aed0-9ea6103f42a6	PDAC124	e68992ef-1a4e-4384-bf7c-4dd0ac400404	PDAC124	829d6e8d-05c3-426e-af02-7b27180d8beb	PDAC124	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
0d9a9a49-4d4d-47db-943e-bd4be769b298	PDAC245	a4acf747-2ac7-42fc-8d8c-6c385d5f3778	PDAC245	0ca6b2e4-3d99-439b-a4bb-5bd980ca252a	PDAC245	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
4ab36525-8640-4763-8e7f-78fceab39f37	PDAC087	18432119-cbe4-41ef-be6e-1ae467f6d2c8	PDAC087	83c86b84-9d2a-49af-8008-8aec71e87f8e	PDAC087	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
07f4493c-0cc2-471f-8295-3a9e8db4e08d	PDAC241	2e4d84a9-5b21-45c2-b25f-b3016514c1ab	PDAC241	a5418e71-773e-4d52-9191-acebd509970f	PDAC241	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
28fbe5bb-7e5a-4172-8c99-1bef859e9259	PDAC240	3231e864-39b6-47ef-a5d1-f53bb220a424	PDAC240	661e8210-219d-4708-8d6d-a1b14d7a7a22	PDAC240	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
2422ff9d-ea24-45b1-bc76-fe58497b694a	PDAC085	92c4020e-429b-419d-8d6c-2522ebb393f9	PDAC085	7b1f0ac3-8130-4fa4-b926-32afcd419746	PDAC085	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
65e5095e-42d3-4163-b2c0-ec3926873f85	PDAC083	8e2524a9-de7b-48b1-9738-2f32f54d56a2	PDAC083	e7044d5a-0e07-49cc-af0b-1322a782da3c	PDAC083	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
1163b877-b45d-474c-bec3-bf9cbe5ab828	PDAC082	71e215f7-1ab9-4f49-835b-f46876986ec2	PDAC082	04aa3d05-75b5-498f-92c8-63c37746f0d2	PDAC082	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
0d4de085-9b73-4297-a866-b22e4fbdfa3c	PDAC080	40561b59-8db1-4aac-9242-df23212ef5a7	PDAC080	208a78e1-1d87-474d-a995-80abe7c32eb6	PDAC080	Proteogenomics Analysis to Develop Precision Medicine for Treatment-Resistant Pancreatic Cancer	Primary Tumor	Pancreas	Pancreatic Ductal Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
526bb46c-0881-11eb-bc0e-0aad30af8a83	9c8e78bf-b03e-4ba0-9909-5ff070_D2	526b12ba-0881-11eb-bc0e-0aad30af8a83	9c8e78bf-b03e-4ba0-9909-5ff070	526a8125-0881-11eb-bc0e-0aad30af8a83	04OV054	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bae65-0881-11eb-bc0e-0aad30af8a83	15524912-685a-47ce-a824-567848_D2	526b0cfc-0881-11eb-bc0e-0aad30af8a83	15524912-685a-47ce-a824-567848	526a7cfe-0881-11eb-bc0e-0aad30af8a83	04OV049	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bab8a-0881-11eb-bc0e-0aad30af8a83	69d552be-7cb2-4bb4-b602-a27b3e_D2	526b0a2a-0881-11eb-bc0e-0aad30af8a83	69d552be-7cb2-4bb4-b602-a27b3e	526a79a5-0881-11eb-bc0e-0aad30af8a83	04OV045	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b7d6d-0881-11eb-bc0e-0aad30af8a83	256ac9f5-1e19-44b4-92fb-fef3fc_D2	526ad7c1-0881-11eb-bc0e-0aad30af8a83	256ac9f5-1e19-44b4-92fb-fef3fc	526a4d66-0881-11eb-bc0e-0aad30af8a83	01OV049	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b88c5-0881-11eb-bc0e-0aad30af8a83	2dc28da8-7ff1-4b9b-b5bd-17cc25_D2	526ae3ba-0881-11eb-bc0e-0aad30af8a83	2dc28da8-7ff1-4b9b-b5bd-17cc25	526a5ae9-0881-11eb-bc0e-0aad30af8a83	02OV035	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b8ecb-0881-11eb-bc0e-0aad30af8a83	42d860a3-8a0c-4c44-a09a-9ad8cf_D2	526ae97d-0881-11eb-bc0e-0aad30af8a83	42d860a3-8a0c-4c44-a09a-9ad8cf	526a6002-0881-11eb-bc0e-0aad30af8a83	04OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be540-0881-11eb-bc0e-0aad30af8a83	6319b36b-533c-4e86-8e12-80552e_D3	526b4c90-0881-11eb-bc0e-0aad30af8a83	6319b36b-533c-4e86-8e12-80552e	526aad86-0881-11eb-bc0e-0aad30af8a83	26OV002	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bd328-0881-11eb-bc0e-0aad30af8a83	46c73531-f531-4ec3-97fe-b39d9d_D2	526b35c3-0881-11eb-bc0e-0aad30af8a83	46c73531-f531-4ec3-97fe-b39d9d	526a9cc6-0881-11eb-bc0e-0aad30af8a83	17OV014	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bf02b-0881-11eb-bc0e-0aad30af8a83	QC9	526b5e46-0881-11eb-bc0e-0aad30af8a83	QC9	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bccba-0881-11eb-bc0e-0aad30af8a83	3fbf076a-824b-4eac-b6dc-bf5e59_D2	526b2dbd-0881-11eb-bc0e-0aad30af8a83	3fbf076a-824b-4eac-b6dc-bf5e59	526a9497-0881-11eb-bc0e-0aad30af8a83	17OV004	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526ba03d-0881-11eb-bc0e-0aad30af8a83	318d53c3-216b-4de1-a098-77d6dd_D2	526afe0f-0881-11eb-bc0e-0aad30af8a83	318d53c3-216b-4de1-a098-77d6dd	526a70a6-0881-11eb-bc0e-0aad30af8a83	04OV031	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9cd6-0881-11eb-bc0e-0aad30af8a83	af95e2c6-25c4-4ab8-bf06-3e15ff_D2	526afa25-0881-11eb-bc0e-0aad30af8a83	af95e2c6-25c4-4ab8-bf06-3e15ff	526a6d21-0881-11eb-bc0e-0aad30af8a83	04OV024	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9b1d-0881-11eb-bc0e-0aad30af8a83	d4791079-c826-4fc7-9d9b-ee20ba_D2	526af861-0881-11eb-bc0e-0aad30af8a83	d4791079-c826-4fc7-9d9b-ee20ba	526a6b52-0881-11eb-bc0e-0aad30af8a83	04OV023	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6f41-0881-11eb-bc0e-0aad30af8a83	a3a26070-fb84-406a-8280-d555e6_D2	526ac797-0881-11eb-bc0e-0aad30af8a83	a3a26070-fb84-406a-8280-d555e6	526a42f3-0881-11eb-bc0e-0aad30af8a83	01OV026	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9f6a-0881-11eb-bc0e-0aad30af8a83	41d0619e-b299-42e2-ac32-29e784_D2	526afcfb-0881-11eb-bc0e-0aad30af8a83	41d0619e-b299-42e2-ac32-29e784	526a6ec8-0881-11eb-bc0e-0aad30af8a83	04OV028	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bc03f-0881-11eb-bc0e-0aad30af8a83	1db5574d-aca7-403c-8100-6e705f_D2	526b1fc9-0881-11eb-bc0e-0aad30af8a83	1db5574d-aca7-403c-8100-6e705f	526a8c5a-0881-11eb-bc0e-0aad30af8a83	14OV011	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526baab1-0881-11eb-bc0e-0aad30af8a83	3dcf8b3c-c0c5-4dfa-9543-5d30fb_D2	526b0874-0881-11eb-bc0e-0aad30af8a83	3dcf8b3c-c0c5-4dfa-9543-5d30fb	526a78cd-0881-11eb-bc0e-0aad30af8a83	04OV044	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bc822-0881-11eb-bc0e-0aad30af8a83	31c15e30-21d4-4843-bd4a-9cd0d8_D2	526b2971-0881-11eb-bc0e-0aad30af8a83	31c15e30-21d4-4843-bd4a-9cd0d8	526a91cb-0881-11eb-bc0e-0aad30af8a83	17OV002	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6b1d-0881-11eb-bc0e-0aad30af8a83	d38f40fb-dd78-43b2-8b7b-4b6977_D2	526ac37d-0881-11eb-bc0e-0aad30af8a83	d38f40fb-dd78-43b2-8b7b-4b6977	526a4022-0881-11eb-bc0e-0aad30af8a83	01OV023	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9a48-0881-11eb-bc0e-0aad30af8a83	fe83e13f-9754-403b-8f74-d6caf8_D2	526af745-0881-11eb-bc0e-0aad30af8a83	fe83e13f-9754-403b-8f74-d6caf8	526a6a80-0881-11eb-bc0e-0aad30af8a83	04OV021	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b65a3-0881-11eb-bc0e-0aad30af8a83	8ed739dd-ae0f-4881-971a-db3cf4_D1_D2	526aba87-0881-11eb-bc0e-0aad30af8a83	8ed739dd-ae0f-4881-971a-db3cf4	526a3b90-0881-11eb-bc0e-0aad30af8a83	01OV013	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bd832-0881-11eb-bc0e-0aad30af8a83	28d0abdb-f682-4bd3-9425-a9c508_D2	526b3a00-0881-11eb-bc0e-0aad30af8a83	28d0abdb-f682-4bd3-9425-a9c508	526aa0b0-0881-11eb-bc0e-0aad30af8a83	17OV018	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bb8c9-0881-11eb-bc0e-0aad30af8a83	91b287fd-eadb-442d-abcd-20b741_D2	526b16c6-0881-11eb-bc0e-0aad30af8a83	91b287fd-eadb-442d-abcd-20b741	526a847d-0881-11eb-bc0e-0aad30af8a83	04OV058	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b932d-0881-11eb-bc0e-0aad30af8a83	efc971f8-54c5-4531-a792-705ecf_D2	526aed76-0881-11eb-bc0e-0aad30af8a83	efc971f8-54c5-4531-a792-705ecf	526a6387-0881-11eb-bc0e-0aad30af8a83	04OV008	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526ba4fb-0881-11eb-bc0e-0aad30af8a83	e9d416e7-f661-400a-896e-388545_D2	526b02b7-0881-11eb-bc0e-0aad30af8a83	e9d416e7-f661-400a-896e-388545	526a743e-0881-11eb-bc0e-0aad30af8a83	04OV037	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526becf7-0881-11eb-bc0e-0aad30af8a83	QC5	526b5888-0881-11eb-bc0e-0aad30af8a83	QC5	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526beb55-0881-11eb-bc0e-0aad30af8a83	QC3	526b55ab-0881-11eb-bc0e-0aad30af8a83	QC3	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bd536-0881-11eb-bc0e-0aad30af8a83	6530147a-efe9-4df6-ac2f-03ece3_D2	526b36f7-0881-11eb-bc0e-0aad30af8a83	6530147a-efe9-4df6-ac2f-03ece3	526a9d9d-0881-11eb-bc0e-0aad30af8a83	17OV015	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6916-0881-11eb-bc0e-0aad30af8a83	eb0a53df-7620-4024-8d2d-051142_D2	526abeba-0881-11eb-bc0e-0aad30af8a83	eb0a53df-7620-4024-8d2d-051142	526a3d60-0881-11eb-bc0e-0aad30af8a83	01OV018	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be379-0881-11eb-bc0e-0aad30af8a83	21efd60f-6a31-4b98-9477-16a905_D2	526b49b6-0881-11eb-bc0e-0aad30af8a83	21efd60f-6a31-4b98-9477-16a905	526aabd0-0881-11eb-bc0e-0aad30af8a83	22OV001	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9676-0881-11eb-bc0e-0aad30af8a83	4ccb249a-6722-491e-97e9-e3b4e7_D2	526af23a-0881-11eb-bc0e-0aad30af8a83	4ccb249a-6722-491e-97e9-e3b4e7	526a6716-0881-11eb-bc0e-0aad30af8a83	04OV013	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526ba7e7-0881-11eb-bc0e-0aad30af8a83	50997c44-1c8b-4d34-b535-4a6cc2_D2	526b05eb-0881-11eb-bc0e-0aad30af8a83	50997c44-1c8b-4d34-b535-4a6cc2	526a75e7-0881-11eb-bc0e-0aad30af8a83	04OV040	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bc567-0881-11eb-bc0e-0aad30af8a83	1c9145ad-1981-4871-aa7e-8b11de_D2	526b2690-0881-11eb-bc0e-0aad30af8a83	1c9145ad-1981-4871-aa7e-8b11de	526a90f2-0881-11eb-bc0e-0aad30af8a83	17OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be6ef-0881-11eb-bc0e-0aad30af8a83	35a345a4-e954-4c81-ae3f-7797cd_D2	526b4f6b-0881-11eb-bc0e-0aad30af8a83	35a345a4-e954-4c81-ae3f-7797cd	526aaf30-0881-11eb-bc0e-0aad30af8a83	26OV009	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bb9a4-0881-11eb-bc0e-0aad30af8a83	bd266bdd-12e4-42cb-9c49-911bfc_D2	526b18ac-0881-11eb-bc0e-0aad30af8a83	bd266bdd-12e4-42cb-9c49-911bfc	526a8634-0881-11eb-bc0e-0aad30af8a83	04OV063	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bca01-0881-11eb-bc0e-0aad30af8a83	627e6e36-3dca-4ee5-9755-6f3510_D2	526b2b50-0881-11eb-bc0e-0aad30af8a83	627e6e36-3dca-4ee5-9755-6f3510	526a91cb-0881-11eb-bc0e-0aad30af8a83	17OV002	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bcd8c-0881-11eb-bc0e-0aad30af8a83	3e746bea-ed68-40e6-b348-6ddf08_D2	526b2f70-0881-11eb-bc0e-0aad30af8a83	3e746bea-ed68-40e6-b348-6ddf08	526a9697-0881-11eb-bc0e-0aad30af8a83	17OV005	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b8307-0881-11eb-bc0e-0aad30af8a83	9e0d47e0-f633-468b-b82b-4d752d_D2	526add8e-0881-11eb-bc0e-0aad30af8a83	9e0d47e0-f633-468b-b82b-4d752d	526a53ac-0881-11eb-bc0e-0aad30af8a83	02OV015	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b711b-0881-11eb-bc0e-0aad30af8a83	340a3769-3031-41ae-bb08-a2f696_D2	526ac970-0881-11eb-bc0e-0aad30af8a83	340a3769-3031-41ae-bb08-a2f696	526a44db-0881-11eb-bc0e-0aad30af8a83	01OV029	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526ba234-0881-11eb-bc0e-0aad30af8a83	285fed94-1495-448e-879b-b55de9_D2	526affcc-0881-11eb-bc0e-0aad30af8a83	285fed94-1495-448e-879b-b55de9	526a717c-0881-11eb-bc0e-0aad30af8a83	04OV033	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be7be-0881-11eb-bc0e-0aad30af8a83	c17b0ff9-9057-4848-a0cc-abb25f_D2	526b513f-0881-11eb-bc0e-0aad30af8a83	c17b0ff9-9057-4848-a0cc-abb25f	526aafff-0881-11eb-bc0e-0aad30af8a83	26OV010	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526ba8be-0881-11eb-bc0e-0aad30af8a83	1b2ab076-c72f-4bbe-b9f9-657d24_D2	526b071b-0881-11eb-bc0e-0aad30af8a83	1b2ab076-c72f-4bbe-b9f9-657d24	526a77f1-0881-11eb-bc0e-0aad30af8a83	04OV041	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9da9-0881-11eb-bc0e-0aad30af8a83	2224c03f-b7b1-4368-887e-2b4cdf_D2	526afb3f-0881-11eb-bc0e-0aad30af8a83	2224c03f-b7b1-4368-887e-2b4cdf	526a6df9-0881-11eb-bc0e-0aad30af8a83	04OV027	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bad8b-0881-11eb-bc0e-0aad30af8a83	161317f3-1a39-438e-af45-cd2502_D2	526b0b46-0881-11eb-bc0e-0aad30af8a83	161317f3-1a39-438e-af45-cd2502	526a7bd7-0881-11eb-bc0e-0aad30af8a83	04OV048	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b8dd4-0881-11eb-bc0e-0aad30af8a83	5c3971ee-87c7-4dff-b66e-f18892_D2	526ae7bb-0881-11eb-bc0e-0aad30af8a83	5c3971ee-87c7-4dff-b66e-f18892	526a5f28-0881-11eb-bc0e-0aad30af8a83	02OV045	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526ba5f0-0881-11eb-bc0e-0aad30af8a83	7d953d1d-84b6-4ecd-b1d7-1ed865_D2	526b03fe-0881-11eb-bc0e-0aad30af8a83	7d953d1d-84b6-4ecd-b1d7-1ed865	526a751a-0881-11eb-bc0e-0aad30af8a83	04OV039	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b7203-0881-11eb-bc0e-0aad30af8a83	51a4ce2f-4166-4c6b-a7e0-942d0a_D2	526aca87-0881-11eb-bc0e-0aad30af8a83	51a4ce2f-4166-4c6b-a7e0-942d0a	526a44db-0881-11eb-bc0e-0aad30af8a83	01OV029	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bb07d-0881-11eb-bc0e-0aad30af8a83	0cc794c3-5bf5-4621-b238-58a0f6_D2	526b0e18-0881-11eb-bc0e-0aad30af8a83	0cc794c3-5bf5-4621-b238-58a0f6	526a7dd0-0881-11eb-bc0e-0aad30af8a83	04OV050	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b8047-0881-11eb-bc0e-0aad30af8a83	1772e913-f62e-446a-8cf3-720348_D2	526adaa3-0881-11eb-bc0e-0aad30af8a83	1772e913-f62e-446a-8cf3-720348	526a5065-0881-11eb-bc0e-0aad30af8a83	02OV005	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bb587-0881-11eb-bc0e-0aad30af8a83	d109a3c0-350e-47f5-bda0-61899c_D2	526b13d4-0881-11eb-bc0e-0aad30af8a83	d109a3c0-350e-47f5-bda0-61899c	526a82cb-0881-11eb-bc0e-0aad30af8a83	04OV055	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bd921-0881-11eb-bc0e-0aad30af8a83	3946a96c-e0ae-442f-83b4-a9350e_D2	526b3be1-0881-11eb-bc0e-0aad30af8a83	3946a96c-e0ae-442f-83b4-a9350e	526aa1ce-0881-11eb-bc0e-0aad30af8a83	17OV019	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b94d2-0881-11eb-bc0e-0aad30af8a83	08296da7-70ea-44df-8646-09f2cc_D2	526af059-0881-11eb-bc0e-0aad30af8a83	08296da7-70ea-44df-8646-09f2cc	526a662f-0881-11eb-bc0e-0aad30af8a83	04OV012	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bf23c-0881-11eb-bc0e-0aad30af8a83	pooled sample	526b5f5f-0881-11eb-bc0e-0aad30af8a83	pooled sample	526ab2b2-0881-11eb-bc0e-0aad30af8a83	pooled sample	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b8bb0-0881-11eb-bc0e-0aad30af8a83	8d78194e-fbef-4819-a7b5-b73ae9_D2	526ae69a-0881-11eb-bc0e-0aad30af8a83	8d78194e-fbef-4819-a7b5-b73ae9	526a5d16-0881-11eb-bc0e-0aad30af8a83	02OV042	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bcad6-0881-11eb-bc0e-0aad30af8a83	b9c1f22e-61f7-45ed-b3b4-5094c7_D2	526b2c74-0881-11eb-bc0e-0aad30af8a83	b9c1f22e-61f7-45ed-b3b4-5094c7	526a93bc-0881-11eb-bc0e-0aad30af8a83	17OV003	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b72d9-0881-11eb-bc0e-0aad30af8a83	a583d3ff-8165-43e9-b764-23b7ef_D1_D2	526acd9d-0881-11eb-bc0e-0aad30af8a83	a583d3ff-8165-43e9-b764-23b7ef	526a45be-0881-11eb-bc0e-0aad30af8a83	01OV030	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bd258-0881-11eb-bc0e-0aad30af8a83	05387aad-2a1f-42c2-8d6f-950598_D3	526b3350-0881-11eb-bc0e-0aad30af8a83	05387aad-2a1f-42c2-8d6f-950598	526a9aa9-0881-11eb-bc0e-0aad30af8a83	17OV013	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be1d7-0881-11eb-bc0e-0aad30af8a83	3a380577-c134-47ba-a1ce-988d7c_D2	526b48a5-0881-11eb-bc0e-0aad30af8a83	3a380577-c134-47ba-a1ce-988d7c	526aab00-0881-11eb-bc0e-0aad30af8a83	20OV005	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bc48d-0881-11eb-bc0e-0aad30af8a83	7c7ce2d7-6c8a-424e-8e6c-d14ad1_D2	526b23b3-0881-11eb-bc0e-0aad30af8a83	7c7ce2d7-6c8a-424e-8e6c-d14ad1	526a8f0c-0881-11eb-bc0e-0aad30af8a83	15OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b7751-0881-11eb-bc0e-0aad30af8a83	3490835c-c004-45ed-91f3-7c206f_D2	526ad0eb-0881-11eb-bc0e-0aad30af8a83	3490835c-c004-45ed-91f3-7c206f	526a488e-0881-11eb-bc0e-0aad30af8a83	01OV041	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9188-0881-11eb-bc0e-0aad30af8a83	3d3e1888-d67e-4c69-ba83-112d0f_D2	526aec5e-0881-11eb-bc0e-0aad30af8a83	3d3e1888-d67e-4c69-ba83-112d0f	526a62a5-0881-11eb-bc0e-0aad30af8a83	04OV005	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be2ab-0881-11eb-bc0e-0aad30af8a83	2b4ce90c-8036-4207-ac3e-54a76f_D2	526b4b77-0881-11eb-bc0e-0aad30af8a83	2b4ce90c-8036-4207-ac3e-54a76f	526aabd0-0881-11eb-bc0e-0aad30af8a83	22OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b7491-0881-11eb-bc0e-0aad30af8a83	5ea22f5e-307b-491d-801f-8b7fa6_D2	526acc6e-0881-11eb-bc0e-0aad30af8a83	5ea22f5e-307b-491d-801f-8b7fa6	526a45be-0881-11eb-bc0e-0aad30af8a83	01OV030	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bedc1-0881-11eb-bc0e-0aad30af8a83	QC6	526b5996-0881-11eb-bc0e-0aad30af8a83	QC6	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9408-0881-11eb-bc0e-0aad30af8a83	a8853382-b726-4ce8-98d5-ca89df_D2	526aef46-0881-11eb-bc0e-0aad30af8a83	a8853382-b726-4ce8-98d5-ca89df	526a6457-0881-11eb-bc0e-0aad30af8a83	04OV011	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b87ee-0881-11eb-bc0e-0aad30af8a83	0c87932d-b6fd-4eb5-b86a-a34d07_D2	526ae1fe-0881-11eb-bc0e-0aad30af8a83	0c87932d-b6fd-4eb5-b86a-a34d07	526a587e-0881-11eb-bc0e-0aad30af8a83	02OV032	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b8502-0881-11eb-bc0e-0aad30af8a83	27f3ca2d-a86f-479d-8e7e-5307c7_D2	526adf71-0881-11eb-bc0e-0aad30af8a83	27f3ca2d-a86f-479d-8e7e-5307c7	526a548e-0881-11eb-bc0e-0aad30af8a83	02OV022	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b79ec-0881-11eb-bc0e-0aad30af8a83	092af714-b97a-457c-b0e9-8c20e8_D2	526ad3c1-0881-11eb-bc0e-0aad30af8a83	092af714-b97a-457c-b0e9-8c20e8	526a4a82-0881-11eb-bc0e-0aad30af8a83	01OV045	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b69fc-0881-11eb-bc0e-0aad30af8a83	2f901c90-617e-46da-9fac-d68369_D2	526ac082-0881-11eb-bc0e-0aad30af8a83	2f901c90-617e-46da-9fac-d68369	526a3f3c-0881-11eb-bc0e-0aad30af8a83	01OV019	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b7826-0881-11eb-bc0e-0aad30af8a83	6e209757-a7f4-45af-b5f3-2ebc02_D2	526ad204-0881-11eb-bc0e-0aad30af8a83	6e209757-a7f4-45af-b5f3-2ebc02	526a488e-0881-11eb-bc0e-0aad30af8a83	01OV041	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6d95-0881-11eb-bc0e-0aad30af8a83	685ec3c2-e67a-40d3-9eb3-aa01c9_D1_D2	526ac49a-0881-11eb-bc0e-0aad30af8a83	685ec3c2-e67a-40d3-9eb3-aa01c9	526a41f5-0881-11eb-bc0e-0aad30af8a83	01OV024	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bc744-0881-11eb-bc0e-0aad30af8a83	e23eb014-69c1-460a-b9d4-9786c8_D2	526b285a-0881-11eb-bc0e-0aad30af8a83	e23eb014-69c1-460a-b9d4-9786c8	526a90f2-0881-11eb-bc0e-0aad30af8a83	17OV001	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bee8e-0881-11eb-bc0e-0aad30af8a83	QC7	526b5b60-0881-11eb-bc0e-0aad30af8a83	QC7	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be10c-0881-11eb-bc0e-0aad30af8a83	a03d1103-b809-42c4-ad5c-5aff58_D2	526b46ec-0881-11eb-bc0e-0aad30af8a83	a03d1103-b809-42c4-ad5c-5aff58	526aaa31-0881-11eb-bc0e-0aad30af8a83	18OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6674-0881-11eb-bc0e-0aad30af8a83	1556af7e-c2ae-4fce-9aae-87c459_D1_D2	526abbe6-0881-11eb-bc0e-0aad30af8a83	1556af7e-c2ae-4fce-9aae-87c459	526a3c86-0881-11eb-bc0e-0aad30af8a83	01OV017	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bc2cd-0881-11eb-bc0e-0aad30af8a83	7edfd606-4bee-4529-9fec-1ca7f0_D2	526b257d-0881-11eb-bc0e-0aad30af8a83	7edfd606-4bee-4529-9fec-1ca7f0	526a8f0c-0881-11eb-bc0e-0aad30af8a83	15OV001	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b7c96-0881-11eb-bc0e-0aad30af8a83	558333b0-ea23-4303-9e3c-4932b1_D2	526ad6a5-0881-11eb-bc0e-0aad30af8a83	558333b0-ea23-4303-9e3c-4932b1	526a4b64-0881-11eb-bc0e-0aad30af8a83	01OV046	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6e6f-0881-11eb-bc0e-0aad30af8a83	347e379b-77c0-4dd3-aa25-18c9d1_D2	526ac672-0881-11eb-bc0e-0aad30af8a83	347e379b-77c0-4dd3-aa25-18c9d1	526a42f3-0881-11eb-bc0e-0aad30af8a83	01OV026	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bba73-0881-11eb-bc0e-0aad30af8a83	a65d8e76-640f-4341-a561-afbb57_D2	526b19e4-0881-11eb-bc0e-0aad30af8a83	a65d8e76-640f-4341-a561-afbb57	526a8712-0881-11eb-bc0e-0aad30af8a83	11OV002	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b9892-0881-11eb-bc0e-0aad30af8a83	f6c215ea-5381-4521-bb61-be8e97_D2	526af583-0881-11eb-bc0e-0aad30af8a83	f6c215ea-5381-4521-bb61-be8e97	526a69a7-0881-11eb-bc0e-0aad30af8a83	04OV018	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be03f-0881-11eb-bc0e-0aad30af8a83	ce1e5dfc-2ef1-4633-af93-5ea4d9_D2	526b45df-0881-11eb-bc0e-0aad30af8a83	ce1e5dfc-2ef1-4633-af93-5ea4d9	526aa956-0881-11eb-bc0e-0aad30af8a83	17OV039	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bec2a-0881-11eb-bc0e-0aad30af8a83	QC4	526b56c5-0881-11eb-bc0e-0aad30af8a83	QC4	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bb380-0881-11eb-bc0e-0aad30af8a83	79b60f32-6cca-4cb6-9a1e-22a3ac_D2	526b10ee-0881-11eb-bc0e-0aad30af8a83	79b60f32-6cca-4cb6-9a1e-22a3ac	526a8051-0881-11eb-bc0e-0aad30af8a83	04OV053	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bdce5-0881-11eb-bc0e-0aad30af8a83	8234f8ea-bdbd-45b0-bd0b-16f1e7_D2	526b4159-0881-11eb-bc0e-0aad30af8a83	8234f8ea-bdbd-45b0-bd0b-16f1e7	526aa60a-0881-11eb-bc0e-0aad30af8a83	17OV030	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b8231-0881-11eb-bc0e-0aad30af8a83	fbb41c94-aabd-49cc-90b2-882c3e_D2	526adc79-0881-11eb-bc0e-0aad30af8a83	fbb41c94-aabd-49cc-90b2-882c3e	526a514c-0881-11eb-bc0e-0aad30af8a83	02OV008	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6bf0-0881-11eb-bc0e-0aad30af8a83	2b73e01c-347a-4dae-a71d-752aeb_D2	526ac1a3-0881-11eb-bc0e-0aad30af8a83	2b73e01c-347a-4dae-a71d-752aeb	526a4022-0881-11eb-bc0e-0aad30af8a83	01OV023	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bdf68-0881-11eb-bc0e-0aad30af8a83	80873a0c-1f40-4d51-bab1-3f2071_D2	526b4436-0881-11eb-bc0e-0aad30af8a83	80873a0c-1f40-4d51-bab1-3f2071	526aa7b2-0881-11eb-bc0e-0aad30af8a83	17OV036	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6836-0881-11eb-bc0e-0aad30af8a83	1a10c200-3895-4648-b951-94f99f_D2	526abda4-0881-11eb-bc0e-0aad30af8a83	1a10c200-3895-4648-b951-94f99f	526a3c86-0881-11eb-bc0e-0aad30af8a83	01OV017	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bd60e-0881-11eb-bc0e-0aad30af8a83	49bd51fe-48a1-4828-b66e-b30c38_D2	526b38c4-0881-11eb-bc0e-0aad30af8a83	49bd51fe-48a1-4828-b66e-b30c38	526a9fbc-0881-11eb-bc0e-0aad30af8a83	17OV017	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b7abf-0881-11eb-bc0e-0aad30af8a83	62f5840e-6cd7-4200-b651-645e53_D2	526ad4de-0881-11eb-bc0e-0aad30af8a83	62f5840e-6cd7-4200-b651-645e53	526a4a82-0881-11eb-bc0e-0aad30af8a83	01OV045	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be887-0881-11eb-bc0e-0aad30af8a83	QC1	526b525e-0881-11eb-bc0e-0aad30af8a83	QC1	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bbf6b-0881-11eb-bc0e-0aad30af8a83	2115808b-6a0d-49bc-a8d7-b83bde_D2	526b20e0-0881-11eb-bc0e-0aad30af8a83	2115808b-6a0d-49bc-a8d7-b83bde	526a8c5a-0881-11eb-bc0e-0aad30af8a83	14OV011	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b979c-0881-11eb-bc0e-0aad30af8a83	eb3f3494-7057-4afe-b212-e6e9a3_D2	526af413-0881-11eb-bc0e-0aad30af8a83	eb3f3494-7057-4afe-b212-e6e9a3	526a67e6-0881-11eb-bc0e-0aad30af8a83	04OV017	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bc1f8-0881-11eb-bc0e-0aad30af8a83	994f9b8e-46cb-413f-8ec8-2c2fed_D2	526b22a0-0881-11eb-bc0e-0aad30af8a83	994f9b8e-46cb-413f-8ec8-2c2fed	526a8e33-0881-11eb-bc0e-0aad30af8a83	14OV029	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b90a3-0881-11eb-bc0e-0aad30af8a83	e3ebe010-cd31-4b5d-8fcb-b7103b_D2	526aea92-0881-11eb-bc0e-0aad30af8a83	e3ebe010-cd31-4b5d-8fcb-b7103b	526a60d3-0881-11eb-bc0e-0aad30af8a83	04OV004	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bbc17-0881-11eb-bc0e-0aad30af8a83	51c1c79e-5a8e-4b0a-bf92-1c0cab_D2	526b1b42-0881-11eb-bc0e-0aad30af8a83	51c1c79e-5a8e-4b0a-bf92-1c0cab	526a88d1-0881-11eb-bc0e-0aad30af8a83	11OV009	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bb15d-0881-11eb-bc0e-0aad30af8a83	76e77c6b-c80e-4391-bdbb-e1dcea_D2	526b0fdf-0881-11eb-bc0e-0aad30af8a83	76e77c6b-c80e-4391-bdbb-e1dcea	526a7f76-0881-11eb-bc0e-0aad30af8a83	04OV051	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bbdba-0881-11eb-bc0e-0aad30af8a83	1de8d3d8-fc0e-4be0-8aa7-127c7b_D2	526b1e15-0881-11eb-bc0e-0aad30af8a83	1de8d3d8-fc0e-4be0-8aa7-127c7b	526a8b79-0881-11eb-bc0e-0aad30af8a83	13OV004	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be61f-0881-11eb-bc0e-0aad30af8a83	2433b136-fc7b-4cea-b958-bc6efb_D2	526b4e60-0881-11eb-bc0e-0aad30af8a83	2433b136-fc7b-4cea-b958-bc6efb	526aae61-0881-11eb-bc0e-0aad30af8a83	26OV008	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bbcef-0881-11eb-bc0e-0aad30af8a83	61f76fe6-a1c6-41b8-bdc2-2f9209_D2	526b1d02-0881-11eb-bc0e-0aad30af8a83	61f76fe6-a1c6-41b8-bdc2-2f9209	526a89a7-0881-11eb-bc0e-0aad30af8a83	11OV010	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526ba31b-0881-11eb-bc0e-0aad30af8a83	10c2d629-0287-4511-ac25-f29031_D2	526b00e8-0881-11eb-bc0e-0aad30af8a83	10c2d629-0287-4511-ac25-f29031	526a724a-0881-11eb-bc0e-0aad30af8a83	04OV036	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bdc01-0881-11eb-bc0e-0aad30af8a83	74a45e5a-a35a-4c60-a4b4-f3f5ea_D2	526b4000-0881-11eb-bc0e-0aad30af8a83	74a45e5a-a35a-4c60-a4b4-f3f5ea	526aa526-0881-11eb-bc0e-0aad30af8a83	17OV029	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526be963-0881-11eb-bc0e-0aad30af8a83	QC2	526b53e0-0881-11eb-bc0e-0aad30af8a83	QC2	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b8ada-0881-11eb-bc0e-0aad30af8a83	927f0958-db5a-4bc5-92b7-2a3695_D2	526ae4d2-0881-11eb-bc0e-0aad30af8a83	927f0958-db5a-4bc5-92b7-2a3695	526a5c31-0881-11eb-bc0e-0aad30af8a83	02OV040	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bda36-0881-11eb-bc0e-0aad30af8a83	e7b656bf-3c34-4ba1-bdf3-c7eefe_D2	526b3cfb-0881-11eb-bc0e-0aad30af8a83	e7b656bf-3c34-4ba1-bdf3-c7eefe	526aa2aa-0881-11eb-bc0e-0aad30af8a83	17OV025	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b756b-0881-11eb-bc0e-0aad30af8a83	8e17b45e-6a06-4e4e-913d-7b1edb_D2	526acf2e-0881-11eb-bc0e-0aad30af8a83	8e17b45e-6a06-4e4e-913d-7b1edb	526a47af-0881-11eb-bc0e-0aad30af8a83	01OV039	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bef60-0881-11eb-bc0e-0aad30af8a83	QC8	526b5c74-0881-11eb-bc0e-0aad30af8a83	QC8	526ab1ce-0881-11eb-bc0e-0aad30af8a83	Ovarian Tumor Sample 5776	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bd053-0881-11eb-bc0e-0aad30af8a83	e6850782-fd2a-4c53-b682-1852fe_D2	526b323d-0881-11eb-bc0e-0aad30af8a83	e6850782-fd2a-4c53-b682-1852fe	526a99c0-0881-11eb-bc0e-0aad30af8a83	17OV012	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bddb6-0881-11eb-bc0e-0aad30af8a83	2563cb02-d58a-4286-8634-7502cd_D2	526b431e-0881-11eb-bc0e-0aad30af8a83	2563cb02-d58a-4286-8634-7502cd	526aa6dd-0881-11eb-bc0e-0aad30af8a83	17OV034	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bdb0e-0881-11eb-bc0e-0aad30af8a83	52c064a7-78d9-4a1a-85b4-27c6d1_D2	526b3ed5-0881-11eb-bc0e-0aad30af8a83	52c064a7-78d9-4a1a-85b4-27c6d1	526aa37f-0881-11eb-bc0e-0aad30af8a83	17OV028	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b7f4d-0881-11eb-bc0e-0aad30af8a83	9a7a86d3-bbf2-4d36-941d-c75c03_D1_D2	526ad98a-0881-11eb-bc0e-0aad30af8a83	9a7a86d3-bbf2-4d36-941d-c75c03	526a4e47-0881-11eb-bc0e-0aad30af8a83	02OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b623a-0881-11eb-bc0e-0aad30af8a83	9b90eb78-2f50-4aeb-b010-d642f9_D2	526ab5e8-0881-11eb-bc0e-0aad30af8a83	9b90eb78-2f50-4aeb-b010-d642f9	526a3222-0881-11eb-bc0e-0aad30af8a83	01OV007	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b85e4-0881-11eb-bc0e-0aad30af8a83	2ed8beb2-bc63-4bad-b5fe-1916a0_D2	526ae0a2-0881-11eb-bc0e-0aad30af8a83	2ed8beb2-bc63-4bad-b5fe-1916a0	526a5774-0881-11eb-bc0e-0aad30af8a83	02OV023	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b6147-0881-11eb-bc0e-0aad30af8a83	1abbcb28-f221-4cd4-8c01-37b9bb_D1_D2	526ab38d-0881-11eb-bc0e-0aad30af8a83	1abbcb28-f221-4cd4-8c01-37b9bb	526a3222-0881-11eb-bc0e-0aad30af8a83	01OV007	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b64c8-0881-11eb-bc0e-0aad30af8a83	0745488e-0bfb-4d1f-8228-dedf76_D1_D2	526ab94f-0881-11eb-bc0e-0aad30af8a83	0745488e-0bfb-4d1f-8228-dedf76	526a3949-0881-11eb-bc0e-0aad30af8a83	01OV010	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bb705-0881-11eb-bc0e-0aad30af8a83	7069e990-4a4e-4984-a66d-4d835a_D2	526b15ac-0881-11eb-bc0e-0aad30af8a83	7069e990-4a4e-4984-a66d-4d835a	526a83a7-0881-11eb-bc0e-0aad30af8a83	04OV057	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526bcf80-0881-11eb-bc0e-0aad30af8a83	cfd76f9a-ce60-4ec7-8e6b-a8fc31_D3	526b3084-0881-11eb-bc0e-0aad30af8a83	cfd76f9a-ce60-4ec7-8e6b-a8fc31	526a9779-0881-11eb-bc0e-0aad30af8a83	17OV011	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
526b630e-0881-11eb-bc0e-0aad30af8a83	b22659b9-e12c-4725-a7db-a833de_D1_D2	526ab71c-0881-11eb-bc0e-0aad30af8a83	b22659b9-e12c-4725-a7db-a833de	526a3812-0881-11eb-bc0e-0aad30af8a83	01OV008	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d6520c82-ad21-4c1c-a55a-b6cbe7b919af	74	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e492a101-8d54-4560-8ee5-fb0eb14abd8d	62	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
050212db-b023-4335-a520-d8bfaf61e621	34	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
edbfd4e1-08aa-45bc-8a72-9977e6b7da32	108	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
485e1fbb-02c1-4677-9bac-4bc14a11c467	111	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a5c829a9-135a-4e5a-841d-166abbaa9c28	29	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2b4f15e8-1e39-42e5-9c21-d2c1db580a49	20	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4a31f9d-2322-433a-89a9-d8700c69e38f	22	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e6970633-a430-493e-a10c-db57d0bb9410	85	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
edf849d0-5a9b-479e-85d1-e4ba836bcdc7	38	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a2c2169d-51cf-4ef4-8fd7-112e4dd66adc	25	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7504c819-72de-4974-ab1c-52b86fdd6c71	61	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
40357ee1-5790-448f-a699-eaa8a80d869f	58	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f5a396ff-8498-404e-b298-7df498f7e748	71	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cdd8a554-71c6-48ce-839a-e3846a1a857a	100	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59a29974-d663-419a-ab7f-66105ad10762	91	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9fec924b-ed28-4e9e-a12e-b69b844a4428	19	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
048b49c8-1eaa-4e0a-a88b-b2c9d26f9142	65	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d060c015-ae24-4400-9d2e-aea7eff7724d	69	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
35f60c3c-5b92-4b90-8ab7-c0c8c0b9e53c	57	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d08f8d02-ff5e-11e9-9a07-0a80fada099c	7316-324	d08e44be-ff5e-11e9-9a07-0a80fada099c	7316-324	d08d4986-ff5e-11e9-9a07-0a80fada099c	C16974	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0910093-ff5e-11e9-9a07-0a80fada099c	7316-445	d08f456c-ff5e-11e9-9a07-0a80fada099c	7316-445	d08e0676-ff5e-11e9-9a07-0a80fada099c	C94956	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fb256-ff5e-11e9-9a07-0a80fada099c	7316-329	d08e5f79-ff5e-11e9-9a07-0a80fada099c	7316-329	d08d5e3c-ff5e-11e9-9a07-0a80fada099c	C22140	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0905be5-ff5e-11e9-9a07-0a80fada099c	7316-206	d08ed5b3-ff5e-11e9-9a07-0a80fada099c	7316-206	d08db475-ff5e-11e9-9a07-0a80fada099c	C58179	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0905918-ff5e-11e9-9a07-0a80fada099c	7316-207	d08ed4bf-ff5e-11e9-9a07-0a80fada099c	7316-207	d08db366-ff5e-11e9-9a07-0a80fada099c	C58056	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f5f27-ff5e-11e9-9a07-0a80fada099c	7316-449	d08e1c5e-ff5e-11e9-9a07-0a80fada099c	7316-449	d08d2c22-ff5e-11e9-9a07-0a80fada099c	C112422	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0902b6e-ff5e-11e9-9a07-0a80fada099c	7316-1854	d08eb561-ff5e-11e9-9a07-0a80fada099c	7316-1854	d08d9c10-ff5e-11e9-9a07-0a80fada099c	C431607	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090456a-ff5e-11e9-9a07-0a80fada099c	7316-321	d08ec7d1-ff5e-11e9-9a07-0a80fada099c	7316-321	d08da9e1-ff5e-11e9-9a07-0a80fada099c	C50553	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090b0da-ff5e-11e9-9a07-0a80fada099c	7316-442	d08f1096-ff5e-11e9-9a07-0a80fada099c	7316-442	d08de025-ff5e-11e9-9a07-0a80fada099c	C74292	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090fb79-ff5e-11e9-9a07-0a80fada099c	7316-443	d08f42c2-ff5e-11e9-9a07-0a80fada099c	7316-443	d08e05bc-ff5e-11e9-9a07-0a80fada099c	C91881	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09038f4-ff5e-11e9-9a07-0a80fada099c	7316-2141	d08ebe69-ff5e-11e9-9a07-0a80fada099c	7316-2141	d08da406-ff5e-11e9-9a07-0a80fada099c	C466293	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0903dc1-ff5e-11e9-9a07-0a80fada099c	7316-2144	d08ec124-ff5e-11e9-9a07-0a80fada099c	7316-2144	d08da670-ff5e-11e9-9a07-0a80fada099c	C476010	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fd0f4-ff5e-11e9-9a07-0a80fada099c	7316-2146	d08e75f2-ff5e-11e9-9a07-0a80fada099c	7316-2146	d08d6ea0-ff5e-11e9-9a07-0a80fada099c	C271092	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f6174-ff5e-11e9-9a07-0a80fada099c	7316-1851	d08e1f58-ff5e-11e9-9a07-0a80fada099c	7316-1851	d08d2f50-ff5e-11e9-9a07-0a80fada099c	C115251	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090375e-ff5e-11e9-9a07-0a80fada099c	7316-2140	d08ebd74-ff5e-11e9-9a07-0a80fada099c	7316-2140	d08da346-ff5e-11e9-9a07-0a80fada099c	C466170	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0902cd9-ff5e-11e9-9a07-0a80fada099c	7316-319	d08eb680-ff5e-11e9-9a07-0a80fada099c	7316-319	d08d9d5c-ff5e-11e9-9a07-0a80fada099c	C43542	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fefb0-ff5e-11e9-9a07-0a80fada099c	7316-1746	d08e8c8d-ff5e-11e9-9a07-0a80fada099c	7316-1746	d08d800f-ff5e-11e9-9a07-0a80fada099c	C337143	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fbee0-ff5e-11e9-9a07-0a80fada099c	7316-2959	d08e6954-ff5e-11e9-9a07-0a80fada099c	7316-2959	d08d661a-ff5e-11e9-9a07-0a80fada099c	C253872	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0904b00-ff5e-11e9-9a07-0a80fada099c	7316-2152	d08eca7e-ff5e-11e9-9a07-0a80fada099c	7316-2152	d08dab5d-ff5e-11e9-9a07-0a80fada099c	C524349	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0901b7c-ff5e-11e9-9a07-0a80fada099c	7316-2154	d08eaaa3-ff5e-11e9-9a07-0a80fada099c	7316-2154	d08d92f9-ff5e-11e9-9a07-0a80fada099c	C38868	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0908d9b-ff5e-11e9-9a07-0a80fada099c	7316-2155	d08ef665-ff5e-11e9-9a07-0a80fada099c	7316-2155	d08dcdb6-ff5e-11e9-9a07-0a80fada099c	C692613	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0905d4b-ff5e-11e9-9a07-0a80fada099c	7316-2156	d08ed780-ff5e-11e9-9a07-0a80fada099c	7316-2156	d08db531-ff5e-11e9-9a07-0a80fada099c	C584373	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090567c-ff5e-11e9-9a07-0a80fada099c	7316-2157	d08ed1ae-ff5e-11e9-9a07-0a80fada099c	7316-2157	d08db0a4-ff5e-11e9-9a07-0a80fada099c	C579945	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090c610-ff5e-11e9-9a07-0a80fada099c	7316-2151	d08f1e56-ff5e-11e9-9a07-0a80fada099c	7316-2151	d08de9f0-ff5e-11e9-9a07-0a80fada099c	C801468	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09043f9-ff5e-11e9-9a07-0a80fada099c	7316-304	d08ec6dc-ff5e-11e9-9a07-0a80fada099c	7316-304	d08da81f-ff5e-11e9-9a07-0a80fada099c	C48216	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08faa6b-ff5e-11e9-9a07-0a80fada099c	7316-302	d08e5a22-ff5e-11e9-9a07-0a80fada099c	7316-302	d08d59eb-ff5e-11e9-9a07-0a80fada099c	C21402	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09048f6-ff5e-11e9-9a07-0a80fada099c	7316-306	d08ec96b-ff5e-11e9-9a07-0a80fada099c	7316-306	d08daaa1-ff5e-11e9-9a07-0a80fada099c	C50799	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090f1dc-ff5e-11e9-9a07-0a80fada099c	7316-3571	d08f3c41-ff5e-11e9-9a07-0a80fada099c	7316-3571	d08e006b-ff5e-11e9-9a07-0a80fada099c	C907125	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090f533-ff5e-11e9-9a07-0a80fada099c	7316-3572	d08f3dd4-ff5e-11e9-9a07-0a80fada099c	7316-3572	d08e0273-ff5e-11e9-9a07-0a80fada099c	C907371	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090f818-ff5e-11e9-9a07-0a80fada099c	7316-3575	d08f413e-ff5e-11e9-9a07-0a80fada099c	7316-3575	d08e03e9-ff5e-11e9-9a07-0a80fada099c	C916473	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090f6b0-ff5e-11e9-9a07-0a80fada099c	7316-3570	d08f3ec2-ff5e-11e9-9a07-0a80fada099c	7316-3570	d08e0330-ff5e-11e9-9a07-0a80fada099c	C907617	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fba56-ff5e-11e9-9a07-0a80fada099c	7316-897	d08e66be-ff5e-11e9-9a07-0a80fada099c	7316-897	d08d6480-ff5e-11e9-9a07-0a80fada099c	C230994	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0907624-ff5e-11e9-9a07-0a80fada099c	7316-2933	d08ee91f-ff5e-11e9-9a07-0a80fada099c	7316-2933	d08dc161-ff5e-11e9-9a07-0a80fada099c	C626070	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0907348-ff5e-11e9-9a07-0a80fada099c	7316-893	d08ee675-ff5e-11e9-9a07-0a80fada099c	7316-893	d08dbff3-ff5e-11e9-9a07-0a80fada099c	C62484	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fb8e5-ff5e-11e9-9a07-0a80fada099c	7316-891	d08e652e-ff5e-11e9-9a07-0a80fada099c	7316-891	d08d6212-ff5e-11e9-9a07-0a80fada099c	C230871	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f760a-ff5e-11e9-9a07-0a80fada099c	7316-892	d08e330d-ff5e-11e9-9a07-0a80fada099c	7316-892	d08d3a0b-ff5e-11e9-9a07-0a80fada099c	C140343	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090c0fd-ff5e-11e9-9a07-0a80fada099c	7316-400	d08f1bc8-ff5e-11e9-9a07-0a80fada099c	7316-400	d08de86c-ff5e-11e9-9a07-0a80fada099c	C78966	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f7c53-ff5e-11e9-9a07-0a80fada099c	7316-884	d08e3867-ff5e-11e9-9a07-0a80fada099c	7316-884	d08d3ebf-ff5e-11e9-9a07-0a80fada099c	C146124	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090dae4-ff5e-11e9-9a07-0a80fada099c	7316-407	d08f2cc2-ff5e-11e9-9a07-0a80fada099c	7316-407	d08df551-ff5e-11e9-9a07-0a80fada099c	C84747	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fa5ed-ff5e-11e9-9a07-0a80fada099c	7316-47	d08e5636-ff5e-11e9-9a07-0a80fada099c	7316-47	d08d571e-ff5e-11e9-9a07-0a80fada099c	C20418	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f9af2-ff5e-11e9-9a07-0a80fada099c	7316-889	d08e4de7-ff5e-11e9-9a07-0a80fada099c	7316-889	d08d501a-ff5e-11e9-9a07-0a80fada099c	C186837	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09015e8-ff5e-11e9-9a07-0a80fada099c	7316-1775	d08ea631-ff5e-11e9-9a07-0a80fada099c	7316-1775	d08d9058-ff5e-11e9-9a07-0a80fada099c	C387450	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fb3b4-ff5e-11e9-9a07-0a80fada099c	7316-2986	d08e615e-ff5e-11e9-9a07-0a80fada099c	7316-2986	d08d5ef9-ff5e-11e9-9a07-0a80fada099c	C22263	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f775c-ff5e-11e9-9a07-0a80fada099c	7316-882	d08e34bf-ff5e-11e9-9a07-0a80fada099c	7316-882	d08d3ad2-ff5e-11e9-9a07-0a80fada099c	C140466	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f8038-ff5e-11e9-9a07-0a80fada099c	7316-883	d08e3b86-ff5e-11e9-9a07-0a80fada099c	7316-883	d08d3fc4-ff5e-11e9-9a07-0a80fada099c	C146247	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f7266-ff5e-11e9-9a07-0a80fada099c	7316-880	d08e3070-ff5e-11e9-9a07-0a80fada099c	7316-880	d08d38f4-ff5e-11e9-9a07-0a80fada099c	C140097	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090797e-ff5e-11e9-9a07-0a80fada099c	7316-2187	d08eeaef-ff5e-11e9-9a07-0a80fada099c	7316-2187	d08dc311-ff5e-11e9-9a07-0a80fada099c	C626193	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0900b21-ff5e-11e9-9a07-0a80fada099c	7316-1771	d08ea08b-ff5e-11e9-9a07-0a80fada099c	7316-1771	d08d8cee-ff5e-11e9-9a07-0a80fada099c	C374412	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f7d98-ff5e-11e9-9a07-0a80fada099c	7316-1772	d08e3a4a-ff5e-11e9-9a07-0a80fada099c	7316-1772	d08d3fc4-ff5e-11e9-9a07-0a80fada099c	C146247	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09009b5-ff5e-11e9-9a07-0a80fada099c	7316-1773	d08e9f99-ff5e-11e9-9a07-0a80fada099c	7316-1773	d08d8c30-ff5e-11e9-9a07-0a80fada099c	C374289	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0906d62-ff5e-11e9-9a07-0a80fada099c	7316-2181	d08ee2d6-ff5e-11e9-9a07-0a80fada099c	7316-2181	d08dbd9e-ff5e-11e9-9a07-0a80fada099c	C607743	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09074c8-ff5e-11e9-9a07-0a80fada099c	7316-2183	d08ee833-ff5e-11e9-9a07-0a80fada099c	7316-2183	d08dc0ae-ff5e-11e9-9a07-0a80fada099c	C625947	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0906ee2-ff5e-11e9-9a07-0a80fada099c	7316-2184	d08ee3de-ff5e-11e9-9a07-0a80fada099c	7316-2184	d08dbe53-ff5e-11e9-9a07-0a80fada099c	C623856	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f85e5-ff5e-11e9-9a07-0a80fada099c	7316-875	d08e3f97-ff5e-11e9-9a07-0a80fada099c	7316-875	d08d42ee-ff5e-11e9-9a07-0a80fada099c	C155103	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d091193c-ff5e-11e9-9a07-0a80fada099c	7316-51	d08f578e-ff5e-11e9-9a07-0a80fada099c	7316-51	d08e14e3-ff5e-11e9-9a07-0a80fada099c	7316-51	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Not Reported	Other	no	Disqualified						Disqualified	Disqualified																									Pediatric Brain Tumor Atlas - CBTN
d08f7396-ff5e-11e9-9a07-0a80fada099c	7316-873	d08e3216-ff5e-11e9-9a07-0a80fada099c	7316-873	d08d3a0b-ff5e-11e9-9a07-0a80fada099c	C140343	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f7b18-ff5e-11e9-9a07-0a80fada099c	7316-878	d08e376f-ff5e-11e9-9a07-0a80fada099c	7316-878	d08d3c6d-ff5e-11e9-9a07-0a80fada099c	C140712	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0906a50-ff5e-11e9-9a07-0a80fada099c	7316-196	d08ee0a6-ff5e-11e9-9a07-0a80fada099c	7316-196	d08dbcde-ff5e-11e9-9a07-0a80fada099c	C60024	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090b256-ff5e-11e9-9a07-0a80fada099c	7316-2755	d08f13b2-ff5e-11e9-9a07-0a80fada099c	7316-2755	d08de1d8-ff5e-11e9-9a07-0a80fada099c	C744888	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0903a5a-ff5e-11e9-9a07-0a80fada099c	7316-194	d08ec026-ff5e-11e9-9a07-0a80fada099c	7316-194	d08da4c1-ff5e-11e9-9a07-0a80fada099c	C47478	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090fd01-ff5e-11e9-9a07-0a80fada099c	7316-1789	d08f4480-ff5e-11e9-9a07-0a80fada099c	7316-1789	d08e0676-ff5e-11e9-9a07-0a80fada099c	C94956	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09053ae-ff5e-11e9-9a07-0a80fada099c	7316-195	d08ecf9b-ff5e-11e9-9a07-0a80fada099c	7316-195	d08daeba-ff5e-11e9-9a07-0a80fada099c	C56826	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090b5b2-ff5e-11e9-9a07-0a80fada099c	7316-2757	d08f151b-ff5e-11e9-9a07-0a80fada099c	7316-2757	d08de294-ff5e-11e9-9a07-0a80fada099c	C745011	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fdef8-ff5e-11e9-9a07-0a80fada099c	7316-2758	d08e8098-ff5e-11e9-9a07-0a80fada099c	7316-2758	d08d76eb-ff5e-11e9-9a07-0a80fada099c	C30012	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f712e-ff5e-11e9-9a07-0a80fada099c	7316-872	d08e2f72-ff5e-11e9-9a07-0a80fada099c	7316-872	d08d37cd-ff5e-11e9-9a07-0a80fada099c	C138990	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0903f33-ff5e-11e9-9a07-0a80fada099c	7316-198	d08ec3e1-ff5e-11e9-9a07-0a80fada099c	7316-198	d08da768-ff5e-11e9-9a07-0a80fada099c	C47724	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0900ea7-ff5e-11e9-9a07-0a80fada099c	7316-3045	d08ea214-ff5e-11e9-9a07-0a80fada099c	7316-3045	d08d8cee-ff5e-11e9-9a07-0a80fada099c	C374412	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0902718-ff5e-11e9-9a07-0a80fada099c	7316-1781	d08eb2e8-ff5e-11e9-9a07-0a80fada099c	7316-1781	d08d99ca-ff5e-11e9-9a07-0a80fada099c	C406761	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fd245-ff5e-11e9-9a07-0a80fada099c	7316-2751	d08e77d3-ff5e-11e9-9a07-0a80fada099c	7316-2751	d08d6ea0-ff5e-11e9-9a07-0a80fada099c	C271092	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08ffbde-ff5e-11e9-9a07-0a80fada099c	7316-1784	d08e9563-ff5e-11e9-9a07-0a80fada099c	7316-1784	d08d8582-ff5e-11e9-9a07-0a80fada099c	C35793	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f6b8e-ff5e-11e9-9a07-0a80fada099c	7316-2193	d08e2b3e-ff5e-11e9-9a07-0a80fada099c	7316-2193	d08d34f8-ff5e-11e9-9a07-0a80fada099c	C136161	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0911ee7-ff5e-11e9-9a07-0a80fada099c	Bridge	d08f5bd2-ff5e-11e9-9a07-0a80fada099c	Bridge	d08e17df-ff5e-11e9-9a07-0a80fada099c	Bridge	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0907c4f-ff5e-11e9-9a07-0a80fada099c	7316-2195	d08eedc4-ff5e-11e9-9a07-0a80fada099c	7316-2195	d08dc484-ff5e-11e9-9a07-0a80fada099c	C650178	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090ac2f-ff5e-11e9-9a07-0a80fada099c	7316-2729	d08f0ddb-ff5e-11e9-9a07-0a80fada099c	7316-2729	d08ddf6f-ff5e-11e9-9a07-0a80fada099c	C736401	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fb4da-ff5e-11e9-9a07-0a80fada099c	7316-20	d08e629c-ff5e-11e9-9a07-0a80fada099c	7316-20	d08d607d-ff5e-11e9-9a07-0a80fada099c	C22509	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f68af-ff5e-11e9-9a07-0a80fada099c	7316-869	d08e2a45-ff5e-11e9-9a07-0a80fada099c	7316-869	d08d340f-ff5e-11e9-9a07-0a80fada099c	C127182	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fb77e-ff5e-11e9-9a07-0a80fada099c	7316-24	d08e643c-ff5e-11e9-9a07-0a80fada099c	7316-24	d08d6139-ff5e-11e9-9a07-0a80fada099c	C22878	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09091e1-ff5e-11e9-9a07-0a80fada099c	7316-186	d08ef8f9-ff5e-11e9-9a07-0a80fada099c	7316-186	d08dd09a-ff5e-11e9-9a07-0a80fada099c	C70602	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0902127-ff5e-11e9-9a07-0a80fada099c	7316-183	d08eae3f-ff5e-11e9-9a07-0a80fada099c	7316-183	d08d96d5-ff5e-11e9-9a07-0a80fada099c	C39483	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0909f07-ff5e-11e9-9a07-0a80fada099c	7316-2723	d08f044a-ff5e-11e9-9a07-0a80fada099c	7316-2723	d08dd7ca-ff5e-11e9-9a07-0a80fada099c	C720165	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09032d4-ff5e-11e9-9a07-0a80fada099c	7316-189	d08ebac9-ff5e-11e9-9a07-0a80fada099c	7316-189	d08da0eb-ff5e-11e9-9a07-0a80fada099c	C46494	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09117b8-ff5e-11e9-9a07-0a80fada099c	7316-4341	d08f567b-ff5e-11e9-9a07-0a80fada099c	7316-4341	d08e1428-ff5e-11e9-9a07-0a80fada099c	7316-4341	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Not Reported	Other	no	Disqualified						Disqualified	Disqualified																									Pediatric Brain Tumor Atlas - CBTN
d09057c9-ff5e-11e9-9a07-0a80fada099c	7316-2167	d08ed2f3-ff5e-11e9-9a07-0a80fada099c	7316-2167	d08db15f-ff5e-11e9-9a07-0a80fada099c	C580068	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0902875-ff5e-11e9-9a07-0a80fada099c	7316-193	d08eb3d9-ff5e-11e9-9a07-0a80fada099c	7316-193	d08d9a87-ff5e-11e9-9a07-0a80fada099c	C41451	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0901758-ff5e-11e9-9a07-0a80fada099c	7316-1751	d08ea7fc-ff5e-11e9-9a07-0a80fada099c	7316-1751	d08d910d-ff5e-11e9-9a07-0a80fada099c	C387573	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f9f04-ff5e-11e9-9a07-0a80fada099c	7316-32	d08e511a-ff5e-11e9-9a07-0a80fada099c	7316-32	d08d5194-ff5e-11e9-9a07-0a80fada099c	C19065	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0901ce7-ff5e-11e9-9a07-0a80fada099c	7316-175	d08eab93-ff5e-11e9-9a07-0a80fada099c	7316-175	d08d93b7-ff5e-11e9-9a07-0a80fada099c	C38991	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0905240-ff5e-11e9-9a07-0a80fada099c	7316-1886	d08eceac-ff5e-11e9-9a07-0a80fada099c	7316-1886	d08dade9-ff5e-11e9-9a07-0a80fada099c	C53382	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0901a1b-ff5e-11e9-9a07-0a80fada099c	7316-173	d08ea8f1-ff5e-11e9-9a07-0a80fada099c	7316-173	d08d92f9-ff5e-11e9-9a07-0a80fada099c	C38868	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0901fb0-ff5e-11e9-9a07-0a80fada099c	7316-1767	d08ead48-ff5e-11e9-9a07-0a80fada099c	7316-1767	d08d95ca-ff5e-11e9-9a07-0a80fada099c	C393477	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0902577-ff5e-11e9-9a07-0a80fada099c	7316-178	d08eb154-ff5e-11e9-9a07-0a80fada099c	7316-178	d08d990a-ff5e-11e9-9a07-0a80fada099c	C39729	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090f00f-ff5e-11e9-9a07-0a80fada099c	7316-1769	d08f3aff-ff5e-11e9-9a07-0a80fada099c	7316-1769	d08dffb9-ff5e-11e9-9a07-0a80fada099c	C88806	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090228d-ff5e-11e9-9a07-0a80fada099c	7316-176	d08eb00e-ff5e-11e9-9a07-0a80fada099c	7316-176	d08d978d-ff5e-11e9-9a07-0a80fada099c	C39606	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09062d2-ff5e-11e9-9a07-0a80fada099c	7316-2174	d08edb39-ff5e-11e9-9a07-0a80fada099c	7316-2174	d08db858-ff5e-11e9-9a07-0a80fada099c	C584865	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0904ea8-ff5e-11e9-9a07-0a80fada099c	7316-3022	d08ecc1c-ff5e-11e9-9a07-0a80fada099c	7316-3022	d08dad31-ff5e-11e9-9a07-0a80fada099c	C53013	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fcc1c-ff5e-11e9-9a07-0a80fada099c	7316-3023	d08e7239-ff5e-11e9-9a07-0a80fada099c	7316-3023	d08d6cd6-ff5e-11e9-9a07-0a80fada099c	C270723	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09004f6-ff5e-11e9-9a07-0a80fada099c	7316-1760	d08e9cc7-ff5e-11e9-9a07-0a80fada099c	7316-1760	d08d89aa-ff5e-11e9-9a07-0a80fada099c	C372321	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090c28c-ff5e-11e9-9a07-0a80fada099c	7316-3025	d08f1cb4-ff5e-11e9-9a07-0a80fada099c	7316-3025	d08de939-ff5e-11e9-9a07-0a80fada099c	C794457	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0901403-ff5e-11e9-9a07-0a80fada099c	7316-1763	d08ea4ab-ff5e-11e9-9a07-0a80fada099c	7316-1763	d08d8f9c-ff5e-11e9-9a07-0a80fada099c	C377856	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f8e56-ff5e-11e9-9a07-0a80fada099c	7316-38	d08e45be-ff5e-11e9-9a07-0a80fada099c	7316-38	d08d4a5d-ff5e-11e9-9a07-0a80fada099c	C17466	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fa953-ff5e-11e9-9a07-0a80fada099c	7316-37	d08e592f-ff5e-11e9-9a07-0a80fada099c	7316-37	d08d57dc-ff5e-11e9-9a07-0a80fada099c	C20541	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Disqualified						Qualified	Disqualified																									Pediatric Brain Tumor Atlas - CBTN
d0905e84-ff5e-11e9-9a07-0a80fada099c	7316-2170	d08ed8b9-ff5e-11e9-9a07-0a80fada099c	7316-2170	d08db6b8-ff5e-11e9-9a07-0a80fada099c	C584496	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090615c-ff5e-11e9-9a07-0a80fada099c	7316-2172	d08eda4c-ff5e-11e9-9a07-0a80fada099c	7316-2172	d08db79e-ff5e-11e9-9a07-0a80fada099c	C584742	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fd74f-ff5e-11e9-9a07-0a80fada099c	7316-84	d08e7b4c-ff5e-11e9-9a07-0a80fada099c	7316-84	d08d7016-ff5e-11e9-9a07-0a80fada099c	C28659	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fc051-ff5e-11e9-9a07-0a80fada099c	7316-89	d08e6a50-ff5e-11e9-9a07-0a80fada099c	7316-89	d08d67c3-ff5e-11e9-9a07-0a80fada099c	C25461	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0907ae6-ff5e-11e9-9a07-0a80fada099c	7316-2667	d08eec31-ff5e-11e9-9a07-0a80fada099c	7316-2667	d08dc3d0-ff5e-11e9-9a07-0a80fada099c	C62730	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08ff73c-ff5e-11e9-9a07-0a80fada099c	7316-162	d08e91ab-ff5e-11e9-9a07-0a80fada099c	7316-162	d08d83da-ff5e-11e9-9a07-0a80fada099c	C35670	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0909d87-ff5e-11e9-9a07-0a80fada099c	7316-2669	d08f0272-ff5e-11e9-9a07-0a80fada099c	7316-2669	d08dd6d3-ff5e-11e9-9a07-0a80fada099c	C717336	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08ff12c-ff5e-11e9-9a07-0a80fada099c	7316-167	d08e8e1c-ff5e-11e9-9a07-0a80fada099c	7316-167	d08d80c8-ff5e-11e9-9a07-0a80fada099c	C33825	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0901020-ff5e-11e9-9a07-0a80fada099c	7316-168	d08ea302-ff5e-11e9-9a07-0a80fada099c	7316-168	d08d8dc2-ff5e-11e9-9a07-0a80fada099c	C37638	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09097b9-ff5e-11e9-9a07-0a80fada099c	7316-166	d08efe7a-ff5e-11e9-9a07-0a80fada099c	7316-166	d08dd3dd-ff5e-11e9-9a07-0a80fada099c	C71094	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0908f09-ff5e-11e9-9a07-0a80fada099c	7316-2663	d08ef80c-ff5e-11e9-9a07-0a80fada099c	7316-2663	d08dce79-ff5e-11e9-9a07-0a80fada099c	C699624	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090d214-ff5e-11e9-9a07-0a80fada099c	7316-2664	d08f2676-ff5e-11e9-9a07-0a80fada099c	7316-2664	d08df1f2-ff5e-11e9-9a07-0a80fada099c	C831849	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f889a-ff5e-11e9-9a07-0a80fada099c	7316-1455	d08e4226-ff5e-11e9-9a07-0a80fada099c	7316-1455	d08d4667-ff5e-11e9-9a07-0a80fada099c	C15990	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0911c14-ff5e-11e9-9a07-0a80fada099c	7316-952	d08f5a2e-ff5e-11e9-9a07-0a80fada099c	7316-952	d08e172a-ff5e-11e9-9a07-0a80fada099c	7316-952	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Not Reported	Other	no	Disqualified						Disqualified	Disqualified																									Pediatric Brain Tumor Atlas - CBTN
d08f9c10-ff5e-11e9-9a07-0a80fada099c	7316-957	d08e4f7b-ff5e-11e9-9a07-0a80fada099c	7316-957	d08d50db-ff5e-11e9-9a07-0a80fada099c	C187083	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f9487-ff5e-11e9-9a07-0a80fada099c	7316-99	d08e4850-ff5e-11e9-9a07-0a80fada099c	7316-99	d08d4cd8-ff5e-11e9-9a07-0a80fada099c	C18081	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f9624-ff5e-11e9-9a07-0a80fada099c	7316-954	d08e4a12-ff5e-11e9-9a07-0a80fada099c	7316-954	d08d4d99-ff5e-11e9-9a07-0a80fada099c	C182655	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090dc5f-ff5e-11e9-9a07-0a80fada099c	7316-394	d08f2db3-ff5e-11e9-9a07-0a80fada099c	7316-394	d08df679-ff5e-11e9-9a07-0a80fada099c	C85731	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0906462-ff5e-11e9-9a07-0a80fada099c	7316-153	d08edcf9-ff5e-11e9-9a07-0a80fada099c	7316-153	d08db9db-ff5e-11e9-9a07-0a80fada099c	C58917	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090e0c6-ff5e-11e9-9a07-0a80fada099c	7316-393	d08f313a-ff5e-11e9-9a07-0a80fada099c	7316-393	d08df8cf-ff5e-11e9-9a07-0a80fada099c	C86100	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08ffecc-ff5e-11e9-9a07-0a80fada099c	7316-156	d08e9822-ff5e-11e9-9a07-0a80fada099c	7316-156	d08d8733-ff5e-11e9-9a07-0a80fada099c	C36408	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09111c9-ff5e-11e9-9a07-0a80fada099c	7316-157	d08f5186-ff5e-11e9-9a07-0a80fada099c	7316-157	d08e111c-ff5e-11e9-9a07-0a80fada099c	7316-157	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Not Reported	Other	no	Disqualified						Disqualified	Disqualified																									Pediatric Brain Tumor Atlas - CBTN
d08fc4c6-ff5e-11e9-9a07-0a80fada099c	7316-278	d08e6ce6-ff5e-11e9-9a07-0a80fada099c	7316-278	d08d6941-ff5e-11e9-9a07-0a80fada099c	C25830	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fc369-ff5e-11e9-9a07-0a80fada099c	7316-91	d08e6bf2-ff5e-11e9-9a07-0a80fada099c	7316-91	d08d6885-ff5e-11e9-9a07-0a80fada099c	C25584	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f91e4-ff5e-11e9-9a07-0a80fada099c	7316-154	d08e4765-ff5e-11e9-9a07-0a80fada099c	7316-154	d08d4b17-ff5e-11e9-9a07-0a80fada099c	C177366	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fa33c-ff5e-11e9-9a07-0a80fada099c	7316-397	d08e53a1-ff5e-11e9-9a07-0a80fada099c	7316-397	d08d5476-ff5e-11e9-9a07-0a80fada099c	C19680	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090a069-ff5e-11e9-9a07-0a80fada099c	7316-2671	d08f0544-ff5e-11e9-9a07-0a80fada099c	7316-2671	d08dd884-ff5e-11e9-9a07-0a80fada099c	C722502	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08ff8aa-ff5e-11e9-9a07-0a80fada099c	7316-160	d08e935c-ff5e-11e9-9a07-0a80fada099c	7316-160	d08d8582-ff5e-11e9-9a07-0a80fada099c	C35793	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d091077d-ff5e-11e9-9a07-0a80fada099c	7316-3765	d08f4997-ff5e-11e9-9a07-0a80fada099c	7316-3765	d08e0ac0-ff5e-11e9-9a07-0a80fada099c	C952635	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090934b-ff5e-11e9-9a07-0a80fada099c	7316-942	d08efb21-ff5e-11e9-9a07-0a80fada099c	7316-942	d08dd1a3-ff5e-11e9-9a07-0a80fada099c	C70848	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090038f-ff5e-11e9-9a07-0a80fada099c	7316-148	d08e9ae8-ff5e-11e9-9a07-0a80fada099c	7316-148	d08d88e7-ff5e-11e9-9a07-0a80fada099c	C36900	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08feb51-ff5e-11e9-9a07-0a80fada099c	7316-946	d08e8a07-ff5e-11e9-9a07-0a80fada099c	7316-946	d08d7dba-ff5e-11e9-9a07-0a80fada099c	C311436	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090a964-ff5e-11e9-9a07-0a80fada099c	7316-944	d08f0a5d-ff5e-11e9-9a07-0a80fada099c	7316-944	d08ddd03-ff5e-11e9-9a07-0a80fada099c	C73062	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090bd72-ff5e-11e9-9a07-0a80fada099c	7316-384	d08f1a27-ff5e-11e9-9a07-0a80fada099c	7316-384	d08de690-ff5e-11e9-9a07-0a80fada099c	C78597	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0908bab-ff5e-11e9-9a07-0a80fada099c	7316-2648	d08ef576-ff5e-11e9-9a07-0a80fada099c	7316-2648	d08dcbc5-ff5e-11e9-9a07-0a80fada099c	C686955	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090e3e2-ff5e-11e9-9a07-0a80fada099c	7316-387	d08f33c4-ff5e-11e9-9a07-0a80fada099c	7316-387	d08dfa48-ff5e-11e9-9a07-0a80fada099c	C88314	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08ffd5d-ff5e-11e9-9a07-0a80fada099c	7316-146	d08e9724-ff5e-11e9-9a07-0a80fada099c	7316-146	d08d8678-ff5e-11e9-9a07-0a80fada099c	C35916	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090083b-ff5e-11e9-9a07-0a80fada099c	7316-267	d08e9e09-ff5e-11e9-9a07-0a80fada099c	7316-267	d08d8a61-ff5e-11e9-9a07-0a80fada099c	C37392	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08ff2b1-ff5e-11e9-9a07-0a80fada099c	7316-388	d08e8f0f-ff5e-11e9-9a07-0a80fada099c	7316-388	d08d8262-ff5e-11e9-9a07-0a80fada099c	C340710	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f7893-ff5e-11e9-9a07-0a80fada099c	7316-1790	d08e35b5-ff5e-11e9-9a07-0a80fada099c	7316-1790	d08d3c6d-ff5e-11e9-9a07-0a80fada099c	C140712	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090c8e6-ff5e-11e9-9a07-0a80fada099c	7316-3055	d08f1f44-ff5e-11e9-9a07-0a80fada099c	7316-3055	d08debdf-ff5e-11e9-9a07-0a80fada099c	C808110	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f8b94-ff5e-11e9-9a07-0a80fada099c	7316-2760	d08e4320-ff5e-11e9-9a07-0a80fada099c	7316-2760	d08d4738-ff5e-11e9-9a07-0a80fada099c	C16605	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0911375-ff5e-11e9-9a07-0a80fada099c	7316-3057	d08f5323-ff5e-11e9-9a07-0a80fada099c	7316-3057	d08e11e6-ff5e-11e9-9a07-0a80fada099c	7316-3057	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Not Reported	Other	no	Disqualified						Disqualified	Disqualified																									Pediatric Brain Tumor Atlas - CBTN
d090ddc7-ff5e-11e9-9a07-0a80fada099c	7316-3299	d08f3043-ff5e-11e9-9a07-0a80fada099c	7316-3299	d08df738-ff5e-11e9-9a07-0a80fada099c	C857433	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fe9da-ff5e-11e9-9a07-0a80fada099c	7316-1793	d08e88c2-ff5e-11e9-9a07-0a80fada099c	7316-1793	d08d7cb4-ff5e-11e9-9a07-0a80fada099c	C311067	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090ee85-ff5e-11e9-9a07-0a80fada099c	7316-391	d08f392c-ff5e-11e9-9a07-0a80fada099c	7316-391	d08dff03-ff5e-11e9-9a07-0a80fada099c	C88683	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fe6f7-ff5e-11e9-9a07-0a80fada099c	7316-949	d08e86f1-ff5e-11e9-9a07-0a80fada099c	7316-949	d08d7bf0-ff5e-11e9-9a07-0a80fada099c	C310083	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090d500-ff5e-11e9-9a07-0a80fada099c	7316-3292	d08f27b5-ff5e-11e9-9a07-0a80fada099c	7316-3292	d08df2b0-ff5e-11e9-9a07-0a80fada099c	C837507	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fcf87-ff5e-11e9-9a07-0a80fada099c	7316-931	d08e7412-ff5e-11e9-9a07-0a80fada099c	7316-931	d08d6cd6-ff5e-11e9-9a07-0a80fada099c	C270723	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f6232-ff5e-11e9-9a07-0a80fada099c	7316-499	d08e205c-ff5e-11e9-9a07-0a80fada099c	7316-499	d08d3049-ff5e-11e9-9a07-0a80fada099c	C116850	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0902e4f-ff5e-11e9-9a07-0a80fada099c	7316-934	d08eb825-ff5e-11e9-9a07-0a80fada099c	7316-934	d08d9e76-ff5e-11e9-9a07-0a80fada099c	C440832	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fd5c5-ff5e-11e9-9a07-0a80fada099c	7316-77	d08e790c-ff5e-11e9-9a07-0a80fada099c	7316-77	d08d6f5e-ff5e-11e9-9a07-0a80fada099c	C27798	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fcab6-ff5e-11e9-9a07-0a80fada099c	7316-932	d08e713d-ff5e-11e9-9a07-0a80fada099c	7316-932	d08d6bb3-ff5e-11e9-9a07-0a80fada099c	C270477	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08ff5cb-ff5e-11e9-9a07-0a80fada099c	7316-130	d08e90af-ff5e-11e9-9a07-0a80fada099c	7316-130	d08d8323-ff5e-11e9-9a07-0a80fada099c	C34440	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f8744-ff5e-11e9-9a07-0a80fada099c	7316-2899	d08e4091-ff5e-11e9-9a07-0a80fada099c	7316-2899	d08d4587-ff5e-11e9-9a07-0a80fada099c	C15744	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090bbdf-ff5e-11e9-9a07-0a80fada099c	7316-370	d08f1937-ff5e-11e9-9a07-0a80fada099c	7316-370	d08de5cf-ff5e-11e9-9a07-0a80fada099c	C77367	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f82d8-ff5e-11e9-9a07-0a80fada099c	7316-371	d08e3e09-ff5e-11e9-9a07-0a80fada099c	7316-371	d08d4235-ff5e-11e9-9a07-0a80fada099c	C15498	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090314c-ff5e-11e9-9a07-0a80fada099c	7316-134	d08eb91d-ff5e-11e9-9a07-0a80fada099c	7316-134	d08da02d-ff5e-11e9-9a07-0a80fada099c	C46371	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090cf18-ff5e-11e9-9a07-0a80fada099c	7316-376	d08f23af-ff5e-11e9-9a07-0a80fada099c	7316-376	d08defaf-ff5e-11e9-9a07-0a80fada099c	C82164	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0911aa4-ff5e-11e9-9a07-0a80fada099c	7316-70	d08f5939-ff5e-11e9-9a07-0a80fada099c	7316-70	d08e166e-ff5e-11e9-9a07-0a80fada099c	7316-70	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Not Reported	Other	no	Disqualified						Disqualified	Disqualified																									Pediatric Brain Tumor Atlas - CBTN
d08f62e4-ff5e-11e9-9a07-0a80fada099c	7316-495	d08e231c-ff5e-11e9-9a07-0a80fada099c	7316-495	d08d313c-ff5e-11e9-9a07-0a80fada099c	C121524	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f6541-ff5e-11e9-9a07-0a80fada099c	7316-496	d08e2686-ff5e-11e9-9a07-0a80fada099c	7316-496	d08d3236-ff5e-11e9-9a07-0a80fada099c	C121647	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090d0a4-ff5e-11e9-9a07-0a80fada099c	7316-3068	d08f249c-ff5e-11e9-9a07-0a80fada099c	7316-3068	d08df067-ff5e-11e9-9a07-0a80fada099c	C829512	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090d7f5-ff5e-11e9-9a07-0a80fada099c	7316-3069	d08f2b04-ff5e-11e9-9a07-0a80fada099c	7316-3069	d08df366-ff5e-11e9-9a07-0a80fada099c	C841320	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090cc44-ff5e-11e9-9a07-0a80fada099c	7316-380	d08f21f5-ff5e-11e9-9a07-0a80fada099c	7316-380	d08deea7-ff5e-11e9-9a07-0a80fada099c	C82041	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fecbc-ff5e-11e9-9a07-0a80fada099c	7316-938	d08e8b9a-ff5e-11e9-9a07-0a80fada099c	7316-938	d08d7f46-ff5e-11e9-9a07-0a80fada099c	C311559	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fe5d7-ff5e-11e9-9a07-0a80fada099c	7316-936	d08e85f3-ff5e-11e9-9a07-0a80fada099c	7316-936	d08d7a66-ff5e-11e9-9a07-0a80fada099c	C308853	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fe47f-ff5e-11e9-9a07-0a80fada099c	7316-937	d08e843b-ff5e-11e9-9a07-0a80fada099c	7316-937	d08d79ac-ff5e-11e9-9a07-0a80fada099c	C308730	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090cafe-ff5e-11e9-9a07-0a80fada099c	7316-3062	d08f20fb-ff5e-11e9-9a07-0a80fada099c	7316-3062	d08dec9c-ff5e-11e9-9a07-0a80fada099c	C818688	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0903441-ff5e-11e9-9a07-0a80fada099c	7316-127	d08ebbbe-ff5e-11e9-9a07-0a80fada099c	7316-127	d08da1a2-ff5e-11e9-9a07-0a80fada099c	C46617	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f5e62-ff5e-11e9-9a07-0a80fada099c	7316-488	d08e1a82-ff5e-11e9-9a07-0a80fada099c	7316-488	d08d2acb-ff5e-11e9-9a07-0a80fada099c	C112176	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090b717-ff5e-11e9-9a07-0a80fada099c	7316-368	d08f16b4-ff5e-11e9-9a07-0a80fada099c	7316-368	d08de34b-ff5e-11e9-9a07-0a80fada099c	C75276	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0906769-ff5e-11e9-9a07-0a80fada099c	7316-120	d08eddf8-ff5e-11e9-9a07-0a80fada099c	7316-120	d08dba97-ff5e-11e9-9a07-0a80fada099c	C59409	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090e273-ff5e-11e9-9a07-0a80fada099c	7316-3316	d08f32db-ff5e-11e9-9a07-0a80fada099c	7316-3316	d08df986-ff5e-11e9-9a07-0a80fada099c	C881049	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090b872-ff5e-11e9-9a07-0a80fada099c	7316-362	d08f17a8-ff5e-11e9-9a07-0a80fada099c	7316-362	d08de511-ff5e-11e9-9a07-0a80fada099c	C75522	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fa831-ff5e-11e9-9a07-0a80fada099c	7316-2900	d08e5787-ff5e-11e9-9a07-0a80fada099c	7316-2900	d08d57dc-ff5e-11e9-9a07-0a80fada099c	C20541	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0900213-ff5e-11e9-9a07-0a80fada099c	7316-2901	d08e99db-ff5e-11e9-9a07-0a80fada099c	7316-2901	d08d8733-ff5e-11e9-9a07-0a80fada099c	C36408	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f6483-ff5e-11e9-9a07-0a80fada099c	7316-3319	d08e2434-ff5e-11e9-9a07-0a80fada099c	7316-3319	d08d3236-ff5e-11e9-9a07-0a80fada099c	C121647	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09094ac-ff5e-11e9-9a07-0a80fada099c	7316-124	d08efc11-ff5e-11e9-9a07-0a80fada099c	7316-124	d08dd257-ff5e-11e9-9a07-0a80fada099c	C70971	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f5fdb-ff5e-11e9-9a07-0a80fada099c	7316-487	d08e1d64-ff5e-11e9-9a07-0a80fada099c	7316-487	d08d2e3b-ff5e-11e9-9a07-0a80fada099c	C114759	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09068df-ff5e-11e9-9a07-0a80fada099c	7316-121	d08edf8e-ff5e-11e9-9a07-0a80fada099c	7316-121	d08dbb4d-ff5e-11e9-9a07-0a80fada099c	C59532	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f6d4d-ff5e-11e9-9a07-0a80fada099c	7316-485	d08e2cd9-ff5e-11e9-9a07-0a80fada099c	7316-485	d08d34f8-ff5e-11e9-9a07-0a80fada099c	C136161	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0908122-ff5e-11e9-9a07-0a80fada099c	7316-2581	d08ef03e-ff5e-11e9-9a07-0a80fada099c	7316-2581	d08dc708-ff5e-11e9-9a07-0a80fada099c	C663585	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0904094-ff5e-11e9-9a07-0a80fada099c	7316-490	d08ec545-ff5e-11e9-9a07-0a80fada099c	7316-490	d08da768-ff5e-11e9-9a07-0a80fada099c	C47724	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090e9e4-ff5e-11e9-9a07-0a80fada099c	7316-3555	d08f368d-ff5e-11e9-9a07-0a80fada099c	7316-3555	d08dfca4-ff5e-11e9-9a07-0a80fada099c	C883632	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090e857-ff5e-11e9-9a07-0a80fada099c	7316-3556	d08f3569-ff5e-11e9-9a07-0a80fada099c	7316-3556	d08dfbeb-ff5e-11e9-9a07-0a80fada099c	C883509	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fc93c-ff5e-11e9-9a07-0a80fada099c	7316-925	d08e6f84-ff5e-11e9-9a07-0a80fada099c	7316-925	d08d6af6-ff5e-11e9-9a07-0a80fada099c	C262605	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f66f6-ff5e-11e9-9a07-0a80fada099c	7316-479	d08e2878-ff5e-11e9-9a07-0a80fada099c	7316-479	d08d3322-ff5e-11e9-9a07-0a80fada099c	C121893	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fdc3e-ff5e-11e9-9a07-0a80fada099c	7316-117	d08e7ef4-ff5e-11e9-9a07-0a80fada099c	7316-117	d08d73c3-ff5e-11e9-9a07-0a80fada099c	C29397	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090aad8-ff5e-11e9-9a07-0a80fada099c	7316-359	d08f0c08-ff5e-11e9-9a07-0a80fada099c	7316-359	d08ddead-ff5e-11e9-9a07-0a80fada099c	C73308	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fe07c-ff5e-11e9-9a07-0a80fada099c	7316-114	d08e818f-ff5e-11e9-9a07-0a80fada099c	7316-114	d08d77c4-ff5e-11e9-9a07-0a80fada099c	C30258	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fae71-ff5e-11e9-9a07-0a80fada099c	7316-913	d08e5cc1-ff5e-11e9-9a07-0a80fada099c	7316-913	d08d5bf5-ff5e-11e9-9a07-0a80fada099c	C216603	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fdac0-ff5e-11e9-9a07-0a80fada099c	7316-119	d08e7df8-ff5e-11e9-9a07-0a80fada099c	7316-119	d08d72af-ff5e-11e9-9a07-0a80fada099c	C29151	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fafd0-ff5e-11e9-9a07-0a80fada099c	7316-3	d08e5e86-ff5e-11e9-9a07-0a80fada099c	7316-3	d08d5d7d-ff5e-11e9-9a07-0a80fada099c	C21771	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090a660-ff5e-11e9-9a07-0a80fada099c	7316-350	d08f096b-ff5e-11e9-9a07-0a80fada099c	7316-350	d08ddd03-ff5e-11e9-9a07-0a80fada099c	C73062	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0907034-ff5e-11e9-9a07-0a80fada099c	7316-230	d08ee587-ff5e-11e9-9a07-0a80fada099c	7316-230	d08dbff3-ff5e-11e9-9a07-0a80fada099c	C62484	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0910abf-ff5e-11e9-9a07-0a80fada099c	7316-472	d08f4d17-ff5e-11e9-9a07-0a80fada099c	7316-472	d08e0e26-ff5e-11e9-9a07-0a80fada099c	C96186	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f818f-ff5e-11e9-9a07-0a80fada099c	7316-6	d08e3d15-ff5e-11e9-9a07-0a80fada099c	7316-6	d08d4169-ff5e-11e9-9a07-0a80fada099c	C15252	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f6e91-ff5e-11e9-9a07-0a80fada099c	7316-470	d08e2dc8-ff5e-11e9-9a07-0a80fada099c	7316-470	d08d365c-ff5e-11e9-9a07-0a80fada099c	C136284	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f5cc5-ff5e-11e9-9a07-0a80fada099c	7316-475	d08e1977-ff5e-11e9-9a07-0a80fada099c	7316-475	d08d263d-ff5e-11e9-9a07-0a80fada099c	C102459	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fe1ed-ff5e-11e9-9a07-0a80fada099c	7316-111	d08e8344-ff5e-11e9-9a07-0a80fada099c	7316-111	d08d78a0-ff5e-11e9-9a07-0a80fada099c	C30381	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090eb52-ff5e-11e9-9a07-0a80fada099c	7316-3561	d08f3841-ff5e-11e9-9a07-0a80fada099c	7316-3561	d08dfd56-ff5e-11e9-9a07-0a80fada099c	C883755	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0909936-ff5e-11e9-9a07-0a80fada099c	7316-2594	d08effd8-ff5e-11e9-9a07-0a80fada099c	7316-2594	d08dd498-ff5e-11e9-9a07-0a80fada099c	C714384	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08facbc-ff5e-11e9-9a07-0a80fada099c	7316-914	d08e5bd4-ff5e-11e9-9a07-0a80fada099c	7316-914	d08d5afe-ff5e-11e9-9a07-0a80fada099c	C216111	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fa026-ff5e-11e9-9a07-0a80fada099c	7316-918	d08e5210-ff5e-11e9-9a07-0a80fada099c	7316-918	d08d53a7-ff5e-11e9-9a07-0a80fada099c	C196554	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0907faa-ff5e-11e9-9a07-0a80fada099c	7316-226	d08eeeb8-ff5e-11e9-9a07-0a80fada099c	7316-226	d08dc646-ff5e-11e9-9a07-0a80fada099c	C65559	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090a4ee-ff5e-11e9-9a07-0a80fada099c	7316-347	d08f07c8-ff5e-11e9-9a07-0a80fada099c	7316-347	d08ddc45-ff5e-11e9-9a07-0a80fada099c	C72570	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090a376-ff5e-11e9-9a07-0a80fada099c	7316-345	d08f06d9-ff5e-11e9-9a07-0a80fada099c	7316-345	d08ddb5b-ff5e-11e9-9a07-0a80fada099c	C72324	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0911036-ff5e-11e9-9a07-0a80fada099c	7316-466	d08f5042-ff5e-11e9-9a07-0a80fada099c	7316-466	d08e1056-ff5e-11e9-9a07-0a80fada099c	C99753	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fd8e9-ff5e-11e9-9a07-0a80fada099c	7316-109	d08e7c56-ff5e-11e9-9a07-0a80fada099c	7316-109	d08d71f0-ff5e-11e9-9a07-0a80fada099c	C28905	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fbd5a-ff5e-11e9-9a07-0a80fada099c	7316-101	d08e67b2-ff5e-11e9-9a07-0a80fada099c	7316-101	d08d6561-ff5e-11e9-9a07-0a80fada099c	C23862	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0908641-ff5e-11e9-9a07-0a80fada099c	7316-222	d08ef2ef-ff5e-11e9-9a07-0a80fada099c	7316-222	d08dca30-ff5e-11e9-9a07-0a80fada099c	C68388	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090af65-ff5e-11e9-9a07-0a80fada099c	7316-344	d08f0f9e-ff5e-11e9-9a07-0a80fada099c	7316-344	d08de025-ff5e-11e9-9a07-0a80fada099c	C74292	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0909a8d-ff5e-11e9-9a07-0a80fada099c	7316-341	d08f0178-ff5e-11e9-9a07-0a80fada099c	7316-341	d08dd54b-ff5e-11e9-9a07-0a80fada099c	C71586	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0910225-ff5e-11e9-9a07-0a80fada099c	7316-3773	d08f470a-ff5e-11e9-9a07-0a80fada099c	7316-3773	d08e072c-ff5e-11e9-9a07-0a80fada099c	C949929	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08f99bc-ff5e-11e9-9a07-0a80fada099c	7316-905	d08e4b06-ff5e-11e9-9a07-0a80fada099c	7316-905	d08d4e51-ff5e-11e9-9a07-0a80fada099c	C186714	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09114f0-ff5e-11e9-9a07-0a80fada099c	7316-334	d08f5425-ff5e-11e9-9a07-0a80fada099c	7316-334	d08e136a-ff5e-11e9-9a07-0a80fada099c	7316-334	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Not Reported	Other	no	Disqualified						Disqualified	Disqualified																									Pediatric Brain Tumor Atlas - CBTN
d09084ba-ff5e-11e9-9a07-0a80fada099c	7316-217	d08ef158-ff5e-11e9-9a07-0a80fada099c	7316-217	d08dc7bd-ff5e-11e9-9a07-0a80fada099c	C66420	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0910c3b-ff5e-11e9-9a07-0a80fada099c	7316-459	d08f4e58-ff5e-11e9-9a07-0a80fada099c	7316-459	d08e0ede-ff5e-11e9-9a07-0a80fada099c	C98031	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09089fb-ff5e-11e9-9a07-0a80fada099c	7316-332	d08ef3db-ff5e-11e9-9a07-0a80fada099c	7316-332	d08dcb0f-ff5e-11e9-9a07-0a80fada099c	C68634	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fc61d-ff5e-11e9-9a07-0a80fada099c	7316-333	d08e6e8f-ff5e-11e9-9a07-0a80fada099c	7316-333	d08d6941-ff5e-11e9-9a07-0a80fada099c	C25830	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d0910947-ff5e-11e9-9a07-0a80fada099c	7316-454	d08f4a95-ff5e-11e9-9a07-0a80fada099c	7316-454	d08e0d18-ff5e-11e9-9a07-0a80fada099c	C96063	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d08fa4d1-ff5e-11e9-9a07-0a80fada099c	7316-451	d08e5491-ff5e-11e9-9a07-0a80fada099c	7316-451	d08d5531-ff5e-11e9-9a07-0a80fada099c	C20172	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d09105c6-ff5e-11e9-9a07-0a80fada099c	7316-452	d08f47f6-ff5e-11e9-9a07-0a80fada099c	7316-452	d08e090f-ff5e-11e9-9a07-0a80fada099c	C95079	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090d68a-ff5e-11e9-9a07-0a80fada099c	7316-3300	d08f29c2-ff5e-11e9-9a07-0a80fada099c	7316-3300	d08df2b0-ff5e-11e9-9a07-0a80fada099c	C837507	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
d090505f-ff5e-11e9-9a07-0a80fada099c	7316-3303	d08ecd0d-ff5e-11e9-9a07-0a80fada099c	7316-3303	d08dad31-ff5e-11e9-9a07-0a80fada099c	C53013	Proteogenomic Analysis of Pediatric Brain Cancer Tumors Pilot Study	Primary Tumor	Brain	Pediatric/AYA Brain Tumors	no	Qualified						Qualified	Qualified																									Pediatric Brain Tumor Atlas - CBTN
eb8c56e7-2b8e-40b5-9255-e2f7973c0779	45	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4f28b99f-a475-425d-93bd-4a47e47ed398	22	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
195614b7-341d-4474-88b4-2c16d15bad73	26	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
70a21417-6d58-4ee4-b1c6-48efe4d422bf	34	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5992a694-2d06-4060-9f89-7a66306ae6f3	80	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e6e16e04-697b-49a6-90d0-e3dc40c8a983	11	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2e8d6c07-7ba5-47ab-bfd0-934db557af1c	44	6ab89fed-44ac-4b44-9de6-9e62de2bb224	CompRef P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
edb5fe07-2d4b-4722-8205-590c13eb19ac	3	92175281-fa41-43c8-b87c-df1d3d51f878	CompRef P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db299c0d-8891-4392-a4c9-85b1f51972b6	NCI7-1.0_pro	0d5e281f-4f2e-4567-9c66-b866f6b89a0a	NCI7-1.0_pro	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
20f536b7-a3be-4ae9-ac2f-706702208c19	NCI7-0.1_pro	c3176869-7ee5-484f-b816-7af6d8b98e3d	NCI7-0.1_pro	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
209334d7-a63d-4dba-9d2a-0ed158594c08	NCI7-1.0_pep	e798c551-1164-4690-b646-837b05b97029	NCI7-1.0_pep	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a42d5403-25f1-4868-b56e-a4a5d8dc2c76	NCI7-0.5_pep	4aed607e-110d-448b-8527-6ed2816c438b	NCI7-0.5_pep	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3f04b11c-ff67-476f-9ba8-1fe7b1df010f	NCI7-0.2_pro	c55a87d2-05c6-44a6-8078-4bffa1497a43	NCI7-0.2_pro	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9740d134-a410-4d28-b760-c4ae673d19cc	NCI7-0.5_pro	4d9a122c-e4bc-4540-b692-9c71af1dc3f0	NCI7-0.5_pro	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9e7be045-5542-4a9a-b6a7-328cb04e175e	NCI7-0.1_pep	5195e39e-2674-4e64-8f29-1281f6b86c08	NCI7-0.1_pep	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba6ef0a0-c47e-438c-a49a-afff0f738765	NCI7-0.2_pep	581c4d1c-7290-4f19-903a-07253d11b4e6	NCI7-0.2_pep	54559a36-d9bc-4373-86f5-98d50a203d76	NCI-7	CPTAC3-Other	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
653e1ba6-b5d2-4a48-a386-e73ae915bbd8	WHIM20.1	31bf913d-4c12-4784-a9ef-236abd4074de	WHIM20.1	5c73bda5-c5a8-489e-9a89-8329d420db55	WHIM20	CPTAC3-Other	Xenograft Tissue	Not Reported	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f2dae4eb-63df-4aa8-bd9d-55ad19e2ffc4	WHIM2.2	617359a7-4b3a-4582-a5b6-b40a687853b9	WHIM2.2	52009f09-b933-4b83-a4fe-cfc9c8fe9681	WHIM2	CPTAC3-Other	Xenograft Tissue	Not Reported	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
732d4ddf-b8d6-406b-87f6-1e264024b2f9	WHIM20.2	1d5010b9-adcc-4ee9-9d58-6e0cf40d5f28	WHIM20.2	5c73bda5-c5a8-489e-9a89-8329d420db55	WHIM20	CPTAC3-Other	Xenograft Tissue	Not Reported	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fe17a6db-229d-4e35-a846-6a2eb5246910	WHIM18.2	a0669ad5-9735-49c1-bcc6-a934b080eeb6	WHIM18.2	d609a99b-d412-42e0-9d43-ef303948316e	WHIM18	CPTAC3-Other	Xenograft Tissue	Not Reported	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5429329d-61e0-4509-9445-68475641ea6e	WHIM14.1	8d4f2640-d8b8-42a8-a529-ce8dc55033b9	WHIM14.1	638d5afc-317b-47c3-b7d7-6850f620a462	WHIM14	CPTAC3-Other	Xenograft Tissue	Not Reported	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
24235099-6e9f-4727-9a7d-4cac829a70c4	CR2	6f04c7f1-1d49-41a5-a5a4-252dc13e78c0	CR2	1324f7bb-34f6-4ebb-81f7-30952f4a5b62	CR2	CPTAC3-Other	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3f0c9758-abcc-4544-bfb4-a3457a6364f8	CR1	94b9d52d-eb3f-4297-99c1-dd6201db47c4	CR1	d3cad9e3-843a-41cf-b335-40dbc287b4e9	CR1	CPTAC3-Other	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
40b41607-8a83-4dcf-a1db-570ae635798d	WHIM2.1	8033b296-228f-4822-b4bf-b81bbef98f3d	WHIM2.1	52009f09-b933-4b83-a4fe-cfc9c8fe9681	WHIM2	CPTAC3-Other	Xenograft Tissue	Not Reported	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a646cc8e-db3e-45da-962f-933a99958732	WHIM18.1	9573e573-5cd3-4c34-92aa-4b5b177e5b5f	WHIM18.1	d609a99b-d412-42e0-9d43-ef303948316e	WHIM18	CPTAC3-Other	Xenograft Tissue	Not Reported	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b768f7ce-101e-406a-a571-41ce68989298	WHIM14.2	72668489-5bcc-43ae-939e-ed5b1594f3c4	WHIM14.2	638d5afc-317b-47c3-b7d7-6850f620a462	WHIM14	CPTAC3-Other	Xenograft Tissue	Not Reported	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d9d5f30c-296b-43e8-9f02-01476582b56d	PTRC_exp12_P5-8	ba307d4b-b0e7-4a84-9029-0d083240f34d	"Late Quizartinib, MOLM14, Flask6"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1da124cb-3eac-4105-a780-b90956769b4d	PTRC_exp12_P5-4	79241fe9-df10-49c7-889e-472bdb1cbbd5	"Early Quizartinib, MOLM14, Flask6, FGF2"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d75b3141-b9fa-4016-b907-b3be2422a2f2	PTRC_exp12_P6-7	52e6f2fc-c3ad-4cd7-81a5-7e5bdd6ac446	"Late Quizartinib, MOLM14, Flask9"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1749f0ca-0862-403c-aaee-eba0944c0fb6	PTRC_exp12_P5-2	baf671ff-e1b6-4cd9-9dfd-5d263db4f5df	"parental MOLM14, 10M"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9a188e05-1866-4a57-af8c-8e34f3b8e2fc	PTRC_exp12_P5-5	5e8f09a7-47a2-487e-8ad6-111059067d24	"Early Quizartinib, MOLM14, Flask7, FGF2"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c718a870-156c-4e76-bc32-d69724aed6fc	PTRC_exp12_P6-2	f37be405-b5da-4a30-9ad8-199c3b83a048	"parental MOLM14, 10M Resistant"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29f0976e-ee64-4348-b9a5-766eba9e4477	PTRC_exp12_P6-1	f37be405-b5da-4a30-9ad8-199c3b83a048	"parental MOLM14, 10M Resistant"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cc7f477c-8d72-40ab-9470-ed97a41206c6	PTRC_exp12_P5-7	f276af09-85d8-493b-9bda-c56b87fc3690	"Late Quizartinib, MOLM14, Flask5"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e56e2bd4-cbca-4123-80b0-871eb70a299a	PTRC_exp12_P6-4	2b80eef8-ca75-4402-944e-26f67453a34d	"Early Quizartinib, MOLM14, Flask10, FLT3"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
15eb5bc0-c7fc-4153-a5cb-c359b9e35352	PTRC_exp12_P6-3	73f48314-8641-4bc3-86ed-1df385895414	"Early Quizartinib, MOLM14, Flask9, FLT3"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7cef24b9-2133-48f9-b6b8-02400a614df7	PTRC_exp12_P6-10	b58f1399-6e40-4b38-8909-15b9ac1bf5c7	"Late Quizartinib, MOLM14, Flask12"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5610ffd5-08ea-4a4b-915d-c270a050b3f2	PTRC_exp12_P6-6	9598ad9c-a212-4867-9c95-66bfc772c816	"Early Quizartinib, MOLM14, Flask12, FLT3"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8a2119a-b0c3-413b-b4a1-3554a7bc7303	PTRC_exp12_P6-8	a464157d-c523-4c9c-b077-5fa22838bfcd	"Late Quizartinib, MOLM14, Flask10"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
113a0009-fa99-4f79-965f-b024a49ab90e	PTRC_exp12_P6-5	1f0f3802-931b-43d3-a222-bd7149768bbf	"Early Quizartinib, MOLM14, Flask11, FLT3"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aaa0fa52-9cf0-49f9-ba16-bae88087976c	PTRC_exp12_P5-6	4bd1b12d-b6f9-4476-af58-b52e2ab763d5	"Early Quizartinib, MOLM14, Flask8, FGF2"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7329f89b-8696-4e40-98f4-feb88253f5b5	PTRC_exp12_P5-10	deca743e-cf7e-4db1-9ac7-3282bf58cbeb	"Late Quizartinib, MOLM14, Flask8"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5aaad6fd-83fe-4f93-82bd-5f46ffe9146f	PTRC_exp12_P5-9	903963c0-eab5-40dd-9b98-8b2b4cefbca7	"Late Quizartinib, MOLM14, Flask7"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8dc69c53-9a45-4b6d-a3c1-4f3637f26440	PTRC_exp12_P5-1	baf671ff-e1b6-4cd9-9dfd-5d263db4f5df	"parental MOLM14, 10M"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fd2a86d3-6e18-4528-a4b6-93891b258ac0	PTRC_exp12_P6-9	6d52fd83-2df1-4818-aafe-c36bf5c9cf9d	"Late Quizartinib, MOLM14, Flask11"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4b72c72-6b2d-493d-9e17-0a8ccf1e1bd1	PTRC_exp12_P5-3	380f7ff9-c1bc-4728-97ad-e32b19a80a10	"Early Quizartinib, MOLM14, Flask5, FGF2"	4a4b2172-550c-4dbd-adad-8b3425f3ddea	MOLM14	Proteogenomic Translational Research Centers (PTRC)	Cell Lines	Hematopoietic and reticuloendothelial systems	Acute Myeloid Leukemia	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f6982ed-2540-4750-8eff-7a597ef44f19	CPT0014150003	32dbd9b9-6977-46fc-bfa7-8260cde5d325	C3N-00194-01	6aeed922-1fb9-11e9-b7f8-0a80fada099c	C3N-00194	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e1e2c6a-9bd5-46c7-b7da-295663fdf055	CPT0019980003	8374ae0a-523f-4878-b50b-a550d02fb09a	C3N-00168-01	675d0c38-1fb9-11e9-b7f8-0a80fada099c	C3N-00168	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
87ad0cd9-9f8d-4945-822b-7173615603fc	CPT0012380003	724888d5-e3a4-4ebf-b2b1-25839e3563cb	C3N-00320-03	7d95243f-1fb9-11e9-b7f8-0a80fada099c	C3N-00320	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a840d8c8-b32e-4ceb-9951-9e25cc1360ac	CPT0014180003	58e6981a-be2c-46f3-a199-64ef3c8128ee	C3N-00194-04	6aeed922-1fb9-11e9-b7f8-0a80fada099c	C3N-00194	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bfdebc82-e41f-48d6-8378-2bb0b2d7dbd3	CPT0006860003	760452bf-7d40-4036-a19e-2fb1a7d24269	C3L-00447-01	c5f8631d-1fb8-11e9-b7f8-0a80fada099c	C3L-00447	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fdb962f8-9963-45f5-84e7-0589e71775ea	CPT0092170003	187d557d-bbd5-47be-8b7d-df740fd05a34	C3L-01607-02	25e420f4-1fb9-11e9-b7f8-0a80fada099c	C3L-01607	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7e7904ea-a01a-4de1-b4f4-c6734dd15eef	CPT0024650006	05f7fc1d-20e2-4335-a5c0-e5455ae6a2ac	C3N-00852-01	987b103d-1fb9-11e9-b7f8-0a80fada099c	C3N-00852	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
439fe47f-d17f-4241-82aa-0f6c4f8e0f53	CPT0084580003	3e5c5cd3-7c50-4262-b63d-b4272bc11dc4	C3N-00149-04	61ea104e-1fb9-11e9-b7f8-0a80fada099c	C3N-00149	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c504cb46-ef70-4078-9252-06da70ce2192	CPT0079400006	cd79c00e-771c-4c48-8709-af6f9ce5d224	C3L-01287-01	0f345723-1fb9-11e9-b7f8-0a80fada099c	C3L-01287	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62087791-ab70-44a7-9f45-7df6cbe9726d	CPT0092300003	b885ec95-9681-4cac-a102-a4836267effe	C3L-01861-03	2e6540fd-1fb9-11e9-b7f8-0a80fada099c	C3L-01861	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a102cf91-b6c3-4cab-ac3b-4ac2cc8c9d62	CPT0064390003	28f97034-facc-49e3-8769-58d60afacda3	C3L-00907-03	ecd1a90e-1fb8-11e9-b7f8-0a80fada099c	C3L-00907	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3603c40b-42f9-43b2-be26-129cd5b2efd0	CPT0069170003	fd7f2826-da6d-4758-9f1f-0ed37ba4f8e2	C3N-00577-03	8e59b323-1fb9-11e9-b7f8-0a80fada099c	C3N-00577	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0536d81f-a8ff-41e7-b124-86a0841071c7	CPT0076320006	d3c6ea5e-1480-493d-8238-d4b97c339fae	C3N-01220-01	a90d356a-1fb9-11e9-b7f8-0a80fada099c	C3N-01220	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
00df7354-24cb-44ea-bf5c-4072d8844f76	CPT0081580003	ff0c43bc-b4fa-46b2-8e98-f85a4598bfaf	C3N-00148-01	6039aa8e-1fb9-11e9-b7f8-0a80fada099c	C3N-00148	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ca59d13e-538e-4f52-b5db-9155d310ea58	CPT0012260006	09664260-28b2-4310-a0fb-917293b4e578	C3N-00317-02	7bfae873-1fb9-11e9-b7f8-0a80fada099c	C3N-00317	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1ada5580-4120-4b95-99c1-7657ac2fcdd5	CPT0025890006	a2ecaeb1-ec96-4585-b69c-86248b2016e3	C3N-00733-02	91b4e8bc-1fb9-11e9-b7f8-0a80fada099c	C3N-00733	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
07e272f7-8166-4462-86ec-b294b549165e	CPT0075120006	56ff6c21-b4f1-43b6-ada3-388c7a466ddb	C3N-01200-01	a4300f90-1fb9-11e9-b7f8-0a80fada099c	C3N-01200	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b8e3b016-0989-476c-9293-681f818de25b	CPT0012070006	53905827-bf65-47ec-8946-f2da8f4331ec	C3N-00314-03	78a71616-1fb9-11e9-b7f8-0a80fada099c	C3N-00314	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a13671d1-6e6d-4d3c-b55e-44703da6710b	CPT0066490003	0f692212-f47b-404c-b620-3b05a51bd018	C3N-00150-02	6386852c-1fb9-11e9-b7f8-0a80fada099c	C3N-00150	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
148b1dcc-2668-4921-915e-0b5ac0357ee5	CPT0020110003	3fbc1fc1-3262-44f3-b028-dc13aa7bfb7c	C3N-00177-02	695400f2-1fb9-11e9-b7f8-0a80fada099c	C3N-00177	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4d35a867-6719-4e53-abff-fe9ae4d75b8f	CPT0017440006	c926a43f-7478-4d01-868f-517bbfb78fef	C3N-00390-04	810c2c81-1fb9-11e9-b7f8-0a80fada099c	C3N-00390	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dda26f87-1e9f-4969-b153-66878b38aade	CPT0009040003	e1a19470-28bb-4d87-a60c-13a92b47b029	C3N-00312-01	754db279-1fb9-11e9-b7f8-0a80fada099c	C3N-00312	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9e5de8e9-9636-489b-8edf-1d21320bcfd5	CPT0069180003	43625e03-e3d4-4b99-882c-cb761d984485	C3N-00577-04	8e59b323-1fb9-11e9-b7f8-0a80fada099c	C3N-00577	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f0a265d3-4d12-4f8f-8873-9440241c2d2a	CPT0077300003	06260df3-5e7a-4581-b007-7dd4880cd7ac	C3N-01524-02	aff10fc2-1fb9-11e9-b7f8-0a80fada099c	C3N-01524	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a26a533c-cd15-4270-8b5c-a36465d28c28	CPT0075540003	aefe401d-b674-43bd-a551-085054fff15e	C3N-01214-01	a767e303-1fb9-11e9-b7f8-0a80fada099c	C3N-01214	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
705b379c-f743-414c-8dc6-fd24b3814e76	CPT0008980003	adefac2e-deba-457b-b15f-fcd9fb77af86	C3N-00310-01	73b649eb-1fb9-11e9-b7f8-0a80fada099c	C3N-00310	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5acf1a1c-068b-4d35-a1bb-8af2bf767221	CPT0006670003	80df9b7b-e29f-4b5e-bd39-db2657fc4a01	C3L-00418-03	c455fb22-1fb8-11e9-b7f8-0a80fada099c	C3L-00418	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
048a7856-4e2d-425c-ade2-0129b10f893f	CPT0077290003	f08752f4-182a-4655-b9c0-e17419ce4837	C3N-01524-01	aff10fc2-1fb9-11e9-b7f8-0a80fada099c	C3N-01524	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ca49df7c-8aea-479e-bf84-6a6ff34e49bf	CPT0077470003	7b607b0a-b907-495b-a00b-20cb92e6538b	C3N-01261-01	aaa7336a-1fb9-11e9-b7f8-0a80fada099c	C3N-01261	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b533abdb-f609-4e08-88e7-9bbd83bb0ef5	CPT0006470003	2096f885-11e5-4c6a-9c20-a75254c422d6	C3L-00369-02	c1195940-1fb8-11e9-b7f8-0a80fada099c	C3L-00369	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9554a26c-2797-4a80-bc22-8cddd3c3238b	CPT0075150006	b7396079-b540-418e-92a7-c6711750dd9f	C3N-01200-04	a4300f90-1fb9-11e9-b7f8-0a80fada099c	C3N-01200	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f8c87a0a-6e4d-4530-9a22-ad91b734b101	CPT0066510003	9b2e7fdb-ed6c-4081-9425-8f8bb9d482c7	C3N-00150-04	6386852c-1fb9-11e9-b7f8-0a80fada099c	C3N-00150	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cdaeaa40-3f01-4cd8-baf3-44920723d1ba	CPT0009050003	19094e4d-a265-4ad8-ab0b-9b7eb1937e06	C3N-00312-02	754db279-1fb9-11e9-b7f8-0a80fada099c	C3N-00312	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
41a90eb2-9bf7-466a-ac7d-8446287abc9e	CPT0009070003	efdd4045-d9bf-4e53-b436-7ca8ec77d36d	C3N-00312-04	754db279-1fb9-11e9-b7f8-0a80fada099c	C3N-00312	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
50ce1803-d56c-4e4b-8051-515ceb223778	CPT0086880003	4d579314-1b73-4bea-9657-939dc3bdba6b	C3L-01836-03	2c9d2692-1fb9-11e9-b7f8-0a80fada099c	C3L-01836	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
112e20a4-c927-4b2b-b4b2-8a746efe9977	CPT0066500003	79886bee-8df6-4d1b-9904-3698e0bc9a73	C3N-00150-03	6386852c-1fb9-11e9-b7f8-0a80fada099c	C3N-00150	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a39189f7-481c-4b96-8b29-20f0dd727256	CPT0020100003	a60b2992-c745-4923-a7d8-46857da884cc	C3N-00177-01	695400f2-1fb9-11e9-b7f8-0a80fada099c	C3N-00177	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b7c53e43-d5ba-4ad0-8366-d582cb6bbb33	CPT0006640003	e0146b7c-f68b-482c-a4e6-15cce110087f	C3L-00418-02	c455fb22-1fb8-11e9-b7f8-0a80fada099c	C3L-00418	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8054321f-0368-488b-96f6-d7c13ba9c65c	CPT0081980003	ad3f3d10-b981-4890-bc47-734259416319	C3N-00646-02	901a5db5-1fb9-11e9-b7f8-0a80fada099c	C3N-00646	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f8c0aa95-0350-4fd6-93f6-69afcb46cd20	CPT0084570003	1bb005d3-befb-4c15-b175-d3846d45af1a	C3N-00149-03	61ea104e-1fb9-11e9-b7f8-0a80fada099c	C3N-00149	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d34b3fc2-f768-4ef5-ad4c-5337e4f1baad	CPT0009010003	a66097ca-4462-49ed-935e-aa2c788a23da	C3N-00310-04	73b649eb-1fb9-11e9-b7f8-0a80fada099c	C3N-00310	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
caf52c5c-5bf2-449b-afe7-e2a0333a03cc	CPT0068980003	e8f9001e-37b0-4df3-9ca7-7a878218089f	C3N-00573-02	8cbd7a01-1fb9-11e9-b7f8-0a80fada099c	C3N-00573	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a1972a9f-3bf6-44ce-aa60-8cd1807022db	CPT0000630003	db80b9fb-ddb4-44d4-851d-6c927d6f815c	C3L-00103-01	b9017fed-1fb8-11e9-b7f8-0a80fada099c	C3L-00103	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
598e6f4e-c971-4106-b5b0-1d405a21cd20	CPT0012560006	a3776b8d-08bd-440a-af26-9fdaf1b9979e	C3N-00437-03	84411cf7-1fb9-11e9-b7f8-0a80fada099c	C3N-00437	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6fdd05a0-9e7b-4cba-a7d4-d55fe8f6eed1	CPT0019150003	aae40a7c-d73f-4a48-8360-1517295b4ef3	C3L-00583-03	cc8a63fd-1fb8-11e9-b7f8-0a80fada099c	C3L-00583	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1ab1cf72-788e-4add-ba92-d8abf615c67c	CPT0065220003	53f42acd-6489-44a1-83d0-c88c1a7f9bde	C3N-00953-01	9a4966c2-1fb9-11e9-b7f8-0a80fada099c	C3N-00953	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4ab51dc-b3d3-4e6e-b485-2bdd9b28a140	CPT0077120003	018113b4-3329-405a-a4dc-785e9da56f42	C3N-01522-02	ae0489d0-1fb9-11e9-b7f8-0a80fada099c	C3N-01522	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ece2425a-a8d2-4e52-b601-2178cad2dfdb	CPT0007330003	bf38719f-3671-4608-b6b1-abecce3d6f98	C3L-00581-02	caf0e98e-1fb8-11e9-b7f8-0a80fada099c	C3L-00581	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
15fbc9e2-6eb7-4ddc-bb15-62052c3763e9	CPT0068990003	8e92f649-02fb-4249-a566-6919817929a4	C3N-00573-03	8cbd7a01-1fb9-11e9-b7f8-0a80fada099c	C3N-00573	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cfd2ff2e-083c-4ac8-98f9-f81c4b59940a	CPT0077480003	d5e81ff6-744d-4c47-94bf-3fc69f207c9b	C3N-01261-02	aaa7336a-1fb9-11e9-b7f8-0a80fada099c	C3N-01261	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
84a7633e-046d-4194-9f76-8a6fefeae258	CPT0017420006	934ee728-4468-450f-bcff-a73a8bbc90ae	C3N-00390-03	810c2c81-1fb9-11e9-b7f8-0a80fada099c	C3N-00390	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a41f40e-76a9-4717-b78f-cd32af648b06	CPT0079420006	7c4d1fd0-5084-4084-aa4d-6affba14f830	C3L-01287-03	0f345723-1fb9-11e9-b7f8-0a80fada099c	C3L-01287	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c7d6eeab-113b-4363-83bd-f4133da55e26	CPT0092180003	3520f876-99c3-4884-808f-3af1e9b5a089	C3L-01607-03	25e420f4-1fb9-11e9-b7f8-0a80fada099c	C3L-01607	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d01ed12-bd6b-4fb6-8321-8a8cec1cd6e6	CPT0086860003	37b6d612-0d75-403a-8886-1964186010f5	C3L-01836-01	2c9d2692-1fb9-11e9-b7f8-0a80fada099c	C3L-01836	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
907aa23f-d448-46b8-8328-c03ad148d1c8	CPT0020010003	38a33869-684f-4cd1-9dd7-3d19dacf9d4d	C3N-00168-04	675d0c38-1fb9-11e9-b7f8-0a80fada099c	C3N-00168	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5fa7bae0-48e2-46e2-ada9-f46273bbcd77	CPT0006910003	5f08b132-76d4-47d1-8bb9-9d3edcdd3a3f	C3L-00447-03	c5f8631d-1fb8-11e9-b7f8-0a80fada099c	C3L-00447	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
388076ea-943e-4c94-9cd4-64499bbddddf	CPT0086940003	67f2ecfd-c95d-44f6-b445-95a6144e44b1	C3L-01286-01	0d99be24-1fb9-11e9-b7f8-0a80fada099c	C3L-01286	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d9f8c734-9432-44c2-a0cf-2fe07e0749c5	CPT0087030003	a92e9938-4c37-41e3-9396-7633e2e8bf93	C3L-01603-02	241693ab-1fb9-11e9-b7f8-0a80fada099c	C3L-01603	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63d2662e-adbe-44d8-9fdd-368cf8a84368	CPT0069150003	e62514af-7462-4738-9230-6ecc2f2a98fe	C3N-00577-01	8e59b323-1fb9-11e9-b7f8-0a80fada099c	C3N-00577	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3cda7fec-cc6f-4071-acbc-7bd601f58497	CPT0075140006	3c15bcee-fc14-46f6-8647-b47ca55321cb	C3N-01200-03	a4300f90-1fb9-11e9-b7f8-0a80fada099c	C3N-01200	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
368c1b25-d119-4450-b399-7414afa4d16f	CPT0092280003	2f83fef2-56a6-4558-8463-8bda8fe03c9e	C3L-01861-01	2e6540fd-1fb9-11e9-b7f8-0a80fada099c	C3L-01861	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
509358a0-d601-4fea-a6a9-c648faa84474	CPT0012360003	5ac86563-3a89-4d24-9ecb-e7693fd71ae5	C3N-00320-01	7d95243f-1fb9-11e9-b7f8-0a80fada099c	C3N-00320	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f7634e1f-817e-4f0c-87a2-820161b955ab	CPT0008990003	126c21d5-da95-4775-a17c-1bb054e2d289	C3N-00310-02	73b649eb-1fb9-11e9-b7f8-0a80fada099c	C3N-00310	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48fe046d-78cf-43fb-b6f7-a96eaab99e71	CPT0012540003	12c27315-7a83-4c53-bf2a-61214da2438e	C3N-00437-01	84411cf7-1fb9-11e9-b7f8-0a80fada099c	C3N-00437	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c00c095c-0934-4564-aee0-641454bae609	CPT0068970003	2db2b8fd-18c5-439b-aeb3-4ae1121390c9	C3N-00573-01	8cbd7a01-1fb9-11e9-b7f8-0a80fada099c	C3N-00573	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a5f7c6e8-a3df-4ab1-819a-457835f4c76d	CPT0086960003	aae86980-2c0a-4d9b-b720-0d10a3f63ad1	C3L-01286-03	0d99be24-1fb9-11e9-b7f8-0a80fada099c	C3L-01286	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea1566b8-2a47-4b2b-93e3-d811f2c6e8e2	CPT0079280003	cb880c06-ee38-4c37-b231-a1d2fae77c01	C3L-00606-02	ce22af84-1fb8-11e9-b7f8-0a80fada099c	C3L-00606	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
233e16f2-133c-438f-ae10-f08199cdff46	CPT0006520003	4e805fad-7c08-4cb6-b70b-c78a70ff747d	C3L-00369-03	c1195940-1fb8-11e9-b7f8-0a80fada099c	C3L-00369	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c28b408d-16ac-47f3-a10b-e6864c13c3f6	CPT0007410003	c8258a05-b722-41ed-89c8-3059bb0460d6	C3L-00581-03	caf0e98e-1fb8-11e9-b7f8-0a80fada099c	C3L-00581	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f98f3759-790d-497b-a334-3f55eed062ec	CPT0024660006	ed575b59-3be0-4b23-a10d-4862bb67d7f6	C3N-00852-02	987b103d-1fb9-11e9-b7f8-0a80fada099c	C3N-00852	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e1ad545-7f42-42b9-8875-8c1f2d7938b9	CPT0079290003	561efeeb-3b32-454d-ae03-c42ec3561995	C3L-00606-03	ce22af84-1fb8-11e9-b7f8-0a80fada099c	C3L-00606	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1694dd60-7b69-45d6-8a27-132f4da47cdc	CPT0012060006	61638732-511f-4735-b7b9-0d607d80cd3e	C3N-00314-02	78a71616-1fb9-11e9-b7f8-0a80fada099c	C3N-00314	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4b7b0976-f3f6-4d8a-a087-b28c67ff2019	CPT0012390003	dd364c13-f9ce-4276-abac-8d186614226b	C3N-00320-04	7d95243f-1fb9-11e9-b7f8-0a80fada099c	C3N-00320	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
94374c4c-45e0-4bf9-82e8-ded1c6890e69	CPT0081610003	e3ddf980-44ef-4ae4-86b6-19ff19eaf395	C3N-00148-04	6039aa8e-1fb9-11e9-b7f8-0a80fada099c	C3N-00148	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9836a7bd-cbb3-4e4a-835a-51d45cf49070	CPT0081970003	384ef4dc-09fa-4b62-8285-f0bad951d660	C3N-00646-01	901a5db5-1fb9-11e9-b7f8-0a80fada099c	C3N-00646	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c2470b06-b64f-406b-af4f-d871cd0eea43	CPT0075160006	1f4db5fc-9066-4dac-9677-e823e4d1d6c6	C3N-01200-05	a4300f90-1fb9-11e9-b7f8-0a80fada099c	C3N-01200	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4aeff164-33fc-4b10-8466-3750314e3f77	CPT0082000003	fdbd85d9-acc4-4cba-9fb5-ad3b12f9b872	C3N-00646-04	901a5db5-1fb9-11e9-b7f8-0a80fada099c	C3N-00646	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10f99ba4-baa3-41e8-a3fc-4d9a28816ac7	CPT0076340006	472fd482-0fd8-4b5f-a1b5-e0814ffdc0fc	C3N-01220-03	a90d356a-1fb9-11e9-b7f8-0a80fada099c	C3N-01220	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
662ea75e-a3fe-40cc-aa8c-7d2be280444b	CPT0019140003	5a3a5bf2-8dbc-4d55-9a34-6b519692435b	C3L-00583-02	cc8a63fd-1fb8-11e9-b7f8-0a80fada099c	C3L-00583	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
904684fc-8542-4b61-9483-26c5b10ed8b2	CPT0064380003	da1e1d40-15c2-4b06-9ea0-bc509c30b2ee	C3L-00907-02	ecd1a90e-1fb8-11e9-b7f8-0a80fada099c	C3L-00907	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
161b1a26-8804-4b35-87cb-a503c02db755	CPT0012880003	162ca2a3-fea0-4388-aa4e-9e5cecc271cc	C3N-00494-01	8966aab1-1fb9-11e9-b7f8-0a80fada099c	C3N-00494	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3c6f250a-8a07-4ad9-b157-b8ee3ba531c6	CPT0012910003	758712bf-ad88-48c9-a664-6795787d0ca3	C3N-00494-04	8966aab1-1fb9-11e9-b7f8-0a80fada099c	C3N-00494	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
acd2d414-4d96-4e8b-8afd-32fc8c842063	CPT0065440003	c92b763a-23cc-43c1-97de-2b0d16aeb895	C3N-00953-03	9a4966c2-1fb9-11e9-b7f8-0a80fada099c	C3N-00953	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
00c3aace-1f8e-4bb1-b8da-f4c4c687eddb	CPT0025900003	80aea6ef-db77-4e0b-93e7-b03ba154a458	C3N-00733-03	91b4e8bc-1fb9-11e9-b7f8-0a80fada099c	C3N-00733	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
460efe88-b2e1-4620-a596-a28467a52aba	CPT0000650003	85d1cc1d-03c3-47bc-98e9-06794da6b46d	C3L-00103-03	b9017fed-1fb8-11e9-b7f8-0a80fada099c	C3L-00103	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a36ab92-f9f7-4f70-8e2e-89e2c094c728	CPT0081590003	cfa62030-90c2-4717-8198-94ae6bea06e1	C3N-00148-02	6039aa8e-1fb9-11e9-b7f8-0a80fada099c	C3N-00148	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e15d8529-75f5-4b78-ab0a-118ed0585983	CPT0087020003	048c768b-9115-41ec-a09c-0a8c944cf935	C3L-01603-01	241693ab-1fb9-11e9-b7f8-0a80fada099c	C3L-01603	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a39e0507-3d5f-46a2-b7ff-b8669a996be4	CPT0077130003	3d4b356a-0858-4fee-bde7-a1d229ce60e2	C3N-01522-03	ae0489d0-1fb9-11e9-b7f8-0a80fada099c	C3N-01522	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9cb3a435-1243-4951-9580-bafcde291692	CPT0012050003	9be33bbe-08ea-46dd-bc4b-2582b8b4d6ce	C3N-00314-01	78a71616-1fb9-11e9-b7f8-0a80fada099c	C3N-00314	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0af6fc23-476d-44d5-bc31-c74aa71c0244	CPT0017380006	d019ca1f-ee58-4898-913c-20aaf7fa72e9	C3N-00390-01	810c2c81-1fb9-11e9-b7f8-0a80fada099c	C3N-00390	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
26b8b258-323c-4f3d-912e-71ba6f2454f8	CPT0075550003	9064f588-3c65-4487-9faf-b5e250745a3d	C3N-01214-02	a767e303-1fb9-11e9-b7f8-0a80fada099c	C3N-01214	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7d0cf853-9e08-4e36-a724-b2f331f334ec	CPT0020000003	8e2e5c4b-ff2d-4905-aaf7-dd0513184383	C3N-00168-03	675d0c38-1fb9-11e9-b7f8-0a80fada099c	C3N-00168	CPTAC3 Discovery and Confirmatory	Primary Tumor	Kidney	Clear Cell Renal Cell Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
42c76e75-9946-4b86-9ee5-90bf359af2fd	P5	1c7f4159-dbff-4a20-9cdf-8d4a1d0823d3	P5	7a1f7596-6e6b-418c-a9e5-21a3b3ffb14c	WHIM 2	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a272c07b-f673-4806-b6d0-d9cde5ab2a1f	P6	5b1b1297-8e83-46c3-b4af-87de6f859816	P6	c3c8dc70-898b-469c-919d-2ea39c0d71db	WHIM 16	CPTAC2 Retrospective	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba1b6a9f-59a6-46ae-bdb3-7e48d9f095e0	AP-AGZG	8f57f70f-3a87-4747-aa32-8e2d61e0872b	AP-AGZG	ebc4f8fa-4364-4057-9671-8f146f02ac67	AP-AGZG	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
9424fa73-d0ba-4d73-b0f7-27f9b972ffb5	AP-E98M	3071585d-fa3c-43f3-a045-c2ba8838780a	AP-E98M	e3c38f0f-db71-445b-95e6-f189c2504bc0	AP-E98M	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
4e18c87f-9aaf-4c19-93f9-2fdf2c65566f	AP-G79N	de076aa7-829f-4488-b4f0-fee0d9b5cf43	AP-G79N	90e33601-748b-4df7-bff3-a60ee8a09df3	AP-G79N	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
9ecb0dba-1446-42d0-830f-720403aa7c02	AP-RA2G	cee7a25b-0de6-4085-b25b-dd05d67de26d	AP-RA2G	5629fe7e-ee5e-4e2e-bc4b-2c4a99183d61	AP-RA2G	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
8e3ffe2a-724b-4607-a1e1-b131e81b4a50	AP-DMUM	89f4ffbf-6f78-49d3-9b7c-56a2d38fcf2f	AP-DMUM	131b3172-8e24-4bb8-be95-38566b0f84c9	AP-DMUM	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
d74a27d1-fec1-4d5a-a31c-873e2c0c0b6f	AP-ZLDH	6e471bb6-0a4a-4b26-98b1-483ce8441727	AP-ZLDH	8fba4d73-5cb9-43fc-b073-ddd05b921cac	AP-ZLDH	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
37983abf-9a55-40ce-8adb-eb69853e4e6a	AP-WTXJ	62386a69-9772-48de-b50d-b5a49a8e10bd	AP-WTXJ	8e3984c5-5f03-44b3-85dc-9c033e0310f5	AP-WTXJ	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
0787210a-ff06-40e0-9948-28908968a939	AP-JK59	819c24fa-fafb-4389-b3c3-eed07a838d7d	AP-JK59	2a306e1b-2a79-4e0e-98c8-0c809025e63a	AP-JK59	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
e520950a-4c4b-46ea-86c8-eb268a3c35ab	AP-5JDU	024ecd9f-2dd6-4dc3-ad69-cdc25bbfe2b2	AP-5JDU	70a5567e-0fb8-4094-9004-5067e4760e59	AP-5JDU	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
99b17b28-063e-4e7f-86fc-5074ff421535	AP-K24D	e5b96e0d-4d1a-4acb-98dc-315c17433ce8	AP-K24D	320a183a-5a99-4084-8a76-82b53360c809	AP-K24D	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
d72ecce0-1b96-4e8c-8fef-3ca7746135f4	AP-UNC9	1e57b799-0655-4f69-82dc-e10099265ed4	AP-UNC9	38cda9f1-23b8-47f1-9c1e-4d3cf20d35f4	AP-UNC9	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
a9441347-262c-429c-8f95-eb7d86dd4145	AP-B9CH	024eed62-6e37-45ec-90bd-f98a8a4329a7	AP-B9CH	3bbc3803-a692-4da4-9da9-5ae279b9d43a	AP-B9CH	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
76fa308b-7212-4721-97ed-df37c85aa7d2	AP-9UHJ	ea2ca51a-57b8-4886-96c0-ed568490b7f5	AP-9UHJ	7bd83ba1-161a-4137-be35-a9d58ee9e7dc	AP-9UHJ	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
afd73014-f3cf-4acc-b39c-5aa5bdf0f016	AP-SS2L	ea62cbb4-d70d-4eea-a531-dc9408fdcc23	AP-SS2L	8e72024e-47b0-40c6-85f1-12e241b8ac7a	AP-SS2L	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
ca1780e6-82a6-4575-9d61-f3b8470aec59	AP-W455	104c1d1b-58fc-4d6c-8cce-728d3d3da61f	AP-W455	989bf594-7d76-4bf8-a5d8-76cdb9cd4326	AP-W455	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
179280be-d5f4-4d19-925f-02daeebfe69f	AP-V6UJ	d0ef6638-e4d3-4580-b58f-7dbfb61819d8	AP-V6UJ	48a71da7-7c31-41b4-8dc4-09eacf767d87	AP-V6UJ	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
95eb993c-5a42-4473-8a03-fbe57fbf52c9	AP-XVLY	fa051024-dbe1-4a38-9652-eb20ecbe7012	AP-XVLY	4b8b5694-3e57-47b8-aec4-2dc2ee192d23	AP-XVLY	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
bd0ba9b2-b53b-4a70-bd10-e2a0dc0f691c	AP-D9X4	17d2f829-c2f8-4c7b-a956-47f615e04f43	AP-D9X4	290611f4-da9c-4614-8c76-56ff8049b0fa	AP-D9X4	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
c0fb8fd3-c289-4338-906e-fe1a74a8ed74	AP-U8MP	89ab5986-36d0-45f6-93c8-82cd8ab14115	AP-U8MP	cd1375b8-77f3-4c0c-ae1e-009720f46551	AP-U8MP	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
7f339198-c201-4e18-92a7-82c9453ba817	Pool	a1362b76-cab3-4be1-9400-8616b0ee641c	Pool	5e79b89c-af0e-4623-8082-0080c2daeeaf	Pool	APOLLO1	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
832377ae-5928-4930-9e75-f2291e110308	AP-LWHD	7cb4e151-81d7-4157-aae5-c9cfc1c8fe7f	AP-LWHD	e93b3594-bcce-4234-b748-2ee7e555ddff	AP-LWHD	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
80c90d8f-e39b-4c88-9eb6-5828fc900844	AP-4LRG	788f8b38-9702-4136-8165-b9d7ecfc2367	AP-4LRG	1917299c-e324-4a06-92ce-79372a1d4efb	AP-4LRG	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
c3485ce9-e40a-4478-a2d0-f650e377fdf5	AP-DT88	59351426-4160-4f3c-9630-c8d79bf9ba1b	AP-DT88	3ca2cf34-fa0c-40e8-81ea-ca353e74e4fe	AP-DT88	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
e2511a9a-0151-4cf9-9811-c4bc7b74a4da	AP-MGNN	aa8c056f-ab75-4133-8a38-cf10edea1fd3	AP-MGNN	a9fe12f6-af72-4d0e-954e-00309fce3120	AP-MGNN	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
63892e21-aae4-45eb-877d-2c286c36e3af	AP-JKPX	fb89e136-0f15-4f3e-95a7-4cb691394f6c	AP-JKPX	bd90e5fe-c02d-4e0d-8a58-23a7f0f8bae9	AP-JKPX	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
08f2bef2-9a82-423e-985d-7cc28d40ef3e	AP-HKYN	d08af5fc-7e4a-4004-b6c6-668787881734	AP-HKYN	ee23abd7-b967-4831-bca5-0e6b53396a78	AP-HKYN	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
473f47c8-c53d-49dd-a317-3eb1b203d49a	AP-VLXG	0c19c7f2-07f6-4164-a366-cb3774043a82	AP-VLXG	f4dff951-f359-40af-aa22-71b4b4c24e5a	AP-VLXG	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
806ebadd-f1ae-4744-8c7d-7cbe4d040046	AP-B2SL	21008591-70d1-4f29-a9ce-5e06dadbffd9	AP-B2SL	3a1fcd67-79a9-4f48-b687-8657b4a0ca03	AP-B2SL	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
a3101cf0-34b6-4d2b-a7a1-5027b5e85336	AP-9PXS	39940078-b2b4-46ac-a24a-fc106be68849	AP-9PXS	2693abc5-4d4f-49c8-a689-0532d9d71fa8	AP-9PXS	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
9a28da01-cc1f-4d64-b810-d84ed5042fa3	AP-EZEX	00879777-8fd6-4975-94d6-e4fa5dc6984d	AP-EZEX	b2b2422f-dab0-466a-8e6f-2f2981aac1fa	AP-EZEX	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
42af905c-0dff-4410-a38a-361484adbfa9	AP-KGMR	f7287fbf-a255-4a02-bfa1-bf364f471fe9	AP-KGMR	208bfb7e-141e-4754-af0f-0dcef3d4fd5a	AP-KGMR	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
79dd3390-c6da-479d-9239-15d91a721cba	AP-52RG	e54bc82c-4e33-454e-b16d-14ae2a487e00	AP-52RG	4fbbdb30-8292-4050-ac65-1dd70e762fac	AP-52RG	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
efa92cd1-1901-4ed2-86b5-597aafff52e8	AP-E9CK	8564cfa1-3359-4264-8271-d0da294900f6	AP-E9CK	62d4788b-a03f-46f3-8438-b64aa60b1b72	AP-E9CK	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
7e7a3a14-0d8b-423d-969c-994c0939106f	AP-Y6T7	595dc5ab-0ae8-48d2-8268-a2afb6adb9c0	AP-Y6T7	6669352a-bd73-438b-91ac-4a0c6939e73b	AP-Y6T7	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
e0b7f64b-3ce3-4c45-bb3b-1bc8e1a2892d	AP-2E8Q	db223cbc-3453-4a79-a770-77caf6fc9ece	AP-2E8Q	0955e456-8de6-4c99-b6bb-f720525e5a28	AP-2E8Q	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
54afc357-8aa7-40f4-b2a1-4f4971b7146d	AP-XSR5	c251d0bc-8acc-4d4b-b41f-f4bf74cbd9bc	AP-XSR5	59fa191b-648f-486e-b3a6-815e12b7fb57	AP-XSR5	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
56e7de2f-9a91-4921-91d9-e88146256f1e	AP-67ZV	1a533239-417d-45a8-8c72-cd7115eb10cc	AP-67ZV	6ab4ef83-840f-45d5-b7df-1108e51b1f1d	AP-67ZV	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
2a760871-8a92-4b0e-8d2a-0276cc4f073a	AP-352Q	c9aedf03-fc99-44dc-966b-720b820b728c	AP-352Q	7af30d07-2bf0-40d2-b07b-58d45cc70b4c	AP-352Q	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
ce6f5919-8c7c-45ed-b93e-fc5af3cc7fb4	AP-HFEA	7848702f-d780-4672-b19f-da6b7c0db53c	AP-HFEA	3c430dc1-7b8b-4ba2-ac4e-554aee3a068e	AP-HFEA	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
ff35b3ff-703c-4622-915a-70a01896dfe7	AP-M3W6	825c7f2a-2805-42b7-a1c5-0d7db391363a	AP-M3W6	29fc111e-69fe-40ae-8cd4-f8f92a7fac7b	AP-M3W6	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
aaef901f-fe4b-4c10-8edb-e0d6e05dabb0	AP-HMFR	569bb543-ac5d-4216-855d-ff3426e428e2	AP-HMFR	0214a752-a1a8-4751-a0f3-7ed1aeb7c82f	AP-HMFR	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
8beae7e2-f3bd-41b1-ba24-72aa77f9b282	AP-NCLP	dddb0418-e2ed-46eb-80eb-ae3e3b20eac3	AP-NCLP	c61eaf35-9aa3-4f69-ab5d-2fea5eb1bb34	AP-NCLP	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
8b759b85-0632-4e72-8aa2-2183ce22c6be	AP-RBLG	4bd0af37-7530-42cd-8ada-08e63fd21a1b	AP-RBLG	ef6488d1-fbef-4022-ac95-d65b8d4090ea	AP-RBLG	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
3c8fc6ee-5f88-4146-8888-b67d39dc23b4	AP-MJ52	099af9a6-559d-4199-ac8b-1ef4039e7199	AP-MJ52	bb359ce4-a2d0-41eb-8b5c-b514a3686b6c	AP-MJ52	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
f4775bc5-18c4-4319-934e-528d9c4c059a	AP-Q7SA	63395dd3-820c-450d-b6a1-45be3304ca5b	AP-Q7SA	fdcf8b88-8aa6-42f8-a422-6874afebae9d	AP-Q7SA	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
69128136-19a7-4e15-8a57-1ff5fabd836b	AP-9D3B	920009fd-7e83-44e5-a1f8-94156067cea4	AP-9D3B	62e371a8-4754-4c85-8c2b-bcf2f93ddd79	AP-9D3B	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
e0efa491-e1f0-46ad-b2e7-8abebcce97f3	AP-YTZ8	6e071fb6-7109-4f09-b266-6f3d62475fba	AP-YTZ8	54d3eb3e-7cef-48de-891b-0be632167c5a	AP-YTZ8	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
ed95974b-67a3-4b82-8918-50918907a621	AP-E7CU	01abf907-0fc0-4b34-be15-dc1cec1a61f4	AP-E7CU	5a807e7e-3916-4bba-b219-b6ec7d3db4e7	AP-E7CU	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
7ba60b55-fafd-4e1b-a870-ca1313e637d8	AP-QAHT	3859669a-9ef4-4211-8274-9e1316bb6c5a	AP-QAHT	4f0d67e3-992d-40f5-b60e-0066b6c80b29	AP-QAHT	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
dddaeed3-32af-4634-8108-4d56dd2e3139	AP-D35H	96127c6a-de5b-435e-98a6-9db952251a1c	AP-D35H	3bb399bd-3ff4-4429-8aac-a792c05cfbf8	AP-D35H	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
26f0e56a-961d-430b-b682-9d29ba4e6c0f	AP-2XNK	daaab869-f83f-4e29-adde-aef91d1436a7	AP-2XNK	cfcf52bd-f674-4475-82bc-433183b6fd52	AP-2XNK	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
98df1c93-e610-45b6-84f0-8c21fa1e6f12	AP-4HYT	952e1c56-d46d-446a-b9e2-1c33b210a2b2	AP-4HYT	a70dd091-32f2-4964-a23c-0504be46371e	AP-4HYT	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
2c91180a-73de-42fd-b9b3-16e9bf63fd8f	AP-EPNF	a1b5b333-991c-4751-a7f5-653bd1d1dc30	AP-EPNF	bab03920-691e-459e-b3b4-b6ce61a924a6	AP-EPNF	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
fe1b3c8c-4a39-4e1b-a05d-8b50e192ef25	AP-AJWE	c59acb93-a1ef-4908-bbef-4d1ade8385b8	AP-AJWE	5ddf94da-57d9-4751-add8-0f5e65f3e509	AP-AJWE	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
87f8f604-5b7d-4036-acc9-3341346cb2a9	AP-4WDE	b19a3e9f-b94b-49cb-8a2b-c9af747d7aa6	AP-4WDE	c9df2c84-48ba-4cc3-b692-b4947f53d927	AP-4WDE	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
a978b6a5-a297-4e33-b402-25b41022eac6	AP-SJVE	0b9ca6ad-b6e2-421f-8f86-3036c6918501	AP-SJVE	b6063e07-2258-4d24-8923-9d05cef350c9	AP-SJVE	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
0869bcd1-882b-4159-a334-a21a7d3c54cb	AP-9LNA	4de7f70b-e75b-4954-817c-e37fa5c9c333	AP-9LNA	9f5c28b5-7ff0-42d5-a112-c12bc43fa797	AP-9LNA	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
c35f91e2-9447-4536-9876-7c281cf3fe8f	AP-KX5B	5f2c798a-c0a0-421c-9be4-c7201b4af465	AP-KX5B	b913cd6a-96b9-4a57-af8a-462443313235	AP-KX5B	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
747bef96-3f1e-47fd-89f4-0b23d67936fb	AP-MUQL	7ef47fd6-13ee-4fd4-81df-3f78d4f22924	AP-MUQL	5757fd61-ceb5-4daf-a663-2a6fb3d72e75	AP-MUQL	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
a535dc0d-8ed4-4252-b165-299b791a2193	AP-HML4	cd72581a-fae5-47df-9747-a9a501ef5d8a	AP-HML4	d758a19f-0401-4af4-b1ac-976f82017cf7	AP-HML4	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
81b4571a-2ac1-4d71-8448-6e62a98600b4	AP-RQNH	d835a2a8-b183-4604-8e48-a11fdc86244a	AP-RQNH	c088d9bd-8c58-4faa-91f8-0cf015ef304c	AP-RQNH	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
dec3a537-0fa0-4ac9-a438-5d93fb7c6a37	AP-WDKZ	7e001c0f-93d0-44a2-9560-b7c2d54daaff	AP-WDKZ	7a0682d0-c23f-4ba2-b1db-263f7442bf99	AP-WDKZ	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
0871b34d-d0f5-475e-b4be-3b6b3f305864	AP-TBFQ	d341bcc2-42ef-4479-ac85-27348ffaca45	AP-TBFQ	3e019b1e-be2a-4139-a0bc-20cd4ddb7142	AP-TBFQ	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
82b09b15-36f3-4cde-a241-719d8dd2455b	AP-62LT	904cf5fb-4f3f-44db-8c45-52612e3fea6a	AP-62LT	934d6b0d-14bf-4c4f-a68f-01c217343789	AP-62LT	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
f844f33f-a9cc-451b-8838-abc25f838a13	AP-CT3G	c9a9680a-35c4-4507-9f09-d0f19df27633	AP-CT3G	d13f25c9-9b53-4cc3-a3c0-eefae74d695a	AP-CT3G	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
cca89e19-4a46-41ae-a160-2a9d667aaa27	AP-8PRJ	d154b83f-dbb2-4a98-b74a-36a665728f58	AP-8PRJ	93f8de86-55ac-4e9f-b6dd-7afa39ed9d81	AP-8PRJ	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
c366df51-e88e-467e-bf49-65ec5fa4b770	AP-JBET	3bc6b765-7000-499c-b467-26f0fcc84a79	AP-JBET	e3f3601e-5f96-4430-b601-1f95e6b9c330	AP-JBET	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
1cfa04bc-9080-4e5e-a5d9-f9ff6e4b70f5	AP-5L2V	c752a89b-9933-409f-a0d0-bb68c2bd18ed	AP-5L2V	2b604152-3251-4abd-a782-fb4ae42e346c	AP-5L2V	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
5b0b5037-0b1b-4511-bf75-5762a84756bd	AP-7KJ6	6d603eb8-a7b7-45e5-af0b-47bad7e56edf	AP-7KJ6	79544443-38fe-441e-8730-17fe46d0f8d0	AP-7KJ6	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
dc7d4c34-6d8c-44f6-b48a-7a8e41187ad0	AP-FX68	da11a6b6-8fac-4030-b050-548014c05ab4	AP-FX68	a7db3849-04ef-49c3-8313-82bb4b02bc9b	AP-FX68	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
f6080f7a-2484-4e55-aa86-d242717e094f	AP-MAZ4	4b142eeb-0ddd-4e7e-8be9-16836dffc528	AP-MAZ4	11362304-fd12-4f36-8e9d-608972ae1a26	AP-MAZ4	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
25c2b879-3cc6-438c-9224-c48ce246551c	AP-YF3B	115e22c6-331a-433b-9c05-904ba233f43d	AP-YF3B	59a5722f-cb98-41a0-b7df-a6ab104f0943	AP-YF3B	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
163cbb89-9cb6-44da-8d93-a0a6bf7db26f	AP-QD4Q	cf0b0507-c838-4ffa-815b-ed681834979e	AP-QD4Q	2993c8b1-bf22-4f09-92ab-0a6d991c93de	AP-QD4Q	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
20dadf5b-9dad-4b1a-b3df-3f664b49e289	AP-3FY5	00df4fa4-6c86-4eea-bb7a-5ca4fd51b75d	AP-3FY5	4a6a400f-651d-4ec8-ad7c-b3e8d6dd1944	AP-3FY5	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
d9bb67f2-10d5-4846-a8d4-d933464adbbd	AP-27JZ	de35d9af-6df9-47a5-8dec-c57399801aba	AP-27JZ	c3d87659-d18b-4f58-8ff1-e4780d5e5a74	AP-27JZ	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
e9adb4df-6f25-4006-b77f-0d232b3aae58	AP-5MX6	3f87962b-937e-4890-8f76-472974ee933d	AP-5MX6	9875f1f5-77ed-4620-a3ed-5687dac3b33b	AP-5MX6	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
0a640ab1-d8f7-48e6-8920-8d63fa2744ab	AP-N8FG	6201be63-a7d3-414f-a72e-86acc670fd9a	AP-N8FG	eddbeb2f-7472-4a03-8c72-a8ea47349071	AP-N8FG	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
f1ff9002-0115-4578-bd92-4880df97968c	AP-NMZS	79d5bb64-3790-4ac9-a989-41e2b07c80cd	AP-NMZS	0d555838-fb25-43e0-9809-82e055fa9a42	AP-NMZS	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
d5f70c1e-9f33-4d55-9e68-2013528e53e0	AP-UG7J	8c22b156-29ef-46de-9d8c-691891c75d1c	AP-UG7J	4141d9a6-f720-44f6-aa21-987e239c28fd	AP-UG7J	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
8dadea8e-ff58-49fe-84ac-3deefec3b13a	AP-DN2V	2856dfbd-3566-414c-bc50-ea0af6fcf6bf	AP-DN2V	7f3ad289-d483-4ad6-abaf-0157df4bb0c6	AP-DN2V	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
61179cf7-2e53-4eea-b018-cd7131b9b166	AP-AAFC	4d7d4067-3463-43d1-9bd1-6e07818e5a15	AP-AAFC	be87bdee-8b47-42de-be58-c866e86e9997	AP-AAFC	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
0ce14968-c319-4b1c-8285-9976c48b6cd7	AP-XCJX	63d240dc-89e4-4308-a09f-94742f8ac9ac	AP-XCJX	eca2961a-e130-48aa-9707-7ef3d7cc3230	AP-XCJX	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
acc7c079-f1b7-4e7e-87e1-2ddfad807d07	AP-QUHC	9669e37b-cb57-4ffa-bbc5-1cc549d741cc	AP-QUHC	aa60046f-d90d-4ee7-b787-eae328dab7b4	AP-QUHC	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
397e9578-1b52-4b0e-953f-611eedfe78da	AP-WEHE	e2252841-8df8-488b-813d-cc2c20b9a1ae	AP-WEHE	be6e2dbe-dbc4-4a6b-9736-7481a973ad2b	AP-WEHE	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
95a77f99-8125-4cb4-b72a-610efead4c8b	AP-8MWD	535ddfef-d8a6-40a0-8d78-e6bdf5ad633a	AP-8MWD	1c3815d3-e6f3-4841-a07f-d50d16c18ce2	AP-8MWD	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
ecc1d589-e23d-4490-99de-ed7811450afd	AP-JDN4	4bf59500-7328-4837-b8d6-caec8a67c9e4	AP-JDN4	12293bed-45a2-4c7e-91f2-fa954cf5ea55	AP-JDN4	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
ef7dd7d1-acdc-4dd5-b6b3-308c31091438	AP-94ED	f889ea26-7fa4-4652-8dc0-256e7ba37dd8	AP-94ED	83bb8353-bc5f-4d85-b3d3-2a162d4427d4	AP-94ED	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
5c3c1b89-4a91-4be3-aae6-4963a71025c6	AP-4HAU	861290f6-083c-4543-adb8-447fc7827d43	AP-4HAU	c318158c-4c5a-41e0-840d-287badd34b26	AP-4HAU	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
e15e9924-8c13-434c-8859-7adbea1bc96e	AP-A5NG	d5ff4c4e-6959-41cc-bafb-f85fb383a251	AP-A5NG	ccc50dce-95dc-4c4a-92b5-c4863e996c0d	AP-A5NG	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
b96e82ec-f597-4985-ab76-9588579205a6	AP-7GDN	3773b1e8-5d27-41d4-bc39-27581ececa8d	AP-7GDN	98766248-72e8-4c82-a6ba-63880d9afdf5	AP-7GDN	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
bd6bd37f-b2c0-4c67-9c56-20baf2833d84	AP-3336	87aba1b8-56f8-468a-9da0-a6a0a15a6514	AP-3336	e4a4fa78-b429-4274-a2a9-9bd08f2114f8	AP-3336	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
615cad4f-433c-434e-9e25-9e421b0f37e0	AP-4M7L	52f2c3f0-bfa6-4514-a4d6-2335d3f056ff	AP-4M7L	e7bc21c5-8d21-445c-b150-7927d213ea32	AP-4M7L	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
ad6a836e-89d0-4c00-8621-5cdf6b8b2c5c	AP-EFHT	7cd516fa-e7c2-4b1a-b3ed-53df06e69cc5	AP-EFHT	90b28d48-fe67-464b-89e2-ee28c7e3573f	AP-EFHT	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
a7ae6dda-077f-4027-8b22-3d9ba5c56a5e	AP-FEPR	a54f543a-1fc9-48a3-948b-529c0110a469	AP-FEPR	220ba648-122a-403d-8b81-9a32a4611c4c	AP-FEPR	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
b35d34db-2e86-489b-92f7-e80da9768fe0	AP-WPAM	c995f644-a1b1-42ab-a819-98b20b6e8b32	AP-WPAM	d11317a3-bac7-47ee-9547-c7790aaf0467	AP-WPAM	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
de8f6a60-e03b-4ea0-b442-fa469f018b68	AP-KNF9	2f737b8e-86e8-49bc-9fce-a10bffd4addc	AP-KNF9	59cf06b0-b257-4e36-9302-ec3615d23dfc	AP-KNF9	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
59fcce98-c804-4b2a-a354-0cd2b12f7f81	AP-SC6Y	b54c4f3c-fe68-4423-b0d3-8bee3a39e69f	AP-SC6Y	a06eaca6-d26c-40c4-90e4-4748e277c876	AP-SC6Y	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Disqualified						Disqualified	Disqualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
669f5c30-a8aa-469c-98b2-244c5f94cb8c	AP-DM87	54e32be8-20d6-40c9-b42c-1544391966ed	AP-DM87	e2aa4eca-a6fd-43bd-b606-9f80bd481c0e	AP-DM87	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
54940e39-8953-4501-92aa-0eefda9fb343	AP-F595	33a6387f-943d-4fe0-8f36-66ec6097d38e	AP-F595	1d5d727b-0bc7-4695-90a3-7a4907f4101a	AP-F595	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
adc2dbe1-1180-4151-a242-e72a5e2e542e	AP-6EWG	9760ec9b-9bb5-475f-b46e-b15d2a63797c	AP-6EWG	811556a8-7ff2-4a9e-be41-7620994b1e9a	AP-6EWG	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
afdce9e2-51ef-4217-b6de-6989bfef865c	AP-KXUT	833617b3-2721-4262-ae34-f3ec82814668	AP-KXUT	c295a6e0-06dd-4ff0-9b1f-f3f8ecc8a56e	AP-KXUT	APOLLO1	Primary Tumor	Bronchus and lung	Lung Adenocarcinoma	No	Qualified						Qualified	Qualified																									Applied Proteogenomics OrganizationaL Learning and Outcomes - APOLLO
b2751f68-fa9b-4e4c-9e72-e62c7464b166	basal_04	68d1b47b-00b3-4e37-abf7-aca49fd412cf	basal_04	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c85fafa4-67d0-4987-966f-d867d4de9cdd	luminal_07	496cebb2-658e-43a1-82a0-63d99c1c8d2b	luminal_07	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83283099-953c-4521-b102-be7466dee5b3	luminal_03	fd9485c4-9451-46f5-873b-0f2c844cab4a	luminal_03	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba2dcd91-77a9-4eac-9629-39ed52107e19	basal_09	a1c6d563-895a-4eab-ab5a-9c3cfa6140f6	basal_09	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c16b4d46-0765-4f99-834d-0959925f18fb	luminal_08	d16a128d-200d-4428-b9b0-747743dfaaf3	luminal_08	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d504eb4a-3343-45cc-a42c-43a75e1e04d3	basal_08	66940b4f-ec43-4602-a5ea-1022bd1da331	basal_08	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4d8c3411-2ac3-497e-805d-07d2f102beab	luminal_04	f96c956d-0563-49f4-8a9a-b35544be69b7	luminal_04	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
05b0814b-3c20-4bbe-8d28-0c844c85e43a	basal_01	49520d62-4484-415f-a600-d7b37b3dbec7	basal_01	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
058d50ee-2650-40cc-b006-11ba440f9842	basal_02	9df4638d-8443-48d6-bd9e-2097f81900f0	basal_02	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f3204ae-da54-4b9f-bdc5-4b37685c8ef2	luminal_01	b3be27ae-d516-4acb-a3f8-8839ad410d9e	luminal_01	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f15914db-2edd-4a22-a62b-5025eda66020	basal_06	c8aa8224-45d6-4bb4-8613-78d639272add	basal_06	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f52f5d39-e005-4767-ad6e-7b8d7e6b495e	basal_10	25c13681-c136-4cfe-8fb9-1ba4aebb17f4	basal_10	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7547c5ee-e53e-4b73-9e7e-aacb6d70e630	luminal_05	025affa5-1a6c-4fce-ad93-b3ffa28510e5	luminal_05	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd13dd29-6c18-485c-bd92-85a49c029bd1	luminal_09	f8a4d775-4841-4a4f-be3f-5de52f146165	luminal_09	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8aea0788-1eae-47af-8a69-c358b65ca12c	luminal_10	9460aec0-3339-470d-80c8-8ddc9173cef3	luminal_10	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a373eb6e-e9db-4f92-87e6-05febd9c66af	luminal_06	0d131b32-36ca-4da9-a251-0b49bdaf6ec2	luminal_06	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
472d4bdb-d9b4-4488-b8c8-2bed2b2e96f3	basal_05	2e01a025-039a-4fed-bf74-ed1d16b2e218	basal_05	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9beba304-e328-4781-b9d3-d8ee60f00991	luminal_02	3417e17c-73f5-43d4-8bff-dfd559dc4b69	luminal_02	4c5e9b7e-79f5-4569-8873-217f0c73d887	Luminal (WHIM 16)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1a66789a-b288-4dd3-aee6-408f0c574db5	basal_03	f07534da-15b5-406e-b5b7-9f47d4158d6a	basal_03	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fe073ac7-319a-4108-ba13-fc5dcf372e60	basal_07	ea9d0324-7a48-4944-8aab-61359e5bfd26	basal_07	bcaa0cc4-074f-4e5f-ae52-bc757045b062	Basal (WHIM2)	CPTAC3-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
24b64102-8beb-11ea-b1fd-0aad30af8a83	P086-1-1	24b50ffb-8beb-11ea-b1fd-0aad30af8a83	P086-1	24b3cbab-8beb-11ea-b1fd-0aad30af8a83	P086	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b585ef-8beb-11ea-b1fd-0aad30af8a83	P013-2-1	24b40f0d-8beb-11ea-b1fd-0aad30af8a83	P013-2	24b3672b-8beb-11ea-b1fd-0aad30af8a83	P013	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e0f2-8beb-11ea-b1fd-0aad30af8a83	P048-2-1	24b48961-8beb-11ea-b1fd-0aad30af8a83	P048-2	24b39652-8beb-11ea-b1fd-0aad30af8a83	P048	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5f5fc-8beb-11ea-b1fd-0aad30af8a83	P056-2-1	24b4a5cb-8beb-11ea-b1fd-0aad30af8a83	P056-2	24b3a2d4-8beb-11ea-b1fd-0aad30af8a83	P056	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e73d-8beb-11ea-b1fd-0aad30af8a83	P051-1-1	24b491b7-8beb-11ea-b1fd-0aad30af8a83	P051-1	24b39a34-8beb-11ea-b1fd-0aad30af8a83	P051	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b60964-8beb-11ea-b1fd-0aad30af8a83	P064-2-1	24b4c261-8beb-11ea-b1fd-0aad30af8a83	P064-2	24b3ab9d-8beb-11ea-b1fd-0aad30af8a83	P064	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b62dc1-8beb-11ea-b1fd-0aad30af8a83	P078-1-1	24b4f2cd-8beb-11ea-b1fd-0aad30af8a83	P078-1	24b3bef1-8beb-11ea-b1fd-0aad30af8a83	P078	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b59b24-8beb-11ea-b1fd-0aad30af8a83	P021-2-1	24b42857-8beb-11ea-b1fd-0aad30af8a83	P021-2	24b371f8-8beb-11ea-b1fd-0aad30af8a83	P021	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b58ef4-8beb-11ea-b1fd-0aad30af8a83	P017-1-1	24b4197c-8beb-11ea-b1fd-0aad30af8a83	P017-1	24b36c03-8beb-11ea-b1fd-0aad30af8a83	P017	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b66826-8beb-11ea-b1fd-0aad30af8a83	P099-2-1	24b54103-8beb-11ea-b1fd-0aad30af8a83	P099-2	24b3d98c-8beb-11ea-b1fd-0aad30af8a83	P099	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b638f7-8beb-11ea-b1fd-0aad30af8a83	P082-2-1	24b504dc-8beb-11ea-b1fd-0aad30af8a83	P082-2	24b3c56f-8beb-11ea-b1fd-0aad30af8a83	P082	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b68574-8beb-11ea-b1fd-0aad30af8a83	QC2_LateStageTumor_pool	24b56407-8beb-11ea-b1fd-0aad30af8a83	QC2_LateStageTumor_pool	24b3e719-8beb-11ea-b1fd-0aad30af8a83	QC2_LateStageTumor_pool	Academia Sinica LUAD-100	Not Reported	Lung	Other	yes	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5d284-8beb-11ea-b1fd-0aad30af8a83	P043-1-1	24b4755d-8beb-11ea-b1fd-0aad30af8a83	P043-1	24b38e5d-8beb-11ea-b1fd-0aad30af8a83	P043	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b59450-8beb-11ea-b1fd-0aad30af8a83	P019-1-1	24b41fc2-8beb-11ea-b1fd-0aad30af8a83	P019-1	24b36ef3-8beb-11ea-b1fd-0aad30af8a83	P019	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b67ba2-8beb-11ea-b1fd-0aad30af8a83	P110-2-1	24b55af8-8beb-11ea-b1fd-0aad30af8a83	P110-2	24b3e25f-8beb-11ea-b1fd-0aad30af8a83	P110	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b4b8-8beb-11ea-b1fd-0aad30af8a83	P031-2-1	24b44c2d-8beb-11ea-b1fd-0aad30af8a83	P031-2	24b37fe2-8beb-11ea-b1fd-0aad30af8a83	P031	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b62531-8beb-11ea-b1fd-0aad30af8a83	P074-2-1	24b4e776-8beb-11ea-b1fd-0aad30af8a83	P074-2	24b3b837-8beb-11ea-b1fd-0aad30af8a83	P074	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5a198-8beb-11ea-b1fd-0aad30af8a83	P023-2-1	24b43017-8beb-11ea-b1fd-0aad30af8a83	P023-2	24b3753f-8beb-11ea-b1fd-0aad30af8a83	P023	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b601cc-8beb-11ea-b1fd-0aad30af8a83	P061-1-1	24b4b4e9-8beb-11ea-b1fd-0aad30af8a83	P061-1	24b3a835-8beb-11ea-b1fd-0aad30af8a83	P061	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b61008-8beb-11ea-b1fd-0aad30af8a83	P066-2-1	24b4c9b7-8beb-11ea-b1fd-0aad30af8a83	P066-2	24b3ae40-8beb-11ea-b1fd-0aad30af8a83	P066	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5aa54-8beb-11ea-b1fd-0aad30af8a83	P027-1-1	24b43c68-8beb-11ea-b1fd-0aad30af8a83	P027-1	24b37a9a-8beb-11ea-b1fd-0aad30af8a83	P027	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5bca7-8beb-11ea-b1fd-0aad30af8a83	P035-1-1	24b4586a-8beb-11ea-b1fd-0aad30af8a83	P035-1	24b3845b-8beb-11ea-b1fd-0aad30af8a83	P035	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5ebc6-8beb-11ea-b1fd-0aad30af8a83	P053-1-1	24b49865-8beb-11ea-b1fd-0aad30af8a83	P053-1	24b39d4b-8beb-11ea-b1fd-0aad30af8a83	P053	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b66069-8beb-11ea-b1fd-0aad30af8a83	P096-1-1	24b534a0-8beb-11ea-b1fd-0aad30af8a83	P096-1	24b3d61f-8beb-11ea-b1fd-0aad30af8a83	P096	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5c26d-8beb-11ea-b1fd-0aad30af8a83	P037-1-1	24b45fea-8beb-11ea-b1fd-0aad30af8a83	P037-1	24b3871b-8beb-11ea-b1fd-0aad30af8a83	P037	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b60527-8beb-11ea-b1fd-0aad30af8a83	P062-2-1	24b4ba8e-8beb-11ea-b1fd-0aad30af8a83	P062-2	24b3a9f0-8beb-11ea-b1fd-0aad30af8a83	P062	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6786c-8beb-11ea-b1fd-0aad30af8a83	P109-2-1	24b557ca-8beb-11ea-b1fd-0aad30af8a83	P109-2	24b3df92-8beb-11ea-b1fd-0aad30af8a83	P109	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5fc6f-8beb-11ea-b1fd-0aad30af8a83	P058-2-1	24b4ad17-8beb-11ea-b1fd-0aad30af8a83	P058-2	24b3a4cf-8beb-11ea-b1fd-0aad30af8a83	P058	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5cd4e-8beb-11ea-b1fd-0aad30af8a83	P041-1-1	24b46f20-8beb-11ea-b1fd-0aad30af8a83	P041-1	24b38b8f-8beb-11ea-b1fd-0aad30af8a83	P041	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6822c-8beb-11ea-b1fd-0aad30af8a83	P112-2-1	24b56101-8beb-11ea-b1fd-0aad30af8a83	P112-2	24b3e42e-8beb-11ea-b1fd-0aad30af8a83	P112	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5adb4-8beb-11ea-b1fd-0aad30af8a83	P028-2-1	24b440f0-8beb-11ea-b1fd-0aad30af8a83	P028-2	24b37c54-8beb-11ea-b1fd-0aad30af8a83	P028	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b58b4c-8beb-11ea-b1fd-0aad30af8a83	P015-2-1	24b41547-8beb-11ea-b1fd-0aad30af8a83	P015-2	24b368d8-8beb-11ea-b1fd-0aad30af8a83	P015	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b63c8b-8beb-11ea-b1fd-0aad30af8a83	P084-1-1	24b508b9-8beb-11ea-b1fd-0aad30af8a83	P084-1	24b3c882-8beb-11ea-b1fd-0aad30af8a83	P084	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5a5d8-8beb-11ea-b1fd-0aad30af8a83	P025-1-1	24b43616-8beb-11ea-b1fd-0aad30af8a83	P025-1	24b3789b-8beb-11ea-b1fd-0aad30af8a83	P025	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b664a9-8beb-11ea-b1fd-0aad30af8a83	P098-1-1	24b53c6d-8beb-11ea-b1fd-0aad30af8a83	P098-1	24b3d7bc-8beb-11ea-b1fd-0aad30af8a83	P098	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5f08d-8beb-11ea-b1fd-0aad30af8a83	P055-1-1	24b49feb-8beb-11ea-b1fd-0aad30af8a83	P055-1	24b3a073-8beb-11ea-b1fd-0aad30af8a83	P055	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b613b2-8beb-11ea-b1fd-0aad30af8a83	P068-1-1	24b4cda5-8beb-11ea-b1fd-0aad30af8a83	P068-1	24b3b0e7-8beb-11ea-b1fd-0aad30af8a83	P068	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b63492-8beb-11ea-b1fd-0aad30af8a83	P080-2-1	24b4fd5e-8beb-11ea-b1fd-0aad30af8a83	P080-2	24b3c21f-8beb-11ea-b1fd-0aad30af8a83	P080	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5dc97-8beb-11ea-b1fd-0aad30af8a83	P046-2-1	24b4817b-8beb-11ea-b1fd-0aad30af8a83	P046-2	24b39353-8beb-11ea-b1fd-0aad30af8a83	P046	Academia Sinica LUAD-100	Tumor	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b62a6b-8beb-11ea-b1fd-0aad30af8a83	P076-2-1	24b4ed2c-8beb-11ea-b1fd-0aad30af8a83	P076-2	24b3bb45-8beb-11ea-b1fd-0aad30af8a83	P076	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b65d03-8beb-11ea-b1fd-0aad30af8a83	P094-2-1	24b52ecb-8beb-11ea-b1fd-0aad30af8a83	P094-2	24b3d37f-8beb-11ea-b1fd-0aad30af8a83	P094	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b66b27-8beb-11ea-b1fd-0aad30af8a83	P100-2-1	24b543ed-8beb-11ea-b1fd-0aad30af8a83	P100-2	24b3da66-8beb-11ea-b1fd-0aad30af8a83	P100	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b90c-8beb-11ea-b1fd-0aad30af8a83	P033-2-1	24b45429-8beb-11ea-b1fd-0aad30af8a83	P033-2	24b38193-8beb-11ea-b1fd-0aad30af8a83	P033	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b58529-8beb-11ea-b1fd-0aad30af8a83	P013-1-1	24b40d40-8beb-11ea-b1fd-0aad30af8a83	P013-1	24b3672b-8beb-11ea-b1fd-0aad30af8a83	P013	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5f3ac-8beb-11ea-b1fd-0aad30af8a83	P056-1-1	24b4a3cc-8beb-11ea-b1fd-0aad30af8a83	P056-1	24b3a2d4-8beb-11ea-b1fd-0aad30af8a83	P056	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6356c-8beb-11ea-b1fd-0aad30af8a83	P081-1-1	24b4ff90-8beb-11ea-b1fd-0aad30af8a83	P081-1	24b3c33a-8beb-11ea-b1fd-0aad30af8a83	P081	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b61fc4-8beb-11ea-b1fd-0aad30af8a83	P073-1-1	24b4e1eb-8beb-11ea-b1fd-0aad30af8a83	P073-1	24b3b62b-8beb-11ea-b1fd-0aad30af8a83	P073	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b598eb-8beb-11ea-b1fd-0aad30af8a83	P021-1-1	24b42647-8beb-11ea-b1fd-0aad30af8a83	P021-1	24b371f8-8beb-11ea-b1fd-0aad30af8a83	P021	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e813-8beb-11ea-b1fd-0aad30af8a83	P051-2-1	24b493a9-8beb-11ea-b1fd-0aad30af8a83	P051-2	24b39a34-8beb-11ea-b1fd-0aad30af8a83	P051	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5c70f-8beb-11ea-b1fd-0aad30af8a83	P039-1-1	24b46757-8beb-11ea-b1fd-0aad30af8a83	P039-1	24b388cc-8beb-11ea-b1fd-0aad30af8a83	P039	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b60899-8beb-11ea-b1fd-0aad30af8a83	P064-1-1	24b4c05c-8beb-11ea-b1fd-0aad30af8a83	P064-1	24b3ab9d-8beb-11ea-b1fd-0aad30af8a83	P064	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5bbdf-8beb-11ea-b1fd-0aad30af8a83	P034-2-1	24b4574f-8beb-11ea-b1fd-0aad30af8a83	P034-2	24b38358-8beb-11ea-b1fd-0aad30af8a83	P034	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5dd78-8beb-11ea-b1fd-0aad30af8a83	P047-1-1	24b4836d-8beb-11ea-b1fd-0aad30af8a83	P047-1	24b39432-8beb-11ea-b1fd-0aad30af8a83	P047	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b121-8beb-11ea-b1fd-0aad30af8a83	P030-1-1	24b44669-8beb-11ea-b1fd-0aad30af8a83	P030-1	24b37e04-8beb-11ea-b1fd-0aad30af8a83	P030	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b58fd3-8beb-11ea-b1fd-0aad30af8a83	P017-2-1	24b41b84-8beb-11ea-b1fd-0aad30af8a83	P017-2	24b36c03-8beb-11ea-b1fd-0aad30af8a83	P017	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6674b-8beb-11ea-b1fd-0aad30af8a83	P099-1-1	24b53f41-8beb-11ea-b1fd-0aad30af8a83	P099-1	24b3d98c-8beb-11ea-b1fd-0aad30af8a83	P099	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5951c-8beb-11ea-b1fd-0aad30af8a83	P019-2-1	24b42188-8beb-11ea-b1fd-0aad30af8a83	P019-2	24b36ef3-8beb-11ea-b1fd-0aad30af8a83	P019	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e1be-8beb-11ea-b1fd-0aad30af8a83	P049-1-1	24b48b67-8beb-11ea-b1fd-0aad30af8a83	P049-1	24b39731-8beb-11ea-b1fd-0aad30af8a83	P049	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5c051-8beb-11ea-b1fd-0aad30af8a83	P036-2-1	24b45e10-8beb-11ea-b1fd-0aad30af8a83	P036-2	24b3853f-8beb-11ea-b1fd-0aad30af8a83	P036	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b60293-8beb-11ea-b1fd-0aad30af8a83	P061-2-1	24b4b6cc-8beb-11ea-b1fd-0aad30af8a83	P061-2	24b3a835-8beb-11ea-b1fd-0aad30af8a83	P061	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b60e03-8beb-11ea-b1fd-0aad30af8a83	P066-1-1	24b4c7d6-8beb-11ea-b1fd-0aad30af8a83	P066-1	24b3ae40-8beb-11ea-b1fd-0aad30af8a83	P066	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b59f18-8beb-11ea-b1fd-0aad30af8a83	P023-1-1	24b42e21-8beb-11ea-b1fd-0aad30af8a83	P023-1	24b3753f-8beb-11ea-b1fd-0aad30af8a83	P023	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b631fb-8beb-11ea-b1fd-0aad30af8a83	P079-2-1	24b4f969-8beb-11ea-b1fd-0aad30af8a83	P079-2	24b3bff6-8beb-11ea-b1fd-0aad30af8a83	P079	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5ab1f-8beb-11ea-b1fd-0aad30af8a83	P027-2-1	24b43e17-8beb-11ea-b1fd-0aad30af8a83	P027-2	24b37a9a-8beb-11ea-b1fd-0aad30af8a83	P027	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5ca26-8beb-11ea-b1fd-0aad30af8a83	P040-1-1	24b46b32-8beb-11ea-b1fd-0aad30af8a83	P040-1	24b38ab2-8beb-11ea-b1fd-0aad30af8a83	P040	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5ec8f-8beb-11ea-b1fd-0aad30af8a83	P053-2-1	24b49a39-8beb-11ea-b1fd-0aad30af8a83	P053-2	24b39d4b-8beb-11ea-b1fd-0aad30af8a83	P053	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b644f4-8beb-11ea-b1fd-0aad30af8a83	P087-2-1	24b51694-8beb-11ea-b1fd-0aad30af8a83	P087-2	24b3cc9f-8beb-11ea-b1fd-0aad30af8a83	P087	Academia Sinica LUAD-100	Tumor	Lung	Other	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b66143-8beb-11ea-b1fd-0aad30af8a83	P096-2-1	24b536e2-8beb-11ea-b1fd-0aad30af8a83	P096-2	24b3d61f-8beb-11ea-b1fd-0aad30af8a83	P096	Academia Sinica LUAD-100	Tumor	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b67e2e-8beb-11ea-b1fd-0aad30af8a83	P111-1-1	24b55c18-8beb-11ea-b1fd-0aad30af8a83	P111-1	24b3e355-8beb-11ea-b1fd-0aad30af8a83	P111	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5d5db-8beb-11ea-b1fd-0aad30af8a83	P044-2-1	24b47a03-8beb-11ea-b1fd-0aad30af8a83	P044-2	24b39063-8beb-11ea-b1fd-0aad30af8a83	P044	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b639c9-8beb-11ea-b1fd-0aad30af8a83	P083-1-1	24b505f3-8beb-11ea-b1fd-0aad30af8a83	P083-1	24b3c64b-8beb-11ea-b1fd-0aad30af8a83	P083	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6044e-8beb-11ea-b1fd-0aad30af8a83	P062-1-1	24b4b8aa-8beb-11ea-b1fd-0aad30af8a83	P062-1	24b3a9f0-8beb-11ea-b1fd-0aad30af8a83	P062	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b583-8beb-11ea-b1fd-0aad30af8a83	P032-1-1	24b44e19-8beb-11ea-b1fd-0aad30af8a83	P032-1	24b380c7-8beb-11ea-b1fd-0aad30af8a83	P032	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b67797-8beb-11ea-b1fd-0aad30af8a83	P109-1-1	24b555af-8beb-11ea-b1fd-0aad30af8a83	P109-1	24b3df92-8beb-11ea-b1fd-0aad30af8a83	P109	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6260a-8beb-11ea-b1fd-0aad30af8a83	P075-1-1	24b4e890-8beb-11ea-b1fd-0aad30af8a83	P075-1	24b3b916-8beb-11ea-b1fd-0aad30af8a83	P075	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b58969-8beb-11ea-b1fd-0aad30af8a83	P015-1-1	24b4134a-8beb-11ea-b1fd-0aad30af8a83	P015-1	24b368d8-8beb-11ea-b1fd-0aad30af8a83	P015	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b64719-8beb-11ea-b1fd-0aad30af8a83	P088-1-1	24b5188e-8beb-11ea-b1fd-0aad30af8a83	P088-1	24b3cdba-8beb-11ea-b1fd-0aad30af8a83	P088	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5acda-8beb-11ea-b1fd-0aad30af8a83	P028-1-1	24b43f34-8beb-11ea-b1fd-0aad30af8a83	P028-1	24b37c54-8beb-11ea-b1fd-0aad30af8a83	P028	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5d909-8beb-11ea-b1fd-0aad30af8a83	P045-1-1	24b47bd5-8beb-11ea-b1fd-0aad30af8a83	P045-1	24b39145-8beb-11ea-b1fd-0aad30af8a83	P045	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5fa0a-8beb-11ea-b1fd-0aad30af8a83	P058-1-1	24b4ab50-8beb-11ea-b1fd-0aad30af8a83	P058-1	24b3a4cf-8beb-11ea-b1fd-0aad30af8a83	P058	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6148a-8beb-11ea-b1fd-0aad30af8a83	P068-2-1	24b4cf75-8beb-11ea-b1fd-0aad30af8a83	P068-2	24b3b0e7-8beb-11ea-b1fd-0aad30af8a83	P068	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5f2c4-8beb-11ea-b1fd-0aad30af8a83	P055-2-1	24b4a1db-8beb-11ea-b1fd-0aad30af8a83	P055-2	24b3a073-8beb-11ea-b1fd-0aad30af8a83	P055	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5c63a-8beb-11ea-b1fd-0aad30af8a83	P038-2-1	24b46572-8beb-11ea-b1fd-0aad30af8a83	P038-2	24b387fe-8beb-11ea-b1fd-0aad30af8a83	P038	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5a6fe-8beb-11ea-b1fd-0aad30af8a83	P025-2-1	24b43834-8beb-11ea-b1fd-0aad30af8a83	P025-2	24b3789b-8beb-11ea-b1fd-0aad30af8a83	P025	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b62b3b-8beb-11ea-b1fd-0aad30af8a83	P077-1-1	24b4ef00-8beb-11ea-b1fd-0aad30af8a83	P077-1	24b3bc2a-8beb-11ea-b1fd-0aad30af8a83	P077	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b668f4-8beb-11ea-b1fd-0aad30af8a83	P100-1-1	24b5421b-8beb-11ea-b1fd-0aad30af8a83	P100-1	24b3da66-8beb-11ea-b1fd-0aad30af8a83	P100	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b65b2c-8beb-11ea-b1fd-0aad30af8a83	P094-1-1	24b52ce2-8beb-11ea-b1fd-0aad30af8a83	P094-1	24b3d37f-8beb-11ea-b1fd-0aad30af8a83	P094	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5d1b7-8beb-11ea-b1fd-0aad30af8a83	P042-2-1	24b4744d-8beb-11ea-b1fd-0aad30af8a83	P042-2	24b38d81-8beb-11ea-b1fd-0aad30af8a83	P042	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b64031-8beb-11ea-b1fd-0aad30af8a83	P085-2-1	24b50e21-8beb-11ea-b1fd-0aad30af8a83	P085-2	24b3c95d-8beb-11ea-b1fd-0aad30af8a83	P085	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b66573-8beb-11ea-b1fd-0aad30af8a83	P098-2-1	24b53e26-8beb-11ea-b1fd-0aad30af8a83	P098-2	24b3d7bc-8beb-11ea-b1fd-0aad30af8a83	P098	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b621ff-8beb-11ea-b1fd-0aad30af8a83	P073-2-1	24b4e45b-8beb-11ea-b1fd-0aad30af8a83	P073-2	24b3b62b-8beb-11ea-b1fd-0aad30af8a83	P073	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6363a-8beb-11ea-b1fd-0aad30af8a83	P081-2-1	24b501b9-8beb-11ea-b1fd-0aad30af8a83	P081-2	24b3c33a-8beb-11ea-b1fd-0aad30af8a83	P081	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5a7ce-8beb-11ea-b1fd-0aad30af8a83	P026-1-1	24b43994-8beb-11ea-b1fd-0aad30af8a83	P026-1	24b379c5-8beb-11ea-b1fd-0aad30af8a83	P026	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b60c0e-8beb-11ea-b1fd-0aad30af8a83	P065-2-1	24b4c67c-8beb-11ea-b1fd-0aad30af8a83	P065-2	24b3ad62-8beb-11ea-b1fd-0aad30af8a83	P065	Academia Sinica LUAD-100	Tumor	Lung	Other	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b5c94e-8beb-11ea-b1fd-0aad30af8a83	P039-2-1	24b46943-8beb-11ea-b1fd-0aad30af8a83	P039-2	24b388cc-8beb-11ea-b1fd-0aad30af8a83	P039	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b65ddf-8beb-11ea-b1fd-0aad30af8a83	P095-1-1	24b530b1-8beb-11ea-b1fd-0aad30af8a83	P095-1	24b3d53f-8beb-11ea-b1fd-0aad30af8a83	P095	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e8db-8beb-11ea-b1fd-0aad30af8a83	P052-1-1	24b494c7-8beb-11ea-b1fd-0aad30af8a83	P052-1	24b39c6d-8beb-11ea-b1fd-0aad30af8a83	P052	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5ff42-8beb-11ea-b1fd-0aad30af8a83	P060-1-1	24b4b10d-8beb-11ea-b1fd-0aad30af8a83	P060-1	24b3a764-8beb-11ea-b1fd-0aad30af8a83	P060	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5bb00-8beb-11ea-b1fd-0aad30af8a83	P034-1-1	24b4558d-8beb-11ea-b1fd-0aad30af8a83	P034-1	24b38358-8beb-11ea-b1fd-0aad30af8a83	P034	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5de45-8beb-11ea-b1fd-0aad30af8a83	P047-2-1	24b48563-8beb-11ea-b1fd-0aad30af8a83	P047-2	24b39432-8beb-11ea-b1fd-0aad30af8a83	P047	Academia Sinica LUAD-100	Tumor	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b1f2-8beb-11ea-b1fd-0aad30af8a83	P030-2-1	24b4484d-8beb-11ea-b1fd-0aad30af8a83	P030-2	24b37e04-8beb-11ea-b1fd-0aad30af8a83	P030	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e39e-8beb-11ea-b1fd-0aad30af8a83	P049-2-1	24b48d8b-8beb-11ea-b1fd-0aad30af8a83	P049-2	24b39731-8beb-11ea-b1fd-0aad30af8a83	P049	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b64427-8beb-11ea-b1fd-0aad30af8a83	P087-1-1	24b514a0-8beb-11ea-b1fd-0aad30af8a83	P087-1	24b3cc9f-8beb-11ea-b1fd-0aad30af8a83	P087	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Other	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5889d-8beb-11ea-b1fd-0aad30af8a83	P014-2-1	24b4120b-8beb-11ea-b1fd-0aad30af8a83	P014-2	24b36807-8beb-11ea-b1fd-0aad30af8a83	P014	Academia Sinica LUAD-100	Tumor	Lung	Other	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b5bf87-8beb-11ea-b1fd-0aad30af8a83	P036-1-1	24b45c08-8beb-11ea-b1fd-0aad30af8a83	P036-1	24b3853f-8beb-11ea-b1fd-0aad30af8a83	P036	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b63111-8beb-11ea-b1fd-0aad30af8a83	P079-1-1	24b4f743-8beb-11ea-b1fd-0aad30af8a83	P079-1	24b3bff6-8beb-11ea-b1fd-0aad30af8a83	P079	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b59e3c-8beb-11ea-b1fd-0aad30af8a83	P022-2-1	24b42c31-8beb-11ea-b1fd-0aad30af8a83	P022-2	24b372d1-8beb-11ea-b1fd-0aad30af8a83	P022	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b63bb2-8beb-11ea-b1fd-0aad30af8a83	P083-2-1	24b507aa-8beb-11ea-b1fd-0aad30af8a83	P083-2	24b3c64b-8beb-11ea-b1fd-0aad30af8a83	P083	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5cc74-8beb-11ea-b1fd-0aad30af8a83	P040-2-1	24b46d24-8beb-11ea-b1fd-0aad30af8a83	P040-2	24b38ab2-8beb-11ea-b1fd-0aad30af8a83	P040	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5f933-8beb-11ea-b1fd-0aad30af8a83	P057-2-1	24b4a9e8-8beb-11ea-b1fd-0aad30af8a83	P057-2	24b3a3f4-8beb-11ea-b1fd-0aad30af8a83	P057	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b67f0e-8beb-11ea-b1fd-0aad30af8a83	P111-2-1	24b55e05-8beb-11ea-b1fd-0aad30af8a83	P111-2	24b3e355-8beb-11ea-b1fd-0aad30af8a83	P111	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b590a3-8beb-11ea-b1fd-0aad30af8a83	P018-1-1	24b41cef-8beb-11ea-b1fd-0aad30af8a83	P018-1	24b36cd2-8beb-11ea-b1fd-0aad30af8a83	P018	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5d50b-8beb-11ea-b1fd-0aad30af8a83	P044-1-1	24b47837-8beb-11ea-b1fd-0aad30af8a83	P044-1	24b39063-8beb-11ea-b1fd-0aad30af8a83	P044	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b610e5-8beb-11ea-b1fd-0aad30af8a83	P067-1-1	24b4cad3-8beb-11ea-b1fd-0aad30af8a83	P067-1	24b3af11-8beb-11ea-b1fd-0aad30af8a83	P067	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b047-8beb-11ea-b1fd-0aad30af8a83	P029-2-1	24b44490-8beb-11ea-b1fd-0aad30af8a83	P029-2	24b37d32-8beb-11ea-b1fd-0aad30af8a83	P029	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6286a-8beb-11ea-b1fd-0aad30af8a83	P075-2-1	24b4ea4e-8beb-11ea-b1fd-0aad30af8a83	P075-2	24b3b916-8beb-11ea-b1fd-0aad30af8a83	P075	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5a27d-8beb-11ea-b1fd-0aad30af8a83	P024-1-1	24b43213-8beb-11ea-b1fd-0aad30af8a83	P024-1	24b37628-8beb-11ea-b1fd-0aad30af8a83	P024	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b68486-8beb-11ea-b1fd-0aad30af8a83	QC1_(Tumor+Adjacent Normal)pool	24b56212-8beb-11ea-b1fd-0aad30af8a83	QC1_(Tumor+Adjacent Normal)pool	24b3e63b-8beb-11ea-b1fd-0aad30af8a83	QC1_(Tumor+Adjacent Normal)pool	Academia Sinica LUAD-100	Not Reported	Lung	Other	yes	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b647f2-8beb-11ea-b1fd-0aad30af8a83	P088-2-1	24b51a89-8beb-11ea-b1fd-0aad30af8a83	P088-2	24b3cdba-8beb-11ea-b1fd-0aad30af8a83	P088	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5eedb-8beb-11ea-b1fd-0aad30af8a83	P054-1-1	24b49c1e-8beb-11ea-b1fd-0aad30af8a83	P054-1	24b39f91-8beb-11ea-b1fd-0aad30af8a83	P054	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b76a-8beb-11ea-b1fd-0aad30af8a83	P032-2-1	24b45015-8beb-11ea-b1fd-0aad30af8a83	P032-2	24b380c7-8beb-11ea-b1fd-0aad30af8a83	P032	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5d9fc-8beb-11ea-b1fd-0aad30af8a83	P045-2-1	24b47dac-8beb-11ea-b1fd-0aad30af8a83	P045-2	24b39145-8beb-11ea-b1fd-0aad30af8a83	P045	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6620f-8beb-11ea-b1fd-0aad30af8a83	P097-1-1	24b538ed-8beb-11ea-b1fd-0aad30af8a83	P097-1	24b3d6ed-8beb-11ea-b1fd-0aad30af8a83	P097	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b59824-8beb-11ea-b1fd-0aad30af8a83	P020-2-1	24b42468-8beb-11ea-b1fd-0aad30af8a83	P020-2	24b36fce-8beb-11ea-b1fd-0aad30af8a83	P020	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b659de-8beb-11ea-b1fd-0aad30af8a83	P093-2-1	24b52b01-8beb-11ea-b1fd-0aad30af8a83	P093-2	24b3d2b5-8beb-11ea-b1fd-0aad30af8a83	P093	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b607c1-8beb-11ea-b1fd-0aad30af8a83	P063-2-1	24b4be61-8beb-11ea-b1fd-0aad30af8a83	P063-2	24b3aace-8beb-11ea-b1fd-0aad30af8a83	P063	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b62ce7-8beb-11ea-b1fd-0aad30af8a83	P077-2-1	24b4f0d4-8beb-11ea-b1fd-0aad30af8a83	P077-2	24b3bc2a-8beb-11ea-b1fd-0aad30af8a83	P077	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5c40a-8beb-11ea-b1fd-0aad30af8a83	P038-1-1	24b46393-8beb-11ea-b1fd-0aad30af8a83	P038-1	24b387fe-8beb-11ea-b1fd-0aad30af8a83	P038	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e541-8beb-11ea-b1fd-0aad30af8a83	P050-2-1	24b490a2-8beb-11ea-b1fd-0aad30af8a83	P050-2	24b3995c-8beb-11ea-b1fd-0aad30af8a83	P050	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b58cf9-8beb-11ea-b1fd-0aad30af8a83	P016-2-1	24b4185a-8beb-11ea-b1fd-0aad30af8a83	P016-2	24b36b1d-8beb-11ea-b1fd-0aad30af8a83	P016	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5d0a2-8beb-11ea-b1fd-0aad30af8a83	P042-1-1	24b47291-8beb-11ea-b1fd-0aad30af8a83	P042-1	24b38d81-8beb-11ea-b1fd-0aad30af8a83	P042	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b63f56-8beb-11ea-b1fd-0aad30af8a83	P085-1-1	24b50c4c-8beb-11ea-b1fd-0aad30af8a83	P085-1	24b3c95d-8beb-11ea-b1fd-0aad30af8a83	P085	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5fe6f-8beb-11ea-b1fd-0aad30af8a83	P059-2-1	24b4aff1-8beb-11ea-b1fd-0aad30af8a83	P059-2	24b3a683-8beb-11ea-b1fd-0aad30af8a83	P059	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b59356-8beb-11ea-b1fd-0aad30af8a83	P018-2-1	24b41eae-8beb-11ea-b1fd-0aad30af8a83	P018-2	24b36cd2-8beb-11ea-b1fd-0aad30af8a83	P018	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5d436-8beb-11ea-b1fd-0aad30af8a83	P043-2-1	24b4771f-8beb-11ea-b1fd-0aad30af8a83	P043-2	24b38e5d-8beb-11ea-b1fd-0aad30af8a83	P043	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b64342-8beb-11ea-b1fd-0aad30af8a83	P086-2-1	24b512ab-8beb-11ea-b1fd-0aad30af8a83	P086-2	24b3cbab-8beb-11ea-b1fd-0aad30af8a83	P086	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e01b-8beb-11ea-b1fd-0aad30af8a83	P048-1-1	24b4875f-8beb-11ea-b1fd-0aad30af8a83	P048-1	24b39652-8beb-11ea-b1fd-0aad30af8a83	P048	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5a97d-8beb-11ea-b1fd-0aad30af8a83	P026-2-1	24b43b50-8beb-11ea-b1fd-0aad30af8a83	P026-2	24b379c5-8beb-11ea-b1fd-0aad30af8a83	P026	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b62e8e-8beb-11ea-b1fd-0aad30af8a83	P078-2-1	24b4f4b1-8beb-11ea-b1fd-0aad30af8a83	P078-2	24b3bef1-8beb-11ea-b1fd-0aad30af8a83	P078	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b65eac-8beb-11ea-b1fd-0aad30af8a83	P095-2-1	24b532a5-8beb-11ea-b1fd-0aad30af8a83	P095-2	24b3d53f-8beb-11ea-b1fd-0aad30af8a83	P095	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5eae7-8beb-11ea-b1fd-0aad30af8a83	P052-2-1	24b4968e-8beb-11ea-b1fd-0aad30af8a83	P052-2	24b39c6d-8beb-11ea-b1fd-0aad30af8a83	P052	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b60b37-8beb-11ea-b1fd-0aad30af8a83	P065-1-1	24b4c465-8beb-11ea-b1fd-0aad30af8a83	P065-1	24b3ad62-8beb-11ea-b1fd-0aad30af8a83	P065	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Other	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b600f7-8beb-11ea-b1fd-0aad30af8a83	P060-2-1	24b4b30e-8beb-11ea-b1fd-0aad30af8a83	P060-2	24b3a764-8beb-11ea-b1fd-0aad30af8a83	P060	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b63814-8beb-11ea-b1fd-0aad30af8a83	P082-1-1	24b5031d-8beb-11ea-b1fd-0aad30af8a83	P082-1	24b3c56f-8beb-11ea-b1fd-0aad30af8a83	P082	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b67ac8-8beb-11ea-b1fd-0aad30af8a83	P110-1-1	24b5592a-8beb-11ea-b1fd-0aad30af8a83	P110-1	24b3e25f-8beb-11ea-b1fd-0aad30af8a83	P110	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b622d6-8beb-11ea-b1fd-0aad30af8a83	P074-1-1	24b4e5b8-8beb-11ea-b1fd-0aad30af8a83	P074-1	24b3b837-8beb-11ea-b1fd-0aad30af8a83	P074	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b3da-8beb-11ea-b1fd-0aad30af8a83	P031-1-1	24b44a3c-8beb-11ea-b1fd-0aad30af8a83	P031-1	24b37fe2-8beb-11ea-b1fd-0aad30af8a83	P031	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b587c5-8beb-11ea-b1fd-0aad30af8a83	P014-1-1	24b4102c-8beb-11ea-b1fd-0aad30af8a83	P014-1	24b36807-8beb-11ea-b1fd-0aad30af8a83	P014	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Other	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b59bf9-8beb-11ea-b1fd-0aad30af8a83	P022-1-1	24b42a44-8beb-11ea-b1fd-0aad30af8a83	P022-1	24b372d1-8beb-11ea-b1fd-0aad30af8a83	P022	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5beb1-8beb-11ea-b1fd-0aad30af8a83	P035-2-1	24b45ac2-8beb-11ea-b1fd-0aad30af8a83	P035-2	24b3845b-8beb-11ea-b1fd-0aad30af8a83	P035	Academia Sinica LUAD-100	Tumor	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5f6d9-8beb-11ea-b1fd-0aad30af8a83	P057-1-1	24b4a7cd-8beb-11ea-b1fd-0aad30af8a83	P057-1	24b3a3f4-8beb-11ea-b1fd-0aad30af8a83	P057	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5c345-8beb-11ea-b1fd-0aad30af8a83	P037-2-1	24b461ba-8beb-11ea-b1fd-0aad30af8a83	P037-2	24b3871b-8beb-11ea-b1fd-0aad30af8a83	P037	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b611b8-8beb-11ea-b1fd-0aad30af8a83	P067-2-1	24b4cc91-8beb-11ea-b1fd-0aad30af8a83	P067-2	24b3af11-8beb-11ea-b1fd-0aad30af8a83	P067	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5efbe-8beb-11ea-b1fd-0aad30af8a83	P054-2-1	24b49e02-8beb-11ea-b1fd-0aad30af8a83	P054-2	24b39f91-8beb-11ea-b1fd-0aad30af8a83	P054	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5a4ea-8beb-11ea-b1fd-0aad30af8a83	P024-2-1	24b43412-8beb-11ea-b1fd-0aad30af8a83	P024-2	24b37628-8beb-11ea-b1fd-0aad30af8a83	P024	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b68158-8beb-11ea-b1fd-0aad30af8a83	P112-1-1	24b55f22-8beb-11ea-b1fd-0aad30af8a83	P112-1	24b3e42e-8beb-11ea-b1fd-0aad30af8a83	P112	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5cfb7-8beb-11ea-b1fd-0aad30af8a83	P041-2-1	24b47135-8beb-11ea-b1fd-0aad30af8a83	P041-2	24b38b8f-8beb-11ea-b1fd-0aad30af8a83	P041	Academia Sinica LUAD-100	Tumor	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b663d6-8beb-11ea-b1fd-0aad30af8a83	P097-2-1	24b53b0e-8beb-11ea-b1fd-0aad30af8a83	P097-2	24b3d6ed-8beb-11ea-b1fd-0aad30af8a83	P097	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b63d5c-8beb-11ea-b1fd-0aad30af8a83	P084-2-1	24b50a79-8beb-11ea-b1fd-0aad30af8a83	P084-2	24b3c882-8beb-11ea-b1fd-0aad30af8a83	P084	Academia Sinica LUAD-100	Tumor	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5e475-8beb-11ea-b1fd-0aad30af8a83	P050-1-1	24b48ee8-8beb-11ea-b1fd-0aad30af8a83	P050-1	24b3995c-8beb-11ea-b1fd-0aad30af8a83	P050	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b632c7-8beb-11ea-b1fd-0aad30af8a83	P080-1-1	24b4fb62-8beb-11ea-b1fd-0aad30af8a83	P080-1	24b3c21f-8beb-11ea-b1fd-0aad30af8a83	P080	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b59747-8beb-11ea-b1fd-0aad30af8a83	P020-1-1	24b4229c-8beb-11ea-b1fd-0aad30af8a83	P020-1	24b36fce-8beb-11ea-b1fd-0aad30af8a83	P020	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b65576-8beb-11ea-b1fd-0aad30af8a83	P093-1-1	24b52932-8beb-11ea-b1fd-0aad30af8a83	P093-1	24b3d2b5-8beb-11ea-b1fd-0aad30af8a83	P093	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b62956-8beb-11ea-b1fd-0aad30af8a83	P076-1-1	24b4eb63-8beb-11ea-b1fd-0aad30af8a83	P076-1	24b3bb45-8beb-11ea-b1fd-0aad30af8a83	P076	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b605f0-8beb-11ea-b1fd-0aad30af8a83	P063-1-1	24b4bc76-8beb-11ea-b1fd-0aad30af8a83	P063-1	24b3aace-8beb-11ea-b1fd-0aad30af8a83	P063	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b58c2a-8beb-11ea-b1fd-0aad30af8a83	P016-1-1	24b4166c-8beb-11ea-b1fd-0aad30af8a83	P016-1	24b36b1d-8beb-11ea-b1fd-0aad30af8a83	P016	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5dac6-8beb-11ea-b1fd-0aad30af8a83	P046-1-1	24b47f8a-8beb-11ea-b1fd-0aad30af8a83	P046-1	24b39353-8beb-11ea-b1fd-0aad30af8a83	P046	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5ae85-8beb-11ea-b1fd-0aad30af8a83	P029-1-1	24b442c0-8beb-11ea-b1fd-0aad30af8a83	P029-1	24b37d32-8beb-11ea-b1fd-0aad30af8a83	P029	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5b83f-8beb-11ea-b1fd-0aad30af8a83	P033-1-1	24b45214-8beb-11ea-b1fd-0aad30af8a83	P033-1	24b38193-8beb-11ea-b1fd-0aad30af8a83	P033	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5fd5b-8beb-11ea-b1fd-0aad30af8a83	P059-1-1	24b4ae2c-8beb-11ea-b1fd-0aad30af8a83	P059-1	24b3a683-8beb-11ea-b1fd-0aad30af8a83	P059	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
df50cced-8f98-11ea-b1fd-0aad30af8a83	CPT0163610003	df4fbd53-8f98-11ea-b1fd-0aad30af8a83	C3N-01946-04	df4ed85e-8f98-11ea-b1fd-0aad30af8a83	C3N-01946	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50b541-8f98-11ea-b1fd-0aad30af8a83	CPT0162990004	df4fa031-8f98-11ea-b1fd-0aad30af8a83	C3N-01754-02	df4ecd30-8f98-11ea-b1fd-0aad30af8a83	C3N-01754	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df506ba0-8f98-11ea-b1fd-0aad30af8a83	CPT0199710003	df4f4654-8f98-11ea-b1fd-0aad30af8a83	C3L-01138-06	df4e9d3d-8f98-11ea-b1fd-0aad30af8a83	C3L-01138	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
df512b28-8f98-11ea-b1fd-0aad30af8a83	CPT0222180003	df502af8-8f98-11ea-b1fd-0aad30af8a83	C3N-03888-02	df4f1689-8f98-11ea-b1fd-0aad30af8a83	C3N-03888	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51453b-8f98-11ea-b1fd-0aad30af8a83	CPT0245600003	df5048c8-8f98-11ea-b1fd-0aad30af8a83	C3N-04280-03	df4f238b-8f98-11ea-b1fd-0aad30af8a83	C3N-04280	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50cb07-8f98-11ea-b1fd-0aad30af8a83	CPT0163530003	df4fb9da-8f98-11ea-b1fd-0aad30af8a83	C3N-01945-01	df4ed786-8f98-11ea-b1fd-0aad30af8a83	C3N-01945	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50ed94-8f98-11ea-b1fd-0aad30af8a83	CPT0226250004	df4fe2c7-8f98-11ea-b1fd-0aad30af8a83	C3N-03011-01	df4ef10e-8f98-11ea-b1fd-0aad30af8a83	C3N-03011	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5081d3-8f98-11ea-b1fd-0aad30af8a83	CPT0250310003	df4f6161-8f98-11ea-b1fd-0aad30af8a83	C3L-04791-04	df4ea9fe-8f98-11ea-b1fd-0aad30af8a83	C3L-04791	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5098af-8f98-11ea-b1fd-0aad30af8a83	CPT0087820003	df4f7dc3-8f98-11ea-b1fd-0aad30af8a83	C3N-00822-01	df4eb76a-8f98-11ea-b1fd-0aad30af8a83	C3N-00822	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df505f66-8f98-11ea-b1fd-0aad30af8a83	CPT0169730003	df4f373c-8f98-11ea-b1fd-0aad30af8a83	C3L-00994-04	df4e970b-8f98-11ea-b1fd-0aad30af8a83	C3L-00994	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e9e4-8f98-11ea-b1fd-0aad30af8a83	CPT0245010003	df4fdeb5-8f98-11ea-b1fd-0aad30af8a83	C3N-03008-01	df4eef1c-8f98-11ea-b1fd-0aad30af8a83	C3N-03008	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df508db6-8f98-11ea-b1fd-0aad30af8a83	CPT0008630003	df4f6fc0-8f98-11ea-b1fd-0aad30af8a83	C3N-00299-02	df4eb20d-8f98-11ea-b1fd-0aad30af8a83	C3N-00299	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50b610-8f98-11ea-b1fd-0aad30af8a83	CPT0163020003	df4fa14c-8f98-11ea-b1fd-0aad30af8a83	C3N-01754-05	df4ecd30-8f98-11ea-b1fd-0aad30af8a83	C3N-01754	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50b995-8f98-11ea-b1fd-0aad30af8a83	CPT0163170003	df4fa6c0-8f98-11ea-b1fd-0aad30af8a83	C3N-01756-05	df4ecf32-8f98-11ea-b1fd-0aad30af8a83	C3N-01756	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df508cdd-8f98-11ea-b1fd-0aad30af8a83	CPT0011130005	df4f6eac-8f98-11ea-b1fd-0aad30af8a83	C3N-00297-02	df4eb063-8f98-11ea-b1fd-0aad30af8a83	C3N-00297	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50d04a-8f98-11ea-b1fd-0aad30af8a83	CPT0226090003	df4fc033-8f98-11ea-b1fd-0aad30af8a83	C3N-01947-05	df4eda1a-8f98-11ea-b1fd-0aad30af8a83	C3N-01947	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510edf-8f98-11ea-b1fd-0aad30af8a83	CPT0194790003	df5009af-8f98-11ea-b1fd-0aad30af8a83	C3N-03612-03	df4f05ee-8f98-11ea-b1fd-0aad30af8a83	C3N-03612	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50db02-8f98-11ea-b1fd-0aad30af8a83	CPT0226130003	df4fcada-8f98-11ea-b1fd-0aad30af8a83	C3N-02693-01	df4ee063-8f98-11ea-b1fd-0aad30af8a83	C3N-02693	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
df50d2c4-8f98-11ea-b1fd-0aad30af8a83	CPT0163650003	df4fc20a-8f98-11ea-b1fd-0aad30af8a83	C3N-01948-01	df4edaf6-8f98-11ea-b1fd-0aad30af8a83	C3N-01948	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50ad85-8f98-11ea-b1fd-0aad30af8a83	CPT0094580003	df4f95b6-8f98-11ea-b1fd-0aad30af8a83	C3N-01340-05	df4ec539-8f98-11ea-b1fd-0aad30af8a83	C3N-01340	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50f21f-8f98-11ea-b1fd-0aad30af8a83	CPT0245130003	df4fe9e1-8f98-11ea-b1fd-0aad30af8a83	C3N-03013-01	df4ef386-8f98-11ea-b1fd-0aad30af8a83	C3N-03013	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df511542-8f98-11ea-b1fd-0aad30af8a83	CPT0196060003	df50116d-8f98-11ea-b1fd-0aad30af8a83	C3N-03620-06	df4f08ad-8f98-11ea-b1fd-0aad30af8a83	C3N-03620	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df511904-8f98-11ea-b1fd-0aad30af8a83	CPT0245560003	df501689-8f98-11ea-b1fd-0aad30af8a83	C3N-03781-04	df4f0b7a-8f98-11ea-b1fd-0aad30af8a83	C3N-03781	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df513064-8f98-11ea-b1fd-0aad30af8a83	CPT0223460003	df503207-8f98-11ea-b1fd-0aad30af8a83	C3N-03928-06	df4f1907-8f98-11ea-b1fd-0aad30af8a83	C3N-03928	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df513b7f-8f98-11ea-b1fd-0aad30af8a83	C3N-04276-06	df503d83-8f98-11ea-b1fd-0aad30af8a83	C3N-04276-06	df4f1ef8-8f98-11ea-b1fd-0aad30af8a83	C3N-04276	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50bfe8-8f98-11ea-b1fd-0aad30af8a83	CPT0163840003	df4fae2e-8f98-11ea-b1fd-0aad30af8a83	C3N-01858-01	df4ed282-8f98-11ea-b1fd-0aad30af8a83	C3N-01858	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e397-8f98-11ea-b1fd-0aad30af8a83	CPT0177220003	df4fd726-8f98-11ea-b1fd-0aad30af8a83	C3N-02714-06	df4ee821-8f98-11ea-b1fd-0aad30af8a83	C3N-02714	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50fcbc-8f98-11ea-b1fd-0aad30af8a83	CPT0226450003	df4ff3b8-8f98-11ea-b1fd-0aad30af8a83	C3N-03028-04	df4ef7ac-8f98-11ea-b1fd-0aad30af8a83	C3N-03028	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50c466-8f98-11ea-b1fd-0aad30af8a83	CPT0163410003	df4fb3e3-8f98-11ea-b1fd-0aad30af8a83	C3N-01943-02	df4ed504-8f98-11ea-b1fd-0aad30af8a83	C3N-01943	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50de76-8f98-11ea-b1fd-0aad30af8a83	CPT0244940004	df4fcf01-8f98-11ea-b1fd-0aad30af8a83	C3N-02695-01	df4ee338-8f98-11ea-b1fd-0aad30af8a83	C3N-02695	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5133e4-8f98-11ea-b1fd-0aad30af8a83	CPT0223970003	df503688-8f98-11ea-b1fd-0aad30af8a83	C3N-04152-01	df4f1b8c-8f98-11ea-b1fd-0aad30af8a83	C3N-04152	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df514e80-8f98-11ea-b1fd-0aad30af8a83	QC1	df50514e-8f98-11ea-b1fd-0aad30af8a83	QC1	df4f2aaf-8f98-11ea-b1fd-0aad30af8a83	QC1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df516716-8f98-11ea-b1fd-0aad30af8a83	QC3	df505445-8f98-11ea-b1fd-0aad30af8a83	QC3	df4f2d98-8f98-11ea-b1fd-0aad30af8a83	QC3	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df506824-8f98-11ea-b1fd-0aad30af8a83	CPT0123260003	df4f4220-8f98-11ea-b1fd-0aad30af8a83	C3L-00999-01	df4e9b42-8f98-11ea-b1fd-0aad30af8a83	C3L-00999	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51161d-8f98-11ea-b1fd-0aad30af8a83	CPT0196210003	df501289-8f98-11ea-b1fd-0aad30af8a83	C3N-03664-01	df4f0a9f-8f98-11ea-b1fd-0aad30af8a83	C3N-03664	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df506c7d-8f98-11ea-b1fd-0aad30af8a83	CPT0199820003	df4f486a-8f98-11ea-b1fd-0aad30af8a83	C3L-01237-04	df4e9e22-8f98-11ea-b1fd-0aad30af8a83	C3L-01237	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5164d2-8f98-11ea-b1fd-0aad30af8a83	QC2	df50532c-8f98-11ea-b1fd-0aad30af8a83	QC2	df4f2cbd-8f98-11ea-b1fd-0aad30af8a83	QC2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df513e8d-8f98-11ea-b1fd-0aad30af8a83	CPT0245410003	df504083-8f98-11ea-b1fd-0aad30af8a83	C3N-04277-04	df4f1fff-8f98-11ea-b1fd-0aad30af8a83	C3N-04277	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51694f-8f98-11ea-b1fd-0aad30af8a83	QC5	df505740-8f98-11ea-b1fd-0aad30af8a83	QC5	df4f3083-8f98-11ea-b1fd-0aad30af8a83	QC5	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51686d-8f98-11ea-b1fd-0aad30af8a83	QC4	df505628-8f98-11ea-b1fd-0aad30af8a83	QC4	df4f2e68-8f98-11ea-b1fd-0aad30af8a83	QC4	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df516aed-8f98-11ea-b1fd-0aad30af8a83	QC7	df505a59-8f98-11ea-b1fd-0aad30af8a83	QC7	df4f3281-8f98-11ea-b1fd-0aad30af8a83	QC7	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df516a1d-8f98-11ea-b1fd-0aad30af8a83	QC6	df50592c-8f98-11ea-b1fd-0aad30af8a83	QC6	df4f3172-8f98-11ea-b1fd-0aad30af8a83	QC6	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50b7e9-8f98-11ea-b1fd-0aad30af8a83	CPT0163090003	df4fa33f-8f98-11ea-b1fd-0aad30af8a83	C3N-01755-01	df4ece54-8f98-11ea-b1fd-0aad30af8a83	C3N-01755	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df516c96-8f98-11ea-b1fd-0aad30af8a83	QC9	df505bb2-8f98-11ea-b1fd-0aad30af8a83	QC9	df4f334e-8f98-11ea-b1fd-0aad30af8a83	QC9	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50a065-8f98-11ea-b1fd-0aad30af8a83	CPT0094350004	df4f8687-8f98-11ea-b1fd-0aad30af8a83	C3N-00857-01	df4ebebb-8f98-11ea-b1fd-0aad30af8a83	C3N-00857	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5064a4-8f98-11ea-b1fd-0aad30af8a83	CPT0169920003	df4f3d3f-8f98-11ea-b1fd-0aad30af8a83	C3L-00995-06	df4e9966-8f98-11ea-b1fd-0aad30af8a83	C3L-00995	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e90b-8f98-11ea-b1fd-0aad30af8a83	CPT0184530003	df4fdce6-8f98-11ea-b1fd-0aad30af8a83	C3N-02925-01	df4eee28-8f98-11ea-b1fd-0aad30af8a83	C3N-02925	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510fa7-8f98-11ea-b1fd-0aad30af8a83	CPT0194800003	df500b7f-8f98-11ea-b1fd-0aad30af8a83	C3N-03612-06	df4f05ee-8f98-11ea-b1fd-0aad30af8a83	C3N-03612	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
df50b296-8f98-11ea-b1fd-0aad30af8a83	CPT0088430003	df4f9d3a-8f98-11ea-b1fd-0aad30af8a83	C3N-01645-05	df4eca22-8f98-11ea-b1fd-0aad30af8a83	C3N-01645	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50fd90-8f98-11ea-b1fd-0aad30af8a83	CPT0235460003	df4ff584-8f98-11ea-b1fd-0aad30af8a83	C3N-03042-04	df4ef87b-8f98-11ea-b1fd-0aad30af8a83	C3N-03042	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510c28-8f98-11ea-b1fd-0aad30af8a83	CPT0195680003	df5006db-8f98-11ea-b1fd-0aad30af8a83	C3N-03490-02	df4f0514-8f98-11ea-b1fd-0aad30af8a83	C3N-03490	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df512406-8f98-11ea-b1fd-0aad30af8a83	CPT0237130004	df502226-8f98-11ea-b1fd-0aad30af8a83	C3N-03849-01	df4f1344-8f98-11ea-b1fd-0aad30af8a83	C3N-03849	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50d65f-8f98-11ea-b1fd-0aad30af8a83	CPT0163790003	df4fc613-8f98-11ea-b1fd-0aad30af8a83	C3N-02279-01	df4eddbb-8f98-11ea-b1fd-0aad30af8a83	C3N-02279	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df513990-8f98-11ea-b1fd-0aad30af8a83	CPT0245350003	df503c6f-8f98-11ea-b1fd-0aad30af8a83	C3N-04276-01	df4f1ef8-8f98-11ea-b1fd-0aad30af8a83	C3N-04276	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50a68b-8f98-11ea-b1fd-0aad30af8a83	CPT0088010003	df4f8dc3-8f98-11ea-b1fd-0aad30af8a83	C3N-01337-06	df4ec190-8f98-11ea-b1fd-0aad30af8a83	C3N-01337	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5080ab-8f98-11ea-b1fd-0aad30af8a83	CPT0243140004	df4f5ff9-8f98-11ea-b1fd-0aad30af8a83	C3L-04354-07	df4ea7d8-8f98-11ea-b1fd-0aad30af8a83	C3L-04354	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50dcae-8f98-11ea-b1fd-0aad30af8a83	CPT0244890004	df4fcdf1-8f98-11ea-b1fd-0aad30af8a83	C3N-02694-02	df4ee240-8f98-11ea-b1fd-0aad30af8a83	C3N-02694	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e018-8f98-11ea-b1fd-0aad30af8a83	CPT0190850003	df4fd2ff-8f98-11ea-b1fd-0aad30af8a83	C3N-02713-03	df4ee623-8f98-11ea-b1fd-0aad30af8a83	C3N-02713	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df509f96-8f98-11ea-b1fd-0aad30af8a83	CPT0024810003	df4f856c-8f98-11ea-b1fd-0aad30af8a83	C3N-00846-02	df4ebcaf-8f98-11ea-b1fd-0aad30af8a83	C3N-00846	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50f602-8f98-11ea-b1fd-0aad30af8a83	CPT0245190003	df4fee1e-8f98-11ea-b1fd-0aad30af8a83	C3N-03015-02	df4ef458-8f98-11ea-b1fd-0aad30af8a83	C3N-03015	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50c390-8f98-11ea-b1fd-0aad30af8a83	C3N-01859-04	df4fb20a-8f98-11ea-b1fd-0aad30af8a83	C3N-01859-04	df4ed42c-8f98-11ea-b1fd-0aad30af8a83	C3N-01859	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50dbdf-8f98-11ea-b1fd-0aad30af8a83	C3N-02693-06	df4fcbfb-8f98-11ea-b1fd-0aad30af8a83	C3N-02693-06	df4ee063-8f98-11ea-b1fd-0aad30af8a83	C3N-02693	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df514da7-8f98-11ea-b1fd-0aad30af8a83	LungTumor3	df50503b-8f98-11ea-b1fd-0aad30af8a83	LungTumor3	df4f29e2-8f98-11ea-b1fd-0aad30af8a83	LungTumor3	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df514a7c-8f98-11ea-b1fd-0aad30af8a83	LungTumor1	df504d5d-8f98-11ea-b1fd-0aad30af8a83	LungTumor1	df4f2713-8f98-11ea-b1fd-0aad30af8a83	LungTumor1	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df514b5c-8f98-11ea-b1fd-0aad30af8a83	LungTumor2	df504e71-8f98-11ea-b1fd-0aad30af8a83	LungTumor2	df4f290c-8f98-11ea-b1fd-0aad30af8a83	LungTumor2	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510a84-8f98-11ea-b1fd-0aad30af8a83	CPT0194250003	df500413-8f98-11ea-b1fd-0aad30af8a83	C3N-03488-03	df4f0338-8f98-11ea-b1fd-0aad30af8a83	C3N-03488	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5068fc-8f98-11ea-b1fd-0aad30af8a83	CPT0123280003	df4f433c-8f98-11ea-b1fd-0aad30af8a83	C3L-00999-06	df4e9b42-8f98-11ea-b1fd-0aad30af8a83	C3L-00999	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50d73a-8f98-11ea-b1fd-0aad30af8a83	CPT0163800003	df4fc7e1-8f98-11ea-b1fd-0aad30af8a83	C3N-02279-05	df4eddbb-8f98-11ea-b1fd-0aad30af8a83	C3N-02279	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5119dc-8f98-11ea-b1fd-0aad30af8a83	CPT0245630003	df5017ed-8f98-11ea-b1fd-0aad30af8a83	C3N-03782-01	df4f0d7f-8f98-11ea-b1fd-0aad30af8a83	C3N-03782	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df508891-8f98-11ea-b1fd-0aad30af8a83	CPT0084650004	df4f69f2-8f98-11ea-b1fd-0aad30af8a83	C3N-00204-06	df4eaeb4-8f98-11ea-b1fd-0aad30af8a83	C3N-00204	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50fb9e-8f98-11ea-b1fd-0aad30af8a83	CPT0226440003	df4ff2b1-8f98-11ea-b1fd-0aad30af8a83	C3N-03028-01	df4ef7ac-8f98-11ea-b1fd-0aad30af8a83	C3N-03028	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df512890-8f98-11ea-b1fd-0aad30af8a83	CPT0237620004	df5027fb-8f98-11ea-b1fd-0aad30af8a83	C3N-03878-01	df4f15be-8f98-11ea-b1fd-0aad30af8a83	C3N-03878	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51483a-8f98-11ea-b1fd-0aad30af8a83	pooled sample	df504b9a-8f98-11ea-b1fd-0aad30af8a83	pooled sample	df4f263e-8f98-11ea-b1fd-0aad30af8a83	pooled sample	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5138b9-8f98-11ea-b1fd-0aad30af8a83	C3N-04275-05	df503a8f-8f98-11ea-b1fd-0aad30af8a83	C3N-04275-05	df4f1d2d-8f98-11ea-b1fd-0aad30af8a83	C3N-04275	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5108a2-8f98-11ea-b1fd-0aad30af8a83	CPT0194960003	df5002fa-8f98-11ea-b1fd-0aad30af8a83	C3N-03487-02	df4f0263-8f98-11ea-b1fd-0aad30af8a83	C3N-03487	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df512bfe-8f98-11ea-b1fd-0aad30af8a83	CPT0222200003	df502d00-8f98-11ea-b1fd-0aad30af8a83	C3N-03888-06	df4f1689-8f98-11ea-b1fd-0aad30af8a83	C3N-03888	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5082ae-8f98-11ea-b1fd-0aad30af8a83	CPT0248330003	df4f6320-8f98-11ea-b1fd-0aad30af8a83	C3L-04844-01	df4eaafe-8f98-11ea-b1fd-0aad30af8a83	C3L-04844	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50907c-8f98-11ea-b1fd-0aad30af8a83	CPT0011320003	df4f72b9-8f98-11ea-b1fd-0aad30af8a83	C3N-00306-05	df4eb2e7-8f98-11ea-b1fd-0aad30af8a83	C3N-00306	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50c2b9-8f98-11ea-b1fd-0aad30af8a83	CPT0163910003	df4fb0fc-8f98-11ea-b1fd-0aad30af8a83	C3N-01859-01	df4ed42c-8f98-11ea-b1fd-0aad30af8a83	C3N-01859	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50f452-8f98-11ea-b1fd-0aad30af8a83	CPT0245140003	df4feb43-8f98-11ea-b1fd-0aad30af8a83	C3N-03013-03	df4ef386-8f98-11ea-b1fd-0aad30af8a83	C3N-03013	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df511199-8f98-11ea-b1fd-0aad30af8a83	CPT0195860003	df500c9a-8f98-11ea-b1fd-0aad30af8a83	C3N-03619-02	df4f07d3-8f98-11ea-b1fd-0aad30af8a83	C3N-03619	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50d4b3-8f98-11ea-b1fd-0aad30af8a83	CPT0163740003	df4fc505-8f98-11ea-b1fd-0aad30af8a83	C3N-02275-04	df4edcd7-8f98-11ea-b1fd-0aad30af8a83	C3N-02275	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df511dae-8f98-11ea-b1fd-0aad30af8a83	CPT0236620003	df501c70-8f98-11ea-b1fd-0aad30af8a83	C3N-03837-01	df4f1155-8f98-11ea-b1fd-0aad30af8a83	C3N-03837	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50a767-8f98-11ea-b1fd-0aad30af8a83	CPT0088060004	df4f8f32-8f98-11ea-b1fd-0aad30af8a83	C3N-01338-01	df4ec26a-8f98-11ea-b1fd-0aad30af8a83	C3N-01338	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df509149-8f98-11ea-b1fd-0aad30af8a83	CPT0008930003	df4f74af-8f98-11ea-b1fd-0aad30af8a83	C3N-00307-02	df4eb3f1-8f98-11ea-b1fd-0aad30af8a83	C3N-00307	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e579-8f98-11ea-b1fd-0aad30af8a83	CPT0177390003	df4fd8e9-8f98-11ea-b1fd-0aad30af8a83	C3N-02716-03	df4ee8fe-8f98-11ea-b1fd-0aad30af8a83	C3N-02716	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50bc51-8f98-11ea-b1fd-0aad30af8a83	CPT0163250003	df4fa99b-8f98-11ea-b1fd-0aad30af8a83	C3N-01757-05	df4ed0d5-8f98-11ea-b1fd-0aad30af8a83	C3N-01757	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50ab04-8f98-11ea-b1fd-0aad30af8a83	CPT0094490004	df4f92c1-8f98-11ea-b1fd-0aad30af8a83	C3N-01339-01	df4ec459-8f98-11ea-b1fd-0aad30af8a83	C3N-01339	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5072d5-8f98-11ea-b1fd-0aad30af8a83	CPT0229230003	df4f4f98-8f98-11ea-b1fd-0aad30af8a83	C3L-02617-07	df4e9ef8-8f98-11ea-b1fd-0aad30af8a83	C3L-02617	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50746f-8f98-11ea-b1fd-0aad30af8a83	CPT0201860004	df4f526b-8f98-11ea-b1fd-0aad30af8a83	C3L-02621-06	df4ea101-8f98-11ea-b1fd-0aad30af8a83	C3L-02621	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50d921-8f98-11ea-b1fd-0aad30af8a83	CPT0176770003	df4fc902-8f98-11ea-b1fd-0aad30af8a83	C3N-02333-02	df4edf88-8f98-11ea-b1fd-0aad30af8a83	C3N-02333	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510b5d-8f98-11ea-b1fd-0aad30af8a83	CPT0194260003	df5005c8-8f98-11ea-b1fd-0aad30af8a83	C3N-03488-06	df4f0338-8f98-11ea-b1fd-0aad30af8a83	C3N-03488	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df512dbf-8f98-11ea-b1fd-0aad30af8a83	CPT0222360003	df502f10-8f98-11ea-b1fd-0aad30af8a83	C3N-03889-02	df4f1830-8f98-11ea-b1fd-0aad30af8a83	C3N-03889	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df506d49-8f98-11ea-b1fd-0aad30af8a83	CPT0199830003	df4f49cc-8f98-11ea-b1fd-0aad30af8a83	C3L-01237-06	df4e9e22-8f98-11ea-b1fd-0aad30af8a83	C3L-01237	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df511cd3-8f98-11ea-b1fd-0aad30af8a83	CPT0245680003	df501ab6-8f98-11ea-b1fd-0aad30af8a83	C3N-03785-03	df4f1067-8f98-11ea-b1fd-0aad30af8a83	C3N-03785	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50b0e8-8f98-11ea-b1fd-0aad30af8a83	CPT0162890003	df4f9a54-8f98-11ea-b1fd-0aad30af8a83	C3N-01643-04	df4ec812-8f98-11ea-b1fd-0aad30af8a83	C3N-01643	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
df50a446-8f98-11ea-b1fd-0aad30af8a83	CPT0087990003	df4f8b7d-8f98-11ea-b1fd-0aad30af8a83	C3N-01337-04	df4ec190-8f98-11ea-b1fd-0aad30af8a83	C3N-01337	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e1f2-8f98-11ea-b1fd-0aad30af8a83	CPT0190860003	df4fd453-8f98-11ea-b1fd-0aad30af8a83	C3N-02713-06	df4ee623-8f98-11ea-b1fd-0aad30af8a83	C3N-02713	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df507d6a-8f98-11ea-b1fd-0aad30af8a83	CPT0278700002	df4f5bdb-8f98-11ea-b1fd-0aad30af8a83	C3L-04350-06	df4ea6f3-8f98-11ea-b1fd-0aad30af8a83	C3L-04350	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50af32-8f98-11ea-b1fd-0aad30af8a83	C3N-01620-05	df4f988c-8f98-11ea-b1fd-0aad30af8a83	C3N-01620-05	df4ec739-8f98-11ea-b1fd-0aad30af8a83	C3N-01620	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df506654-8f98-11ea-b1fd-0aad30af8a83	CPT0123190003	df4f4037-8f98-11ea-b1fd-0aad30af8a83	C3L-00997-07	df4e9a58-8f98-11ea-b1fd-0aad30af8a83	C3L-00997	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df507685-8f98-11ea-b1fd-0aad30af8a83	CPT0241980004	df4f5440-8f98-11ea-b1fd-0aad30af8a83	C3L-02651-04	df4ea1e7-8f98-11ea-b1fd-0aad30af8a83	C3L-02651	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510298-8f98-11ea-b1fd-0aad30af8a83	CPT0194420003	df4ffbb7-8f98-11ea-b1fd-0aad30af8a83	C3N-03226-02	df4efb5a-8f98-11ea-b1fd-0aad30af8a83	C3N-03226	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50f530-8f98-11ea-b1fd-0aad30af8a83	CPT0245180003	df4fed08-8f98-11ea-b1fd-0aad30af8a83	C3N-03015-01	df4ef458-8f98-11ea-b1fd-0aad30af8a83	C3N-03015	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50abd4-8f98-11ea-b1fd-0aad30af8a83	CPT0094560004	df4f949e-8f98-11ea-b1fd-0aad30af8a83	C3N-01340-01	df4ec539-8f98-11ea-b1fd-0aad30af8a83	C3N-01340	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df514174-8f98-11ea-b1fd-0aad30af8a83	CPT0245460003	df504484-8f98-11ea-b1fd-0aad30af8a83	C3N-04278-05	df4f20dd-8f98-11ea-b1fd-0aad30af8a83	C3N-04278	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50ee5e-8f98-11ea-b1fd-0aad30af8a83	CPT0226270003	df4fe4ae-8f98-11ea-b1fd-0aad30af8a83	C3N-03011-03	df4ef10e-8f98-11ea-b1fd-0aad30af8a83	C3N-03011	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51424b-8f98-11ea-b1fd-0aad30af8a83	CPT0245500003	df5045ea-8f98-11ea-b1fd-0aad30af8a83	C3N-04279-01	df4f22b3-8f98-11ea-b1fd-0aad30af8a83	C3N-04279	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df511e79-8f98-11ea-b1fd-0aad30af8a83	CPT0236640003	df501d83-8f98-11ea-b1fd-0aad30af8a83	C3N-03837-03	df4f1155-8f98-11ea-b1fd-0aad30af8a83	C3N-03837	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df507e42-8f98-11ea-b1fd-0aad30af8a83	CPT0243090003	df4f5de7-8f98-11ea-b1fd-0aad30af8a83	C3L-04354-02	df4ea7d8-8f98-11ea-b1fd-0aad30af8a83	C3L-04354	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df508605-8f98-11ea-b1fd-0aad30af8a83	CPT0281470002	df4f671e-8f98-11ea-b1fd-0aad30af8a83	C3L-05257-03	df4ead02-8f98-11ea-b1fd-0aad30af8a83	C3L-05257	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df508537-8f98-11ea-b1fd-0aad30af8a83	CPT0248520003	df4f6605-8f98-11ea-b1fd-0aad30af8a83	C3L-04849-02	df4eac21-8f98-11ea-b1fd-0aad30af8a83	C3L-04849	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5127ad-8f98-11ea-b1fd-0aad30af8a83	CPT0237500003	df502618-8f98-11ea-b1fd-0aad30af8a83	C3N-03876-03	df4f14e8-8f98-11ea-b1fd-0aad30af8a83	C3N-03876	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df509331-8f98-11ea-b1fd-0aad30af8a83	CPT0008960003	df4f76bb-8f98-11ea-b1fd-0aad30af8a83	C3N-00307-05	df4eb3f1-8f98-11ea-b1fd-0aad30af8a83	C3N-00307	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50782e-8f98-11ea-b1fd-0aad30af8a83	CPT0199880003	df4f577c-8f98-11ea-b1fd-0aad30af8a83	C3L-03378-04	df4ea3f5-8f98-11ea-b1fd-0aad30af8a83	C3L-03378	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5073a8-8f98-11ea-b1fd-0aad30af8a83	CPT0201830004	df4f5158-8f98-11ea-b1fd-0aad30af8a83	C3L-02621-03	df4ea101-8f98-11ea-b1fd-0aad30af8a83	C3L-02621	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df508bbc-8f98-11ea-b1fd-0aad30af8a83	C3N-00295-05	df4f6cd2-8f98-11ea-b1fd-0aad30af8a83	C3N-00295-05	df4eaf8f-8f98-11ea-b1fd-0aad30af8a83	C3N-00295	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df509ada-8f98-11ea-b1fd-0aad30af8a83	CPT0094280004	df4f7f88-8f98-11ea-b1fd-0aad30af8a83	C3N-00825-03	df4eb92f-8f98-11ea-b1fd-0aad30af8a83	C3N-00825	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df514465-8f98-11ea-b1fd-0aad30af8a83	C3N-04279-05	df5047ab-8f98-11ea-b1fd-0aad30af8a83	C3N-04279-05	df4f22b3-8f98-11ea-b1fd-0aad30af8a83	C3N-04279	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510376-8f98-11ea-b1fd-0aad30af8a83	CPT0246540003	df4ffcc6-8f98-11ea-b1fd-0aad30af8a83	C3N-03433-02	df4efd1a-8f98-11ea-b1fd-0aad30af8a83	C3N-03433	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50b466-8f98-11ea-b1fd-0aad30af8a83	CPT0162940003	df4f9e53-8f98-11ea-b1fd-0aad30af8a83	C3N-01752-02	df4ecafb-8f98-11ea-b1fd-0aad30af8a83	C3N-01752	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510018-8f98-11ea-b1fd-0aad30af8a83	CPT0235910003	df4ff8a0-8f98-11ea-b1fd-0aad30af8a83	C3N-03045-01	df4efa74-8f98-11ea-b1fd-0aad30af8a83	C3N-03045	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df511aa6-8f98-11ea-b1fd-0aad30af8a83	CPT0245730003	df5019a0-8f98-11ea-b1fd-0aad30af8a83	C3N-03783-01	df4f0e55-8f98-11ea-b1fd-0aad30af8a83	C3N-03783	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e716-8f98-11ea-b1fd-0aad30af8a83	CPT0207870004	df4fdbca-8f98-11ea-b1fd-0aad30af8a83	C3N-02730-01	df4eec12-8f98-11ea-b1fd-0aad30af8a83	C3N-02730	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5136cf-8f98-11ea-b1fd-0aad30af8a83	CPT0245300003	df503973-8f98-11ea-b1fd-0aad30af8a83	C3N-04275-04	df4f1d2d-8f98-11ea-b1fd-0aad30af8a83	C3N-04275	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50bb7b-8f98-11ea-b1fd-0aad30af8a83	CPT0163240003	df4fa881-8f98-11ea-b1fd-0aad30af8a83	C3N-01757-04	df4ed0d5-8f98-11ea-b1fd-0aad30af8a83	C3N-01757	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50b1c6-8f98-11ea-b1fd-0aad30af8a83	CPT0088410003	df4f9b69-8f98-11ea-b1fd-0aad30af8a83	C3N-01645-02	df4eca22-8f98-11ea-b1fd-0aad30af8a83	C3N-01645	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50bf10-8f98-11ea-b1fd-0aad30af8a83	C3N-01758-04	df4fac69-8f98-11ea-b1fd-0aad30af8a83	C3N-01758-04	df4ed1b2-8f98-11ea-b1fd-0aad30af8a83	C3N-01758	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51330d-8f98-11ea-b1fd-0aad30af8a83	CPT0220620003	df5034c7-8f98-11ea-b1fd-0aad30af8a83	C3N-03933-06	df4f19d3-8f98-11ea-b1fd-0aad30af8a83	C3N-03933	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df510e07-8f98-11ea-b1fd-0aad30af8a83	CPT0195700003	df50089f-8f98-11ea-b1fd-0aad30af8a83	C3N-03490-06	df4f0514-8f98-11ea-b1fd-0aad30af8a83	C3N-03490	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5096f9-8f98-11ea-b1fd-0aad30af8a83	CPT0013430003	df4f7af4-8f98-11ea-b1fd-0aad30af8a83	C3N-00519-02	df4eb697-8f98-11ea-b1fd-0aad30af8a83	C3N-00519	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50940e-8f98-11ea-b1fd-0aad30af8a83	CPT0013000004	df4f7820-8f98-11ea-b1fd-0aad30af8a83	C3N-00498-02	df4eb5b7-8f98-11ea-b1fd-0aad30af8a83	C3N-00498	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df509bbf-8f98-11ea-b1fd-0aad30af8a83	CPT0013130003	df4f80a8-8f98-11ea-b1fd-0aad30af8a83	C3N-00828-04	df4eba07-8f98-11ea-b1fd-0aad30af8a83	C3N-00828	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df507b2f-8f98-11ea-b1fd-0aad30af8a83	CPT0256560003	df4f5a9b-8f98-11ea-b1fd-0aad30af8a83	C3L-04025-03	df4ea4dc-8f98-11ea-b1fd-0aad30af8a83	C3L-04025	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51133e-8f98-11ea-b1fd-0aad30af8a83	CPT0196040003	df500f8c-8f98-11ea-b1fd-0aad30af8a83	C3N-03620-02	df4f08ad-8f98-11ea-b1fd-0aad30af8a83	C3N-03620	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50df4d-8f98-11ea-b1fd-0aad30af8a83	CPT0177010003	df4fd0ef-8f98-11ea-b1fd-0aad30af8a83	C3N-02700-01	df4ee534-8f98-11ea-b1fd-0aad30af8a83	C3N-02700	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50f07a-8f98-11ea-b1fd-0aad30af8a83	CPT0226340003	df4fe5c9-8f98-11ea-b1fd-0aad30af8a83	C3N-03012-01	df4ef2ab-8f98-11ea-b1fd-0aad30af8a83	C3N-03012	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5070d6-8f98-11ea-b1fd-0aad30af8a83	CPT0229220002	df4f4e74-8f98-11ea-b1fd-0aad30af8a83	C3L-02617-06	df4e9ef8-8f98-11ea-b1fd-0aad30af8a83	C3L-02617	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50c688-8f98-11ea-b1fd-0aad30af8a83	CPT0163430003	df4fb4fa-8f98-11ea-b1fd-0aad30af8a83	C3N-01943-06	df4ed504-8f98-11ea-b1fd-0aad30af8a83	C3N-01943	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50f92c-8f98-11ea-b1fd-0aad30af8a83	CPT0226400003	df4ff0e6-8f98-11ea-b1fd-0aad30af8a83	C3N-03027-03	df4ef6b1-8f98-11ea-b1fd-0aad30af8a83	C3N-03027	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50c0b0-8f98-11ea-b1fd-0aad30af8a83	CPT0163860003	df4faf3f-8f98-11ea-b1fd-0aad30af8a83	C3N-01858-05	df4ed282-8f98-11ea-b1fd-0aad30af8a83	C3N-01858	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e2d0-8f98-11ea-b1fd-0aad30af8a83	CPT0177200003	df4fd60a-8f98-11ea-b1fd-0aad30af8a83	C3N-02714-02	df4ee821-8f98-11ea-b1fd-0aad30af8a83	C3N-02714	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50cc06-8f98-11ea-b1fd-0aad30af8a83	CPT0163600003	df4fbbea-8f98-11ea-b1fd-0aad30af8a83	C3N-01946-01	df4ed85e-8f98-11ea-b1fd-0aad30af8a83	C3N-01946	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5061f5-8f98-11ea-b1fd-0aad30af8a83	CPT0169750003	df4f3a47-8f98-11ea-b1fd-0aad30af8a83	C3L-00994-07	df4e970b-8f98-11ea-b1fd-0aad30af8a83	C3L-00994	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df512197-8f98-11ea-b1fd-0aad30af8a83	CPT0236870003	df502056-8f98-11ea-b1fd-0aad30af8a83	C3N-03841-03	df4f1268-8f98-11ea-b1fd-0aad30af8a83	C3N-03841	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5125fc-8f98-11ea-b1fd-0aad30af8a83	CPT0237480004	df50250d-8f98-11ea-b1fd-0aad30af8a83	C3N-03876-01	df4f14e8-8f98-11ea-b1fd-0aad30af8a83	C3N-03876	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5107cc-8f98-11ea-b1fd-0aad30af8a83	CPT0246670003	df50013e-8f98-11ea-b1fd-0aad30af8a83	C3N-03458-01	df4f0094-8f98-11ea-b1fd-0aad30af8a83	C3N-03458	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51044b-8f98-11ea-b1fd-0aad30af8a83	CPT0246590003	df4ffeb8-8f98-11ea-b1fd-0aad30af8a83	C3N-03456-01	df4efdf1-8f98-11ea-b1fd-0aad30af8a83	C3N-03456	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df512965-8f98-11ea-b1fd-0aad30af8a83	CPT0237640003	df502909-8f98-11ea-b1fd-0aad30af8a83	C3N-03878-03	df4f15be-8f98-11ea-b1fd-0aad30af8a83	C3N-03878	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5087b9-8f98-11ea-b1fd-0aad30af8a83	CPT0084630009	df4f68dd-8f98-11ea-b1fd-0aad30af8a83	C3N-00204-03	df4eaeb4-8f98-11ea-b1fd-0aad30af8a83	C3N-00204	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df507a57-8f98-11ea-b1fd-0aad30af8a83	CPT0199890003	df4f58a8-8f98-11ea-b1fd-0aad30af8a83	C3L-03378-05	df4ea3f5-8f98-11ea-b1fd-0aad30af8a83	C3L-03378	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5062c2-8f98-11ea-b1fd-0aad30af8a83	CPT0169890003	df4f3c26-8f98-11ea-b1fd-0aad30af8a83	C3L-00995-02	df4e9966-8f98-11ea-b1fd-0aad30af8a83	C3L-00995	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df509eb7-8f98-11ea-b1fd-0aad30af8a83	CPT0013250003	df4f8393-8f98-11ea-b1fd-0aad30af8a83	C3N-00829-05	df4ebbd7-8f98-11ea-b1fd-0aad30af8a83	C3N-00829	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5120be-8f98-11ea-b1fd-0aad30af8a83	CPT0236850004	df501f47-8f98-11ea-b1fd-0aad30af8a83	C3N-03841-01	df4f1268-8f98-11ea-b1fd-0aad30af8a83	C3N-03841	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df508f9c-8f98-11ea-b1fd-0aad30af8a83	CPT0011290003	df4f71a3-8f98-11ea-b1fd-0aad30af8a83	C3N-00306-02	df4eb2e7-8f98-11ea-b1fd-0aad30af8a83	C3N-00306	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df505d94-8f98-11ea-b1fd-0aad30af8a83	CPT0169640003	df4f3418-8f98-11ea-b1fd-0aad30af8a83	C3L-00977-02	df4e907e-8f98-11ea-b1fd-0aad30af8a83	C3L-00977	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df507761-8f98-11ea-b1fd-0aad30af8a83	CPT0242000004	df4f555f-8f98-11ea-b1fd-0aad30af8a83	C3L-02651-06	df4ea1e7-8f98-11ea-b1fd-0aad30af8a83	C3L-02651	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50895c-8f98-11ea-b1fd-0aad30af8a83	CPT0008520008	df4f6bc1-8f98-11ea-b1fd-0aad30af8a83	C3N-00295-03	df4eaf8f-8f98-11ea-b1fd-0aad30af8a83	C3N-00295	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50bd19-8f98-11ea-b1fd-0aad30af8a83	CPT0163340003	df4fab53-8f98-11ea-b1fd-0aad30af8a83	C3N-01758-03	df4ed1b2-8f98-11ea-b1fd-0aad30af8a83	C3N-01758	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df509c91-8f98-11ea-b1fd-0aad30af8a83	CPT0013210004	df4f8281-8f98-11ea-b1fd-0aad30af8a83	C3N-00829-01	df4ebbd7-8f98-11ea-b1fd-0aad30af8a83	C3N-00829	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50a29f-8f98-11ea-b1fd-0aad30af8a83	C3N-00857-05	df4f8873-8f98-11ea-b1fd-0aad30af8a83	C3N-00857-05	df4ebebb-8f98-11ea-b1fd-0aad30af8a83	C3N-00857	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df506589-8f98-11ea-b1fd-0aad30af8a83	CPT0123180003	df4f3f1d-8f98-11ea-b1fd-0aad30af8a83	C3L-00997-04	df4e9a58-8f98-11ea-b1fd-0aad30af8a83	C3L-00997	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50b8be-8f98-11ea-b1fd-0aad30af8a83	CPT0163160003	df4fa54a-8f98-11ea-b1fd-0aad30af8a83	C3N-01756-01	df4ecf32-8f98-11ea-b1fd-0aad30af8a83	C3N-01756	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50eab2-8f98-11ea-b1fd-0aad30af8a83	CPT0245020003	df4fdfd2-8f98-11ea-b1fd-0aad30af8a83	C3N-03008-03	df4eef1c-8f98-11ea-b1fd-0aad30af8a83	C3N-03008	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50845d-8f98-11ea-b1fd-0aad30af8a83	CPT0248350003	df4f6447-8f98-11ea-b1fd-0aad30af8a83	C3L-04844-03	df4eaafe-8f98-11ea-b1fd-0aad30af8a83	C3L-04844	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df513f68-8f98-11ea-b1fd-0aad30af8a83	CPT0245450003	df504274-8f98-11ea-b1fd-0aad30af8a83	C3N-04278-01	df4f20dd-8f98-11ea-b1fd-0aad30af8a83	C3N-04278	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50c765-8f98-11ea-b1fd-0aad30af8a83	CPT0163480003	df4fb6da-8f98-11ea-b1fd-0aad30af8a83	C3N-01944-01	df4ed5d3-8f98-11ea-b1fd-0aad30af8a83	C3N-01944	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df514762-8f98-11ea-b1fd-0aad30af8a83	CPT0261520003	df504a87-8f98-11ea-b1fd-0aad30af8a83	C3N-04611-01	df4f2567-8f98-11ea-b1fd-0aad30af8a83	C3N-04611	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50e64f-8f98-11ea-b1fd-0aad30af8a83	CPT0177710003	df4fda01-8f98-11ea-b1fd-0aad30af8a83	C3N-02727-02	df4eeb29-8f98-11ea-b1fd-0aad30af8a83	C3N-02727	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51252e-8f98-11ea-b1fd-0aad30af8a83	CPT0237150003	df502332-8f98-11ea-b1fd-0aad30af8a83	C3N-03849-03	df4f1344-8f98-11ea-b1fd-0aad30af8a83	C3N-03849	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50f850-8f98-11ea-b1fd-0aad30af8a83	CPT0226390003	df4fefd8-8f98-11ea-b1fd-0aad30af8a83	C3N-03027-01	df4ef6b1-8f98-11ea-b1fd-0aad30af8a83	C3N-03027	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df505e97-8f98-11ea-b1fd-0aad30af8a83	CPT0127050003	df4f3614-8f98-11ea-b1fd-0aad30af8a83	C3L-00987-01	df4e95d2-8f98-11ea-b1fd-0aad30af8a83	C3L-00987	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50cf46-8f98-11ea-b1fd-0aad30af8a83	CPT0226030003	df4fbf1d-8f98-11ea-b1fd-0aad30af8a83	C3N-01947-02	df4eda1a-8f98-11ea-b1fd-0aad30af8a83	C3N-01947	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50c833-8f98-11ea-b1fd-0aad30af8a83	CPT0163490003	df4fb7f3-8f98-11ea-b1fd-0aad30af8a83	C3N-01944-04	df4ed5d3-8f98-11ea-b1fd-0aad30af8a83	C3N-01944	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50700b-8f98-11ea-b1fd-0aad30af8a83	CPT0229210003	df4f4ca1-8f98-11ea-b1fd-0aad30af8a83	C3L-02617-05	df4e9ef8-8f98-11ea-b1fd-0aad30af8a83	C3L-02617	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
df50a37a-8f98-11ea-b1fd-0aad30af8a83	CPT0094420004	df4f8990-8f98-11ea-b1fd-0aad30af8a83	C3N-00871-01	df4ebfa3-8f98-11ea-b1fd-0aad30af8a83	C3N-00871	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5106b7-8f98-11ea-b1fd-0aad30af8a83	CPT0246620003	df4fffe4-8f98-11ea-b1fd-0aad30af8a83	C3N-03457-02	df4effbc-8f98-11ea-b1fd-0aad30af8a83	C3N-03457	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50ecb9-8f98-11ea-b1fd-0aad30af8a83	CPT0245060004	df4fe1b4-8f98-11ea-b1fd-0aad30af8a83	C3N-03009-01	df4ef039-8f98-11ea-b1fd-0aad30af8a83	C3N-03009	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df513c77-8f98-11ea-b1fd-0aad30af8a83	CPT0245400003	df503f6c-8f98-11ea-b1fd-0aad30af8a83	C3N-04277-02	df4f1fff-8f98-11ea-b1fd-0aad30af8a83	C3N-04277	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df51313e-8f98-11ea-b1fd-0aad30af8a83	CPT0220610003	df5033be-8f98-11ea-b1fd-0aad30af8a83	C3N-03933-03	df4f19d3-8f98-11ea-b1fd-0aad30af8a83	C3N-03933	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5135ed-8f98-11ea-b1fd-0aad30af8a83	CPT0245230004	df50379b-8f98-11ea-b1fd-0aad30af8a83	C3N-04273-01	df4f1c60-8f98-11ea-b1fd-0aad30af8a83	C3N-04273	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5094d9-8f98-11ea-b1fd-0aad30af8a83	CPT0013030003	df4f79d8-8f98-11ea-b1fd-0aad30af8a83	C3N-00498-05	df4eb5b7-8f98-11ea-b1fd-0aad30af8a83	C3N-00498	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df511273-8f98-11ea-b1fd-0aad30af8a83	CPT0195880003	df500e73-8f98-11ea-b1fd-0aad30af8a83	C3N-03619-06	df4f07d3-8f98-11ea-b1fd-0aad30af8a83	C3N-03619	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5100e7-8f98-11ea-b1fd-0aad30af8a83	CPT0235920003	df4ff9c7-8f98-11ea-b1fd-0aad30af8a83	C3N-03045-02	df4efa74-8f98-11ea-b1fd-0aad30af8a83	C3N-03045	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5097e3-8f98-11ea-b1fd-0aad30af8a83	CPT0013460003	df4f7ca6-8f98-11ea-b1fd-0aad30af8a83	C3N-00519-05	df4eb697-8f98-11ea-b1fd-0aad30af8a83	C3N-00519	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df512e97-8f98-11ea-b1fd-0aad30af8a83	CPT0223450003	df5030f2-8f98-11ea-b1fd-0aad30af8a83	C3N-03928-03	df4f1907-8f98-11ea-b1fd-0aad30af8a83	C3N-03928	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50611b-8f98-11ea-b1fd-0aad30af8a83	CPT0169740004	df4f391f-8f98-11ea-b1fd-0aad30af8a83	C3L-00994-06	df4e970b-8f98-11ea-b1fd-0aad30af8a83	C3L-00994	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50d3e3-8f98-11ea-b1fd-0aad30af8a83	CPT0163720003	df4fc332-8f98-11ea-b1fd-0aad30af8a83	C3N-02275-02	df4edcd7-8f98-11ea-b1fd-0aad30af8a83	C3N-02275	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Disqualified						Qualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
df506f35-8f98-11ea-b1fd-0aad30af8a83	CPT0229190003	df4f4b89-8f98-11ea-b1fd-0aad30af8a83	C3L-02617-03	df4e9ef8-8f98-11ea-b1fd-0aad30af8a83	C3L-02617	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50ff40-8f98-11ea-b1fd-0aad30af8a83	CPT0235470002	df4ff693-8f98-11ea-b1fd-0aad30af8a83	C3N-03042-05	df4ef87b-8f98-11ea-b1fd-0aad30af8a83	C3N-03042	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50a9df-8f98-11ea-b1fd-0aad30af8a83	CPT0088080003	df4f90f5-8f98-11ea-b1fd-0aad30af8a83	C3N-01338-05	df4ec26a-8f98-11ea-b1fd-0aad30af8a83	C3N-01338	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50ae63-8f98-11ea-b1fd-0aad30af8a83	CPT0095040003	df4f977a-8f98-11ea-b1fd-0aad30af8a83	C3N-01620-03	df4ec739-8f98-11ea-b1fd-0aad30af8a83	C3N-01620	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5069c6-8f98-11ea-b1fd-0aad30af8a83	CPT0199700003	df4f453d-8f98-11ea-b1fd-0aad30af8a83	C3L-01138-01	df4e9d3d-8f98-11ea-b1fd-0aad30af8a83	C3L-01138	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df5116e9-8f98-11ea-b1fd-0aad30af8a83	CPT0245550003	df501477-8f98-11ea-b1fd-0aad30af8a83	C3N-03781-01	df4f0b7a-8f98-11ea-b1fd-0aad30af8a83	C3N-03781	CPTAC3 Discovery and Confirmatory	Primary Tumor	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df50f151-8f98-11ea-b1fd-0aad30af8a83	CPT0226350003	df4fe7c6-8f98-11ea-b1fd-0aad30af8a83	C3N-03012-05	df4ef2ab-8f98-11ea-b1fd-0aad30af8a83	C3N-03012	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Head and Neck	Head and Neck Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
24b64ef0-8beb-11ea-b1fd-0aad30af8a83	P091-1-1	24b522c8-8beb-11ea-b1fd-0aad30af8a83	P091-1	24b3d10e-8beb-11ea-b1fd-0aad30af8a83	P091	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6547d-8beb-11ea-b1fd-0aad30af8a83	P092-2-1	24b5275f-8beb-11ea-b1fd-0aad30af8a83	P092-2	24b3d1ea-8beb-11ea-b1fd-0aad30af8a83	P092	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b61b19-8beb-11ea-b1fd-0aad30af8a83	P071-1-1	24b4d8e1-8beb-11ea-b1fd-0aad30af8a83	P071-1	24b3b47b-8beb-11ea-b1fd-0aad30af8a83	P071	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b56c52-8beb-11ea-b1fd-0aad30af8a83	P003-2-1	24b3f107-8beb-11ea-b1fd-0aad30af8a83	P003-2	24b35997-8beb-11ea-b1fd-0aad30af8a83	P003	Academia Sinica LUAD-100	Tumor	Lung	Other	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b66c0d-8beb-11ea-b1fd-0aad30af8a83	P101-1-1	24b545d7-8beb-11ea-b1fd-0aad30af8a83	P101-1	24b3db33-8beb-11ea-b1fd-0aad30af8a83	P101	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b56b66-8beb-11ea-b1fd-0aad30af8a83	P003-1-1	24b3efc4-8beb-11ea-b1fd-0aad30af8a83	P003-1	24b35997-8beb-11ea-b1fd-0aad30af8a83	P003	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Other	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b6182f-8beb-11ea-b1fd-0aad30af8a83	P070-1-1	24b4d507-8beb-11ea-b1fd-0aad30af8a83	P070-1	24b3b292-8beb-11ea-b1fd-0aad30af8a83	P070	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b65217-8beb-11ea-b1fd-0aad30af8a83	P092-1-1	24b52598-8beb-11ea-b1fd-0aad30af8a83	P092-1	24b3d1ea-8beb-11ea-b1fd-0aad30af8a83	P092	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b64af9-8beb-11ea-b1fd-0aad30af8a83	P089-2-1	24b51e9f-8beb-11ea-b1fd-0aad30af8a83	P089-2	24b3ce90-8beb-11ea-b1fd-0aad30af8a83	P089	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b65141-8beb-11ea-b1fd-0aad30af8a83	P091-2-1	24b52486-8beb-11ea-b1fd-0aad30af8a83	P091-2	24b3d10e-8beb-11ea-b1fd-0aad30af8a83	P091	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5689c-8beb-11ea-b1fd-0aad30af8a83	P002-1-1	24b3ebd3-8beb-11ea-b1fd-0aad30af8a83	P002-1	24b35854-8beb-11ea-b1fd-0aad30af8a83	P002	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b671ba-8beb-11ea-b1fd-0aad30af8a83	P103-1-1	24b54d70-8beb-11ea-b1fd-0aad30af8a83	P103-1	24b3dde2-8beb-11ea-b1fd-0aad30af8a83	P103	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b61554-8beb-11ea-b1fd-0aad30af8a83	P069-1-1	24b4d149-8beb-11ea-b1fd-0aad30af8a83	P069-1	24b3b1c6-8beb-11ea-b1fd-0aad30af8a83	P069	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b674a1-8beb-11ea-b1fd-0aad30af8a83	P104-1-1	24b551a4-8beb-11ea-b1fd-0aad30af8a83	P104-1	24b3dec3-8beb-11ea-b1fd-0aad30af8a83	P104	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b648c1-8beb-11ea-b1fd-0aad30af8a83	P089-1-1	24b51c8d-8beb-11ea-b1fd-0aad30af8a83	P089-1	24b3ce90-8beb-11ea-b1fd-0aad30af8a83	P089	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b57894-8beb-11ea-b1fd-0aad30af8a83	P008-1-1	24b3fec2-8beb-11ea-b1fd-0aad30af8a83	P008-1	24b3607a-8beb-11ea-b1fd-0aad30af8a83	P008	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b570aa-8beb-11ea-b1fd-0aad30af8a83	P005-2-1	24b3f70a-8beb-11ea-b1fd-0aad30af8a83	P005-2	24b35cd4-8beb-11ea-b1fd-0aad30af8a83	P005	Academia Sinica LUAD-100	Tumor	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b56971-8beb-11ea-b1fd-0aad30af8a83	P002-2-1	24b3ee5a-8beb-11ea-b1fd-0aad30af8a83	P002-2	24b35854-8beb-11ea-b1fd-0aad30af8a83	P002	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b61eec-8beb-11ea-b1fd-0aad30af8a83	P072-2-1	24b4dee3-8beb-11ea-b1fd-0aad30af8a83	P072-2	24b3b55c-8beb-11ea-b1fd-0aad30af8a83	P072	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b581ae-8beb-11ea-b1fd-0aad30af8a83	P011-2-1	24b40940-8beb-11ea-b1fd-0aad30af8a83	P011-2	24b3645a-8beb-11ea-b1fd-0aad30af8a83	P011	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b57f09-8beb-11ea-b1fd-0aad30af8a83	P010-2-1	24b4065f-8beb-11ea-b1fd-0aad30af8a83	P010-2	24b36376-8beb-11ea-b1fd-0aad30af8a83	P010	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b580cd-8beb-11ea-b1fd-0aad30af8a83	P011-1-1	24b4077c-8beb-11ea-b1fd-0aad30af8a83	P011-1	24b3645a-8beb-11ea-b1fd-0aad30af8a83	P011	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b67579-8beb-11ea-b1fd-0aad30af8a83	P104-2-1	24b553ae-8beb-11ea-b1fd-0aad30af8a83	P104-2	24b3dec3-8beb-11ea-b1fd-0aad30af8a83	P104	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b573cc-8beb-11ea-b1fd-0aad30af8a83	P006-1-1	24b3f8de-8beb-11ea-b1fd-0aad30af8a83	P006-1	24b35dac-8beb-11ea-b1fd-0aad30af8a83	P006	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b56efa-8beb-11ea-b1fd-0aad30af8a83	P004-2-1	24b3f403-8beb-11ea-b1fd-0aad30af8a83	P004-2	24b35be2-8beb-11ea-b1fd-0aad30af8a83	P004	Academia Sinica LUAD-100	Tumor	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b64e18-8beb-11ea-b1fd-0aad30af8a83	P090-2-1	24b521b3-8beb-11ea-b1fd-0aad30af8a83	P090-2	24b3cf5e-8beb-11ea-b1fd-0aad30af8a83	P090	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b6175b-8beb-11ea-b1fd-0aad30af8a83	P069-2-1	24b4d329-8beb-11ea-b1fd-0aad30af8a83	P069-2	24b3b1c6-8beb-11ea-b1fd-0aad30af8a83	P069	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b61cb5-8beb-11ea-b1fd-0aad30af8a83	P072-1-1	24b4dcdc-8beb-11ea-b1fd-0aad30af8a83	P072-1	24b3b55c-8beb-11ea-b1fd-0aad30af8a83	P072	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b64bd7-8beb-11ea-b1fd-0aad30af8a83	P090-1-1	24b51ff8-8beb-11ea-b1fd-0aad30af8a83	P090-1	24b3cf5e-8beb-11ea-b1fd-0aad30af8a83	P090	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5844b-8beb-11ea-b1fd-0aad30af8a83	P012-2-1	24b40c21-8beb-11ea-b1fd-0aad30af8a83	P012-2	24b36531-8beb-11ea-b1fd-0aad30af8a83	P012	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b57a88-8beb-11ea-b1fd-0aad30af8a83	P009-1-1	24b401d2-8beb-11ea-b1fd-0aad30af8a83	P009-1	24b36177-8beb-11ea-b1fd-0aad30af8a83	P009	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b57d14-8beb-11ea-b1fd-0aad30af8a83	P009-2-1	24b402ee-8beb-11ea-b1fd-0aad30af8a83	P009-2	24b36177-8beb-11ea-b1fd-0aad30af8a83	P009	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b66ce0-8beb-11ea-b1fd-0aad30af8a83	P101-2-1	24b547bc-8beb-11ea-b1fd-0aad30af8a83	P101-2	24b3db33-8beb-11ea-b1fd-0aad30af8a83	P101	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b618fb-8beb-11ea-b1fd-0aad30af8a83	P070-2-1	24b4d6eb-8beb-11ea-b1fd-0aad30af8a83	P070-2	24b3b292-8beb-11ea-b1fd-0aad30af8a83	P070	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b56d22-8beb-11ea-b1fd-0aad30af8a83	P004-1-1	24b3f2d7-8beb-11ea-b1fd-0aad30af8a83	P004-1	24b35be2-8beb-11ea-b1fd-0aad30af8a83	P004	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b56529-8beb-11ea-b1fd-0aad30af8a83	P001-1-1	24b3e7fb-8beb-11ea-b1fd-0aad30af8a83	P001-1	24b35310-8beb-11ea-b1fd-0aad30af8a83	P001	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Other	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b66edf-8beb-11ea-b1fd-0aad30af8a83	P102-1-1	24b5499a-8beb-11ea-b1fd-0aad30af8a83	P102-1	24b3dbf9-8beb-11ea-b1fd-0aad30af8a83	P102	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5679c-8beb-11ea-b1fd-0aad30af8a83	P001-2-1	24b3eaa0-8beb-11ea-b1fd-0aad30af8a83	P001-2	24b35310-8beb-11ea-b1fd-0aad30af8a83	P001	Academia Sinica LUAD-100	Tumor	Lung	Other	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b66fb7-8beb-11ea-b1fd-0aad30af8a83	P102-2-1	24b54b82-8beb-11ea-b1fd-0aad30af8a83	P102-2	24b3dbf9-8beb-11ea-b1fd-0aad30af8a83	P102	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b574c5-8beb-11ea-b1fd-0aad30af8a83	P006-2-1	24b3f9f4-8beb-11ea-b1fd-0aad30af8a83	P006-2	24b35dac-8beb-11ea-b1fd-0aad30af8a83	P006	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5759c-8beb-11ea-b1fd-0aad30af8a83	P007-1-1	24b3fbcc-8beb-11ea-b1fd-0aad30af8a83	P007-1	24b35f98-8beb-11ea-b1fd-0aad30af8a83	P007	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b67294-8beb-11ea-b1fd-0aad30af8a83	P103-2-1	24b54f6c-8beb-11ea-b1fd-0aad30af8a83	P103-2	24b3dde2-8beb-11ea-b1fd-0aad30af8a83	P103	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b5827b-8beb-11ea-b1fd-0aad30af8a83	P012-1-1	24b40a5e-8beb-11ea-b1fd-0aad30af8a83	P012-1	24b36531-8beb-11ea-b1fd-0aad30af8a83	P012	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b61bec-8beb-11ea-b1fd-0aad30af8a83	P071-2-1	24b4dada-8beb-11ea-b1fd-0aad30af8a83	P071-2	24b3b47b-8beb-11ea-b1fd-0aad30af8a83	P071	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b57e36-8beb-11ea-b1fd-0aad30af8a83	P010-1-1	24b404ff-8beb-11ea-b1fd-0aad30af8a83	P010-1	24b36376-8beb-11ea-b1fd-0aad30af8a83	P010	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b56fd6-8beb-11ea-b1fd-0aad30af8a83	P005-1-1	24b3f5de-8beb-11ea-b1fd-0aad30af8a83	P005-1	24b35cd4-8beb-11ea-b1fd-0aad30af8a83	P005	Academia Sinica LUAD-100	Normal Adjacent Tissue	Lung	Lung Squamous Cell Carcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
24b579ab-8beb-11ea-b1fd-0aad30af8a83	P008-2-1	24b3ffdd-8beb-11ea-b1fd-0aad30af8a83	P008-2	24b3607a-8beb-11ea-b1fd-0aad30af8a83	P008	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Disqualified						Disqualified	Disqualified																									International Cancer Proteogenome Consortium
24b5779f-8beb-11ea-b1fd-0aad30af8a83	P007-2-1	24b3fcde-8beb-11ea-b1fd-0aad30af8a83	P007-2	24b35f98-8beb-11ea-b1fd-0aad30af8a83	P007	Academia Sinica LUAD-100	Tumor	Lung	Lung Adenocarcinoma	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
45964de9-f3b7-11e8-a44b-0a9c39d33490	AL25730263-1	af11921c-f3b3-11e8-a44b-0a9c39d33490	SA25730263-1	b7a788a4-f3a7-11e8-a44b-0a9c39d33490	CA25730263-1	Quantitative digital maps of tissue biopsies	Normal	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
471bb3b2-f3b7-11e8-a44b-0a9c39d33490	AL25730263-2	b17afbf5-f3b3-11e8-a44b-0a9c39d33490	SA25730263-2	b7a788a4-f3a7-11e8-a44b-0a9c39d33490	CA25730263-1	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
48cac280-f3b7-11e8-a44b-0a9c39d33490	AL25730263-3	b40e32c3-f3b3-11e8-a44b-0a9c39d33490	SA25730263-3	b9458a58-f3a7-11e8-a44b-0a9c39d33490	CA25730263-2	Quantitative digital maps of tissue biopsies	Normal	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
4a4a0119-f3b7-11e8-a44b-0a9c39d33490	AL25730263-4	b6778c4b-f3b3-11e8-a44b-0a9c39d33490	SA25730263-4	b9458a58-f3a7-11e8-a44b-0a9c39d33490	CA25730263-2	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
4bc6f9d0-f3b7-11e8-a44b-0a9c39d33490	AL25730263-5	b906b0bc-f3b3-11e8-a44b-0a9c39d33490	SA25730263-5	baa9907d-f3a7-11e8-a44b-0a9c39d33490	CA25730263-3	Quantitative digital maps of tissue biopsies	Normal	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
4d4a6873-f3b7-11e8-a44b-0a9c39d33490	AL25730263-6	bb704ef3-f3b3-11e8-a44b-0a9c39d33490	SA25730263-6	baa9907d-f3a7-11e8-a44b-0a9c39d33490	CA25730263-3	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
4eca9e86-f3b7-11e8-a44b-0a9c39d33490	AL25730263-7	bdd809dc-f3b3-11e8-a44b-0a9c39d33490	SA25730263-7	bc2a1a07-f3a7-11e8-a44b-0a9c39d33490	CA25730263-4	Quantitative digital maps of tissue biopsies	Normal	Kidney	Papillary Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
50487ad2-f3b7-11e8-a44b-0a9c39d33490	AL25730263-8	c03a3261-f3b3-11e8-a44b-0a9c39d33490	SA25730263-8	bc2a1a07-f3a7-11e8-a44b-0a9c39d33490	CA25730263-4	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Papillary Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
51c6ed77-f3b7-11e8-a44b-0a9c39d33490	AL25730263-9	c2ab1d90-f3b3-11e8-a44b-0a9c39d33490	SA25730263-9	bdc07b2c-f3a7-11e8-a44b-0a9c39d33490	CA25730263-5	Quantitative digital maps of tissue biopsies	Normal	Kidney	Chromophobe Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
5349b387-f3b7-11e8-a44b-0a9c39d33490	AL25730263-10	c5175320-f3b3-11e8-a44b-0a9c39d33490	SA25730263-10	bdc07b2c-f3a7-11e8-a44b-0a9c39d33490	CA25730263-5	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Chromophobe Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
54c30cbc-f3b7-11e8-a44b-0a9c39d33490	AL25730263-11	c7a99bd8-f3b3-11e8-a44b-0a9c39d33490	SA25730263-11	bf5e9985-f3a7-11e8-a44b-0a9c39d33490	CA25730263-6	Quantitative digital maps of tissue biopsies	Normal	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
566e0543-f3b7-11e8-a44b-0a9c39d33490	AL25730263-12	ca094336-f3b3-11e8-a44b-0a9c39d33490	SA25730263-12	bf5e9985-f3a7-11e8-a44b-0a9c39d33490	CA25730263-6	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
582a74c7-f3b7-11e8-a44b-0a9c39d33490	AL25730263-13	cc7f928c-f3b3-11e8-a44b-0a9c39d33490	SA25730263-13	c0ec6f7a-f3a7-11e8-a44b-0a9c39d33490	CA25730263-7	Quantitative digital maps of tissue biopsies	Normal	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
59bd922d-f3b7-11e8-a44b-0a9c39d33490	AL25730263-14	cee0593f-f3b3-11e8-a44b-0a9c39d33490	SA25730263-14	c0ec6f7a-f3a7-11e8-a44b-0a9c39d33490	CA25730263-7	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
5b5ac37b-f3b7-11e8-a44b-0a9c39d33490	AL25730263-15	d1438284-f3b3-11e8-a44b-0a9c39d33490	SA25730263-15	c1fe6bed-f3a7-11e8-a44b-0a9c39d33490	CA25730263-8	Quantitative digital maps of tissue biopsies	Normal	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
5cd70b90-f3b7-11e8-a44b-0a9c39d33490	AL25730263-16	d3ab37fb-f3b3-11e8-a44b-0a9c39d33490	SA25730263-16	c1fe6bed-f3a7-11e8-a44b-0a9c39d33490	CA25730263-8	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Clear Cell Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
5e8cb8bb-f3b7-11e8-a44b-0a9c39d33490	AL25730263-17	d611a7bc-f3b3-11e8-a44b-0a9c39d33490	SA25730263-17	c2cd08c2-f3a7-11e8-a44b-0a9c39d33490	CA25730263-9	Quantitative digital maps of tissue biopsies	Normal	Kidney	Papillary Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
600ba4c9-f3b7-11e8-a44b-0a9c39d33490	AL25730263-18	d8a35be7-f3b3-11e8-a44b-0a9c39d33490	SA25730263-18	c2cd08c2-f3a7-11e8-a44b-0a9c39d33490	CA25730263-9	Quantitative digital maps of tissue biopsies	Tumor	Kidney	Papillary Renal Cell Carcinoma	no	Qualified						Qualified	Qualified																									Quantitative digital maps of tissue biopsies
a9633bba-7cb4-464b-b6fb-c4834c423f59	WHIM74	7457b65b-d0d2-4263-9945-ea4b58ece067	WHIM74	395ce860-c2a6-46d2-972e-83620e058dbf	WHIM74	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e7db3b7b-90d0-462c-a094-f188ea3b2299	WHIM30	da92fac3-6aef-4ba2-a742-1560e8c8c4a2	WHIM30	a16d828e-b6a6-4884-92a4-884ef03de57c	WHIM30	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb9016bc-f352-433f-9147-02fa5dec0cee	HCI027	2018930e-2e98-4001-9030-46630284a0f3	HCI027	4b6b7f5a-0f83-4102-98c1-51b5c5158c94	HCI027	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e4437238-f406-422c-b7d3-c9ef1fd31c3d	WHIM75	4e621db7-780f-47b1-98bf-95f4103acb58	WHIM75	4105096b-ce19-4783-b383-a80632b77254	WHIM75	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ab97665e-1847-409c-bcb9-71e507c8901c	WHIM12	d4ca1a1e-bfa0-440c-821c-17610417edb6	WHIM12	1fdbbc88-2258-4ec9-b7d8-f5fe633e990a	WHIM12	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae6b860e-d7f6-44a8-b47b-2dfea31999db	WHIM14	d1b66c2f-c55a-4d0f-89d2-4699cac456fc	WHIM14	7eb3e9c7-a440-4e0f-bc6a-d77a0052ffee	WHIM14	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9dafda75-9366-4b2e-90b1-9c7d65a7bb8e	WHIM68	bcfaccce-031e-41e0-a3d4-20d1b3cd88f1	WHIM68	21ac97b6-c265-410a-b98e-31735d669ab4	WHIM68	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
353a06da-ef10-4598-af49-43814857fe09	HCI030	3edcaec7-359e-40c4-84c4-711e6079cd7e	HCI030	6cea33b1-3543-4a57-942d-e94f76c0c705	HCI030	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dd720e9f-1ff5-4b74-87de-5b0507b57e22	PDX  CR	428b5be0-66af-43a2-b220-ff61a87d96b4	PDX  CR	1835a3be-cbd4-4ad4-91b0-184192e46443	PDX  CR	Proteogenomic Translational Research Centers (PTRC)	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
81a8161f-9f3e-4b20-9775-706c0d5dd3e5	HCI009	42370fda-92a9-4a88-af66-b74aafab3177	HCI009	ed8b6ab4-a0b4-4341-88f5-375d0e221a59	HCI009	Proteogenomic Translational Research Centers (PTRC)	Xenograft Tissue	Breast	Breast Invasive Carcinoma	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
121f9b5d-ecfa-11ea-b1fd-0aad30af8a83	LSCC KGG CR	121d7fc1-ecfa-11ea-b1fd-0aad30af8a83	LSCC KGG CR	121b989b-ecfa-11ea-b1fd-0aad30af8a83	LSCC KGG CR	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
121f9d9d-ecfa-11ea-b1fd-0aad30af8a83	LUAD KGG CR	121d80df-ecfa-11ea-b1fd-0aad30af8a83	LUAD KGG CR	121b9a4d-ecfa-11ea-b1fd-0aad30af8a83	LUAD KGG CR	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2b294290-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A18U-01A-61-A21W-30	72fc29f7-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A18U-01A	ebd22406-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A18U	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
193edb9b-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0C0-01A-23-A21V-30	591485c9-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0C0-01A	da282277-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0C0	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6efaaab4-6428-11e8-bcf1-0a2705229b82	TCGA-A8-A08Z-01A-12-A21V-30	7ac0f154-641f-11e8-bcf1-0a2705229b82	TCGA-A8-A08Z-01A	3d3122af-63d8-11e8-bcf1-0a2705229b82	TCGA-A8-A08Z	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0a79f19c-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A0TY-01A-22-A21W-30	47697538-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A0TY-01A	cd853e7e-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A0TY	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6b32ba78-6428-11e8-bcf1-0a2705229b82	TCGA-A8-A076-01A-23-A21V-30	754da049-641f-11e8-bcf1-0a2705229b82	TCGA-A8-A076-01A	3964c3f9-63d8-11e8-bcf1-0a2705229b82	TCGA-A8-A076	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
23a0af9d-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0EE-01A-41-A21V-30	682cb1ae-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0EE-01A	e421b52e-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0EE	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1a8c1e44-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0C1-01A-41-A21W-30	5ab8e18b-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0C1-01A	db63cb90-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0C1	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0d07ef6f-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A1AP-01A-22-A21W-30	4acc8a2a-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A1AP-01A	cffaa5e5-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A1AP	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10e04588-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A1AV-01A-41-A21V-30	5008a7f6-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A1AV-01A	d3aef0d7-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A1AV	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2c775cc0-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A18V-01A-31-A21W-30	750614c8-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A18V-01A	ed0e994d-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A18V	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eefcf4f3-6428-11e8-bcf1-0a2705229b82	TCGA-AN-A0AM-01A-22-A21W-30	21de5092-6420-11e8-bcf1-0a2705229b82	TCGA-AN-A0AM-01A	b36a5af5-63d8-11e8-bcf1-0a2705229b82	TCGA-AN-A0AM	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64d59458-6428-11e8-bcf1-0a2705229b82	TCGA-A7-A0CE-01A-41-A21V-30	6c7ed1e7-641f-11e8-bcf1-0a2705229b82	TCGA-A7-A0CE-01A	330e4133-63d8-11e8-bcf1-0a2705229b82	TCGA-A7-A0CE	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e6ceb96-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0DG-01A-41-A21V-30	5ff684c3-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0DG-01A	df249a75-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0DG	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f823da58-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A0JC-01A-41-A21V-30	2e0419f9-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A0JC-01A	bc10255d-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A0JC	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
36ac45e4-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A12Z-01A-41-A21V-30	86f71dd8-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A12Z-01A	f70a83c6-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A12Z	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e697c1c-6429-11e8-bcf1-0a2705229b82	TCGA-D8-A13Y-01A-22-A21W-30	918f02ea-6420-11e8-bcf1-0a2705229b82	TCGA-D8-A13Y-01A	fe883733-63d8-11e8-bcf1-0a2705229b82	TCGA-D8-A13Y	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5149777c-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0T2-01A-13-A21W-30	51ff436b-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0T2-01A	202280ea-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0T2	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f08d01b-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A12P-01A-22-A21W-30	7913efa3-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A12P-01A	ef85a16e-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A12P	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03fcb451-6429-11e8-bcf1-0a2705229b82	TCGA-AO-A12F-01A-41-A21V-30	3e859ff1-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A12F-01A	c757547c-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A12F	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
30569ced-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A12Q-01A-51-A21V-30	7b48e12f-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A12Q-01A	f0cb13ee-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A12Q	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
121e6c86-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A1AW-01A-41-A21V-30	51cb96df-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A1AW-01A	d4e8179c-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A1AW	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5289671c-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0T3-01A-22-A21V-30	53d2c189-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0T3-01A	217889b2-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0T3	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
49979e7e-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0EV-01A-41-A21V-30	4765b4bc-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0EV-01A	18768947-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0EV	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f44c1d41-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A03O-01A-41-A21V-30	29102b69-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A03O-01A	b85cf2e2-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A03O	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f30f1fa0-6428-11e8-bcf1-0a2705229b82	TCGA-AN-A0FL-01A-12-A21V-30	273a38e4-6420-11e8-bcf1-0a2705229b82	TCGA-AN-A0FL-01A	b72047f9-63d8-11e8-bcf1-0a2705229b82	TCGA-AN-A0FL	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6894c79c-6428-11e8-bcf1-0a2705229b82	TCGA-A8-A06N-01A-41-A21V-30	71e070f3-641f-11e8-bcf1-0a2705229b82	TCGA-A8-A06N-01A	36cfed45-63d8-11e8-bcf1-0a2705229b82	TCGA-A8-A06N	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
07b71288-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A0TV-01A-41-A21V-30	43c357fc-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A0TV-01A	cb0d61b4-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A0TV	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
42463be9-6429-11e8-bcf1-0a2705229b82	TCGA-E2-A150-01A-12-A21W-30	96f69c5f-6420-11e8-bcf1-0a2705229b82	TCGA-E2-A150-01A	024cad7d-63d9-11e8-bcf1-0a2705229b82	TCGA-E2-A150	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f972b320-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A0JE-01A-41-A21V-30	2ffecfa6-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A0JE-01A	bd4adbe5-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A0JE	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
356ef6b4-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A12W-01A-41-A21V-30	8533d83d-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A12W-01A	f5ccbe11-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A12W	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
66252f45-6428-11e8-bcf1-0a2705229b82	TCGA-A7-A0CJ-01A-32-A21V-30	6e49d005-641f-11e8-bcf1-0a2705229b82	TCGA-A7-A0CJ-01A	344adec2-63d8-11e8-bcf1-0a2705229b82	TCGA-A7-A0CJ	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
44d3a897-6429-11e8-bcf1-0a2705229b82	TCGA-E2-A158-01A-31-A21W-30	9abbf3fd-6420-11e8-bcf1-0a2705229b82	TCGA-E2-A158-01A	04c68980-63d9-11e8-bcf1-0a2705229b82	TCGA-E2-A158	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
34317a3a-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A12V-01A-41-A21V-30	83929378-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A12V-01A	f49043f6-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A12V	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
55162c6e-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0T7-01A-41-A21V-30	573964a7-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0T7-01A	240188c9-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0T7	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32e20271-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A12U-01A-41-A21V-30	80553173-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A12U-01A	f35034a7-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A12U	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
46123a3f-6429-11e8-bcf1-0a2705229b82	TCGA-E2-A159-01A-12-A21W-30	9ccb7d7d-6420-11e8-bcf1-0a2705229b82	TCGA-E2-A159-01A	0608bb08-63d9-11e8-bcf1-0a2705229b82	TCGA-E2-A159	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
39499ce3-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A131-01A-41-A21V-30	8a8f1c0b-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A131-01A	f98c2cb5-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A131	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
052bd132-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A0TR-01A-41-A21V-30	4057ac5e-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A0TR-01A	c894884f-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A0TR	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a47a598-ec51-11e9-81b4-2a2ae2dbcce4	Internal Reference	6a4791ac-ec51-11e9-81b4-2a2ae2dbcce4	Internal Reference	6a4781d0-ec51-11e9-81b4-2a2ae2dbcce4	Internal Reference	CPTAC2 Retrospective	Not Reported	Not Reported	Other	yes																																	Clinical Proteomic Tumor Analysis Consortium
1d3026fa-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0DD-01A-41-A21V-30	5e1def46-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0DD-01A	dde21323-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0DD	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
02a1e4ed-6429-11e8-bcf1-0a2705229b82	TCGA-AO-A12E-01A-41-A21V-30	3cf3663b-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A12E-01A	c61a65b2-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A12E	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0e45a664-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A1AQ-01A-12-A21W-30	4ca43c5f-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A1AQ-01A	d136d079-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A1AQ	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a3cd12c-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0YG-01A-41-A21V-30	5e37f9af-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0YG-01A	28fe59bd-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0YG	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fc01ce2b-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A0JL-01A-41-A21W-30	33eade1f-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A0JL-01A	bfc9877a-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A0JL	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63667884-6428-11e8-bcf1-0a2705229b82	TCGA-A7-A0CD-01A-22-A21W-30	6aad15ab-641f-11e8-bcf1-0a2705229b82	TCGA-A7-A0CD-01A	31d4b8ba-63d8-11e8-bcf1-0a2705229b82	TCGA-A7-A0CD	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1bd88667-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0C7-01A-31-A21V-30	5c7c9ab2-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0C7-01A	dca21779-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0C7	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
53d3f14b-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0T6-01A-41-A21V-30	55633158-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0T6-01A	22c2b43e-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0T6	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48eea94d-642a-11e8-bcf1-0a2705229b82	blcdb9-I	0ce8096e-6421-11e8-bcf1-0a2705229b82	blcdb9-I	1c91a7a9-63d9-11e8-bcf1-0a2705229b82	blcdb9-I	CPTAC2 Retrospective	Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fd50c409-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A0JM-01A-41-A21V-30	35800901-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A0JM-01A	c10409cb-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A0JM	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
472d3703-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0D2-01A-12-A21W-30	4401b622-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0D2-01A	15fadb80-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0D2	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
70476ed6-6428-11e8-bcf1-0a2705229b82	TCGA-A8-A09G-01A-41-A21W-30	7c958bad-641f-11e8-bcf1-0a2705229b82	TCGA-A8-A09G-01A	3e79db01-63d8-11e8-bcf1-0a2705229b82	TCGA-A8-A09G	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
58efa944-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0YF-01A-41-A21V-30	5c7459f1-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0YF-01A	27bf90ad-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0YF	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0669f611-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A0TT-01A-22-A21V-30	41ef0ce7-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A0TT-01A	c9d1d603-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A0TT	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4d7112cf-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0SW-01A-41-A21V-30	4cd28e61-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0SW-01A	1c39d311-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0SW	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0003cc2c-6429-11e8-bcf1-0a2705229b82	TCGA-AO-A12B-01A-41-A21V-30	398a4199-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A12B-01A	c3a38e6a-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A12B	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e076753-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0YM-01A-22-A21W-30	63745eef-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0YM-01A	2cbe7b53-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0YM	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
47b645da-642a-11e8-bcf1-0a2705229b82	263d3f-I	0af2fa91-6421-11e8-bcf1-0a2705229b82	263d3f-I	1b4c05eb-63d9-11e8-bcf1-0a2705229b82	263d3f-I	CPTAC2 Retrospective	Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
380c08c1-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A130-01A-41-A21V-30	8896ce14-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A130-01A	f84e09f9-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A130	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
17ccb772-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0BZ-01A-41-A21V-30	5740d2a2-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0BZ-01A	d8dc8ed7-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0BZ	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4ae63431-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0EX-01A-41-A21V-30	49399de2-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0EX-01A	19bc0395-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0EX	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
138d74bb-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0AV-01A-32-A21V-30	5377b0e2-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0AV-01A	d625ee3c-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0AV	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3193c273-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A12T-01A-41-A21V-30	7ceabbea-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A12T-01A	f209fb00-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A12T	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4350befe-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0CM-01A-11-A21V-30	3ec16f32-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0CM-01A	12047797-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0CM	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
486c343d-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0EQ-01A-41-A21W-30	45c4c1dc-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0EQ-01A	17380b66-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0EQ	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
260aca30-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0HP-01A-41-A21V-30	6bf90f0b-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0HP-01A	e6e186c1-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0HP	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1fb9b049-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0E0-01A-41-A21V-30	61b9857d-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0E0-01A	e0617dfe-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0E0	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f59c7ca4-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A0J6-01A-22-A21W-30	2aa3b036-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A0J6-01A	b9986c9b-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A0J6	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21150c33-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0E1-01A-41-A21V-30	638a9edc-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0E1-01A	e1a03084-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0E1	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5664928c-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0YC-01A-41-A21V-30	58d99b9a-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0YC-01A	253cee23-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0YC	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
092ab5cc-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A0TX-01A-41-A21V-30	4562af51-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A0TX-01A	cc4a5557-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A0TX	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fec54f06-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A126-01A-22-A21W-30	37b7b81b-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A126-01A	c2633b5b-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A126	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4c2618da-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0EY-01A-41-A21V-30	4afe1bf8-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0EY-01A	1afb10ed-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0EY	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3bd508c2-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A135-01A-41-A21V-30	8e25319f-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A135-01A	fc0ec4a7-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A135	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3fbd4482-6429-11e8-bcf1-0a2705229b82	TCGA-D8-A142-01A-41-A21V-30	932ed82b-6420-11e8-bcf1-0a2705229b82	TCGA-D8-A142-01A	ffc8b74d-63d8-11e8-bcf1-0a2705229b82	TCGA-D8-A142	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f07c3152-6428-11e8-bcf1-0a2705229b82	TCGA-AN-A0AS-01A-22-A21W-30	23a0de39-6420-11e8-bcf1-0a2705229b82	TCGA-AN-A0AS-01A	b4a640a3-63d8-11e8-bcf1-0a2705229b82	TCGA-AN-A0AS	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fab4c704-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A0JJ-01A-31-A21W-30	31a120b9-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A0JJ-01A	be89e3d3-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A0JJ	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ec71b709-6428-11e8-bcf1-0a2705229b82	TCGA-AN-A0AJ-01A-22-A21W-30	1e36ebed-6420-11e8-bcf1-0a2705229b82	TCGA-AN-A0AJ-01A	b0cedd28-63d8-11e8-bcf1-0a2705229b82	TCGA-AN-A0AJ	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ccab209-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0YL-01A-41-A21V-30	61d21df5-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0YL-01A	2b811776-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0YL	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6c6fb2e2-6428-11e8-bcf1-0a2705229b82	TCGA-A8-A079-01A-12-A21V-30	76f03a7b-641f-11e8-bcf1-0a2705229b82	TCGA-A8-A079-01A	3aa0a974-63d8-11e8-bcf1-0a2705229b82	TCGA-A8-A079	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
57b2db74-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0YD-01A-41-A21V-30	5ace852e-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0YD-01A	267ec01a-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0YD	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29ece8e5-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A18R-01A-22-A21W-30	70fe80ce-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A18R-01A	ea9581b7-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A18R	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4ffd58af-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0T1-01A-12-A21V-30	506e0a01-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0T1-01A	1ebafb1f-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0T1	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2760c52f-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A18N-01A-41-A21V-30	6d89d3fe-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A18N-01A	e81fdd02-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A18N	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
edc14b7d-6428-11e8-bcf1-0a2705229b82	TCGA-AN-A0AL-01A-22-A21W-30	1fda25b4-6420-11e8-bcf1-0a2705229b82	TCGA-AN-A0AL-01A	b224e773-63d8-11e8-bcf1-0a2705229b82	TCGA-AN-A0AL	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
475fc5d1-6429-11e8-bcf1-0a2705229b82	TCGA-E2-A15A-01A-41-A21W-30	9e8680fb-6420-11e8-bcf1-0a2705229b82	TCGA-E2-A15A-01A	07468279-63d9-11e8-bcf1-0a2705229b82	TCGA-E2-A15A	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6dbd35fe-6428-11e8-bcf1-0a2705229b82	TCGA-A8-A08G-01A-13-A21W-30	78f43d0f-641f-11e8-bcf1-0a2705229b82	TCGA-A8-A08G-01A	3bdfde9b-63d8-11e8-bcf1-0a2705229b82	TCGA-A8-A08G	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f93ca1a-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A1AS-01A-41-A21W-30	4e66df70-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A1AS-01A	d270e7a5-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A1AS	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a882e6d-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A134-01A-41-A21V-30	8c2f8951-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A134-01A	faca7c9c-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A134	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
22534968-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0E9-01B-22-A21V-30	651dde10-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0E9-01B	e2e48fc0-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0E9	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
15c01b6e-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0BV-01A-41-A21V-30	557d70a5-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0BV-01A	d7988a9c-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0BV	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4ebfb075-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0SX-01A-41-A21V-30	4e946546-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0SX-01A	1d759414-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0SX	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4a50a114-642a-11e8-bcf1-0a2705229b82	c4155b-C	0eef2e69-6421-11e8-bcf1-0a2705229b82	c4155b-C	1df7f83f-63d9-11e8-bcf1-0a2705229b82	c4155b-C	CPTAC2 Retrospective	Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
289ee34c-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A18Q-01A-41-A21W-30	6f5dbf57-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A18Q-01A	e959b0d7-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A18Q	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
43a56be0-6429-11e8-bcf1-0a2705229b82	TCGA-E2-A154-01A-41-A21V-30	98f7264a-6420-11e8-bcf1-0a2705229b82	TCGA-E2-A154-01A	038a0679-63d9-11e8-bcf1-0a2705229b82	TCGA-E2-A154	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2dcc81a4-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A12L-01A-41-A21V-30	774c9833-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A12L-01A	ee487139-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A12L	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb24f0e5-6428-11e8-bcf1-0a2705229b82	TCGA-AN-A04A-01A-31-A21W-30	1c72d1b5-6420-11e8-bcf1-0a2705229b82	TCGA-AN-A04A-01A	af738f95-63d8-11e8-bcf1-0a2705229b82	TCGA-AN-A04A	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0140af49-6429-11e8-bcf1-0a2705229b82	TCGA-AO-A12D-01A-41-A21V-30	3b201882-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A12D-01A	c4deba9f-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A12D	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
410a1984-6429-11e8-bcf1-0a2705229b82	TCGA-E2-A10A-01A-12-A21V-30	9532a8b4-6420-11e8-bcf1-0a2705229b82	TCGA-E2-A10A-01A	010df72d-63d9-11e8-bcf1-0a2705229b82	TCGA-E2-A10A	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
24dd5de9-6429-11e8-bcf1-0a2705229b82	TCGA-BH-A0HK-01A-41-A21V-30	6a211551-6420-11e8-bcf1-0a2705229b82	TCGA-BH-A0HK-01A	e59670cd-63d8-11e8-bcf1-0a2705229b82	TCGA-BH-A0HK	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3d1b786d-6429-11e8-bcf1-0a2705229b82	TCGA-C8-A138-01A-14-A21W-30	8fca141c-6420-11e8-bcf1-0a2705229b82	TCGA-C8-A138-01A	fd4c139d-63d8-11e8-bcf1-0a2705229b82	TCGA-C8-A138	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
45def69d-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0D1-01A-22-A21W-30	42580322-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0D1-01A	14b73c43-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0D1	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7185dbc9-6428-11e8-bcf1-0a2705229b82	TCGA-A8-A09I-01A-13-A21V-30	7e27c4ba-641f-11e8-bcf1-0a2705229b82	TCGA-A8-A09I-01A	3fb775e7-63d8-11e8-bcf1-0a2705229b82	TCGA-A8-A09I	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b7b88ae-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0YI-01A-11-A21V-30	600b49d2-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0YI-01A	2a407548-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0YI	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0bb9a4de-6429-11e8-bcf1-0a2705229b82	TCGA-AR-A0U4-01A-22-A21V-30	4909431d-6420-11e8-bcf1-0a2705229b82	TCGA-AR-A0U4-01A	cec09f8e-63d8-11e8-bcf1-0a2705229b82	TCGA-AR-A0U4	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f6e7a4d6-6428-11e8-bcf1-0a2705229b82	TCGA-AO-A0J9-01A-41-A21V-30	2c740d6c-6420-11e8-bcf1-0a2705229b82	TCGA-AO-A0J9-01A	bad4ad66-63d8-11e8-bcf1-0a2705229b82	TCGA-AO-A0J9	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
44a0aa5b-6428-11e8-bcf1-0a2705229b82	TCGA-A2-A0D0-01A-41-A21W-30	4063987b-641f-11e8-bcf1-0a2705229b82	TCGA-A2-A0D0-01A	1341b7df-63d8-11e8-bcf1-0a2705229b82	TCGA-A2-A0D0	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1c157aa-6428-11e8-bcf1-0a2705229b82	TCGA-AN-A0FK-01A-22-A21W-30	25754d32-6420-11e8-bcf1-0a2705229b82	TCGA-AN-A0FK-01A	b5e2fb26-63d8-11e8-bcf1-0a2705229b82	TCGA-AN-A0FK	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
69e2c586-6428-11e8-bcf1-0a2705229b82	TCGA-A8-A06Z-01A-22-A21V-30	7383b570-641f-11e8-bcf1-0a2705229b82	TCGA-A8-A06Z-01A	381030bf-63d8-11e8-bcf1-0a2705229b82	TCGA-A8-A06Z	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6778e470-6428-11e8-bcf1-0a2705229b82	TCGA-A7-A13F-01A-51-A21V-30	703f6192-641f-11e8-bcf1-0a2705229b82	TCGA-A7-A13F-01A	3588ee7d-63d8-11e8-bcf1-0a2705229b82	TCGA-A7-A13F	CPTAC2 Retrospective	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32814606-0a5d-11eb-bc0e-0aad30af8a83	01f203fd-e664-4d78-bea0-7c40cf_D2	32803c33-0a5d-11eb-bc0e-0aad30af8a83	01f203fd-e664-4d78-bea0-7c40cf	327f7599-0a5d-11eb-bc0e-0aad30af8a83	03BR013	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32818b6c-0a5d-11eb-bc0e-0aad30af8a83	314de592-f356-4801-8ace-278173_D2	3280a3bc-0a5d-11eb-bc0e-0aad30af8a83	314de592-f356-4801-8ace-278173	327fd0be-0a5d-11eb-bc0e-0aad30af8a83	11BR032	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c155-0a5d-11eb-bc0e-0aad30af8a83	547f521a-5851-426c-a125-d9d82c_D2	32810850-0a5d-11eb-bc0e-0aad30af8a83	547f521a-5851-426c-a125-d9d82c	327ffd6b-0a5d-11eb-bc0e-0aad30af8a83	20BR007	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32816f7c-0a5d-11eb-bc0e-0aad30af8a83	98225215-ff21-4893-8b6d-d9b7e7_D2	32807501-0a5d-11eb-bc0e-0aad30af8a83	98225215-ff21-4893-8b6d-d9b7e7	327fac01-0a5d-11eb-bc0e-0aad30af8a83	11BR012	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32813396-0a5d-11eb-bc0e-0aad30af8a83	c646b902-e1e0-4e3e-a4c5-daca71_D2	328027bd-0a5d-11eb-bc0e-0aad30af8a83	c646b902-e1e0-4e3e-a4c5-daca71	327f6256-0a5d-11eb-bc0e-0aad30af8a83	01BR033	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281bb7f-0a5d-11eb-bc0e-0aad30af8a83	392b8aa4-9f99-4250-b693-326260_D2	3280fded-0a5d-11eb-bc0e-0aad30af8a83	392b8aa4-9f99-4250-b693-326260	327ff81e-0a5d-11eb-bc0e-0aad30af8a83	18BR017	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281989c-0a5d-11eb-bc0e-0aad30af8a83	56b488cf-a189-47a8-b4e2-d976eb_D2	3280bc27-0a5d-11eb-bc0e-0aad30af8a83	56b488cf-a189-47a8-b4e2-d976eb	327fda9e-0a5d-11eb-bc0e-0aad30af8a83	11BR051	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281273b-0a5d-11eb-bc0e-0aad30af8a83	d154d194-2b08-46d4-a199-84cfb8_D8	32801486-0a5d-11eb-bc0e-0aad30af8a83	d154d194-2b08-46d4-a199-84cfb8	327f5945-0a5d-11eb-bc0e-0aad30af8a83	01BR018	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281bc50-0a5d-11eb-bc0e-0aad30af8a83	0edcba67-0714-4b04-b433-77834e_D2	3280ff32-0a5d-11eb-bc0e-0aad30af8a83	0edcba67-0714-4b04-b433-77834e	327ff8f1-0a5d-11eb-bc0e-0aad30af8a83	18BR019	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b514-0a5d-11eb-bc0e-0aad30af8a83	436297af-feb7-4754-96b7-c5bfb5_D2	3280ef1c-0a5d-11eb-bc0e-0aad30af8a83	436297af-feb7-4754-96b7-c5bfb5	327ff275-0a5d-11eb-bc0e-0aad30af8a83	18BR003	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812b16-0a5d-11eb-bc0e-0aad30af8a83	d6d42051-ad8e-4fb2-8cfc-829353_D2	32801a2c-0a5d-11eb-bc0e-0aad30af8a83	d6d42051-ad8e-4fb2-8cfc-829353	327f5bee-0a5d-11eb-bc0e-0aad30af8a83	01BR025	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281403e-0a5d-11eb-bc0e-0aad30af8a83	071be0fb-b7fd-4165-b3c5-348352	32803675-0a5d-11eb-bc0e-0aad30af8a83	071be0fb-b7fd-4165-b3c5-348352	327f701b-0a5d-11eb-bc0e-0aad30af8a83	03BR006	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328191db-0a5d-11eb-bc0e-0aad30af8a83	6d34d499-167e-42aa-9790-316fca_D2	3280ade2-0a5d-11eb-bc0e-0aad30af8a83	6d34d499-167e-42aa-9790-316fca	327fd561-0a5d-11eb-bc0e-0aad30af8a83	11BR043	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281716e-0a5d-11eb-bc0e-0aad30af8a83	faadb553-9437-42cb-b469-498d67_D2	328076d0-0a5d-11eb-bc0e-0aad30af8a83	faadb553-9437-42cb-b469-498d67	327fae36-0a5d-11eb-bc0e-0aad30af8a83	11BR013	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a233-0a5d-11eb-bc0e-0aad30af8a83	5d27516f-58d7-4155-80b4-4c7f39_D2	3280cf23-0a5d-11eb-bc0e-0aad30af8a83	5d27516f-58d7-4155-80b4-4c7f39	327fe5c7-0a5d-11eb-bc0e-0aad30af8a83	11BR073	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328123ea-0a5d-11eb-bc0e-0aad30af8a83	26ecef2d-fcf3-4b85-9647-5e5d29_D1	32800f03-0a5d-11eb-bc0e-0aad30af8a83	26ecef2d-fcf3-4b85-9647-5e5d29	327f52eb-0a5d-11eb-bc0e-0aad30af8a83	01BR010	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b715-0a5d-11eb-bc0e-0aad30af8a83	bebb15ad-03f1-4773-b3d4-2f78e3_D2	3280f2b6-0a5d-11eb-bc0e-0aad30af8a83	bebb15ad-03f1-4773-b3d4-2f78e3	327ff40f-0a5d-11eb-bc0e-0aad30af8a83	18BR006	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281283d-0a5d-11eb-bc0e-0aad30af8a83	3fd68501-514a-4a30-9ce1-2fca26_D1	3280165b-0a5d-11eb-bc0e-0aad30af8a83	3fd68501-514a-4a30-9ce1-2fca26	327f5a36-0a5d-11eb-bc0e-0aad30af8a83	01BR020	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812077-0a5d-11eb-bc0e-0aad30af8a83	CPT000814-0004	3280076e-0a5d-11eb-bc0e-0aad30af8a83	CPT000814	327f4a65-0a5d-11eb-bc0e-0aad30af8a83	604	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328164f5-0a5d-11eb-bc0e-0aad30af8a83	150c2086-1815-40d2-bc5d-8eeb48_D2	328065d1-0a5d-11eb-bc0e-0aad30af8a83	150c2086-1815-40d2-bc5d-8eeb48	327f9d7a-0a5d-11eb-bc0e-0aad30af8a83	09BR005	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32813c08-0a5d-11eb-bc0e-0aad30af8a83	ca576d30-be91-4bf5-a31d-80f7eb_D2	328030ca-0a5d-11eb-bc0e-0aad30af8a83	ca576d30-be91-4bf5-a31d-80f7eb	327f6add-0a5d-11eb-bc0e-0aad30af8a83	03BR002	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281ae0d-0a5d-11eb-bc0e-0aad30af8a83	ca14c6dd-2069-4bc5-b1f2-6f2297_D2	3280e2ae-0a5d-11eb-bc0e-0aad30af8a83	ca14c6dd-2069-4bc5-b1f2-6f2297	327fec71-0a5d-11eb-bc0e-0aad30af8a83	14BR008	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819c0d-0a5d-11eb-bc0e-0aad30af8a83	e45c73a8-da96-4269-a039-d43942_D2	3280c3bd-0a5d-11eb-bc0e-0aad30af8a83	e45c73a8-da96-4269-a039-d43942	327fdfb5-0a5d-11eb-bc0e-0aad30af8a83	11BR056	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328190b3-0a5d-11eb-bc0e-0aad30af8a83	a176fcc2-97b5-45c3-a0f3-3b2e41_D2	3280abff-0a5d-11eb-bc0e-0aad30af8a83	a176fcc2-97b5-45c3-a0f3-3b2e41	327fd483-0a5d-11eb-bc0e-0aad30af8a83	11BR042	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281619f-0a5d-11eb-bc0e-0aad30af8a83	3799eeb5-c966-4059-a78f-ace269_D2	32805c60-0a5d-11eb-bc0e-0aad30af8a83	3799eeb5-c966-4059-a78f-ace269	327f9693-0a5d-11eb-bc0e-0aad30af8a83	06BR006	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281634e-0a5d-11eb-bc0e-0aad30af8a83	20506075-36a7-4754-8e5e-628918	32805ff8-0a5d-11eb-bc0e-0aad30af8a83	20506075-36a7-4754-8e5e-628918	327f9a31-0a5d-11eb-bc0e-0aad30af8a83	09BR001	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32816a27-0a5d-11eb-bc0e-0aad30af8a83	3208e021-1dae-42fd-bd36-0f3c3d	32806c14-0a5d-11eb-bc0e-0aad30af8a83	3208e021-1dae-42fd-bd36-0f3c3d	327fa44c-0a5d-11eb-bc0e-0aad30af8a83	11BR006	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32816d57-0a5d-11eb-bc0e-0aad30af8a83	436db08d-c316-44b5-b0de-62617d_D2	32807173-0a5d-11eb-bc0e-0aad30af8a83	436db08d-c316-44b5-b0de-62617d	327fa7d6-0a5d-11eb-bc0e-0aad30af8a83	11BR010	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c85b-0a5d-11eb-bc0e-0aad30af8a83	39f81c85-1832-45eb-829a-3040ad	32811537-0a5d-11eb-bc0e-0aad30af8a83	39f81c85-1832-45eb-829a-3040ad	3280018b-0a5d-11eb-bc0e-0aad30af8a83	21BR010	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281880c-0a5d-11eb-bc0e-0aad30af8a83	4749ba99-d3b8-4ae3-b6f6-458bc7	32809e64-0a5d-11eb-bc0e-0aad30af8a83	4749ba99-d3b8-4ae3-b6f6-458bc7	327fcac6-0a5d-11eb-bc0e-0aad30af8a83	11BR030	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281aa0a-0a5d-11eb-bc0e-0aad30af8a83	e2c7113f-957f-4088-b57d-55d2f2_D2	3280dd02-0a5d-11eb-bc0e-0aad30af8a83	e2c7113f-957f-4088-b57d-55d2f2	327fe9e1-0a5d-11eb-bc0e-0aad30af8a83	11BR080	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328135b5-0a5d-11eb-bc0e-0aad30af8a83	4df35993-eab6-4289-822c-d77da9_D2	32802b4b-0a5d-11eb-bc0e-0aad30af8a83	4df35993-eab6-4289-822c-d77da9	327f65b9-0a5d-11eb-bc0e-0aad30af8a83	01BR042	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328175ec-0a5d-11eb-bc0e-0aad30af8a83	a7d58d61-5049-488f-9d0a-0a4411_D2	32807e2f-0a5d-11eb-bc0e-0aad30af8a83	a7d58d61-5049-488f-9d0a-0a4411	327fb3fd-0a5d-11eb-bc0e-0aad30af8a83	11BR016	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281841c-0a5d-11eb-bc0e-0aad30af8a83	413d7d87-7b86-4b76-af93-8e8136_D2	32809876-0a5d-11eb-bc0e-0aad30af8a83	413d7d87-7b86-4b76-af93-8e8136	327fc656-0a5d-11eb-bc0e-0aad30af8a83	11BR027	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a5a5-0a5d-11eb-bc0e-0aad30af8a83	5504c643-4a9c-4ec4-ab07-bebdaf_D2	3280d683-0a5d-11eb-bc0e-0aad30af8a83	5504c643-4a9c-4ec4-ab07-bebdaf	327fe768-0a5d-11eb-bc0e-0aad30af8a83	11BR075	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815143-0a5d-11eb-bc0e-0aad30af8a83	48d1b543-dbf6-4594-b34a-d0e30a_D2	32804528-0a5d-11eb-bc0e-0aad30af8a83	48d1b543-dbf6-4594-b34a-d0e30a	327f7f64-0a5d-11eb-bc0e-0aad30af8a83	05BR009	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32817f74-0a5d-11eb-bc0e-0aad30af8a83	9efd41a5-3db1-445b-accb-040c2b_D2	328090cc-0a5d-11eb-bc0e-0aad30af8a83	9efd41a5-3db1-445b-accb-040c2b	327fc219-0a5d-11eb-bc0e-0aad30af8a83	11BR024	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328137e3-0a5d-11eb-bc0e-0aad30af8a83	CPT001846-0005	32802eef-0a5d-11eb-bc0e-0aad30af8a83	CPT001846	327f6928-0a5d-11eb-bc0e-0aad30af8a83	01BR044	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328153ec-0a5d-11eb-bc0e-0aad30af8a83	3f957017-d081-45f4-b458-ec3f8d_D2	32804701-0a5d-11eb-bc0e-0aad30af8a83	3f957017-d081-45f4-b458-ec3f8d	327f8188-0a5d-11eb-bc0e-0aad30af8a83	05BR016	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281cac6-0a5d-11eb-bc0e-0aad30af8a83	a2637649-1fa1-4c20-a19d-5d5f11_D2	3281190c-0a5d-11eb-bc0e-0aad30af8a83	a2637649-1fa1-4c20-a19d-5d5f11	32800338-0a5d-11eb-bc0e-0aad30af8a83	22BR006	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32818a51-0a5d-11eb-bc0e-0aad30af8a83	3fdf0dbe-e05c-465f-8bed-4a92dd_D2	3280a1e7-0a5d-11eb-bc0e-0aad30af8a83	3fdf0dbe-e05c-465f-8bed-4a92dd	327fcc44-0a5d-11eb-bc0e-0aad30af8a83	11BR031	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819553-0a5d-11eb-bc0e-0aad30af8a83	81116212-b7e6-454b-9579-105cf3	3280b69c-0a5d-11eb-bc0e-0aad30af8a83	81116212-b7e6-454b-9579-105cf3	327fd721-0a5d-11eb-bc0e-0aad30af8a83	11BR047	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281ab21-0a5d-11eb-bc0e-0aad30af8a83	878c2524-208e-40b2-8089-ceb820_D2	3280deda-0a5d-11eb-bc0e-0aad30af8a83	878c2524-208e-40b2-8089-ceb820	327feabe-0a5d-11eb-bc0e-0aad30af8a83	13BR009	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32817ce3-0a5d-11eb-bc0e-0aad30af8a83	0a80d3c4-0758-447a-958c-ea868c	32808d16-0a5d-11eb-bc0e-0aad30af8a83	0a80d3c4-0758-447a-958c-ea868c	327fc001-0a5d-11eb-bc0e-0aad30af8a83	11BR023	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328134a8-0a5d-11eb-bc0e-0aad30af8a83	4a25e3da-2226-4e23-a595-c11709_D2	32802980-0a5d-11eb-bc0e-0aad30af8a83	4a25e3da-2226-4e23-a595-c11709	327f6408-0a5d-11eb-bc0e-0aad30af8a83	01BR040	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281627e-0a5d-11eb-bc0e-0aad30af8a83	b2d62dca-3741-4d59-92b8-bdcfed_D2	32805e2c-0a5d-11eb-bc0e-0aad30af8a83	b2d62dca-3741-4d59-92b8-bdcfed	327f988c-0a5d-11eb-bc0e-0aad30af8a83	06BR014	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819ce8-0a5d-11eb-bc0e-0aad30af8a83	8886aaca-adcf-4416-920a-794bf0_D2	3280c58e-0a5d-11eb-bc0e-0aad30af8a83	8886aaca-adcf-4416-920a-794bf0	327fe08e-0a5d-11eb-bc0e-0aad30af8a83	11BR057	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a3de-0a5d-11eb-bc0e-0aad30af8a83	12ce8313-6c54-4bee-a996-1aa7f8_D2	3280d2f1-0a5d-11eb-bc0e-0aad30af8a83	12ce8313-6c54-4bee-a996-1aa7f8	327fe698-0a5d-11eb-bc0e-0aad30af8a83	11BR074	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328178ce-0a5d-11eb-bc0e-0aad30af8a83	855256a7-e41e-4158-b02f-ba61a9_D2	32808427-0a5d-11eb-bc0e-0aad30af8a83	855256a7-e41e-4158-b02f-ba61a9	327fb7df-0a5d-11eb-bc0e-0aad30af8a83	11BR018	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812e5e-0a5d-11eb-bc0e-0aad30af8a83	1990853a-0e82-40b3-a025-91cdc1_D2	32802080-0a5d-11eb-bc0e-0aad30af8a83	1990853a-0e82-40b3-a025-91cdc1	327f5d9e-0a5d-11eb-bc0e-0aad30af8a83	01BR027	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812c2e-0a5d-11eb-bc0e-0aad30af8a83	884659ef-cce7-4b4a-b28b-0e1f49	32801c50-0a5d-11eb-bc0e-0aad30af8a83	884659ef-cce7-4b4a-b28b-0e1f49	327f5cc6-0a5d-11eb-bc0e-0aad30af8a83	01BR026	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b838-0a5d-11eb-bc0e-0aad30af8a83	1ae5772a-ba49-4c00-b890-7513d0_D2	3280f4c2-0a5d-11eb-bc0e-0aad30af8a83	1ae5772a-ba49-4c00-b890-7513d0	327ff4e2-0a5d-11eb-bc0e-0aad30af8a83	18BR007	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328124bc-0a5d-11eb-bc0e-0aad30af8a83	42cc89e1-a896-4f57-b8d9-e7fe56_D2	328010d1-0a5d-11eb-bc0e-0aad30af8a83	42cc89e1-a896-4f57-b8d9-e7fe56	327f53c8-0a5d-11eb-bc0e-0aad30af8a83	01BR015	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819b31-0a5d-11eb-bc0e-0aad30af8a83	4533a2d6-e850-43f3-9c44-621c07_D2	3280c1e5-0a5d-11eb-bc0e-0aad30af8a83	4533a2d6-e850-43f3-9c44-621c07	327fde8b-0a5d-11eb-bc0e-0aad30af8a83	11BR055	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32816e68-0a5d-11eb-bc0e-0aad30af8a83	bc9fe67f-c4a2-43ba-87bd-438bda_D2	3280733d-0a5d-11eb-bc0e-0aad30af8a83	bc9fe67f-c4a2-43ba-87bd-438bda	327fa99f-0a5d-11eb-bc0e-0aad30af8a83	11BR011	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32816b37-0a5d-11eb-bc0e-0aad30af8a83	4798bb9d-7100-43aa-b615-85897d_D2	32806dea-0a5d-11eb-bc0e-0aad30af8a83	4798bb9d-7100-43aa-b615-85897d	327fa44c-0a5d-11eb-bc0e-0aad30af8a83	11BR006	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32816c47-0a5d-11eb-bc0e-0aad30af8a83	3324361b-df55-4e53-a2ef-4f8df2_D2	32806fac-0a5d-11eb-bc0e-0aad30af8a83	3324361b-df55-4e53-a2ef-4f8df2	327fa60f-0a5d-11eb-bc0e-0aad30af8a83	11BR009	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812168-0a5d-11eb-bc0e-0aad30af8a83	17d55745-4ab3-4a80-a182-af938b_D2	3280099b-0a5d-11eb-bc0e-0aad30af8a83	17d55745-4ab3-4a80-a182-af938b	327f4fe6-0a5d-11eb-bc0e-0aad30af8a83	01BR001	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32818200-0a5d-11eb-bc0e-0aad30af8a83	8d7fc1ef-a0ac-44bb-8381-1444a0_D2	3280949b-0a5d-11eb-bc0e-0aad30af8a83	8d7fc1ef-a0ac-44bb-8381-1444a0	327fc435-0a5d-11eb-bc0e-0aad30af8a83	11BR025	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c77d-0a5d-11eb-bc0e-0aad30af8a83	68ef4aa9-00b0-4528-8828-4d3e43_D2	32811349-0a5d-11eb-bc0e-0aad30af8a83	68ef4aa9-00b0-4528-8828-4d3e43	3280018b-0a5d-11eb-bc0e-0aad30af8a83	21BR010	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812315-0a5d-11eb-bc0e-0aad30af8a83	0ecabbfa-8095-4875-acdb-051582_D1	32800d31-0a5d-11eb-bc0e-0aad30af8a83	0ecabbfa-8095-4875-acdb-051582	327f5207-0a5d-11eb-bc0e-0aad30af8a83	01BR009	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32818eb8-0a5d-11eb-bc0e-0aad30af8a83	d7b05dce-4362-4e8f-a77a-07dd74_D2	3280aa13-0a5d-11eb-bc0e-0aad30af8a83	d7b05dce-4362-4e8f-a77a-07dd74	327fd3a1-0a5d-11eb-bc0e-0aad30af8a83	11BR040	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a4b3-0a5d-11eb-bc0e-0aad30af8a83	3367406e-d39c-4641-a3e7-44e1f3	3280d4b8-0a5d-11eb-bc0e-0aad30af8a83	3367406e-d39c-4641-a3e7-44e1f3	327fe698-0a5d-11eb-bc0e-0aad30af8a83	11BR074	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815774-0a5d-11eb-bc0e-0aad30af8a83	d1e36453-8d78-4247-8c3c-3b2a6f_D2	328049a9-0a5d-11eb-bc0e-0aad30af8a83	d1e36453-8d78-4247-8c3c-3b2a6f	327f8397-0a5d-11eb-bc0e-0aad30af8a83	05BR026	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815a69-0a5d-11eb-bc0e-0aad30af8a83	942e63bd-84d6-4227-b3de-03e182_D2	32804f86-0a5d-11eb-bc0e-0aad30af8a83	942e63bd-84d6-4227-b3de-03e182	327f87bb-0a5d-11eb-bc0e-0aad30af8a83	05BR038	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281bfa5-0a5d-11eb-bc0e-0aad30af8a83	2f398497-d53e-4838-8006-d60f3e_D2	328104c8-0a5d-11eb-bc0e-0aad30af8a83	2f398497-d53e-4838-8006-d60f3e	327ffbc5-0a5d-11eb-bc0e-0aad30af8a83	20BR005	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812f70-0a5d-11eb-bc0e-0aad30af8a83	1f5a9aad-61a1-4a64-a9b0-38cd2b_D2	32802293-0a5d-11eb-bc0e-0aad30af8a83	1f5a9aad-61a1-4a64-a9b0-38cd2b	327f5e74-0a5d-11eb-bc0e-0aad30af8a83	01BR030	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281bdf5-0a5d-11eb-bc0e-0aad30af8a83	abee08ca-606d-4e2a-a2e6-24780f_D2	328102af-0a5d-11eb-bc0e-0aad30af8a83	abee08ca-606d-4e2a-a2e6-24780f	327ffaef-0a5d-11eb-bc0e-0aad30af8a83	20BR002	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819dc5-0a5d-11eb-bc0e-0aad30af8a83	80a970f7-7b36-4450-aff8-0b55dc_D2	3280c764-0a5d-11eb-bc0e-0aad30af8a83	80a970f7-7b36-4450-aff8-0b55dc	327fe16b-0a5d-11eb-bc0e-0aad30af8a83	11BR058	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812242-0a5d-11eb-bc0e-0aad30af8a83	cfa2809f-5468-4457-870c-467c39_D1	32800b69-0a5d-11eb-bc0e-0aad30af8a83	cfa2809f-5468-4457-870c-467c39	327f5116-0a5d-11eb-bc0e-0aad30af8a83	01BR008	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328173c7-0a5d-11eb-bc0e-0aad30af8a83	cab796c6-0129-43cf-bd27-7da395_D2	32807a7c-0a5d-11eb-bc0e-0aad30af8a83	cab796c6-0129-43cf-bd27-7da395	327fb213-0a5d-11eb-bc0e-0aad30af8a83	11BR015	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a15e-0a5d-11eb-bc0e-0aad30af8a83	59318d66-8b88-45b2-9b97-90e9a7_D2	3280cd12-0a5d-11eb-bc0e-0aad30af8a83	59318d66-8b88-45b2-9b97-90e9a7	327fe4df-0a5d-11eb-bc0e-0aad30af8a83	11BR072	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b9df-0a5d-11eb-bc0e-0aad30af8a83	0bb9d596-774e-452b-9c89-a6643c_D2	3280f86f-0a5d-11eb-bc0e-0aad30af8a83	0bb9d596-774e-452b-9c89-a6643c	327ff67e-0a5d-11eb-bc0e-0aad30af8a83	18BR010	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328185e4-0a5d-11eb-bc0e-0aad30af8a83	3b177fd6-e7d2-4312-bec7-4a253d_D2	32809c99-0a5d-11eb-bc0e-0aad30af8a83	3b177fd6-e7d2-4312-bec7-4a253d	327fc87e-0a5d-11eb-bc0e-0aad30af8a83	11BR028	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281bd22-0a5d-11eb-bc0e-0aad30af8a83	358296ad-e2a7-40cd-849e-8590fd_D2	3281016e-0a5d-11eb-bc0e-0aad30af8a83	358296ad-e2a7-40cd-849e-8590fd	327ff9d7-0a5d-11eb-bc0e-0aad30af8a83	20BR001	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32816913-0a5d-11eb-bc0e-0aad30af8a83	48de7e82-4cba-423c-9e39-89ac6b_D2	32806950-0a5d-11eb-bc0e-0aad30af8a83	48de7e82-4cba-423c-9e39-89ac6b	327fa292-0a5d-11eb-bc0e-0aad30af8a83	11BR004	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328176df-0a5d-11eb-bc0e-0aad30af8a83	241ecd0e-89bd-4d3a-81b3-55a250	3280801b-0a5d-11eb-bc0e-0aad30af8a83	241ecd0e-89bd-4d3a-81b3-55a250	327fb5ed-0a5d-11eb-bc0e-0aad30af8a83	11BR017	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328192f6-0a5d-11eb-bc0e-0aad30af8a83	d92a2942-dba6-4fff-b0d0-0566fb_D2	3280afc4-0a5d-11eb-bc0e-0aad30af8a83	d92a2942-dba6-4fff-b0d0-0566fb	327fd641-0a5d-11eb-bc0e-0aad30af8a83	11BR044	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32817a6c-0a5d-11eb-bc0e-0aad30af8a83	94176301-9658-4151-9110-5139de_D2	328087c0-0a5d-11eb-bc0e-0aad30af8a83	94176301-9658-4151-9110-5139de	327fbbe8-0a5d-11eb-bc0e-0aad30af8a83	11BR020	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328129e7-0a5d-11eb-bc0e-0aad30af8a83	c875a9a4-035f-425a-9348-26129c_D1	32801844-0a5d-11eb-bc0e-0aad30af8a83	c875a9a4-035f-425a-9348-26129c	327f5b14-0a5d-11eb-bc0e-0aad30af8a83	01BR023	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281cc86-0a5d-11eb-bc0e-0aad30af8a83	Internal Reference - Pooled Sample	32811b11-0a5d-11eb-bc0e-0aad30af8a83	Internal Reference - Pooled Sample	32800407-0a5d-11eb-bc0e-0aad30af8a83	Internal Reference - Pooled Sample	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b1dc-0a5d-11eb-bc0e-0aad30af8a83	7557b796-f11c-4077-a1af-b249c8_D2	3280e995-0a5d-11eb-bc0e-0aad30af8a83	7557b796-f11c-4077-a1af-b249c8	327ff0d3-0a5d-11eb-bc0e-0aad30af8a83	16BR012	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a06b-0a5d-11eb-bc0e-0aad30af8a83	97cc4d46-cf80-41f1-b99c-bc4829_D2	3280cb28-0a5d-11eb-bc0e-0aad30af8a83	97cc4d46-cf80-41f1-b99c-bc4829	327fe319-0a5d-11eb-bc0e-0aad30af8a83	11BR060	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281496e-0a5d-11eb-bc0e-0aad30af8a83	ffc76bfb-61f6-4492-a782-c23321_D2	32803fbc-0a5d-11eb-bc0e-0aad30af8a83	ffc76bfb-61f6-4492-a782-c23321	327f7984-0a5d-11eb-bc0e-0aad30af8a83	05BR003	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32817b3b-0a5d-11eb-bc0e-0aad30af8a83	428de0d4-7f84-4075-bae1-352af6	32808984-0a5d-11eb-bc0e-0aad30af8a83	428de0d4-7f84-4075-bae1-352af6	327fbbe8-0a5d-11eb-bc0e-0aad30af8a83	11BR020	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281327c-0a5d-11eb-bc0e-0aad30af8a83	e5e1306b-719e-4c3e-b85b-fd1231_D2	32802607-0a5d-11eb-bc0e-0aad30af8a83	e5e1306b-719e-4c3e-b85b-fd1231	327f604b-0a5d-11eb-bc0e-0aad30af8a83	01BR032	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32814e9a-0a5d-11eb-bc0e-0aad30af8a83	6838157f-361d-4e95-b933-35bd46_D2	32804356-0a5d-11eb-bc0e-0aad30af8a83	6838157f-361d-4e95-b933-35bd46	327f7d6e-0a5d-11eb-bc0e-0aad30af8a83	05BR005	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815993-0a5d-11eb-bc0e-0aad30af8a83	7ac27de9-0932-4ff5-aab8-29c527	32804d96-0a5d-11eb-bc0e-0aad30af8a83	7ac27de9-0932-4ff5-aab8-29c527	327f85a8-0a5d-11eb-bc0e-0aad30af8a83	05BR029	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c2f8-0a5d-11eb-bc0e-0aad30af8a83	acf022b3-7f01-43b3-ac14-86f97d	32810be9-0a5d-11eb-bc0e-0aad30af8a83	acf022b3-7f01-43b3-ac14-86f97d	327ffe40-0a5d-11eb-bc0e-0aad30af8a83	20BR008	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32817dbb-0a5d-11eb-bc0e-0aad30af8a83	079b5600-6afc-4785-bb22-48cfab_D2	32808eee-0a5d-11eb-bc0e-0aad30af8a83	079b5600-6afc-4785-bb22-48cfab	327fc001-0a5d-11eb-bc0e-0aad30af8a83	11BR023	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b0c4-0a5d-11eb-bc0e-0aad30af8a83	433c2eb6-560f-4387-93af-6c2e1a_D2	3280e780-0a5d-11eb-bc0e-0aad30af8a83	433c2eb6-560f-4387-93af-6c2e1a	327fefbb-0a5d-11eb-bc0e-0aad30af8a83	15BR003	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b627-0a5d-11eb-bc0e-0aad30af8a83	b292e992-0611-4254-872f-af8275_D2	3280f0ec-0a5d-11eb-bc0e-0aad30af8a83	b292e992-0611-4254-872f-af8275	327ff343-0a5d-11eb-bc0e-0aad30af8a83	18BR004	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a307-0a5d-11eb-bc0e-0aad30af8a83	1664b920-5e60-4e3b-9aab-fe121c	3280d12c-0a5d-11eb-bc0e-0aad30af8a83	1664b920-5e60-4e3b-9aab-fe121c	327fe5c7-0a5d-11eb-bc0e-0aad30af8a83	11BR073	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281cd6e-0a5d-11eb-bc0e-0aad30af8a83	RetroIR	32811d1b-0a5d-11eb-bc0e-0aad30af8a83	RetroIR	328004d8-0a5d-11eb-bc0e-0aad30af8a83	RetroIR	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281940f-0a5d-11eb-bc0e-0aad30af8a83	ef52c640-13a9-4855-9ce2-0be77a_D2	3280b458-0a5d-11eb-bc0e-0aad30af8a83	ef52c640-13a9-4855-9ce2-0be77a	327fd721-0a5d-11eb-bc0e-0aad30af8a83	11BR047	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32816420-0a5d-11eb-bc0e-0aad30af8a83	cfc121b5-9562-4a6d-b792-3cd6d5_D2	328061c9-0a5d-11eb-bc0e-0aad30af8a83	cfc121b5-9562-4a6d-b792-3cd6d5	327f9bd2-0a5d-11eb-bc0e-0aad30af8a83	09BR004	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c5df-0a5d-11eb-bc0e-0aad30af8a83	32944ee6-428e-44fc-97d6-22665e	32811165-0a5d-11eb-bc0e-0aad30af8a83	32944ee6-428e-44fc-97d6-22665e	327fffdd-0a5d-11eb-bc0e-0aad30af8a83	21BR002	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32818da1-0a5d-11eb-bc0e-0aad30af8a83	4e766d9f-ede3-4311-bf09-b1f9ba_D2	3280a7ec-0a5d-11eb-bc0e-0aad30af8a83	4e766d9f-ede3-4311-bf09-b1f9ba	327fd2c0-0a5d-11eb-bc0e-0aad30af8a83	11BR038	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328174dc-0a5d-11eb-bc0e-0aad30af8a83	6c660b6b-bfda-47b0-9499-160d49	32807c51-0a5d-11eb-bc0e-0aad30af8a83	6c660b6b-bfda-47b0-9499-160d49	327fb213-0a5d-11eb-bc0e-0aad30af8a83	11BR015	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328177f7-0a5d-11eb-bc0e-0aad30af8a83	241c8dec-b317-4794-8cc2-07c14c_D2	3280821f-0a5d-11eb-bc0e-0aad30af8a83	241c8dec-b317-4794-8cc2-07c14c	327fb5ed-0a5d-11eb-bc0e-0aad30af8a83	11BR017	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328136c5-0a5d-11eb-bc0e-0aad30af8a83	c4015b28-269b-4dc4-8b2e-1b83f7_D2	32802d20-0a5d-11eb-bc0e-0aad30af8a83	c4015b28-269b-4dc4-8b2e-1b83f7	327f6771-0a5d-11eb-bc0e-0aad30af8a83	01BR043	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815b64-0a5d-11eb-bc0e-0aad30af8a83	8ab1a564-9a18-43bf-aee3-7fceb0_D2	328051ba-0a5d-11eb-bc0e-0aad30af8a83	8ab1a564-9a18-43bf-aee3-7fceb0	327f89d1-0a5d-11eb-bc0e-0aad30af8a83	05BR042	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b400-0a5d-11eb-bc0e-0aad30af8a83	e3d45dc6-66ef-4e0b-9d96-1b5db5	3280ed59-0a5d-11eb-bc0e-0aad30af8a83	e3d45dc6-66ef-4e0b-9d96-1b5db5	327ff275-0a5d-11eb-bc0e-0aad30af8a83	18BR003	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328142ac-0a5d-11eb-bc0e-0aad30af8a83	49f55bd6-a89a-4d18-b732-139c3d_D2	3280386c-0a5d-11eb-bc0e-0aad30af8a83	49f55bd6-a89a-4d18-b732-139c3d	327f71ea-0a5d-11eb-bc0e-0aad30af8a83	03BR010	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32818c85-0a5d-11eb-bc0e-0aad30af8a83	45b99ac4-0859-4a3d-8b1e-ce5590_D2	3280a58b-0a5d-11eb-bc0e-0aad30af8a83	45b99ac4-0859-4a3d-8b1e-ce5590	327fd1dc-0a5d-11eb-bc0e-0aad30af8a83	11BR036	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812d49-0a5d-11eb-bc0e-0aad30af8a83	64ee175f-f3ce-446e-bbf4-9b6fa8_D1	32801e4e-0a5d-11eb-bc0e-0aad30af8a83	64ee175f-f3ce-446e-bbf4-9b6fa8	327f5d9e-0a5d-11eb-bc0e-0aad30af8a83	01BR027	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328172ac-0a5d-11eb-bc0e-0aad30af8a83	ddc680ad-63cf-4807-b535-9ccc88_D2	328078a9-0a5d-11eb-bc0e-0aad30af8a83	ddc680ad-63cf-4807-b535-9ccc88	327fb028-0a5d-11eb-bc0e-0aad30af8a83	11BR014	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32814396-0a5d-11eb-bc0e-0aad30af8a83	60c8c914-f53d-4f72-a1ce-5fb803	32803a7a-0a5d-11eb-bc0e-0aad30af8a83	60c8c914-f53d-4f72-a1ce-5fb803	327f73c0-0a5d-11eb-bc0e-0aad30af8a83	03BR011	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c082-0a5d-11eb-bc0e-0aad30af8a83	3f52e236-1daa-4aa0-9a77-e3d043_D2	32810687-0a5d-11eb-bc0e-0aad30af8a83	3f52e236-1daa-4aa0-9a77-e3d043	327ffc97-0a5d-11eb-bc0e-0aad30af8a83	20BR006	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281799e-0a5d-11eb-bc0e-0aad30af8a83	8dd1d8be-dc7e-44f5-9f44-77ecf0_D2	328085db-0a5d-11eb-bc0e-0aad30af8a83	8dd1d8be-dc7e-44f5-9f44-77ecf0	327fb9da-0a5d-11eb-bc0e-0aad30af8a83	11BR019	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328158b9-0a5d-11eb-bc0e-0aad30af8a83	d0ce3c06-9c4c-41bd-b583-9254b0_D2	32804baa-0a5d-11eb-bc0e-0aad30af8a83	d0ce3c06-9c4c-41bd-b583-9254b0	327f85a8-0a5d-11eb-bc0e-0aad30af8a83	05BR029	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32813d1d-0a5d-11eb-bc0e-0aad30af8a83	4683de9c-49ca-4ddd-9d1a-be8121_D2	328032ab-0a5d-11eb-bc0e-0aad30af8a83	4683de9c-49ca-4ddd-9d1a-be8121	327f6c98-0a5d-11eb-bc0e-0aad30af8a83	03BR004	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32814bfb-0a5d-11eb-bc0e-0aad30af8a83	71e07184-b085-4d3d-aabf-6e1420_D1	32804183-0a5d-11eb-bc0e-0aad30af8a83	71e07184-b085-4d3d-aabf-6e1420	327f7b7d-0a5d-11eb-bc0e-0aad30af8a83	05BR004	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815dfd-0a5d-11eb-bc0e-0aad30af8a83	92862537-5f30-47db-a3e2-cc9d0c_D2	3280572b-0a5d-11eb-bc0e-0aad30af8a83	92862537-5f30-47db-a3e2-cc9d0c	327f903a-0a5d-11eb-bc0e-0aad30af8a83	05BR045	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819ea6-0a5d-11eb-bc0e-0aad30af8a83	fc0aa1e4-c1d8-43ed-a5cd-038f61_D2	3280c93e-0a5d-11eb-bc0e-0aad30af8a83	fc0aa1e4-c1d8-43ed-a5cd-038f61	327fe245-0a5d-11eb-bc0e-0aad30af8a83	11BR059	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819681-0a5d-11eb-bc0e-0aad30af8a83	2e700669-85b0-43fa-a9c7-3eaf5a_D2	3280b8b0-0a5d-11eb-bc0e-0aad30af8a83	2e700669-85b0-43fa-a9c7-3eaf5a	327fd7f9-0a5d-11eb-bc0e-0aad30af8a83	11BR049	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c227-0a5d-11eb-bc0e-0aad30af8a83	33adae13-5dbd-4530-a5d5-3763e4	32810a1d-0a5d-11eb-bc0e-0aad30af8a83	33adae13-5dbd-4530-a5d5-3763e4	327ffd6b-0a5d-11eb-bc0e-0aad30af8a83	20BR007	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819a4c-0a5d-11eb-bc0e-0aad30af8a83	b10c7b72-1d44-4668-a637-a536b2_D2	3280c00e-0a5d-11eb-bc0e-0aad30af8a83	b10c7b72-1d44-4668-a637-a536b2	327fdc5e-0a5d-11eb-bc0e-0aad30af8a83	11BR054	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32813089-0a5d-11eb-bc0e-0aad30af8a83	96c52a27-3d9a-49e7-8ae8-a71e7c_D2	3280244b-0a5d-11eb-bc0e-0aad30af8a83	96c52a27-3d9a-49e7-8ae8-a71e7c	327f5f4b-0a5d-11eb-bc0e-0aad30af8a83	01BR031	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b2ed-0a5d-11eb-bc0e-0aad30af8a83	fe591474-99d7-44d3-be73-c3b8ed_D2	3280eb98-0a5d-11eb-bc0e-0aad30af8a83	fe591474-99d7-44d3-be73-c3b8ed	327ff1a7-0a5d-11eb-bc0e-0aad30af8a83	18BR002	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328167f1-0a5d-11eb-bc0e-0aad30af8a83	2dc74c29-2e89-4600-80bf-1e3637_D2	3280682c-0a5d-11eb-bc0e-0aad30af8a83	2dc74c29-2e89-4600-80bf-1e3637	327fa0db-0a5d-11eb-bc0e-0aad30af8a83	11BR003	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281b90c-0a5d-11eb-bc0e-0aad30af8a83	5c9ee07a-ca8f-49bf-9c03-2dc513_D2	3280f693-0a5d-11eb-bc0e-0aad30af8a83	5c9ee07a-ca8f-49bf-9c03-2dc513	327ff5b2-0a5d-11eb-bc0e-0aad30af8a83	18BR009	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281af9e-0a5d-11eb-bc0e-0aad30af8a83	d1034660-11ce-4e38-9ad0-8b9b72_D2	3280e56d-0a5d-11eb-bc0e-0aad30af8a83	d1034660-11ce-4e38-9ad0-8b9b72	327fee92-0a5d-11eb-bc0e-0aad30af8a83	14BR014	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328165db-0a5d-11eb-bc0e-0aad30af8a83	6cb5d29a-9437-430d-b91c-57ee3d_D2	32806716-0a5d-11eb-bc0e-0aad30af8a83	6cb5d29a-9437-430d-b91c-57ee3d	327f9f23-0a5d-11eb-bc0e-0aad30af8a83	09BR007	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a8e9-0a5d-11eb-bc0e-0aad30af8a83	8c9232b9-bd06-4474-8236-70dd8a_D2	3280db1e-0a5d-11eb-bc0e-0aad30af8a83	8c9232b9-bd06-4474-8236-70dd8a	327fe90a-0a5d-11eb-bc0e-0aad30af8a83	11BR078	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281a7c0-0a5d-11eb-bc0e-0aad30af8a83	5a9e89e9-4ac6-4c2f-b05e-c956ba_D2	3280d920-0a5d-11eb-bc0e-0aad30af8a83	5a9e89e9-4ac6-4c2f-b05e-c956ba	327fe83a-0a5d-11eb-bc0e-0aad30af8a83	11BR076	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32813f55-0a5d-11eb-bc0e-0aad30af8a83	96c95de1-514b-44a5-b487-dc390b_D2	3280348e-0a5d-11eb-bc0e-0aad30af8a83	96c95de1-514b-44a5-b487-dc390b	327f6e5a-0a5d-11eb-bc0e-0aad30af8a83	03BR005	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815ed6-0a5d-11eb-bc0e-0aad30af8a83	31b13596-554e-452f-91a4-7e67a8_D2	328058e6-0a5d-11eb-bc0e-0aad30af8a83	31b13596-554e-452f-91a4-7e67a8	327f9271-0a5d-11eb-bc0e-0aad30af8a83	06BR003	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328180fc-0a5d-11eb-bc0e-0aad30af8a83	53723086-8858-4395-93d7-0baa68	328092ae-0a5d-11eb-bc0e-0aad30af8a83	53723086-8858-4395-93d7-0baa68	327fc219-0a5d-11eb-bc0e-0aad30af8a83	11BR024	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32817c0f-0a5d-11eb-bc0e-0aad30af8a83	da3d7876-ca79-4f21-a00e-27e6b6_D2	32808b46-0a5d-11eb-bc0e-0aad30af8a83	da3d7876-ca79-4f21-a00e-27e6b6	327fbdf0-0a5d-11eb-bc0e-0aad30af8a83	11BR022	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328182d0-0a5d-11eb-bc0e-0aad30af8a83	1740224c-32d1-4c9f-98c6-653363	3280967e-0a5d-11eb-bc0e-0aad30af8a83	1740224c-32d1-4c9f-98c6-653363	327fc435-0a5d-11eb-bc0e-0aad30af8a83	11BR025	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c4b4-0a5d-11eb-bc0e-0aad30af8a83	1fb9fca2-cf63-41f2-9381-d9108c	32810f8f-0a5d-11eb-bc0e-0aad30af8a83	1fb9fca2-cf63-41f2-9381-d9108c	327fff0c-0a5d-11eb-bc0e-0aad30af8a83	21BR001	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281bab1-0a5d-11eb-bc0e-0aad30af8a83	3bbf4310-6a83-4d3b-8772-a5dbb6_D2	3280fa4e-0a5d-11eb-bc0e-0aad30af8a83	3bbf4310-6a83-4d3b-8772-a5dbb6	327ff752-0a5d-11eb-bc0e-0aad30af8a83	18BR016	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c9e0-0a5d-11eb-bc0e-0aad30af8a83	12110cb8-8da4-4461-ac1a-1af490_D2	3281171f-0a5d-11eb-bc0e-0aad30af8a83	12110cb8-8da4-4461-ac1a-1af490	3280026a-0a5d-11eb-bc0e-0aad30af8a83	22BR005	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281c3c9-0a5d-11eb-bc0e-0aad30af8a83	b87e7f88-a1f2-425a-8cff-8ae4b9_D2	32810db7-0a5d-11eb-bc0e-0aad30af8a83	b87e7f88-a1f2-425a-8cff-8ae4b9	327ffe40-0a5d-11eb-bc0e-0aad30af8a83	20BR008	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32812591-0a5d-11eb-bc0e-0aad30af8a83	09659708-7747-4d59-a3b9-e221e0_D2	328012a4-0a5d-11eb-bc0e-0aad30af8a83	09659708-7747-4d59-a3b9-e221e0	327f57e4-0a5d-11eb-bc0e-0aad30af8a83	01BR017	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32818938-0a5d-11eb-bc0e-0aad30af8a83	63a05d68-f0f7-42d9-a45f-df0f7e_D2	3280a023-0a5d-11eb-bc0e-0aad30af8a83	63a05d68-f0f7-42d9-a45f-df0f7e	327fcac6-0a5d-11eb-bc0e-0aad30af8a83	11BR030	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281977a-0a5d-11eb-bc0e-0aad30af8a83	d8a5467b-549b-48ed-9ae5-c9c39d_D2	3280ba6c-0a5d-11eb-bc0e-0aad30af8a83	d8a5467b-549b-48ed-9ae5-c9c39d	327fd9af-0a5d-11eb-bc0e-0aad30af8a83	11BR050	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815fd9-0a5d-11eb-bc0e-0aad30af8a83	25db2586-55b0-4456-9bba-c24e06_D2	32805aa1-0a5d-11eb-bc0e-0aad30af8a83	25db2586-55b0-4456-9bba-c24e06	327f94c9-0a5d-11eb-bc0e-0aad30af8a83	06BR005	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328184f4-0a5d-11eb-bc0e-0aad30af8a83	885fe794-a98e-4f81-a284-ac4bb8	32809a8e-0a5d-11eb-bc0e-0aad30af8a83	885fe794-a98e-4f81-a284-ac4bb8	327fc87e-0a5d-11eb-bc0e-0aad30af8a83	11BR028	CPTAC2 Confirmatory	Solid Tissue Normal	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815d2d-0a5d-11eb-bc0e-0aad30af8a83	d01714eb-22bf-4ad7-95d9-f95bdf_D2	32805574-0a5d-11eb-bc0e-0aad30af8a83	d01714eb-22bf-4ad7-95d9-f95bdf	327f8e0f-0a5d-11eb-bc0e-0aad30af8a83	05BR044	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281aca1-0a5d-11eb-bc0e-0aad30af8a83	2386c36d-8d5d-4fd4-bbfa-39cc8d_D2	3280e0c0-0a5d-11eb-bc0e-0aad30af8a83	2386c36d-8d5d-4fd4-bbfa-39cc8d	327feb91-0a5d-11eb-bc0e-0aad30af8a83	14BR005	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32819972-0a5d-11eb-bc0e-0aad30af8a83	fb526979-ee2d-4edf-b41d-01074f_D2	3280be2d-0a5d-11eb-bc0e-0aad30af8a83	fb526979-ee2d-4edf-b41d-01074f	327fdb81-0a5d-11eb-bc0e-0aad30af8a83	11BR053	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
328146f1-0a5d-11eb-bc0e-0aad30af8a83	55d3d4bb-0bf5-4b4e-8ef8-d77a5d_D2	32803df1-0a5d-11eb-bc0e-0aad30af8a83	55d3d4bb-0bf5-4b4e-8ef8-d77a5d	327f7770-0a5d-11eb-bc0e-0aad30af8a83	05BR001	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32815c54-0a5d-11eb-bc0e-0aad30af8a83	6eaf19bf-dd93-4b0b-93c5-e2bca3_D2	328053bc-0a5d-11eb-bc0e-0aad30af8a83	6eaf19bf-dd93-4b0b-93c5-e2bca3	327f8beb-0a5d-11eb-bc0e-0aad30af8a83	05BR043	CPTAC2 Confirmatory	Primary Tumor	Breast	Breast Invasive Carcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281cf0c-0a5d-11eb-bc0e-0aad30af8a83	P5	32811e40-0a5d-11eb-bc0e-0aad30af8a83	P5	328005a9-0a5d-11eb-bc0e-0aad30af8a83	P5	CPTAC2 Confirmatory	Xenograft Tissue	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3281cff0-0a5d-11eb-bc0e-0aad30af8a83	P6	32811f5d-0a5d-11eb-bc0e-0aad30af8a83	P6	32800688-0a5d-11eb-bc0e-0aad30af8a83	P6	CPTAC2 Confirmatory	Xenograft Tissue	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dc141-2139-11ea-aee1-0e1aae319e49	CPT0206330003	104d2868-2139-11ea-aee1-0e1aae319e49	C3N-02788-01	104c7a9a-2139-11ea-aee1-0e1aae319e49	C3N-02788	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104da8e7-2139-11ea-aee1-0e1aae319e49	CPT0186100003	104d0931-2139-11ea-aee1-0e1aae319e49	C3N-01851-01	104c6224-2139-11ea-aee1-0e1aae319e49	C3N-01851	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d53a6-2139-11ea-aee1-0e1aae319e49	CPT0123530003	104ca288-2139-11ea-aee1-0e1aae319e49	C3L-01045-03	104c0df1-2139-11ea-aee1-0e1aae319e49	C3L-01045	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d6965-2139-11ea-aee1-0e1aae319e49	CPT0201710003	104cc2e6-2139-11ea-aee1-0e1aae319e49	C3L-02642-03	104c273b-2139-11ea-aee1-0e1aae319e49	C3L-02642	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d865c-2139-11ea-aee1-0e1aae319e49	CPT0216920008	104ce116-2139-11ea-aee1-0e1aae319e49	C3L-03744-71	104c407d-2139-11ea-aee1-0e1aae319e49	C3L-03744	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5e43-2139-11ea-aee1-0e1aae319e49	CPT0218890004	104cb472-2139-11ea-aee1-0e1aae319e49	"C3L-01155-01, C3L-01155-02"	104c1938-2139-11ea-aee1-0e1aae319e49	C3L-01155	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d7b5a-2139-11ea-aee1-0e1aae319e49	CPT0224390004	104cd4dc-2139-11ea-aee1-0e1aae319e49	C3L-03390-03	104c35a5-2139-11ea-aee1-0e1aae319e49	C3L-03390	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dd557-2139-11ea-aee1-0e1aae319e49	CPT0204390003	104d4089-2139-11ea-aee1-0e1aae319e49	GTEX-R55F-0011-R10A-SM-HAKXY	104c8c6e-2139-11ea-aee1-0e1aae319e49	GTEX-R55F-0011-R10A-SM-HAKXY	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d98c9-2139-11ea-aee1-0e1aae319e49	CPT0093590003	104cf7f7-2139-11ea-aee1-0e1aae319e49	C3N-01368-03	104c5325-2139-11ea-aee1-0e1aae319e49	C3N-01368	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104da191-2139-11ea-aee1-0e1aae319e49	CPT0167750004	104d009a-2139-11ea-aee1-0e1aae319e49	"C3N-01798-01, C3N-01798-02"	104c5b6d-2139-11ea-aee1-0e1aae319e49	C3N-01798	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dd91c-2139-11ea-aee1-0e1aae319e49	CPT0204400003	104d4618-2139-11ea-aee1-0e1aae319e49	GTEX-WVLH-0011-R10A-SM-HAKXZ	104c92ad-2139-11ea-aee1-0e1aae319e49	GTEX-WVLH-0011-R10A-SM-HAKXZ	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d9c72-2139-11ea-aee1-0e1aae319e49	CPT0079790003	104cfc7f-2139-11ea-aee1-0e1aae319e49	C3N-01515-01	104c56ef-2139-11ea-aee1-0e1aae319e49	C3N-01515	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5adc-2139-11ea-aee1-0e1aae319e49	CPT0218690004	104caf0a-2139-11ea-aee1-0e1aae319e49	"C3L-01146-02, C3L-01146-05"	104c1581-2139-11ea-aee1-0e1aae319e49	C3L-01146	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dcef5-2139-11ea-aee1-0e1aae319e49	CPT0204370003	104d3972-2139-11ea-aee1-0e1aae319e49	GTEX-NPJ7-0011-R10A-SM-HAKXW	104c8607-2139-11ea-aee1-0e1aae319e49	GTEX-NPJ7-0011-R10A-SM-HAKXW	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d689c-2139-11ea-aee1-0e1aae319e49	CPT0161730003	104cc1cb-2139-11ea-aee1-0e1aae319e49	C3L-02542-03	104c257c-2139-11ea-aee1-0e1aae319e49	C3L-02542	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104db237-2139-11ea-aee1-0e1aae319e49	CPT0168720003	104d13fb-2139-11ea-aee1-0e1aae319e49	C3N-02186-03	104c6aa6-2139-11ea-aee1-0e1aae319e49	C3N-02186	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dc9cb-2139-11ea-aee1-0e1aae319e49	CPT0206880003	104d3385-2139-11ea-aee1-0e1aae319e49	C3N-03186-01	104c8277-2139-11ea-aee1-0e1aae319e49	C3N-03186	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d6c2d-2139-11ea-aee1-0e1aae319e49	CPT0189650004	104cc5fd-2139-11ea-aee1-0e1aae319e49	"C3L-02705-71, C3L-02705-72, C3L-02705-75"	104c291d-2139-11ea-aee1-0e1aae319e49	C3L-02705	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dd67c-2139-11ea-aee1-0e1aae319e49	CPT0204350003	104d4190-2139-11ea-aee1-0e1aae319e49	GTEX-RN5K-0011-R10A-SM-HAKXU	104c8d61-2139-11ea-aee1-0e1aae319e49	GTEX-RN5K-0011-R10A-SM-HAKXU	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104daedf-2139-11ea-aee1-0e1aae319e49	CPT0168380003	104d0f6d-2139-11ea-aee1-0e1aae319e49	C3N-02181-02	104c66c7-2139-11ea-aee1-0e1aae319e49	C3N-02181	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dbb9a-2139-11ea-aee1-0e1aae319e49	CPT0205890003	104d2257-2139-11ea-aee1-0e1aae319e49	C3N-02783-05	104c757a-2139-11ea-aee1-0e1aae319e49	C3N-02783	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d746c-2139-11ea-aee1-0e1aae319e49	CPT0217880003	104cce1d-2139-11ea-aee1-0e1aae319e49	C3L-02970-03	104c2f4b-2139-11ea-aee1-0e1aae319e49	C3L-02970	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dc5b4-2139-11ea-aee1-0e1aae319e49	CPT0206560003	104d2e02-2139-11ea-aee1-0e1aae319e49	C3N-03182-02	104c7ef9-2139-11ea-aee1-0e1aae319e49	C3N-03182	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8d24-2139-11ea-aee1-0e1aae319e49	CPT0087680003	104ce971-2139-11ea-aee1-0e1aae319e49	C3N-00662-03	104c4900-2139-11ea-aee1-0e1aae319e49	C3N-00662	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dbd9d-2139-11ea-aee1-0e1aae319e49	CPT0206000004	104d2464-2139-11ea-aee1-0e1aae319e49	"C3N-02784-01, C3N-02784-03"	104c772f-2139-11ea-aee1-0e1aae319e49	C3N-02784	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d7175-2139-11ea-aee1-0e1aae319e49	CPT0218670003	104ccb54-2139-11ea-aee1-0e1aae319e49	C3L-02900-01	104c2c9e-2139-11ea-aee1-0e1aae319e49	C3L-02900	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dd218-2139-11ea-aee1-0e1aae319e49	CPT0204340003	104d3d7e-2139-11ea-aee1-0e1aae319e49	GTEX-Q2AG-0011-R10A-SM-HAKXT	104c88e0-2139-11ea-aee1-0e1aae319e49	GTEX-Q2AG-0011-R10A-SM-HAKXT	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d6e77-2139-11ea-aee1-0e1aae319e49	CPT0189850004	104cc808-2139-11ea-aee1-0e1aae319e49	"C3L-02707-71, C3L-02707-72, C3L-02707-75"	104c2aed-2139-11ea-aee1-0e1aae319e49	C3L-02707	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d7a84-2139-11ea-aee1-0e1aae319e49	CPT0224330003	104cd3d3-2139-11ea-aee1-0e1aae319e49	C3L-03387-01	104c33ac-2139-11ea-aee1-0e1aae319e49	C3L-03387	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5a05-2139-11ea-aee1-0e1aae319e49	CPT0218330004	104cad0e-2139-11ea-aee1-0e1aae319e49	"C3L-01142-01, C3L-01142-02"	104c14b2-2139-11ea-aee1-0e1aae319e49	C3L-01142	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d9f5d-2139-11ea-aee1-0e1aae319e49	CPT0167640003	104cff54-2139-11ea-aee1-0e1aae319e49	C3N-01518-01	104c5a8f-2139-11ea-aee1-0e1aae319e49	C3N-01518	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d4e99-2139-11ea-aee1-0e1aae319e49	CPT0002410011	104c9aa3-2139-11ea-aee1-0e1aae319e49	C3L-00365-01	104c0852-2139-11ea-aee1-0e1aae319e49	C3L-00365	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d9534-2139-11ea-aee1-0e1aae319e49	CPT0093450003	104cf31d-2139-11ea-aee1-0e1aae319e49	C3N-01364-02	104c4fbb-2139-11ea-aee1-0e1aae319e49	C3N-01364	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dbe80-2139-11ea-aee1-0e1aae319e49	CPT0206110003	104d25b1-2139-11ea-aee1-0e1aae319e49	C3N-02785-01	104c780c-2139-11ea-aee1-0e1aae319e49	C3N-02785	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d578d-2139-11ea-aee1-0e1aae319e49	CPT0217430008	104ca845-2139-11ea-aee1-0e1aae319e49	C3L-01049-01	104c11d9-2139-11ea-aee1-0e1aae319e49	C3L-01049	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8818-2139-11ea-aee1-0e1aae319e49	CPT0217000004	104ce2d4-2139-11ea-aee1-0e1aae319e49	"C3L-03747-01, C3L-03747-02, C3L-03747-03"	104c415d-2139-11ea-aee1-0e1aae319e49	C3L-03747	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Disqualified						Disqualified	Disqualified																									Clinical Proteomic Tumor Analysis Consortium
104d7250-2139-11ea-aee1-0e1aae319e49	CPT0196850003	104ccc63-2139-11ea-aee1-0e1aae319e49	C3L-02955-01	104c2e6e-2139-11ea-aee1-0e1aae319e49	C3L-02955	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d7772-2139-11ea-aee1-0e1aae319e49	CPT0189250003	104cd0f8-2139-11ea-aee1-0e1aae319e49	C3L-03260-01	104c3202-2139-11ea-aee1-0e1aae319e49	C3L-03260	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d6f54-2139-11ea-aee1-0e1aae319e49	CPT0189570004	104cc964-2139-11ea-aee1-0e1aae319e49	"C3L-02708-01, C3L-02708-02"	104c2bce-2139-11ea-aee1-0e1aae319e49	C3L-02708	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d9ace-2139-11ea-aee1-0e1aae319e49	CPT0162020003	104cf9b3-2139-11ea-aee1-0e1aae319e49	C3N-01369-01	104c53f6-2139-11ea-aee1-0e1aae319e49	C3N-01369	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d9e89-2139-11ea-aee1-0e1aae319e49	CPT0167530003	104cfd94-2139-11ea-aee1-0e1aae319e49	C3N-01517-01	104c5875-2139-11ea-aee1-0e1aae319e49	C3N-01517	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dcbef-2139-11ea-aee1-0e1aae319e49	CPT0207030003	104d3564-2139-11ea-aee1-0e1aae319e49	C3N-03188-02	104c8344-2139-11ea-aee1-0e1aae319e49	C3N-03188	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d52da-2139-11ea-aee1-0e1aae319e49	CPT0127420003	104ca0ab-2139-11ea-aee1-0e1aae319e49	C3L-01043-01	104c0d21-2139-11ea-aee1-0e1aae319e49	C3L-01043	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104db9f1-2139-11ea-aee1-0e1aae319e49	CPT0205670004	104d1e67-2139-11ea-aee1-0e1aae319e49	"C3N-02770-08, C3N-02770-10"	104c73ca-2139-11ea-aee1-0e1aae319e49	C3N-02770	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dc216-2139-11ea-aee1-0e1aae319e49	CPT0208980003	104d2a27-2139-11ea-aee1-0e1aae319e49	C3N-03070-02	104c7b7e-2139-11ea-aee1-0e1aae319e49	C3N-03070	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dc8ea-2139-11ea-aee1-0e1aae319e49	CPT0206780003	104d31af-2139-11ea-aee1-0e1aae319e49	C3N-03184-02	104c81a1-2139-11ea-aee1-0e1aae319e49	C3N-03184	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dab4b-2139-11ea-aee1-0e1aae319e49	CPT0182500003	104d0b38-2139-11ea-aee1-0e1aae319e49	C3N-01852-04	104c62fe-2139-11ea-aee1-0e1aae319e49	C3N-01852	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5858-2139-11ea-aee1-0e1aae319e49	CPT0217710008	104caaf6-2139-11ea-aee1-0e1aae319e49	"C3L-01061-01, C3L-01061-02"	104c13d8-2139-11ea-aee1-0e1aae319e49	C3L-01061	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104db30d-2139-11ea-aee1-0e1aae319e49	CPT0168830003	104d1510-2139-11ea-aee1-0e1aae319e49	C3N-02188-03	104c6ce5-2139-11ea-aee1-0e1aae319e49	C3N-02188	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104db666-2139-11ea-aee1-0e1aae319e49	CPT0182550003	104d18c1-2139-11ea-aee1-0e1aae319e49	C3N-02255-02	104c701e-2139-11ea-aee1-0e1aae319e49	C3N-02255	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d784e-2139-11ea-aee1-0e1aae319e49	CPT0189460003	104cd20d-2139-11ea-aee1-0e1aae319e49	C3L-03266-01	104c32dc-2139-11ea-aee1-0e1aae319e49	C3L-03266	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104da26c-2139-11ea-aee1-0e1aae319e49	CPT0167860004	104d027b-2139-11ea-aee1-0e1aae319e49	"C3N-01814-01, C3N-01814-02"	104c5c3e-2139-11ea-aee1-0e1aae319e49	C3N-01814	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d9469-2139-11ea-aee1-0e1aae319e49	CPT0125220003	104cf11f-2139-11ea-aee1-0e1aae319e49	C3N-01334-03	104c4ee1-2139-11ea-aee1-0e1aae319e49	C3N-01334	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d51ff-2139-11ea-aee1-0e1aae319e49	CPT0171580008	104c9ec7-2139-11ea-aee1-0e1aae319e49	"C3L-01040-02, C3L-01040-03"	104c0c43-2139-11ea-aee1-0e1aae319e49	C3L-01040	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8ef6-2139-11ea-aee1-0e1aae319e49	CPT0087730003	104ceb47-2139-11ea-aee1-0e1aae319e49	C3N-00663-01	104c49d4-2139-11ea-aee1-0e1aae319e49	C3N-00663	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d6449-2139-11ea-aee1-0e1aae319e49	CPT0104330003	104cbbf4-2139-11ea-aee1-0e1aae319e49	C3L-01887-01	104c2075-2139-11ea-aee1-0e1aae319e49	C3L-01887	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104db086-2139-11ea-aee1-0e1aae319e49	CPT0168590003	104d1237-2139-11ea-aee1-0e1aae319e49	C3N-02185-01	104c69cf-2139-11ea-aee1-0e1aae319e49	C3N-02185	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104db3fb-2139-11ea-aee1-0e1aae319e49	CPT0205450004	104d16e1-2139-11ea-aee1-0e1aae319e49	"C3N-02190-01, C3N-02190-02"	104c6dbe-2139-11ea-aee1-0e1aae319e49	C3N-02190	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d7d9d-2139-11ea-aee1-0e1aae319e49	CPT0219080004	104cd6a7-2139-11ea-aee1-0e1aae319e49	"C3L-03392-01, C3L-03392-03"	104c3685-2139-11ea-aee1-0e1aae319e49	C3L-03392	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8c56-2139-11ea-aee1-0e1aae319e49	CPT0087570003	104ce864-2139-11ea-aee1-0e1aae319e49	C3N-00661-01	104c47ef-2139-11ea-aee1-0e1aae319e49	C3N-00661	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104ddd46-2139-11ea-aee1-0e1aae319e49	ref	104d4bcd-2139-11ea-aee1-0e1aae319e49	ref	104c97f7-2139-11ea-aee1-0e1aae319e49	ref	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dad38-2139-11ea-aee1-0e1aae319e49	CPT0162140003	104d0e55-2139-11ea-aee1-0e1aae319e49	"C3N-01857-01, C3N-01857-02"	104c65ee-2139-11ea-aee1-0e1aae319e49	C3N-01857	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d67ca-2139-11ea-aee1-0e1aae319e49	CPT0175060003	104cbfec-2139-11ea-aee1-0e1aae319e49	C3L-02504-01	104c2495-2139-11ea-aee1-0e1aae319e49	C3L-02504	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dbacc-2139-11ea-aee1-0e1aae319e49	CPT0205780003	104d205e-2139-11ea-aee1-0e1aae319e49	C3N-02782-01	104c74a2-2139-11ea-aee1-0e1aae319e49	C3N-02782	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5f10-2139-11ea-aee1-0e1aae319e49	CPT0218960004	104cb627-2139-11ea-aee1-0e1aae319e49	"C3L-01156-01, C3L-01156-02"	104c1b5c-2139-11ea-aee1-0e1aae319e49	C3L-01156	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d4f76-2139-11ea-aee1-0e1aae319e49	CPT0064650003	104c9bdf-2139-11ea-aee1-0e1aae319e49	C3L-00674-71	104c0976-2139-11ea-aee1-0e1aae319e49	C3L-00674	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d65eb-2139-11ea-aee1-0e1aae319e49	CPT0125570003	104cbedb-2139-11ea-aee1-0e1aae319e49	C3L-02465-02	104c22ff-2139-11ea-aee1-0e1aae319e49	C3L-02465	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8234-2139-11ea-aee1-0e1aae319e49	CPT0190360004	104cdad1-2139-11ea-aee1-0e1aae319e49	"C3L-03407-01, C3L-03407-02, C3L-03407-03, C3L-03407-04, C3L-03407-05"	104c3a87-2139-11ea-aee1-0e1aae319e49	C3L-03407	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dc6c9-2139-11ea-aee1-0e1aae319e49	CPT0206670004	104d2fd5-2139-11ea-aee1-0e1aae319e49	"C3N-03183-02, C3N-03183-03"	104c7fc8-2139-11ea-aee1-0e1aae319e49	C3N-03183	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dcfcb-2139-11ea-aee1-0e1aae319e49	CPT0204380003	104d3b74-2139-11ea-aee1-0e1aae319e49	GTEX-P44H-0011-R10A-SM-HAKXX	104c86dc-2139-11ea-aee1-0e1aae319e49	GTEX-P44H-0011-R10A-SM-HAKXX	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d4cd6-2139-11ea-aee1-0e1aae319e49	CPT0092440003	104c98ce-2139-11ea-aee1-0e1aae319e49	C3L-00104-01	104c0406-2139-11ea-aee1-0e1aae319e49	C3L-00104	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dac62-2139-11ea-aee1-0e1aae319e49	CPT0162100003	104d0c9a-2139-11ea-aee1-0e1aae319e49	C3N-01856-03	104c63cb-2139-11ea-aee1-0e1aae319e49	C3N-01856	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d830a-2139-11ea-aee1-0e1aae319e49	CPT0221180003	104cdcc5-2139-11ea-aee1-0e1aae319e49	C3L-03681-03	104c3b55-2139-11ea-aee1-0e1aae319e49	C3L-03681	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8591-2139-11ea-aee1-0e1aae319e49	CPT0225760003	104cdfbe-2139-11ea-aee1-0e1aae319e49	C3L-03728-01	104c3e4d-2139-11ea-aee1-0e1aae319e49	C3L-03728	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d972b-2139-11ea-aee1-0e1aae319e49	CPT0093510003	104cf505-2139-11ea-aee1-0e1aae319e49	C3N-01366-02	104c5089-2139-11ea-aee1-0e1aae319e49	C3N-01366	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d7545-2139-11ea-aee1-0e1aae319e49	CPT0190240004	104ccf2b-2139-11ea-aee1-0e1aae319e49	"C3L-02984-01, C3L-02984-02, C3L-02984-03, C3L-02984-04"	104c3018-2139-11ea-aee1-0e1aae319e49	C3L-02984	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d89c1-2139-11ea-aee1-0e1aae319e49	CPT0228220003	104ce59a-2139-11ea-aee1-0e1aae319e49	C3L-03968-01	104c44b0-2139-11ea-aee1-0e1aae319e49	C3L-03968	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dda05-2139-11ea-aee1-0e1aae319e49	CPT0204410003	104d471b-2139-11ea-aee1-0e1aae319e49	GTEX-Y8DK-0011-R10A-SM-HAKY1	104c9383-2139-11ea-aee1-0e1aae319e49	GTEX-Y8DK-0011-R10A-SM-HAKY1	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d7e76-2139-11ea-aee1-0e1aae319e49	CPT0224540004	104cd7df-2139-11ea-aee1-0e1aae319e49	C3L-03400-02	104c3751-2139-11ea-aee1-0e1aae319e49	C3L-03400	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dc2de-2139-11ea-aee1-0e1aae319e49	CPT0209440003	104d2b32-2139-11ea-aee1-0e1aae319e49	C3N-03088-01	104c7c51-2139-11ea-aee1-0e1aae319e49	C3N-03088	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d9ba3-2139-11ea-aee1-0e1aae319e49	CPT0089150003	104cfac9-2139-11ea-aee1-0e1aae319e49	C3N-01505-01	104c5609-2139-11ea-aee1-0e1aae319e49	C3N-01505	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dd2f2-2139-11ea-aee1-0e1aae319e49	CPT0204360003	104d3ecc-2139-11ea-aee1-0e1aae319e49	GTEX-QVJO-0011-R10A-SM-HAKXV	104c89b9-2139-11ea-aee1-0e1aae319e49	GTEX-QVJO-0011-R10A-SM-HAKXV	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104da5c7-2139-11ea-aee1-0e1aae319e49	CPT0168080003	104d055c-2139-11ea-aee1-0e1aae319e49	C3N-01816-01	104c5f4b-2139-11ea-aee1-0e1aae319e49	C3N-01816	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d938e-2139-11ea-aee1-0e1aae319e49	CPT0078580003	104cef21-2139-11ea-aee1-0e1aae319e49	C3N-01196-04	104c4d31-2139-11ea-aee1-0e1aae319e49	C3N-01196	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5574-2139-11ea-aee1-0e1aae319e49	CPT0127480003	104ca46c-2139-11ea-aee1-0e1aae319e49	"C3L-01046-01, C3L-01046-04"	104c101f-2139-11ea-aee1-0e1aae319e49	C3L-01046	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dd81b-2139-11ea-aee1-0e1aae319e49	CPT0204420003	104d4453-2139-11ea-aee1-0e1aae319e49	GTEX-UTHO-0011-R10A-SM-HAKY2	104c9078-2139-11ea-aee1-0e1aae319e49	GTEX-UTHO-0011-R10A-SM-HAKY2	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5d69-2139-11ea-aee1-0e1aae319e49	CPT0218830004	104cb315-2139-11ea-aee1-0e1aae319e49	"C3L-01154-02, C3L-01154-03"	104c1862-2139-11ea-aee1-0e1aae319e49	C3L-01154	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d84b7-2139-11ea-aee1-0e1aae319e49	CPT0225730003	104cde0e-2139-11ea-aee1-0e1aae319e49	C3L-03727-01	104c3d6f-2139-11ea-aee1-0e1aae319e49	C3L-03727	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8fcc-2139-11ea-aee1-0e1aae319e49	CPT0093360003	104cec4a-2139-11ea-aee1-0e1aae319e49	C3N-00665-01	104c4b82-2139-11ea-aee1-0e1aae319e49	C3N-00665	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104da811-2139-11ea-aee1-0e1aae319e49	CPT0168270003	104d0741-2139-11ea-aee1-0e1aae319e49	C3N-01818-02	104c6019-2139-11ea-aee1-0e1aae319e49	C3N-01818	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dc4de-2139-11ea-aee1-0e1aae319e49	CPT0206450003	104d2cf4-2139-11ea-aee1-0e1aae319e49	C3N-03180-02	104c7e20-2139-11ea-aee1-0e1aae319e49	C3N-03180	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dccc7-2139-11ea-aee1-0e1aae319e49	CPT0207090003	104d3781-2139-11ea-aee1-0e1aae319e49	C3N-03473-01	104c852f-2139-11ea-aee1-0e1aae319e49	C3N-03473	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d6277-2139-11ea-aee1-0e1aae319e49	CPT0104220003	104cba2e-2139-11ea-aee1-0e1aae319e49	C3L-01834-02	104c1f4b-2139-11ea-aee1-0e1aae319e49	C3L-01834	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8116-2139-11ea-aee1-0e1aae319e49	CPT0224600003	104cd9b5-2139-11ea-aee1-0e1aae319e49	C3L-03405-01	104c39a6-2139-11ea-aee1-0e1aae319e49	C3L-03405	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d918a-2139-11ea-aee1-0e1aae319e49	CPT0087950003	104cee1a-2139-11ea-aee1-0e1aae319e49	C3N-01192-05	104c4c5f-2139-11ea-aee1-0e1aae319e49	C3N-01192	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dd74e-2139-11ea-aee1-0e1aae319e49	CPT0204330003	104d434a-2139-11ea-aee1-0e1aae319e49	GTEX-RU72-0011-R10A-SM-HAKXS	104c8f7f-2139-11ea-aee1-0e1aae319e49	GTEX-RU72-0011-R10A-SM-HAKXS	CPTAC3 Discovery and Confirmatory	Solid Tissue Normal	Brain	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d60d7-2139-11ea-aee1-0e1aae319e49	CPT0199770003	104cb73b-2139-11ea-aee1-0e1aae319e49	C3L-01157-03	104c1c36-2139-11ea-aee1-0e1aae319e49	C3L-01157	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104db824-2139-11ea-aee1-0e1aae319e49	CPT0205570003	104d1c5f-2139-11ea-aee1-0e1aae319e49	C3N-02769-02	104c7225-2139-11ea-aee1-0e1aae319e49	C3N-02769	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d9800-2139-11ea-aee1-0e1aae319e49	CPT0093550003	104cf6e0-2139-11ea-aee1-0e1aae319e49	C3N-01367-02	104c524a-2139-11ea-aee1-0e1aae319e49	C3N-01367	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104da4ea-2139-11ea-aee1-0e1aae319e49	CPT0167970003	104d0454-2139-11ea-aee1-0e1aae319e49	C3N-01815-01	104c5e6c-2139-11ea-aee1-0e1aae319e49	C3N-01815	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104db75a-2139-11ea-aee1-0e1aae319e49	CPT0182580003	104d19c5-2139-11ea-aee1-0e1aae319e49	C3N-02256-01	104c7150-2139-11ea-aee1-0e1aae319e49	C3N-02256	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dafb5-2139-11ea-aee1-0e1aae319e49	CPT0168480003	104d1123-2139-11ea-aee1-0e1aae319e49	C3N-02183-01	104c679a-2139-11ea-aee1-0e1aae319e49	C3N-02183	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104dbf54-2139-11ea-aee1-0e1aae319e49	CPT0206230003	104d2761-2139-11ea-aee1-0e1aae319e49	C3N-02786-02	104c78dc-2139-11ea-aee1-0e1aae319e49	C3N-02786	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d6b55-2139-11ea-aee1-0e1aae319e49	CPT0189750004	104cc4d7-2139-11ea-aee1-0e1aae319e49	"C3L-02704-71, C3L-02704-72, C3L-02704-73"	104c2847-2139-11ea-aee1-0e1aae319e49	C3L-02704	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d8b82-2139-11ea-aee1-0e1aae319e49	CPT0217100003	104ce6a7-2139-11ea-aee1-0e1aae319e49	C3L-04084-04	104c46fd-2139-11ea-aee1-0e1aae319e49	C3L-04084	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d61ac-2139-11ea-aee1-0e1aae319e49	CPT0064890003	104cb916-2139-11ea-aee1-0e1aae319e49	C3L-01327-01	104c1d05-2139-11ea-aee1-0e1aae319e49	C3L-01327	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d567a-2139-11ea-aee1-0e1aae319e49	CPT0217190003	104ca657-2139-11ea-aee1-0e1aae319e49	C3L-01048-02	104c1105-2139-11ea-aee1-0e1aae319e49	C3L-01048	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5ba8-2139-11ea-aee1-0e1aae319e49	CPT0218770003	104cb105-2139-11ea-aee1-0e1aae319e49	C3L-01149-01	104c178c-2139-11ea-aee1-0e1aae319e49	C3L-01149	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d651e-2139-11ea-aee1-0e1aae319e49	CPT0125510003	104cbd0a-2139-11ea-aee1-0e1aae319e49	C3L-02041-02	104c2149-2139-11ea-aee1-0e1aae319e49	C3L-02041	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d88f7-2139-11ea-aee1-0e1aae319e49	CPT0217060003	104ce3e3-2139-11ea-aee1-0e1aae319e49	C3L-03748-04	104c43cc-2139-11ea-aee1-0e1aae319e49	C3L-03748	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
104d5040-2139-11ea-aee1-0e1aae319e49	CPT0071100003	104c9db2-2139-11ea-aee1-0e1aae319e49	C3L-00677-72	104c0a5a-2139-11ea-aee1-0e1aae319e49	C3L-00677	CPTAC3 Discovery and Confirmatory	Primary Tumor	Brain	Glioblastoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5f565aa6-6428-11e8-bcf1-0a2705229b82	TCGA-A6-3807-01A-22-2150-27	6546c731-641f-11e8-bcf1-0a2705229b82	TCGA-A6-3807-01A	2dfc05ef-63d8-11e8-bcf1-0a2705229b82	TCGA-A6-3807	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
60aca319-6428-11e8-bcf1-0a2705229b82	TCGA-A6-3808-01A-22-2150-27	670a67f3-641f-11e8-bcf1-0a2705229b82	TCGA-A6-3808-01A	2f35a510-63d8-11e8-bcf1-0a2705229b82	TCGA-A6-3808	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62199412-6428-11e8-bcf1-0a2705229b82	TCGA-A6-3810-01A-22-2150-27	69180d5a-641f-11e8-bcf1-0a2705229b82	TCGA-A6-3810-01A	3073d082-63d8-11e8-bcf1-0a2705229b82	TCGA-A6-3810	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
72d774c3-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3518-01A-11-2150-27	80300cbd-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3518-01A	40f43066-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3518	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7425442f-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3525-01A-12-2150-27	81c1307f-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3525-01A	423218ed-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3525	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7562afbe-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3526-01A-11-2150-27	8393dca8-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3526-01A	4377f550-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3526	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
76b2ba5b-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3529-01A-12-2150-27	85364e69-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3529-01A	44b504f0-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3529	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
77ed565a-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3531-01A-22-2150-27	87552140-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3531-01A	45f0cbee-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3531	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7943d515-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3534-01A-22-2150-27	8928dafc-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3534-01A	472f0ffd-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3534	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a7ff526-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3552-01A-22-2150-27	8b50022a-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3552-01A	48696542-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3552	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7bcf4476-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3554-01A-22-2150-27	8cf77db4-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3554-01A	49b093b2-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3554	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7d1e00f2-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3558-01A-22-2150-27	8ecb0ca5-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3558-01A	4afcfca3-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3558	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7e5b789d-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3561-01A-22-2150-27	908de2b0-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3561-01A	4c39731c-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3561	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7fadc3f1-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3664-01A-22-2150-27	9278742b-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3664-01A	4d755a0c-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3664	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
80ea6aaf-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3666-01A-31-2150-27	94097fd1-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3666-01A	4eb1190e-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3666	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8237540e-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3672-01A-22-2150-27	95dc4de0-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3672-01A	4fef1084-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3672	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83869af5-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3684-01A-31-2150-27	976f2cc2-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3684-01A	5168c0f2-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3684	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
84c79b22-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3695-01A-22-2150-27	997e7105-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3695-01A	52c1dfe9-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3695	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8618ceb6-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3710-01A-22-2150-27	9b0c8151-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3710-01A	53ffab37-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3710	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8745a033-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3715-01A-22-2150-27	9ce106e6-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3715-01A	55548339-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3715	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8882029a-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3818-01A-22-2150-27	9e8875ff-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3818-01A	56954cc3-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3818	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
89cf0966-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3848-01A-22-2150-27	a0af7617-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3848-01A	57da6e5e-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3848	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8b1249e7-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3864-01A-22-2150-27	a284cd7a-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3864-01A	591895b2-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3864	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8c50a0f1-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3986-01A-12-2150-27	a447df59-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3986-01A	5a578797-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3986	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8d9e593d-6428-11e8-bcf1-0a2705229b82	TCGA-AA-3989-01A-22-2150-27	a5e8f98a-641f-11e8-bcf1-0a2705229b82	TCGA-AA-3989-01A	5bd59267-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-3989	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8f1491d1-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A004-01A-22-A20O-27	a7edf2c4-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A004-01A	5d13fcec-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A004	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9051cf41-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00A-01A-22-A20O-27	a9b26b45-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00A-01A	5e4f679d-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00A	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
91a9b206-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00A-01A-41-A20O-27	a9b26b45-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00A-01A	5e4f679d-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00A	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
933a324a-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00E-01A-31-A20O-27	abbbcfae-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00E-01A	5f930e6f-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00E	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
94fda603-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00F-01A-31-A20O-27	ad4c1942-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00F-01A	60d3e64a-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00F	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
96e91e78-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00J-01A-12-A20O-27	af3fa285-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00J-01A	621a752f-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00J	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9975fd56-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00K-01A-12-A20O-27	b0c71626-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00K-01A	63649645-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00K	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9827b436-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00K-01A-31-A20O-27	b0c71626-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00K-01A	63649645-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00K	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9c025e8a-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00N-01A-32-A20O-27	b29a2b34-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00N-01A	64a2daab-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00N	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9ac4ad88-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00N-01A-41-A20O-27	b29a2b34-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00N-01A	64a2daab-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00N	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9d54015b-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00O-01A-13-A20O-27	b43a84f2-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00O-01A	65e185dd-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00O	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9e918d0f-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00R-01A-22-A20O-27	b5dc4962-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00R-01A	6724e778-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00R	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9fe00e24-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00R-01A-31-A20O-27	b5dc4962-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00R-01A	6724e778-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00R	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a12d6de5-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A00U-01A-41-A20O-27	b7ab1cdb-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A00U-01A	6860e8b8-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A00U	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cfda21bc-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A002-01A-23-A20O-27	f8b4077b-641f-11e8-bcf1-0a2705229b82	TCGA-AG-A002-01A	9615897c-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A002	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a26a0545-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A010-01A-31-A20O-27	b97e9918-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A010-01A	699e7081-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A010	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d1156189-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A008-01A-23-A20O-27	fa87fa0c-641f-11e8-bcf1-0a2705229b82	TCGA-AG-A008-01A	974f5654-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A008	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a3f7b401-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A017-01A-22-A20O-27	bb40d07d-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A017-01A	6adc680a-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A017	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d2632188-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A00C-01A-23-A20O-27	fc8ce04a-641f-11e8-bcf1-0a2705229b82	TCGA-AG-A00C-01A	988d66de-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A00C	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a56063c3-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01C-01A-22-A20O-27	bce50b2a-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01C-01A	6c2116cf-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01C	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d3a62409-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A00H-01A-22-A20O-27	fe8281c2-641f-11e8-bcf1-0a2705229b82	TCGA-AG-A00H-01A	99cb2cec-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A00H	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a6ae1f0d-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01D-01A-23-A20O-27	beec13fa-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01D-01A	6d5fca8a-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01D	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4f51b43-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A00H-01A-31-A20O-27	fe8281c2-641f-11e8-bcf1-0a2705229b82	TCGA-AG-A00H-01A	99cb2cec-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A00H	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a7db64db-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01F-01A-23-A20O-27	c0af3979-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01F-01A	6ea93395-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01F	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d674b627-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A00Y-01A-12-A20O-27	0024718b-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A00Y-01A	9b082d45-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A00Y	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a9211ee0-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01I-01A-12-A20O-27	c2f03eda-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01I-01A	6ffd96e5-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01I	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d7b2f5ac-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A011-01A-32-A20O-27	0219bf06-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A011-01A	9c4dfa82-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A011	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa5e3614-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01K-01A-31-A20O-27	c4812326-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01K-01A	719c4076-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01K	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d904d542-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A014-01A-12-A20O-27	03bb5acf-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A014-01A	9d8d548f-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A014	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
abac3ac4-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01P-01A-23-A20O-27	c6542144-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01P-01A	72e26998-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01P	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da40139b-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A015-01A-51-A20O-27	058796c7-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A015-01A	9ec81956-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A015	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
acd88c42-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01R-01A-23-A20O-27	c7e60c7b-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01R-01A	742176df-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01R	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db8ddd90-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A016-01A-23-A20O-27	07281eac-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A016-01A	a005feb4-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A016	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ae25f66f-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01S-01A-23-A20O-27	c9b9bcd6-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01S-01A	75615f99-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01S	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dcdb02a0-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A01J-01A-22-A20O-27	08fc1185-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A01J-01A	a1414a42-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A01J	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
af9c911d-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01T-01A-23-A20O-27	cb5b7c4e-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01T-01A	769eda03-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01T	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de17b790-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A01L-01A-22-A20O-27	0ac7b47b-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A01L-01A	a27abe5c-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A01L	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b10da36b-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01V-01A-24-A20O-27	cd5018b0-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01V-01A	77dfb88f-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01V	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df6f1661-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A01N-01A-23-A20O-27	0ccd76b2-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A01N-01A	a3b8a741-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A01N	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b25edb64-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01X-01A-23-A20O-27	cef5fff3-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01X-01A	7921f294-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01X	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e0abe147-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A01W-01A-23-A20O-27	0e5d9a16-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A01W-01A	a4f480ac-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A01W	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b39dbcdf-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A01Z-01A-13-A20O-27	d0b80e49-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A01Z-01A	7a77aded-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A01Z	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e1fd9c4c-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A01Y-01A-43-A20O-27	103079f2-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A01Y-01A	a639563c-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A01Y	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b4d9c934-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A022-01A-23-A20O-27	d28fb542-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A022-01A	7bb26f73-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A022	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e39e84cc-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A020-01A-23-A20O-27	11c6425d-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A020-01A	a77625be-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A020	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b626bcaa-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A024-01A-32-A20O-27	d45c9f53-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A024-01A	7cf1133a-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A024	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e4ddc5d9-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A026-01A-71-A20O-27	1399b6c7-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A026-01A	a908ac2c-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A026	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b763a60d-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A029-01A-41-A20O-27	d65edfa0-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A029-01A	7e38c19b-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A029	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e60a85c2-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A02N-01A-31-A20O-27	153b4403-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A02N-01A	aa6d638b-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A02N	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b8b3958d-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A02E-01A-23-A20O-27	d881eb2c-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A02E-01A	7f9ddc5a-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A02E	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e756cf17-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A02X-01A-32-A20O-27	17379371-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A02X-01A	abb6edd1-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A02X	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba03edc3-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A02H-01A-32-A20O-27	da24199c-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A02H-01A	80dab332-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A02H	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e894bec1-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A032-01A-31-A20O-27	18d9be3f-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A032-01A	acf3687c-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A032	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb72739a-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A02J-01A-23-A20O-27	dbed4f31-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A02J-01A	8217472f-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A02J	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e9e230c6-6428-11e8-bcf1-0a2705229b82	TCGA-AG-A036-01A-22-A20O-27	1acc67d8-6420-11e8-bcf1-0a2705229b82	TCGA-AG-A036-01A	ae381fa3-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-A036	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bcc04ffa-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A02O-01A-23-A20O-27	dd8e3764-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A02O-01A	835b8135-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A02O	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bdfd5b88-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A02R-01A-23-A20O-27	df611959-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A02R-01A	8498bc72-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A02R	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bf4c3551-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A02Y-01A-31-A20O-27	e12a7393-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A02Y-01A	85e1d2b8-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A02Y	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c099b9d3-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A03F-01A-41-A20O-27	e2ed3b97-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A03F-01A	87208dbd-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A03F	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c1d8cb51-6428-11e8-bcf1-0a2705229b82	TCGA-AA-A03J-01A-23-A20O-27	e491a39a-641f-11e8-bcf1-0a2705229b82	TCGA-AA-A03J-01A	885ec435-63d8-11e8-bcf1-0a2705229b82	TCGA-AA-A03J	CPTAC2 Retrospective	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c326c44a-6428-11e8-bcf1-0a2705229b82	TCGA-AF-2691-01A-41-2150-27	e6acdd3d-641f-11e8-bcf1-0a2705229b82	TCGA-AF-2691-01A	89999ae4-63d8-11e8-bcf1-0a2705229b82	TCGA-AF-2691	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c463d14d-6428-11e8-bcf1-0a2705229b82	TCGA-AF-2692-01A-41-2150-27	e851e4bc-641f-11e8-bcf1-0a2705229b82	TCGA-AF-2692-01A	8ad3214f-63d8-11e8-bcf1-0a2705229b82	TCGA-AF-2692	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c5b13a5b-6428-11e8-bcf1-0a2705229b82	TCGA-AF-3400-01A-41-2150-27	ea47e918-641f-11e8-bcf1-0a2705229b82	TCGA-AF-3400-01A	8c19f139-63d8-11e8-bcf1-0a2705229b82	TCGA-AF-3400	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c6e555c2-6428-11e8-bcf1-0a2705229b82	TCGA-AF-3913-01A-12-2150-27	ebec2566-641f-11e8-bcf1-0a2705229b82	TCGA-AF-3913-01A	8d5b1a5f-63d8-11e8-bcf1-0a2705229b82	TCGA-AF-3913	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c8222482-6428-11e8-bcf1-0a2705229b82	TCGA-AG-3574-01A-22-2150-27	edef6e6c-641f-11e8-bcf1-0a2705229b82	TCGA-AG-3574-01A	8e9702c3-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-3574	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c96fc796-6428-11e8-bcf1-0a2705229b82	TCGA-AG-3580-01A-22-2150-27	ef91e027-641f-11e8-bcf1-0a2705229b82	TCGA-AG-3580-01A	8fd2207a-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-3580	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
caacfbe4-6428-11e8-bcf1-0a2705229b82	TCGA-AG-3584-01A-22-2150-27	f1a76d7b-641f-11e8-bcf1-0a2705229b82	TCGA-AG-3584-01A	910e8e39-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-3584	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cbfc8c26-6428-11e8-bcf1-0a2705229b82	TCGA-AG-3593-01A-22-2150-27	f344d72a-641f-11e8-bcf1-0a2705229b82	TCGA-AG-3593-01A	92584f35-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-3593	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd4e69cc-6428-11e8-bcf1-0a2705229b82	TCGA-AG-3594-01A-12-2150-27	f5181973-641f-11e8-bcf1-0a2705229b82	TCGA-AG-3594-01A	939d5b1e-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-3594	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ce8ac1e4-6428-11e8-bcf1-0a2705229b82	TCGA-AG-4007-01A-22-2150-27	f71e7be6-641f-11e8-bcf1-0a2705229b82	TCGA-AG-4007-01A	94d189be-63d8-11e8-bcf1-0a2705229b82	TCGA-AG-4007	CPTAC2 Retrospective	Primary Tumor	Rectum	Rectum Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0b917b43-6428-11e8-bcf1-0a2705229b82	TCGA-36-2530-01A-31-2222-28	feec214d-641e-11e8-bcf1-0a2705229b82	TCGA-36-2530-01A	e4bc1db1-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2530	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a9b55ba3-6427-11e8-bcf1-0a2705229b82	TCGA-24-2289-01A-31-2222-28	8dcb6462-641e-11e8-bcf1-0a2705229b82	TCGA-24-2289-01A	9517810d-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2289	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
54825de0-6427-11e8-bcf1-0a2705229b82	TCGA-13-1501-01A-31-2222-28	27450f1b-641e-11e8-bcf1-0a2705229b82	TCGA-13-1501-01A	4cddd56b-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1501	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a47aab6-ec51-11e9-81b4-2a2ae2dbcce4	OVARIAN-CONTROL	6a4798be-ec51-11e9-81b4-2a2ae2dbcce4	OVARIAN-CONTROL	6a47870c-ec51-11e9-81b4-2a2ae2dbcce4	OVARIAN-CONTROL	CPTAC2 Retrospective	Not Reported	Not Reported	Other	no																																	Clinical Proteomic Tumor Analysis Consortium
d41d7570-6427-11e8-bcf1-0a2705229b82	TCGA-29-1693-01A-31-2222-28	bea317b9-641e-11e8-bcf1-0a2705229b82	TCGA-29-1693-01A	b7ac2e48-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1693	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0cd46536-6428-11e8-bcf1-0a2705229b82	TCGA-36-2532-01A-31-2223-28	00f117ba-641f-11e8-bcf1-0a2705229b82	TCGA-36-2532-01A	e5fb589e-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2532	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da85b80e-6427-11e8-bcf1-0a2705229b82	TCGA-29-1698-01A-31-2222-28	c3de3621-641e-11e8-bcf1-0a2705229b82	TCGA-29-1698-01A	bb65da7b-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1698	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4e3644cd-6427-11e8-bcf1-0a2705229b82	TCGA-13-1494-01A-31-2222-28	1e5f5978-641e-11e8-bcf1-0a2705229b82	TCGA-13-1494-01A	469cc236-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1494	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
849ed649-6427-11e8-bcf1-0a2705229b82	TCGA-24-1553-01A-31-2222-28	654745ea-641e-11e8-bcf1-0a2705229b82	TCGA-24-1553-01A	77c6c6ac-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1553	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6c20aabd-6427-11e8-bcf1-0a2705229b82	TCGA-24-1416-01A-31-2222-28	46a56c1f-641e-11e8-bcf1-0a2705229b82	TCGA-24-1416-01A	6235da72-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1416	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fbe131b8-6427-11e8-bcf1-0a2705229b82	TCGA-30-1887-01A-31-2222-28	ea981ff3-641e-11e8-bcf1-0a2705229b82	TCGA-30-1887-01A	d6eaaeea-63d7-11e8-bcf1-0a2705229b82	TCGA-30-1887	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dd14964c-6427-11e8-bcf1-0a2705229b82	TCGA-29-1705-01A-31-2222-28	c7804e62-641e-11e8-bcf1-0a2705229b82	TCGA-29-1705-01A	bde9c627-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1705	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
41458dc1-6427-11e8-bcf1-0a2705229b82	TCGA-13-1483-01A-31-2222-28	11d49f1a-641e-11e8-bcf1-0a2705229b82	TCGA-13-1483-01A	3dee2ec8-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1483	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4b8c095e-6427-11e8-bcf1-0a2705229b82	TCGA-13-1492-01A-31-2222-28	1cbd97a8-641e-11e8-bcf1-0a2705229b82	TCGA-13-1492-01A	455df4a4-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1492	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e7883ea6-6427-11e8-bcf1-0a2705229b82	TCGA-29-1768-01A-31-2222-28	d2937cc1-641e-11e8-bcf1-0a2705229b82	TCGA-29-1768-01A	c566f20e-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1768	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6704410c-6427-11e8-bcf1-0a2705229b82	TCGA-24-1103-01A-31-2222-28	4197faa8-641e-11e8-bcf1-0a2705229b82	TCGA-24-1103-01A	5e6fa63a-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1103	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb40294c-6427-11e8-bcf1-0a2705229b82	TCGA-29-1770-01A-31-2222-28	d5f78ef0-641e-11e8-bcf1-0a2705229b82	TCGA-29-1770-01A	c7fc73e0-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1770	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7ba3966d-6427-11e8-bcf1-0a2705229b82	TCGA-24-1474-01A-31-2222-28	593a0367-641e-11e8-bcf1-0a2705229b82	TCGA-24-1474-01A	6eaae670-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1474	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c5fb01ee-6427-11e8-bcf1-0a2705229b82	TCGA-25-2396-01A-31-2223-28	b0d855a8-641e-11e8-bcf1-0a2705229b82	TCGA-25-2396-01A	ada3f24a-63d7-11e8-bcf1-0a2705229b82	TCGA-25-2396	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
97b91658-6427-11e8-bcf1-0a2705229b82	TCGA-24-1927-01A-31-2223-28	7a569f8d-641e-11e8-bcf1-0a2705229b82	TCGA-24-1927-01A	872efef8-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1927	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dbd21591-6427-11e8-bcf1-0a2705229b82	TCGA-29-1702-01A-31-2222-28	c5df1f98-641e-11e8-bcf1-0a2705229b82	TCGA-29-1702-01A	bca9389e-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1702	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9b936cc5-6427-11e8-bcf1-0a2705229b82	TCGA-24-2024-01A-41-2222-28	7f93088f-641e-11e8-bcf1-0a2705229b82	TCGA-24-2024-01A	8b0bd36f-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2024	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
054acf0e-6428-11e8-bcf1-0a2705229b82	TCGA-36-1578-01A-31-2222-28	f7eaf89f-641e-11e8-bcf1-0a2705229b82	TCGA-36-1578-01A	dfb55980-63d7-11e8-bcf1-0a2705229b82	TCGA-36-1578	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b3fdc0c8-6427-11e8-bcf1-0a2705229b82	TCGA-25-1318-01A-22-2223-28	9af4d032-641e-11e8-bcf1-0a2705229b82	TCGA-25-1318-01A	9e32b552-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1318	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3baaaf95-6428-11e8-bcf1-0a2705229b82	TCGA-61-2088-01A-31-2223-28	33ecf5ff-641f-11e8-bcf1-0a2705229b82	TCGA-61-2088-01A	0a774083-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2088	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c885b627-6427-11e8-bcf1-0a2705229b82	TCGA-25-2399-01A-31-2223-28	b4718b0b-641e-11e8-bcf1-0a2705229b82	TCGA-25-2399-01A	b0216d38-63d7-11e8-bcf1-0a2705229b82	TCGA-25-2399	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bbb85104-6427-11e8-bcf1-0a2705229b82	TCGA-25-1329-01A-22-2223-28	a5f8b165-641e-11e8-bcf1-0a2705229b82	TCGA-25-1329-01A	a5a73d5c-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1329	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d0119b1f-6427-11e8-bcf1-0a2705229b82	TCGA-29-1688-01A-31-2222-28	bb3e49c8-641e-11e8-bcf1-0a2705229b82	TCGA-29-1688-01A	b52c7e99-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1688	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
31175de6-6428-11e8-bcf1-0a2705229b82	TCGA-61-1918-01A-31-2223-28	2ae2c809-641f-11e8-bcf1-0a2705229b82	TCGA-61-1918-01A	043a5f9d-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1918	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
77901de0-6427-11e8-bcf1-0a2705229b82	TCGA-24-1464-01A-31-2222-28	53299c51-641e-11e8-bcf1-0a2705229b82	TCGA-24-1464-01A	6aefca09-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1464	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3d6518f3-6427-11e8-bcf1-0a2705229b82	TCGA-13-1409-01A-31-2222-28	0ca8de2b-641e-11e8-bcf1-0a2705229b82	TCGA-13-1409-01A	3a36a497-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1409	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ffed4820-6427-11e8-bcf1-0a2705229b82	TCGA-36-1570-01A-31-2222-28	f044d6e8-641e-11e8-bcf1-0a2705229b82	TCGA-36-1570-01A	dab3a19a-63d7-11e8-bcf1-0a2705229b82	TCGA-36-1570	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
73b39b00-6427-11e8-bcf1-0a2705229b82	TCGA-24-1435-01A-31-2222-28	4fb4a022-641e-11e8-bcf1-0a2705229b82	TCGA-24-1435-01A	686f8e1f-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1435	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fd30e2c4-6427-11e8-bcf1-0a2705229b82	TCGA-30-1891-01A-31-2222-28	ec39ef01-641e-11e8-bcf1-0a2705229b82	TCGA-30-1891-01A	d82e4023-63d7-11e8-bcf1-0a2705229b82	TCGA-30-1891	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8c5cbc92-6427-11e8-bcf1-0a2705229b82	TCGA-24-1558-01A-31-2222-28	6c452e8b-641e-11e8-bcf1-0a2705229b82	TCGA-24-1558-01A	7cc6b787-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1558	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e639c094-6427-11e8-bcf1-0a2705229b82	TCGA-29-1766-01A-31-2222-28	d0b99da7-641e-11e8-bcf1-0a2705229b82	TCGA-29-1766-01A	c4228beb-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1766	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dfd39da7-6427-11e8-bcf1-0a2705229b82	TCGA-29-1711-01A-31-2222-28	cb1df936-641e-11e8-bcf1-0a2705229b82	TCGA-29-1711-01A	c0618182-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1711	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c35aca3d-6427-11e8-bcf1-0a2705229b82	TCGA-25-1631-01A-31-2222-28	ad634a64-641e-11e8-bcf1-0a2705229b82	TCGA-25-1631-01A	aad9f35e-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1631	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03cabe41-6428-11e8-bcf1-0a2705229b82	TCGA-36-1577-01A-31-2222-28	f6480b6a-641e-11e8-bcf1-0a2705229b82	TCGA-36-1577-01A	de6ce6a6-63d7-11e8-bcf1-0a2705229b82	TCGA-36-1577	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c7383f4c-6427-11e8-bcf1-0a2705229b82	TCGA-25-2397-01A-31-2223-28	b29c41cb-641e-11e8-bcf1-0a2705229b82	TCGA-25-2397-01A	aee1b135-63d7-11e8-bcf1-0a2705229b82	TCGA-25-2397	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0e215a3e-6428-11e8-bcf1-0a2705229b82	TCGA-36-2534-01A-31-2223-28	02c02cba-641f-11e8-bcf1-0a2705229b82	TCGA-36-2534-01A	e741fc42-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2534	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2941f1fb-6428-11e8-bcf1-0a2705229b82	TCGA-61-1910-01A-31-2223-28	24153a40-641f-11e8-bcf1-0a2705229b82	TCGA-61-1910-01A	ff24e095-63d7-11e8-bcf1-0a2705229b82	TCGA-61-1910	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2bb97ba9-6428-11e8-bcf1-0a2705229b82	TCGA-61-1911-01A-31-2222-28	25ed85d4-641f-11e8-bcf1-0a2705229b82	TCGA-61-1911-01A	0067a0e0-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1911	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de949fcd-6427-11e8-bcf1-0a2705229b82	TCGA-29-1710-01A-41-2222-28	c9745cf8-641e-11e8-bcf1-0a2705229b82	TCGA-29-1710-01A	bf27811f-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1710	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9f6d3153-6427-11e8-bcf1-0a2705229b82	TCGA-24-2030-01A-31-2222-28	835fca45-641e-11e8-bcf1-0a2705229b82	TCGA-24-2030-01A	8d929b06-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2030	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3ce8c187-6428-11e8-bcf1-0a2705229b82	TCGA-61-2094-01A-31-2223-28	358ea51a-641f-11e8-bcf1-0a2705229b82	TCGA-61-2094-01A	0bbad2ef-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2094	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
15c4320e-6428-11e8-bcf1-0a2705229b82	TCGA-36-2547-01A-31-2223-28	0da32a70-641f-11e8-bcf1-0a2705229b82	TCGA-36-2547-01A	eedf8a3d-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2547	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f2e8c208-6427-11e8-bcf1-0a2705229b82	TCGA-29-1785-01A-31-2222-28	e0620a4d-641e-11e8-bcf1-0a2705229b82	TCGA-29-1785-01A	cf738c51-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1785	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c592ed4-6427-11e8-bcf1-0a2705229b82	TCGA-13-2061-01A-41-2223-28	31fa232f-641e-11e8-bcf1-0a2705229b82	TCGA-13-2061-01A	5481781f-63d7-11e8-bcf1-0a2705229b82	TCGA-13-2061	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2804a2e5-6428-11e8-bcf1-0a2705229b82	TCGA-61-1907-01A-31-2222-28	2252069d-641f-11e8-bcf1-0a2705229b82	TCGA-61-1907-01A	fde688bb-63d7-11e8-bcf1-0a2705229b82	TCGA-61-1907	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8ec5ce7b-6427-11e8-bcf1-0a2705229b82	TCGA-24-1562-01A-31-2222-28	6e18e4e2-641e-11e8-bcf1-0a2705229b82	TCGA-24-1562-01A	7e05678b-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1562	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5da9c01a-6427-11e8-bcf1-0a2705229b82	TCGA-13-2065-01A-41-2223-28	339b4b8e-641e-11e8-bcf1-0a2705229b82	TCGA-13-2065-01A	55c53353-63d7-11e8-bcf1-0a2705229b82	TCGA-13-2065	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7cdf8b75-6427-11e8-bcf1-0a2705229b82	TCGA-24-1544-01A-31-2222-28	5ada1ab1-641e-11e8-bcf1-0a2705229b82	TCGA-24-1544-01A	6fe98d15-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1544	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62bf9923-6427-11e8-bcf1-0a2705229b82	TCGA-23-1122-01A-31-2222-28	3c703a21-641e-11e8-bcf1-0a2705229b82	TCGA-23-1122-01A	5ab4a191-63d7-11e8-bcf1-0a2705229b82	TCGA-23-1122	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
72634e7d-6427-11e8-bcf1-0a2705229b82	TCGA-24-1431-01A-31-2222-28	4db09a80-641e-11e8-bcf1-0a2705229b82	TCGA-24-1431-01A	67344504-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1431	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ac471a14-6427-11e8-bcf1-0a2705229b82	TCGA-24-2290-01A-31-2222-28	8faed2c3-641e-11e8-bcf1-0a2705229b82	TCGA-24-2290-01A	9688e191-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2290	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
952f194a-6427-11e8-bcf1-0a2705229b82	TCGA-24-1920-01A-31-2223-28	76f3a771-641e-11e8-bcf1-0a2705229b82	TCGA-24-1920-01A	84aa3863-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1920	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba67f555-6427-11e8-bcf1-0a2705229b82	TCGA-25-1323-01A-22-2223-28	a402a561-641e-11e8-bcf1-0a2705229b82	TCGA-25-1323-01A	a46d3e08-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1323	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f813a3ad-6427-11e8-bcf1-0a2705229b82	TCGA-29-2431-01A-31-2223-28	e569db02-641e-11e8-bcf1-0a2705229b82	TCGA-29-2431-01A	d3302e81-63d7-11e8-bcf1-0a2705229b82	TCGA-29-2431	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b1703a9b-6427-11e8-bcf1-0a2705229b82	TCGA-25-1313-01A-22-2223-28	9710dab2-641e-11e8-bcf1-0a2705229b82	TCGA-25-1313-01A	9bb8865d-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1313	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cc4244db-6427-11e8-bcf1-0a2705229b82	TCGA-25-2404-01A-31-2222-28	b7d7b9cc-641e-11e8-bcf1-0a2705229b82	TCGA-25-2404-01A	b2a4a0c4-63d7-11e8-bcf1-0a2705229b82	TCGA-25-2404	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d2deb9ef-6427-11e8-bcf1-0a2705229b82	TCGA-29-1690-01A-31-2222-28	bcceabef-641e-11e8-bcf1-0a2705229b82	TCGA-29-1690-01A	b66911c2-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1690	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d946cfd2-6427-11e8-bcf1-0a2705229b82	TCGA-29-1697-01A-31-2222-28	c23cbaaa-641e-11e8-bcf1-0a2705229b82	TCGA-29-1697-01A	ba2f7e13-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1697	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e3aedc20-6427-11e8-bcf1-0a2705229b82	TCGA-29-1763-01A-31-2222-28	cef5b8b0-641e-11e8-bcf1-0a2705229b82	TCGA-29-1763-01A	c2e2d572-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1763	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3ff460fa-6427-11e8-bcf1-0a2705229b82	TCGA-13-1482-01A-31-2222-28	10000df6-641e-11e8-bcf1-0a2705229b82	TCGA-13-1482-01A	3cafc3bc-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1482	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
22956291-6428-11e8-bcf1-0a2705229b82	TCGA-61-1741-01A-31-2222-28	1ed74007-641f-11e8-bcf1-0a2705229b82	TCGA-61-1741-01A	fb5f829f-63d7-11e8-bcf1-0a2705229b82	TCGA-61-1741	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ec7ec764-6427-11e8-bcf1-0a2705229b82	TCGA-29-1771-01A-31-2222-28	d78c1c9f-641e-11e8-bcf1-0a2705229b82	TCGA-29-1771-01A	c9374747-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1771	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
38483175-6427-11e8-bcf1-0a2705229b82	TCGA-09-1664-01A-22-2223-28	074e8cf2-641e-11e8-bcf1-0a2705229b82	TCGA-09-1664-01A	367f624e-63d7-11e8-bcf1-0a2705229b82	TCGA-09-1664	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f91b89b-6428-11e8-bcf1-0a2705229b82	TCGA-61-1915-01A-31-2223-28	2951b09b-641f-11e8-bcf1-0a2705229b82	TCGA-61-1915-01A	02f4db2f-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1915	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
50a56faa-6427-11e8-bcf1-0a2705229b82	TCGA-13-1497-01A-31-2222-28	22194c6e-641e-11e8-bcf1-0a2705229b82	TCGA-13-1497-01A	491eedde-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1497	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f6abb5e-6427-11e8-bcf1-0a2705229b82	TCGA-24-1548-01A-22-2223-28	5e3f42c7-641e-11e8-bcf1-0a2705229b82	TCGA-24-1548-01A	72a73c91-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1548	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
764396f3-6427-11e8-bcf1-0a2705229b82	TCGA-24-1436-01A-31-2222-28	518932b4-641e-11e8-bcf1-0a2705229b82	TCGA-24-1436-01A	69ad9617-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1436	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
887e7123-6427-11e8-bcf1-0a2705229b82	TCGA-24-1555-01A-31-2222-28	671a15a3-641e-11e8-bcf1-0a2705229b82	TCGA-24-1555-01A	7904baf7-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1555	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aeb0b4fd-6427-11e8-bcf1-0a2705229b82	TCGA-24-2298-01A-31-2223-28	937613fb-641e-11e8-bcf1-0a2705229b82	TCGA-24-2298-01A	991a95d6-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2298	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd8155fc-6427-11e8-bcf1-0a2705229b82	TCGA-25-2409-01A-31-2222-28	b96bd217-641e-11e8-bcf1-0a2705229b82	TCGA-25-2409-01A	b3ebc033-63d7-11e8-bcf1-0a2705229b82	TCGA-25-2409	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c2d4bb2-6428-11e8-bcf1-0a2705229b82	TCGA-59-2351-01A-31-2223-28	1645a41c-641f-11e8-bcf1-0a2705229b82	TCGA-59-2351-01A	f5242085-63d7-11e8-bcf1-0a2705229b82	TCGA-59-2351	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
584c721d-6427-11e8-bcf1-0a2705229b82	TCGA-13-1511-01A-31-2222-28	2cc5bd75-641e-11e8-bcf1-0a2705229b82	TCGA-13-1511-01A	50cd5e0c-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1511	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21474b24-6428-11e8-bcf1-0a2705229b82	TCGA-61-1727-01A-31-2222-28	1d145d4e-641f-11e8-bcf1-0a2705229b82	TCGA-61-1727-01A	fa22022f-63d7-11e8-bcf1-0a2705229b82	TCGA-61-1727	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
133b3ca9-6428-11e8-bcf1-0a2705229b82	TCGA-36-2544-01A-31-2223-28	09c6004b-641f-11e8-bcf1-0a2705229b82	TCGA-36-2544-01A	ec5cacb8-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2544	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a5eb75e-6428-11e8-bcf1-0a2705229b82	TCGA-61-2087-01A-31-2223-28	31f895e9-641f-11e8-bcf1-0a2705229b82	TCGA-61-2087-01A	0939ac6b-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2087	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
43cdaf62-6427-11e8-bcf1-0a2705229b82	TCGA-13-1485-01A-31-2222-28	1569b6ae-641e-11e8-bcf1-0a2705229b82	TCGA-13-1485-01A	406b207b-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1485	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
599b3d70-6427-11e8-bcf1-0a2705229b82	TCGA-13-2059-01A-41-2223-28	2ea33154-641e-11e8-bcf1-0a2705229b82	TCGA-13-2059-01A	5209aea6-63d7-11e8-bcf1-0a2705229b82	TCGA-13-2059	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4a3796d6-6427-11e8-bcf1-0a2705229b82	TCGA-13-1489-01A-41-2222-28	1ab37279-641e-11e8-bcf1-0a2705229b82	TCGA-13-1489-01A	44232167-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1489	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3ad75780-6427-11e8-bcf1-0a2705229b82	TCGA-09-2056-01B-31-2223-28	09154516-641e-11e8-bcf1-0a2705229b82	TCGA-09-2056-01B	37c198b5-63d7-11e8-bcf1-0a2705229b82	TCGA-09-2056	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d6a9e29d-6427-11e8-bcf1-0a2705229b82	TCGA-29-1696-01A-31-2222-28	c049099a-641e-11e8-bcf1-0a2705229b82	TCGA-29-1696-01A	b8ebbb4c-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1696	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
570d629b-6427-11e8-bcf1-0a2705229b82	TCGA-13-1507-01A-31-2222-28	2ad23d5e-641e-11e8-bcf1-0a2705229b82	TCGA-13-1507-01A	4f90a2a7-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1507	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d7b57e3-6428-11e8-bcf1-0a2705229b82	TCGA-59-2352-01A-31-2223-28	1809f3fe-641f-11e8-bcf1-0a2705229b82	TCGA-59-2352-01A	f665049e-63d7-11e8-bcf1-0a2705229b82	TCGA-59-2352	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
451b3fb3-6427-11e8-bcf1-0a2705229b82	TCGA-13-1487-01A-31-2222-28	170d7a57-641e-11e8-bcf1-0a2705229b82	TCGA-13-1487-01A	41a983c2-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1487	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1ebcf1f8-6428-11e8-bcf1-0a2705229b82	TCGA-59-2372-01A-31-2223-28	19b2a5f0-641f-11e8-bcf1-0a2705229b82	TCGA-59-2372-01A	f7a2ad1e-63d7-11e8-bcf1-0a2705229b82	TCGA-59-2372	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea1662d8-6427-11e8-bcf1-0a2705229b82	TCGA-29-1769-01A-31-2222-28	d423c4cc-641e-11e8-bcf1-0a2705229b82	TCGA-29-1769-01A	c6b6a66e-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1769	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6183305c-6427-11e8-bcf1-0a2705229b82	TCGA-23-1121-01A-31-2222-28	3a462dfa-641e-11e8-bcf1-0a2705229b82	TCGA-23-1121-01A	596fbde2-63d7-11e8-bcf1-0a2705229b82	TCGA-23-1121	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d6e4b16-6427-11e8-bcf1-0a2705229b82	TCGA-24-1422-01A-31-2222-28	4877f794-641e-11e8-bcf1-0a2705229b82	TCGA-24-1422-01A	63722b39-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1422	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
feb04541-6427-11e8-bcf1-0a2705229b82	TCGA-36-1569-01A-31-2222-28	ee22e1f2-641e-11e8-bcf1-0a2705229b82	TCGA-36-1569-01A	d96dc4bd-63d7-11e8-bcf1-0a2705229b82	TCGA-36-1569	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
17134306-6428-11e8-bcf1-0a2705229b82	TCGA-36-2549-01A-31-2223-28	0f3497d9-641f-11e8-bcf1-0a2705229b82	TCGA-36-2549-01A	f01b8281-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2549	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3eb5a07e-6427-11e8-bcf1-0a2705229b82	TCGA-13-1410-01A-31-2222-28	0e4a52f7-641e-11e8-bcf1-0a2705229b82	TCGA-13-1410-01A	3b72a8e5-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1410	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1488464b-6428-11e8-bcf1-0a2705229b82	TCGA-36-2545-01A-31-2223-28	0bcbd138-641f-11e8-bcf1-0a2705229b82	TCGA-36-2545-01A	eda3394b-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2545	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a1fee09e-6427-11e8-bcf1-0a2705229b82	TCGA-24-2033-01A-31-2223-28	84f0e03d-641e-11e8-bcf1-0a2705229b82	TCGA-24-2033-01A	8ed8ea8d-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2033	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10ac5ee6-6428-11e8-bcf1-0a2705229b82	TCGA-36-2542-01A-31-2223-28	06551eab-641f-11e8-bcf1-0a2705229b82	TCGA-36-2542-01A	e9cb13b8-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2542	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
be44f6c6-6427-11e8-bcf1-0a2705229b82	TCGA-25-1623-01A-31-2222-28	a800aa65-641e-11e8-bcf1-0a2705229b82	TCGA-25-1623-01A	a6e43985-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1623	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8b0bd46b-6427-11e8-bcf1-0a2705229b82	TCGA-24-1557-01A-31-2222-28	6ab64ed0-641e-11e8-bcf1-0a2705229b82	TCGA-24-1557-01A	7b889f56-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1557	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
420031e0-6428-11e8-bcf1-0a2705229b82	TCGA-61-2613-01A-31-2223-28	3c8f0d54-641f-11e8-bcf1-0a2705229b82	TCGA-61-2613-01A	10c6a31e-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2613	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b92a540d-6427-11e8-bcf1-0a2705229b82	TCGA-25-1322-01A-22-2223-28	a25e17a0-641e-11e8-bcf1-0a2705229b82	TCGA-25-1322-01A	a32f28e0-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1322	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
47acfc26-6427-11e8-bcf1-0a2705229b82	TCGA-13-1488-01A-31-2222-28	19137300-641e-11e8-bcf1-0a2705229b82	TCGA-13-1488-01A	42e5fc6a-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1488	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
37d15710-6428-11e8-bcf1-0a2705229b82	TCGA-61-2008-01A-41-2222-28	301f9ad9-641f-11e8-bcf1-0a2705229b82	TCGA-61-2008-01A	07f9368e-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2008	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a489dcf9-6427-11e8-bcf1-0a2705229b82	TCGA-24-2261-01A-31-2223-28	88541c84-641e-11e8-bcf1-0a2705229b82	TCGA-24-2261-01A	915465f9-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2261	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5332ac72-6427-11e8-bcf1-0a2705229b82	TCGA-13-1500-01A-31-2222-28	257fdcb2-641e-11e8-bcf1-0a2705229b82	TCGA-13-1500-01A	4b99e241-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1500	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f6c6586e-6427-11e8-bcf1-0a2705229b82	TCGA-29-2427-01A-31-2222-28	e3c95fd3-641e-11e8-bcf1-0a2705229b82	TCGA-29-2427-01A	d1ed97b4-63d7-11e8-bcf1-0a2705229b82	TCGA-29-2427	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3c27b4af-6427-11e8-bcf1-0a2705229b82	TCGA-13-1404-01A-31-2222-28	0ae5db85-641e-11e8-bcf1-0a2705229b82	TCGA-13-1404-01A	38fc229e-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1404	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01410a2f-6428-11e8-bcf1-0a2705229b82	TCGA-36-1571-01A-31-2222-28	f2ad4155-641e-11e8-bcf1-0a2705229b82	TCGA-36-1571-01A	dbf2e1fa-63d7-11e8-bcf1-0a2705229b82	TCGA-36-1571	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0334b83-6427-11e8-bcf1-0a2705229b82	TCGA-25-1312-01A-21-2223-28	954d7d6b-641e-11e8-bcf1-0a2705229b82	TCGA-25-1312-01A	9a58eb4b-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1312	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
36835469-6428-11e8-bcf1-0a2705229b82	TCGA-61-1995-01A-31-2222-28	2e4d84eb-641f-11e8-bcf1-0a2705229b82	TCGA-61-1995-01A	06b79e23-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1995	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f5e3b39-6428-11e8-bcf1-0a2705229b82	TCGA-36-2537-01A-31-2223-28	04c71716-641f-11e8-bcf1-0a2705229b82	TCGA-36-2537-01A	e88917ea-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2537	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bf932377-6427-11e8-bcf1-0a2705229b82	TCGA-25-1628-01A-31-2222-28	a9f50b7c-641e-11e8-bcf1-0a2705229b82	TCGA-25-1628-01A	a8629627-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1628	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2e43346f-6428-11e8-bcf1-0a2705229b82	TCGA-61-1914-01A-31-2222-28	277d969c-641f-11e8-bcf1-0a2705229b82	TCGA-61-1914-01A	01b2691b-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1914	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1af26bed-6428-11e8-bcf1-0a2705229b82	TCGA-59-2348-01A-31-2223-28	14a511a3-641f-11e8-bcf1-0a2705229b82	TCGA-59-2348-01A	f3d461cc-63d7-11e8-bcf1-0a2705229b82	TCGA-59-2348	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
068b0330-6428-11e8-bcf1-0a2705229b82	TCGA-36-1580-01A-31-2222-28	f9dd607e-641e-11e8-bcf1-0a2705229b82	TCGA-36-1580-01A	e0f3cdc7-63d7-11e8-bcf1-0a2705229b82	TCGA-36-1580	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
200c8ce4-6428-11e8-bcf1-0a2705229b82	TCGA-61-1724-01A-31-2222-28	1b7304bb-641f-11e8-bcf1-0a2705229b82	TCGA-61-1724-01A	f8e64f02-63d7-11e8-bcf1-0a2705229b82	TCGA-61-1724	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7127f228-6427-11e8-bcf1-0a2705229b82	TCGA-24-1430-01A-31-2222-28	4c0f155c-641e-11e8-bcf1-0a2705229b82	TCGA-24-1430-01A	65f1931c-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1430	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5b1aaf3f-6427-11e8-bcf1-0a2705229b82	TCGA-13-2060-01A-31-2223-28	3032e53e-641e-11e8-bcf1-0a2705229b82	TCGA-13-2060-01A	5344fc26-63d7-11e8-bcf1-0a2705229b82	TCGA-13-2060	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
55bde2ea-6427-11e8-bcf1-0a2705229b82	TCGA-13-1504-01A-31-2222-28	28fc4d4f-641e-11e8-bcf1-0a2705229b82	TCGA-13-1504-01A	4e18b240-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1504	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ee7e3cd-6427-11e8-bcf1-0a2705229b82	TCGA-13-2066-01A-41-2223-28	356f5863-641e-11e8-bcf1-0a2705229b82	TCGA-13-2066-01A	57017226-63d7-11e8-bcf1-0a2705229b82	TCGA-13-2066	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9160ee87-6427-11e8-bcf1-0a2705229b82	TCGA-24-1565-01A-31-2222-28	71e25753-641e-11e8-bcf1-0a2705229b82	TCGA-24-1565-01A	80cea38e-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1565	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e1219aaa-6427-11e8-bcf1-0a2705229b82	TCGA-29-1762-01A-31-2222-28	ccf05813-641e-11e8-bcf1-0a2705229b82	TCGA-29-1762-01A	c1a57e52-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1762	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8730b3a5-6427-11e8-bcf1-0a2705229b82	TCGA-24-1555-01A-32-2224-29	671a15a3-641e-11e8-bcf1-0a2705229b82	TCGA-24-1555-01A	7904baf7-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1555	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b7dcd14a-6427-11e8-bcf1-0a2705229b82	TCGA-25-1321-01A-22-2225-29	a04d43ad-641e-11e8-bcf1-0a2705229b82	TCGA-25-1321-01A	a1f1f212-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1321	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
40c23597-6428-11e8-bcf1-0a2705229b82	TCGA-61-2612-01A-31-2224-29	3abbe219-641f-11e8-bcf1-0a2705229b82	TCGA-61-2612-01A	0f80f1fe-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2612	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
69954dbb-6427-11e8-bcf1-0a2705229b82	TCGA-24-1104-01A-31-2224-29	43395758-641e-11e8-bcf1-0a2705229b82	TCGA-24-1104-01A	5fb453f2-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1104	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d56a91d4-6427-11e8-bcf1-0a2705229b82	TCGA-29-1693-01A-32-2224-29	bea317b9-641e-11e8-bcf1-0a2705229b82	TCGA-29-1693-01A	b7ac2e48-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1693	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
11fafe2d-6428-11e8-bcf1-0a2705229b82	TCGA-36-2543-01A-31-2224-29	0834ee8a-641f-11e8-bcf1-0a2705229b82	TCGA-36-2543-01A	eb1039c3-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2543	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
82012c5b-6427-11e8-bcf1-0a2705229b82	TCGA-24-1551-01A-31-2224-29	61a8f161-641e-11e8-bcf1-0a2705229b82	TCGA-24-1551-01A	75298f3c-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1551	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
85e105d0-6427-11e8-bcf1-0a2705229b82	TCGA-24-1553-01A-32-2224-29	654745ea-641e-11e8-bcf1-0a2705229b82	TCGA-24-1553-01A	77c6c6ac-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1553	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b698e409-6427-11e8-bcf1-0a2705229b82	TCGA-25-1320-01A-22-2225-29	9e8a7cd5-641e-11e8-bcf1-0a2705229b82	TCGA-25-1320-01A	a0ad4f83-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1320	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a0c19e7b-6427-11e8-bcf1-0a2705229b82	TCGA-24-2030-01A-32-2224-29	835fca45-641e-11e8-bcf1-0a2705229b82	TCGA-24-2030-01A	8d929b06-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2030	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0914f84e-6428-11e8-bcf1-0a2705229b82	TCGA-36-2529-01A-31-2224-29	fd4a60b1-641e-11e8-bcf1-0a2705229b82	TCGA-36-2529-01A	e37e827e-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2529	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
80b73ce2-6427-11e8-bcf1-0a2705229b82	TCGA-24-1550-01A-31-2224-29	60086039-641e-11e8-bcf1-0a2705229b82	TCGA-24-1550-01A	73e3518e-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1550	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1854c245-6428-11e8-bcf1-0a2705229b82	TCGA-42-2588-01A-31-2224-29	1108aeba-641f-11e8-bcf1-0a2705229b82	TCGA-42-2588-01A	f158835b-63d7-11e8-bcf1-0a2705229b82	TCGA-42-2588	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f9506101-6427-11e8-bcf1-0a2705229b82	TCGA-29-2432-01A-31-2224-29	e72ddd9c-641e-11e8-bcf1-0a2705229b82	TCGA-29-2432-01A	d46de821-63d7-11e8-bcf1-0a2705229b82	TCGA-29-2432	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8daae115-6427-11e8-bcf1-0a2705229b82	TCGA-24-1562-01A-32-2224-29	6e18e4e2-641e-11e8-bcf1-0a2705229b82	TCGA-24-1562-01A	7e05678b-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1562	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b2bfbe2e-6427-11e8-bcf1-0a2705229b82	TCGA-25-1316-01A-22-2225-29	98b3382a-641e-11e8-bcf1-0a2705229b82	TCGA-25-1316-01A	9cf6e69d-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1316	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
929def15-6427-11e8-bcf1-0a2705229b82	TCGA-24-1603-01A-31-2224-29	7383a2a5-641e-11e8-bcf1-0a2705229b82	TCGA-24-1603-01A	822fbbdd-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1603	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
428fedc4-6427-11e8-bcf1-0a2705229b82	TCGA-13-1484-01A-31-2224-29	13962897-641e-11e8-bcf1-0a2705229b82	TCGA-13-1484-01A	3f2e40bf-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1484	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a4e25e8-6427-11e8-bcf1-0a2705229b82	TCGA-24-1467-01A-31-2224-29	56fc3b6b-641e-11e8-bcf1-0a2705229b82	TCGA-24-1467-01A	6d6e91a5-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1467	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4cc82069-6427-11e8-bcf1-0a2705229b82	TCGA-13-1494-01A-32-2224-29	1e5f5978-641e-11e8-bcf1-0a2705229b82	TCGA-13-1494-01A	469cc236-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1494	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9a568bb4-6427-11e8-bcf1-0a2705229b82	TCGA-24-2023-01A-31-2224-29	7dbf6bef-641e-11e8-bcf1-0a2705229b82	TCGA-24-2023-01A	89ced9ab-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2023	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f05dea79-6427-11e8-bcf1-0a2705229b82	TCGA-29-1776-01A-31-2224-29	dcca5163-641e-11e8-bcf1-0a2705229b82	TCGA-29-1776-01A	ccfe401b-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1776	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a71962fd-6427-11e8-bcf1-0a2705229b82	TCGA-24-2288-01A-31-2224-29	8bc6ccff-641e-11e8-bcf1-0a2705229b82	TCGA-24-2288-01A	93d92ef2-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2288	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c0cffd80-6427-11e8-bcf1-0a2705229b82	TCGA-25-1628-01A-32-2224-29	a9f50b7c-641e-11e8-bcf1-0a2705229b82	TCGA-25-1628-01A	a8629627-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1628	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c4ae5583-6427-11e8-bcf1-0a2705229b82	TCGA-25-1635-01A-31-2224-29	af046a47-641e-11e8-bcf1-0a2705229b82	TCGA-25-1635-01A	ac5bbaf4-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1635	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6034cf4c-6427-11e8-bcf1-0a2705229b82	TCGA-13-2071-01A-31-2224-29	373124f9-641e-11e8-bcf1-0a2705229b82	TCGA-13-2071-01A	5835414d-63d7-11e8-bcf1-0a2705229b82	TCGA-13-2071	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7e2d2cb3-6427-11e8-bcf1-0a2705229b82	TCGA-24-1545-01A-31-2224-29	5c9e0157-641e-11e8-bcf1-0a2705229b82	TCGA-24-1545-01A	712748c9-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1545	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a34c8f83-6427-11e8-bcf1-0a2705229b82	TCGA-24-2260-01A-31-2224-29	86c39c1d-641e-11e8-bcf1-0a2705229b82	TCGA-24-2260-01A	9017ac55-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2260	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
390db2bf-6428-11e8-bcf1-0a2705229b82	TCGA-61-2008-01A-42-2224-29	301f9ad9-641f-11e8-bcf1-0a2705229b82	TCGA-61-2008-01A	07f9368e-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2008	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cecfea1f-6427-11e8-bcf1-0a2705229b82	TCGA-25-2409-01A-32-2225-29	b96bd217-641e-11e8-bcf1-0a2705229b82	TCGA-25-2409-01A	b3ebc033-63d7-11e8-bcf1-0a2705229b82	TCGA-25-2409	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64153008-6427-11e8-bcf1-0a2705229b82	TCGA-23-1123-01A-21-2225-29	3e3218d9-641e-11e8-bcf1-0a2705229b82	TCGA-23-1123-01A	5bf3a933-63d7-11e8-bcf1-0a2705229b82	TCGA-23-1123	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9ce327e0-6427-11e8-bcf1-0a2705229b82	TCGA-24-2024-01A-42-2224-29	7f93088f-641e-11e8-bcf1-0a2705229b82	TCGA-24-2024-01A	8b0bd36f-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2024	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e27164ce-6427-11e8-bcf1-0a2705229b82	TCGA-29-1762-01A-32-2224-29	ccf05813-641e-11e8-bcf1-0a2705229b82	TCGA-29-1762-01A	c1a57e52-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1762	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
99071b34-6427-11e8-bcf1-0a2705229b82	TCGA-24-2020-01A-31-2224-29	7c1a9401-641e-11e8-bcf1-0a2705229b82	TCGA-24-2020-01A	886ebf74-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2020	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
901468c7-6427-11e8-bcf1-0a2705229b82	TCGA-24-1563-01A-31-2224-29	6feab7a5-641e-11e8-bcf1-0a2705229b82	TCGA-24-1563-01A	7f4d826f-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1563	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
027d252e-6428-11e8-bcf1-0a2705229b82	TCGA-36-1576-01A-31-2224-29	f44f29d2-641e-11e8-bcf1-0a2705229b82	TCGA-36-1576-01A	dd374872-63d7-11e8-bcf1-0a2705229b82	TCGA-36-1576	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1ab4f75-6427-11e8-bcf1-0a2705229b82	TCGA-29-1777-01A-31-2224-29	de6fb99a-641e-11e8-bcf1-0a2705229b82	TCGA-29-1777-01A	ce397416-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1777	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
19a25e54-6428-11e8-bcf1-0a2705229b82	TCGA-42-2590-01A-31-2224-29	12a94a30-641f-11e8-bcf1-0a2705229b82	TCGA-42-2590-01A	f294b8c4-63d7-11e8-bcf1-0a2705229b82	TCGA-42-2590	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
07d8623f-6428-11e8-bcf1-0a2705229b82	TCGA-36-1581-01A-41-2224-29	fb896453-641e-11e8-bcf1-0a2705229b82	TCGA-36-1581-01A	e2392707-63d7-11e8-bcf1-0a2705229b82	TCGA-36-1581	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83502e92-6427-11e8-bcf1-0a2705229b82	TCGA-24-1552-01A-31-2224-29	637c5df4-641e-11e8-bcf1-0a2705229b82	TCGA-24-1552-01A	766f86d2-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1552	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a8678ae8-6427-11e8-bcf1-0a2705229b82	TCGA-24-2289-01A-32-2224-29	8dcb6462-641e-11e8-bcf1-0a2705229b82	TCGA-24-2289-01A	9517810d-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2289	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
93f10716-6427-11e8-bcf1-0a2705229b82	TCGA-24-1604-01A-31-2224-29	7546aebc-641e-11e8-bcf1-0a2705229b82	TCGA-24-1604-01A	836ba4d0-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1604	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
75010d91-6427-11e8-bcf1-0a2705229b82	TCGA-24-1435-01A-32-2224-29	4fb4a022-641e-11e8-bcf1-0a2705229b82	TCGA-24-1435-01A	686f8e1f-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1435	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cb15d180-6427-11e8-bcf1-0a2705229b82	TCGA-25-2404-01A-32-2225-29	b7d7b9cc-641e-11e8-bcf1-0a2705229b82	TCGA-25-2404-01A	b2a4a0c4-63d7-11e8-bcf1-0a2705229b82	TCGA-25-2404	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
edcbcb3d-6427-11e8-bcf1-0a2705229b82	TCGA-29-1774-01A-31-2224-29	d96170cd-641e-11e8-bcf1-0a2705229b82	TCGA-29-1774-01A	ca7f4369-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1774	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
33a228ac-6428-11e8-bcf1-0a2705229b82	TCGA-61-1995-01A-32-2224-29	2e4d84eb-641f-11e8-bcf1-0a2705229b82	TCGA-61-1995-01A	06b79e23-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1995	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48ea3960-6427-11e8-bcf1-0a2705229b82	TCGA-13-1489-01A-42-2224-29	1ab37279-641e-11e8-bcf1-0a2705229b82	TCGA-13-1489-01A	44232167-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1489	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
685198bb-6427-11e8-bcf1-0a2705229b82	TCGA-24-1103-01A-32-2224-29	4197faa8-641e-11e8-bcf1-0a2705229b82	TCGA-24-1103-01A	5e6fa63a-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1103	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ef202c6b-6427-11e8-bcf1-0a2705229b82	TCGA-29-1775-01A-31-2224-29	daf3335a-641e-11e8-bcf1-0a2705229b82	TCGA-29-1775-01A	cbbb778c-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1775	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b54b8292-6427-11e8-bcf1-0a2705229b82	TCGA-25-1319-01A-22-2225-29	9cb7608a-641e-11e8-bcf1-0a2705229b82	TCGA-25-1319-01A	9f71a995-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1319	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6583b410-6427-11e8-bcf1-0a2705229b82	TCGA-23-1124-01A-31-2224-29	3fd3be00-641e-11e8-bcf1-0a2705229b82	TCGA-23-1124-01A	5d2fb710-63d7-11e8-bcf1-0a2705229b82	TCGA-23-1124	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d15fb500-6427-11e8-bcf1-0a2705229b82	TCGA-29-1688-01A-32-2224-29	bb3e49c8-641e-11e8-bcf1-0a2705229b82	TCGA-29-1688-01A	b52c7e99-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1688	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a5db963a-6427-11e8-bcf1-0a2705229b82	TCGA-24-2267-01A-31-2224-29	8a3620d9-641e-11e8-bcf1-0a2705229b82	TCGA-24-2267-01A	929c0fda-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2267	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f58bd44e-6427-11e8-bcf1-0a2705229b82	TCGA-29-2414-01A-41-2224-29	e2016489-641e-11e8-bcf1-0a2705229b82	TCGA-29-2414-01A	d0b0f8b4-63d7-11e8-bcf1-0a2705229b82	TCGA-29-2414	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
faa3e591-6427-11e8-bcf1-0a2705229b82	TCGA-30-1866-01A-31-2224-29	e8ce65f4-641e-11e8-bcf1-0a2705229b82	TCGA-30-1866-01A	d5ac1143-63d7-11e8-bcf1-0a2705229b82	TCGA-30-1866	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4f78a44a-6427-11e8-bcf1-0a2705229b82	TCGA-13-1495-01A-31-2224-29	2060f7fa-641e-11e8-bcf1-0a2705229b82	TCGA-13-1495-01A	47e19302-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1495	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0a4108a3-6428-11e8-bcf1-0a2705229b82	TCGA-36-2530-01A-32-2225-29	feec214d-641e-11e8-bcf1-0a2705229b82	TCGA-36-2530-01A	e4bc1db1-63d7-11e8-bcf1-0a2705229b82	TCGA-36-2530	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
241501f6-6428-11e8-bcf1-0a2705229b82	TCGA-61-1741-01A-32-2224-29	1ed74007-641f-11e8-bcf1-0a2705229b82	TCGA-61-1741-01A	fb5f829f-63d7-11e8-bcf1-0a2705229b82	TCGA-61-1741	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
26a0d4ca-6428-11e8-bcf1-0a2705229b82	TCGA-61-1907-01A-32-2224-29	2252069d-641f-11e8-bcf1-0a2705229b82	TCGA-61-1907-01A	fde688bb-63d7-11e8-bcf1-0a2705229b82	TCGA-61-1907	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
967c81fe-6427-11e8-bcf1-0a2705229b82	TCGA-24-1923-01A-31-2224-29	78b5ca54-641e-11e8-bcf1-0a2705229b82	TCGA-24-1923-01A	85f308a1-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1923	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
89cd56fc-6427-11e8-bcf1-0a2705229b82	TCGA-24-1556-01A-31-2224-29	68aa47a0-641e-11e8-bcf1-0a2705229b82	TCGA-24-1556-01A	7a42cc9a-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1556	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
78fff8db-6427-11e8-bcf1-0a2705229b82	TCGA-24-1466-01A-31-2224-29	555b82af-641e-11e8-bcf1-0a2705229b82	TCGA-24-1466-01A	6c315d5f-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1466	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
399b1113-6427-11e8-bcf1-0a2705229b82	TCGA-09-1664-01A-23-2225-29	074e8cf2-641e-11e8-bcf1-0a2705229b82	TCGA-09-1664-01A	367f624e-63d7-11e8-bcf1-0a2705229b82	TCGA-09-1664	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c9c3867d-6427-11e8-bcf1-0a2705229b82	TCGA-25-2400-01A-31-2224-29	b603bbbd-641e-11e8-bcf1-0a2705229b82	TCGA-25-2400-01A	b15da313-63d7-11e8-bcf1-0a2705229b82	TCGA-25-2400	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
325759fa-6428-11e8-bcf1-0a2705229b82	TCGA-61-1919-01A-31-2224-29	2cbb60ef-641f-11e8-bcf1-0a2705229b82	TCGA-61-1919-01A	0578f49d-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1919	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e4fcdf13-6427-11e8-bcf1-0a2705229b82	TCGA-29-1763-01A-32-2224-29	cef5b8b0-641e-11e8-bcf1-0a2705229b82	TCGA-29-1763-01A	c2e2d572-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1763	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
51f47c0a-6427-11e8-bcf1-0a2705229b82	TCGA-13-1499-01A-31-2224-29	23de5430-641e-11e8-bcf1-0a2705229b82	TCGA-13-1499-01A	4a5b0f8b-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1499	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6eac198d-6427-11e8-bcf1-0a2705229b82	TCGA-24-1428-01A-31-2224-29	4a39eb83-641e-11e8-bcf1-0a2705229b82	TCGA-24-1428-01A	64b49f60-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1428	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a6b4244-6428-11e8-bcf1-0a2705229b82	TCGA-61-1911-01A-32-2224-29	25ed85d4-641f-11e8-bcf1-0a2705229b82	TCGA-61-1911-01A	0067a0e0-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1911	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6fd8153f-6427-11e8-bcf1-0a2705229b82	TCGA-24-1430-01A-32-2224-29	4c0f155c-641e-11e8-bcf1-0a2705229b82	TCGA-24-1430-01A	65f1931c-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1430	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
254d709b-6428-11e8-bcf1-0a2705229b82	TCGA-61-1900-01A-31-2224-29	207f36d5-641f-11e8-bcf1-0a2705229b82	TCGA-61-1900-01A	fc9d336a-63d7-11e8-bcf1-0a2705229b82	TCGA-61-1900	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8c7dd69-6427-11e8-bcf1-0a2705229b82	TCGA-29-1768-01A-32-2224-29	d2937cc1-641e-11e8-bcf1-0a2705229b82	TCGA-29-1768-01A	c566f20e-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1768	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e36cd8e-6428-11e8-bcf1-0a2705229b82	TCGA-61-2095-01A-31-2224-29	37517909-641f-11e8-bcf1-0a2705229b82	TCGA-61-2095-01A	0cfb6014-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2095	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9e1e5e0a-6427-11e8-bcf1-0a2705229b82	TCGA-24-2027-01A-31-2224-29	815600a4-641e-11e8-bcf1-0a2705229b82	TCGA-24-2027-01A	8c49b204-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2027	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f43c152a-6427-11e8-bcf1-0a2705229b82	TCGA-29-1785-01A-32-2224-29	e0620a4d-641e-11e8-bcf1-0a2705229b82	TCGA-29-1785-01A	cf738c51-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1785	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c21de109-6427-11e8-bcf1-0a2705229b82	TCGA-25-1630-01A-31-2224-29	ab975dc6-641e-11e8-bcf1-0a2705229b82	TCGA-25-1630-01A	a99f5b43-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1630	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
46600a44-6427-11e8-bcf1-0a2705229b82	TCGA-13-1488-01A-32-2224-29	19137300-641e-11e8-bcf1-0a2705229b82	TCGA-13-1488-01A	42e5fc6a-63d7-11e8-bcf1-0a2705229b82	TCGA-13-1488	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aaf16fc0-6427-11e8-bcf1-0a2705229b82	TCGA-24-2290-01A-32-2224-29	8faed2c3-641e-11e8-bcf1-0a2705229b82	TCGA-24-2290-01A	9688e191-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2290	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3f73fe35-6428-11e8-bcf1-0a2705229b82	TCGA-61-2096-01A-31-2224-29	38f96605-641f-11e8-bcf1-0a2705229b82	TCGA-61-2096-01A	0e419aab-63d8-11e8-bcf1-0a2705229b82	TCGA-61-2096	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2d057160-6428-11e8-bcf1-0a2705229b82	TCGA-61-1914-01A-32-2224-29	277d969c-641f-11e8-bcf1-0a2705229b82	TCGA-61-1914-01A	01b2691b-63d8-11e8-bcf1-0a2705229b82	TCGA-61-1914	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ad738765-6427-11e8-bcf1-0a2705229b82	TCGA-24-2295-01A-31-2224-29	91831303-641e-11e8-bcf1-0a2705229b82	TCGA-24-2295-01A	97d4f695-63d7-11e8-bcf1-0a2705229b82	TCGA-24-2295	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6ae43bbf-6427-11e8-bcf1-0a2705229b82	TCGA-24-1105-01A-31-2224-29	4502cfe0-641e-11e8-bcf1-0a2705229b82	TCGA-24-1105-01A	60f2f721-63d7-11e8-bcf1-0a2705229b82	TCGA-24-1105	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bd06724c-6427-11e8-bcf1-0a2705229b82	TCGA-25-1623-01A-32-2224-29	a800aa65-641e-11e8-bcf1-0a2705229b82	TCGA-25-1623-01A	a6e43985-63d7-11e8-bcf1-0a2705229b82	TCGA-25-1623	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d7fac4cb-6427-11e8-bcf1-0a2705229b82	TCGA-29-1697-01A-32-2224-29	c23cbaaa-641e-11e8-bcf1-0a2705229b82	TCGA-29-1697-01A	ba2f7e13-63d7-11e8-bcf1-0a2705229b82	TCGA-29-1697	CPTAC2 Retrospective	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2de529de-6427-11e8-bcf1-0a2705229b82	fd4edc52-09ef-4b01-be7c-f23f05_D2	25567fdb-641d-11e8-bcf1-0a2705229b82	fd4edc52-09ef-4b01-be7c-f23f05	cae72878-63d6-11e8-bcf1-0a2705229b82	14CO003	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
74fbcca2-6425-11e8-bcf1-0a2705229b82	8af80ae9-2088-4124-91fb-8d6c17_D2	96851e33-641b-11e8-bcf1-0a2705229b82	8af80ae9-2088-4124-91fb-8d6c17	24cb0fcb-63d6-11e8-bcf1-0a2705229b82	05CO044	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
806b7fe7-6423-11e8-bcf1-0a2705229b82	21cab01c-e968-42cc-9651-1e53c0_D2	af117140-641c-11e8-bcf1-0a2705229b82	21cab01c-e968-42cc-9651-1e53c0	9e5a2210-63d6-11e8-bcf1-0a2705229b82	11CO036	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b08b04ea-6425-11e8-bcf1-0a2705229b82	98742d96-cc2f-43f0-9de2-bc7afe_D2	7a092725-641c-11e8-bcf1-0a2705229b82	98742d96-cc2f-43f0-9de2-bc7afe	8e4e8ba7-63d6-11e8-bcf1-0a2705229b82	11CO008	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f22abdb-6427-11e8-bcf1-0a2705229b82	fe4b3b1c-9f7f-4109-8a76-ca1d6f_D2	ee1eb8d9-641c-11e8-bcf1-0a2705229b82	fe4b3b1c-9f7f-4109-8a76-ca1d6f	b2dc3f43-63d6-11e8-bcf1-0a2705229b82	11CO060	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c1c58ab5-6426-11e8-bcf1-0a2705229b82	e295a7d1-a0d0-4b0b-bdc2-729a0d_D2	bba19a8b-641c-11e8-bcf1-0a2705229b82	e295a7d1-a0d0-4b0b-bdc2-729a0d	a0e04ed9-63d6-11e8-bcf1-0a2705229b82	11CO039	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
49caa5dc-6426-11e8-bcf1-0a2705229b82	c8694e31-2c8f-4eb6-a7ef-a137d9_D2	f8dc9401-641c-11e8-bcf1-0a2705229b82	c8694e31-2c8f-4eb6-a7ef-a137d9	b692a393-63d6-11e8-bcf1-0a2705229b82	11CO070	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29a64b2c-6425-11e8-bcf1-0a2705229b82	77c493b1-34ba-4efc-8def-987116_D2	0213fd06-641d-11e8-bcf1-0a2705229b82	77c493b1-34ba-4efc-8def-987116	ba6da9c2-63d6-11e8-bcf1-0a2705229b82	11CO079	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e6ab3eb3-6424-11e8-bcf1-0a2705229b82	66b829db-1cdd-460d-b2f3-0e9ca9_D2	afe6c7ed-641b-11e8-bcf1-0a2705229b82	66b829db-1cdd-460d-b2f3-0e9ca9	2c346c06-63d6-11e8-bcf1-0a2705229b82	05CO053	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dc54ff77-6424-11e8-bcf1-0a2705229b82	64b606d7-d40f-41ae-b220-a66324_D2	fcca5035-641c-11e8-bcf1-0a2705229b82	64b606d7-d40f-41ae-b220-a66324	b7dda873-63d6-11e8-bcf1-0a2705229b82	11CO072	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bd863553-6424-11e8-bcf1-0a2705229b82	5da00abd-5fa7-4deb-95f1-7982e0_D2	98698249-641c-11e8-bcf1-0a2705229b82	5da00abd-5fa7-4deb-95f1-7982e0	97f45829-63d6-11e8-bcf1-0a2705229b82	11CO027	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
92c3ea96-6424-11e8-bcf1-0a2705229b82	5557e478-3e6f-475b-8acc-1b4159_D2	0051bce7-641d-11e8-bcf1-0a2705229b82	5557e478-3e6f-475b-8acc-1b4159	b9178503-63d6-11e8-bcf1-0a2705229b82	11CO077	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
313a46ef-6424-11e8-bcf1-0a2705229b82	43192517-085e-450e-9481-0a6713_D2	b55aa4c1-641b-11e8-bcf1-0a2705229b82	43192517-085e-450e-9481-0a6713	2d701098-63d6-11e8-bcf1-0a2705229b82	05CO054	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
529e988c-6423-11e8-bcf1-0a2705229b82	17cd2121-d347-431c-9cc7-fbab14_D2	aab07fab-641b-11e8-bcf1-0a2705229b82	17cd2121-d347-431c-9cc7-fbab14	2af8ac24-63d6-11e8-bcf1-0a2705229b82	05CO050	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a1ae05d-6426-11e8-bcf1-0a2705229b82	d3078fa8-0692-411f-8441-0c7c48_D2	e70af089-641c-11e8-bcf1-0a2705229b82	d3078fa8-0692-411f-8441-0c7c48	b05c2057-63d6-11e8-bcf1-0a2705229b82	11CO058	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d0dec1d4-6426-11e8-bcf1-0a2705229b82	e515eb5c-8005-416a-9b42-59de9d_D2	e3b65238-641c-11e8-bcf1-0a2705229b82	e515eb5c-8005-416a-9b42-59de9d	af1d550b-63d6-11e8-bcf1-0a2705229b82	11CO057	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
08b2a2bf-6427-11e8-bcf1-0a2705229b82	f69deaeb-6b6f-4c61-8900-fd0f26_D2	f6cce507-641b-11e8-bcf1-0a2705229b82	f69deaeb-6b6f-4c61-8900-fd0f26	459e3b69-63d6-11e8-bcf1-0a2705229b82	09CO022	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c9e8a92-6427-11e8-bcf1-0a2705229b82	f6a7f764-2495-4a1d-89a2-e12f51_D2	dfe3b739-641c-11e8-bcf1-0a2705229b82	f6a7f764-2495-4a1d-89a2-e12f51	add7dfac-63d6-11e8-bcf1-0a2705229b82	11CO054	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f44933a3-6426-11e8-bcf1-0a2705229b82	ecf1ca92-c8b7-470f-baf4-81cf73_D2	dc66f500-641c-11e8-bcf1-0a2705229b82	ecf1ca92-c8b7-470f-baf4-81cf73	aca14699-63d6-11e8-bcf1-0a2705229b82	11CO053	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ffcb17fc-6422-11e8-bcf1-0a2705229b82	0630ecb0-b664-4e75-bb3c-fb62ee_D2	d64baeee-641c-11e8-bcf1-0a2705229b82	0630ecb0-b664-4e75-bb3c-fb62ee	ab0c12f7-63d6-11e8-bcf1-0a2705229b82	11CO052	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7651f9f6-6425-11e8-bcf1-0a2705229b82	8c73f3a5-fea8-4942-90c0-966f66_D2	f1f8a867-641c-11e8-bcf1-0a2705229b82	8c73f3a5-fea8-4942-90c0-966f66	b4188575-63d6-11e8-bcf1-0a2705229b82	11CO061	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
40dd10e8-6425-11e8-bcf1-0a2705229b82	7e3d5ae0-3dcc-4207-8dd2-59ab4b_D2	c662f158-641c-11e8-bcf1-0a2705229b82	7e3d5ae0-3dcc-4207-8dd2-59ab4b	a494498b-63d6-11e8-bcf1-0a2705229b82	11CO044	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
930bfcfd-6425-11e8-bcf1-0a2705229b82	92c1ebb5-ac1d-4bf5-a14f-516e1d_D2	9a3fa38b-641b-11e8-bcf1-0a2705229b82	92c1ebb5-ac1d-4bf5-a14f-516e1d	260fb98a-63d6-11e8-bcf1-0a2705229b82	05CO045	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d228c92-6426-11e8-bcf1-0a2705229b82	cf795cd2-317b-4897-a35e-390001_D2	8fc85282-641c-11e8-bcf1-0a2705229b82	cf795cd2-317b-4897-a35e-390001	95307d66-63d6-11e8-bcf1-0a2705229b82	11CO021	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
058bca73-6424-11e8-bcf1-0a2705229b82	3ca0ab23-70ae-4083-bd7d-9f71d8_D2	cd97182e-641c-11e8-bcf1-0a2705229b82	3ca0ab23-70ae-4083-bd7d-9f71d8	a725c269-63d6-11e8-bcf1-0a2705229b82	11CO047	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7efd467d-6423-11e8-bcf1-0a2705229b82	21c6f56a-8881-421b-81fa-c354cb_D2	9158ecef-641c-11e8-bcf1-0a2705229b82	21c6f56a-8881-421b-81fa-c354cb	9691960e-63d6-11e8-bcf1-0a2705229b82	11CO022	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1832376c-6427-11e8-bcf1-0a2705229b82	f9d6fb1b-988e-4d28-9272-cc672f_D2	647b910e-641a-11e8-bcf1-0a2705229b82	f9d6fb1b-988e-4d28-9272-cc672f	900e6eff-63d5-11e8-bcf1-0a2705229b82	01CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9aa06530-6425-11e8-bcf1-0a2705229b82	9452572f-e3ec-4063-a82e-43ac90_D2	67d6ca9d-641a-11e8-bcf1-0a2705229b82	9452572f-e3ec-4063-a82e-43ac90	914af33a-63d5-11e8-bcf1-0a2705229b82	01CO008	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cb91d6c7-6425-11e8-bcf1-0a2705229b82	9fb0c084-16fd-4d54-ab60-d94303_D2	555d88b4-641b-11e8-bcf1-0a2705229b82	9fb0c084-16fd-4d54-ab60-d94303	0e47d03c-63d6-11e8-bcf1-0a2705229b82	05CO004	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb7938b9-6425-11e8-bcf1-0a2705229b82	a8955d38-7a72-4f9d-9c70-5c0f08_D2	57432490-641b-11e8-bcf1-0a2705229b82	a8955d38-7a72-4f9d-9c70-5c0f08	0f9261c8-63d6-11e8-bcf1-0a2705229b82	05CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b1d0b25f-6425-11e8-bcf1-0a2705229b82	9899e1ad-62e1-4cc2-91fc-49b85c_D2	5cbac05e-641b-11e8-bcf1-0a2705229b82	9899e1ad-62e1-4cc2-91fc-49b85c	10c75345-63d6-11e8-bcf1-0a2705229b82	05CO007	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5922d1bb-6425-11e8-bcf1-0a2705229b82	8495cc54-eb88-40ab-b03f-363edf_D2	60b62a2d-641b-11e8-bcf1-0a2705229b82	8495cc54-eb88-40ab-b03f-363edf	123ebacf-63d6-11e8-bcf1-0a2705229b82	05CO011	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2478c8a8-6424-11e8-bcf1-0a2705229b82	416bb805-e4cd-4ca6-8fdd-1eec2d_D2	62a6f815-641b-11e8-bcf1-0a2705229b82	416bb805-e4cd-4ca6-8fdd-1eec2d	139a0253-63d6-11e8-bcf1-0a2705229b82	05CO015	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4aac0218-6425-11e8-bcf1-0a2705229b82	803736b3-9ca9-4f9f-bdfe-8783e3_D2	6608aa59-641b-11e8-bcf1-0a2705229b82	803736b3-9ca9-4f9f-bdfe-8783e3	15d7eb12-63d6-11e8-bcf1-0a2705229b82	05CO020	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bc874577-6426-11e8-bcf1-0a2705229b82	e0068ac5-f557-443a-bd4b-bdfcef_D2	6f460e53-641b-11e8-bcf1-0a2705229b82	e0068ac5-f557-443a-bd4b-bdfcef	193b277a-63d6-11e8-bcf1-0a2705229b82	05CO028	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9ee4d657-6424-11e8-bcf1-0a2705229b82	58a92726-4d1f-4e44-8938-52b97d_D2	713d4256-641b-11e8-bcf1-0a2705229b82	58a92726-4d1f-4e44-8938-52b97d	1aa5bc23-63d6-11e8-bcf1-0a2705229b82	05CO029	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
709f5b0b-6423-11e8-bcf1-0a2705229b82	1ea1d7ee-e382-4a68-8e7c-74e833_D2	e4bbd04d-641b-11e8-bcf1-0a2705229b82	1ea1d7ee-e382-4a68-8e7c-74e833	406db86e-63d6-11e8-bcf1-0a2705229b82	09CO014	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7ac54c16-6426-11e8-bcf1-0a2705229b82	d068de5f-8394-46bc-b03a-c6dc9c_D2	ea2daf45-641b-11e8-bcf1-0a2705229b82	d068de5f-8394-46bc-b03a-c6dc9c	41b23df2-63d6-11e8-bcf1-0a2705229b82	09CO015	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1394f5e6-6425-11e8-bcf1-0a2705229b82	743c74e4-cd76-4f38-8cb4-3c9107_D2	ed80bfbc-641b-11e8-bcf1-0a2705229b82	743c74e4-cd76-4f38-8cb4-3c9107	42f4ed44-63d6-11e8-bcf1-0a2705229b82	09CO018	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1efa591d-6426-11e8-bcf1-0a2705229b82	b913f361-c5c2-4e49-91ca-719bd8_D2	f12a6e20-641b-11e8-bcf1-0a2705229b82	b913f361-c5c2-4e49-91ca-719bd8	443f2901-63d6-11e8-bcf1-0a2705229b82	09CO019	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
efb182ee-6424-11e8-bcf1-0a2705229b82	695b0b00-a86b-43c0-a6c8-50a840_D2	76494710-641b-11e8-bcf1-0a2705229b82	695b0b00-a86b-43c0-a6c8-50a840	1c11288a-63d6-11e8-bcf1-0a2705229b82	05CO032	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c6e6c786-6423-11e8-bcf1-0a2705229b82	2f8b02e4-1848-4abc-a95e-dd9eb5_D2	79ad03f9-641b-11e8-bcf1-0a2705229b82	2f8b02e4-1848-4abc-a95e-dd9eb5	1d469d14-63d6-11e8-bcf1-0a2705229b82	05CO033	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62aef3b9-6425-11e8-bcf1-0a2705229b82	87408d9e-4029-4e8f-b14c-8efc04_D2	c36205a7-641b-11e8-bcf1-0a2705229b82	87408d9e-4029-4e8f-b14c-8efc04	33c37478-63d6-11e8-bcf1-0a2705229b82	06CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
655032cd-6424-11e8-bcf1-0a2705229b82	4b263734-430f-41dc-a296-8691f0_D2	c5270de8-641b-11e8-bcf1-0a2705229b82	4b263734-430f-41dc-a296-8691f0	350842fa-63d6-11e8-bcf1-0a2705229b82	06CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1baf3c3-6426-11e8-bcf1-0a2705229b82	ec9afcc4-ccf7-4226-b0e8-d6897d_D2	d1558d9b-641b-11e8-bcf1-0a2705229b82	ec9afcc4-ccf7-4226-b0e8-d6897d	3a099f1d-63d6-11e8-bcf1-0a2705229b82	09CO005	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
38b5597a-6426-11e8-bcf1-0a2705229b82	c2c53076-b5db-4b7d-983c-a35740_D2	d828f425-641b-11e8-bcf1-0a2705229b82	c2c53076-b5db-4b7d-983c-a35740	3b526aa4-63d6-11e8-bcf1-0a2705229b82	09CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1e61309-6425-11e8-bcf1-0a2705229b82	aa0f5b40-3290-4255-8f4d-f45d4e_D2	dbae3a2b-641b-11e8-bcf1-0a2705229b82	aa0f5b40-3290-4255-8f4d-f45d4e	3c9e4169-63d6-11e8-bcf1-0a2705229b82	09CO008	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6023131b-6425-11e8-bcf1-0a2705229b82	85930155-5a70-4aab-97e3-e9c5a9_D2	1bba2fce-641d-11e8-bcf1-0a2705229b82	85930155-5a70-4aab-97e3-e9c5a9	c86c67c3-63d6-11e8-bcf1-0a2705229b82	14CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
abcd99ce-6424-11e8-bcf1-0a2705229b82	5a85e6e7-35ab-4ca9-ab62-707e77_D2	1d8ca0bd-641d-11e8-bcf1-0a2705229b82	5a85e6e7-35ab-4ca9-ab62-707e77	c9ab199d-63d6-11e8-bcf1-0a2705229b82	14CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9efe6d0b-6426-11e8-bcf1-0a2705229b82	d8345fa1-f692-4025-bc82-bfaec6_D2	af021f55-641d-11e8-bcf1-0a2705229b82	d8345fa1-f692-4025-bc82-bfaec6	1833a52c-63d7-11e8-bcf1-0a2705229b82	20CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b76746de-6423-11e8-bcf1-0a2705229b82	2d266d2d-4bb3-436c-a3e7-06acb2_D2	b235371f-641d-11e8-bcf1-0a2705229b82	2d266d2d-4bb3-436c-a3e7-06acb2	196e410d-63d7-11e8-bcf1-0a2705229b82	20CO003	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
459c30ad-6423-11e8-bcf1-0a2705229b82	159c49fd-40ff-4616-b6b6-be21a6_D2	4dd76f3e-641b-11e8-bcf1-0a2705229b82	159c49fd-40ff-4616-b6b6-be21a6	0bc46cbd-63d6-11e8-bcf1-0a2705229b82	05CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a7f4d835-6424-11e8-bcf1-0a2705229b82	59891744-2db3-4541-a86a-7f911f_D2	60f362d8-641a-11e8-bcf1-0a2705229b82	59891744-2db3-4541-a86a-7f911f	8ed302f7-63d5-11e8-bcf1-0a2705229b82	01CO005	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f6336dd-6425-11e8-bcf1-0a2705229b82	760f15d2-444c-4deb-b133-62f3ca_D2	5d2d9410-641a-11e8-bcf1-0a2705229b82	760f15d2-444c-4deb-b133-62f3ca	8d8d42ae-63d5-11e8-bcf1-0a2705229b82	01CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a768d81-6425-11e8-bcf1-0a2705229b82	7cc7f69f-99f5-4b23-a9e0-ba0dc8_D2	515ca889-641b-11e8-bcf1-0a2705229b82	7cc7f69f-99f5-4b23-a9e0-ba0dc8	0d04dd23-63d6-11e8-bcf1-0a2705229b82	05CO003	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
971462f8-6426-11e8-bcf1-0a2705229b82	d7608884-a0d6-4e9e-aac7-6cd813_D2	a8eda2fc-641b-11e8-bcf1-0a2705229b82	d7608884-a0d6-4e9e-aac7-6cd813	29bd5349-63d6-11e8-bcf1-0a2705229b82	05CO049	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d4ebc340-6425-11e8-bcf1-0a2705229b82	a2f03d85-5f1a-4b3e-9dbf-74e67e_D2	eb61629b-641d-11e8-bcf1-0a2705229b82	a2f03d85-5f1a-4b3e-9dbf-74e67e	28d18f3d-63d7-11e8-bcf1-0a2705229b82	22CO004	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a952fd8a-6424-11e8-bcf1-0a2705229b82	5a007558-764c-463b-a788-fdbccb_D2	884edf7c-641b-11e8-bcf1-0a2705229b82	5a007558-764c-463b-a788-fdbccb	2114ec5d-63d6-11e8-bcf1-0a2705229b82	05CO037	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
70ccecff-6425-11e8-bcf1-0a2705229b82	8960a27e-69d8-4ec8-a795-c6cf8a_D2	abaeb372-641c-11e8-bcf1-0a2705229b82	8960a27e-69d8-4ec8-a795-c6cf8a	9d1df687-63d6-11e8-bcf1-0a2705229b82	11CO033	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6dae02b5-6423-11e8-bcf1-0a2705229b82	1e451f20-718d-458e-abeb-93f1d8_D2	c52ec5c3-641d-11e8-bcf1-0a2705229b82	1e451f20-718d-458e-abeb-93f1d8	1be99027-63d7-11e8-bcf1-0a2705229b82	20CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a021b9b3-6424-11e8-bcf1-0a2705229b82	591fb460-703a-437d-8d9a-ff2a35_D2	c0f100cf-641c-11e8-bcf1-0a2705229b82	591fb460-703a-437d-8d9a-ff2a35	a359097e-63d6-11e8-bcf1-0a2705229b82	11CO043	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eefbd00d-6422-11e8-bcf1-0a2705229b82	0065bfd9-e1b9-43a8-9379-9658ba_D2	cb2589b5-641d-11e8-bcf1-0a2705229b82	0065bfd9-e1b9-43a8-9379-9658ba	1d23f919-63d7-11e8-bcf1-0a2705229b82	20CO007	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
67de113c-6424-11e8-bcf1-0a2705229b82	4b68d71e-48b4-45ba-a041-9d6aa0_D2	bf2e99ec-641c-11e8-bcf1-0a2705229b82	4b68d71e-48b4-45ba-a041-9d6aa0	a21c4839-63d6-11e8-bcf1-0a2705229b82	11CO042	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1b2e72f-6422-11e8-bcf1-0a2705229b82	01d1ffca-4235-4dfe-bf62-56f71d_D2	a4c9e63c-641c-11e8-bcf1-0a2705229b82	01d1ffca-4235-4dfe-bf62-56f71d	9bdc5a63-63d6-11e8-bcf1-0a2705229b82	11CO032	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
07c441fc-6425-11e8-bcf1-0a2705229b82	6f5853a3-1d47-4a54-94dc-970c1c_D2	42721865-641d-11e8-bcf1-0a2705229b82	6f5853a3-1d47-4a54-94dc-970c1c	d66d8cc1-63d6-11e8-bcf1-0a2705229b82	16CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0b09ad27-6424-11e8-bcf1-0a2705229b82	3d797911-d476-436f-9cce-33e20c_D2	84df4d37-641c-11e8-bcf1-0a2705229b82	3d797911-d476-436f-9cce-33e20c	91102308-63d6-11e8-bcf1-0a2705229b82	11CO018	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a3c81689-6425-11e8-bcf1-0a2705229b82	97423edb-6f19-4b41-a7cb-af1635_D2	493fc652-641d-11e8-bcf1-0a2705229b82	97423edb-6f19-4b41-a7cb-af1635	d903920d-63d6-11e8-bcf1-0a2705229b82	16CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
43749c48-6426-11e8-bcf1-0a2705229b82	c6ae57a7-65a0-438e-bae2-97b1c8_D2	a317c573-641c-11e8-bcf1-0a2705229b82	c6ae57a7-65a0-438e-bae2-97b1c8	9a9977f0-63d6-11e8-bcf1-0a2705229b82	11CO031	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
34646fcc-6423-11e8-bcf1-0a2705229b82	1425a1a1-c835-47a2-a9b9-4db5d0_D2	dd74eeeb-641b-11e8-bcf1-0a2705229b82	1425a1a1-c835-47a2-a9b9-4db5d0	3de574db-63d6-11e8-bcf1-0a2705229b82	09CO011	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4c447597-6426-11e8-bcf1-0a2705229b82	c952715e-35ca-4e18-ad6f-dd4e39_D2	8f51c47c-641b-11e8-bcf1-0a2705229b82	c952715e-35ca-4e18-ad6f-dd4e39	2254625e-63d6-11e8-bcf1-0a2705229b82	05CO039	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c52cd33c-6424-11e8-bcf1-0a2705229b82	5f823547-ee16-45b7-a6a0-ef25d6_D2	dcce7b36-641d-11e8-bcf1-0a2705229b82	5f823547-ee16-45b7-a6a0-ef25d6	239c3712-63d7-11e8-bcf1-0a2705229b82	21CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29a3ad19-6424-11e8-bcf1-0a2705229b82	42216d99-e8ff-43c9-b6db-28c3a6_D2	7f0ba129-641b-11e8-bcf1-0a2705229b82	42216d99-e8ff-43c9-b6db-28c3a6	1e8db80f-63d6-11e8-bcf1-0a2705229b82	05CO034	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32cdf2c6-6425-11e8-bcf1-0a2705229b82	7a0266b4-b07c-41dc-8ddd-350e1b_D2	80e0ff59-641a-11e8-bcf1-0a2705229b82	7a0266b4-b07c-41dc-8ddd-350e1b	9791bd4c-63d5-11e8-bcf1-0a2705229b82	01CO022	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fe7c0f08-6426-11e8-bcf1-0a2705229b82	f0bb6ff4-7cb8-427f-84bf-7f51d7_D2	c21ecde6-641d-11e8-bcf1-0a2705229b82	f0bb6ff4-7cb8-427f-84bf-7f51d7	1aa8ef3a-63d7-11e8-bcf1-0a2705229b82	20CO004	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ec5850b-6424-11e8-bcf1-0a2705229b82	4976cbf9-cad4-48ce-b234-622c70_D2	a17631ba-641b-11e8-bcf1-0a2705229b82	4976cbf9-cad4-48ce-b234-622c70	28873930-63d6-11e8-bcf1-0a2705229b82	05CO048	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bb5b4072-6426-11e8-bcf1-0a2705229b82	dffcac99-9eac-4717-aeb6-f4a2e7_D2	e31a7d8f-641b-11e8-bcf1-0a2705229b82	dffcac99-9eac-4717-aeb6-f4a2e7	3f240d38-63d6-11e8-bcf1-0a2705229b82	09CO013	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dbf49fda-6425-11e8-bcf1-0a2705229b82	a467b905-fc0b-427b-8753-6d38dd_D2	dea76295-641d-11e8-bcf1-0a2705229b82	a467b905-fc0b-427b-8753-6d38dd	251e36a8-63d7-11e8-bcf1-0a2705229b82	21CO007	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
19f1e32b-6425-11e8-bcf1-0a2705229b82	74f7759a-279c-4098-b080-358900_D2	37bbd200-641d-11e8-bcf1-0a2705229b82	74f7759a-279c-4098-b080-358900	d2b0df58-63d6-11e8-bcf1-0a2705229b82	15CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e2310796-6426-11e8-bcf1-0a2705229b82	e8faa3a7-9fc7-428e-9334-a0afd0_D2	f554d621-641c-11e8-bcf1-0a2705229b82	e8faa3a7-9fc7-428e-9334-a0afd0	b554027e-63d6-11e8-bcf1-0a2705229b82	11CO062	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3335c788-6423-11e8-bcf1-0a2705229b82	1312a0e0-5025-433e-9670-0595bb_D2	82a9e5d6-641b-11e8-bcf1-0a2705229b82	1312a0e0-5025-433e-9670-0595bb	1fd9f337-63d6-11e8-bcf1-0a2705229b82	05CO035	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
546e249a-6424-11e8-bcf1-0a2705229b82	47b9deba-dea0-4e0c-8b0a-4864c3_D2	4404e43e-641d-11e8-bcf1-0a2705229b82	47b9deba-dea0-4e0c-8b0a-4864c3	d7b50f28-63d6-11e8-bcf1-0a2705229b82	16CO003	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
110bf3eb-6425-11e8-bcf1-0a2705229b82	722378ea-d1a7-4cfc-aca5-ba45f9_D2	8885994c-641c-11e8-bcf1-0a2705229b82	722378ea-d1a7-4cfc-aca5-ba45f9	9273e183-63d6-11e8-bcf1-0a2705229b82	11CO019	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6e493cd7-6424-11e8-bcf1-0a2705229b82	4cdeecb5-19fb-493c-91f5-eb0efc_D2	9a2206b9-641c-11e8-bcf1-0a2705229b82	4cdeecb5-19fb-493c-91f5-eb0efc	99502308-63d6-11e8-bcf1-0a2705229b82	11CO030	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9d2ae97a-6424-11e8-bcf1-0a2705229b82	573048dd-2502-40e0-8e8c-c41bb8_D2	795f30a1-641a-11e8-bcf1-0a2705229b82	573048dd-2502-40e0-8e8c-c41bb8	964ccbbb-63d5-11e8-bcf1-0a2705229b82	01CO019	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
22f1f2d5-6426-11e8-bcf1-0a2705229b82	bc574f73-89ba-44d7-992e-82622c_D2	71189ae6-641c-11e8-bcf1-0a2705229b82	bc574f73-89ba-44d7-992e-82622c	8b89647a-63d6-11e8-bcf1-0a2705229b82	11CO005	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1c6c8bee-6426-11e8-bcf1-0a2705229b82	b873f54a-5a86-4dca-90f9-715820_D2	77bf01ce-641a-11e8-bcf1-0a2705229b82	b873f54a-5a86-4dca-90f9-715820	9505127b-63d5-11e8-bcf1-0a2705229b82	01CO015	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3b588de3-6426-11e8-bcf1-0a2705229b82	c2db7236-990c-42b6-9ffb-2ad150_D2	36129f58-641d-11e8-bcf1-0a2705229b82	c2db7236-990c-42b6-9ffb-2ad150	d173b7b0-63d6-11e8-bcf1-0a2705229b82	15CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e92fcb3-6424-11e8-bcf1-0a2705229b82	43e0432b-343d-4e12-817f-21281c_D2	cf38aae7-641c-11e8-bcf1-0a2705229b82	43e0432b-343d-4e12-817f-21281c	a8735982-63d6-11e8-bcf1-0a2705229b82	11CO048	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a41bd31f-6426-11e8-bcf1-0a2705229b82	d91f20f5-f59f-421d-9164-e5fd19_D2	10baa78d-641d-11e8-bcf1-0a2705229b82	d91f20f5-f59f-421d-9164-e5fd19	c0b461af-63d6-11e8-bcf1-0a2705229b82	13CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
78534591-6426-11e8-bcf1-0a2705229b82	d0511ea6-43c3-4c61-b08e-cf49b7_D2	05acea3e-641e-11e8-bcf1-0a2705229b82	d0511ea6-43c3-4c61-b08e-cf49b7	3535c42f-63d7-11e8-bcf1-0a2705229b82	27CO004	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
28ed17fd-6423-11e8-bcf1-0a2705229b82	0f757044-9bc8-4ed4-90f3-e0a49a_D2	7dfa9110-641c-11e8-bcf1-0a2705229b82	0f757044-9bc8-4ed4-90f3-e0a49a	8fb486ea-63d6-11e8-bcf1-0a2705229b82	11CO010	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
119541c9-6426-11e8-bcf1-0a2705229b82	b4dd4a04-5eda-43dd-8298-215b07_D2	932dd64e-641b-11e8-bcf1-0a2705229b82	b4dd4a04-5eda-43dd-8298-215b07	238fa734-63d6-11e8-bcf1-0a2705229b82	05CO041	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
89d335b3-6424-11e8-bcf1-0a2705229b82	52d61ab1-5781-4b47-8e88-37c2ea_D2	8bdf9e5c-641c-11e8-bcf1-0a2705229b82	52d61ab1-5781-4b47-8e88-37c2ea	93d3df99-63d6-11e8-bcf1-0a2705229b82	11CO020	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2da4c83a-6425-11e8-bcf1-0a2705229b82	799893aa-d523-4a08-9ea7-611cca_D2	76b4fc25-641c-11e8-bcf1-0a2705229b82	799893aa-d523-4a08-9ea7-611cca	8cea9947-63d6-11e8-bcf1-0a2705229b82	11CO007	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0af64a9c-6426-11e8-bcf1-0a2705229b82	b2615b47-5ac2-4775-9205-50990d_D2	6bf07977-641b-11e8-bcf1-0a2705229b82	b2615b47-5ac2-4775-9205-50990d	175ccf46-63d6-11e8-bcf1-0a2705229b82	05CO026	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0625bdae-6427-11e8-bcf1-0a2705229b82	f4bccfe4-98d0-466b-a6d7-44341b_D2	c9b7d7b8-641c-11e8-bcf1-0a2705229b82	f4bccfe4-98d0-466b-a6d7-44341b	a5d790a6-63d6-11e8-bcf1-0a2705229b82	11CO045	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
248ac7b6-6425-11e8-bcf1-0a2705229b82	7782134d-02db-44ee-adfa-fc1372_D2	4ae1389c-641d-11e8-bcf1-0a2705229b82	7782134d-02db-44ee-adfa-fc1372	da4722f0-63d6-11e8-bcf1-0a2705229b82	16CO011	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b22155a4-6426-11e8-bcf1-0a2705229b82	db3f5ad9-d14d-4126-a3e7-d80faa_D2	299ed88b-641d-11e8-bcf1-0a2705229b82	db3f5ad9-d14d-4126-a3e7-d80faa	cc25d271-63d6-11e8-bcf1-0a2705229b82	14CO005	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
70d48de9-6424-11e8-bcf1-0a2705229b82	4d86cf19-8d5b-46b5-ab4c-ace0b2_D2	eebbd9d6-641d-11e8-bcf1-0a2705229b82	4d86cf19-8d5b-46b5-ab4c-ace0b2	2a0e6d9d-63d7-11e8-bcf1-0a2705229b82	22CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
44412365-6423-11e8-bcf1-0a2705229b82	1563ef63-d2e6-406f-adc1-255949_D2	b480f76a-641c-11e8-bcf1-0a2705229b82	1563ef63-d2e6-406f-adc1-255949	9fa2feac-63d6-11e8-bcf1-0a2705229b82	11CO037	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56e942da-6429-11e8-bcf1-0a2705229b82	8cc7e656-0152-4359-8566-0581c3	cf6dc37b-6420-11e8-bcf1-0a2705229b82	8cc7e656-0152-4359-8566-0581c3	914af33a-63d5-11e8-bcf1-0a2705229b82	01CO008	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b4e4c30c-6424-11e8-bcf1-0a2705229b82	5c70e654-583c-4dd3-ad42-0d9b39_D2	aad19205-641d-11e8-bcf1-0a2705229b82	5c70e654-583c-4dd3-ad42-0d9b39	1833a52c-63d7-11e8-bcf1-0a2705229b82	20CO001	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
81ca5e1d-6429-11e8-bcf1-0a2705229b82	0065bfd9-e1b9-43a8-9379-9658ba_D3	cb2589b5-641d-11e8-bcf1-0a2705229b82	0065bfd9-e1b9-43a8-9379-9658ba	1d23f919-63d7-11e8-bcf1-0a2705229b82	20CO007	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f10cebf-642a-11e8-bcf1-0a2705229b82	d8805fa4-30f9-4417-907e-fdc50c_D2	986bfc0f-641b-11e8-bcf1-0a2705229b82	d8805fa4-30f9-4417-907e-fdc50c	24cb0fcb-63d6-11e8-bcf1-0a2705229b82	05CO044	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ca87b11b-6429-11e8-bcf1-0a2705229b82	58a92726-4d1f-4e44-8938-52b97d_D3	713d4256-641b-11e8-bcf1-0a2705229b82	58a92726-4d1f-4e44-8938-52b97d	1aa5bc23-63d6-11e8-bcf1-0a2705229b82	05CO029	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cbc448f8-6429-11e8-bcf1-0a2705229b82	591fb460-703a-437d-8d9a-ff2a35_D3	c0f100cf-641c-11e8-bcf1-0a2705229b82	591fb460-703a-437d-8d9a-ff2a35	a359097e-63d6-11e8-bcf1-0a2705229b82	11CO043	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
58437814-6429-11e8-bcf1-0a2705229b82	a90eb718-6a8f-4cbf-89c1-f9e9bd_D2	d11f9f28-6420-11e8-bcf1-0a2705229b82	a90eb718-6a8f-4cbf-89c1-f9e9bd	da4722f0-63d6-11e8-bcf1-0a2705229b82	16CO011	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa7f4717-6424-11e8-bcf1-0a2705229b82	5a3aa99d-ca10-45f6-939f-12392a_D2	5b3948f0-641a-11e8-bcf1-0a2705229b82	5a3aa99d-ca10-45f6-939f-12392a	8d8d42ae-63d5-11e8-bcf1-0a2705229b82	01CO001	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a03d02d-6425-11e8-bcf1-0a2705229b82	8fab37a4-cdf9-4ce8-9081-7b9148_D2	535112f5-641b-11e8-bcf1-0a2705229b82	8fab37a4-cdf9-4ce8-9081-7b9148	0d04dd23-63d6-11e8-bcf1-0a2705229b82	05CO003	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
dcee2e17-6429-11e8-bcf1-0a2705229b82	6797a69d-2f74-44b9-8147-cd4fac_D2	64596a20-641b-11e8-bcf1-0a2705229b82	6797a69d-2f74-44b9-8147-cd4fac	139a0253-63d6-11e8-bcf1-0a2705229b82	05CO015	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59939af0-6429-11e8-bcf1-0a2705229b82	ea6df59d-5240-4927-b19d-d44590_D2	d2d18a4d-6420-11e8-bcf1-0a2705229b82	ea6df59d-5240-4927-b19d-d44590	cae72878-63d6-11e8-bcf1-0a2705229b82	14CO003	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e8ff4f3-642a-11e8-bcf1-0a2705229b82	e8faa3a7-9fc7-428e-9334-a0afd0_D3	f554d621-641c-11e8-bcf1-0a2705229b82	e8faa3a7-9fc7-428e-9334-a0afd0	b554027e-63d6-11e8-bcf1-0a2705229b82	11CO062	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0d7cb47d-6426-11e8-bcf1-0a2705229b82	b2978e90-cd2a-4665-b1bf-508a99_D2	75fdce21-641a-11e8-bcf1-0a2705229b82	b2978e90-cd2a-4665-b1bf-508a99	9505127b-63d5-11e8-bcf1-0a2705229b82	01CO015	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
36b74966-642a-11e8-bcf1-0a2705229b82	e0068ac5-f557-443a-bd4b-bdfcef_D3	6f460e53-641b-11e8-bcf1-0a2705229b82	e0068ac5-f557-443a-bd4b-bdfcef	193b277a-63d6-11e8-bcf1-0a2705229b82	05CO028	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ace67ef-6429-11e8-bcf1-0a2705229b82	2167c594-c33f-4795-b95b-69bd07_D2	d4836a2d-6420-11e8-bcf1-0a2705229b82	2167c594-c33f-4795-b95b-69bd07	a21c4839-63d6-11e8-bcf1-0a2705229b82	11CO042	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4c2b9219-6423-11e8-bcf1-0a2705229b82	16ac8458-5200-4302-9ad0-b311df_D2	fab5cb9a-641c-11e8-bcf1-0a2705229b82	16ac8458-5200-4302-9ad0-b311df	b7dda873-63d6-11e8-bcf1-0a2705229b82	11CO072	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
063c1eb5-6423-11e8-bcf1-0a2705229b82	0784c7b3-e6a4-42a8-9288-eb4ba0_D2	5ecf0523-641a-11e8-bcf1-0a2705229b82	0784c7b3-e6a4-42a8-9288-eb4ba0	8ed302f7-63d5-11e8-bcf1-0a2705229b82	01CO005	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d8fe7e5a-6429-11e8-bcf1-0a2705229b82	64ed43a2-f083-43cb-9d0d-118495_D2	a3394ff3-641b-11e8-bcf1-0a2705229b82	64ed43a2-f083-43cb-9d0d-118495	28873930-63d6-11e8-bcf1-0a2705229b82	05CO048	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
05ff9e15-642a-11e8-bcf1-0a2705229b82	9a48cf57-e1f0-4ea1-9804-d563f2_D2	e96ef79f-641d-11e8-bcf1-0a2705229b82	9a48cf57-e1f0-4ea1-9804-d563f2	28d18f3d-63d7-11e8-bcf1-0a2705229b82	22CO004	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
28a4f91b-642a-11e8-bcf1-0a2705229b82	d0511ea6-43c3-4c61-b08e-cf49b7_D3	05acea3e-641e-11e8-bcf1-0a2705229b82	d0511ea6-43c3-4c61-b08e-cf49b7	3535c42f-63d7-11e8-bcf1-0a2705229b82	27CO004	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5c1cec21-6429-11e8-bcf1-0a2705229b82	526c3664-5b9b-4a2b-a00e-a14623_D2	d625d444-6420-11e8-bcf1-0a2705229b82	526c3664-5b9b-4a2b-a00e-a14623	d7b50f28-63d6-11e8-bcf1-0a2705229b82	16CO003	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
354c7451-6425-11e8-bcf1-0a2705229b82	7bdfa5c9-d11f-4600-9c44-a87996_D2	03f86067-641d-11e8-bcf1-0a2705229b82	7bdfa5c9-d11f-4600-9c44-a87996	ba6da9c2-63d6-11e8-bcf1-0a2705229b82	11CO079	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5aa5401d-6425-11e8-bcf1-0a2705229b82	853ecf90-71e6-4156-a56f-a34b65_D2	b62398ae-641c-11e8-bcf1-0a2705229b82	853ecf90-71e6-4156-a56f-a34b65	9fa2feac-63d6-11e8-bcf1-0a2705229b82	11CO037	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
37f4ee69-642a-11e8-bcf1-0a2705229b82	e070ff10-058b-4733-93ab-bdd702_D2	848d797e-641b-11e8-bcf1-0a2705229b82	e070ff10-058b-4733-93ab-bdd702	1fd9f337-63d6-11e8-bcf1-0a2705229b82	05CO035	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48bfcb6a-6429-11e8-bcf1-0a2705229b82	092c5a37-325b-4181-b230-2d8fff_D2	b92043f8-6420-11e8-bcf1-0a2705229b82	092c5a37-325b-4181-b230-2d8fff	aca14699-63d6-11e8-bcf1-0a2705229b82	11CO053	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3d8c5992-6423-11e8-bcf1-0a2705229b82	154115ac-2ec2-439d-b55e-0464ee_D2	d9d9ff46-641b-11e8-bcf1-0a2705229b82	154115ac-2ec2-439d-b55e-0464ee	3c9e4169-63d6-11e8-bcf1-0a2705229b82	09CO008	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01fd2398-642a-11e8-bcf1-0a2705229b82	963fc8db-f412-4427-a198-23f660_D2	5ae7ad39-641b-11e8-bcf1-0a2705229b82	963fc8db-f412-4427-a198-23f660	10c75345-63d6-11e8-bcf1-0a2705229b82	05CO007	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
49ec82ed-6429-11e8-bcf1-0a2705229b82	79097be1-cd36-4a23-99d1-3d744f_D2	bb02c3e6-6420-11e8-bcf1-0a2705229b82	79097be1-cd36-4a23-99d1-3d744f	443f2901-63d6-11e8-bcf1-0a2705229b82	09CO019	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4b2e24f4-6429-11e8-bcf1-0a2705229b82	8b9e4266-7754-4f2c-ac9e-329905_D2	bcb6edc8-6420-11e8-bcf1-0a2705229b82	8b9e4266-7754-4f2c-ac9e-329905	406db86e-63d6-11e8-bcf1-0a2705229b82	09CO014	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4c7b3b50-6429-11e8-bcf1-0a2705229b82	642fc6c3-8d4a-4e3d-ad0a-cc088a_D2	be6813c3-6420-11e8-bcf1-0a2705229b82	642fc6c3-8d4a-4e3d-ad0a-cc088a	95307d66-63d6-11e8-bcf1-0a2705229b82	11CO021	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4db9f9ca-6429-11e8-bcf1-0a2705229b82	e196a0b4-2a05-43de-bb30-ceb761_D2	c0507740-6420-11e8-bcf1-0a2705229b82	e196a0b4-2a05-43de-bb30-ceb761	1aa8ef3a-63d7-11e8-bcf1-0a2705229b82	20CO004	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8dafd699-6424-11e8-bcf1-0a2705229b82	54565eae-05c5-4dae-bde9-ae4874_D2	a4ec3a1b-641b-11e8-bcf1-0a2705229b82	54565eae-05c5-4dae-bde9-ae4874	29bd5349-63d6-11e8-bcf1-0a2705229b82	05CO049	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
42639ae9-642a-11e8-bcf1-0a2705229b82	f4bccfe4-98d0-466b-a6d7-44341b_D3	c9b7d7b8-641c-11e8-bcf1-0a2705229b82	f4bccfe4-98d0-466b-a6d7-44341b	a5d790a6-63d6-11e8-bcf1-0a2705229b82	11CO045	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
56fb8b1c-6424-11e8-bcf1-0a2705229b82	47d2a435-b203-4438-ae72-53c424_D2	f0343abe-641c-11e8-bcf1-0a2705229b82	47d2a435-b203-4438-ae72-53c424	b4188575-63d6-11e8-bcf1-0a2705229b82	11CO061	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
804a2055-6424-11e8-bcf1-0a2705229b82	51590333-cfe5-4ce5-b8ff-58fa3c_D2	27760ff4-641d-11e8-bcf1-0a2705229b82	51590333-cfe5-4ce5-b8ff-58fa3c	cc25d271-63d6-11e8-bcf1-0a2705229b82	14CO005	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
074c3457-642a-11e8-bcf1-0a2705229b82	9a6879b1-4f78-4ac6-9fca-dad049_D2	c8cee5fe-641d-11e8-bcf1-0a2705229b82	9a6879b1-4f78-4ac6-9fca-dad049	1be99027-63d7-11e8-bcf1-0a2705229b82	20CO006	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4f17cf11-6429-11e8-bcf1-0a2705229b82	f6173181-0993-4a5f-a4cd-5f30b1_D2	c245d383-6420-11e8-bcf1-0a2705229b82	f6173181-0993-4a5f-a4cd-5f30b1	274d1bfb-63d6-11e8-bcf1-0a2705229b82	05CO047	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
192bd904-642a-11e8-bcf1-0a2705229b82	bc574f73-89ba-44d7-992e-82622c_D3	71189ae6-641c-11e8-bcf1-0a2705229b82	bc574f73-89ba-44d7-992e-82622c	8b89647a-63d6-11e8-bcf1-0a2705229b82	11CO005	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5556f8a2-6425-11e8-bcf1-0a2705229b82	82157a70-12f1-4913-b548-d98881_D2	c6ca4f71-641b-11e8-bcf1-0a2705229b82	82157a70-12f1-4913-b548-d98881	350842fa-63d6-11e8-bcf1-0a2705229b82	06CO002	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c94e0407-6429-11e8-bcf1-0a2705229b82	573048dd-2502-40e0-8e8c-c41bb8_D3	795f30a1-641a-11e8-bcf1-0a2705229b82	573048dd-2502-40e0-8e8c-c41bb8	964ccbbb-63d5-11e8-bcf1-0a2705229b82	01CO019	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d7b00d24-6429-11e8-bcf1-0a2705229b82	63c1f7ac-b1ae-4c28-95aa-ce21e5_D2	e0e9ebc1-641b-11e8-bcf1-0a2705229b82	63c1f7ac-b1ae-4c28-95aa-ce21e5	3f240d38-63d6-11e8-bcf1-0a2705229b82	09CO013	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
50440647-6429-11e8-bcf1-0a2705229b82	6e20c8e9-ab75-4996-9296-445b00_D2	c3f91dc2-6420-11e8-bcf1-0a2705229b82	6e20c8e9-ab75-4996-9296-445b00	9505127b-63d5-11e8-bcf1-0a2705229b82	01CO015	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21005497-642a-11e8-bcf1-0a2705229b82	c7aeb685-31b3-445e-8177-a3e729_D3	6ddbad08-641a-11e8-bcf1-0a2705229b82	c7aeb685-31b3-445e-8177-a3e729	9287d60b-63d5-11e8-bcf1-0a2705229b82	01CO013	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fb9622c8-6429-11e8-bcf1-0a2705229b82	8af80ae9-2088-4124-91fb-8d6c17_D3	96851e33-641b-11e8-bcf1-0a2705229b82	8af80ae9-2088-4124-91fb-8d6c17	24cb0fcb-63d6-11e8-bcf1-0a2705229b82	05CO044	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5198ec68-6429-11e8-bcf1-0a2705229b82	cd89ffbb-574a-4052-bd9a-00c890_D2	c5f49654-6420-11e8-bcf1-0a2705229b82	cd89ffbb-574a-4052-bd9a-00c890	d173b7b0-63d6-11e8-bcf1-0a2705229b82	15CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
52d51f75-6429-11e8-bcf1-0a2705229b82	c1b66358-d103-493c-b8ec-92c43b_D1	c87e95b3-6420-11e8-bcf1-0a2705229b82	c1b66358-d103-493c-b8ec-92c43b	123ebacf-63d6-11e8-bcf1-0a2705229b82	05CO011	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
04ca4d38-642a-11e8-bcf1-0a2705229b82	98742d96-cc2f-43f0-9de2-bc7afe_D3	7a092725-641c-11e8-bcf1-0a2705229b82	98742d96-cc2f-43f0-9de2-bc7afe	8e4e8ba7-63d6-11e8-bcf1-0a2705229b82	11CO008	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3a7ff31d-642a-11e8-bcf1-0a2705229b82	e3c012aa-51c2-42b0-a478-bd620f_D2	cf8be6c9-641b-11e8-bcf1-0a2705229b82	e3c012aa-51c2-42b0-a478-bd620f	3a099f1d-63d6-11e8-bcf1-0a2705229b82	09CO005	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3ff06c78-642a-11e8-bcf1-0a2705229b82	ec9afcc4-ccf7-4226-b0e8-d6897d_D3	d1558d9b-641b-11e8-bcf1-0a2705229b82	ec9afcc4-ccf7-4226-b0e8-d6897d	3a099f1d-63d6-11e8-bcf1-0a2705229b82	09CO005	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7db8f9a3-6429-11e8-bcf1-0a2705229b82	b2400046-1d25-429d-a821-6040a6	05b75f4a-6421-11e8-bcf1-0a2705229b82	b2400046-1d25-429d-a821-6040a6	1833a52c-63d7-11e8-bcf1-0a2705229b82	20CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
775f87bf-6429-11e8-bcf1-0a2705229b82	2b810478-7956-4a8b-870d-184859_D2	fcb9d4df-6420-11e8-bcf1-0a2705229b82	2b810478-7956-4a8b-870d-184859	9691960e-63d6-11e8-bcf1-0a2705229b82	11CO022	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e5c0c237-6429-11e8-bcf1-0a2705229b82	722378ea-d1a7-4cfc-aca5-ba45f9_D8	8885994c-641c-11e8-bcf1-0a2705229b82	722378ea-d1a7-4cfc-aca5-ba45f9	9273e183-63d6-11e8-bcf1-0a2705229b82	11CO019	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b83cf881-6429-11e8-bcf1-0a2705229b82	42216d99-e8ff-43c9-b6db-28c3a6_D3	7f0ba129-641b-11e8-bcf1-0a2705229b82	42216d99-e8ff-43c9-b6db-28c3a6	1e8db80f-63d6-11e8-bcf1-0a2705229b82	05CO034	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
67c6cf97-6425-11e8-bcf1-0a2705229b82	87b0e853-43ea-4efb-8a22-dd221f_D2	ac52470d-641b-11e8-bcf1-0a2705229b82	87b0e853-43ea-4efb-8a22-dd221f	2af8ac24-63d6-11e8-bcf1-0a2705229b82	05CO050	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c7ee54f1-6429-11e8-bcf1-0a2705229b82	5557e478-3e6f-475b-8acc-1b4159_D8	0051bce7-641d-11e8-bcf1-0a2705229b82	5557e478-3e6f-475b-8acc-1b4159	b9178503-63d6-11e8-bcf1-0a2705229b82	11CO077	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0b35ddf0-642a-11e8-bcf1-0a2705229b82	a2f03d85-5f1a-4b3e-9dbf-74e67e_D3	eb61629b-641d-11e8-bcf1-0a2705229b82	a2f03d85-5f1a-4b3e-9dbf-74e67e	28d18f3d-63d7-11e8-bcf1-0a2705229b82	22CO004	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
48437bb2-6425-11e8-bcf1-0a2705229b82	7fd386f0-e7f6-4ee1-9cd7-b3318a_D2	f707df14-641c-11e8-bcf1-0a2705229b82	7fd386f0-e7f6-4ee1-9cd7-b3318a	b692a393-63d6-11e8-bcf1-0a2705229b82	11CO070	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ce3943fd-6424-11e8-bcf1-0a2705229b82	62627b73-1763-48bc-8eea-e5bd76_D2	477a4eaa-641d-11e8-bcf1-0a2705229b82	62627b73-1763-48bc-8eea-e5bd76	d903920d-63d6-11e8-bcf1-0a2705229b82	16CO006	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
78bcfbd1-6429-11e8-bcf1-0a2705229b82	f6b1079b-9d67-4c63-b3d0-d562b5_D2	fea067e1-6420-11e8-bcf1-0a2705229b82	f6b1079b-9d67-4c63-b3d0-d562b5	a9cb3450-63d6-11e8-bcf1-0a2705229b82	11CO051	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7f1705d8-6429-11e8-bcf1-0a2705229b82	e2e83b72-b14b-4b06-9461-1115d6_D2	0779cd43-6421-11e8-bcf1-0a2705229b82	e2e83b72-b14b-4b06-9461-1115d6	2114ec5d-63d6-11e8-bcf1-0a2705229b82	05CO037	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
119f45c4-642a-11e8-bcf1-0a2705229b82	aa0f5b40-3290-4255-8f4d-f45d4e_D3	dbae3a2b-641b-11e8-bcf1-0a2705229b82	aa0f5b40-3290-4255-8f4d-f45d4e	3c9e4169-63d6-11e8-bcf1-0a2705229b82	09CO008	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
86e12dc8-6429-11e8-bcf1-0a2705229b82	04ded2cd-3b57-4aec-9c11-48f58e_D2	95163f27-641c-11e8-bcf1-0a2705229b82	04ded2cd-3b57-4aec-9c11-48f58e	97f45829-63d6-11e8-bcf1-0a2705229b82	11CO027	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
92d5e69c-6429-11e8-bcf1-0a2705229b82	1425a1a1-c835-47a2-a9b9-4db5d0_D8	dd74eeeb-641b-11e8-bcf1-0a2705229b82	1425a1a1-c835-47a2-a9b9-4db5d0	3de574db-63d6-11e8-bcf1-0a2705229b82	09CO011	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
64962b87-6423-11e8-bcf1-0a2705229b82	1c070992-647b-4173-a481-904c4d_D2	ed05f315-641d-11e8-bcf1-0a2705229b82	1c070992-647b-4173-a481-904c4d	2a0e6d9d-63d7-11e8-bcf1-0a2705229b82	22CO006	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bec3a7fb-6424-11e8-bcf1-0a2705229b82	5de06adb-e00d-4114-8d76-04bd30_D2	ce88b2cd-641d-11e8-bcf1-0a2705229b82	5de06adb-e00d-4114-8d76-04bd30	1d23f919-63d7-11e8-bcf1-0a2705229b82	20CO007	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2c96a58f-642a-11e8-bcf1-0a2705229b82	d7608884-a0d6-4e9e-aac7-6cd813_D3	a8eda2fc-641b-11e8-bcf1-0a2705229b82	d7608884-a0d6-4e9e-aac7-6cd813	29bd5349-63d6-11e8-bcf1-0a2705229b82	05CO049	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9d66f92f-6423-11e8-bcf1-0a2705229b82	26acb513-3ffe-49ad-8581-9dfc97_D2	e1c07123-641c-11e8-bcf1-0a2705229b82	26acb513-3ffe-49ad-8581-9dfc97	af1d550b-63d6-11e8-bcf1-0a2705229b82	11CO057	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e762f84-642a-11e8-bcf1-0a2705229b82	c307b7b0-534a-45fa-a420-35f773_D2	4c9394da-641d-11e8-bcf1-0a2705229b82	c307b7b0-534a-45fa-a420-35f773	da4722f0-63d6-11e8-bcf1-0a2705229b82	16CO011	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c010f10f-6424-11e8-bcf1-0a2705229b82	5e886f1c-8165-4232-9591-d80799_D2	db1d7011-641d-11e8-bcf1-0a2705229b82	5e886f1c-8165-4232-9591-d80799	239c3712-63d7-11e8-bcf1-0a2705229b82	21CO006	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
79e9d916-6429-11e8-bcf1-0a2705229b82	cfb4831f-e9ee-4e11-80fb-958f6f_D2	006338a0-6421-11e8-bcf1-0a2705229b82	cfb4831f-e9ee-4e11-80fb-958f6f	a8735982-63d6-11e8-bcf1-0a2705229b82	11CO048	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8043b3e7-6429-11e8-bcf1-0a2705229b82	f9d6fb1b-988e-4D88-9272-cc672f_D8	095f59b9-6421-11e8-bcf1-0a2705229b82	f9d6fb1b-988e-4D88-9272-cc672f	900e6eff-63d5-11e8-bcf1-0a2705229b82	01CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9afe0c55-6423-11e8-bcf1-0a2705229b82	2666323d-522f-4f0a-823c-ff8866_D2	6d93f3b3-641b-11e8-bcf1-0a2705229b82	2666323d-522f-4f0a-823c-ff8866	193b277a-63d6-11e8-bcf1-0a2705229b82	05CO028	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fce64dc7-6429-11e8-bcf1-0a2705229b82	8c73f3a5-fea8-4942-90c0-966f66_D3	f1f8a867-641c-11e8-bcf1-0a2705229b82	8c73f3a5-fea8-4942-90c0-966f66	b4188575-63d6-11e8-bcf1-0a2705229b82	11CO061	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c1249dcc-6429-11e8-bcf1-0a2705229b82	4cdeecb5-19fb-493c-91f5-eb0efc_D3	9a2206b9-641c-11e8-bcf1-0a2705229b82	4cdeecb5-19fb-493c-91f5-eb0efc	99502308-63d6-11e8-bcf1-0a2705229b82	11CO030	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6f81cedb-6425-11e8-bcf1-0a2705229b82	88c621d7-7fb3-4825-abbe-82ae4c_D2	9322710a-641c-11e8-bcf1-0a2705229b82	88c621d7-7fb3-4825-abbe-82ae4c	9691960e-63d6-11e8-bcf1-0a2705229b82	11CO022	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0118c476-6423-11e8-bcf1-0a2705229b82	067db520-1b1f-4569-9414-e37a6e_D2	86511cf8-641b-11e8-bcf1-0a2705229b82	067db520-1b1f-4569-9414-e37a6e	2114ec5d-63d6-11e8-bcf1-0a2705229b82	05CO037	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a47b1dc-ec51-11e9-81b4-2a2ae2dbcce4	ColonRef	6a47a138-ec51-11e9-81b4-2a2ae2dbcce4	ColonRef	6a478d6a-ec51-11e9-81b4-2a2ae2dbcce4	ColonRef	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	yes																																	Clinical Proteomic Tumor Analysis Consortium
8b270359-6423-11e8-bcf1-0a2705229b82	23e938d0-92b8-4aea-90c1-4385df_D2	cb9c92d6-641c-11e8-bcf1-0a2705229b82	23e938d0-92b8-4aea-90c1-4385df	a725c269-63d6-11e8-bcf1-0a2705229b82	11CO047	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a102591f-6429-11e8-bcf1-0a2705229b82	21cab01c-e968-42cc-9651-1e53c0_D3	af117140-641c-11e8-bcf1-0a2705229b82	21cab01c-e968-42cc-9651-1e53c0	9e5a2210-63d6-11e8-bcf1-0a2705229b82	11CO036	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
208ebc64-6425-11e8-bcf1-0a2705229b82	76498650-fdbf-4f5d-a19a-cce9a2_D2	f4af3e4d-641b-11e8-bcf1-0a2705229b82	76498650-fdbf-4f5d-a19a-cce9a2	459e3b69-63d6-11e8-bcf1-0a2705229b82	09CO022	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a48e03e-6429-11e8-bcf1-0a2705229b82	dfdf03a6-c324-4d8c-a909-ea7345_D2	ea27f85e-6420-11e8-bcf1-0a2705229b82	dfdf03a6-c324-4d8c-a909-ea7345	1fd9f337-63d6-11e8-bcf1-0a2705229b82	05CO035	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0ef3ede8-642a-11e8-bcf1-0a2705229b82	a5c8bf1d-776c-406f-82a3-2d9ce6_D2	7b700717-641b-11e8-bcf1-0a2705229b82	a5c8bf1d-776c-406f-82a3-2d9ce6	1d469d14-63d6-11e8-bcf1-0a2705229b82	05CO033	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0da6137b-642a-11e8-bcf1-0a2705229b82	a467b905-fc0b-427b-8753-6d38dd_D3	dea76295-641d-11e8-bcf1-0a2705229b82	a467b905-fc0b-427b-8753-6d38dd	251e36a8-63d7-11e8-bcf1-0a2705229b82	21CO007	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7b27e54f-6429-11e8-bcf1-0a2705229b82	f6afe41c-111d-4818-8485-fe95e0_D2	024b66ca-6421-11e8-bcf1-0a2705229b82	f6afe41c-111d-4818-8485-fe95e0	ba6da9c2-63d6-11e8-bcf1-0a2705229b82	11CO079	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
12fd55ee-6426-11e8-bcf1-0a2705229b82	b6b41ba2-6415-41aa-b5f5-4d47db_D2	62a63502-641a-11e8-bcf1-0a2705229b82	b6b41ba2-6415-41aa-b5f5-4d47db	900e6eff-63d5-11e8-bcf1-0a2705229b82	01CO006	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b2f2a1dd-6429-11e8-bcf1-0a2705229b82	3d797911-d476-436f-9cce-33e20c_D8	84df4d37-641c-11e8-bcf1-0a2705229b82	3d797911-d476-436f-9cce-33e20c	91102308-63d6-11e8-bcf1-0a2705229b82	11CO018	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7c7b38c5-6429-11e8-bcf1-0a2705229b82	b4e91300-405e-4239-b8da-5e1a42_D2	04048eb7-6421-11e8-bcf1-0a2705229b82	b4e91300-405e-4239-b8da-5e1a42	9791bd4c-63d5-11e8-bcf1-0a2705229b82	01CO022	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0d2c6571-6425-11e8-bcf1-0a2705229b82	71b2c1cc-0a31-4ca8-8beb-251e17_D2	03eae3ab-641e-11e8-bcf1-0a2705229b82	71b2c1cc-0a31-4ca8-8beb-251e17	3535c42f-63d7-11e8-bcf1-0a2705229b82	27CO004	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6b75ebcc-6429-11e8-bcf1-0a2705229b82	9bf309bc-0fb6-4060-aba2-888eb3_D2	ec3ecc1d-6420-11e8-bcf1-0a2705229b82	9bf309bc-0fb6-4060-aba2-888eb3	add7dfac-63d6-11e8-bcf1-0a2705229b82	11CO054	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
896d8e65-6429-11e8-bcf1-0a2705229b82	0630ecb0-b664-4e75-bb3c-fb62ee_D3	d64baeee-641c-11e8-bcf1-0a2705229b82	0630ecb0-b664-4e75-bb3c-fb62ee	ab0c12f7-63d6-11e8-bcf1-0a2705229b82	11CO052	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4ed7f52d-6423-11e8-bcf1-0a2705229b82	176d1b96-8c6e-44fe-8a32-e15194_D2	6f64d51a-641c-11e8-bcf1-0a2705229b82	176d1b96-8c6e-44fe-8a32-e15194	8b89647a-63d6-11e8-bcf1-0a2705229b82	11CO005	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
721e3d8e-6425-11e8-bcf1-0a2705229b82	8980bb9d-65c1-41cb-9f90-dddd5f_D2	69e8a3de-641b-11e8-bcf1-0a2705229b82	8980bb9d-65c1-41cb-9f90-dddd5f	175ccf46-63d6-11e8-bcf1-0a2705229b82	05CO026	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
17fc37f4-642a-11e8-bcf1-0a2705229b82	b871c0c1-a97b-4ac1-887c-0317b6_D2	de31f440-641c-11e8-bcf1-0a2705229b82	b871c0c1-a97b-4ac1-887c-0317b6	add7dfac-63d6-11e8-bcf1-0a2705229b82	11CO054	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3bcd6595-642a-11e8-bcf1-0a2705229b82	e515eb5c-8005-416a-9b42-59de9d_D8	e3b65238-641c-11e8-bcf1-0a2705229b82	e515eb5c-8005-416a-9b42-59de9d	af1d550b-63d6-11e8-bcf1-0a2705229b82	11CO057	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6cb34d40-6429-11e8-bcf1-0a2705229b82	cd6a4013-2958-44b9-a4f1-45c9e4_D2	edf00c89-6420-11e8-bcf1-0a2705229b82	cd6a4013-2958-44b9-a4f1-45c9e4	a725c269-63d6-11e8-bcf1-0a2705229b82	11CO047	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2dc2fbca-642a-11e8-bcf1-0a2705229b82	d80408d6-598d-4411-ab34-eb2545_D2	d9e4fbfc-641c-11e8-bcf1-0a2705229b82	d80408d6-598d-4411-ab34-eb2545	aca14699-63d6-11e8-bcf1-0a2705229b82	11CO053	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eadb3da3-6429-11e8-bcf1-0a2705229b82	799893aa-d523-4a08-9ea7-611cca_D3	76b4fc25-641c-11e8-bcf1-0a2705229b82	799893aa-d523-4a08-9ea7-611cca	8cea9947-63d6-11e8-bcf1-0a2705229b82	11CO007	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6e011b12-6429-11e8-bcf1-0a2705229b82	1ab06c24-ffc0-4323-a0cc-e9f5c5_D2	efa2d9fc-6420-11e8-bcf1-0a2705229b82	1ab06c24-ffc0-4323-a0cc-e9f5c5	41b23df2-63d6-11e8-bcf1-0a2705229b82	09CO015	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6f568f1c-6429-11e8-bcf1-0a2705229b82	0aef1fe8-ca61-4113-81d0-d82ee7_D2	f16eb2e9-6420-11e8-bcf1-0a2705229b82	0aef1fe8-ca61-4113-81d0-d82ee7	139a0253-63d6-11e8-bcf1-0a2705229b82	05CO015	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10430efa-642a-11e8-bcf1-0a2705229b82	a84149b1-8453-45f0-8400-d7b12f_D2	c7f28a6b-641c-11e8-bcf1-0a2705229b82	a84149b1-8453-45f0-8400-d7b12f	a5d790a6-63d6-11e8-bcf1-0a2705229b82	11CO045	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
25b541d6-6424-11e8-bcf1-0a2705229b82	41a04113-2061-4923-bca5-da586c_D2	b2bd7ee2-641c-11e8-bcf1-0a2705229b82	41a04113-2061-4923-bca5-da586c	9e5a2210-63d6-11e8-bcf1-0a2705229b82	11CO036	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
263c66c0-642a-11e8-bcf1-0a2705229b82	cc271b3d-ed33-481f-9d23-15f2f6_D2	4f9db1ce-641b-11e8-bcf1-0a2705229b82	cc271b3d-ed33-481f-9d23-15f2f6	0bc46cbd-63d6-11e8-bcf1-0a2705229b82	05CO002	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
342842a5-642a-11e8-bcf1-0a2705229b82	df479b07-bbf6-472d-a580-c3fd0c_D2	5901cc76-641b-11e8-bcf1-0a2705229b82	df479b07-bbf6-472d-a580-c3fd0c	0f9261c8-63d6-11e8-bcf1-0a2705229b82	05CO006	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c67c9cc-642a-11e8-bcf1-0a2705229b82	a313f6ef-5994-4d49-9e66-c26911_D2	781da505-641b-11e8-bcf1-0a2705229b82	a313f6ef-5994-4d49-9e66-c26911	1c11288a-63d6-11e8-bcf1-0a2705229b82	05CO032	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
70a46cf8-6429-11e8-bcf1-0a2705229b82	4bb08fad-fa5e-471e-978b-6b09ab_D2	f383ba08-6420-11e8-bcf1-0a2705229b82	4bb08fad-fa5e-471e-978b-6b09ab	d903920d-63d6-11e8-bcf1-0a2705229b82	16CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e0a58bbf-6429-11e8-bcf1-0a2705229b82	6b0a3188-d8ca-4d50-a377-a8fe4c_D2	409eb541-641d-11e8-bcf1-0a2705229b82	6b0a3188-d8ca-4d50-a377-a8fe4c	d66d8cc1-63d6-11e8-bcf1-0a2705229b82	16CO002	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
224d8bde-642a-11e8-bcf1-0a2705229b82	c8694e31-2c8f-4eb6-a7ef-a137d9_D3	f8dc9401-641c-11e8-bcf1-0a2705229b82	c8694e31-2c8f-4eb6-a7ef-a137d9	b692a393-63d6-11e8-bcf1-0a2705229b82	11CO070	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
83081969-6429-11e8-bcf1-0a2705229b82	019cd0c0-733d-4b25-90e3-d54ce0_D2	e556a5b7-641c-11e8-bcf1-0a2705229b82	019cd0c0-733d-4b25-90e3-d54ce0	b05c2057-63d6-11e8-bcf1-0a2705229b82	11CO058	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
732a72fe-6423-11e8-bcf1-0a2705229b82	1f79fed9-f0d4-4c45-acd2-ea1441_D2	9ddc0394-641b-11e8-bcf1-0a2705229b82	1f79fed9-f0d4-4c45-acd2-ea1441	274d1bfb-63d6-11e8-bcf1-0a2705229b82	05CO047	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2b66aa96-6427-11e8-bcf1-0a2705229b82	fc9b09af-23b8-4ffe-b6c6-41236d_D2	45c8bf1b-641d-11e8-bcf1-0a2705229b82	fc9b09af-23b8-4ffe-b6c6-41236d	d7b50f28-63d6-11e8-bcf1-0a2705229b82	16CO003	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d826799-6429-11e8-bcf1-0a2705229b82	e1cd3d70-132b-452f-ba10-026721_D2	d8464f46-6420-11e8-bcf1-0a2705229b82	e1cd3d70-132b-452f-ba10-026721	2a0e6d9d-63d7-11e8-bcf1-0a2705229b82	22CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
00ae7d6c-642a-11e8-bcf1-0a2705229b82	92c1ebb5-ac1d-4bf5-a14f-516e1d_D3	9a3fa38b-641b-11e8-bcf1-0a2705229b82	92c1ebb5-ac1d-4bf5-a14f-516e1d	260fb98a-63d6-11e8-bcf1-0a2705229b82	05CO045	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b1a1a4ce-6429-11e8-bcf1-0a2705229b82	3a17283c-a0f4-4514-956b-080d11_D2	91384e2d-641b-11e8-bcf1-0a2705229b82	3a17283c-a0f4-4514-956b-080d11	238fa734-63d6-11e8-bcf1-0a2705229b82	05CO041	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5eaf88b1-6429-11e8-bcf1-0a2705229b82	66b57abc-0d49-46bb-a390-0e11a9_D2	da08db4a-6420-11e8-bcf1-0a2705229b82	66b57abc-0d49-46bb-a390-0e11a9	2254625e-63d6-11e8-bcf1-0a2705229b82	05CO039	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
411ca9f7-642a-11e8-bcf1-0a2705229b82	efee6bb9-69dd-46c2-85b3-b55962_D2	e22bedc8-641d-11e8-bcf1-0a2705229b82	efee6bb9-69dd-46c2-85b3-b55962	251e36a8-63d7-11e8-bcf1-0a2705229b82	21CO007	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
85b4c205-6429-11e8-bcf1-0a2705229b82	02cde0c0-6840-495b-9b11-007d82_D2	5ebe4729-641b-11e8-bcf1-0a2705229b82	02cde0c0-6840-495b-9b11-007d82	123ebacf-63d6-11e8-bcf1-0a2705229b82	05CO011	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
037c8c69-642a-11e8-bcf1-0a2705229b82	974e136f-7020-4a38-b9c1-094df9_D2	39a0219c-641d-11e8-bcf1-0a2705229b82	974e136f-7020-4a38-b9c1-094df9	d2b0df58-63d6-11e8-bcf1-0a2705229b82	15CO002	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8b509494-6425-11e8-bcf1-0a2705229b82	903d5fe0-970a-47be-a97f-3cc914_D2	1f252d32-641d-11e8-bcf1-0a2705229b82	903d5fe0-970a-47be-a97f-3cc914	c9ab199d-63d6-11e8-bcf1-0a2705229b82	14CO002	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5febda13-6429-11e8-bcf1-0a2705229b82	c9730cb4-b52c-4ca8-9652-4509d0_D2	dc22020e-6420-11e8-bcf1-0a2705229b82	c9730cb4-b52c-4ca8-9652-4509d0	93c55f6f-63d5-11e8-bcf1-0a2705229b82	01CO014	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b8591c6b-6424-11e8-bcf1-0a2705229b82	5cf5e61d-21ff-4678-9126-14e9bb_D2	d832eaed-641c-11e8-bcf1-0a2705229b82	5cf5e61d-21ff-4678-9126-14e9bb	ab0c12f7-63d6-11e8-bcf1-0a2705229b82	11CO052	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
077440e1-6427-11e8-bcf1-0a2705229b82	f5ed5ebc-881d-456a-80d7-42c9e7_D2	80ddf503-641b-11e8-bcf1-0a2705229b82	f5ed5ebc-881d-456a-80d7-42c9e7	1e8db80f-63d6-11e8-bcf1-0a2705229b82	05CO034	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
24dd6016-642a-11e8-bcf1-0a2705229b82	cbd0e774-c741-4753-9c9e-391a7d_D2	d0ea1446-641c-11e8-bcf1-0a2705229b82	cbd0e774-c741-4753-9c9e-391a7d	a8735982-63d6-11e8-bcf1-0a2705229b82	11CO048	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2b7b2623-6423-11e8-bcf1-0a2705229b82	1136008b-97ce-49b0-bf24-abbea6_D2	a6a48385-641c-11e8-bcf1-0a2705229b82	1136008b-97ce-49b0-bf24-abbea6	9bdc5a63-63d6-11e8-bcf1-0a2705229b82	11CO032	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8b20e10e-6424-11e8-bcf1-0a2705229b82	5347d2ce-df0c-4d81-a3e2-22db11_D2	6608de85-641a-11e8-bcf1-0a2705229b82	5347d2ce-df0c-4d81-a3e2-22db11	914af33a-63d5-11e8-bcf1-0a2705229b82	01CO008	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
31a02279-642a-11e8-bcf1-0a2705229b82	da95f6f8-be46-4ed8-a493-2c99f0_D2	67bff15a-641b-11e8-bcf1-0a2705229b82	da95f6f8-be46-4ed8-a493-2c99f0	15d7eb12-63d6-11e8-bcf1-0a2705229b82	05CO020	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
de1a20d8-6429-11e8-bcf1-0a2705229b82	694e8df1-d9ee-473b-bec1-4f9237_D2	8d514dac-641b-11e8-bcf1-0a2705229b82	694e8df1-d9ee-473b-bec1-4f9237	2254625e-63d6-11e8-bcf1-0a2705229b82	05CO039	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e1e7b25c-6429-11e8-bcf1-0a2705229b82	6d9f8b06-f28c-4e9b-823b-33ebb7_D2	c2a2770e-641c-11e8-bcf1-0a2705229b82	6d9f8b06-f28c-4e9b-823b-33ebb7	a359097e-63d6-11e8-bcf1-0a2705229b82	11CO043	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
613ac6ea-6429-11e8-bcf1-0a2705229b82	820a3f08-5bb1-44b3-a133-ee167e_D2	ddd85197-6420-11e8-bcf1-0a2705229b82	820a3f08-5bb1-44b3-a133-ee167e	d66d8cc1-63d6-11e8-bcf1-0a2705229b82	16CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1bb4f4c3-642a-11e8-bcf1-0a2705229b82	bed27f66-ef3b-4868-b4ad-205018_D2	9d85c8dd-641c-11e8-bcf1-0a2705229b82	bed27f66-ef3b-4868-b4ad-205018	99502308-63d6-11e8-bcf1-0a2705229b82	11CO030	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
af0e0627-6429-11e8-bcf1-0a2705229b82	3765c09a-fff7-4b37-bf2b-452b23_D2	f39a868e-641c-11e8-bcf1-0a2705229b82	3765c09a-fff7-4b37-bf2b-452b23	b554027e-63d6-11e8-bcf1-0a2705229b82	11CO062	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e819654-6424-11e8-bcf1-0a2705229b82	411d9597-c785-4de5-b449-29a80d_D2	b80c665e-641c-11e8-bcf1-0a2705229b82	411d9597-c785-4de5-b449-29a80d	a0e04ed9-63d6-11e8-bcf1-0a2705229b82	11CO039	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1fe57e80-6423-11e8-bcf1-0a2705229b82	0d5554d1-1653-4589-a44f-43113e_D2	7f1df05f-641a-11e8-bcf1-0a2705229b82	0d5554d1-1653-4589-a44f-43113e	9791bd4c-63d5-11e8-bcf1-0a2705229b82	01CO022	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
102bd1b1-6426-11e8-bcf1-0a2705229b82	b3696374-c6c0-49dd-833e-596e26_D2	d2d01e93-641c-11e8-bcf1-0a2705229b82	b3696374-c6c0-49dd-833e-596e26	a9cb3450-63d6-11e8-bcf1-0a2705229b82	11CO051	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
db8d1085-6429-11e8-bcf1-0a2705229b82	66b829db-1cdd-460d-b2f3-0e9ca9_D3	afe6c7ed-641b-11e8-bcf1-0a2705229b82	66b829db-1cdd-460d-b2f3-0e9ca9	2c346c06-63d6-11e8-bcf1-0a2705229b82	05CO053	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ab36e8fb-6429-11e8-bcf1-0a2705229b82	325b5314-6f3c-4d79-9b36-4e7ded_D2	86c33347-641c-11e8-bcf1-0a2705229b82	325b5314-6f3c-4d79-9b36-4e7ded	9273e183-63d6-11e8-bcf1-0a2705229b82	11CO019	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f909daa5-6429-11e8-bcf1-0a2705229b82	8960a27e-69d8-4ec8-a795-c6cf8a_D3	abaeb372-641c-11e8-bcf1-0a2705229b82	8960a27e-69d8-4ec8-a795-c6cf8a	9d1df687-63d6-11e8-bcf1-0a2705229b82	11CO033	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b978e8ec-6429-11e8-bcf1-0a2705229b82	43192517-085e-450e-9481-0a6713_D3	b55aa4c1-641b-11e8-bcf1-0a2705229b82	43192517-085e-450e-9481-0a6713	2d701098-63d6-11e8-bcf1-0a2705229b82	05CO054	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
84550b53-6429-11e8-bcf1-0a2705229b82	01d1ffca-4235-4dfe-bf62-56f71d_D3	a4c9e63c-641c-11e8-bcf1-0a2705229b82	01d1ffca-4235-4dfe-bf62-56f71d	9bdc5a63-63d6-11e8-bcf1-0a2705229b82	11CO032	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
09d72f87-642a-11e8-bcf1-0a2705229b82	a27cf22d-836e-49a7-802f-47c1db_D2	d67e293a-641b-11e8-bcf1-0a2705229b82	a27cf22d-836e-49a7-802f-47c1db	3b526aa4-63d6-11e8-bcf1-0a2705229b82	09CO006	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
54261cd7-6429-11e8-bcf1-0a2705229b82	372c900a-fced-4eef-9dc4-7282ec_D2	cacb514b-6420-11e8-bcf1-0a2705229b82	372c900a-fced-4eef-9dc4-7282ec	42f4ed44-63d6-11e8-bcf1-0a2705229b82	09CO018	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3954bb0f-642a-11e8-bcf1-0a2705229b82	e14c2cbe-eca0-4745-97f6-8f27bd_D2	72dea085-641b-11e8-bcf1-0a2705229b82	e14c2cbe-eca0-4745-97f6-8f27bd	1aa5bc23-63d6-11e8-bcf1-0a2705229b82	05CO029	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ade0f0f0-6429-11e8-bcf1-0a2705229b82	359f5c81-2575-497e-8630-e4866f_D2	a17658b2-641c-11e8-bcf1-0a2705229b82	359f5c81-2575-497e-8630-e4866f	9a9977f0-63d6-11e8-bcf1-0a2705229b82	11CO031	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
304ff2ec-642a-11e8-bcf1-0a2705229b82	da747cee-5026-4923-af63-ad9f81_D2	b6fce450-641b-11e8-bcf1-0a2705229b82	da747cee-5026-4923-af63-ad9f81	2d701098-63d6-11e8-bcf1-0a2705229b82	05CO054	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
27696cde-642a-11e8-bcf1-0a2705229b82	cd3a9d59-bf13-48f3-ae97-bdbca4_D2	b398649c-641b-11e8-bcf1-0a2705229b82	cd3a9d59-bf13-48f3-ae97-bdbca4	2c346c06-63d6-11e8-bcf1-0a2705229b82	05CO053	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1fd357de-642a-11e8-bcf1-0a2705229b82	c6ae57a7-65a0-438e-bae2-97b1c8_D3	a317c573-641c-11e8-bcf1-0a2705229b82	c6ae57a7-65a0-438e-bae2-97b1c8	9a9977f0-63d6-11e8-bcf1-0a2705229b82	11CO031	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
558645fe-6429-11e8-bcf1-0a2705229b82	05a33362-82bb-48ac-8feb-ad2ea1_D2	cd87c567-6420-11e8-bcf1-0a2705229b82	05a33362-82bb-48ac-8feb-ad2ea1	8ed302f7-63d5-11e8-bcf1-0a2705229b82	01CO005	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
789586c9-6423-11e8-bcf1-0a2705229b82	206f3bd9-f62c-4663-8fdb-5b731b_D2	7f8b1e31-641c-11e8-bcf1-0a2705229b82	206f3bd9-f62c-4663-8fdb-5b731b	8fb486ea-63d6-11e8-bcf1-0a2705229b82	11CO010	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2b38e317-642a-11e8-bcf1-0a2705229b82	d6584b4a-ca99-4a2a-8b4e-c8b22e_D3	ba017407-641c-11e8-bcf1-0a2705229b82	d6584b4a-ca99-4a2a-8b4e-c8b22e	a0e04ed9-63d6-11e8-bcf1-0a2705229b82	11CO039	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32fec6d0-642a-11e8-bcf1-0a2705229b82	db3f5ad9-d14d-4126-a3e7-d80faa_D3	299ed88b-641d-11e8-bcf1-0a2705229b82	db3f5ad9-d14d-4126-a3e7-d80faa	cc25d271-63d6-11e8-bcf1-0a2705229b82	14CO005	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
238bbaec-642a-11e8-bcf1-0a2705229b82	c9f0f144-47f3-4d64-b29f-bcedfa_D2	f2ccc685-641b-11e8-bcf1-0a2705229b82	c9f0f144-47f3-4d64-b29f-bcedfa	443f2901-63d6-11e8-bcf1-0a2705229b82	09CO019	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ed65672a-6429-11e8-bcf1-0a2705229b82	7cc7f69f-99f5-4b23-a9e0-ba0dc8_D8	515ca889-641b-11e8-bcf1-0a2705229b82	7cc7f69f-99f5-4b23-a9e0-ba0dc8	0d04dd23-63d6-11e8-bcf1-0a2705229b82	05CO003	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f54247c5-6429-11e8-bcf1-0a2705229b82	87408d9e-4029-4e8f-b14c-8efc04_D3	c36205a7-641b-11e8-bcf1-0a2705229b82	87408d9e-4029-4e8f-b14c-8efc04	33c37478-63d6-11e8-bcf1-0a2705229b82	06CO001	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
be96898a-6429-11e8-bcf1-0a2705229b82	4b263734-430f-41dc-a296-8691f0_D3	c5270de8-641b-11e8-bcf1-0a2705229b82	4b263734-430f-41dc-a296-8691f0	350842fa-63d6-11e8-bcf1-0a2705229b82	06CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7ee1cb61-6424-11e8-bcf1-0a2705229b82	515040a4-bbfb-4a15-9e53-e7b6e6_D2	ebbc2b4e-641b-11e8-bcf1-0a2705229b82	515040a4-bbfb-4a15-9e53-e7b6e6	42f4ed44-63d6-11e8-bcf1-0a2705229b82	09CO018	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
71cf5ada-6429-11e8-bcf1-0a2705229b82	bd67de01-ad7d-431a-9ad6-4dd5a1	f5366a61-6420-11e8-bcf1-0a2705229b82	bd67de01-ad7d-431a-9ad6-4dd5a1	1be99027-63d7-11e8-bcf1-0a2705229b82	20CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
08997e1b-642a-11e8-bcf1-0a2705229b82	a243b765-61ab-4aa6-88e1-226896_D2	34384cc5-641d-11e8-bcf1-0a2705229b82	a243b765-61ab-4aa6-88e1-226896	d173b7b0-63d6-11e8-bcf1-0a2705229b82	15CO001	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3d428176-642a-11e8-bcf1-0a2705229b82	e74089a9-f78c-4ffe-8174-aef71b_D2	7bc82d21-641c-11e8-bcf1-0a2705229b82	e74089a9-f78c-4ffe-8174-aef71b	8e4e8ba7-63d6-11e8-bcf1-0a2705229b82	11CO008	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
155da464-642a-11e8-bcf1-0a2705229b82	b4dd4a04-5eda-43dd-8298-215b07_D3	932dd64e-641b-11e8-bcf1-0a2705229b82	b4dd4a04-5eda-43dd-8298-215b07	238fa734-63d6-11e8-bcf1-0a2705229b82	05CO041	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
731f3230-6429-11e8-bcf1-0a2705229b82	c65afd57-530c-4366-b2c8-463a46_D2	f720d3a2-6420-11e8-bcf1-0a2705229b82	c65afd57-530c-4366-b2c8-463a46	d2b0df58-63d6-11e8-bcf1-0a2705229b82	15CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
692cf532-6424-11e8-bcf1-0a2705229b82	4c9dcc8c-ccdc-4336-8e23-107feb_D2	6ff8b334-641a-11e8-bcf1-0a2705229b82	4c9dcc8c-ccdc-4336-8e23-107feb	93c55f6f-63d5-11e8-bcf1-0a2705229b82	01CO014	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
45e53510-6425-11e8-bcf1-0a2705229b82	7fd2eea8-bf99-4f97-8b9e-fb703f_D2	e81fbe7c-641b-11e8-bcf1-0a2705229b82	7fd2eea8-bf99-4f97-8b9e-fb703f	41b23df2-63d6-11e8-bcf1-0a2705229b82	09CO015	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ac82df55-6429-11e8-bcf1-0a2705229b82	348f6009-e1be-44d2-a093-9ca844_D2	aa088504-641c-11e8-bcf1-0a2705229b82	348f6009-e1be-44d2-a093-9ca844	9d1df687-63d6-11e8-bcf1-0a2705229b82	11CO033	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f18830ab-6429-11e8-bcf1-0a2705229b82	803736b3-9ca9-4f9f-bdfe-8783e3_D3	6608aa59-641b-11e8-bcf1-0a2705229b82	803736b3-9ca9-4f9f-bdfe-8783e3	15d7eb12-63d6-11e8-bcf1-0a2705229b82	05CO020	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
14d30a11-6425-11e8-bcf1-0a2705229b82	7478980a-60fb-4f5e-aa1c-2d7941_D2	748e3411-641c-11e8-bcf1-0a2705229b82	7478980a-60fb-4f5e-aa1c-2d7941	8cea9947-63d6-11e8-bcf1-0a2705229b82	11CO007	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d51f9d0a-6429-11e8-bcf1-0a2705229b82	5f823547-ee16-45b7-a6a0-ef25d6_D3	dcce7b36-641d-11e8-bcf1-0a2705229b82	5f823547-ee16-45b7-a6a0-ef25d6	239c3712-63d7-11e8-bcf1-0a2705229b82	21CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
746de5e2-6429-11e8-bcf1-0a2705229b82	0f238226-864c-4de0-8c61-01e729_D2	f8e6e3ed-6420-11e8-bcf1-0a2705229b82	0f238226-864c-4de0-8c61-01e729	b7dda873-63d6-11e8-bcf1-0a2705229b82	11CO072	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
75ad9aa7-6429-11e8-bcf1-0a2705229b82	b605fafc-f7dd-44cc-9c86-da04e3_D2	fafccc38-6420-11e8-bcf1-0a2705229b82	b605fafc-f7dd-44cc-9c86-da04e3	a494498b-63d6-11e8-bcf1-0a2705229b82	11CO044	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a76f89ce-6429-11e8-bcf1-0a2705229b82	2cc46aec-6142-4fb9-aca5-c442b9_D2	c46cb715-641c-11e8-bcf1-0a2705229b82	2cc46aec-6142-4fb9-aca5-c442b9	a494498b-63d6-11e8-bcf1-0a2705229b82	11CO044	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
27196faa-6425-11e8-bcf1-0a2705229b82	7784e2e5-c0e1-4b85-8cc1-7faac8_D2	7b424b8e-641a-11e8-bcf1-0a2705229b82	7784e2e5-c0e1-4b85-8cc1-7faac8	964ccbbb-63d5-11e8-bcf1-0a2705229b82	01CO019	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
44f5b956-642a-11e8-bcf1-0a2705229b82	f69deaeb-6b6f-4c61-8900-fd0f26_D3	f6cce507-641b-11e8-bcf1-0a2705229b82	f69deaeb-6b6f-4c61-8900-fd0f26	459e3b69-63d6-11e8-bcf1-0a2705229b82	09CO022	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
356752e0-642a-11e8-bcf1-0a2705229b82	dffcac99-9eac-4717-aeb6-f4a2e7_D8	e31a7d8f-641b-11e8-bcf1-0a2705229b82	dffcac99-9eac-4717-aeb6-f4a2e7	3f240d38-63d6-11e8-bcf1-0a2705229b82	09CO013	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d145e52f-6429-11e8-bcf1-0a2705229b82	5da00abd-5fa7-4deb-95f1-7982e0_D3	98698249-641c-11e8-bcf1-0a2705229b82	5da00abd-5fa7-4deb-95f1-7982e0	97f45829-63d6-11e8-bcf1-0a2705229b82	11CO027	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d03f596-642a-11e8-bcf1-0a2705229b82	c2c53076-b5db-4b7d-983c-a35740_D3	d828f425-641b-11e8-bcf1-0a2705229b82	c2c53076-b5db-4b7d-983c-a35740	3b526aa4-63d6-11e8-bcf1-0a2705229b82	09CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
117d788d-6424-11e8-bcf1-0a2705229b82	3e8019e8-125f-4615-a1fa-a448e9_D2	b605521f-641d-11e8-bcf1-0a2705229b82	3e8019e8-125f-4615-a1fa-a448e9	196e410d-63d7-11e8-bcf1-0a2705229b82	20CO003	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a9e988ca-6429-11e8-bcf1-0a2705229b82	2f8b02e4-1848-4abc-a95e-dd9eb5_D3	79ad03f9-641b-11e8-bcf1-0a2705229b82	2f8b02e4-1848-4abc-a95e-dd9eb5	1d469d14-63d6-11e8-bcf1-0a2705229b82	05CO033	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6349abad-6423-11e8-bcf1-0a2705229b82	1bf00d93-240f-47e8-8055-f546b0_D2	c17d65b3-641b-11e8-bcf1-0a2705229b82	1bf00d93-240f-47e8-8055-f546b0	33c37478-63d6-11e8-bcf1-0a2705229b82	06CO001	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
62770fa5-6429-11e8-bcf1-0a2705229b82	f635496c-0046-4ecd-89bc-7a4f33_D2	df90f549-6420-11e8-bcf1-0a2705229b82	f635496c-0046-4ecd-89bc-7a4f33	0bc46cbd-63d6-11e8-bcf1-0a2705229b82	05CO002	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1a79239c-642a-11e8-bcf1-0a2705229b82	bda3787a-1397-4716-bb17-4992a8_D2	9bf8448c-641b-11e8-bcf1-0a2705229b82	bda3787a-1397-4716-bb17-4992a8	260fb98a-63d6-11e8-bcf1-0a2705229b82	05CO045	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3ba4851b-6424-11e8-bcf1-0a2705229b82	43bc845e-d22e-4c10-b3e8-bc54e6_D2	bd5ba41c-641c-11e8-bcf1-0a2705229b82	43bc845e-d22e-4c10-b3e8-bc54e6	a21c4839-63d6-11e8-bcf1-0a2705229b82	11CO042	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
63dbe3ae-6429-11e8-bcf1-0a2705229b82	321fb3b2-ebb6-4ea5-b737-081264_D2	e157985b-6420-11e8-bcf1-0a2705229b82	321fb3b2-ebb6-4ea5-b737-081264	93d3df99-63d6-11e8-bcf1-0a2705229b82	11CO020	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a89be7a4-6429-11e8-bcf1-0a2705229b82	2d266d2d-4bb3-436c-a3e7-06acb2_D3	b235371f-641d-11e8-bcf1-0a2705229b82	2d266d2d-4bb3-436c-a3e7-06acb2	196e410d-63d7-11e8-bcf1-0a2705229b82	20CO003	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
da3da40d-6429-11e8-bcf1-0a2705229b82	65867ab1-5eab-44a8-b2bb-d27263_D2	8dc2b3f5-641c-11e8-bcf1-0a2705229b82	65867ab1-5eab-44a8-b2bb-d27263	95307d66-63d6-11e8-bcf1-0a2705229b82	11CO021	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
881f8274-6429-11e8-bcf1-0a2705229b82	059a7065-3a5f-4eea-97e5-85ab01_D2	831d637c-641c-11e8-bcf1-0a2705229b82	059a7065-3a5f-4eea-97e5-85ab01	91102308-63d6-11e8-bcf1-0a2705229b82	11CO018	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
956866c8-6429-11e8-bcf1-0a2705229b82	1563ef63-d2e6-406f-adc1-255949_D3	b480f76a-641c-11e8-bcf1-0a2705229b82	1563ef63-d2e6-406f-adc1-255949	9fa2feac-63d6-11e8-bcf1-0a2705229b82	11CO037	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
df57b541-6429-11e8-bcf1-0a2705229b82	695b0b00-a86b-43c0-a6c8-50a840_D3	76494710-641b-11e8-bcf1-0a2705229b82	695b0b00-a86b-43c0-a6c8-50a840	1c11288a-63d6-11e8-bcf1-0a2705229b82	05CO032	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
650810e0-6429-11e8-bcf1-0a2705229b82	92f7419c-c57a-4b50-bdc9-4d09ca_D2	e33a89f5-6420-11e8-bcf1-0a2705229b82	92f7419c-c57a-4b50-bdc9-4d09ca	28873930-63d6-11e8-bcf1-0a2705229b82	05CO048	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
665759ef-6429-11e8-bcf1-0a2705229b82	41ee934e-f7a3-4ef5-8a83-e2ac56_D2	e4fab8db-6420-11e8-bcf1-0a2705229b82	41ee934e-f7a3-4ef5-8a83-e2ac56	175ccf46-63d6-11e8-bcf1-0a2705229b82	05CO026	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
75d91b82-6423-11e8-bcf1-0a2705229b82	1fbb1add-4660-4ec1-b8c2-360f9f_D2	6a0c32e5-641a-11e8-bcf1-0a2705229b82	1fbb1add-4660-4ec1-b8c2-360f9f	9287d60b-63d5-11e8-bcf1-0a2705229b82	01CO013	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7c8f70a2-6423-11e8-bcf1-0a2705229b82	211cbcef-cb1f-4c80-a1c8-a76d3c_D2	fe7b5be1-641c-11e8-bcf1-0a2705229b82	211cbcef-cb1f-4c80-a1c8-a76d3c	b9178503-63d6-11e8-bcf1-0a2705229b82	11CO077	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b05bc19e-6429-11e8-bcf1-0a2705229b82	377cdd37-d1bd-4042-997e-478a0f_D2	8a26e8e2-641c-11e8-bcf1-0a2705229b82	377cdd37-d1bd-4042-997e-478a0f	93d3df99-63d6-11e8-bcf1-0a2705229b82	11CO020	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
889d2c86-6423-11e8-bcf1-0a2705229b82	233ec093-9a30-4ef4-a12c-91757e_D2	bcc79c72-641d-11e8-bcf1-0a2705229b82	233ec093-9a30-4ef4-a12c-91757e	1aa8ef3a-63d7-11e8-bcf1-0a2705229b82	20CO004	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
9039ae28-6429-11e8-bcf1-0a2705229b82	0f757044-9bc8-4ed4-90f3-e0a49a_D3	7dfa9110-641c-11e8-bcf1-0a2705229b82	0f757044-9bc8-4ed4-90f3-e0a49a	8fb486ea-63d6-11e8-bcf1-0a2705229b82	11CO010	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
19799c88-6423-11e8-bcf1-0a2705229b82	0c330883-ab58-4a5a-bff7-07d283_D2	eaa2553e-641c-11e8-bcf1-0a2705229b82	0c330883-ab58-4a5a-bff7-07d283	b2dc3f43-63d6-11e8-bcf1-0a2705229b82	11CO060	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29f9c6cb-642a-11e8-bcf1-0a2705229b82	d3078fa8-0692-411f-8441-0c7c48_D8	e70af089-641c-11e8-bcf1-0a2705229b82	d3078fa8-0692-411f-8441-0c7c48	b05c2057-63d6-11e8-bcf1-0a2705229b82	11CO058	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6793eb9b-6429-11e8-bcf1-0a2705229b82	37219a7c-6fe2-4684-a494-d0be08_D2	e6af1f8f-6420-11e8-bcf1-0a2705229b82	37219a7c-6fe2-4684-a494-d0be08	0f9261c8-63d6-11e8-bcf1-0a2705229b82	05CO006	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
68e33d9f-6429-11e8-bcf1-0a2705229b82	5271982c-5de1-4d6e-b414-b1f3ef_D2	e85ea846-6420-11e8-bcf1-0a2705229b82	5271982c-5de1-4d6e-b414-b1f3ef	2af8ac24-63d6-11e8-bcf1-0a2705229b82	05CO050	CPTAC2 Confirmatory	Primary Tumor	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4c82de01-6424-11e8-bcf1-0a2705229b82	46dfc1e4-0110-4d9f-888e-6a29ab_D2	df28b430-641b-11e8-bcf1-0a2705229b82	46dfc1e4-0110-4d9f-888e-6a29ab	3de574db-63d6-11e8-bcf1-0a2705229b82	09CO011	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
01069982-6425-11e8-bcf1-0a2705229b82	6e0d04fc-e6a8-41ed-b6f3-45537d_D2	e66e4d35-641b-11e8-bcf1-0a2705229b82	6e0d04fc-e6a8-41ed-b6f3-45537d	406db86e-63d6-11e8-bcf1-0a2705229b82	09CO014	CPTAC2 Confirmatory	Solid Tissue Normal	Colon	Colon Adenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a47acd2-ec51-11e9-81b4-2a2ae2dbcce4	PNNL-JHU Ref	6a479b48-ec51-11e9-81b4-2a2ae2dbcce4	PNNL-JHU Ref	6a4788b0-ec51-11e9-81b4-2a2ae2dbcce4	PNNL-JHU Ref	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0f287777-6427-11e8-bcf1-0a2705229b82	f6c215ea-5381-4521-bb61-be8e97_D5	526af583-0881-11eb-bc0e-0aad30af8a83	f6c215ea-5381-4521-bb61-be8e97	526a69a7-0881-11eb-bc0e-0aad30af8a83	04OV018	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5f7b305c-6423-11e8-bcf1-0a2705229b82	1abbcb28-f221-4cd4-8c01-37b9bb_D1_D5	526ab38d-0881-11eb-bc0e-0aad30af8a83	1abbcb28-f221-4cd4-8c01-37b9bb	526a3222-0881-11eb-bc0e-0aad30af8a83	01OV007	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
82313cc9-6425-11e8-bcf1-0a2705229b82	8df6697b-56a1-4ff0-97cf-42b966_D5	614d2fef-641d-11e8-bcf1-0a2705229b82	8df6697b-56a1-4ff0-97cf-42b966	526a9697-0881-11eb-bc0e-0aad30af8a83	17OV005	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
afaacb26-6423-11e8-bcf1-0a2705229b82	28d0abdb-f682-4bd3-9425-a9c508_D5	526b3a00-0881-11eb-bc0e-0aad30af8a83	28d0abdb-f682-4bd3-9425-a9c508	526aa0b0-0881-11eb-bc0e-0aad30af8a83	17OV018	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8551cbde-6424-11e8-bcf1-0a2705229b82	52c064a7-78d9-4a1a-85b4-27c6d1_D5	526b3ed5-0881-11eb-bc0e-0aad30af8a83	52c064a7-78d9-4a1a-85b4-27c6d1	526aa37f-0881-11eb-bc0e-0aad30af8a83	17OV028	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fb4da884-6423-11e8-bcf1-0a2705229b82	3b044c9b-ac09-4b4b-8f37-462411_D2	d5863c20-641a-11e8-bcf1-0a2705229b82	3b044c9b-ac09-4b4b-8f37-462411	bde12fa7-63d5-11e8-bcf1-0a2705229b82	02OV036	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c2a2a2f2-6424-11e8-bcf1-0a2705229b82	5ea22f5e-307b-491d-801f-8b7fa6_D5	526acc6e-0881-11eb-bc0e-0aad30af8a83	5ea22f5e-307b-491d-801f-8b7fa6	526a45be-0881-11eb-bc0e-0aad30af8a83	01OV030	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6a47b394-ec51-11e9-81b4-2a2ae2dbcce4	JHU QC	6a47a2be-ec51-11e9-81b4-2a2ae2dbcce4	JHU QC	6a478efa-ec51-11e9-81b4-2a2ae2dbcce4	JHU QC	CPTAC2 Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
817665cd-6424-11e8-bcf1-0a2705229b82	51a4ce2f-4166-4c6b-a7e0-942d0a_D5	526aca87-0881-11eb-bc0e-0aad30af8a83	51a4ce2f-4166-4c6b-a7e0-942d0a	526a44db-0881-11eb-bc0e-0aad30af8a83	01OV029	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
90802877-6426-11e8-bcf1-0a2705229b82	d4791079-c826-4fc7-9d9b-ee20ba_D5	526af861-0881-11eb-bc0e-0aad30af8a83	d4791079-c826-4fc7-9d9b-ee20ba	526a6b52-0881-11eb-bc0e-0aad30af8a83	04OV023	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
514de24b-6423-11e8-bcf1-0a2705229b82	1772e913-f62e-446a-8cf3-720348_D5	526adaa3-0881-11eb-bc0e-0aad30af8a83	1772e913-f62e-446a-8cf3-720348	526a5065-0881-11eb-bc0e-0aad30af8a83	02OV005	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e56ea641-6424-11e8-bcf1-0a2705229b82	665f4f0f-130c-4b09-9762-cd0696_D2	0633de6c-641d-11e8-bcf1-0a2705229b82	665f4f0f-130c-4b09-9762-cd0696	526a8712-0881-11eb-bc0e-0aad30af8a83	11OV002	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d452e0a-6424-11e8-bcf1-0a2705229b82	407c600a-c0ac-41a6-8d87-fd8a3c_D2	12d4eae8-641d-11e8-bcf1-0a2705229b82	407c600a-c0ac-41a6-8d87-fd8a3c	c1ef8404-63d6-11e8-bcf1-0a2705229b82	13OV003	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8caee087-6425-11e8-bcf1-0a2705229b82	91b287fd-eadb-442d-abcd-20b741_D5	526b16c6-0881-11eb-bc0e-0aad30af8a83	91b287fd-eadb-442d-abcd-20b741	526a847d-0881-11eb-bc0e-0aad30af8a83	04OV058	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ca99aa32-6426-11e8-bcf1-0a2705229b82	e3ebe010-cd31-4b5d-8fcb-b7103b_D5	526aea92-0881-11eb-bc0e-0aad30af8a83	e3ebe010-cd31-4b5d-8fcb-b7103b	526a60d3-0881-11eb-bc0e-0aad30af8a83	04OV004	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d33d3861-6424-11e8-bcf1-0a2705229b82	6319b36b-533c-4e86-8e12-80552e_D2	526b4c90-0881-11eb-bc0e-0aad30af8a83	6319b36b-533c-4e86-8e12-80552e	526aad86-0881-11eb-bc0e-0aad30af8a83	26OV002	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2ad0061b-6424-11e8-bcf1-0a2705229b82	4253f4a4-50b9-409a-b9a8-f94658_D2	7e62ba20-641d-11e8-bcf1-0a2705229b82	4253f4a4-50b9-409a-b9a8-f94658	f46d8b34-63d6-11e8-bcf1-0a2705229b82	17OV033	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cfef4b3d-6423-11e8-bcf1-0a2705229b82	318d53c3-216b-4de1-a098-77d6dd_D5	526afe0f-0881-11eb-bc0e-0aad30af8a83	318d53c3-216b-4de1-a098-77d6dd	526a70a6-0881-11eb-bc0e-0aad30af8a83	04OV031	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4bfc643e-6425-11e8-bcf1-0a2705229b82	80873a0c-1f40-4d51-bab1-3f2071_D5	526b4436-0881-11eb-bc0e-0aad30af8a83	80873a0c-1f40-4d51-bab1-3f2071	526aa7b2-0881-11eb-bc0e-0aad30af8a83	17OV036	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3927bbaf-6425-11e8-bcf1-0a2705229b82	7c7ce2d7-6c8a-424e-8e6c-d14ad1_D5	526b23b3-0881-11eb-bc0e-0aad30af8a83	7c7ce2d7-6c8a-424e-8e6c-d14ad1	526a8f0c-0881-11eb-bc0e-0aad30af8a83	15OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e2c10004-6424-11e8-bcf1-0a2705229b82	6530147a-efe9-4df6-ac2f-03ece3_D5	526b36f7-0881-11eb-bc0e-0aad30af8a83	6530147a-efe9-4df6-ac2f-03ece3	526a9d9d-0881-11eb-bc0e-0aad30af8a83	17OV015	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e393e6d3-6423-11e8-bcf1-0a2705229b82	347e379b-77c0-4dd3-aa25-18c9d1_D5	526ac672-0881-11eb-bc0e-0aad30af8a83	347e379b-77c0-4dd3-aa25-18c9d1	526a42f3-0881-11eb-bc0e-0aad30af8a83	01OV026	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b015955b-6424-11e8-bcf1-0a2705229b82	5b5c81b1-4e73-48d3-9469-108edd_D2	d8f0cedb-641a-11e8-bcf1-0a2705229b82	5b5c81b1-4e73-48d3-9469-108edd	c0597d45-63d5-11e8-bcf1-0a2705229b82	02OV041	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5409254c-6425-11e8-bcf1-0a2705229b82	8120e7d6-bd09-4334-841c-70a214_D2	bfdcc07e-641a-11e8-bcf1-0a2705229b82	8120e7d6-bd09-4334-841c-70a214	b32ade51-63d5-11e8-bcf1-0a2705229b82	02OV006	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03b0970a-6423-11e8-bcf1-0a2705229b82	0745488e-0bfb-4d1f-8228-dedf76_D1_D5	526ab94f-0881-11eb-bc0e-0aad30af8a83	0745488e-0bfb-4d1f-8228-dedf76	526a3949-0881-11eb-bc0e-0aad30af8a83	01OV010	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
231cc8ea-6425-11e8-bcf1-0a2705229b82	76e77c6b-c80e-4391-bdbb-e1dcea_D5	526b0fdf-0881-11eb-bc0e-0aad30af8a83	76e77c6b-c80e-4391-bdbb-e1dcea	526a7f76-0881-11eb-bc0e-0aad30af8a83	04OV051	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03ba5057-6427-11e8-bcf1-0a2705229b82	f4034d75-d533-47c2-8453-068e37_D2	859baf4e-641d-11e8-bcf1-0a2705229b82	f4034d75-d533-47c2-8453-068e37	f9687f24-63d6-11e8-bcf1-0a2705229b82	17OV040	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4827a7df-6423-11e8-bcf1-0a2705229b82	161317f3-1a39-438e-af45-cd2502_D5	526b0b46-0881-11eb-bc0e-0aad30af8a83	161317f3-1a39-438e-af45-cd2502	526a7bd7-0881-11eb-bc0e-0aad30af8a83	04OV048	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
87481829-6423-11e8-bcf1-0a2705229b82	2224c03f-b7b1-4368-887e-2b4cdf_D5	526afb3f-0881-11eb-bc0e-0aad30af8a83	2224c03f-b7b1-4368-887e-2b4cdf	526a6df9-0881-11eb-bc0e-0aad30af8a83	04OV027	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
84e94a77-6425-11e8-bcf1-0a2705229b82	8e17b45e-6a06-4e4e-913d-7b1edb_D5	526acf2e-0881-11eb-bc0e-0aad30af8a83	8e17b45e-6a06-4e4e-913d-7b1edb	526a47af-0881-11eb-bc0e-0aad30af8a83	01OV039	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1124493-6424-11e8-bcf1-0a2705229b82	69d552be-7cb2-4bb4-b602-a27b3e_D5	526b0a2a-0881-11eb-bc0e-0aad30af8a83	69d552be-7cb2-4bb4-b602-a27b3e	526a79a5-0881-11eb-bc0e-0aad30af8a83	04OV045	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b31e638b-6425-11e8-bcf1-0a2705229b82	994f9b8e-46cb-413f-8ec8-2c2fed_D5	526b22a0-0881-11eb-bc0e-0aad30af8a83	994f9b8e-46cb-413f-8ec8-2c2fed	526a8e33-0881-11eb-bc0e-0aad30af8a83	14OV029	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d0a23627-6424-11e8-bcf1-0a2705229b82	627e6e36-3dca-4ee5-9755-6f3510_D5	526b2b50-0881-11eb-bc0e-0aad30af8a83	627e6e36-3dca-4ee5-9755-6f3510	526a91cb-0881-11eb-bc0e-0aad30af8a83	17OV002	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6725f34e-6423-11e8-bcf1-0a2705229b82	1c9145ad-1981-4871-aa7e-8b11de_D5	526b2690-0881-11eb-bc0e-0aad30af8a83	1c9145ad-1981-4871-aa7e-8b11de	526a90f2-0881-11eb-bc0e-0aad30af8a83	17OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0aa00398-6425-11e8-bcf1-0a2705229b82	7069e990-4a4e-4984-a66d-4d835a_D5	526b15ac-0881-11eb-bc0e-0aad30af8a83	7069e990-4a4e-4984-a66d-4d835a	526a83a7-0881-11eb-bc0e-0aad30af8a83	04OV057	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b4e884ce-6423-11e8-bcf1-0a2705229b82	2b73e01c-347a-4dae-a71d-752aeb_D5	526ac1a3-0881-11eb-bc0e-0aad30af8a83	2b73e01c-347a-4dae-a71d-752aeb	526a4022-0881-11eb-bc0e-0aad30af8a83	01OV023	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ba752af3-6425-11e8-bcf1-0a2705229b82	9a7a86d3-bbf2-4d36-941d-c75c03_D1_D5	526ad98a-0881-11eb-bc0e-0aad30af8a83	9a7a86d3-bbf2-4d36-941d-c75c03	526a4e47-0881-11eb-bc0e-0aad30af8a83	02OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f8647290-6423-11e8-bcf1-0a2705229b82	3a380577-c134-47ba-a1ce-988d7c_D5	526b48a5-0881-11eb-bc0e-0aad30af8a83	3a380577-c134-47ba-a1ce-988d7c	526aab00-0881-11eb-bc0e-0aad30af8a83	20OV005	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3cf05eb8-6425-11e8-bcf1-0a2705229b82	7d953d1d-84b6-4ecd-b1d7-1ed865_D5	526b03fe-0881-11eb-bc0e-0aad30af8a83	7d953d1d-84b6-4ecd-b1d7-1ed865	526a751a-0881-11eb-bc0e-0aad30af8a83	04OV039	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7da0bf65-6424-11e8-bcf1-0a2705229b82	51171486-e865-4140-b726-e77088_D5	ad85dd31-641a-11e8-bcf1-0a2705229b82	51171486-e865-4140-b726-e77088	526a47af-0881-11eb-bc0e-0aad30af8a83	01OV039	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
343c54d1-6427-11e8-bcf1-0a2705229b82	fe83e13f-9754-403b-8f74-d6caf8_D5	526af745-0881-11eb-bc0e-0aad30af8a83	fe83e13f-9754-403b-8f74-d6caf8	526a6a80-0881-11eb-bc0e-0aad30af8a83	04OV021	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f6e96cd7-6422-11e8-bcf1-0a2705229b82	0331bd9b-94a5-4d02-ae43-6288e9_D2	ff17310a-641d-11e8-bcf1-0a2705229b82	0331bd9b-94a5-4d02-ae43-6288e9	33f2e3fb-63d7-11e8-bcf1-0a2705229b82	26OV013	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
fd4dd478-6426-11e8-bcf1-0a2705229b82	f02d54bd-b3c7-4375-bc82-167395_D1_D5	99ab7064-641a-11e8-bcf1-0a2705229b82	f02d54bd-b3c7-4375-bc82-167395	526a3f3c-0881-11eb-bc0e-0aad30af8a83	01OV019	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5fbdb0a4-6426-11e8-bcf1-0a2705229b82	cfb8cb2c-53c6-40d7-8069-a1a804_D5	7c5cf47c-641d-11e8-bcf1-0a2705229b82	cfb8cb2c-53c6-40d7-8069-a1a804	526aa60a-0881-11eb-bc0e-0aad30af8a83	17OV030	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a8234c0c-6423-11e8-bcf1-0a2705229b82	27f3ca2d-a86f-479d-8e7e-5307c7_D5	526adf71-0881-11eb-bc0e-0aad30af8a83	27f3ca2d-a86f-479d-8e7e-5307c7	526a548e-0881-11eb-bc0e-0aad30af8a83	02OV022	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2a6551c8-6426-11e8-bcf1-0a2705229b82	bd22174a-86c1-489f-bcb7-93e12b_D5	51c452c9-641d-11e8-bcf1-0a2705229b82	bd22174a-86c1-489f-bcb7-93e12b	526a90f2-0881-11eb-bc0e-0aad30af8a83	17OV001	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1be8f8c0-6423-11e8-bcf1-0a2705229b82	0c87932d-b6fd-4eb5-b86a-a34d07_D5	526ae1fe-0881-11eb-bc0e-0aad30af8a83	0c87932d-b6fd-4eb5-b86a-a34d07	526a587e-0881-11eb-bc0e-0aad30af8a83	02OV032	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
081733e8-6424-11e8-bcf1-0a2705229b82	3d3e1888-d67e-4c69-ba83-112d0f_D5	526aec5e-0881-11eb-bc0e-0aad30af8a83	3d3e1888-d67e-4c69-ba83-112d0f	526a62a5-0881-11eb-bc0e-0aad30af8a83	04OV005	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f1d89be0-6423-11e8-bcf1-0a2705229b82	38f29517-c046-4da5-ba0d-67d614_D2	75304b8f-641d-11e8-bcf1-0a2705229b82	38f29517-c046-4da5-ba0d-67d614	ef7219fa-63d6-11e8-bcf1-0a2705229b82	17OV027	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1692a4b3-6424-11e8-bcf1-0a2705229b82	3fbf076a-824b-4eac-b6dc-bf5e59_D5	526b2dbd-0881-11eb-bc0e-0aad30af8a83	3fbf076a-824b-4eac-b6dc-bf5e59	526a9497-0881-11eb-bc0e-0aad30af8a83	17OV004	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5ce0487e-6423-11e8-bcf1-0a2705229b82	1a10c200-3895-4648-b951-94f99f_D5	526abda4-0881-11eb-bc0e-0aad30af8a83	1a10c200-3895-4648-b951-94f99f	526a3c86-0881-11eb-bc0e-0aad30af8a83	01OV017	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
edde2a5d-6426-11e8-bcf1-0a2705229b82	eb0a53df-7620-4024-8d2d-051142_D5	526abeba-0881-11eb-bc0e-0aad30af8a83	eb0a53df-7620-4024-8d2d-051142	526a3d60-0881-11eb-bc0e-0aad30af8a83	01OV018	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
877a2b21-6425-11e8-bcf1-0a2705229b82	8ed739dd-ae0f-4881-971a-db3cf4_D1_D5	526aba87-0881-11eb-bc0e-0aad30af8a83	8ed739dd-ae0f-4881-971a-db3cf4	526a3b90-0881-11eb-bc0e-0aad30af8a83	01OV013	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ea4d5386-6425-11e8-bcf1-0a2705229b82	a8853382-b726-4ce8-98d5-ca89df_D5	526aef46-0881-11eb-bc0e-0aad30af8a83	a8853382-b726-4ce8-98d5-ca89df	526a6457-0881-11eb-bc0e-0aad30af8a83	04OV011	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1628d2a0-6425-11e8-bcf1-0a2705229b82	74a45e5a-a35a-4c60-a4b4-f3f5ea_D5	526b4000-0881-11eb-bc0e-0aad30af8a83	74a45e5a-a35a-4c60-a4b4-f3f5ea	526aa526-0881-11eb-bc0e-0aad30af8a83	17OV029	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7b40c1cc-6423-11e8-bcf1-0a2705229b82	2115808b-6a0d-49bc-a8d7-b83bde_D5	526b20e0-0881-11eb-bc0e-0aad30af8a83	2115808b-6a0d-49bc-a8d7-b83bde	526a8c5a-0881-11eb-bc0e-0aad30af8a83	14OV011	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2ea7eaa5-6424-11e8-bcf1-0a2705229b82	42d860a3-8a0c-4c44-a09a-9ad8cf_D5	526ae97d-0881-11eb-bc0e-0aad30af8a83	42d860a3-8a0c-4c44-a09a-9ad8cf	526a6002-0881-11eb-bc0e-0aad30af8a83	04OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2d22dee1-6426-11e8-bcf1-0a2705229b82	bd266bdd-12e4-42cb-9c49-911bfc_D5	526b18ac-0881-11eb-bc0e-0aad30af8a83	bd266bdd-12e4-42cb-9c49-911bfc	526a8634-0881-11eb-bc0e-0aad30af8a83	04OV063	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2120e091-6427-11e8-bcf1-0a2705229b82	fbb41c94-aabd-49cc-90b2-882c3e_D5	526adc79-0881-11eb-bc0e-0aad30af8a83	fbb41c94-aabd-49cc-90b2-882c3e	526a514c-0881-11eb-bc0e-0aad30af8a83	02OV008	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
36874f23-6425-11e8-bcf1-0a2705229b82	7c2aeacf-a30d-4104-b60a-7545ee_D2	63b5647c-641d-11e8-bcf1-0a2705229b82	7c2aeacf-a30d-4104-b60a-7545ee	e2fc7190-63d6-11e8-bcf1-0a2705229b82	17OV010	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
91bdfed8-6423-11e8-bcf1-0a2705229b82	2433b136-fc7b-4cea-b958-bc6efb_D5	526b4e60-0881-11eb-bc0e-0aad30af8a83	2433b136-fc7b-4cea-b958-bc6efb	526aae61-0881-11eb-bc0e-0aad30af8a83	26OV008	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
864a24d9-6425-11e8-bcf1-0a2705229b82	8e6a9f67-7c53-4386-9ba0-e48101_D2	e07941b5-641a-11e8-bcf1-0a2705229b82	8e6a9f67-7c53-4386-9ba0-e48101	c58bad65-63d5-11e8-bcf1-0a2705229b82	02OV046	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2ee48807-6425-11e8-bcf1-0a2705229b82	79b60f32-6cca-4cb6-9a1e-22a3ac_D5	526b10ee-0881-11eb-bc0e-0aad30af8a83	79b60f32-6cca-4cb6-9a1e-22a3ac	526a8051-0881-11eb-bc0e-0aad30af8a83	04OV053	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4349ac25-6425-11e8-bcf1-0a2705229b82	7edfd606-4bee-4529-9fec-1ca7f0_D5	526b257d-0881-11eb-bc0e-0aad30af8a83	7edfd606-4bee-4529-9fec-1ca7f0	526a8f0c-0881-11eb-bc0e-0aad30af8a83	15OV001	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ccd82d4f-6424-11e8-bcf1-0a2705229b82	61f76fe6-a1c6-41b8-bdc2-2f9209_D5	526b1d02-0881-11eb-bc0e-0aad30af8a83	61f76fe6-a1c6-41b8-bdc2-2f9209	526a89a7-0881-11eb-bc0e-0aad30af8a83	11OV010	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3fbfe384-6424-11e8-bcf1-0a2705229b82	44a9e976-f859-4a0d-9f4f-70b95b_D2	fd0ea375-641d-11e8-bcf1-0a2705229b82	44a9e976-f859-4a0d-9f4f-70b95b	32b6f61f-63d7-11e8-bcf1-0a2705229b82	26OV011	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c608d6a-6424-11e8-bcf1-0a2705229b82	3dcf8b3c-c0c5-4dfa-9543-5d30fb_D5	526b0874-0881-11eb-bc0e-0aad30af8a83	3dcf8b3c-c0c5-4dfa-9543-5d30fb	526a78cd-0881-11eb-bc0e-0aad30af8a83	04OV044	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b0f7225d-6423-11e8-bcf1-0a2705229b82	2a237fd4-f966-4563-bab1-61dbd7_D2	ba9b5f8b-641a-11e8-bcf1-0a2705229b82	2a237fd4-f966-4563-bab1-61dbd7	af749561-63d5-11e8-bcf1-0a2705229b82	01OV047	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aa7595cd-6426-11e8-bcf1-0a2705229b82	d945689a-dcf3-44f4-a42f-1ded6d_D2	c89afdaf-641a-11e8-bcf1-0a2705229b82	d945689a-dcf3-44f4-a42f-1ded6d	ba01d738-63d5-11e8-bcf1-0a2705229b82	02OV029	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
652969bf-6426-11e8-bcf1-0a2705229b82	cfd76f9a-ce60-4ec7-8e6b-a8fc31_D2	526b3084-0881-11eb-bc0e-0aad30af8a83	cfd76f9a-ce60-4ec7-8e6b-a8fc31	526a9779-0881-11eb-bc0e-0aad30af8a83	17OV011	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
605ba31d-6424-11e8-bcf1-0a2705229b82	49bd51fe-48a1-4828-b66e-b30c38_D5	526b38c4-0881-11eb-bc0e-0aad30af8a83	49bd51fe-48a1-4828-b66e-b30c38	526a9fbc-0881-11eb-bc0e-0aad30af8a83	17OV017	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e0e21b1f-6426-11e8-bcf1-0a2705229b82	e7b656bf-3c34-4ba1-bdf3-c7eefe_D5	526b3cfb-0881-11eb-bc0e-0aad30af8a83	e7b656bf-3c34-4ba1-bdf3-c7eefe	526aa2aa-0881-11eb-bc0e-0aad30af8a83	17OV025	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
eb7b7f66-6423-11e8-bcf1-0a2705229b82	35a345a4-e954-4c81-ae3f-7797cd_D5	526b4f6b-0881-11eb-bc0e-0aad30af8a83	35a345a4-e954-4c81-ae3f-7797cd	526aaf30-0881-11eb-bc0e-0aad30af8a83	26OV009	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
79ea6cc7-6424-11e8-bcf1-0a2705229b82	50997c44-1c8b-4d34-b535-4a6cc2_D5	526b05eb-0881-11eb-bc0e-0aad30af8a83	50997c44-1c8b-4d34-b535-4a6cc2	526a75e7-0881-11eb-bc0e-0aad30af8a83	04OV040	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
abe04136-6423-11e8-bcf1-0a2705229b82	285fed94-1495-448e-879b-b55de9_D5	526affcc-0881-11eb-bc0e-0aad30af8a83	285fed94-1495-448e-879b-b55de9	526a717c-0881-11eb-bc0e-0aad30af8a83	04OV033	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f08b0697-6426-11e8-bcf1-0a2705229b82	eb3f3494-7057-4afe-b212-e6e9a3_D5	526af413-0881-11eb-bc0e-0aad30af8a83	eb3f3494-7057-4afe-b212-e6e9a3	526a67e6-0881-11eb-bc0e-0aad30af8a83	04OV017	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
81311e02-6426-11e8-bcf1-0a2705229b82	d109a3c0-350e-47f5-bda0-61899c_D5	526b13d4-0881-11eb-bc0e-0aad30af8a83	d109a3c0-350e-47f5-bda0-61899c	526a82cb-0881-11eb-bc0e-0aad30af8a83	04OV055	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0828005d-6426-11e8-bcf1-0a2705229b82	b22659b9-e12c-4725-a7db-a833de_D1_D5	526ab71c-0881-11eb-bc0e-0aad30af8a83	b22659b9-e12c-4725-a7db-a833de	526a3812-0881-11eb-bc0e-0aad30af8a83	01OV008	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
b373b3bc-6426-11e8-bcf1-0a2705229b82	dd3a1c3b-6b49-4ec8-b6df-cdf22e_D5	11b3c6b8-641b-11e8-bcf1-0a2705229b82	dd3a1c3b-6b49-4ec8-b6df-cdf22e	526a724a-0881-11eb-bc0e-0aad30af8a83	04OV036	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2c65c4a9-6425-11e8-bcf1-0a2705229b82	78c151c7-0d5b-4aae-88d3-87463b_D5	59bae932-641d-11e8-bcf1-0a2705229b82	78c151c7-0d5b-4aae-88d3-87463b	526a91cb-0881-11eb-bc0e-0aad30af8a83	17OV002	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
faa2e9a2-6426-11e8-bcf1-0a2705229b82	efc971f8-54c5-4531-a792-705ecf_D5	526aed76-0881-11eb-bc0e-0aad30af8a83	efc971f8-54c5-4531-a792-705ecf	526a6387-0881-11eb-bc0e-0aad30af8a83	04OV008	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
28403e05-6424-11e8-bcf1-0a2705229b82	41d0619e-b299-42e2-ac32-29e784_D5	526afcfb-0881-11eb-bc0e-0aad30af8a83	41d0619e-b299-42e2-ac32-29e784	526a6ec8-0881-11eb-bc0e-0aad30af8a83	04OV028	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5a76aecd-6426-11e8-bcf1-0a2705229b82	ce1e5dfc-2ef1-4633-af93-5ea4d9_D5	526b45df-0881-11eb-bc0e-0aad30af8a83	ce1e5dfc-2ef1-4633-af93-5ea4d9	526aa956-0881-11eb-bc0e-0aad30af8a83	17OV039	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03a4c398-6425-11e8-bcf1-0a2705229b82	6e81377c-d0d6-4881-87f6-01c909_D5	07d548c2-641d-11e8-bcf1-0a2705229b82	6e81377c-d0d6-4881-87f6-01c909	526a8712-0881-11eb-bc0e-0aad30af8a83	11OV002	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
69e6cbac-6423-11e8-bcf1-0a2705229b82	1db5574d-aca7-403c-8100-6e705f_D5	526b1fc9-0881-11eb-bc0e-0aad30af8a83	1db5574d-aca7-403c-8100-6e705f	526a8c5a-0881-11eb-bc0e-0aad30af8a83	14OV011	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e63dab1d-6426-11e8-bcf1-0a2705229b82	e9d416e7-f661-400a-896e-388545_D5	526b02b7-0881-11eb-bc0e-0aad30af8a83	e9d416e7-f661-400a-896e-388545	526a743e-0881-11eb-bc0e-0aad30af8a83	04OV037	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4a07cf18-6424-11e8-bcf1-0a2705229b82	46c73531-f531-4ec3-97fe-b39d9d_D5	526b35c3-0881-11eb-bc0e-0aad30af8a83	46c73531-f531-4ec3-97fe-b39d9d	526a9cc6-0881-11eb-bc0e-0aad30af8a83	17OV014	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c142a86a-6425-11e8-bcf1-0a2705229b82	9c8e78bf-b03e-4ba0-9909-5ff070_D5	526b12ba-0881-11eb-bc0e-0aad30af8a83	9c8e78bf-b03e-4ba0-9909-5ff070	526a8125-0881-11eb-bc0e-0aad30af8a83	04OV054	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c50574a9-6425-11e8-bcf1-0a2705229b82	9e0d47e0-f633-468b-b82b-4d752d_D5	526add8e-0881-11eb-bc0e-0aad30af8a83	9e0d47e0-f633-468b-b82b-4d752d	526a53ac-0881-11eb-bc0e-0aad30af8a83	02OV015	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e763f71b-6423-11e8-bcf1-0a2705229b82	3490835c-c004-45ed-91f3-7c206f_D5	526ad0eb-0881-11eb-bc0e-0aad30af8a83	3490835c-c004-45ed-91f3-7c206f	526a488e-0881-11eb-bc0e-0aad30af8a83	01OV041	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
10723806-6423-11e8-bcf1-0a2705229b82	08296da7-70ea-44df-8646-09f2cc_D5	526af059-0881-11eb-bc0e-0aad30af8a83	08296da7-70ea-44df-8646-09f2cc	526a662f-0881-11eb-bc0e-0aad30af8a83	04OV012	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8cc78bbe-6426-11e8-bcf1-0a2705229b82	d38f40fb-dd78-43b2-8b7b-4b6977_D5	526ac37d-0881-11eb-bc0e-0aad30af8a83	d38f40fb-dd78-43b2-8b7b-4b6977	526a4022-0881-11eb-bc0e-0aad30af8a83	01OV023	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3ed82670-6423-11e8-bcf1-0a2705229b82	15524912-685a-47ce-a824-567848_D5	526b0cfc-0881-11eb-bc0e-0aad30af8a83	15524912-685a-47ce-a824-567848	526a7cfe-0881-11eb-bc0e-0aad30af8a83	04OV049	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
205a1a64-6426-11e8-bcf1-0a2705229b82	b9c1f22e-61f7-45ed-b3b4-5094c7_D5	526b2c74-0881-11eb-bc0e-0aad30af8a83	b9c1f22e-61f7-45ed-b3b4-5094c7	526a93bc-0881-11eb-bc0e-0aad30af8a83	17OV003	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4303f2ff-6423-11e8-bcf1-0a2705229b82	1556af7e-c2ae-4fce-9aae-87c459_D1_D5	526abbe6-0881-11eb-bc0e-0aad30af8a83	1556af7e-c2ae-4fce-9aae-87c459	526a3c86-0881-11eb-bc0e-0aad30af8a83	01OV017	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e0fb993b-6423-11e8-bcf1-0a2705229b82	340a3769-3031-41ae-bb08-a2f696_D5	526ac970-0881-11eb-bc0e-0aad30af8a83	340a3769-3031-41ae-bb08-a2f696	526a44db-0881-11eb-bc0e-0aad30af8a83	01OV029	CPTAC2 Confirmatory	Solid Tissue Normal	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c42a0580-6423-11e8-bcf1-0a2705229b82	2ed8beb2-bc63-4bad-b5fe-1916a0_D5	526ae0a2-0881-11eb-bc0e-0aad30af8a83	2ed8beb2-bc63-4bad-b5fe-1916a0	526a5774-0881-11eb-bc0e-0aad30af8a83	02OV023	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
bd115095-6425-11e8-bcf1-0a2705229b82	9b90eb78-2f50-4aeb-b010-d642f9_D5	526ab5e8-0881-11eb-bc0e-0aad30af8a83	9b90eb78-2f50-4aeb-b010-d642f9	526a3222-0881-11eb-bc0e-0aad30af8a83	01OV007	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d36d393-6423-11e8-bcf1-0a2705229b82	0cc794c3-5bf5-4621-b238-58a0f6_D5	526b0e18-0881-11eb-bc0e-0aad30af8a83	0cc794c3-5bf5-4621-b238-58a0f6	526a7dd0-0881-11eb-bc0e-0aad30af8a83	04OV050	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd10f2d3-6425-11e8-bcf1-0a2705229b82	a03d1103-b809-42c4-ad5c-5aff58_D5	526b46ec-0881-11eb-bc0e-0aad30af8a83	a03d1103-b809-42c4-ad5c-5aff58	526aaa31-0881-11eb-bc0e-0aad30af8a83	18OV001	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ff4824b4-6425-11e8-bcf1-0a2705229b82	af95e2c6-25c4-4ab8-bf06-3e15ff_D5	526afa25-0881-11eb-bc0e-0aad30af8a83	af95e2c6-25c4-4ab8-bf06-3e15ff	526a6d21-0881-11eb-bc0e-0aad30af8a83	04OV024	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f9741e25-6422-11e8-bcf1-0a2705229b82	05387aad-2a1f-42c2-8d6f-950598_D2	526b3350-0881-11eb-bc0e-0aad30af8a83	05387aad-2a1f-42c2-8d6f-950598	526a9aa9-0881-11eb-bc0e-0aad30af8a83	17OV013	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d1cd0b3-6424-11e8-bcf1-0a2705229b82	4ccb249a-6722-491e-97e9-e3b4e7_D5	526af23a-0881-11eb-bc0e-0aad30af8a83	4ccb249a-6722-491e-97e9-e3b4e7	526a6716-0881-11eb-bc0e-0aad30af8a83	04OV013	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f8eaa2c5-6424-11e8-bcf1-0a2705229b82	6c9a5bdc-0f0e-4cc8-aec5-63091c_D2	dd09e3ac-641a-11e8-bcf1-0a2705229b82	6c9a5bdc-0f0e-4cc8-aec5-63091c	c2cf7e96-63d5-11e8-bcf1-0a2705229b82	02OV044	CPTAC2 Confirmatory	Primary Tumor	Ovary	Ovarian Serous Cystadenocarcinoma	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c8031a6b-e20f-4311-916e-da313e4eac91	CAKI1-AZD1775	9987d1b1-cab4-419c-8f26-7d0dd20e9a3d	CAKI1-AZD1775	94c16198-7dbb-4956-bd96-9c1b7957a253	CAKI-1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
265de529-8ec4-49c6-9af0-51f678fe3b60	CAKI2-TAK228	b40a5e46-76b3-4b1b-b856-23e4f988a739	CAKI2-TAK228	47080ec6-a3c1-42ad-bbc3-442cc5302947	CAKI-2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29f14048-f34f-48f2-b099-c94c58159104	CAKI2-AZD1775	68eb6d89-3762-4509-9efd-6952427c63db	CAKI2-AZD1775	47080ec6-a3c1-42ad-bbc3-442cc5302947	CAKI-2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0b7c19e9-ec41-4f99-9d09-295acb0f8ab5	769P-TAK228	c0ccc530-6e72-43c4-ad0e-46914fc3a1d6	769P-TAK228	d4129001-7324-4a1b-a876-2cf981fa9191	769-P	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
257be7f3-bdde-42eb-897c-773236cfbee5	CAKI1-everolimus	623de37e-57bc-43fc-96c3-c8a8991e3d86	CAKI1-everolimus	94c16198-7dbb-4956-bd96-9c1b7957a253	CAKI-1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
791bc5b0-e0ee-42d6-a46c-cfb47fdec776	CAKI2-everolimus	be4afac4-d5ad-4b42-97e4-48afe6bf9cb1	CAKI2-everolimus	47080ec6-a3c1-42ad-bbc3-442cc5302947	CAKI-2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
86323cdc-cde3-47c5-bb15-e458b08a3be5	786O-AZD1775	e6736ccf-179b-4347-865c-08db65fbef9d	786O-AZD1775	9bbde4ad-dc88-487f-aa15-652be70975aa	786-O	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3e9f164a-6711-492b-84b2-e4cc1bc017cc	CAKI2-gefitinib	32a0a38a-af42-4a63-ba1b-d196d611d69b	CAKI2-gefitinib	47080ec6-a3c1-42ad-bbc3-442cc5302947	CAKI-2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
03442789-f171-49a6-beb6-10472517a61d	CAKI1-TAK228	449c0b4f-6310-441a-b8f9-e2f3593e89d0	CAKI1-TAK228	94c16198-7dbb-4956-bd96-9c1b7957a253	CAKI-1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a5742389-dcfd-4ea4-9fc4-89bb1180706c	A498-everolimus	f5f04adb-c733-484c-a60f-45ac70d72d99	A498-everolimus	792a4397-366c-480c-8ec8-7abcc8f399ce	A-498	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5934129f-cc99-4c78-aa2a-833ef28865ff	786O-gefitinib	3acc286f-8198-4d11-a10f-0d7ee90e926b	786O-gefitinib	9bbde4ad-dc88-487f-aa15-652be70975aa	786-O	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
099a2227-dd94-4095-bd62-7ca5049fcf85	769P-gefitinib	b14a2f9f-a0af-4b26-b98c-5ae940b5b4b4	769P-gefitinib	d4129001-7324-4a1b-a876-2cf981fa9191	769-P	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8f2b02b8-8be9-454b-8ed6-25aae039878a	A498-TAK228	e87ab10c-2e7b-4684-b895-1277177396f9	A498-TAK228	792a4397-366c-480c-8ec8-7abcc8f399ce	A-498	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8a243819-600f-4f31-a5e2-fd27ad9f39e7	CAKI1-trametinib	016ba895-58b4-4dc9-9c9f-d785b11880d3	CAKI1-trametinib	94c16198-7dbb-4956-bd96-9c1b7957a253	CAKI-1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a6e7d6f3-dcfc-482b-aa38-f63a4b8156ba	769P-AZD1775	d8b0dc66-6d1f-43ea-b2fc-6af9de8c0e3e	769P-AZD1775	d4129001-7324-4a1b-a876-2cf981fa9191	769-P	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a29379a2-2740-4980-8d05-c356fa0bc137	CAKI2-control	af60fd5f-790f-495e-8614-ead6792158cb	CAKI2-control	47080ec6-a3c1-42ad-bbc3-442cc5302947	CAKI-2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
aaa9d016-333c-4b8e-9581-3223c79a5bce	CAKI2-trametinib	4418758b-f8ce-4805-bb90-da745f4de757	CAKI2-trametinib	47080ec6-a3c1-42ad-bbc3-442cc5302947	CAKI-2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
72f6beb6-bbbf-4dc7-a936-38cd1dfe297c	786O-trametinib	f8084ad9-e43e-430b-8dea-86404ad510cc	786O-trametinib	9bbde4ad-dc88-487f-aa15-652be70975aa	786-O	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f24daf7-20fd-4e52-9241-a228f08e8de3	CAKI1-control	bc002717-4e0f-44f6-aea1-95e3e6be0759	CAKI1-control	94c16198-7dbb-4956-bd96-9c1b7957a253	CAKI-1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c8cebb3f-bb4d-407c-bb83-5845bd13cfb1	A498-AZD1775	cd5ddc24-1da0-4807-9493-213bd9c2b6a3	A498-AZD1775	792a4397-366c-480c-8ec8-7abcc8f399ce	A-498	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
84e1fc72-a097-40e9-b602-413817c5d164	A498-gefitinib	cf4b89de-642d-483e-a7df-e888a5bc6be2	A498-gefitinib	792a4397-366c-480c-8ec8-7abcc8f399ce	A-498	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
91a1388a-0f7e-4887-b11f-4d6633254050	786O-TAK228	95b5a1eb-049c-4655-8668-395e6de9436e	786O-TAK228	9bbde4ad-dc88-487f-aa15-652be70975aa	786-O	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2591e711-a431-4736-8d18-f4a9ef6599dc	A498-trametinib	b4d430ed-7c64-4347-8db4-367ec2a9551a	A498-trametinib	792a4397-366c-480c-8ec8-7abcc8f399ce	A-498	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
f2915796-9bc8-47bc-9ae5-326e5d648668	786O-everolimus	9309964f-0370-4d6b-9669-cfc39a1741a1	786O-everolimus	9bbde4ad-dc88-487f-aa15-652be70975aa	786-O	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
ecdfecab-efb3-40ce-b95f-bf104a342852	CAKI1-gefitinib	4e70bdc6-41d4-4a05-a163-edcc4fbb1640	CAKI1-gefitinib	94c16198-7dbb-4956-bd96-9c1b7957a253	CAKI-1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
16d26178-9fc9-4476-bc58-b4e0fdbf6adc	769P-everolimus	e77057cd-4509-4423-82ce-853100e19ca9	769P-everolimus	d4129001-7324-4a1b-a876-2cf981fa9191	769-P	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
806a361f-db35-4ae3-a2c0-ebe3f964c513	769P-control	8b872167-459b-4279-9f86-3bb75dc9fc86	769P-control	d4129001-7324-4a1b-a876-2cf981fa9191	769-P	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
59299bf9-9bd3-4b7c-9863-4b9e6e8402ce	A498-control	80f7196a-983d-4456-b258-6e5f0af1655d	A498-control	792a4397-366c-480c-8ec8-7abcc8f399ce	A-498	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d8d1841c-df24-4c2f-ae44-e6ae4dc4ac63	769P-trametinib	40d381a8-0d62-4fee-b774-0cc28485b265	769P-trametinib	d4129001-7324-4a1b-a876-2cf981fa9191	769-P	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
7a469fd1-6822-4b6a-9b19-41faa354bcdc	786O-control	21daa930-af5c-4387-b172-88b54671411d	786O-control	9bbde4ad-dc88-487f-aa15-652be70975aa	786-O	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cdd292e3-412d-46a0-a8ec-d8a2f82cf3a9	CR3	519dd6f1-5c2b-489a-971c-164e3e12bf43	CR3	6e7561ef-f5b3-4bf0-8148-f0d155fb0d9d	CR3	CPTAC3-Other	Not Reported	Not Reported	Other	Yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2ca7d56f-2054-11e9-b7f8-0a80fada099c	QC5	0abbe6ca-204e-11e9-b7f8-0a80fada099c	QC5	0e79bef5-1fba-11e9-b7f8-0a80fada099c	QC5	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1d7fe458-2054-11e9-b7f8-0a80fada099c	NCI7-3	fe08d02b-204d-11e9-b7f8-0a80fada099c	NCI7-3	02b84fb5-1fba-11e9-b7f8-0a80fada099c	NCI7-3	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2e4e2a15-2054-11e9-b7f8-0a80fada099c	QC7	0edc5985-204e-11e9-b7f8-0a80fada099c	QC7	11b585a4-1fba-11e9-b7f8-0a80fada099c	QC7	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2af8fd10-2054-11e9-b7f8-0a80fada099c	QC3	0635b755-204e-11e9-b7f8-0a80fada099c	QC3	0b43d28c-1fba-11e9-b7f8-0a80fada099c	QC3	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1e677a3c-2054-11e9-b7f8-0a80fada099c	NCI7-4	ffbd88ac-204d-11e9-b7f8-0a80fada099c	NCI7-4	04556aba-1fba-11e9-b7f8-0a80fada099c	NCI7-4	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2bc4bef1-2054-11e9-b7f8-0a80fada099c	QC4	086d94cd-204e-11e9-b7f8-0a80fada099c	QC4	0cdd85f4-1fba-11e9-b7f8-0a80fada099c	QC4	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2d8207f0-2054-11e9-b7f8-0a80fada099c	QC6	0ca44a76-204e-11e9-b7f8-0a80fada099c	QC6	10135c5c-1fba-11e9-b7f8-0a80fada099c	QC6	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3040dd8d-2054-11e9-b7f8-0a80fada099c	Pooled Sample	12589be6-204e-11e9-b7f8-0a80fada099c	Pooled Sample	153161ec-1fba-11e9-b7f8-0a80fada099c	Pooled Sample	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f2e39ec-2054-11e9-b7f8-0a80fada099c	NCI7-5	018c9266-204e-11e9-b7f8-0a80fada099c	NCI7-5	062fdb7f-1fba-11e9-b7f8-0a80fada099c	NCI7-5	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1cb3cb3d-2054-11e9-b7f8-0a80fada099c	NCI7-2	fc86d5da-204d-11e9-b7f8-0a80fada099c	NCI7-2	00dc49de-1fba-11e9-b7f8-0a80fada099c	NCI7-2	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2f2781cd-2054-11e9-b7f8-0a80fada099c	QC8	105d534c-204e-11e9-b7f8-0a80fada099c	QC8	139225aa-1fba-11e9-b7f8-0a80fada099c	QC8	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
29de104b-2054-11e9-b7f8-0a80fada099c	QC2	04afc8fb-204e-11e9-b7f8-0a80fada099c	QC2	09a53ad8-1fba-11e9-b7f8-0a80fada099c	QC2	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1b95826b-2054-11e9-b7f8-0a80fada099c	NCI7-1	fab7e97d-204d-11e9-b7f8-0a80fada099c	NCI7-1	ff40730d-1fb9-11e9-b7f8-0a80fada099c	NCI7-1	CPTAC3 Discovery and Confirmatory	Cell Lines	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2915e723-2054-11e9-b7f8-0a80fada099c	QC1	03394f84-204e-11e9-b7f8-0a80fada099c	QC1	0809987b-1fba-11e9-b7f8-0a80fada099c	QC1	CPTAC3 Discovery and Confirmatory	Not Reported	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21f6cf1f-2054-11e9-b7f8-0a80fada099c	P93_270	ae67a900-d0a6-11e9-9a07-0a80fada099c	WHIM-P93	f1ee4ead-cf1e-11e9-9a07-0a80fada099c	WHIM-P93	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1ff8f08e-2054-11e9-b7f8-0a80fada099c	P93_263	ae67a900-d0a6-11e9-9a07-0a80fada099c	WHIM-P93	f1ee4ead-cf1e-11e9-9a07-0a80fada099c	WHIM-P93	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
23ca1446-2054-11e9-b7f8-0a80fada099c	P93_278	ae67a900-d0a6-11e9-9a07-0a80fada099c	WHIM-P93	f1ee4ead-cf1e-11e9-9a07-0a80fada099c	WHIM-P93	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
25660883-2054-11e9-b7f8-0a80fada099c	P94_23	ae7ed6cd-d0a6-11e9-9a07-0a80fada099c	WHIM-P94	f1ee500a-cf1e-11e9-9a07-0a80fada099c	WHIM-P94	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
24931169-2054-11e9-b7f8-0a80fada099c	P94_21	ae7ed6cd-d0a6-11e9-9a07-0a80fada099c	WHIM-P94	f1ee500a-cf1e-11e9-9a07-0a80fada099c	WHIM-P94	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
26fa0ecd-2054-11e9-b7f8-0a80fada099c	P94_27	ae7ed6cd-d0a6-11e9-9a07-0a80fada099c	WHIM-P94	f1ee500a-cf1e-11e9-9a07-0a80fada099c	WHIM-P94	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2129cc7e-2054-11e9-b7f8-0a80fada099c	P93_267	ae67a900-d0a6-11e9-9a07-0a80fada099c	WHIM-P93	f1ee4ead-cf1e-11e9-9a07-0a80fada099c	WHIM-P93	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
22c37b0f-2054-11e9-b7f8-0a80fada099c	P93_274	ae67a900-d0a6-11e9-9a07-0a80fada099c	WHIM-P93	f1ee4ead-cf1e-11e9-9a07-0a80fada099c	WHIM-P93	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
2630c59e-2054-11e9-b7f8-0a80fada099c	P94_25	ae7ed6cd-d0a6-11e9-9a07-0a80fada099c	WHIM-P94	f1ee500a-cf1e-11e9-9a07-0a80fada099c	WHIM-P94	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
27c860d8-2054-11e9-b7f8-0a80fada099c	P94_71	ae7ed6cd-d0a6-11e9-9a07-0a80fada099c	WHIM-P94	f1ee500a-cf1e-11e9-9a07-0a80fada099c	WHIM-P94	CPTAC3 Discovery and Confirmatory	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1f0125df-a578-43fb-9aa3-fc78043a108f	WHIMIR	bde04f68-a615-49e6-ab48-d92989f8e350	WHIMIR	fbe0c8fa-12b4-4c24-86c6-b57085bdd95b	WHIMIR	CPTAC2-Other	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
a5909bae-1578-43cc-8da4-f36a4b7d1cdd	WHIM27	51a48529-eb42-4fb6-92ac-0f2e294fc684	WHIM27	5d66255e-9161-42b2-a59f-4764a4e7b570	WHIM27	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
d59b3262-c1fb-43f8-b95f-b687586edb42	WHIM30	8571ba7f-0b2d-4a47-ae70-d47158afbb85	WHIM30	221c00a5-5af5-4793-988d-223263ecfb38	WHIM30	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
4dc9face-985d-410c-8371-4734e0e7565e	TaxolIR	2a84d49f-1d9c-44f9-8ec6-e2d960745cec	TaxolIR	49d79df1-4e2e-476e-a91a-5c4c1f51deb7	TaxolIR	CPTAC2-Other	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5e4ccc68-43c1-4610-b342-4ee13122da9f	WHIM14	1f99ba40-2df0-45e7-b860-e855585b7e72	WHIM14	287695c7-59dd-47b2-bf0f-0895b23258c0	WHIM14	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
6d6a94e7-a630-4848-b7e2-efc67988356a	WHIM12	8a180607-019e-4966-af89-0acf8ade46d4	WHIM12	f5cb2682-d250-4727-834c-222c47662412	WHIM12	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	No	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
147657f9-0794-4144-9952-dcf78b3e235b	WHIM13	602e8a12-9143-4e7a-b18e-5cd90b63b808	WHIM13	5b309f1b-9aec-45fb-82e4-ed0da0e12ed8	WHIM13	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
21e53958-1835-4f3c-88ad-757af747fabd	WHIM18	c040e234-4e55-4cc6-bf9d-44fef2e4362c	WHIM18	b44f3ebf-e0aa-4e5e-ab5b-8b19933b8ce1	WHIM18	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c4f20109-3b1b-456e-8260-43618b98941e	WHIM20	4368dc72-f677-488c-9e34-4905770edfe3	WHIM20	14cee5b1-828e-442a-9d93-d08532062508	WHIM20	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
60a20ca0-2a2d-40b8-a506-13afdcb75862	WHIM4	01ebd1a6-05fe-4f5c-9a2b-de98528a6b3a	WHIM4	05030046-763c-48d8-b727-100f34c9d6a5	WHIM4	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
90137571-563a-4751-9168-a87198b98a79	WHIM43	1d0cfdf0-cfdc-48d9-99f3-ff5966955ce4	WHIM43	78a0147b-4098-49fa-8a8a-70718f320490	WHIM43	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
930cbf9c-65bc-47c5-91ab-5532deb800da	WHIM25	5167fa8d-622b-49fd-9c1d-2e882657290a	WHIM25	29182985-6507-4015-9312-8492afc060ad	WHIM25	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
38bf354b-34d5-4000-97c7-aef49e180d52	WHIM47	0ad7255b-45fc-4107-b483-3da794f98980	WHIM47	414d1928-3385-49b1-a4a8-3f3ad07acdb7	WHIM47	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
60548be1-1825-4645-8171-f5caa034bea2	HumanIR	255671b8-8a88-4dd4-9b0f-370bf2c69d6c	HumanIR	8e984f66-c1db-4588-bd01-691870ba0225	HumanIR	CPTAC2-Other	Not Reported	Not Reported	Other	yes	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
05be2736-3f84-4790-aeb0-a44b6dff1fe1	WHIM35	76632a59-bb46-4627-bdae-23c169bdd6a3	WHIM35	e1b97674-6507-4955-bb07-cf8c617b9c69	WHIM35	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
cd23080f-50e6-4375-a118-f944bff1bd75	WHIM46	3776b35a-6997-4393-bd78-2bd7d4c24735	WHIM46	adfe3073-938e-4789-bb6e-3e18c0c226ee	WHIM46	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
3b1f9e98-d01c-46da-9a68-0a15f452476c	WHIM17	2cb15a81-3709-4c6c-ad41-e2a6d10b3245	WHIM17	9c960cec-278f-4287-b11a-b3599560be25	WHIM17	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
1aa32c9c-70e5-4c40-a72e-8bfd32b874d9	WHIM37	9d35ddf4-4147-473c-b78d-8d2911beb119	WHIM37	7599a933-49b1-4c8c-8bff-f74a39341418	WHIM37	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
99d36d0e-c7b8-4a24-843d-4072cd9f978b	WHIM21	91945321-868f-4710-a602-bd18f7ea69c0	WHIM21	58369844-d03e-492a-8964-241e31aea807	WHIM21	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
5d2757a6-4126-4677-b343-6cbf66335dc2	WHIM26	15b239d7-67ef-4839-a416-0ac414872808	WHIM26	a136beb8-8193-4b45-81e2-43b39b1cc8e5	WHIM26	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
898871e6-2f31-4b49-82b4-badbe654d0cc	WHIM8	d57b4732-5953-49bb-a73b-563cd24e0ede	WHIM8	aa68d315-3c85-4ca4-acc8-a83631bb35d4	WHIM8	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
c7a42293-64bc-49fb-8d8d-f2a68eafaa68	WHIM2	1a86f11e-27d0-43bf-8f74-204c7f94978e	WHIM2	7e593a86-39ae-4062-b95b-36ed1c79d031	WHIM2	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
54235434-d812-4a96-b5f6-5515198bcdd4	WHIM6	addc9591-edc0-4b0c-8967-bdf096af103b	WHIM6	808964d8-5b57-4c65-bc80-c13289818e7f	WHIM6	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
8e837921-342b-4b3b-a63a-5f7c0bb99967	WHIM11	31b7083e-ee54-4a81-9f81-668d48009d64	WHIM11	35adc129-34de-4a9e-8243-caece2a6c6d2	WHIM11	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
308e4045-d6cb-4675-b743-bcb1e11e2c18	WHIM9	93be933a-3142-4e78-aaab-2d9d0045af06	WHIM9	43174e44-bdcc-43a4-99e8-206cf06e345b	WHIM9	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
0c3f85a7-7697-4853-b3b7-acf9c2adcaef	WHIM24	25ee6445-4a14-468e-ae14-8d0fce330736	WHIM24	0fc99975-d413-4582-b800-ea22bc755c7b	WHIM24	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
32f0d2b2-2431-4bc9-9d18-826202cb4a3b	WHIM16	8b842148-910e-4659-884c-4415dd70e012	WHIM16	be491e8c-3ffe-4b60-91a9-416db5e65ffd	WHIM16	CPTAC2-Other	Xenograft Tissue	Not Reported	Other	no	Qualified						Qualified	Qualified																									Clinical Proteomic Tumor Analysis Consortium
e8da868c-693a-11ea-b1fd-0aad30af8a83	N123	e8d6fffa-693a-11ea-b1fd-0aad30af8a83	adjacent Pat32	e8d58460-693a-11ea-b1fd-0aad30af8a83	32	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db0eb5-693a-11ea-b1fd-0aad30af8a83	N5381	e8d80b57-693a-11ea-b1fd-0aad30af8a83	adjacent Pat79	e8d6484a-693a-11ea-b1fd-0aad30af8a83	79	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dafd12-693a-11ea-b1fd-0aad30af8a83	N247	e8d7f251-693a-11ea-b1fd-0aad30af8a83	adjacent Pat67	e8d638c3-693a-11ea-b1fd-0aad30af8a83	67	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbfb3d-693a-11ea-b1fd-0aad30af8a83	T226	e8d9816e-693a-11ea-b1fd-0aad30af8a83	Tumor Pat64	e8d6351c-693a-11ea-b1fd-0aad30af8a83	64	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da2729-693a-11ea-b1fd-0aad30af8a83	N21	e8d64f96-693a-11ea-b1fd-0aad30af8a83	adjacent Pat4	e8d52234-693a-11ea-b1fd-0aad30af8a83	4	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db0a48-693a-11ea-b1fd-0aad30af8a83	N5263	e8d804d2-693a-11ea-b1fd-0aad30af8a83	adjacent Pat76	e8d64485-693a-11ea-b1fd-0aad30af8a83	76	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dafde8-693a-11ea-b1fd-0aad30af8a83	N249	e8d7f480-693a-11ea-b1fd-0aad30af8a83	adjacent Pat68	e8d639ac-693a-11ea-b1fd-0aad30af8a83	68	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da2814-693a-11ea-b1fd-0aad30af8a83	N23	e8d68d3a-693a-11ea-b1fd-0aad30af8a83	adjacent Pat5	e8d55d7f-693a-11ea-b1fd-0aad30af8a83	5	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db081a-693a-11ea-b1fd-0aad30af8a83	N2397	e8d8023a-693a-11ea-b1fd-0aad30af8a83	adjacent Pat75	e8d6429c-693a-11ea-b1fd-0aad30af8a83	75	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db59de-693a-11ea-b1fd-0aad30af8a83	T60	e8d88fb0-693a-11ea-b1fd-0aad30af8a83	Tumor Pat19	e8d56feb-693a-11ea-b1fd-0aad30af8a83	19	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da29e7-693a-11ea-b1fd-0aad30af8a83	N25	e8d68f45-693a-11ea-b1fd-0aad30af8a83	adjacent Pat6	e8d55f58-693a-11ea-b1fd-0aad30af8a83	6	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbb9bb-693a-11ea-b1fd-0aad30af8a83	T192	e8d933e6-693a-11ea-b1fd-0aad30af8a83	Tumor Pat51	e8d5ecd7-693a-11ea-b1fd-0aad30af8a83	51	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5bef-693a-11ea-b1fd-0aad30af8a83	T62	e8d891b6-693a-11ea-b1fd-0aad30af8a83	Tumor Pat20	e8d571e2-693a-11ea-b1fd-0aad30af8a83	20	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da2ad3-693a-11ea-b1fd-0aad30af8a83	N27	e8d69150-693a-11ea-b1fd-0aad30af8a83	adjacent Pat7	e8d5605f-693a-11ea-b1fd-0aad30af8a83	7	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbb7ac-693a-11ea-b1fd-0aad30af8a83	T190	e8d93206-693a-11ea-b1fd-0aad30af8a83	Tumor Pat50	e8d5eab5-693a-11ea-b1fd-0aad30af8a83	50	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5cd6-693a-11ea-b1fd-0aad30af8a83	T64	e8d893b6-693a-11ea-b1fd-0aad30af8a83	Tumor Pat21	e8d572cc-693a-11ea-b1fd-0aad30af8a83	21	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da2caa-693a-11ea-b1fd-0aad30af8a83	N29	e8d69328-693a-11ea-b1fd-0aad30af8a83	adjacent Pat8	e8d56253-693a-11ea-b1fd-0aad30af8a83	8	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5db5-693a-11ea-b1fd-0aad30af8a83	T66	e8d894da-693a-11ea-b1fd-0aad30af8a83	Tumor Pat22	e8d573ad-693a-11ea-b1fd-0aad30af8a83	22	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5fd9-693a-11ea-b1fd-0aad30af8a83	T68	e8d896bb-693a-11ea-b1fd-0aad30af8a83	Tumor Pat23	e8d575af-693a-11ea-b1fd-0aad30af8a83	23	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db6590-693a-11ea-b1fd-0aad30af8a83	T112	e8d89fb8-693a-11ea-b1fd-0aad30af8a83	Tumor Pat28	e8d57cfb-693a-11ea-b1fd-0aad30af8a83	28	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbfd0d-693a-11ea-b1fd-0aad30af8a83	T232	e8d982a4-693a-11ea-b1fd-0aad30af8a83	Tumor Pat65	e8d6361d-693a-11ea-b1fd-0aad30af8a83	65	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbbcac-693a-11ea-b1fd-0aad30af8a83	T196	e8d93701-693a-11ea-b1fd-0aad30af8a83	Tumor Pat53	e8d5efda-693a-11ea-b1fd-0aad30af8a83	53	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbbaa1-693a-11ea-b1fd-0aad30af8a83	T194	e8d93513-693a-11ea-b1fd-0aad30af8a83	Tumor Pat52	e8d5edcb-693a-11ea-b1fd-0aad30af8a83	52	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dafc2c-693a-11ea-b1fd-0aad30af8a83	N235	e8d7f01f-693a-11ea-b1fd-0aad30af8a83	adjacent Pat66	e8d63703-693a-11ea-b1fd-0aad30af8a83	66	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da8231-693a-11ea-b1fd-0aad30af8a83	N115	e8d6f68e-693a-11ea-b1fd-0aad30af8a83	adjacent Pat29	e8d57f0d-693a-11ea-b1fd-0aad30af8a83	29	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbc88b-693a-11ea-b1fd-0aad30af8a83	T218	e8d97c3a-693a-11ea-b1fd-0aad30af8a83	Tumor Pat61	e8d62e91-693a-11ea-b1fd-0aad30af8a83	61	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbc7ac-693a-11ea-b1fd-0aad30af8a83	T216	e8d97a2d-693a-11ea-b1fd-0aad30af8a83	Tumor Pat60	e8d5fba5-693a-11ea-b1fd-0aad30af8a83	60	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dafa3f-693a-11ea-b1fd-0aad30af8a83	N231	e8d7ede1-693a-11ea-b1fd-0aad30af8a83	adjacent Pat65	e8d6361d-693a-11ea-b1fd-0aad30af8a83	65	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da8057-693a-11ea-b1fd-0aad30af8a83	N111	e8d6f46a-693a-11ea-b1fd-0aad30af8a83	adjacent Pat28	e8d57cfb-693a-11ea-b1fd-0aad30af8a83	28	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daede0-693a-11ea-b1fd-0aad30af8a83	N199	e8d794eb-693a-11ea-b1fd-0aad30af8a83	adjacent Pat54	e8d5f0cc-693a-11ea-b1fd-0aad30af8a83	54	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbc56d-693a-11ea-b1fd-0aad30af8a83	T214	e8d9423b-693a-11ea-b1fd-0aad30af8a83	Tumor Pat59	e8d5fa33-693a-11ea-b1fd-0aad30af8a83	59	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db0d5e-693a-11ea-b1fd-0aad30af8a83	N5373	e8d80939-693a-11ea-b1fd-0aad30af8a83	adjacent Pat78	e8d64650-693a-11ea-b1fd-0aad30af8a83	78	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da8319-693a-11ea-b1fd-0aad30af8a83	N117	e8d6fb52-693a-11ea-b1fd-0aad30af8a83	adjacent Pat30	e8d58072-693a-11ea-b1fd-0aad30af8a83	30	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da2d9a-693a-11ea-b1fd-0aad30af8a83	N31	e8d69504-693a-11ea-b1fd-0aad30af8a83	adjacent Pat9	e8d56345-693a-11ea-b1fd-0aad30af8a83	9	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da83f0-693a-11ea-b1fd-0aad30af8a83	N119	e8d6fde5-693a-11ea-b1fd-0aad30af8a83	adjacent Pat31	e8d582aa-693a-11ea-b1fd-0aad30af8a83	31	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da2f86-693a-11ea-b1fd-0aad30af8a83	N33	e8d696e2-693a-11ea-b1fd-0aad30af8a83	adjacent Pat10	e8d56429-693a-11ea-b1fd-0aad30af8a83	10	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da306c-693a-11ea-b1fd-0aad30af8a83	N35	e8d698d5-693a-11ea-b1fd-0aad30af8a83	adjacent Pat11	e8d565f6-693a-11ea-b1fd-0aad30af8a83	11	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbb6c0-693a-11ea-b1fd-0aad30af8a83	T182	e8d930ca-693a-11ea-b1fd-0aad30af8a83	Tumor Pat49	e8d5e9de-693a-11ea-b1fd-0aad30af8a83	49	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da3288-693a-11ea-b1fd-0aad30af8a83	N37	e8d69ac3-693a-11ea-b1fd-0aad30af8a83	adjacent Pat12	e8d566e0-693a-11ea-b1fd-0aad30af8a83	12	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbb515-693a-11ea-b1fd-0aad30af8a83	T180	e8d92eed-693a-11ea-b1fd-0aad30af8a83	Tumor Pat48	e8d5e8f8-693a-11ea-b1fd-0aad30af8a83	48	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da3377-693a-11ea-b1fd-0aad30af8a83	N39	e8d69d74-693a-11ea-b1fd-0aad30af8a83	adjacent Pat13	e8d567bd-693a-11ea-b1fd-0aad30af8a83	13	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbcbfe-693a-11ea-b1fd-0aad30af8a83	T222	e8d97f83-693a-11ea-b1fd-0aad30af8a83	Tumor Pat63	e8d632ed-693a-11ea-b1fd-0aad30af8a83	63	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbcb16-693a-11ea-b1fd-0aad30af8a83	T220	e8d97e50-693a-11ea-b1fd-0aad30af8a83	Tumor Pat62	e8d631ab-693a-11ea-b1fd-0aad30af8a83	62	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da8e83-693a-11ea-b1fd-0aad30af8a83	N145	e8d73d3f-693a-11ea-b1fd-0aad30af8a83	adjacent Pat38	e8d5db73-693a-11ea-b1fd-0aad30af8a83	38	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db0402-693a-11ea-b1fd-0aad30af8a83	N267	e8d7fc4b-693a-11ea-b1fd-0aad30af8a83	adjacent Pat72	e8d63e0e-693a-11ea-b1fd-0aad30af8a83	72	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da8f6d-693a-11ea-b1fd-0aad30af8a83	N147	e8d73f2d-693a-11ea-b1fd-0aad30af8a83	adjacent Pat39	e8d5dd83-693a-11ea-b1fd-0aad30af8a83	39	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db0503-693a-11ea-b1fd-0aad30af8a83	N269	e8d7fe46-693a-11ea-b1fd-0aad30af8a83	adjacent Pat73	e8d64095-693a-11ea-b1fd-0aad30af8a83	73	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbfedc-693a-11ea-b1fd-0aad30af8a83	T248	e8d985ba-693a-11ea-b1fd-0aad30af8a83	Tumor Pat67	e8d638c3-693a-11ea-b1fd-0aad30af8a83	67	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da8c87-693a-11ea-b1fd-0aad30af8a83	N143	e8d73b32-693a-11ea-b1fd-0aad30af8a83	adjacent Pat37	e8d5d9dc-693a-11ea-b1fd-0aad30af8a83	37	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db01c8-693a-11ea-b1fd-0aad30af8a83	N265	e8d7fa58-693a-11ea-b1fd-0aad30af8a83	adjacent Pat71	e8d63d36-693a-11ea-b1fd-0aad30af8a83	71	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da357a-693a-11ea-b1fd-0aad30af8a83	N41	e8d69f8a-693a-11ea-b1fd-0aad30af8a83	adjacent Pat14	e8d5698f-693a-11ea-b1fd-0aad30af8a83	14	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da9044-693a-11ea-b1fd-0aad30af8a83	N149	e8d74123-693a-11ea-b1fd-0aad30af8a83	adjacent Pat40	e8d5de83-693a-11ea-b1fd-0aad30af8a83	40	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da365c-693a-11ea-b1fd-0aad30af8a83	N43	e8d6a176-693a-11ea-b1fd-0aad30af8a83	adjacent Pat15	e8d56a7d-693a-11ea-b1fd-0aad30af8a83	15	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da3861-693a-11ea-b1fd-0aad30af8a83	N45	e8d6a374-693a-11ea-b1fd-0aad30af8a83	adjacent Pat16	e8d56b56-693a-11ea-b1fd-0aad30af8a83	16	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db60c2-693a-11ea-b1fd-0aad30af8a83	T88	e8d897e9-693a-11ea-b1fd-0aad30af8a83	Tumor Pat24	e8d57696-693a-11ea-b1fd-0aad30af8a83	24	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db072d-693a-11ea-b1fd-0aad30af8a83	N271	e8d80040-693a-11ea-b1fd-0aad30af8a83	adjacent Pat74	e8d641ae-693a-11ea-b1fd-0aad30af8a83	74	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dba19c-693a-11ea-b1fd-0aad30af8a83	T132	e8d8e2cc-693a-11ea-b1fd-0aad30af8a83	Tumor Pat33	e8d5d358-693a-11ea-b1fd-0aad30af8a83	33	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc0183-693a-11ea-b1fd-0aad30af8a83	T254	e8d988d4-693a-11ea-b1fd-0aad30af8a83	Tumor Pat69	e8d63a87-693a-11ea-b1fd-0aad30af8a83	69	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbffb9-693a-11ea-b1fd-0aad30af8a83	T250	e8d987a4-693a-11ea-b1fd-0aad30af8a83	Tumor Pat68	e8d639ac-693a-11ea-b1fd-0aad30af8a83	68	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da887a-693a-11ea-b1fd-0aad30af8a83	N135	e8d70420-693a-11ea-b1fd-0aad30af8a83	adjacent Pat34	e8d5d5bc-693a-11ea-b1fd-0aad30af8a83	34	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db00c0-693a-11ea-b1fd-0aad30af8a83	N257	e8d7f864-693a-11ea-b1fd-0aad30af8a83	adjacent Pat70	e8d63c4d-693a-11ea-b1fd-0aad30af8a83	70	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db6939-693a-11ea-b1fd-0aad30af8a83	T118	e8d8dd84-693a-11ea-b1fd-0aad30af8a83	Tumor Pat30	e8d58072-693a-11ea-b1fd-0aad30af8a83	30	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da8ab2-693a-11ea-b1fd-0aad30af8a83	N137	e8d73687-693a-11ea-b1fd-0aad30af8a83	adjacent Pat35	e8d5d6ea-693a-11ea-b1fd-0aad30af8a83	35	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db67de-693a-11ea-b1fd-0aad30af8a83	T116	e8d8a1c2-693a-11ea-b1fd-0aad30af8a83	Tumor Pat29	e8d57f0d-693a-11ea-b1fd-0aad30af8a83	29	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da879e-693a-11ea-b1fd-0aad30af8a83	N131	e8d70209-693a-11ea-b1fd-0aad30af8a83	adjacent Pat33	e8d5d358-693a-11ea-b1fd-0aad30af8a83	33	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daffe0-693a-11ea-b1fd-0aad30af8a83	N253	e8d7f677-693a-11ea-b1fd-0aad30af8a83	adjacent Pat69	e8d63a87-693a-11ea-b1fd-0aad30af8a83	69	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbfe00-693a-11ea-b1fd-0aad30af8a83	T236	e8d9848b-693a-11ea-b1fd-0aad30af8a83	Tumor Pat66	e8d63703-693a-11ea-b1fd-0aad30af8a83	66	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db0b2b-693a-11ea-b1fd-0aad30af8a83	N5357	e8d8071f-693a-11ea-b1fd-0aad30af8a83	adjacent Pat77	e8d64572-693a-11ea-b1fd-0aad30af8a83	77	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db61a0-693a-11ea-b1fd-0aad30af8a83	T90	e8d899d3-693a-11ea-b1fd-0aad30af8a83	Tumor Pat25	e8d578a1-693a-11ea-b1fd-0aad30af8a83	25	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db63d1-693a-11ea-b1fd-0aad30af8a83	T92	e8d89bc8-693a-11ea-b1fd-0aad30af8a83	Tumor Pat26	e8d5798b-693a-11ea-b1fd-0aad30af8a83	26	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da8baf-693a-11ea-b1fd-0aad30af8a83	N139	e8d738ed-693a-11ea-b1fd-0aad30af8a83	adjacent Pat36	e8d5d8e5-693a-11ea-b1fd-0aad30af8a83	36	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da3952-693a-11ea-b1fd-0aad30af8a83	N53	e8d6a56d-693a-11ea-b1fd-0aad30af8a83	adjacent Pat17	e8d56d36-693a-11ea-b1fd-0aad30af8a83	17	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da3b6d-693a-11ea-b1fd-0aad30af8a83	N55	e8d6a76a-693a-11ea-b1fd-0aad30af8a83	adjacent Pat18	e8d56e95-693a-11ea-b1fd-0aad30af8a83	18	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db115a-693a-11ea-b1fd-0aad30af8a83	N5759	e8d83c97-693a-11ea-b1fd-0aad30af8a83	adjacent Pat80	e8d64935-693a-11ea-b1fd-0aad30af8a83	80	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db64b8-693a-11ea-b1fd-0aad30af8a83	T96	e8d89dbd-693a-11ea-b1fd-0aad30af8a83	Tumor Pat27	e8d57c15-693a-11ea-b1fd-0aad30af8a83	27	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da3c5b-693a-11ea-b1fd-0aad30af8a83	N59	e8d6aa17-693a-11ea-b1fd-0aad30af8a83	adjacent Pat19	e8d56feb-693a-11ea-b1fd-0aad30af8a83	19	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db124a-693a-11ea-b1fd-0aad30af8a83	T14	e8d83eb9-693a-11ea-b1fd-0aad30af8a83	Tumor Pat1	e8d51d01-693a-11ea-b1fd-0aad30af8a83	1	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db447a-693a-11ea-b1fd-0aad30af8a83	T16	e8d8410a-693a-11ea-b1fd-0aad30af8a83	Tumor Pat2	e8d51ec9-693a-11ea-b1fd-0aad30af8a83	2	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db6cb2-693a-11ea-b1fd-0aad30af8a83	T124	e8d8e191-693a-11ea-b1fd-0aad30af8a83	Tumor Pat32	e8d58460-693a-11ea-b1fd-0aad30af8a83	32	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db465b-693a-11ea-b1fd-0aad30af8a83	T18	e8d8425b-693a-11ea-b1fd-0aad30af8a83	Tumor Pat3	e8d51fb3-693a-11ea-b1fd-0aad30af8a83	3	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db6a56-693a-11ea-b1fd-0aad30af8a83	T120	e8d8df87-693a-11ea-b1fd-0aad30af8a83	Tumor Pat31	e8d582aa-693a-11ea-b1fd-0aad30af8a83	31	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da9959-693a-11ea-b1fd-0aad30af8a83	N167	e8d74adb-693a-11ea-b1fd-0aad30af8a83	adjacent Pat45	e8d5e53f-693a-11ea-b1fd-0aad30af8a83	45	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daeed5-693a-11ea-b1fd-0aad30af8a83	N201	e8d796c8-693a-11ea-b1fd-0aad30af8a83	adjacent Pat55	e8d5f2f1-693a-11ea-b1fd-0aad30af8a83	55	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da9a4e-693a-11ea-b1fd-0aad30af8a83	N169	e8d74cdc-693a-11ea-b1fd-0aad30af8a83	adjacent Pat46	e8d5e62c-693a-11ea-b1fd-0aad30af8a83	46	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daefb2-693a-11ea-b1fd-0aad30af8a83	N203	e8d798a2-693a-11ea-b1fd-0aad30af8a83	adjacent Pat56	e8d5f3d8-693a-11ea-b1fd-0aad30af8a83	56	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da9628-693a-11ea-b1fd-0aad30af8a83	N163	e8d746ec-693a-11ea-b1fd-0aad30af8a83	adjacent Pat43	e8d5e233-693a-11ea-b1fd-0aad30af8a83	43	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da970e-693a-11ea-b1fd-0aad30af8a83	N165	e8d748e4-693a-11ea-b1fd-0aad30af8a83	adjacent Pat44	e8d5e352-693a-11ea-b1fd-0aad30af8a83	44	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc040b-693a-11ea-b1fd-0aad30af8a83	T268	e8d98ee2-693a-11ea-b1fd-0aad30af8a83	Tumor Pat72	e8d63e0e-693a-11ea-b1fd-0aad30af8a83	72	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbaa0b-693a-11ea-b1fd-0aad30af8a83	T148	e8d8ebf6-693a-11ea-b1fd-0aad30af8a83	Tumor Pat39	e8d5dd83-693a-11ea-b1fd-0aad30af8a83	39	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da7595-693a-11ea-b1fd-0aad30af8a83	N61	e8d6e3f0-693a-11ea-b1fd-0aad30af8a83	adjacent Pat20	e8d571e2-693a-11ea-b1fd-0aad30af8a83	20	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc0cf8-693a-11ea-b1fd-0aad30af8a83	T5760	e8da2155-693a-11ea-b1fd-0aad30af8a83	Tumor Pat80	e8d64935-693a-11ea-b1fd-0aad30af8a83	80	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daf16b-693a-11ea-b1fd-0aad30af8a83	N209	e8d79a83-693a-11ea-b1fd-0aad30af8a83	adjacent Pat57	e8d5f604-693a-11ea-b1fd-0aad30af8a83	57	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da77cf-693a-11ea-b1fd-0aad30af8a83	N63	e8d6e665-693a-11ea-b1fd-0aad30af8a83	adjacent Pat21	e8d572cc-693a-11ea-b1fd-0aad30af8a83	21	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da78ef-693a-11ea-b1fd-0aad30af8a83	N65	e8d6e8b2-693a-11ea-b1fd-0aad30af8a83	adjacent Pat22	e8d573ad-693a-11ea-b1fd-0aad30af8a83	22	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da7ae6-693a-11ea-b1fd-0aad30af8a83	N67	e8d6eab4-693a-11ea-b1fd-0aad30af8a83	adjacent Pat23	e8d575af-693a-11ea-b1fd-0aad30af8a83	23	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc04de-693a-11ea-b1fd-0aad30af8a83	T270	e8d990ed-693a-11ea-b1fd-0aad30af8a83	Tumor Pat73	e8d64095-693a-11ea-b1fd-0aad30af8a83	73	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db475b-693a-11ea-b1fd-0aad30af8a83	T22	e8d8444c-693a-11ea-b1fd-0aad30af8a83	Tumor Pat4	e8d52234-693a-11ea-b1fd-0aad30af8a83	4	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db493a-693a-11ea-b1fd-0aad30af8a83	T24	e8d84586-693a-11ea-b1fd-0aad30af8a83	Tumor Pat5	e8d55d7f-693a-11ea-b1fd-0aad30af8a83	5	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbabd1-693a-11ea-b1fd-0aad30af8a83	T156	e8d8f1b0-693a-11ea-b1fd-0aad30af8a83	Tumor Pat41	e8d5df6b-693a-11ea-b1fd-0aad30af8a83	41	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db4a2b-693a-11ea-b1fd-0aad30af8a83	T26	e8d8476b-693a-11ea-b1fd-0aad30af8a83	Tumor Pat6	e8d55f58-693a-11ea-b1fd-0aad30af8a83	6	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da9c8d-693a-11ea-b1fd-0aad30af8a83	N173	e8d74edb-693a-11ea-b1fd-0aad30af8a83	adjacent Pat47	e8d5e707-693a-11ea-b1fd-0aad30af8a83	47	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db4b0e-693a-11ea-b1fd-0aad30af8a83	T28	e8d8489a-693a-11ea-b1fd-0aad30af8a83	Tumor Pat7	e8d5605f-693a-11ea-b1fd-0aad30af8a83	7	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbaaf8-693a-11ea-b1fd-0aad30af8a83	T150	e8d8eded-693a-11ea-b1fd-0aad30af8a83	Tumor Pat40	e8d5de83-693a-11ea-b1fd-0aad30af8a83	40	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc06c4-693a-11ea-b1fd-0aad30af8a83	T272	e8d992ff-693a-11ea-b1fd-0aad30af8a83	Tumor Pat74	e8d641ae-693a-11ea-b1fd-0aad30af8a83	74	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dba483-693a-11ea-b1fd-0aad30af8a83	T138	e8d8e5d1-693a-11ea-b1fd-0aad30af8a83	Tumor Pat35	e8d5d6ea-693a-11ea-b1fd-0aad30af8a83	35	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dba37f-693a-11ea-b1fd-0aad30af8a83	T136	e8d8e49b-693a-11ea-b1fd-0aad30af8a83	Tumor Pat34	e8d5d5bc-693a-11ea-b1fd-0aad30af8a83	34	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da92fc-693a-11ea-b1fd-0aad30af8a83	N155	e8d74311-693a-11ea-b1fd-0aad30af8a83	adjacent Pat41	e8d5df6b-693a-11ea-b1fd-0aad30af8a83	41	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc0269-693a-11ea-b1fd-0aad30af8a83	T258	e8d98aca-693a-11ea-b1fd-0aad30af8a83	Tumor Pat70	e8d63c4d-693a-11ea-b1fd-0aad30af8a83	70	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc096b-693a-11ea-b1fd-0aad30af8a83	T5358	e8da1ce6-693a-11ea-b1fd-0aad30af8a83	Tumor Pat77	e8d64572-693a-11ea-b1fd-0aad30af8a83	77	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db4cd9-693a-11ea-b1fd-0aad30af8a83	T30	e8d84a84-693a-11ea-b1fd-0aad30af8a83	Tumor Pat8	e8d56253-693a-11ea-b1fd-0aad30af8a83	8	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db4dcb-693a-11ea-b1fd-0aad30af8a83	T32	e8d84bae-693a-11ea-b1fd-0aad30af8a83	Tumor Pat9	e8d56345-693a-11ea-b1fd-0aad30af8a83	9	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db4eb3-693a-11ea-b1fd-0aad30af8a83	T34	e8d84da2-693a-11ea-b1fd-0aad30af8a83	Tumor Pat10	e8d56429-693a-11ea-b1fd-0aad30af8a83	10	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db509d-693a-11ea-b1fd-0aad30af8a83	T36	e8d85071-693a-11ea-b1fd-0aad30af8a83	Tumor Pat11	e8d565f6-693a-11ea-b1fd-0aad30af8a83	11	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc033c-693a-11ea-b1fd-0aad30af8a83	T266	e8d98cd8-693a-11ea-b1fd-0aad30af8a83	Tumor Pat71	e8d63d36-693a-11ea-b1fd-0aad30af8a83	71	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5184-693a-11ea-b1fd-0aad30af8a83	T38	e8d852fa-693a-11ea-b1fd-0aad30af8a83	Tumor Pat12	e8d566e0-693a-11ea-b1fd-0aad30af8a83	12	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dba83d-693a-11ea-b1fd-0aad30af8a83	T146	e8d8eac6-693a-11ea-b1fd-0aad30af8a83	Tumor Pat38	e8d5db73-693a-11ea-b1fd-0aad30af8a83	38	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da93ff-693a-11ea-b1fd-0aad30af8a83	N161	e8d744f4-693a-11ea-b1fd-0aad30af8a83	adjacent Pat42	e8d5e145-693a-11ea-b1fd-0aad30af8a83	42	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dba763-693a-11ea-b1fd-0aad30af8a83	T144	e8d8e8dc-693a-11ea-b1fd-0aad30af8a83	Tumor Pat37	e8d5d9dc-693a-11ea-b1fd-0aad30af8a83	37	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dba678-693a-11ea-b1fd-0aad30af8a83	T140	e8d8e7ad-693a-11ea-b1fd-0aad30af8a83	Tumor Pat36	e8d5d8e5-693a-11ea-b1fd-0aad30af8a83	36	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daa14f-693a-11ea-b1fd-0aad30af8a83	N189	e8d78d03-693a-11ea-b1fd-0aad30af8a83	adjacent Pat50	e8d5eab5-693a-11ea-b1fd-0aad30af8a83	50	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daf96a-693a-11ea-b1fd-0aad30af8a83	N225	e8d7a8c9-693a-11ea-b1fd-0aad30af8a83	adjacent Pat64	e8d6351c-693a-11ea-b1fd-0aad30af8a83	64	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc07b4-693a-11ea-b1fd-0aad30af8a83	T2398	e8da1897-693a-11ea-b1fd-0aad30af8a83	Tumor Pat75	e8d6429c-693a-11ea-b1fd-0aad30af8a83	75	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbc086-693a-11ea-b1fd-0aad30af8a83	T204	e8d93c26-693a-11ea-b1fd-0aad30af8a83	Tumor Pat56	e8d5f3d8-693a-11ea-b1fd-0aad30af8a83	56	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbbfb4-693a-11ea-b1fd-0aad30af8a83	T202	e8d93a23-693a-11ea-b1fd-0aad30af8a83	Tumor Pat55	e8d5f2f1-693a-11ea-b1fd-0aad30af8a83	55	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daf887-693a-11ea-b1fd-0aad30af8a83	N221	e8d7a6bf-693a-11ea-b1fd-0aad30af8a83	adjacent Pat63	e8d632ed-693a-11ea-b1fd-0aad30af8a83	63	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da7be7-693a-11ea-b1fd-0aad30af8a83	N87	e8d6ec99-693a-11ea-b1fd-0aad30af8a83	adjacent Pat24	e8d57696-693a-11ea-b1fd-0aad30af8a83	24	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da7ccb-693a-11ea-b1fd-0aad30af8a83	N89	e8d6ee7d-693a-11ea-b1fd-0aad30af8a83	adjacent Pat25	e8d578a1-693a-11ea-b1fd-0aad30af8a83	25	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbb241-693a-11ea-b1fd-0aad30af8a83	T170	e8d92b5e-693a-11ea-b1fd-0aad30af8a83	Tumor Pat46	e8d5e62c-693a-11ea-b1fd-0aad30af8a83	46	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5261-693a-11ea-b1fd-0aad30af8a83	T40	e8d8551e-693a-11ea-b1fd-0aad30af8a83	Tumor Pat13	e8d567bd-693a-11ea-b1fd-0aad30af8a83	13	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db544a-693a-11ea-b1fd-0aad30af8a83	T42	e8d85744-693a-11ea-b1fd-0aad30af8a83	Tumor Pat14	e8d5698f-693a-11ea-b1fd-0aad30af8a83	14	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc0c16-693a-11ea-b1fd-0aad30af8a83	T5382	e8da2020-693a-11ea-b1fd-0aad30af8a83	Tumor Pat79	e8d6484a-693a-11ea-b1fd-0aad30af8a83	79	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5531-693a-11ea-b1fd-0aad30af8a83	T44	e8d888b7-693a-11ea-b1fd-0aad30af8a83	Tumor Pat15	e8d56a7d-693a-11ea-b1fd-0aad30af8a83	15	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5611-693a-11ea-b1fd-0aad30af8a83	T46	e8d88aaf-693a-11ea-b1fd-0aad30af8a83	Tumor Pat16	e8d56b56-693a-11ea-b1fd-0aad30af8a83	16	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc0890-693a-11ea-b1fd-0aad30af8a83	T5264	e8da1ab8-693a-11ea-b1fd-0aad30af8a83	Tumor Pat76	e8d64485-693a-11ea-b1fd-0aad30af8a83	76	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daeb0e-693a-11ea-b1fd-0aad30af8a83	N193	e8d79129-693a-11ea-b1fd-0aad30af8a83	adjacent Pat52	e8d5edcb-693a-11ea-b1fd-0aad30af8a83	52	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbc497-693a-11ea-b1fd-0aad30af8a83	T212	e8d94031-693a-11ea-b1fd-0aad30af8a83	Tumor Pat58	e8d5f6f3-693a-11ea-b1fd-0aad30af8a83	58	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daec07-693a-11ea-b1fd-0aad30af8a83	N195	e8d79311-693a-11ea-b1fd-0aad30af8a83	adjacent Pat53	e8d5efda-693a-11ea-b1fd-0aad30af8a83	53	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbc38a-693a-11ea-b1fd-0aad30af8a83	T210	e8d93e2c-693a-11ea-b1fd-0aad30af8a83	Tumor Pat57	e8d5f604-693a-11ea-b1fd-0aad30af8a83	57	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbb31b-693a-11ea-b1fd-0aad30af8a83	T174	e8d92d9d-693a-11ea-b1fd-0aad30af8a83	Tumor Pat47	e8d5e707-693a-11ea-b1fd-0aad30af8a83	47	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dae938-693a-11ea-b1fd-0aad30af8a83	N191	e8d78f1a-693a-11ea-b1fd-0aad30af8a83	adjacent Pat51	e8d5ecd7-693a-11ea-b1fd-0aad30af8a83	51	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daf257-693a-11ea-b1fd-0aad30af8a83	N211	e8d79c7a-693a-11ea-b1fd-0aad30af8a83	adjacent Pat58	e8d5f6f3-693a-11ea-b1fd-0aad30af8a83	58	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da9d71-693a-11ea-b1fd-0aad30af8a83	N179	e8d7514e-693a-11ea-b1fd-0aad30af8a83	adjacent Pat48	e8d5e8f8-693a-11ea-b1fd-0aad30af8a83	48	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daf331-693a-11ea-b1fd-0aad30af8a83	N213	e8d79e6d-693a-11ea-b1fd-0aad30af8a83	adjacent Pat59	e8d5fa33-693a-11ea-b1fd-0aad30af8a83	59	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da7e9b-693a-11ea-b1fd-0aad30af8a83	N91	e8d6f085-693a-11ea-b1fd-0aad30af8a83	adjacent Pat26	e8d5798b-693a-11ea-b1fd-0aad30af8a83	26	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daf6b0-693a-11ea-b1fd-0aad30af8a83	N219	e8d7a4b4-693a-11ea-b1fd-0aad30af8a83	adjacent Pat62	e8d631ab-693a-11ea-b1fd-0aad30af8a83	62	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da7f83-693a-11ea-b1fd-0aad30af8a83	N95	e8d6f278-693a-11ea-b1fd-0aad30af8a83	adjacent Pat27	e8d57c15-693a-11ea-b1fd-0aad30af8a83	27	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daf4fa-693a-11ea-b1fd-0aad30af8a83	N215	e8d7a061-693a-11ea-b1fd-0aad30af8a83	adjacent Pat60	e8d5fba5-693a-11ea-b1fd-0aad30af8a83	60	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daf5db-693a-11ea-b1fd-0aad30af8a83	N217	e8d7a293-693a-11ea-b1fd-0aad30af8a83	adjacent Pat61	e8d62e91-693a-11ea-b1fd-0aad30af8a83	61	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da2355-693a-11ea-b1fd-0aad30af8a83	N13	e8d64a13-693a-11ea-b1fd-0aad30af8a83	adjacent Pat1	e8d51d01-693a-11ea-b1fd-0aad30af8a83	1	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5815-693a-11ea-b1fd-0aad30af8a83	T54	e8d88cab-693a-11ea-b1fd-0aad30af8a83	Tumor Pat17	e8d56d36-693a-11ea-b1fd-0aad30af8a83	17	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da246a-693a-11ea-b1fd-0aad30af8a83	N15	e8d64c52-693a-11ea-b1fd-0aad30af8a83	adjacent Pat2	e8d51ec9-693a-11ea-b1fd-0aad30af8a83	2	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8db5901-693a-11ea-b1fd-0aad30af8a83	T56	e8d88ddd-693a-11ea-b1fd-0aad30af8a83	Tumor Pat18	e8d56e95-693a-11ea-b1fd-0aad30af8a83	18	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8da2553-693a-11ea-b1fd-0aad30af8a83	N17	e8d64d5e-693a-11ea-b1fd-0aad30af8a83	adjacent Pat3	e8d51fb3-693a-11ea-b1fd-0aad30af8a83	3	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dc0a3d-693a-11ea-b1fd-0aad30af8a83	T5374	e8da1e25-693a-11ea-b1fd-0aad30af8a83	Tumor Pat78	e8d64650-693a-11ea-b1fd-0aad30af8a83	78	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8daa04f-693a-11ea-b1fd-0aad30af8a83	N181	e8d75349-693a-11ea-b1fd-0aad30af8a83	adjacent Pat49	e8d5e9de-693a-11ea-b1fd-0aad30af8a83	49	Human Early-Onset Gastric Cancer - Korea University	Solid Tissue Normal	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbbed1-693a-11ea-b1fd-0aad30af8a83	T200	e8d9382f-693a-11ea-b1fd-0aad30af8a83	Tumor Pat54	e8d5f0cc-693a-11ea-b1fd-0aad30af8a83	54	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbb15c-693a-11ea-b1fd-0aad30af8a83	T168	e8d92952-693a-11ea-b1fd-0aad30af8a83	Tumor Pat45	e8d5e53f-693a-11ea-b1fd-0aad30af8a83	45	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbaf71-693a-11ea-b1fd-0aad30af8a83	T166	e8d8f826-693a-11ea-b1fd-0aad30af8a83	Tumor Pat44	e8d5e352-693a-11ea-b1fd-0aad30af8a83	44	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbae95-693a-11ea-b1fd-0aad30af8a83	T164	e8d8f60f-693a-11ea-b1fd-0aad30af8a83	Tumor Pat43	e8d5e233-693a-11ea-b1fd-0aad30af8a83	43	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
e8dbada9-693a-11ea-b1fd-0aad30af8a83	T162	e8d8f403-693a-11ea-b1fd-0aad30af8a83	Tumor Pat42	e8d5e145-693a-11ea-b1fd-0aad30af8a83	42	Human Early-Onset Gastric Cancer - Korea University	Tumor	Stomach	Early Onset Gastric Cancer	no	Qualified						Qualified	Qualified																									International Cancer Proteogenome Consortium
